<SEC-DOCUMENT>0001055726-24-000046.txt : 20240808
<SEC-HEADER>0001055726-24-000046.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808160058
ACCESSION NUMBER:		0001055726-24-000046
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		241188018

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ino-20240630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0d8c4537-ca52-4f1a-a8a1-280952f330d4,g:ffaafe34-d428-4f21-bdf4-6dece8c876eb,d:ddea4a5604314afc969e1f7c0aef53d6-->
<html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ino="http://www.inovio.com/20240630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20240630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-29">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-30">12/31</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-12" decimals="6" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-147">0.083333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-12" decimals="6" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-276">0.083333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-71" decimals="6" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-368">0.083333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20240630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="position"><xbrli:measure>ino:position</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="agreement"><xbrli:measure>ino:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="director"><xbrli:measure>ino:director</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-24</xbrli:startDate><xbrli:endDate>2024-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsTotalShareholderReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-131 f-132 f-133 f-134 f-135 f-136 f-137 f-138 f-139 f-140 f-141 f-142 f-143 f-144 f-145 f-146" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-166 f-167 f-172 f-173 f-176 f-177 f-190 f-191 f-196 f-197 f-202 f-203 f-214 f-215 f-222 f-223 f-228 f-229 f-232 f-233 f-246 f-247 f-252 f-253 f-256 f-257 f-270 f-271" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/></ix:resources></ix:header></div><div id="iddea4a5604314afc969e1f7c0aef53d6_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.333%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">JUNE 30, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.465%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-14888</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:186.00pt"><tr><td style="width:1.0pt"/><td style="width:184.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><img src="ino-20240630_g1.jpg" alt="inoviologosw.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.276%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 110</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Plymouth Meeting</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Pennsylvania</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">19462</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">440-4200</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.069%"><tr><td style="width:1.0%"/><td style="width:41.965%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.799%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.333%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.077%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.490%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">        &#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">25,964,268</ix:nonFraction> as of August&#160;8, 2024.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:186.00pt"><tr><td style="width:1.0pt"/><td style="width:184.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended June&#160;30, 2024</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:81.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_13">Part I.  Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_16">a) Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_19">b) Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_25">c) Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_28">d) Condensed Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_34">e) Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_34">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_37">f) Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_37">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_112">Item&#160;2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_112">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_130">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_130">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_133">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_133">30</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_136">Part II.  Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_136">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_139">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_139">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_142">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_142">31</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_148">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_148">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_151">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_151">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_154">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_154">60</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_10"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Item 1A. Risk Factors herein. These risk factors include, but are not limited to, the following: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain FDA approval of our proprietary devices and DNA medicine candidates, we will not be able to commercialize them in the United States. In particular, because our product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with developing and manufacturing a drug-device combination product. In addition, if the FDA and similar regulatory agencies do not provide marketing authorization for our CELLECTRA delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA delivery devices are a novel approach to administering medicines, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop or our devices could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic and, thus, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with developing and manufacturing a drug-device combination product. In addition, if the FDA and similar regulatory agencies do not provide marketing authorization for our delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we and the contract manufacturers upon whom we rely fail to produce our proprietary devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary devices and DNA medicine candidates. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have agreements with government agencies that are subject to termination and uncertain future funding. Termination or cessation of funding would have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may be harmed if our corporate restructuring plans and cost reduction efforts do not achieve the anticipated results or cause undesirable consequences. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense and increasing competition and steps taken by our competitors, such as the introduction of a new, disruptive technology may impede our ability to develop and commercialize our DNA medicines.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have entered into collaborations with Chinese companies and rely on clinical materials manufactured in China for our development efforts. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.  Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_13"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.  Financial Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_16"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"/><td style="width:74.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-31">34,392,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-32">14,310,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-33">76,029,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-34">130,982,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-35">1,773,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-36">2,405,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-37">5,365,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-38">5,393,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:fixed-zero" scale="0" id="f-39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="f-40">20,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-41">117,561,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-42">153,113,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-43">4,510,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-44">4,960,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-45">2,319,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-46">2,780,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-47">8,819,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-48">9,491,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-49">585,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-50">605,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-51">133,797,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-52">170,951,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-53">16,634,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-54">19,847,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-55">1,921,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-56">1,070,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-57">5,499,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-58">2,365,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-59">2,321,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-60">2,406,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:fixed-zero" scale="0" id="f-61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-62">87,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="f-63">21,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="f-64">21,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:ConvertibleDebtCurrent" format="ixt:fixed-zero" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:ConvertibleDebtCurrent" format="ixt:num-dot-decimal" id="f-66">16,770,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-67">26,399,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-68">42,570,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-69">10,658,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-70">11,032,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-71">37,057,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-72">53,602,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-75">25,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-76">22,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-77">1,783,074,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-78">1,740,954,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-79">1,685,672,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-80">1,622,965,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-81">689,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-82">662,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-83">96,739,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-84">117,349,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-85">133,797,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-86">170,951,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:52.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from collaborative arrangements and other contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-87">100,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-88">225,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-89">100,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-90">340,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-91">23,090,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-92">23,743,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-93">44,001,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-94">53,920,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-95">10,206,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-96">13,523,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-97">20,781,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-98">27,413,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-99">33,297,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-100">37,267,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-101">64,782,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-102">81,334,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-103">33,196,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-104">37,041,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-105">64,681,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-106">80,993,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="f-107">1,307,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="f-108">2,168,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="f-109">2,807,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="f-110">4,375,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:InterestExpenseOperating" format="ixt:fixed-zero" scale="0" id="f-111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:InterestExpenseOperating" format="ixt:num-dot-decimal" scale="0" id="f-112">313,488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestExpenseOperating" format="ixt:num-dot-decimal" scale="0" id="f-113">177,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:InterestExpenseOperating" format="ixt:num-dot-decimal" scale="0" id="f-114">626,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-115">334,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-116">156,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-117">460,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-118">773,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-119">20,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-120">922,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-121">480,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-122">4,141,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-123">7,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-124">1,427,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-125">674,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-126">3,853,543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-127">32,237,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-128">35,534,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-129">62,706,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-130">76,183,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-131"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-132">1.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-133"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-134">1.61</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-135"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-136">2.48</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-137"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-138">3.50</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares used to compute net loss per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-139"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-140">27,197,802</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-141"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-142">22,029,486</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-143"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-144">25,244,657</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-145"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-146">21,784,343</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> <ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</ix:footnote></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-148">32,237,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-149">35,534,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-150">62,706,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-151">76,183,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="0" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="f-153">376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-154">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-155">2,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Unrealized (loss) gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-156">13,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-157">108,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-158">59,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-159">9,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-160">32,250,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-161">35,642,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-162">62,733,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-163">76,176,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:35.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Six Months Ended June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-164">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-166">22,793,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-167">22,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-168">1,740,954,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-169">1,622,965,136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-170">662,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-171">117,349,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" id="f-172">543,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="f-173">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" id="f-174">5,224,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-175">5,225,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-176">34,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-177">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-178">174,282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-179">174,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-180">2,525,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-181">2,525,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-182">30,469,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-183">30,469,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-184">46,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-185">46,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-186">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-187">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-188">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-190">23,371,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-191">23,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-192">1,748,529,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-193">1,653,435,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-194">676,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-195">94,441,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-196">2,536,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-197">2,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-198">17,057,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-199">17,059,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of pre-funded warrants for cash, net of financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-200">16,146,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-201">16,146,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-202">56,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-203">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-204">172,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-205">172,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-206">1,514,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-207">1,514,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-208">32,237,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-209">32,237,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-210">13,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-211">13,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-212">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-214">25,963,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-215">25,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-216">1,783,074,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-217">1,685,672,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-218">689,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-219">96,739,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:35.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Six Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-220">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-222">21,090,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-223">21,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-224">1,710,888,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-225">1,487,847,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-226">698,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-227">222,362,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for legal settlement</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" id="f-228">760,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="f-229">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" id="f-230">13,999,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-231">14,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-232">43,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-233">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-234">424,748</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-235">424,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-236">3,809,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-237">3,809,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-238">40,649,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-239">40,649,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-240">117,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-241">117,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-242">1,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-243">1,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-244">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-246">21,894,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-247">21,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-248">1,728,271,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-249">1,528,497,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-250">582,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-251">199,213,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-252">425,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="f-253">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-254">2,914,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-255">2,915,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-256">19,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-257">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-258">32,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-259">32,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-260">2,917,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-261">2,917,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-262">35,534,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-263">35,534,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-264">108,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-265">108,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="f-266">376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="f-267">376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-268">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-270">22,339,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-271">22,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-272">1,734,072,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-273">1,564,031,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-274">691,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-275">169,371,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote">All share amounts in this column, including appropriate reclassifications between common stock and additional paid-in capital, have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</ix:footnote></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_34"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-277">62,706,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-278">76,183,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-279">916,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-280">1,410,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-282">145,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-283">672,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-284">739,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="0" id="f-286">1,984,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-287">4,039,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-288">6,727,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest on senior convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-289">355,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-290">93,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discounts on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="f-291">1,154,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="f-292">2,402,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sales of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="f-293">692,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="f-294">3,853,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="f-295">21,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="f-296">334,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on equity investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-297">460,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-298">773,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-299">480,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-300">4,141,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, including from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-301">631,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-302">6,621,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-303">48,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-304">41,191,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-305">19,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-306">17,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses, including due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-307">2,362,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-308">43,955,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="f-309">3,134,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="f-310">4,421,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="f-311">458,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="f-312">1,406,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability, including from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-313">87,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-314">1,185,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-315">56,969,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-316">68,979,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-317">29,359,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-318">106,741,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-319">85,196,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-320">173,898,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-321">487,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-322">320,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Proceeds from sale of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-324">6,071,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-325">55,348,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-326">72,906,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="f-327">16,415,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="0" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of pre-funded warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-329">16,146,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="0" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-331">22,284,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-332">2,915,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-333">67,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="f-335">414,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="f-336">456,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-337">21,669,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-338">2,458,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-339">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-340">2,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase in cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-341">20,081,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-342">6,383,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-343">14,310,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-344">46,329,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-345">34,392,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-346">52,712,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-347">533,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-348">533,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock as part of litigation settlement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="0" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="0" id="f-350">14,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_40"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-351" continuedAt="f-351-1" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="f-351-1"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA delivery devices are designed to optimally deliver the plasmids into the body's cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a life-long, rare disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in August 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_43"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-352" continuedAt="f-352-1" escape="true">Basis of Presentation, Liquidity and Risks and Uncertainties</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-353" continuedAt="f-353-1" escape="true"><ix:continuation id="f-352-1" continuedAt="f-352-2"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June&#160;30, 2024, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2024 and 2023 and the condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three and six months ended June 30, 2024 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2023, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;6, 2024. The balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-352-2" continuedAt="f-352-3"><ix:continuation id="f-353-1" continuedAt="f-353-2"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of June&#160;30, 2024 and December 31, 2023, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-354">32.2</ix:nonFraction> million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-355">62.7</ix:nonFraction> million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six months ended June 30, 2024, respectively. The Company had working capital of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ino:WorkingCapital" scale="6" id="f-356">91.2</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="f-357">1.7</ix:nonFraction> billion as of June&#160;30, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed an underwritten registered direct offering (the &#8220;Offering&#8221;) relating to the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-358">2,536,258</ix:nonFraction> shares (the &#8220;Shares&#8221;) of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-359">0.001</ix:nonFraction> per share, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-360">7.693</ix:nonFraction> per share and pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-67" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-361">2,135,477</ix:nonFraction> shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-68" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-362">7.692</ix:nonFraction> per Pre-Funded Warrant, which represents the per share price for the Shares less the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-68" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-363">0.001</ix:nonFraction> per share exercise price for each Pre-Funded Warrant. The net proceeds from the Offering were $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-364">33.2</ix:nonFraction>&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-365">110.4</ix:nonFraction> million as of June&#160;30, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are expected to be sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the Offering described above, and the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-366">5.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-367">5.5</ix:nonFraction>&#160;million under a Sales Agreement during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2024 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-353-2">The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended, to effect a 1-for-12 reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;).  As a result of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The reverse stock split was reflected on the Nasdaq Capital Market beginning with the opening of trading on January 25, 2024. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from "Additional paid-in capital" to "Common stock" on the balance sheet and statement of changes in stockholders&#8217; equity. Any fractional post-split shares as a result of the reverse stock split were eliminated by the payment of cash for the value of such fractional share. As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and outstanding shares of Series C Cumulative Convertible Preferred Stock and to the number of shares of common stock issuable under the Company's equity incentive plans. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-352-3"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reverse stock split did not change the par value of the Company's common stock or the authorized number of shares of the Company's common stock. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_49"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-369" continuedAt="f-369-1" escape="true">Critical Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-369-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-370" continuedAt="f-370-1" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-370-1">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;).</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-371" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_55"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-373" continuedAt="f-373-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-372" continuedAt="f-372-1" escape="true">Short-term Investments and Fair Value Measurements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-373-1" continuedAt="f-373-2"><ix:continuation id="f-372-1" continuedAt="f-372-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-374" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of June&#160;30, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-375">45,541,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-377">3,042,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-378">42,498,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-73" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-379">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-380">29,676,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="f-381">517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-382">2,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-383">29,674,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-75" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-384">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-385">2,979,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-386">10,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="f-387">290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-388">2,990,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-389">1,301,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-391">435,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-392">866,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-393">79,498,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-394">11,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-395">3,481,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-396">76,029,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-397">55,389,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-399">3,522,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-400">51,866,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;<ix:nonNumeric contextRef="c-79" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-401">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-402">75,164,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-403">24,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-405">75,189,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-81" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-406">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-407">2,978,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-408">11,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="f-409">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-410">2,990,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-411">1,340,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-413">403,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-414">936,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-415">134,873,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-416">36,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-417">3,927,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-418">130,982,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June 30, 2024, the Company recorded gross realized gains on investments of $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="f-419">300</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="f-420">500</ix:nonFraction>, respectively, and gross realized losses on investments of $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="0" id="f-421">2,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="0" id="f-422">693,000</ix:nonFraction>, respectively. During the three and six months ended June 30, 2023, the Company recorded gross realized gains on investments of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="f-423">200</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="f-424">500</ix:nonFraction>, respectively, and gross realized losses on investments of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-425">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-426">3.9</ix:nonFraction>&#160;million, respectively. During the three and six months ended June 30, 2024, the Company recorded net unrealized (loss) gain on available-for-sale equity securities of $(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-427">21,000</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-428">480,000</ix:nonFraction>, respectively. During the three and six months ended June 30, 2023, the Company recorded net unrealized gain on available-for-sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-429">923,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-430">4.1</ix:nonFraction>&#160;million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three and six months ended June 30, 2024 and 2023. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of June&#160;30, 2024, the Company had <ix:nonFraction unitRef="position" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-431">22</ix:nonFraction> available-for-sale securities with an aggregate </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-373-2" continuedAt="f-373-3"><ix:continuation id="f-372-2" continuedAt="f-372-3"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">total unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="f-432">3.5</ix:nonFraction> million. Of these securities, <ix:nonFraction unitRef="position" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="f-433">19</ix:nonFraction> had been in a loss position for longer than 12 months as of June&#160;30, 2024.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;June&#160;30, 2024&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at June&#160;30, 2024, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-434" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-435">42,498,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-436">42,498,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-439">29,674,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-440">29,674,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-443">2,990,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-445">2,990,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-447">866,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-449">866,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-451">76,029,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-452">72,172,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-453">3,856,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-455">2,319,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-456">2,319,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-459">78,349,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-460">74,492,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-461">3,856,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-463">51,866,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-464">51,866,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-467">75,189,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-468">75,189,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-471">2,990,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-473">2,990,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-475">936,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-477">936,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-479">130,982,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-480">127,056,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-481">3,926,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-483">2,780,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-484">2,780,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-487">133,763,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-488">129,836,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-489">3,926,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at June&#160;30, 2024 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-491">597,808</ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain or loss on investment in affiliated entity.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-373-3"><ix:continuation id="f-372-3"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at June&#160;30, 2024 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of June&#160;30, 2024 or December 31, 2023.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_61"></div><div style="margin-top:5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentAssetsTextBlock" id="f-492" continuedAt="f-492-1" escape="true">Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="f-492-1"><ix:nonNumeric contextRef="c-1" name="ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="f-493" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical expenses (a)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ino:PrepaidClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-494">2,341,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ino:PrepaidClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-495">3,410,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-496">3,024,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-497">1,983,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-498">5,365,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-499">5,393,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-500" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" id="f-501">4,487,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" id="f-502">3,577,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" id="f-503">8,642,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" id="f-504">9,837,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses (b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-505">3,504,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-506">6,432,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-507">16,634,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-508">19,847,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a)        As of June 30, 2024 and December 31, 2023, balance includes $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ino:PrepaidManufacturingExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-509">22,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ino:PrepaidManufacturingExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="f-510">1.5</ix:nonFraction>&#160;million, respectively, of prepaid manufacturing expenses.</span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;As of June 30, 2024 and December 31, 2023, balance includes $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ino:GrantLiability" format="ixt:num-dot-decimal" scale="6" id="f-511">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="ino:GrantLiability" format="ixt:num-dot-decimal" scale="6" id="f-512">4.3</ix:nonFraction>&#160;million, respectively, of liability for unused grant funding.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><div style="text-indent:-4.5pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_67"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-513" continuedAt="f-513-1" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="f-513-1"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-514"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-515">78.5</ix:nonFraction></ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="c-125" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-516"><ix:nonFraction unitRef="number" contextRef="c-126" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-517">6.50</ix:nonFraction></ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-518">75.7</ix:nonFraction>&#160;million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of <ix:nonFraction unitRef="number" contextRef="c-126" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-519">6.50</ix:nonFraction>% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-520">16.9</ix:nonFraction>&#160;million obligation in full, including accrued interest.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the six months ended June 30, 2024,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:InterestExpenseOperating" format="ixt:num-dot-decimal" scale="0" id="f-521">178,000</ix:nonFraction> of interest expense related to the Notes, all of which related to the contractual interes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">t coupon. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and six months ended June 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:InterestExpenseOperating" format="ixt:num-dot-decimal" scale="0" id="f-522">313,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:InterestExpenseOperating" format="ixt:num-dot-decimal" scale="0" id="f-523">627,000</ix:nonFraction>, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="f-524">267,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="f-525">533,000</ix:nonFraction>, respectively, related to the contractual interest coupon.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-526" continuedAt="f-526-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-526-1" continuedAt="f-526-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-527" escape="true"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of June&#160;30, 2024 and December&#160;31, 2023: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-528"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-529">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-530">600,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-531">25,963,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-532">25,963,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-533">22,793,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-132" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-534"><ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-535">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-536">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-537">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-538">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-539">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Stock and Pre-Funded Warrants</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 18, 2024, the Company closed the Offering of Shares and Pre-Funded Warrants (see &#8220;Liquidity&#8221; in Note 2 above). As the Pre-Funded Warrants are indexed to the Company's own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Pre-Funded Warrants as additional paid-in capital on the Company's condensed consolidated balance sheet as of June 30, 2024.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Pre-Funded Warrant has an initial exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-68" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-540">0.001</ix:nonFraction>, subject to certain adjustments. The Pre-Funded Warrants may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than <ix:nonFraction unitRef="number" contextRef="c-66" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipPercent" scale="-2" id="f-541">9.99</ix:nonFraction>% of the Company&#8217;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of <ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipPercent" scale="-2" id="f-542">19.99</ix:nonFraction>% upon 61 days&#8217; notice to the Company subject to the terms of the Pre-Funded Warrants.  As of June 30, 2024, no Pre-Funded Warrants had been exercised.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-543">300.0</ix:nonFraction>&#160;million. The 2021 Sales Agreement provides that the Sales Agents were entitled to compensation in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="c-135" decimals="3" name="ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage" scale="-2" id="f-544">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the three months ended March 31, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-545">543,620</ix:nonFraction> shares of its common stock under the 2021 Sales Agreement at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-136" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="f-546">9.76</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="f-547">5.2</ix:nonFraction>&#160;million. During the year ended December 31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-548">875,305</ix:nonFraction> shares of its common stock under the 2021 Sales Agreement at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="f-549">6.33</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="f-550">5.5</ix:nonFraction>&#160;million. The registration statement relating to the shares of common stock issuable under the 2021 Sales Agreement has expired, and in August 2024 we terminated the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="ino:LitigationSettlementAmountAwardedToOtherPartyShares" format="ixt:num-dot-decimal" scale="0" id="f-551">760,083</ix:nonFraction> shares of common stock pursuant to the securities class action settlement, as described in Note 11.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#8220;2023 Plan&#8221;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2023 Plan will not exceed the sum of <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-552">1,166,666</ix:nonFraction> shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#8220;2016 Plan&#8221;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At June&#160;30, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-553">800,051</ix:nonFraction> shares of common stock available for future grant under the 2023 Plan, <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-554">188,804</ix:nonFraction> shares underlying outstanding RSUs and <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-555">276,163</ix:nonFraction> shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over <ix:nonNumeric contextRef="c-141" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-556">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="c-141" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-557">ten years</ix:nonNumeric>. The 2023 Plan terminates by its terms on March&#160;24, 2033. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-558">142,295</ix:nonFraction> shares underlying outstanding but unvested RSUs and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-559">947,606</ix:nonFraction> shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over <ix:nonNumeric contextRef="c-143" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-560">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="c-143" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-561">ten years</ix:nonNumeric>. Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-526-2" continuedAt="f-526-3"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan will not exceed <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-562">166,666</ix:nonFraction> shares. At June&#160;30, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-563">110,527</ix:nonFraction> shares of common stock available for future grant under the 2022 Inducement Plan, <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-564">10,274</ix:nonFraction> shares underlying outstanding but unvested RSUs and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-565">38,318</ix:nonFraction> shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="f-526-3" continuedAt="f-526-4"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on M</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-526-4">arch&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At June&#160;30, 2024, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-566">97,618</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The outstanding awards granted under the 2007 Incentive Plan are fully vested and generally have a maximum contractual term of <ix:nonNumeric contextRef="c-147" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-567">ten years</ix:nonNumeric>.</ix:continuation> </span></div><div><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_76"></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.  <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-568" continuedAt="f-568-1" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="f-568-1" continuedAt="f-568-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-569" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The outstanding Pre-Funded Warrants (see Note 7) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the three and six months ended June 30, 2024 given their nominal exercise price.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and RSUs and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the Notes previously issued by the Company (discussed in Note 6) was considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three and six months ended June 30, 2024 and 2023, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options, service-based RSUs, performance-and market-based RSUs and the potentially dilutive shares issuable upon conversion of the Notes prior to their repayment on March 1, 2024 would have been anti-dilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" id="f-570" continuedAt="f-570-1" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share for the three and six months ended June 30, 2024 and 2023 are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-571">32,237,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-572">35,534,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="ino:WeightedAverageNumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-573">25,461,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="ino:WeightedAverageNumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-574">22,029,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" format="ixt:num-dot-decimal" scale="0" id="f-575">1,736,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" format="ixt:fixed-zero" scale="0" id="f-576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-577"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-578">27,197,802</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-579"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-580">22,029,486</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-581"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-582">1.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-583"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-584">1.61</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-568-2"><ix:continuation id="f-570-1"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-585">62,706,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-586">76,183,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ino:WeightedAverageNumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-587">24,376,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="ino:WeightedAverageNumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-588">21,784,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" format="ixt:num-dot-decimal" scale="0" id="f-589">868,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" format="ixt:fixed-zero" scale="0" id="f-590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-591"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-592">25,244,657</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-593"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-594">21,784,343</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-595"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-596">2.48</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-597"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-598">3.50</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-599" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three and Six Months Ended June 30</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-600"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-601">1,359,705</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-602"><ix:nonFraction unitRef="shares" contextRef="c-151" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-603">1,263,891</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-152" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-604"><ix:nonFraction unitRef="shares" contextRef="c-153" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-605">341,373</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-154" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-606"><ix:nonFraction unitRef="shares" contextRef="c-155" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-607">305,434</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-and market-based restricted stock units</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-156" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-608"><ix:nonFraction unitRef="shares" contextRef="c-157" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-609">82,000</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-610"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-611">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-160" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-612"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-613">275</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-162" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-614"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-615">275</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-164" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-616"><ix:nonFraction unitRef="shares" contextRef="c-165" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-617">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-166" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-618"><ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-619">254,165</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-620"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-621">1,783,353</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-622"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-623">1,823,765</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_79"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.  <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-624" continuedAt="f-624-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-624-1" continuedAt="f-624-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-625" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to service-based RSUs, performance-based RSUs  and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-626" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-627">4.42</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-628">3.45</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-170" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-629">4.23</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-171" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-630">4.05</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-631">106</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-632">101</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-170" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-633">105</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-171" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-634">100</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-168" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-635">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-169" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-636">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-170" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-637">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-171" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-638">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-639">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-640">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-170" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-641">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-642">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-643">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-644">3.9</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-645">581,000</ix:nonFraction> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-624-2" continuedAt="f-624-3"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-646">1.6</ix:nonFraction> million, respectively, was included in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-647">890,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-648">2.3</ix:nonFraction> million, respectively, was included in general and administrative expenses. Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-649">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-650">6.4</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-651">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-652">2.7</ix:nonFraction> million, respectively, was included in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-653">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-654">3.7</ix:nonFraction> million, respectively, was included in general and administrative expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-655">3.7</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-656">1.6</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-657">8.80</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-658">6.96</ix:nonFraction> for employee and director stock options granted during the three and six months ended June 30, 2024, respectively, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-659">7.20</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-660">11.28</ix:nonFraction> for the three and six months ended June 30, 2023, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-661">3.4</ix:nonFraction> million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-185" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-662">1.7</ix:nonNumeric> years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-186" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-663">11.00</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-664">8.61</ix:nonFraction> for service-based RSUs granted during the three and six months ended June 30, 2024, respectively and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-187" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-665">9.24</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-188" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-666">10.32</ix:nonFraction> for the three and six months ended June 30, 2023, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-667">43,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-668">146,000</ix:nonFraction>, respectively. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-669">146,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-670">366,000</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-and Market-Based RSUs </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2024, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-193" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-671">82,000</ix:nonFraction> performance-and market-based RSUs (such performance-based grants, the "PSU Awards") to key employees under the 2023 Plan. Each PSU was expressed as a target number of RSUs. With respect to the PSU Awards, the Company's Board of Directors established specified performance goals and corresponding performance periods over which the goals must be attained, the satisfaction of which are conditions to earning the PSU Awards and vesting of the underlying RSUs. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the target number of RSUs underlying each PSU Award, up to <ix:nonFraction unitRef="number" contextRef="c-194" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-672">70</ix:nonFraction>% (the "Milestone-based RSUs") will vest based on the achievement of specified milestones relating to the development, regulatory status and commercialization of the Company&#8217;s lead product candidate INO-3107 (each, a "Milestone," and collectively, the "Milestones"). Each Milestone has a specified deadline for achievement ranging between the end of 2025 and the end of 2027.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining <ix:nonFraction unitRef="number" contextRef="c-195" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-673">30</ix:nonFraction>% of the target number of RSUs underlying each PSU Award (the "Market-based RSUs") will be eligible to vest based on the Company&#8217;s achievement of total stockholder return relative to a peer group consisting of companies in the Russell 2000 Biotechnology Subsector index (the &#8220;Relative TSR&#8221;) over the period beginning on June 1, 2024 and ending on December 31, 2027 (the &#8220;Performance Period&#8221;), expressed as a percentile ranking.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Marked-based RSUs, if any, actually earned based on the achievement of the Relative TSR goal may range from <ix:nonFraction unitRef="number" contextRef="c-196" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" scale="-2" id="f-674">50</ix:nonFraction>% of the target number of RSUs for performance at a specified threshold percentile, to <ix:nonFraction unitRef="number" contextRef="c-193" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" scale="-2" id="f-675">100</ix:nonFraction>% of the target number of RSUs for performance at the target percentile, and up to <ix:nonFraction unitRef="number" contextRef="c-197" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" scale="-2" id="f-676">150</ix:nonFraction>% of the target number of RSUs for performance at or above a specified maximum percentile. In the event that actual Relative TSR performance is between the threshold and target levels or between the target and maximum levels, the number of RSUs earned based on Relative TSR will be determined based on linear interpolation between the specified percentiles. If the Company&#8217;s actual Relative TSR performance is below the threshold percentile, then no RSUs would be earned based on Relative TSR. The number of RSUs earned based on Relative TSR may not exceed the target number of RSUs eligible to vest based on Relative TSR if the Company&#8217;s total stockholder return is negative for the Performance Period.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values the Milestone-based RSUs based on the grant date closing price per share. The Company recognizes stock-based compensation expense over the performance period, if it is probable that the performance condition will be achieved. Adjustments to stock-based compensation expense are made, as needed, each reporting period based on changes in the Company's estimate of the number of units that are probable of vesting. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values the Market-based RSUs on the grant date using the Monte Carlo simulation method, a generally accepted statistical technique used to simulate a range of possible future stock prices for the Company and the peer group. The determination of fair value is affected by the Company's stock price and a number of assumptions including the expected volatility and the risk-free interest rate. The Company will recognize stock-based compensation expense ratably over the performance period of the award. The market-based RSUs will cliff-vest at the end of the <ix:nonNumeric contextRef="c-195" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-677">three-year</ix:nonNumeric> period ranging from <ix:nonFraction unitRef="number" contextRef="c-198" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-678">0</ix:nonFraction> percent to <ix:nonFraction unitRef="number" contextRef="c-199" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-679">150</ix:nonFraction> percent of the target number of awards granted. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-624-3" continuedAt="f-624-4"><ix:nonNumeric contextRef="c-1" name="ino:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="f-680" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Monte Carlo simulation method were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:78.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-200" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-681">4.60</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-200" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-682">90</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-200" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-683">3.61</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-200" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-684">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the Milestone-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-685">629,000</ix:nonFraction> based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-194" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-686">10.96</ix:nonFraction>. As of June 30, 2024, the underlying performance milestones of the Milestone-based RSUs were determined to be not probable of achievement, and <ix:nonFraction unitRef="usd" contextRef="c-201" decimals="INF" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="0" id="f-687"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="INF" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="0" id="f-688">no</ix:nonFraction></ix:nonFraction> stock-based compensation expense was recognized for the three and six months then ended.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-624-4">The grant date fair value of the Market-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-689">263,000</ix:nonFraction> based on the fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-690">10.69</ix:nonFraction> per share as determined using the Monte Carlo simulation method. For both the three and six months ended June 30, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-691"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-692">8,000</ix:nonFraction></ix:nonFraction> in stock-based compensation for the Market-based RSUs.</ix:continuation>  </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_85"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-693" continuedAt="f-693-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-693-1"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned <ix:nonFraction unitRef="shares" contextRef="c-204" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-694">597,808</ix:nonFraction> shares of common stock in PLS as of June&#160;30, 2024, representing an ownership interest of <ix:nonFraction unitRef="number" contextRef="c-204" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-695">17.8</ix:nonFraction>%, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar") and an Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" scale="6" id="f-696">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="c-205" name="ino:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="f-697">five-year</ix:nonNumeric> term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="f-698">10.7</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2021 to $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="f-699">13.6</ix:nonFraction>&#160;million, for the preclinical development and translational studies of DMAbs as countermeasures for COVID-19, with funding extended through August 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The sub-grant also includes an option for an additional $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="ino:CollaborativeAgreementAwardedOptionAmount" format="ixt:num-dot-decimal" scale="6" id="f-700">1.6</ix:nonFraction>&#160;million in funding through September 2025. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="f-701">1.2</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2024 to $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="f-702">2.4</ix:nonFraction>&#160;million with funding through November 2024, with an option for an additional $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="ino:CollaborativeAgreementAwardedOptionAmount" format="ixt:num-dot-decimal" scale="6" id="f-703">4.2</ix:nonFraction>&#160;million in funding that extends the sub-grant through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (dLNPs) for vaccination against HIV infection.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three and six months ended June 30, 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="f-704">9,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="f-705">149,000</ix:nonFraction>, respectively, and for the three and six months ended June 30, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="f-706">179,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="f-707">390,000</ix:nonFraction>, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to collaborative research agreements. Research and development expenses recorded from Wistar for the three and six months ended June 30, 2024 were $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-708">455,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-709">1.0</ix:nonFraction> million, respectively. Research and development expenses recorded from Wistar for the three and six months ended June 30, 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-710">510,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-711">932,000</ix:nonFraction>, respectively. At June&#160;30, 2024 and December&#160;31, 2023, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-712">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-713">2.4</ix:nonFraction> million, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-714">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-715">1.1</ix:nonFraction> million, respectively, related to Wistar. At each of June&#160;30, 2024 and December&#160;31, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" format="ixt:num-dot-decimal" scale="0" id="f-716"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" format="ixt:num-dot-decimal" scale="0" id="f-717">22,000</ix:nonFraction></ix:nonFraction> as deferred grant funding on its condensed consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_88"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-718" continuedAt="f-718-1" escape="true">Commitments and Contingencies                                                  </ix:nonNumeric></span></div><ix:continuation id="f-718-1" continuedAt="f-718-2"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="c-220" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-719">56,600</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and approximately <ix:nonFraction unitRef="sqft" contextRef="c-221" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-720">57,400</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of June&#160;30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of <ix:nonNumeric contextRef="c-222" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-721">2.9</ix:nonNumeric> to <ix:nonNumeric contextRef="c-223" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-722">5.5</ix:nonNumeric> ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-718-2" continuedAt="f-718-3"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company entered into a lease agreement for research and development laboratory space in San Diego, California. The total space under the lease is approximately <ix:nonFraction unitRef="sqft" contextRef="c-224" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-723">5,600</ix:nonFraction> square feet. The term of the lease commenced on February 10, 2024 and the initial term is <ix:nonNumeric contextRef="c-225" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-724">4.3</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the lease. Rent payments under the lease will include base rent with an annual increase of approximately <ix:nonFraction unitRef="number" contextRef="c-224" decimals="2" name="ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" format="ixt-sec:numwordsen" scale="-2" id="f-725">three</ix:nonFraction> percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-726" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of June&#160;30, 2024, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="f-727">1,696,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-728">3,467,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-729">3,555,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="f-730">2,955,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="f-731">2,310,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="0" id="f-732">2,132,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-733">16,115,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-734">3,135,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-735">12,980,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-736">2,322,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-737">10,658,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-738">4.8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-739">9.0</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2024 were $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-740">521,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-741">1.4</ix:nonFraction> million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-742">856,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-743">1.7</ix:nonFraction>&#160;million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third and fourth quarters of 2023, the Company entered into agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="c-226" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-744">4,400</ix:nonFraction> and <ix:nonFraction unitRef="sqft" contextRef="c-227" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-745">7,000</ix:nonFraction> square feet, respectively, in its Plymouth Meeting headquarters, in each case with sublease terms through December 31, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into <ix:nonFraction unitRef="agreement" contextRef="c-228" decimals="INF" name="ino:LesseeOperatingLeaseNumberOfAgreementsToSublease" format="ixt-sec:numwordsen" scale="0" id="f-746">two</ix:nonFraction> agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="c-229" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-747">13,500</ix:nonFraction> square feet in its Plymouth Meeting headquarters, with one sublease term through March 31, 2025 and the other month-to-month.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-718-3" continuedAt="f-718-4"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The plaintiffs&#8217; complaint was later amended to include certain of the Company&#8217;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-748">30.0</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="ino:LossContingencyEstimateOfPossibleLossValueOfShares" format="ixt:num-dot-decimal" scale="6" id="f-749">14.0</ix:nonFraction>&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers paid the $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-750">30.0</ix:nonFraction>&#160;million cash component of the settlement. During the three months ended March 31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="ino:LitigationSettlementAmountAwardedToOtherPartyShares" format="ixt:num-dot-decimal" scale="0" id="f-751">760,083</ix:nonFraction> shares of common stock pursuant to the securities class action settlement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming <ix:nonFraction unitRef="director" contextRef="c-231" decimals="INF" name="us-gaap:LossContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="f-752">eight</ix:nonFraction> current and former directors of the Company as defendants. The lawsuit asserted state and federal claims and was based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accused the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff sought unspecified monetary damages on behalf of the Company as well as governance reforms. Between June 2020 and August 2020, additional shareholder derivative complaints were filed and later consolidated by the court. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, an additional shareholder derivative complaint was filed in the Delaware Court of Chancery, asserting substantially similar claims as those in the consolidated derivative action. In May 2022, the Delaware Court of Chancery entered a stay of the litigation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania. The proposed settlement provided for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the court entered an order preliminarily approving the proposed settlement of the derivative claims, in accordance with a Stipulation of Settlement. The Stipulation of Settlement contemplated that, following the settlement hearing and the final approval of the settlement by the court, the Company would implement certain corporate governance reforms described in the Stipulation of Settlement. The preliminary order also approved the form and manner of the notice of the Settlement. As part of the Settlement, in July 2023 the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="6" id="f-753">1.2</ix:nonFraction>&#160;million to plaintiffs&#8217; counsel for their fees and expenses. In October 2023, the court entered an order and final judgment approving the Settlement, which became effective in November 2023. The Company has implemented the corporate governance reforms in response to the provisions of the Stipulation of Settlement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. The Company filed an answer to VGXI&#8217;s </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-718-4"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. In October 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On February 29, 2024, the Company filed a motion for summary judgment. On April 1, 2024, GeneOne filed an opposition to the Company&#8217;s motion for summary judgment. On June 28, 2024, the court denied the motion for summary judgment. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_91"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-754" continuedAt="f-754-1" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="f-754-1" continuedAt="f-754-2"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. In the fourth quarter of 2022, the Company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility was assured. For the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2023, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-755">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-756">2.4</ix:nonFraction>&#160;million, respectively, from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. <ix:nonFraction unitRef="usd" contextRef="c-235" decimals="INF" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:fixed-zero" scale="0" id="f-757"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="INF" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:fixed-zero" scale="0" id="f-758">No</ix:nonFraction></ix:nonFraction> funding was received during the three and six months ended June 30, 2024.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), which was amended on June 14, 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-754-2"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" scale="6" id="f-759">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="c-237" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:duryear" id="f-760">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three and six months ended June 30, 2024, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-761"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-762">101,000</ix:nonFraction></ix:nonFraction> from the ApolloBio Agreement that was recorded as revenue. There were <ix:nonFraction unitRef="usd" contextRef="c-239" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-763"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-764">no</ix:nonFraction></ix:nonFraction> significant reimbursable program costs under the ApolloBio Agreement during the three and six months ended June 30, 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI, pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-765">56</ix:nonFraction>&#160;million of costs over a <ix:nonNumeric contextRef="c-241" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" format="ixt-sec:durwordsen" id="f-766">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. For both</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the three and six months ended June 30, 2024, the Company received <ix:nonFraction unitRef="usd" contextRef="c-241" decimals="0" name="ino:CollaborativeAgreementFundingReceived" format="ixt:fixed-zero" scale="0" id="f-767"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="0" name="ino:CollaborativeAgreementFundingReceived" format="ixt:fixed-zero" scale="0" id="f-768">no</ix:nonFraction></ix:nonFraction> funding related to these grants. During the three and six months ended June 30, 2023, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="f-769">303,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="f-770">1.9</ix:nonFraction>&#160;million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of each of June&#160;30, 2024 and December 31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-771"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-772">2.2</ix:nonFraction></ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded as an accrued liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheet related to these CEPI grants.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="f-773">9.0</ix:nonFraction> million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="f-774">6.9</ix:nonFraction> million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="f-775">5.0</ix:nonFraction> million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="f-776">1.3</ix:nonFraction> million to support large-scale manufacturing of INO-4800. For both the three and six months ended June 30, 2024 the Company received <ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:fixed-zero" scale="0" id="f-777"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:fixed-zero" scale="0" id="f-778">no</ix:nonFraction></ix:nonFraction> funding from CEPI related to these grants for INO-4800. During the three and six months ended June 30, 2023, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="f-779">135,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="f-780">188,000</ix:nonFraction>, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="f-781">2.2</ix:nonFraction> million to advance the development of DMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="f-782">1.1</ix:nonFraction> million for the project. During the three and six months ended June 30, 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="f-783">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="f-784">39,000</ix:nonFraction>, respectively, as contra-research and development expense related to the Gates DMAb grant. During the three and six months ended June 30, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="f-785">12,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="f-786">70,000</ix:nonFraction>, respectively, as contra-research and development expense related to the Gates dMAb grant. As of June&#160;30, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-787">49,000</ix:nonFraction> recorded as an </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheet related to the grant.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_94"></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-788" continuedAt="f-788-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-788-1" continuedAt="f-788-2"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</span></div></ix:continuation><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-788-2">&#160;For the six months ended June 30, 2024 and 2023, the Company did not record any income tax provision/(benefit) due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-789" continuedAt="f-789-1" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><ix:continuation id="f-789-1" continuedAt="f-789-2"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos Therapeutics to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a series of financing transactions through June 2020, the Company held less than a majority of the outstanding equity of Geneos on an as-converted to common stock basis, which triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance. Accordingly, the Company deconsolidated its investment in Geneos in 2020.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its investment at fair value. The Company determined that its investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment is marked to fair value.&#160;There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" sign="-" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" format="ixt:num-dot-decimal" scale="6" id="f-790">1.5</ix:nonFraction>&#160;million; however, only $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="f-791">434,000</ix:nonFraction> was recorded, reducing the Company's total investment in Geneos to $<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-792">0</ix:nonFraction>. Of the total amount, $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="f-793">819,000</ix:nonFraction> was allocated to the equity method investment, reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-794">0</ix:nonFraction> as of March 31, 2021. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-795">4.2</ix:nonFraction>&#160;million loss was allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-796">0</ix:nonFraction> as of March 31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of its Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="c-268" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-797">35</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-798">2.0</ix:nonFraction>&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="c-270" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-799">28</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-2 preferred stock was based on the per share price paid by third-party investors. The Company concluded that its Series A-2 preferred stock investment was a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="f-800">165,000</ix:nonFraction>.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-801">2.2</ix:nonFraction>&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-802">0</ix:nonFraction> as of March 31, 2022.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any further investment in Geneos subsequent to March 31, 2022. The Company will not reduce its investment below $<ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-803">0</ix:nonFraction> and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><ix:continuation id="f-789-2" continuedAt="f-789-3"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, Geneos completed the closing of its Series A-3 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="c-273" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-804">23</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. </span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="f-789-3" continuedAt="f-789-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-789-4">immunotherapy and CELLECTRA&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</ix:continuation>  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Quarterly Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information appearing elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes for the year ended December 31, 2023 included in our Annual Report on Form 10-K, or 2023 Annual Report, filed with the U.S. Securities and Exchange Commission, or SEC, on March 6, 2024. Readers are also urged to carefully review and consider the various disclosures made by us that attempt to advise interested parties of the factors that affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;II of this Quarterly Report under the captions &#8220;Risk Factors&#8221; and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the disclosures made in our 2023 Annual Report under the caption &#8220;Risk Factors&#8221; and in our audited consolidated financial statements and related notes. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that preclinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our proprietary smart device technology and DNA medicine candidates may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture our DNA medicine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; and the impact of government healthcare laws and proposals.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INOVIO, CELLECTRA, the INOVIO logo, and our other trademarks or service marks appearing in this Quarterly Report are our property. Solely for convenience, the trademarks and trade names in this report are referred to without the &#174; and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. Products or service names of other companies mentioned in this Quarterly Report may be trademarks, trade names or service marks of their respective owners.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">References herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;INOVIO&#8221; or the &#8220;Company&#8221; refer to INOVIO Pharmaceuticals, Inc. and its consolidated subsidiaries. References herein to &#8220;DNA medicines&#8221; refers to our product candidates in development for diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_115"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Our platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use proprietary technology to design DNA plasmids which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA delivery devices are designed to optimally deliver the plasmids into the body's cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, a life-long, rare disease characterized by the growth of small tumors, or papillomas, in the respiratory tract primarily caused by HPV-6 and/or HPV-11 genotypes. Although mostly benign, these papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. The standard of care for RRP is surgery. The most widely cited U.S. epidemiology data, published in 1995, estimated that there were 14,000 active cases for both adults and juveniles, and about 1.8 new cases per 100,000 adults each year.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% (26/32) of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. Of these 32 patients, nine did not require surgical intervention during or after the dosing window. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the trial had a median range of 4 surgeries (2-8) in the year prior to dosing. There was a statistically significant median decrease of three surgical interventions when comparing the year following treatment to the year prior to treatment. Treatment with INO-3107 generated a strong immune response in the trial, inducing activated CD4 T cells and activated CD8 T cells with lytic potential. T-cell responses were also observed at Week 52, indicating a persistent cellular memory response. INO-3107 was well tolerated by participants in the trial, resulting in mostly low-grade (Grade 1) treatment-emergent adverse effects such as injection site pain and fatigue.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we received feedback from the U.S. Food and Drug Administration, or FDA, that the data from this completed trial could be used to support the submission of a Biologic License Application, or BLA, for review under the FDA&#8217;s accelerated approval program. As part of submitting our BLA under the accelerated program, we will need to satisfy all FDA filing requirements and initiate a confirmatory clinical trial prior to BLA submission. We previously expected to be able to submit our BLA by the end of 2024; however, during our device testing process we have recently identified a manufacturing issue involving the single use disposable administration component of the CELLECTRA 5PSP device that we plan to use in the confirmatory trial. We are currently working to resolve the manufacturing issue, but we now expect that the timing for submission of the BLA will likely be delayed until mid-2025.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing INO-3112, a DNA medicine candidate targeting HPV 16/18 combined with a DNA plasmid encoding for human IL-12 as an immune activator, for the treatment of oropharyngeal squamous cell carcinoma, or OPSCC, a type of head and neck cancer commonly known as throat cancer. The incidence of HPV-related throat cancer has increased rapidly in recent years in the United States, with an estimated 20,000 new cases each year. HPV-related throat cancer has surpassed cervical cancer as the most common HPV-related cancer. In the United States, men are four to five times more likely to be diagnosed with HPV-associated oropharyngeal cancers than women.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) in a clinical trial for patients with locoregionally advanced, high-risk, HPV16/18 positive OPSCC. Under the terms of the supply agreement, Coherus will provide LOQTORZI for a planned Phase 3 clinical trial. The manufacturing issue with the single use disposable administration component of the CELLECTRA 5PSP device that is impacting INO-3107 will also need be resolved before we can commence the Phase 3 trial with INO-3112.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing INO-5401, an immunotherapy consisting of three DNA plasmids encoding for three tumor associated antigens, for the treatment of glioblastoma multiforme, or GBM, an aggressive type of brain cancer that accounts for more than 50% of all primary malignant brain tumors. GBM is one of the most complex, deadly, and treatment-resistant cancers. In the United States, nearly 15,000 people were expected to receive a GBM diagnosis in 2023, and it is estimated that more than 10,000 individuals will succumb to the disease each year.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our development efforts with the product candidates described above, we are actively developing or planning to develop DNA medicines for other indications, including HPV-related anal dysplasia; cancers in people with certain gene mutations; and a potential vaccine booster to protect against the Ebola virus. We were previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions, or HSIL, but announced in August 2023 that we were ceasing development for this indication in the United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our DNA medicine candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any material revenues unless and until we obtain marketing approval for and successfully commercialize INO-3107 and our other product candidates. We earn revenue from license fees and milestone revenue and collaborative research and development agreements and contracts. Our DNA medicine candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All DNA medicine candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had an accumulated deficit of $1.7 billion. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_118"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting estimates since December 31, 2023. For a description of our critical accounting estimates and significant judgments used in the preparation of our condensed consolidated financial statements, refer to Note 3 to our Condensed Consolidated Financial Statements included in this Quarterly Report, as well as Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2023 Annual Report and Note 2 to our audited Consolidated Financial Statements contained in our 2023 Annual Report. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_124"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $101,000 for both the three and six months ended June 30, 2024, respectively, as compared to $226,000 and $341,000 for the three and six months ended June 30, 2023, respectively, all of which was derived under collaborative arrangements and other contracts.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to contract research organizations and other consultants, and outside expenses. We utilize a labor reporting system to record employee compensation on a project-by-project basis. Unallocated research and development expenses include engineering and device-related expenses that are not allocable to a specific project, as well as stock-based compensation, other employee-related expenses that are not related to a specific project, and facilities and depreciation expenses.    </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our research and development expense by product candidate for the three and six months ended June 30, 2024 and 2023:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:37.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-3107</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-5401 and other Immuno-oncology </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Engineering and device-related </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated expenses (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,099)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(652)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:37.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.021%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-3107</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-5401 and other Immuno-oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,029)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Engineering and device-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated expenses (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,920)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Net of contributions received from grant agreements and recorded as contra- research and development expense.</span></div><div style="margin-top:5pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Includes impairment of intangible assets of $2.0 million recorded in the second quarter of 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in research and development expenses for the three and six-month periods year over year was primarily the result of:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$733,000 and $7.4 million, respectively, in lower drug manufacturing and clinical study expenses related to INO-4800 after we discontinued this program in the fourth quarter of 2022;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.4 million and $7.2 million, respectively, in lower employee and consultant compensation, including stock-based compensation, due to lower headcount; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.1 million and $3.2 million, respectively, in lower drug manufacturing and engineering services related to other COVID-19 studies that we ceased after we discontinued development of INO-4800;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$4.7 million and $4.7 million, respectively, in lower drug manufacturing expenses for other programs; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$2.0 million related to the impairment charge on intangible assets in the second quarter of 2023 which did not recur during 2024;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$712,000 and $1.7 million, respectively, in lower clinical study expenses related to VGX-3100 as we discontinued development of this product candidate in the third quarter of 2023; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$183,000 and $1.5 million, respectively, in lower clinical study and subcontractor expenses related to our CEPI LASSA and MERS grants; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$490,000 and $745,000, respectively, in lower immunology and clinical study expenses related to INO-3107.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were offset by:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$5.3 million and $8.5 million, respectively, in higher drug manufacturing related to INO-3107; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.9 million and $3.0 million, respectively in higher engineering professional and outside services related to our device development; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.8 million and $2.9 million, respectively, of higher expensed inventory; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.8 million and $4.7 million, respectively, of lower contra-research and development expense recorded from grant agreements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $9,000 and $188,000 for the three and six months ended June 30, 2024, respectively, as compared to $1.8 million and $4.9 million for the three and six months ended June 30, 2023, respectively. The decrease for the three- and six-month periods year over year was primarily due to a decrease of $303,000 and $1.9 million, respectively, earned under the CEPI LASSA and MERS grants and $1.2 million and $2.4 million, respectively, in reimbursements from Advaccine.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses, which include business development expenses and patent expenses, were $10.2 million and $20.8 million for the three and six months ended June 30, 2024, respectively, as compared to $13.5 million and $27.4 million for the three and six months ended June 30, 2023, respectively. Decreases for the three- and six-month periods year over year included:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$1.9 million and $3.9 million, respectively, in employee compensation, including employee and consultant stock-based compensation, due to lower headcount; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$1.2 million and $2.3 million, respectively, in legal expenses related to litigation matters settled in 2023 that did not recur in 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite vesting period. Total employee and director stock-based compensation expense for the three and six months ended June 30, 2024 was $1.5 million and $3.9 million, of which $581,000 and $1.6 million was included in research and development expenses and $890,000 and $2.3 million was included in general and administrative expenses, respectively. Total employee and director stock-based compensation expense for the three and six months ended June 30, 2023 was $2.8 million and $6.4 million, respectively. Of these amounts, $1.3 million and $2.7 million, respectively, was included in research and development expenses, and $1.5 million and $3.7 million, respectively, was included in general and administrative expenses. The decrease was due to a lower weighted average grant date fair value for the awards granted during 2024.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three and six months ended June 30, 2024 was $1.3 million and $2.8 million, respectively, as compared to $2.2 million and $4.4 million for the three and six months ended June 30, 2023, respectively. The decrease for the three- and six-month periods year over year was primarily due to a lower short-term investment balance.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three and six months ended June 30, 2024 was $0 and $178,000, respectively, as compared to $313,000 and $627,000 for the three and six months ended June 30, 2023, respectively. The decrease was primarily due to lower interest expense on our senior convertible promissory notes that were repaid in full on March 1, 2024.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Loss) gain on investment in affiliated entities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (loss) gain resulted from the change in the fair market value of our investment in PLS of $(334,000) and $(460,000) for the three and six months ended June 30, 2024, respectively, as compared to $157,000 and $773,000 for the three and six months ended June 30, 2023, respectively. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the condensed consolidated statements of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net unrealized (loss) gain on available-for-sale equity securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized (loss) gain on available-for-sale equity securities for the three and six months ended June 30, 2024 of $(21,000) and $480,000, respectively, as compared to $923,000 and $4.1 million for the three and six months ended June 30, 2023, respectively, resulted from a change in the fair market value of the investments.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, for the three and six months ended June 30, 2024 of $8,000 and $(675,000), respectively, as compared to $(1.4) million and $(3.9) million for the three and six months ended June 30, 2023, respectively, related primarily to the realized loss on short-term investments sold during the periods.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_127"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities for the advancement of DNA medicine candidates. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had cash, cash equivalents and short-term investments of $110.4 million and working capital of $91.2 million, as compared to $145.3 million and $110.5 million, respectively, as of December&#160;31, 2023. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $57.0 million and $69.0 million for the six months ended June 30, 2024 and 2023, respectively. The variance was primarily due to the timing and changes in working capital balances, offset by decreased operating expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $55.3 million and $72.9 million for the six months ended June 30, 2024 and 2023, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $21.7 million and $2.5 million for the six months ended June 30, 2024 and 2023, respectively. The variance was primarily due to the net proceeds from the April 2024 Offering (defined below) of $33.2 million and net proceeds of $5.2 million from the sale of common stock under the 2021 Sales Agreement (defined below), offset by the repayment of our convertible senior notes of $16.4 million.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of Common Stock and Pre-Funded Warrants</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, we closed an underwritten registered direct offering, or the Offering, relating to the issuance and sale of 2,536,258 shares at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock, or the Pre-Funded Warrants, at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the Offering were $33.2 million, after deducting the underwriting discounts and commissions and offering expenses paid by us. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, we entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement, or the 2021 Sales Agreement, with outside sale</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s agents, or collectively, the Sales Agents, under which we were able to offer and sell shares of our common stock with aggregate gross proceeds of up to $300.0 million, through the Sales Agents.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three months ended March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, we sold 543,620 shares of our common stock under the 2021 Sales Agreement at a weighted average price of $9.76 per share, resulting in aggregate net proceeds of $5.2 million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">year ended December 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, we sold 875,305 shares of our common stock under the 2021 Sales Agreement at a weighted average price of $6.33 per share, resulting in aggregate net proceeds of $5.5&#160;million. The registration statement relating to the shares of common stock issuable under the 2021 Sales Agreement has expired, and in August 2024 we terminated the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock options to purcha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">se 8,159</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock were exercised for aggregate net proceeds to us of $68,000, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $414,000. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, no stock options were exercised and tax payments of $457,000 were made related to net share settlement of RSU awards.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we issued 760,083 shares of common stock pursuant to a securities class action settlement, as described in Note 11 to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had an accumulated deficit of $1.7 billion, and we expect to continue to operate at a loss for the near term. The amount of our accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. Our current cash resources </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will not be sufficient to complete the clinical development of our product candidates beyond INO-3107, and we anticipate that additional financing will be required in order to complete the development of and to commercialize and generate revenues from the sale of INO-3107 or any other product candidates that may receive regulatory approval. If these activities are successful and if we receive approval from the FDA to market our DNA medicine candidates, then we will need to raise additional funding to market and sell the approved products and equipment. In addition to the potential issuance of equity or debt securities in order to raise capital, we are also evaluating potential collaborations as an additional way to fund our operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date of this report. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our cash runway to extend into the third quarter of 2025, without giving effect to any further capital raising activities that we may undertake.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have existing supply agreements with contract manufacturers to manufacture drug substance. At June&#160;30, 2024, we had approximately $5.1 mil</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lion in minimum purchase obligations in connection with these agreements. We expect to satisfy these obligations from existing cash over the next twelve months.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2024, except for the repayment in full of our convertible senior notes as described above, there have been no other significant changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our 2023 Annual Report.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_130"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in short-term investment-grade securities. During much of 2022 and 2023, there was a pronounced overall increase in prevailing interest rates in the United States compared to the first half of 2022, which has contributed to the unrealized loss of $3.5 million in the market value of our investment portfolio as of June 30, 2024.</span></div><div style="margin-top:5pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate primarily in the United States and most transactions during the six months ended June 30, 2024 were made in United States dollars. Accordingly, we do not have any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor. Although inflation has increased generally in the United States in recent years, we do not believe that inflation has had a material effect on our business, financial condition or results of operations during the six months ended June 30, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_133"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Quarterly Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of June&#160;30, 2024 at the reasonable assurance level. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the quarter ended June&#160;30, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_139"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our appeal, in July 2020 VGXI filed counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. We filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and GeneOne. We terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. We filed preliminary objections to the complaint, which were overruled. In September 2021, we filed an answer to the complaint, new matter, and counterclaims. Our counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. On October 18, 2021, GeneOne filed its answer to our counterclaims and new matter. On February 29, 2024, we filed a motion for summary judgment. On April 1, 2024, GeneOne filed an opposition to our motion for summary judgment. On June 28, 2024, the court denied the motion for summary judgment. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our counterclaims against GeneOne and to vigorously defend ourselves against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_142"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;  RISK FACTORS</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to numerous risks. You should carefully consider and evaluate each of the following factors as well as the other information in this Quarterly Report on Form&#160;10-Q, including our financial statements and the related notes, the risk factors discussed in our 2023 Annual Report, which we filed with the SEC on March 6, 2024, in evaluating our business and prospects. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations. If any of the following risks actually occur, our business and financial results could be harmed. In that case, the trading price of our common stock could decline. You should also consider the more detailed description of our business contained in our 2023 Annual Report. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses over the last several years. As of June&#160;30, 2024, our accumulated deficit was $1.7 billion. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA medicine candidates or proprietary smart device technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently generate any revenue from the commercial sale of products. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our DNA medicine candidates, including securing regulatory approval for conducting clinical trials with DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">developing our proprietary device technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary device and DNA medicine candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our proprietary device and DNA medicine candidates as combination products before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of proprietary devices and DNA medicine products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts have accounted for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past we have derived a significant portion of our revenue from a limited number of licensing partners and government grants and contracts, and we expect that a significant portion of our revenue will continue to be derived from a limited number of licensing partners and/or government grants and contracts unless and until we are able to commercialize our product candidates. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our DNA medicine candidates and proprietary device technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the related costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility, particularly in light of geopolitical turmoil, inflation and rising interest rates, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Rising interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our proprietary devices and DNA medicine candidates, we will not be able to commercialize them in the United States. In particular, because our product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with developing and manufacturing a drug-device combination product. In addition, if the FDA and similar regulatory agencies do not provide marketing authorization for our CELLECTRA delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our proprietary device and DNA medicine candidates as combination products in the United States. If we fail to obtain FDA approval to market our proprietary device and DNA medicine candidates as combination products, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our combination products as well as the evaluation of our device design, manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our proprietary device and DNA medicine candidates are both safe and effective for each indication for which approval is sought. In determining what is needed to demonstrate the safety and effectiveness of a combination product, the FDA takes into account the questions and considerations, reflected in the statutory and regulatory provisions associated with each constituent part in the FDA&#8217;s review of the combination product as a whole and its constituent parts. This includes how the constituent parts may interact and interrelate and is a complex process. To the extent that our DNA medicine candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our proprietary device and any of our DNA medicine candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our proprietary device and DNA medicine candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our product candidates or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because our product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with developing and manufacturing a drug-device combination product. In addition, if the FDA and similar regulatory agencies do not provide marketing authorization for our delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device. Such delays or failure to obtain marketing authorization for our devices would result in significant harm to our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pursuing accelerated approval for INO-3107 or any of our other product candidates may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We plan to pursue accelerated approval for our product candidate INO-3107 and may in the future decide to pursue accelerated approval for one or more of our other product candidates. Under the FDA&#8217;s accelerated approval program, the FDA may approve a drug or biologic for a serious or life-threatening disease or condition that provides a meaningful advantage over </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">available therapies based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. For drugs or biologics granted accelerated approval, post-marketing confirmatory trials are required to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence, and the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we pursue accelerated approval for INO-3107 for the treatment or RRP, or a future product candidate for another disease or condition, we would do so on the basis that there is no available therapy for that disease or condition or that our product candidate provides a benefit over available therapy. If standard of care were to evolve or if any of our competitors were to receive full approval on the basis of a confirmatory trial for a drug or biologic for a disease or condition for which we are seeking accelerated approval before we receive accelerated approval, the disease or condition would no longer qualify as one for which there is no available therapy, and accelerated approval of our product candidate would not occur without a showing of benefit over available therapy. The treatment landscape can change quickly as the FDA converts accelerated approvals to full approvals on the basis of successful confirmatory trials. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have received feedback from the FDA that data from our completed Phase 1/2 clinical trial of INO-3107 for the treatment of RRP can be used to support the submission of a BLA for review under the accelerated approval program; however, whether any trial is sufficient to receive FDA approval under the accelerated approval pathway will depend on the safety and efficacy results of such trial and will only be determined by the FDA upon review of a submitted BLA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA may withdraw approval of INO-3107 or any future product candidate approved under the accelerated approval pathway if, for example:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the trial or trials required to verify the predicted clinical benefit of our product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with such product;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">we fail to conduct any required post-approval trial of our product candidate with due diligence; or</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">we disseminate false or misleading promotional materials relating to the relevant product candidate.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA may terminate the accelerated approval program or change the standards under which accelerated approvals are considered and granted in response to public pressure or other concerns regarding the accelerated approval program. Changes to or termination of the accelerated approval program could prevent or limit our ability to obtain accelerated approval of any of our clinical development programs. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States, and the same risk applies for products approved outside the United States, with respect to regulatory approval in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any proprietary device and DNA medicine candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval, and the regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Furthermore, regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our DNA medicine candidates may not be approved for all indications requested, which could limit the uses of our DNA medicine candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain, particularly when the clinical testing involves combination products such as ours. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and DNA medicine candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our proprietary device meets the standard of reasonable assurance of safety and effectiveness or that our product candidate is safe and effective for any indication; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of clinical or statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary device or DNA medicine candidates' clinical and other benefits outweigh their safety risks; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary device or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our DNA medicine candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or that of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulations or marketing authorization and approval policies of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for marketing authorization or approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third-party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our proprietary device and DNA medicine candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining Institutional Review Board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest, including geopolitical risks emanating from countries such as Russia and China, global pathogen outbreaks or pandemics, terrorist activities, the conflict between Israel and Hamas, bank failures and other economic and other external factors beyond our control.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to clinical trials of product candidates for rare diseases, such as our planned confirmatory trial of INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, we may encounter difficulties in recruiting a sufficient number of patients to enroll in the trial due to the small number of patients with the disease. Because RRP is caused by specific HPV types, 6 and 11, and there is currently no standard protocol for diagnostic/screening of RRP patients unless there are symptoms of dysphonia, respiratory distress or other symptoms related to the presence of papillomas, it may be difficult to identify and diagnose patients for whom INO-3107 may be a potential treatment.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our proprietary device and our DNA medicine candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our DNA medicines programs are in various stages of research and development, and currently include DNA medicine candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of DNA medicine candidates compared with conventional therapies, including vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our DNA medicine candidates. The success of our efforts to develop and commercialize our DNA medicine candidates could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our DNA medicine candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale, particularly given the complexity concerning the manufacturing of combination products, or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We previously expended significant resources on the development of a COVID-19 vaccine candidate. We are now only pursuing development in collaboration with third parties, as both a primary and heterologous booster vaccine, but there can be no assurance that our candidate will ever receive regulatory approval as a primary vaccine or a booster in any country, whether by Emergency Use Authorization or otherwise.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, we expended significant resources on the clinical development of a COVID-19 vaccine candidate, INO-4800. We were previously conducting a Phase 2/3 clinical trial of INO-4800 called INNOVATE. Based on regulatory feedback and the competitive landscape for COVID-19 vaccines, in 2022 we discontinued the INNOVATE trial and pursued a strategy to develop our COVID-19 vaccine as a potential heterologous booster following administration of other primary vaccines. Following an assessment of the current global demand for COVID-19 vaccines, changes in regulatory timelines and requirements, diminishing government financial support, and the overall growing uncertainty related to opportunities for heterologous booster vaccines, in the fourth quarter of 2022 we discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are no longer conducting any active clinical trials of INO-4800 and do not expect that it will ever receive regulatory approval in the United States. Our collaborator Advaccine has completed enrollment of its 200-participant homologous and 267-participant heterologous booster vaccine trials in China. They may seek an Emergency Use Authorization, or EUA, from regulatory authorities in China and other countries in Asia for the use of INO-4800 as a heterologous booster. However, any such decision would be made by Advaccine, and there is no guarantee that Advaccine will apply for an EUA or other similar authorization or, if it does apply, that Advaccine will be able to obtain such authorization. An EUA may not be available if countries are no longer in a state of public health emergency, in which case full approval would need to be sought. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We await the results of our COVID-19 vaccine candidate's participation in the World Health Organization&#8217;s Solidarity Trial Vaccines. Depending on the results of that trial, we could also pursue a strategy of seeking EUA for the vaccine candidate in other countries outside of the United States. Even if an EUA or other authorization is ultimately granted, we will rely on the applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our vaccine candidate. If these policies and guidance change unexpectedly and/or materially or if we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">misinterpret them, potential sales of our product could be adversely impacted. Regulatory authorities may also terminate an EUA if safety issues or other concerns about our product arise or if we or Advaccine fail to comply with the conditions of authorization. If we or Advaccine apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our and Advaccine&#8217;s ability to market and sell our COVID-19 vaccine.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA delivery devices are a novel approach to administering medicines, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop or our devices could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No DNA medicines have been granted EUA or have been approved to date by the FDA. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of DNA medicine, or other products that are perceived to be similar to DNA medicines, such as those related to other nucleic acid based vaccines such as mRNA vaccines, gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our pipeline of DNA medicine candidates could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by U.S., state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, even if our product candidates receive regulatory approval from the FDA and similar regulatory agencies, the novelty of our CELLECTRA delivery devices may make it difficult to demonstrate to physicians and third-party payors that this delivery system is an appropriate approach for DNA medicines and provides advantages compared to the current standards of care. Further, if we or our commercialization and collaboration partners are not successful in conveying to physicians, patients and third-party payors that our CELLECTRA delivery devices provide useful patient outcomes, we or our commercialization and collaboration partners may experience reluctance, or refusal, on the part of physicians to order and use, and third-party payors to cover and provide adequate reimbursement for, our DNA medicines. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our proprietary devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary device and DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We manufacture some components of our proprietary devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our DNA medicine candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our DNA medicine candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls that meet the relevant current good manufacturing practice (cGMP) requirements for combination products. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and DNA medicine candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our proprietary device to our partners and to supply DNA medicine candidates for clinical trials or to commercially launch a product would be jeopardized. For example, as part of the testing process required for BLA submission for INO-3107, we recently identified a manufacturing issue in the single use administration component of our CELLECTRA 5PSP device that we are working to resolve. However, the timeline on which we expect to be able to commence our confirmatory trial and submit our BLA for INO-3107 has been delayed as a result. There can be no assurance we will be able to rectify this manufacturing issue on the timeline we expect or at all or that we will not identify additional issues with our device that could further delay our planned regulatory submission or impair our ability to receive regulatory approval.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we previously relied on VGXI to manufacture DNA plasmids for our DNA medicine candidates before they became unable to produce the necessary plasmids due to a lack of manufacturing capacity. As a result, we had to engage several additional third-party contract manufacturers. However, there can be no assurance that we will be able to secure adequate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional manufacturing capacity for any of our DNA medicine candidates on commercially reasonable terms. Our inability to secure sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for our DNA medicine candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to pass preapproval inspection of our manufacturing facilities and obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the quality system regulations, and any amendments thereto, or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our proprietary device and DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our proprietary device and DNA medicine candidates. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that may not be interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes, and finished goods exposes us to several risks, including disruptions in supply, price increases, or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our product candidates or investigational medicines, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to supply our investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our reliance on these suppliers, service providers, and manufacturers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays to the development timelines for our development candidates or investigational medicines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a lack of long-term supply arrangements for key components with our suppliers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">damage to our reputation caused by defective components produced by our suppliers; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if FDA regulatory approval is obtained, regulators may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and devices and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our DNA medicine candidates, or the manufacturing facilities for our DNA medicine candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate injunction actions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing some of our investigational DNA medicines using new endpoints or methodologies for the treatment of diseases in which there is little clinical experience. As a result, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. There has been limited clinical trial experience for the development of pharmaceuticals to treat these rare diseases in general, and we are not aware of a registrational trial that led to approval of a drug to treat these diseases. There have been some historical trials with other agents which may have utilized clinical endpoints that are less applicable to our efforts that address the underlying defect. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. For example, our product candidate INO-3107 is being developed for RRP, a rare condition for which there are no approved non-surgical treatments. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have obtained Orphan Drug Designation for one of our DNA medicine candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional DNA medicine candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of RRP. We have sought and may continue to seek Orphan Drug Designation for one or more of our other DNA medicine candidates, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of RRP, and even if we obtain Orphan Drug Designation for our other DNA medicine candidates in specific indications, we may not be the first to obtain marketing approval of these DNA medicine candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our DNA medicine candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our DNA medicine candidates, we may never receive such designations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have received breakthrough therapy designation for INO-3107 and may seek this designation for one or more of our other investigational medicines. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the regulatory submission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our investigational medicines meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. Even if we are successful in obtaining accelerated approval in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval of the drug may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">be withdrawn. In addition, even if one or more of our investigational medicines qualify as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our DNA medicine candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to strategically enter into agreements with other organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate, implement and execute a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies that are subject to termination and uncertain future funding. Termination or cessation of funding would have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases (NIH NIAID), Defense Advanced Research Projects Agency (DARPA), Medical CBRN Defense Consortium (MCDC) and the Department of Defense (DoD) Joint Program Executive Office (JPEO) for Chemical, Biological, Radiological and Nuclear Defense (CBRN), and we intend to continue entering into these types of agreements with government agencies in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in 2021 the DoD discontinued funding for the planned Phase 3 trial of our COVID-19 product candidate, which resulted in increased expenditures by us.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our DNA medicine candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our proprietary device and DNA medicine candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our DNA medicine candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our DNA medicine candidates. As a result, our financial results and the commercial prospects for our DNA medicine candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">agree to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically agree to indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sub licensees&#8217; exercise of rights under the agreement. With respect to our commercial agreements, we have agreed to indemnify our vendors from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we typically agree to indemnify them from claims arising from the good faith performance of their services.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage or not covered by insurance, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator or other third party to indemnify us and the collaborator or other third party is denied insurance coverage or otherwise does not have assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our DNA Medicine Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have only a small marketing organization and no sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, if approved, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have only a small commercial organization to support pre-commercial activities for our proprietary device and DNA medicine candidates, if approved, and we do not currently have a sales organization. In order to successfully commercialize INO-3107 or any other products that may receive regulatory approval, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of a sales force, either on our own or in conjunction with third parties, will be expensive and time-consuming and could delay any product launch, and we may not be able to successfully develop or acquire this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In the event we are unable to successfully develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our DNA medicine candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our proprietary device and DNA medicine candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and patient population. Coverage and reimbursement of our DNA medicine candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration, including the acceptance and usage of our proprietary device by the medical community; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential public perception of new therapies and the reputational challenges that the industry is facing related to drug costs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our proprietary device and DNA medicine candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our DNA medicine candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our DNA medicine candidates, could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our proprietary device and DNA medicine candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our DNA medicine candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors in the United States generally require that drug products and vaccines have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, co-payments may be required that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products. Even if we obtain coverage for our products, the revenue generated may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our DNA medicine candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our DNA medicine candidates or procedures using our DNA medicine candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may be harmed if our corporate restructuring plans and cost reduction efforts do not achieve the anticipated results or cause undesirable consequences.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between July 2022 and January 2023, we undertook a corporate restructuring that resulted in a total reduction in headcount of more than 25% of our employees and a significant majority of our contractors. In August 2023 we announced a further headcount reduction of approximately 30%. As a result, our full-time employee headcount has declined from more than 300 employees in early 2022 to approximately 127 currently.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring plans may yield unintended consequences, such as attrition beyond our intended reduction in workforce and reduced employee morale, which may cause our employees who were not affected by the reduction in workforce to seek alternate employment. During the second half of 2022, we experienced increased voluntary attrition after conducting the first reduction in force. Additional attrition could impede our ability to meet our operational goals, which could have a material adverse effect on our financial performance. In addition, as a result of the reductions in our workforce, we may face an increased risk of employment litigation. </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, employees whose positions have been or will be eliminated in connection with these restructuring plans may seek future employment with our competitors. Although all our employees are required to sign a confidentiality agreement with us at the time of hire, we cannot be certain that the confidential nature of our proprietary information will be maintained in the course of such future employment. We cannot be certain that any of our restructuring efforts will be successful, or that we will be able to realize the cost savings and other anticipated benefits from our current or any future restructuring plans. In addition, if we continue to reduce our workforce, it may adversely impact our ability to respond rapidly to any new growth or revenue opportunities. Any restructuring activities we undertake may take longer than expected and may require changes to our business that we are unable to implement. If we are unsuccessful in implementing our cost saving initiatives and restructuring plans or if we do not achieve our expected results, our results of operations and cash flows could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, numerous purported shareholder class action and shareholder derivative complaints were filed against us beginning in 2020, naming us and our directors and executive officers as defendants, alleging that we made materially false and misleading statements in violation of federal securities laws. Although we have resolved these actions, there can be no guarantee that we will not become subject to similar claims in the future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. There can be no assurance that we will ultimately prevail in the ongoing litigation matters described in this report or in future litigation matters. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our DNA medicine candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and DNA medicine candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, in 2020 a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines were negatively impacted. Similar events could result in future business and manufacturing disruption, or in reduced operations, any of which would materially affect our business, financial condition and results of operations. The COVID-19 pandemic also caused supply chain disruptions and supply shortages globally. As a result, we experienced delays and disruptions in obtaining clinical supplies, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing supplies and components, and had to secure new vendors for certain supplies and components at higher prices. There can be no assurance that we will not encounter similar difficulties in the future.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future health epidemics could adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain participants and principal investigators and site staff who, as healthcare providers, may have heightened exposure if an outbreak occurs in their geography. Trial participants may not be able to or may not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for our clinical trials. Further, future epidemics could also result in delays in our clinical trials due to prioritization of hospital resources toward the disease, restrictions in travel, potential unwillingness of participants to enroll in trials, participants withdrawing from trials following enrollment as a result of contracting disease or other health conditions. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and steps taken by our competitors such as the introduction of a new, disruptive technology may impede our ability to develop and commercialize our DNA medicines. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates and introduce new, disruptive technology, we may not be able to complete the development of or commercialize our product candidates, and sales of any commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or product candidates obsolete or non-competitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors and potential competitors include large pharmaceutical companies broadly engaged in vaccine/immunotherapy research and development, such as Janssen Pharmaceuticals (part of J&amp;J), Sanofi-Aventis, GlaxoSmithKline, Merck, Pfizer, Roche, AbbVie, Novartis, Bristol-Myers Squibb, and AstraZeneca, as well as various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies, such as CureVac, Dynavax, Genexine, Hookipa, Iovance, Nektar, Nykode, Precigen, Zydus, and Vir Biotechnology. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low-grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is a surgical procedure and is the current standard of care in the United States and other high income countries for treating high-grade cervical dysplasia. In RRP caused by HPV subtypes 6 and 11, Precigen is developing a potential treatment for RRP based on a gorilla adenovirus vector and has publicly stated its plans to submit a BLA in 2024 based on a completed Phase 1/2 study. As a result, Precigen could receive marketing approval for its RRP product candidate before we can obtain regulatory approval for INO-3107, which could put us at a competitive disadvantage in this indication. Advaxis, Genexine, and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to pre-cancers and cancers we are targeting.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen production and immune responses to prevent or treat various diseases. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small biotechnology companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or those of third parties upon which we rely or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to, regulatory investigations and actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue and profits; and other adverse consequences.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential, proprietary or otherwise sensitive information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls designed to maintain the confidentiality, availability and integrity of such information as appropriate. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the compromise of information stored in our or our third-party providers' systems, portable media or storage devices. Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities threaten our information and information technology systems and those of third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect and come from a variety of sources such as traditional computer &#8220;hackers,&#8221; threat actors, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through error or malfeasance), sophisticated national states and nation-state support actors (for example, in conjunction with military conflicts). During times of war and other major conflicts, we may be vulnerable to a heightened risk of these attacks. We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to: business interruption, loss of information, theft of information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), social-engineering attacks (including through deep fakes and phishing attacks), malicious code (such as viruses and worms), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, telecommunications failures, natural disasters, and other similar threats, any of which may compromise our system infrastructure or lead to data compromise. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of data, reputational harm and diversion of funds. Extortion payments may alleviate some of the negative impact of a ransomware attack but we may be unwilling or unable to make such payments. Remote work has also become more common and increased risks to our information technology systems and data. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities as our systems could be negatively affected by vulnerabilities resent in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during diligence of such acquired or integrated entities and it may be difficult to integrate such entities into our programs. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on service providers and third-party technologies to operate critical business systems to process sensitive information in a variety of contexts, including without limitation, cloud-based infrastructure, personnel email, data hosting, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited and these service providers may not have adequate information security measures in place. If our service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our service providers fail to satisfy their privacy or security-related obligations to us, any aware may be insufficient or we may be unable to recover such award.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented measures designed to protect our data and information technology systems, there can be no assurance that our efforts will be effective (including, without limitation prevent service interruptions or security incidents). We take steps designed to detect, mitigate and remediate vulnerabilities in our information systems (such as our hardware and software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities on a timely or effective basis. Vulnerabilities could be exploited and result in a security incident. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific or reasonable security measures.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, regulators, and other stakeholders of security incidents.  Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our proprietary device and DNA medicine candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. The ACA, among other things, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts (increased to 70 percent, effective as of January 1, 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected expanded the types of entities eligible for the 340B drug discount program; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive, judicial, and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage was eliminated, along with the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011 included reductions to Medicare payments to providers of 2% per fiscal year, which, due to subsequent legislative amendments to the statute will remain in effect until 2032, unless Congressional action is taken. The American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methodologies for products. For example, at the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Health Insurance Portability and Accountability Act (HIPAA), which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and related regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Food, Drug and Cosmetic Act (FDCA), which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our DNA medicine candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and rely on clinical materials manufactured in China for our development efforts. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a license and collaboration agreement with a China-based company, ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Because Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, China's "zero COVID" policy caused delays in Advaccine&#8217;s conduct of clinical trials for INO-4800 in China </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our collaboration with them, which in turn resulted in delays in obtaining clinical data to evaluate the safety and potential efficacy of INO-4800. In addition, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on ApolloBio or Advaccine, which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, including the threat of a trade war between the United States and China, could lead to supply chain disruptions or increased costs for clinical materials manufactured in China that are necessary for our development efforts. These interruptions or failures could then impede commercialization of our DNA medicine candidates and impair our competitive position. We may also be exposed to fluctuations in the value of the local currency in China. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions; provide accurate information to the FDA, the EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee litigation and unfavorable publicity could negatively affect our future business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our proprietary device and DNA medicine candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governments in the United States or abroad may prevent us from enforcing patents on our vaccines, which could prevent us from excluding competitors from those markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our DNA medicine candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Capital Market, we cannot be certain that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, which are not exhaustive, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for our vaccines or other DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceptions of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">global unrest including geopolitical risks emanating from countries such as Russia and China, terrorist activities, the conflict between Israel and Hamas, bank failures, and other economic and other external factors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general can experience relatively large price and volume fluctuations from time to time. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our cash, cash equivalents, and investments, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. For example, our operating expenses increased significantly from 2020 to 2022 due to development and manufacturing activities for our COVID-19 vaccine program, for which we discontinued internal funding in the fourth quarter of 2022. We may not deploy our current capital resources effectively. The failure by our management to apply our funds effectively could result in financial losses that could have a material adverse impact on our business, cause the price of our common stock to decline, and delay the development of our product candidates. Pending their use, we may invest our cash, cash equivalents, and investments in a manner that does not produce income or that loses value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the revised Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain significant shareholders over a rolling three year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our share ownership, some of which would be outside our control. If our ability to use our net operating losses and other tax attributes is limited by ownership changes, we may be unable to utilize a material portion of our net operating losses and other tax attributes to offset our future taxable income. In addition, there is also a risk that due to changes </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in laws and regulations, such as alternative minimum taxes or suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our proprietary device, DNA medicine candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our proprietary device and DNA medicine candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our DNA medicine candidates receive regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, rising interest rates, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in 2023, several banking institutions were closed or seized by the Federal Deposit Insurance Corporation, leading to significant liquidity concerns in the broader financial services industry. </span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we did not have any deposits at any of the banks impacted by the adverse developments in 2023, we maintain deposits at financial institutions as a part of doing business that could be at risk if another similar event were to occur. Our ongoing cash management strategy is to maintain the majority of our deposit accounts in large financial institutions, but there can be no assurance this strategy will be successful. Increasing concerns regarding the U.S. or international financial systems, including bank failures and bailouts, and their potential broader effects and potential systemic risk on the banking sector generally, may adversely affect our access to capital. Any decline in available funding or access to our cash and liquidity resources could, among other risks, limit our ability to meet our capital needs and fund future growth or fulfill our other obligations, or result in breaches of our financial and/or contractual obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. In 2017, tax legislation commonly known as the Tax Cuts and Jobs Act, or Tax Act, was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The Tax Act, among other things, resulted in significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). It is uncertain if and to what extent various states will conform to the federal tax law. The issuance of additional regulatory or accounting guidance related to the Tax Act, or legislative changes proposed or implemented, could materially affect our tax obligations and effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, participants may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.  Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, and financial information (collectively, sensitive data).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws).  In the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), applies to personal data of consumers, business representatives, and employees who are California residents, and requires certain businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages.  Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security.  For example, the European Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal data. For example, under GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows.  Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries.  In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate.  Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.  Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.  If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.  Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups.  Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups.  We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.  We publish privacy policies, marketing materials, and other statements regarding data privacy and security.  If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty.  Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions.  Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations.  Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations.  If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data.  In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands.  Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations.  Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.  </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_148"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) <ix:nonNumeric contextRef="c-9" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-805"><ix:nonNumeric contextRef="c-9" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-806">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-9" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-807"><ix:nonNumeric contextRef="c-9" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-808">terminated</ix:nonNumeric></ix:nonNumeric> any contracts, instructions or written plans for the purchase or sale of our securities.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2024, we provided notice to BofA Securities, Inc., RBC Capital Markets, LLC and Oppenheimer &amp; Co. Inc. to terminate the 2021 Sales Agreement described in Part I, Item 2 of this report. We sold an aggregate of 4,289,403 shares of our common stock pursuant to the 2021 Sales Agreement for net proceeds of $93.6 million.</span></div><div style="text-indent:27pt"><span><br/></span></div><div id="iddea4a5604314afc969e1f7c0aef53d6_151"></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iddea4a5604314afc969e1f7c0aef53d6_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments prior to December 31, 2023 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s registration statement on Form S-3, filed on July 23, 2014).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000119312524015380/d736726d8k.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000119312524015380/d736726d8k.htm">Certificate of Amendment to Certificate of Incorporation, effective as of January 24, 2024 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s current report on Form 8-K filed on January 25, 2024).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August 10, 2011 (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s current report on Form 8-K filed on August 12, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000119312524099067/d817715d8k.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000119312524099067/d817715d8k.htm">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Current Report on Form 8-K filed on April 17, 2024).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63024x10qex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63024x10qex311.htm">Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-6302410qex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-6302410qex312.htm">Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63024x10qex321.htm">32.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63024x10qex321.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.&#160;Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).*</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page formatted as Inline XBRL and contained in Exhibit 101.</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.906%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. </span></div><div style="margin-top:7.5pt;padding-left:11.25pt;text-indent:-11.25pt"><span><br/></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="iddea4a5604314afc969e1f7c0aef53d6_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:4.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JACQUELINE E. SHEA&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline E. Shea</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ino-63024x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ied545be7e0584b24aabb134b1ee5e732_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jacqueline E. Shea, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:5pt;margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;JACQUELINE E. SHEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                       (Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ino-6302410qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i46dc3c31ff0449b4a179041be740f00e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-top:9pt;padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer                                                                    (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ino-63024x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibac8bd6bc4054758a226939383971aa1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ending June&#160;30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;JACQUELINE E. SHEA</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and is not filed with the Securities and Exchange Commission as part of the Form&#160;10-Q or as a separate disclosure document and is not incorporated by reference into any filing of Inovio Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ino-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0d8c4537-ca52-4f1a-a8a1-280952f330d4,g:ffaafe34-d428-4f21-bdf4-6dece8c876eb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20240630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20240630">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.inovio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>9952152 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsParenthetical" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952157 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://www.inovio.com/role/OrganizationandOperations">
        <link:definition>9952158 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertainties" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties">
        <link:definition>9952159 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPolicies" roleURI="http://www.inovio.com/role/CriticalAccountingPolicies">
        <link:definition>9952160 - Disclosure - Critical Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurements" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements">
        <link:definition>9952161 - Disclosure - Short-term Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItems" roleURI="http://www.inovio.com/role/CertainBalanceSheetItems">
        <link:definition>9952162 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>9952163 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>9952164 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.inovio.com/role/NetLossPerShare">
        <link:definition>9952165 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.inovio.com/role/StockBasedCompensation">
        <link:definition>9952166 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>9952167 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.inovio.com/role/CommitmentsandContingencies">
        <link:definition>9952168 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>9952169 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>9952170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>9952171 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies">
        <link:definition>9954471 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables">
        <link:definition>9954472 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables">
        <link:definition>9954473 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>9954474 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.inovio.com/role/NetLossPerShareTables">
        <link:definition>9954475 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.inovio.com/role/StockBasedCompensationTables">
        <link:definition>9954476 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables">
        <link:definition>9954477 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesDetails" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
        <link:definition>9954478 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>9954479 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>9954480 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9954481 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails">
        <link:definition>9954482 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails">
        <link:definition>9954483 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtDetails">
        <link:definition>9954484 - Disclosure - Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
        <link:definition>9954485 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9954486 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9954487 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntidilutiveDetails" roleURI="http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails">
        <link:definition>9954488 - Disclosure - Net Loss Per Share - Anti-dilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>9954489 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9954490 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails">
        <link:definition>9954491 - Disclosure - Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9954492 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>9954493 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails">
        <link:definition>9954494 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>9954495 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDetails">
        <link:definition>9954496 - Disclosure - Geneos Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateCurrent" abstract="false" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonCashInterestIncomeExpense" abstract="false" name="NonCashInterestIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" abstract="false" name="ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CertainBalanceSheetItemsAbstract" abstract="true" name="CertainBalanceSheetItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_UnderwrittenRegisteredDirectOfferingMember" abstract="true" name="UnderwrittenRegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_PrepaidClinicalExpensesCurrent" abstract="false" name="PrepaidClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesTable" abstract="true" name="AccountsPayableAndAccruedExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesLineItems" abstract="true" name="AccountsPayableAndAccruedExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_PrepaidManufacturingExpenseCurrent" abstract="false" name="PrepaidManufacturingExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantLiability" abstract="false" name="GrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2021SalesAgreementMember" abstract="true" name="A2021SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" abstract="true" name="McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2023IncentivePlanMember" abstract="true" name="A2023IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2022InducementPlanMember" abstract="true" name="A2022InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" abstract="false" name="ClassOfWarrantOrRightCommonStockOwnershipPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" abstract="false" name="SaleOfStockSalesProceedsOfAnyCommonStockPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LitigationSettlementAmountAwardedToOtherPartyShares" abstract="false" name="LitigationSettlementAmountAwardedToOtherPartyShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_WeightedAverageNumberOfSharesOutstanding" abstract="false" name="WeightedAverageNumberOfSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" abstract="false" name="IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_RestrictedStockUnitsRSUsMilestoneBasedMember" abstract="true" name="RestrictedStockUnitsRSUsMilestoneBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_RestrictedStockUnitsRSUsMarketBasedMember" abstract="true" name="RestrictedStockUnitsRSUsMarketBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" abstract="true" name="RestrictedStockUnitsRSUsTotalShareholderReturnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAmendedAmount" abstract="false" name="CollaborativeAgreementAmendedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SanDiegoOfficeMember" abstract="true" name="SanDiegoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_SanDiegoCaliforniaMember" abstract="true" name="SanDiegoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_BehestiVKimEtAlMember" abstract="true" name="BehestiVKimEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" abstract="false" name="LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" abstract="false" name="LesseeOperatingLeaseNumberOfAgreementsToSublease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_LossContingencyEstimateOfPossibleLossValueOfShares" abstract="false" name="LossContingencyEstimateOfPossibleLossValueOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AdvaccineMember" abstract="true" name="AdvaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_INO4800Member" abstract="true" name="INO4800Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" abstract="true" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingReceived" abstract="false" name="CollaborativeAgreementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_SeriesAOnePreferredStockMember" abstract="true" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_SeriesA2OnePreferredStockMember" abstract="true" name="SeriesA2OnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" abstract="false" name="IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ino-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0d8c4537-ca52-4f1a-a8a1-280952f330d4,g:ffaafe34-d428-4f21-bdf4-6dece8c876eb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_903e7c98-5c30-43a5-88ca-7121f204b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8c10a742-3513-45cc-8fe3-b90ba52db6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_903e7c98-5c30-43a5-88ca-7121f204b7a5" xlink:to="loc_us-gaap_PreferredStockValue_8c10a742-3513-45cc-8fe3-b90ba52db6e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_aee664d7-275a-48a8-8fd9-40df05e55d89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_903e7c98-5c30-43a5-88ca-7121f204b7a5" xlink:to="loc_us-gaap_CommonStockValue_aee664d7-275a-48a8-8fd9-40df05e55d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_74ca3a18-2f8b-4ec2-81f7-29d7ac5f85a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_903e7c98-5c30-43a5-88ca-7121f204b7a5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_74ca3a18-2f8b-4ec2-81f7-29d7ac5f85a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c7446aa3-1229-4801-a60b-b219d36adc10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_903e7c98-5c30-43a5-88ca-7121f204b7a5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c7446aa3-1229-4801-a60b-b219d36adc10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36e477f5-772f-4623-914a-ebfa713ea46b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_903e7c98-5c30-43a5-88ca-7121f204b7a5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36e477f5-772f-4623-914a-ebfa713ea46b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2cc4068e-6fbd-4e29-8b4f-d9e40102d8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cd7615c4-0dde-419b-856a-a760bf222ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2cc4068e-6fbd-4e29-8b4f-d9e40102d8f8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cd7615c4-0dde-419b-856a-a760bf222ac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0f7e3b25-c901-4519-a1c5-fe77f73a9830" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2cc4068e-6fbd-4e29-8b4f-d9e40102d8f8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0f7e3b25-c901-4519-a1c5-fe77f73a9830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_85a27394-203b-4427-a132-f88b96bc95e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2cc4068e-6fbd-4e29-8b4f-d9e40102d8f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_85a27394-203b-4427-a132-f88b96bc95e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c6ba8fc1-f0e8-41c5-b2f4-321c5343a7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2cc4068e-6fbd-4e29-8b4f-d9e40102d8f8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c6ba8fc1-f0e8-41c5-b2f4-321c5343a7ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_26e35db9-a88f-45c6-af0c-daec494670e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2cc4068e-6fbd-4e29-8b4f-d9e40102d8f8" xlink:to="loc_us-gaap_AssetsCurrent_26e35db9-a88f-45c6-af0c-daec494670e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9ce2260b-c691-4605-b87f-2409569b8427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_24c967d8-b462-4829-a4f7-80538e69bace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9ce2260b-c691-4605-b87f-2409569b8427" xlink:to="loc_us-gaap_LiabilitiesCurrent_24c967d8-b462-4829-a4f7-80538e69bace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ab5d4338-3bab-4ab4-b0e1-a15fa37ef12f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9ce2260b-c691-4605-b87f-2409569b8427" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ab5d4338-3bab-4ab4-b0e1-a15fa37ef12f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_da177778-feda-4001-a904-7a97610918f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_60f3a4de-b92d-42ff-9646-f02b4008864c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_da177778-feda-4001-a904-7a97610918f8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_60f3a4de-b92d-42ff-9646-f02b4008864c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_bfa5f4f5-0645-4845-a61e-5c1654031f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_da177778-feda-4001-a904-7a97610918f8" xlink:to="loc_us-gaap_ShortTermInvestments_bfa5f4f5-0645-4845-a61e-5c1654031f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_61e4eeef-3a93-4b65-b64e-f7873bcf69ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_da177778-feda-4001-a904-7a97610918f8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_61e4eeef-3a93-4b65-b64e-f7873bcf69ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c8215d12-1aae-468b-95e4-7bab7f6a6794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_da177778-feda-4001-a904-7a97610918f8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c8215d12-1aae-468b-95e4-7bab7f6a6794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_c6d1f681-1d6f-4293-854e-85f5f7ff7fb8" xlink:href="ino-20240630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_da177778-feda-4001-a904-7a97610918f8" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_c6d1f681-1d6f-4293-854e-85f5f7ff7fb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc0f3018-c2f9-4213-93eb-510280e3381d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b031b118-a4cf-4508-b485-b9690b1318a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc0f3018-c2f9-4213-93eb-510280e3381d" xlink:to="loc_us-gaap_Liabilities_b031b118-a4cf-4508-b485-b9690b1318a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a9fbebaa-bae6-499f-9292-8a328ba7213a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc0f3018-c2f9-4213-93eb-510280e3381d" xlink:to="loc_us-gaap_StockholdersEquity_a9fbebaa-bae6-499f-9292-8a328ba7213a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_21525502-148a-4094-8e2d-6694ef7e05b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b64dcd9c-84a6-4d81-aeb3-1aaae10dcb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21525502-148a-4094-8e2d-6694ef7e05b8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b64dcd9c-84a6-4d81-aeb3-1aaae10dcb7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_a2dfcf84-d5da-4d09-9878-214de95a9243" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21525502-148a-4094-8e2d-6694ef7e05b8" xlink:to="loc_ino_DeferredGrantFundingCurrent_a2dfcf84-d5da-4d09-9878-214de95a9243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_a03985d4-e714-406b-a26d-22ea3e021c70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21525502-148a-4094-8e2d-6694ef7e05b8" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_a03985d4-e714-406b-a26d-22ea3e021c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_21d4b272-1970-4323-b45f-60628935493e" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21525502-148a-4094-8e2d-6694ef7e05b8" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_21d4b272-1970-4323-b45f-60628935493e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c09dc99-ef70-4d99-8c6f-4c18b11b7984" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21525502-148a-4094-8e2d-6694ef7e05b8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c09dc99-ef70-4d99-8c6f-4c18b11b7984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_8d622676-4c08-4601-a3c5-9b31a05bf8c3" xlink:href="ino-20240630.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21525502-148a-4094-8e2d-6694ef7e05b8" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_8d622676-4c08-4601-a3c5-9b31a05bf8c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_20289be5-d519-4b0d-9d8d-ece15b983092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_df75fc76-62b2-4606-b5e7-e687b670fc99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_20289be5-d519-4b0d-9d8d-ece15b983092" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_df75fc76-62b2-4606-b5e7-e687b670fc99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b3b4db90-057a-4dcc-ab4d-2752bbe725f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_20289be5-d519-4b0d-9d8d-ece15b983092" xlink:to="loc_us-gaap_OperatingExpenses_b3b4db90-057a-4dcc-ab4d-2752bbe725f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bce5a933-a948-4f03-aeca-7435aac8699c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0b9f8de1-7aa1-471a-a500-2a0ea2f35c82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_bce5a933-a948-4f03-aeca-7435aac8699c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0b9f8de1-7aa1-471a-a500-2a0ea2f35c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5c17ffc2-1db0-4095-9949-2cf3548fc25c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_bce5a933-a948-4f03-aeca-7435aac8699c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5c17ffc2-1db0-4095-9949-2cf3548fc25c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3107815d-4b8d-4ad9-94ab-2b994390fe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7dcd0581-49d0-48f5-a2eb-477a45d28bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3107815d-4b8d-4ad9-94ab-2b994390fe3b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7dcd0581-49d0-48f5-a2eb-477a45d28bb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_6415eca3-2747-4393-b1c7-5fb6c9e725b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3107815d-4b8d-4ad9-94ab-2b994390fe3b" xlink:to="loc_us-gaap_InterestIncomeOperating_6415eca3-2747-4393-b1c7-5fb6c9e725b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_3e388b70-accb-4a2b-b297-477c648a1de8" xlink:href="ino-20240630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3107815d-4b8d-4ad9-94ab-2b994390fe3b" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_3e388b70-accb-4a2b-b297-477c648a1de8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e60660b2-41c2-4ed6-95e9-4cb6d35fabaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3107815d-4b8d-4ad9-94ab-2b994390fe3b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e60660b2-41c2-4ed6-95e9-4cb6d35fabaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5eef5e25-8bc2-4837-8488-6a87ee88ebaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3107815d-4b8d-4ad9-94ab-2b994390fe3b" xlink:to="loc_us-gaap_OperatingIncomeLoss_5eef5e25-8bc2-4837-8488-6a87ee88ebaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating_344988e3-4e34-4964-8012-6792a9bf6a01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3107815d-4b8d-4ad9-94ab-2b994390fe3b" xlink:to="loc_us-gaap_InterestExpenseOperating_344988e3-4e34-4964-8012-6792a9bf6a01" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3fd4ab3c-52ff-4bc0-bf5a-5153213303be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7cd10274-18cb-4b44-8edd-3aef6032f70b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3fd4ab3c-52ff-4bc0-bf5a-5153213303be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7cd10274-18cb-4b44-8edd-3aef6032f70b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_51d7b37d-c7a2-4b68-a198-b467ae2a13af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3fd4ab3c-52ff-4bc0-bf5a-5153213303be" xlink:to="loc_us-gaap_NetIncomeLoss_51d7b37d-c7a2-4b68-a198-b467ae2a13af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_82ffe69d-4183-4b52-905e-d8c753e19089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3fd4ab3c-52ff-4bc0-bf5a-5153213303be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_82ffe69d-4183-4b52-905e-d8c753e19089" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2817ff91-1423-4f94-b2f3-f773300c2b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_Depreciation_2817ff91-1423-4f94-b2f3-f773300c2b1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_76e71450-090d-4620-9f2f-6879fd1d415a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_76e71450-090d-4620-9f2f-6879fd1d415a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_d34ad779-abb9-4db0-8cff-2d0a4a7f2c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_d34ad779-abb9-4db0-8cff-2d0a4a7f2c2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a7706058-ec29-4b91-bb23-b0d7126b3af6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a7706058-ec29-4b91-bb23-b0d7126b3af6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_076a4271-e31d-4ec3-b0f7-e347ac01c976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_076a4271-e31d-4ec3-b0f7-e347ac01c976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_c07d8cfa-9445-4c97-9834-bed6b949b1a3" xlink:href="ino-20240630.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_c07d8cfa-9445-4c97-9834-bed6b949b1a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_989938b9-b157-4ac1-9898-29713b97a8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_989938b9-b157-4ac1-9898-29713b97a8dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_3f9aa3b6-a860-4ab4-9f8d-615ae20879f3" xlink:href="ino-20240630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_3f9aa3b6-a860-4ab4-9f8d-615ae20879f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e85d7929-7af4-40e0-aa80-72b0bf755dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e85d7929-7af4-40e0-aa80-72b0bf755dbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_d7622e9a-812c-4841-8d01-2a26ff14f5d7" xlink:href="ino-20240630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_d7622e9a-812c-4841-8d01-2a26ff14f5d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5845d1f4-b4de-452c-9ed3-6037e3a19658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_NetIncomeLoss_5845d1f4-b4de-452c-9ed3-6037e3a19658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_998e4972-7177-4203-89cf-5428adbc7805" xlink:href="ino-20240630.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_ino_NonCashInterestIncomeExpense_998e4972-7177-4203-89cf-5428adbc7805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_02128e7f-4238-4c6f-99fc-a36693b52712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_02128e7f-4238-4c6f-99fc-a36693b52712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_749669fd-149c-4ada-aa5e-e0041699854b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_749669fd-149c-4ada-aa5e-e0041699854b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a31b4ce8-6826-4e22-b227-3dcded7d4f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a31b4ce8-6826-4e22-b227-3dcded7d4f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_34e66685-1985-4eee-b0d8-aa1a19ce9395" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_34e66685-1985-4eee-b0d8-aa1a19ce9395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_72279408-5973-4709-9e92-d328d87d6971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_ShareBasedCompensation_72279408-5973-4709-9e92-d328d87d6971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_57555930-034c-4760-b45c-1dd4e78c395d" xlink:href="ino-20240630.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_57555930-034c-4760-b45c-1dd4e78c395d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0e19ead2-7476-4a8f-9df2-235766797bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25be1e8-3c2c-45d7-bfb9-7da67e244f02" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0e19ead2-7476-4a8f-9df2-235766797bcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a9f20c7-1782-4972-a851-bbafc95fb8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0edd7b73-cab9-4d63-a4e1-9856c7018b74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a9f20c7-1782-4972-a851-bbafc95fb8d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0edd7b73-cab9-4d63-a4e1-9856c7018b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ab52982f-75bf-4c7c-a5d1-8d48dcc3353c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a9f20c7-1782-4972-a851-bbafc95fb8d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ab52982f-75bf-4c7c-a5d1-8d48dcc3353c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff58317f-e292-4e10-a561-04cd06e1104c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a9f20c7-1782-4972-a851-bbafc95fb8d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff58317f-e292-4e10-a561-04cd06e1104c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3341c0e3-0476-4367-a6ad-8c0234bda5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a9f20c7-1782-4972-a851-bbafc95fb8d2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3341c0e3-0476-4367-a6ad-8c0234bda5a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_947f7a61-ce84-487c-a93b-3edea718f839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_52b5ee25-0d02-4c1e-bc55-6594d1728391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_947f7a61-ce84-487c-a93b-3edea718f839" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_52b5ee25-0d02-4c1e-bc55-6594d1728391" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0f450bcb-b0f5-49d2-bcc1-bea022de86b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_947f7a61-ce84-487c-a93b-3edea718f839" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0f450bcb-b0f5-49d2-bcc1-bea022de86b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_6903eb91-6780-4622-a9db-fdc9cb22d569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_947f7a61-ce84-487c-a93b-3edea718f839" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_6903eb91-6780-4622-a9db-fdc9cb22d569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c1b4f57-5198-4ee8-80fb-5bcfb781309e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_947f7a61-ce84-487c-a93b-3edea718f839" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c1b4f57-5198-4ee8-80fb-5bcfb781309e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51d334de-7382-44f0-a3c1-308668e283f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_157708e3-d904-4338-a150-073612e6ab18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51d334de-7382-44f0-a3c1-308668e283f8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_157708e3-d904-4338-a150-073612e6ab18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_87124eaa-b6f8-4467-993f-36fa4e85ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51d334de-7382-44f0-a3c1-308668e283f8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_87124eaa-b6f8-4467-993f-36fa4e85ce5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_379f9fab-65a0-4efc-a379-2347610b6446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51d334de-7382-44f0-a3c1-308668e283f8" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_379f9fab-65a0-4efc-a379-2347610b6446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b798e896-37f6-4327-b5d3-9f55a7b8235d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51d334de-7382-44f0-a3c1-308668e283f8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b798e896-37f6-4327-b5d3-9f55a7b8235d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_89938a3f-7fbb-4027-a27f-567da539924e" xlink:href="ino-20240630.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51d334de-7382-44f0-a3c1-308668e283f8" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_89938a3f-7fbb-4027-a27f-567da539924e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d2553453-b452-4ba0-833b-94a7c94f09e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d3810297-d31e-491d-8bfe-88be8399a8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d2553453-b452-4ba0-833b-94a7c94f09e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d3810297-d31e-491d-8bfe-88be8399a8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d2899b9-4570-46c9-999c-1f9a87e71950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d2553453-b452-4ba0-833b-94a7c94f09e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d2899b9-4570-46c9-999c-1f9a87e71950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e5412ec-98e8-4350-9355-f6d89dcfdda6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d2553453-b452-4ba0-833b-94a7c94f09e3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e5412ec-98e8-4350-9355-f6d89dcfdda6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_637f6eec-59f0-48c7-a3a6-e046a3343bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a4464e3-2018-4caf-a312-33a2f9f9f166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_637f6eec-59f0-48c7-a3a6-e046a3343bf8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a4464e3-2018-4caf-a312-33a2f9f9f166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d5cfb9f1-2f9b-4dab-9110-f9fb36b1d5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_637f6eec-59f0-48c7-a3a6-e046a3343bf8" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d5cfb9f1-2f9b-4dab-9110-f9fb36b1d5d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c497af53-d7e3-4182-bedb-e2ef841da934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidClinicalExpensesCurrent_6f836c5b-eeb7-4b08-8f5e-2714216dfa5d" xlink:href="ino-20240630.xsd#ino_PrepaidClinicalExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c497af53-d7e3-4182-bedb-e2ef841da934" xlink:to="loc_ino_PrepaidClinicalExpensesCurrent_6f836c5b-eeb7-4b08-8f5e-2714216dfa5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_be040e38-ef35-4ab7-99f5-5ffe84053804" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c497af53-d7e3-4182-bedb-e2ef841da934" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_be040e38-ef35-4ab7-99f5-5ffe84053804" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_53c2f805-3184-4c82-ad93-35acd26b2060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_f74874f3-91e7-49d3-b896-580ac71d040c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_53c2f805-3184-4c82-ad93-35acd26b2060" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_f74874f3-91e7-49d3-b896-580ac71d040c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_b8b225d8-5c93-4ac2-8ba9-d45c37f12091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_53c2f805-3184-4c82-ad93-35acd26b2060" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_b8b225d8-5c93-4ac2-8ba9-d45c37f12091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_69923aa1-f22d-41d0-b57c-efd23cca1280" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_53c2f805-3184-4c82-ad93-35acd26b2060" xlink:to="loc_us-gaap_AccruedSalariesCurrent_69923aa1-f22d-41d0-b57c-efd23cca1280" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e0215e4-72f2-4b02-b57f-840319920b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding_08832bc9-cd09-4ab7-b687-64b01aa3da92" xlink:href="ino-20240630.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e0215e4-72f2-4b02-b57f-840319920b2c" xlink:to="loc_ino_WeightedAverageNumberOfSharesOutstanding_08832bc9-cd09-4ab7-b687-64b01aa3da92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_8ef54491-17f6-485c-adec-5f9f025a9967" xlink:href="ino-20240630.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e0215e4-72f2-4b02-b57f-840319920b2c" xlink:to="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_8ef54491-17f6-485c-adec-5f9f025a9967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a1043c18-143b-4f46-9e52-fcb7568a2f22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding_00a0936e-4ebd-479f-8874-809a623ddc61" xlink:href="ino-20240630.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a1043c18-143b-4f46-9e52-fcb7568a2f22" xlink:to="loc_ino_WeightedAverageNumberOfSharesOutstanding_00a0936e-4ebd-479f-8874-809a623ddc61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_0caee2f0-75b1-4923-a438-77a633562f75" xlink:href="ino-20240630.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a1043c18-143b-4f46-9e52-fcb7568a2f22" xlink:to="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_0caee2f0-75b1-4923-a438-77a633562f75" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ded75717-0b05-4943-872a-cfeb45139980" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8ef24534-d058-4c38-aa4a-1c48060049d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ded75717-0b05-4943-872a-cfeb45139980" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8ef24534-d058-4c38-aa4a-1c48060049d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_572e6551-b303-4984-b5ea-b0851bf9f949" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ded75717-0b05-4943-872a-cfeb45139980" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_572e6551-b303-4984-b5ea-b0851bf9f949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f173f1f3-81f8-42a7-9545-f7f1c6c2f493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4e07812e-8989-4d21-80ac-af6c50c1aebb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f173f1f3-81f8-42a7-9545-f7f1c6c2f493" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4e07812e-8989-4d21-80ac-af6c50c1aebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0d4ccd45-bd86-4878-9977-3b742e694208" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f173f1f3-81f8-42a7-9545-f7f1c6c2f493" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0d4ccd45-bd86-4878-9977-3b742e694208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e41dd753-8982-4f56-8f2c-d08cd7b76f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f173f1f3-81f8-42a7-9545-f7f1c6c2f493" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e41dd753-8982-4f56-8f2c-d08cd7b76f3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_32fd575f-3874-4026-825a-5ffe5e2f0fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f173f1f3-81f8-42a7-9545-f7f1c6c2f493" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_32fd575f-3874-4026-825a-5ffe5e2f0fd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dbb00bc5-96b5-48dc-a008-435cdc352676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f173f1f3-81f8-42a7-9545-f7f1c6c2f493" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dbb00bc5-96b5-48dc-a008-435cdc352676" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_041d1776-5ecc-46d8-a53c-b1dae0405dee" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f173f1f3-81f8-42a7-9545-f7f1c6c2f493" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_041d1776-5ecc-46d8-a53c-b1dae0405dee" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ino-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0d8c4537-ca52-4f1a-a8a1-280952f330d4,g:ffaafe34-d428-4f21-bdf4-6dece8c876eb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b8246f86-4d7d-42dd-9763-d7a69265a530" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fbedf581-446b-451e-87b8-ae75189202fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b8246f86-4d7d-42dd-9763-d7a69265a530" xlink:to="loc_us-gaap_StatementTable_fbedf581-446b-451e-87b8-ae75189202fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bf0a701c-ac38-4abc-b719-6c93bf6c9021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fbedf581-446b-451e-87b8-ae75189202fd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bf0a701c-ac38-4abc-b719-6c93bf6c9021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bf0a701c-ac38-4abc-b719-6c93bf6c9021_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bf0a701c-ac38-4abc-b719-6c93bf6c9021" xlink:to="loc_us-gaap_RelatedPartyDomain_bf0a701c-ac38-4abc-b719-6c93bf6c9021_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d28858ec-c565-49f2-8cc5-b39232dc3c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bf0a701c-ac38-4abc-b719-6c93bf6c9021" xlink:to="loc_us-gaap_RelatedPartyDomain_d28858ec-c565-49f2-8cc5-b39232dc3c3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_32c82f4b-bc08-40cb-a9c6-a278a60adc61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d28858ec-c565-49f2-8cc5-b39232dc3c3b" xlink:to="loc_us-gaap_NonrelatedPartyMember_32c82f4b-bc08-40cb-a9c6-a278a60adc61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_794fd077-52c4-4a48-bd28-61269fe2ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d28858ec-c565-49f2-8cc5-b39232dc3c3b" xlink:to="loc_us-gaap_RelatedPartyMember_794fd077-52c4-4a48-bd28-61269fe2ddba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b8246f86-4d7d-42dd-9763-d7a69265a530" xlink:to="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9e02d40-8009-4b7d-8643-ac84d929b156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9e02d40-8009-4b7d-8643-ac84d929b156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_dcccb636-a209-46ed-a4a4-60c9c1e5d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_us-gaap_ShortTermInvestments_dcccb636-a209-46ed-a4a4-60c9c1e5d7a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_407a7d08-dda2-45cf-bc9b-11740e8033ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_407a7d08-dda2-45cf-bc9b-11740e8033ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d879576f-265d-4d07-950b-40cad18f10e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d879576f-265d-4d07-950b-40cad18f10e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_648c0ba9-9829-4f7c-b970-726e4185cfc0" xlink:href="ino-20240630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_648c0ba9-9829-4f7c-b970-726e4185cfc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a762e3ec-8e8f-4c88-8e87-049f7a6fc617" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_us-gaap_AssetsCurrent_a762e3ec-8e8f-4c88-8e87-049f7a6fc617" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de3cd34e-ff28-42bb-a54d-197c2f4fd9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_de3cd34e-ff28-42bb-a54d-197c2f4fd9c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_249fe031-6697-48c1-97fc-fd24c41992f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_249fe031-6697-48c1-97fc-fd24c41992f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7312efd9-8af2-466a-b0da-0baf256afda9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7312efd9-8af2-466a-b0da-0baf256afda9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_62e3f116-5221-414d-95b4-d3ce46d9b54b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_62e3f116-5221-414d-95b4-d3ce46d9b54b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5edc4405-009a-4974-bc17-21213fe0ae90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_Assets_5edc4405-009a-4974-bc17-21213fe0ae90" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b8246f86-4d7d-42dd-9763-d7a69265a530" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c4f28786-0926-4789-afec-bbbf71a6e6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c4f28786-0926-4789-afec-bbbf71a6e6fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_23633dd8-a370-470d-aabb-b2a73a41d842" xlink:href="ino-20240630.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_23633dd8-a370-470d-aabb-b2a73a41d842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae96af40-e4bc-4c81-8105-fe03df05ca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae96af40-e4bc-4c81-8105-fe03df05ca5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_b57d8aa9-ba16-4291-ade2-2ae8f6205c91" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_ino_DeferredGrantFundingCurrent_b57d8aa9-ba16-4291-ade2-2ae8f6205c91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4bc0d9de-ae1f-4a5e-aadf-a28c289b9bdd" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4bc0d9de-ae1f-4a5e-aadf-a28c289b9bdd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_243f8a40-afec-4446-8f60-915b8c95857e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_243f8a40-afec-4446-8f60-915b8c95857e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ed2a9af9-a745-4bd1-9aeb-3f18a4035f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_us-gaap_LiabilitiesCurrent_ed2a9af9-a745-4bd1-9aeb-3f18a4035f1f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d9456116-03e9-434f-b23c-ecdd1e55c459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d9456116-03e9-434f-b23c-ecdd1e55c459" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7cfd0ad7-ab0f-41c5-a6f2-bf75306482d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:to="loc_us-gaap_Liabilities_7cfd0ad7-ab0f-41c5-a6f2-bf75306482d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5916f41f-e966-403b-8cb1-24c02ebc2dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_PreferredStockValue_5916f41f-e966-403b-8cb1-24c02ebc2dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b3c5f573-7c65-4e27-b77f-a486177abe81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_CommonStockValue_b3c5f573-7c65-4e27-b77f-a486177abe81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d1d08fbe-780c-4d68-bcfd-c18e9d1a13a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d1d08fbe-780c-4d68-bcfd-c18e9d1a13a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71f1cf97-dec4-47b4-b9f6-2c3ee1f8593d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71f1cf97-dec4-47b4-b9f6-2c3ee1f8593d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d4a9c6f7-dbc6-4f96-932f-d7ed11f9f890" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d4a9c6f7-dbc6-4f96-932f-d7ed11f9f890" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b7d25d3-a173-450a-a6cd-aa5506e48c30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_StockholdersEquity_7b7d25d3-a173-450a-a6cd-aa5506e48c30" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d7aa974-a69f-436d-bbed-45b4a596e772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d7aa974-a69f-436d-bbed-45b4a596e772" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_78292f59-60b7-4d60-b238-635e8bb68ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_799a15b4-c784-44ab-9acf-8b2b6d50410b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_78292f59-60b7-4d60-b238-635e8bb68ee0" xlink:to="loc_us-gaap_StatementTable_799a15b4-c784-44ab-9acf-8b2b6d50410b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_de45cd97-14e6-42f1-a3ed-30eaebb37145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_799a15b4-c784-44ab-9acf-8b2b6d50410b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_de45cd97-14e6-42f1-a3ed-30eaebb37145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_de45cd97-14e6-42f1-a3ed-30eaebb37145_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_de45cd97-14e6-42f1-a3ed-30eaebb37145" xlink:to="loc_us-gaap_EquityComponentDomain_de45cd97-14e6-42f1-a3ed-30eaebb37145_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_de45cd97-14e6-42f1-a3ed-30eaebb37145" xlink:to="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_94e8842d-a16e-4398-a78e-13b2ccf72e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:to="loc_us-gaap_PreferredStockMember_94e8842d-a16e-4398-a78e-13b2ccf72e0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0f333a31-d4df-481a-b210-b9bac66cc23f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:to="loc_us-gaap_CommonStockMember_0f333a31-d4df-481a-b210-b9bac66cc23f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_623b76a4-e1a5-431e-8282-2d5be1854bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_623b76a4-e1a5-431e-8282-2d5be1854bea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ca52c778-624b-4d64-89c9-27db2944c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:to="loc_us-gaap_RetainedEarningsMember_ca52c778-624b-4d64-89c9-27db2944c59c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472ba77e-e29b-49a4-a965-2ea8575face0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472ba77e-e29b-49a4-a965-2ea8575face0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78292f59-60b7-4d60-b238-635e8bb68ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_fab3b6be-7b08-41aa-8e61-b29f544e2424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_SharesIssued_fab3b6be-7b08-41aa-8e61-b29f544e2424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_734df0c9-d2e2-4193-a4d1-91eab734cea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockholdersEquity_734df0c9-d2e2-4193-a4d1-91eab734cea0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4a661fa6-ad61-465c-8b02-5583eadefe9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4a661fa6-ad61-465c-8b02-5583eadefe9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d3e2643d-c5fe-4e9b-8837-41e16be9ce2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d3e2643d-c5fe-4e9b-8837-41e16be9ce2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b02393ea-d8cf-4a16-a78d-4e63b31f02da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b02393ea-d8cf-4a16-a78d-4e63b31f02da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0e19afb8-fff4-40eb-bf55-dca6f7b2c45a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0e19afb8-fff4-40eb-bf55-dca6f7b2c45a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7df554f8-7117-4de2-a6fb-b3500674ced0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7df554f8-7117-4de2-a6fb-b3500674ced0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d26f411e-306e-476b-bd99-09fa3c60b7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d26f411e-306e-476b-bd99-09fa3c60b7a9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_435024e5-386b-48c4-bedf-e9585adce526" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_NetIncomeLoss_435024e5-386b-48c4-bedf-e9585adce526" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9d602719-310e-43e3-ad09-7a3bdd5b6b64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9d602719-310e-43e3-ad09-7a3bdd5b6b64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4f2a601c-e8f8-49c3-ab1f-a26774288323" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4f2a601c-e8f8-49c3-ab1f-a26774288323" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_7393fee5-2acc-4859-b774-7a553fbd9660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8fceb70-c9de-4382-a72d-74cc8560d2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1ceed53a-1070-43f4-99d6-9a0d32c04889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1ceed53a-1070-43f4-99d6-9a0d32c04889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ceed53a-1070-43f4-99d6-9a0d32c04889_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1ceed53a-1070-43f4-99d6-9a0d32c04889" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ceed53a-1070-43f4-99d6-9a0d32c04889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80dd381a-65b4-4813-b654-2e28351ece66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1ceed53a-1070-43f4-99d6-9a0d32c04889" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80dd381a-65b4-4813-b654-2e28351ece66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember_074a0245-3e1d-4aaa-9bb9-3fe4198470cd" xlink:href="ino-20240630.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80dd381a-65b4-4813-b654-2e28351ece66" xlink:to="loc_ino_UnderwrittenRegisteredDirectOfferingMember_074a0245-3e1d-4aaa-9bb9-3fe4198470cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b677c5b3-4076-4d0b-be1f-77f1a8372497" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b677c5b3-4076-4d0b-be1f-77f1a8372497" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b677c5b3-4076-4d0b-be1f-77f1a8372497_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b677c5b3-4076-4d0b-be1f-77f1a8372497" xlink:to="loc_us-gaap_ClassOfStockDomain_b677c5b3-4076-4d0b-be1f-77f1a8372497_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d35a4ea0-53ac-4cb3-bd17-262c0264d4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b677c5b3-4076-4d0b-be1f-77f1a8372497" xlink:to="loc_us-gaap_ClassOfStockDomain_d35a4ea0-53ac-4cb3-bd17-262c0264d4f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_30924e22-672f-4291-adb3-39f8d8cce30a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d35a4ea0-53ac-4cb3-bd17-262c0264d4f5" xlink:to="loc_us-gaap_CommonStockMember_30924e22-672f-4291-adb3-39f8d8cce30a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3bbd30c-efa7-4bdb-9cc3-2c19fc1cc117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3bbd30c-efa7-4bdb-9cc3-2c19fc1cc117" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3bbd30c-efa7-4bdb-9cc3-2c19fc1cc117_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3bbd30c-efa7-4bdb-9cc3-2c19fc1cc117" xlink:to="loc_us-gaap_EquityComponentDomain_d3bbd30c-efa7-4bdb-9cc3-2c19fc1cc117_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aecbe33c-8c0b-415e-ba78-26ffd4e21d26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3bbd30c-efa7-4bdb-9cc3-2c19fc1cc117" xlink:to="loc_us-gaap_EquityComponentDomain_aecbe33c-8c0b-415e-ba78-26ffd4e21d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4690e9a6-e271-48db-a5e5-3aa1e891ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aecbe33c-8c0b-415e-ba78-26ffd4e21d26" xlink:to="loc_us-gaap_CommonStockMember_4690e9a6-e271-48db-a5e5-3aa1e891ad44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0b42299b-2e77-435d-a4ed-8509947b70bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aecbe33c-8c0b-415e-ba78-26ffd4e21d26" xlink:to="loc_us-gaap_WarrantMember_0b42299b-2e77-435d-a4ed-8509947b70bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_99457ffd-5e51-4065-b34e-6a34f8e84d33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_NetIncomeLoss_99457ffd-5e51-4065-b34e-6a34f8e84d33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_f75751ee-e116-4474-aac3-a32761fd09cb" xlink:href="ino-20240630.xsd#ino_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_ino_WorkingCapital_f75751ee-e116-4474-aac3-a32761fd09cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed4f32aa-b70c-4cad-8e71-6877f7f737e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed4f32aa-b70c-4cad-8e71-6877f7f737e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8054999d-6d0b-4b4c-86d8-16271b2b9c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8054999d-6d0b-4b4c-86d8-16271b2b9c7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cf1ba595-1157-4430-a1f3-7beec34b7fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cf1ba595-1157-4430-a1f3-7beec34b7fb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_275d4065-c0b5-4a95-ba37-f284ff15a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_275d4065-c0b5-4a95-ba37-f284ff15a7bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_55e7bb2c-dd1d-42af-a26f-46b3c82c6d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_55e7bb2c-dd1d-42af-a26f-46b3c82c6d25" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c3a76e61-1f6b-45c6-b983-fdc714c5a3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c3a76e61-1f6b-45c6-b983-fdc714c5a3e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f6060200-0ea9-49ef-8ad0-c39a546b6641" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f6060200-0ea9-49ef-8ad0-c39a546b6641" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27cd791c-2c85-4a28-b436-ff8e0bec9f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27cd791c-2c85-4a28-b436-ff8e0bec9f28" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3bc6b1f2-f694-4f16-9192-304f088964f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3bc6b1f2-f694-4f16-9192-304f088964f8" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3ce66935-791e-4ddd-bad4-fa930998af73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9959b725-9b49-4c5b-9b25-007f2f0714ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3ce66935-791e-4ddd-bad4-fa930998af73" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9959b725-9b49-4c5b-9b25-007f2f0714ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_61b4c210-387f-4834-94d3-c9ce5021c4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9959b725-9b49-4c5b-9b25-007f2f0714ae" xlink:to="loc_us-gaap_FinancialInstrumentAxis_61b4c210-387f-4834-94d3-c9ce5021c4c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61b4c210-387f-4834-94d3-c9ce5021c4c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_61b4c210-387f-4834-94d3-c9ce5021c4c1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61b4c210-387f-4834-94d3-c9ce5021c4c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_61b4c210-387f-4834-94d3-c9ce5021c4c1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_263aa408-1ffc-4879-b51f-dce530acec79" xlink:href="ino-20240630.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:to="loc_ino_MutualFundsMember_263aa408-1ffc-4879-b51f-dce530acec79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_9f89502a-fd58-48c1-acf5-d9c8dbbf7c57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_9f89502a-fd58-48c1-acf5-d9c8dbbf7c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ae89d809-a93e-446f-968e-a98fe61b537e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ae89d809-a93e-446f-968e-a98fe61b537e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_73caf577-3926-40e1-ba12-31507967bc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_73caf577-3926-40e1-ba12-31507967bc8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_8bfbf175-bda0-47c0-a9e6-7c505a7ccab5" xlink:href="ino-20240630.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3ce66935-791e-4ddd-bad4-fa930998af73" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_8bfbf175-bda0-47c0-a9e6-7c505a7ccab5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3ce66935-791e-4ddd-bad4-fa930998af73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8f3624e0-9e93-4882-b72e-975d200e03e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8f3624e0-9e93-4882-b72e-975d200e03e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9094f3ae-d42b-45af-bc33-23e81a2c6652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9094f3ae-d42b-45af-bc33-23e81a2c6652" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bb3cf2e3-f287-4217-811e-0f5564db889a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bb3cf2e3-f287-4217-811e-0f5564db889a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_81841bce-99e6-4b3b-ac7f-718a29b48925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_81841bce-99e6-4b3b-ac7f-718a29b48925" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_11ffe297-2728-41fb-b33c-eeb4ff0bc25e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_11ffe297-2728-41fb-b33c-eeb4ff0bc25e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f908212f-60dc-41a0-b76f-deb5ba96aad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_11ffe297-2728-41fb-b33c-eeb4ff0bc25e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f908212f-60dc-41a0-b76f-deb5ba96aad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f908212f-60dc-41a0-b76f-deb5ba96aad9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f908212f-60dc-41a0-b76f-deb5ba96aad9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f908212f-60dc-41a0-b76f-deb5ba96aad9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f54bb00b-6f2f-4760-a08b-ca0ecbbe80ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f908212f-60dc-41a0-b76f-deb5ba96aad9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f54bb00b-6f2f-4760-a08b-ca0ecbbe80ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5a2d23d8-6593-47cc-8a7f-b654be674cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f54bb00b-6f2f-4760-a08b-ca0ecbbe80ac" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5a2d23d8-6593-47cc-8a7f-b654be674cb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e6660142-1ba3-4466-be26-059223bdcc81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e6660142-1ba3-4466-be26-059223bdcc81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3a7d6962-d545-4566-96cc-e892965c4233" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3a7d6962-d545-4566-96cc-e892965c4233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b347eb79-e2b9-4d75-8538-08451f1272be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b347eb79-e2b9-4d75-8538-08451f1272be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b3068066-a059-46b8-9649-7cbeaf545030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b3068066-a059-46b8-9649-7cbeaf545030" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_87f46994-8d9d-4fc1-bcf4-666dc6bf89ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_87f46994-8d9d-4fc1-bcf4-666dc6bf89ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_3269c315-7475-47a9-a179-7ba3f00ebc72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_3269c315-7475-47a9-a179-7ba3f00ebc72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_e7f96b96-22d4-494a-9f75-cf16fa4d8fee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_e7f96b96-22d4-494a-9f75-cf16fa4d8fee" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a2c89470-2ad7-4f3f-92a3-c9be77f36c55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a2c89470-2ad7-4f3f-92a3-c9be77f36c55" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_efb85c4a-0a5a-4caa-98c8-ca598b9ceab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_efb85c4a-0a5a-4caa-98c8-ca598b9ceab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_efb85c4a-0a5a-4caa-98c8-ca598b9ceab9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_efb85c4a-0a5a-4caa-98c8-ca598b9ceab9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_efb85c4a-0a5a-4caa-98c8-ca598b9ceab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c236ed2b-ec7b-4931-a323-030a248bcbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_efb85c4a-0a5a-4caa-98c8-ca598b9ceab9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c236ed2b-ec7b-4931-a323-030a248bcbe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d8ed6a82-c053-4d87-995b-e943c9611db2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c236ed2b-ec7b-4931-a323-030a248bcbe8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d8ed6a82-c053-4d87-995b-e943c9611db2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_93888533-350a-42a7-86bf-517cdfd6007a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:to="loc_us-gaap_FinancialInstrumentAxis_93888533-350a-42a7-86bf-517cdfd6007a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_93888533-350a-42a7-86bf-517cdfd6007a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_93888533-350a-42a7-86bf-517cdfd6007a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_93888533-350a-42a7-86bf-517cdfd6007a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_93888533-350a-42a7-86bf-517cdfd6007a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_59f3fc76-fb08-4113-ba0f-64c201db8173" xlink:href="ino-20240630.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:to="loc_ino_MutualFundsMember_59f3fc76-fb08-4113-ba0f-64c201db8173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_53c54668-510a-49e5-b1ac-6a4bcdced7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_53c54668-510a-49e5-b1ac-6a4bcdced7a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_60477faf-771a-4be3-b236-9ed5d596fad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_60477faf-771a-4be3-b236-9ed5d596fad2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_9ae93ce8-fd85-4bfa-9305-6d0399e734eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_9ae93ce8-fd85-4bfa-9305-6d0399e734eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a71919b3-4e1d-4d5c-afd3-d649f8122fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a71919b3-4e1d-4d5c-afd3-d649f8122fd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a71919b3-4e1d-4d5c-afd3-d649f8122fd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a71919b3-4e1d-4d5c-afd3-d649f8122fd2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a71919b3-4e1d-4d5c-afd3-d649f8122fd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b51e4d3-ab90-4f4a-b1a0-50502147d8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a71919b3-4e1d-4d5c-afd3-d649f8122fd2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b51e4d3-ab90-4f4a-b1a0-50502147d8a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c7dbf695-969e-48aa-95c8-789fc250fb30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b51e4d3-ab90-4f4a-b1a0-50502147d8a6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c7dbf695-969e-48aa-95c8-789fc250fb30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7f194786-0afb-486e-b954-c49cf1dbd090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b51e4d3-ab90-4f4a-b1a0-50502147d8a6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7f194786-0afb-486e-b954-c49cf1dbd090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_85719e47-4aee-40b4-b5b9-08d78045050e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b51e4d3-ab90-4f4a-b1a0-50502147d8a6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_85719e47-4aee-40b4-b5b9-08d78045050e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3a274872-42e7-4106-9e05-274d08df5f06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a2c89470-2ad7-4f3f-92a3-c9be77f36c55" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3a274872-42e7-4106-9e05-274d08df5f06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f01e90f9-77ac-4229-a414-e268f10a09c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3a274872-42e7-4106-9e05-274d08df5f06" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f01e90f9-77ac-4229-a414-e268f10a09c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_77b20f5c-1fad-4b31-a2c3-40de178d49e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3a274872-42e7-4106-9e05-274d08df5f06" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_77b20f5c-1fad-4b31-a2c3-40de178d49e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_62941f76-8a7f-4e6a-9844-c3fb4b7b4f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3a274872-42e7-4106-9e05-274d08df5f06" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_62941f76-8a7f-4e6a-9844-c3fb4b7b4f72" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:href="ino-20240630.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_140d36ed-1005-460f-8156-693c52c4643c" xlink:href="ino-20240630.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_140d36ed-1005-460f-8156-693c52c4643c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8b4e65a9-2283-422f-8bd7-56c675ebf2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_140d36ed-1005-460f-8156-693c52c4643c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8b4e65a9-2283-422f-8bd7-56c675ebf2cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8b4e65a9-2283-422f-8bd7-56c675ebf2cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8b4e65a9-2283-422f-8bd7-56c675ebf2cb" xlink:to="loc_us-gaap_RelatedPartyDomain_8b4e65a9-2283-422f-8bd7-56c675ebf2cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b417759f-7ad0-4afe-bcbe-b6ebd007fda2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8b4e65a9-2283-422f-8bd7-56c675ebf2cb" xlink:to="loc_us-gaap_RelatedPartyDomain_b417759f-7ad0-4afe-bcbe-b6ebd007fda2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_3d4ea2ee-00b5-4621-b133-670d9436b318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b417759f-7ad0-4afe-bcbe-b6ebd007fda2" xlink:to="loc_us-gaap_NonrelatedPartyMember_3d4ea2ee-00b5-4621-b133-670d9436b318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_34ce760c-b419-44de-a636-c48aceaa41d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_34ce760c-b419-44de-a636-c48aceaa41d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_5bb07161-96b7-41e7-a6b5-f456adc6c382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_us-gaap_AccruedSalariesCurrent_5bb07161-96b7-41e7-a6b5-f456adc6c382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_43e9ee3a-2a7d-4dd4-abcb-e94b5c532d97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_43e9ee3a-2a7d-4dd4-abcb-e94b5c532d97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c526b506-3fef-47f2-ac2c-cf3f2b2478d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c526b506-3fef-47f2-ac2c-cf3f2b2478d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpenseCurrent_10862a43-8568-4e88-9ecb-8cecd204b933" xlink:href="ino-20240630.xsd#ino_PrepaidManufacturingExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_ino_PrepaidManufacturingExpenseCurrent_10862a43-8568-4e88-9ecb-8cecd204b933" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantLiability_d6656122-2878-4d4d-b594-a61a71d04b46" xlink:href="ino-20240630.xsd#ino_GrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_ino_GrantLiability_d6656122-2878-4d4d-b594-a61a71d04b46" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#ConvertibleDebtDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f0341c5c-0223-45ed-8d76-197e11fdd26f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_DebtInstrumentTable_f0341c5c-0223-45ed-8d76-197e11fdd26f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fea92008-9291-4812-8a13-2c8f1151a7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f0341c5c-0223-45ed-8d76-197e11fdd26f" xlink:to="loc_us-gaap_DebtInstrumentAxis_fea92008-9291-4812-8a13-2c8f1151a7b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fea92008-9291-4812-8a13-2c8f1151a7b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fea92008-9291-4812-8a13-2c8f1151a7b5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fea92008-9291-4812-8a13-2c8f1151a7b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b172176-f0f0-4324-b537-d1d9b0371e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fea92008-9291-4812-8a13-2c8f1151a7b5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b172176-f0f0-4324-b537-d1d9b0371e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7dc07fa5-271d-4cd6-8bbc-3603bf257fad" xlink:href="ino-20240630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3b172176-f0f0-4324-b537-d1d9b0371e64" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7dc07fa5-271d-4cd6-8bbc-3603bf257fad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c8191b31-b588-48fb-8eeb-4d153da7eb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f0341c5c-0223-45ed-8d76-197e11fdd26f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c8191b31-b588-48fb-8eeb-4d153da7eb9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c8191b31-b588-48fb-8eeb-4d153da7eb9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c8191b31-b588-48fb-8eeb-4d153da7eb9c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c8191b31-b588-48fb-8eeb-4d153da7eb9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_faaade06-2f2f-4871-b2e7-673ac2ef2a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c8191b31-b588-48fb-8eeb-4d153da7eb9c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_faaade06-2f2f-4871-b2e7-673ac2ef2a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_41c8aa2d-56ef-4f3a-ab39-ab16b3344a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_faaade06-2f2f-4871-b2e7-673ac2ef2a9f" xlink:to="loc_us-gaap_ConvertibleDebtMember_41c8aa2d-56ef-4f3a-ab39-ab16b3344a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d0deffdb-58c6-4be0-bbc1-084664e5ee0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d0deffdb-58c6-4be0-bbc1-084664e5ee0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_112cb84a-3fc6-43ef-9a9b-10cb3ec15ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_112cb84a-3fc6-43ef-9a9b-10cb3ec15ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_ce59c930-6f17-4051-8b5e-32c07cb3d5db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_ce59c930-6f17-4051-8b5e-32c07cb3d5db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_fbfcb5b7-7b2f-43ff-9341-6e8801f65183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_fbfcb5b7-7b2f-43ff-9341-6e8801f65183" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating_285ff7b1-d215-4175-8cc7-e459bd56e78e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_InterestExpenseOperating_285ff7b1-d215-4175-8cc7-e459bd56e78e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_121add1a-da0d-440d-9406-16b1d32e1a93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_InterestExpenseDebt_121add1a-da0d-440d-9406-16b1d32e1a93" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cc4d965b-9562-4c5a-99d9-60bbd930e187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0350b3f8-1fbb-4be3-a0b8-6fe04c010929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc4d965b-9562-4c5a-99d9-60bbd930e187" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0350b3f8-1fbb-4be3-a0b8-6fe04c010929" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_90098619-4d98-4c9f-9534-ef470b136a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0350b3f8-1fbb-4be3-a0b8-6fe04c010929" xlink:to="loc_us-gaap_StatementClassOfStockAxis_90098619-4d98-4c9f-9534-ef470b136a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_90098619-4d98-4c9f-9534-ef470b136a0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90098619-4d98-4c9f-9534-ef470b136a0d" xlink:to="loc_us-gaap_ClassOfStockDomain_90098619-4d98-4c9f-9534-ef470b136a0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b05d034-c642-4538-bf2c-b9a21048160c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90098619-4d98-4c9f-9534-ef470b136a0d" xlink:to="loc_us-gaap_ClassOfStockDomain_0b05d034-c642-4538-bf2c-b9a21048160c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6af4c2a6-cc90-41ed-9256-896f260fb6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b05d034-c642-4538-bf2c-b9a21048160c" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6af4c2a6-cc90-41ed-9256-896f260fb6bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc4d965b-9562-4c5a-99d9-60bbd930e187" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_00e34281-4012-4895-afb9-5f5967343dca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_00e34281-4012-4895-afb9-5f5967343dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c741c755-cab5-401f-be92-2522c5fcb725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c741c755-cab5-401f-be92-2522c5fcb725" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3aea9eaf-c2a3-45ca-af05-a461f091a3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_CommonStockSharesIssued_3aea9eaf-c2a3-45ca-af05-a461f091a3a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a818100e-d867-4abc-b4d0-8980b07bdb44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a818100e-d867-4abc-b4d0-8980b07bdb44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_70f9b1a9-b88c-4cea-9ede-fe31c3e17336" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_70f9b1a9-b88c-4cea-9ede-fe31c3e17336" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f5d18420-d841-4c0e-8eee-29b76cbef489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f5d18420-d841-4c0e-8eee-29b76cbef489" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5e5e2e1b-a0fe-4105-9e45-2f425bf58580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5e5e2e1b-a0fe-4105-9e45-2f425bf58580" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5adca82c-50f2-4b27-8d09-f0334f373dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5adca82c-50f2-4b27-8d09-f0334f373dbf" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19903d09-4d58-43f9-b410-197c96573db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19903d09-4d58-43f9-b410-197c96573db9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_19903d09-4d58-43f9-b410-197c96573db9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19903d09-4d58-43f9-b410-197c96573db9" xlink:to="loc_us-gaap_ClassOfStockDomain_19903d09-4d58-43f9-b410-197c96573db9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e7b841e4-0e38-438c-9dad-57d19a830e16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19903d09-4d58-43f9-b410-197c96573db9" xlink:to="loc_us-gaap_ClassOfStockDomain_e7b841e4-0e38-438c-9dad-57d19a830e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ce46e4a5-6436-48e2-a63e-55c5a8b05cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e7b841e4-0e38-438c-9dad-57d19a830e16" xlink:to="loc_us-gaap_CommonStockMember_ce46e4a5-6436-48e2-a63e-55c5a8b05cd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_84c8747d-e600-4555-b3ad-49530a539e12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_84c8747d-e600-4555-b3ad-49530a539e12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_84c8747d-e600-4555-b3ad-49530a539e12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_84c8747d-e600-4555-b3ad-49530a539e12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_84c8747d-e600-4555-b3ad-49530a539e12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b71818d8-5f3c-4726-a073-c51d40f219d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_84c8747d-e600-4555-b3ad-49530a539e12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b71818d8-5f3c-4726-a073-c51d40f219d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember_a584b723-03d1-4bc5-937a-20a03be1601e" xlink:href="ino-20240630.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b71818d8-5f3c-4726-a073-c51d40f219d5" xlink:to="loc_ino_UnderwrittenRegisteredDirectOfferingMember_a584b723-03d1-4bc5-937a-20a03be1601e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_5d99666f-efdf-4eab-87b0-b9a395d0285a" xlink:href="ino-20240630.xsd#ino_A2021SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b71818d8-5f3c-4726-a073-c51d40f219d5" xlink:to="loc_ino_A2021SalesAgreementMember_5d99666f-efdf-4eab-87b0-b9a395d0285a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3e2e0bd2-4ae1-416a-bf1f-7fdb5cfb372f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_srt_LitigationCaseAxis_3e2e0bd2-4ae1-416a-bf1f-7fdb5cfb372f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3e2e0bd2-4ae1-416a-bf1f-7fdb5cfb372f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_3e2e0bd2-4ae1-416a-bf1f-7fdb5cfb372f" xlink:to="loc_srt_LitigationCaseTypeDomain_3e2e0bd2-4ae1-416a-bf1f-7fdb5cfb372f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_40bfe8b4-2d76-44b5-9636-8ebccd48c56e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_3e2e0bd2-4ae1-416a-bf1f-7fdb5cfb372f" xlink:to="loc_srt_LitigationCaseTypeDomain_40bfe8b4-2d76-44b5-9636-8ebccd48c56e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_a5b2edac-7e42-4e93-8ce7-209894ccd3e7" xlink:href="ino-20240630.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40bfe8b4-2d76-44b5-9636-8ebccd48c56e" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_a5b2edac-7e42-4e93-8ce7-209894ccd3e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e082f92b-a82e-4769-8cb8-19fccf199e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_us-gaap_PlanNameAxis_e082f92b-a82e-4769-8cb8-19fccf199e50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e082f92b-a82e-4769-8cb8-19fccf199e50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e082f92b-a82e-4769-8cb8-19fccf199e50" xlink:to="loc_us-gaap_PlanNameDomain_e082f92b-a82e-4769-8cb8-19fccf199e50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e082f92b-a82e-4769-8cb8-19fccf199e50" xlink:to="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember_379f9299-cd3e-4061-b4cf-22ff5e7ffce7" xlink:href="ino-20240630.xsd#ino_A2023IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:to="loc_ino_A2023IncentivePlanMember_379f9299-cd3e-4061-b4cf-22ff5e7ffce7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_2bdc1fca-d1aa-43da-8be7-87b006afcb7c" xlink:href="ino-20240630.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:to="loc_ino_A2016IncentivePlanMember_2bdc1fca-d1aa-43da-8be7-87b006afcb7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_16b1e735-2f25-4fe1-9f27-1e8b44ab4909" xlink:href="ino-20240630.xsd#ino_A2022InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:to="loc_ino_A2022InducementPlanMember_16b1e735-2f25-4fe1-9f27-1e8b44ab4909" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_16a390f3-425e-47da-a410-232a31de0b6a" xlink:href="ino-20240630.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:to="loc_ino_A2007IncentivePlanMember_16a390f3-425e-47da-a410-232a31de0b6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d87048d9-3448-4ad4-86a6-439cf206ec90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d87048d9-3448-4ad4-86a6-439cf206ec90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d87048d9-3448-4ad4-86a6-439cf206ec90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d87048d9-3448-4ad4-86a6-439cf206ec90" xlink:to="loc_us-gaap_EquityComponentDomain_d87048d9-3448-4ad4-86a6-439cf206ec90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc66aa10-bfff-4314-b359-f206364cc034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d87048d9-3448-4ad4-86a6-439cf206ec90" xlink:to="loc_us-gaap_EquityComponentDomain_bc66aa10-bfff-4314-b359-f206364cc034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6959f515-3054-485a-9535-546011dcd90e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bc66aa10-bfff-4314-b359-f206364cc034" xlink:to="loc_us-gaap_WarrantMember_6959f515-3054-485a-9535-546011dcd90e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_000af9b6-78f2-487c-9bfb-ed6a1abbf697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bc66aa10-bfff-4314-b359-f206364cc034" xlink:to="loc_us-gaap_CommonStockMember_000af9b6-78f2-487c-9bfb-ed6a1abbf697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14fff475-dc21-4a3a-9b07-be9c4fca1ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14fff475-dc21-4a3a-9b07-be9c4fca1ba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_a62f7187-62af-43be-b1f2-7e5765a72908" xlink:href="ino-20240630.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_a62f7187-62af-43be-b1f2-7e5765a72908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_9dc769b2-3871-4d7b-a401-bb581ea04dad" xlink:href="ino-20240630.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_9dc769b2-3871-4d7b-a401-bb581ea04dad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_99c158c8-bb6e-4e43-925a-fe865bdb9b08" xlink:href="ino-20240630.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_99c158c8-bb6e-4e43-925a-fe865bdb9b08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_2b5a7d8f-bb78-4d75-9e9f-17fbae4d5590" xlink:href="ino-20240630.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_2b5a7d8f-bb78-4d75-9e9f-17fbae4d5590" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_ec3ecad7-ed49-49fb-a4be-d5c77bd62c56" xlink:href="ino-20240630.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_ec3ecad7-ed49-49fb-a4be-d5c77bd62c56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_27be5cd2-13c9-485d-a52e-00e9151566ba" xlink:href="ino-20240630.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_27be5cd2-13c9-485d-a52e-00e9151566ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_111e7aff-cd6a-4378-8cf8-550ab3e460d6" xlink:href="ino-20240630.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_111e7aff-cd6a-4378-8cf8-550ab3e460d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_521156a8-4128-4e12-803f-f1e347889b70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_521156a8-4128-4e12-803f-f1e347889b70" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529c817-b7a9-4f6b-8e78-9d6277e630bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529c817-b7a9-4f6b-8e78-9d6277e630bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63eb8324-fe33-4444-b543-3d21a8a4b714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63eb8324-fe33-4444-b543-3d21a8a4b714" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_2ebeb52c-340d-4f3c-a7d9-568f3e549a76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_2ebeb52c-340d-4f3c-a7d9-568f3e549a76" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f65e762a-6179-4edb-8a39-187e22a30e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f65e762a-6179-4edb-8a39-187e22a30e1d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ff68caa7-1039-4416-a7e9-017846fa08ff" xlink:href="ino-20240630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ff68caa7-1039-4416-a7e9-017846fa08ff" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#NetLossPerShareAntidilutiveDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9909960b-587a-434e-8a58-e9a0e8576977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6c378a3d-0b45-4923-ae89-4581cb3d54e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9909960b-587a-434e-8a58-e9a0e8576977" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6c378a3d-0b45-4923-ae89-4581cb3d54e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b77f91-2749-473a-924f-ad47188f297a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6c378a3d-0b45-4923-ae89-4581cb3d54e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b77f91-2749-473a-924f-ad47188f297a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_19b77f91-2749-473a-924f-ad47188f297a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b77f91-2749-473a-924f-ad47188f297a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_19b77f91-2749-473a-924f-ad47188f297a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b77f91-2749-473a-924f-ad47188f297a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b1741eee-6558-470a-bdd2-2b91a9100689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b1741eee-6558-470a-bdd2-2b91a9100689" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_95e9045a-717b-4e15-b589-230dd48d1a63" xlink:href="ino-20240630.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_95e9045a-717b-4e15-b589-230dd48d1a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_14c225b2-cfeb-4f8d-a35d-21f1d2db6635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_14c225b2-cfeb-4f8d-a35d-21f1d2db6635" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_6ce101aa-7143-4dd1-9bc6-0c7c093181b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_6ce101aa-7143-4dd1-9bc6-0c7c093181b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_19af3ee9-5b96-4c04-923a-f36585bdf96d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_19af3ee9-5b96-4c04-923a-f36585bdf96d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_463ee7f0-5bcc-45a3-bb5d-781dbd687518" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9909960b-587a-434e-8a58-e9a0e8576977" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_463ee7f0-5bcc-45a3-bb5d-781dbd687518" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#StockBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3accf127-84a8-488a-b122-f87227e5c288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3accf127-84a8-488a-b122-f87227e5c288" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_618b43b2-bb9e-4d74-a627-3adc4dc13ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3accf127-84a8-488a-b122-f87227e5c288" xlink:to="loc_us-gaap_AwardTypeAxis_618b43b2-bb9e-4d74-a627-3adc4dc13ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_618b43b2-bb9e-4d74-a627-3adc4dc13ff8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_618b43b2-bb9e-4d74-a627-3adc4dc13ff8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_618b43b2-bb9e-4d74-a627-3adc4dc13ff8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_140762b4-5818-4b24-b5b5-1a91ee6f7ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_618b43b2-bb9e-4d74-a627-3adc4dc13ff8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_140762b4-5818-4b24-b5b5-1a91ee6f7ab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_61f55391-8f08-4527-91e0-f94b631cad96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_140762b4-5818-4b24-b5b5-1a91ee6f7ab2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_61f55391-8f08-4527-91e0-f94b631cad96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_30cbfab1-71a2-462e-b246-80223ff371ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3accf127-84a8-488a-b122-f87227e5c288" xlink:to="loc_srt_TitleOfIndividualAxis_30cbfab1-71a2-462e-b246-80223ff371ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_30cbfab1-71a2-462e-b246-80223ff371ac_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_30cbfab1-71a2-462e-b246-80223ff371ac" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_30cbfab1-71a2-462e-b246-80223ff371ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81306a4f-1460-4614-b7af-60ade689d5f4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_30cbfab1-71a2-462e-b246-80223ff371ac" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81306a4f-1460-4614-b7af-60ade689d5f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_69a7139e-708c-45af-9eda-aac200c617b1" xlink:href="ino-20240630.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81306a4f-1460-4614-b7af-60ade689d5f4" xlink:to="loc_ino_EmployeesAndDirectorsMember_69a7139e-708c-45af-9eda-aac200c617b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_96f1a890-8d9b-432c-8915-3a26b9dc6dac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_96f1a890-8d9b-432c-8915-3a26b9dc6dac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_009349aa-378c-42bd-b1e4-804c7d5bc282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_009349aa-378c-42bd-b1e4-804c7d5bc282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_02a23b21-872e-4920-b0fc-ab58db0e0a66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_02a23b21-872e-4920-b0fc-ab58db0e0a66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6e0e6965-3fc4-467a-9256-87bbd8f7d583" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6e0e6965-3fc4-467a-9256-87bbd8f7d583" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8525a05d-8281-44b2-92db-0d32ab474bab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:to="loc_srt_TitleOfIndividualAxis_8525a05d-8281-44b2-92db-0d32ab474bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8525a05d-8281-44b2-92db-0d32ab474bab_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_8525a05d-8281-44b2-92db-0d32ab474bab" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8525a05d-8281-44b2-92db-0d32ab474bab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41130c8d-ee62-4881-a307-5d7011cac827" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_8525a05d-8281-44b2-92db-0d32ab474bab" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41130c8d-ee62-4881-a307-5d7011cac827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_acdc7048-5904-4c24-a676-0e1fa329a980" xlink:href="ino-20240630.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41130c8d-ee62-4881-a307-5d7011cac827" xlink:to="loc_ino_EmployeesAndDirectorsMember_acdc7048-5904-4c24-a676-0e1fa329a980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_fcb9418a-ba59-48ca-a253-62113276fd71" xlink:href="ino-20240630.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41130c8d-ee62-4881-a307-5d7011cac827" xlink:to="loc_ino_NonEmployeeMember_fcb9418a-ba59-48ca-a253-62113276fd71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_205e57d2-8b27-41d1-860b-cbd30d1f5659" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_205e57d2-8b27-41d1-860b-cbd30d1f5659" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_205e57d2-8b27-41d1-860b-cbd30d1f5659_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_205e57d2-8b27-41d1-860b-cbd30d1f5659" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_205e57d2-8b27-41d1-860b-cbd30d1f5659_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_82f7f222-8cfa-443c-ab66-e9a08bdedcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_205e57d2-8b27-41d1-860b-cbd30d1f5659" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_82f7f222-8cfa-443c-ab66-e9a08bdedcb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a15175d3-e5cc-4428-9517-c77af80745ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82f7f222-8cfa-443c-ab66-e9a08bdedcb0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a15175d3-e5cc-4428-9517-c77af80745ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_385397c3-7ca5-494a-9ef4-a3462eff7726" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82f7f222-8cfa-443c-ab66-e9a08bdedcb0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_385397c3-7ca5-494a-9ef4-a3462eff7726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_096b1e92-daf6-4b28-b4c8-b9df615a0517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:to="loc_us-gaap_AwardTypeAxis_096b1e92-daf6-4b28-b4c8-b9df615a0517" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_096b1e92-daf6-4b28-b4c8-b9df615a0517_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_096b1e92-daf6-4b28-b4c8-b9df615a0517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_096b1e92-daf6-4b28-b4c8-b9df615a0517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34048ee2-732f-43a3-82d3-75fd124380b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_096b1e92-daf6-4b28-b4c8-b9df615a0517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34048ee2-732f-43a3-82d3-75fd124380b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_5d7f9687-6c52-4e40-9189-8cc2fbc76eb7" xlink:href="ino-20240630.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34048ee2-732f-43a3-82d3-75fd124380b3" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_5d7f9687-6c52-4e40-9189-8cc2fbc76eb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_468f5d6c-997d-4f34-ae4c-4789032d8cab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34048ee2-732f-43a3-82d3-75fd124380b3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_468f5d6c-997d-4f34-ae4c-4789032d8cab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_944c75a3-da37-43d7-82a8-c2b9d1180839" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_468f5d6c-997d-4f34-ae4c-4789032d8cab" xlink:to="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_944c75a3-da37-43d7-82a8-c2b9d1180839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_2ab9967a-9bfb-4fb8-9dbd-6823e10f914a" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_468f5d6c-997d-4f34-ae4c-4789032d8cab" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_2ab9967a-9bfb-4fb8-9dbd-6823e10f914a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_8d880fc1-0175-4235-832d-4eb5560e754c" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_468f5d6c-997d-4f34-ae4c-4789032d8cab" xlink:to="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_8d880fc1-0175-4235-832d-4eb5560e754c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_44f04a6a-4dbf-47c3-aae6-25e29b6ee5d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:to="loc_srt_RangeAxis_44f04a6a-4dbf-47c3-aae6-25e29b6ee5d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44f04a6a-4dbf-47c3-aae6-25e29b6ee5d5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_44f04a6a-4dbf-47c3-aae6-25e29b6ee5d5" xlink:to="loc_srt_RangeMember_44f04a6a-4dbf-47c3-aae6-25e29b6ee5d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_192dafaf-6198-45f1-928d-c4074d7d6265" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_44f04a6a-4dbf-47c3-aae6-25e29b6ee5d5" xlink:to="loc_srt_RangeMember_192dafaf-6198-45f1-928d-c4074d7d6265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f905b5b5-3cee-4629-b267-604fc700549c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_192dafaf-6198-45f1-928d-c4074d7d6265" xlink:to="loc_srt_MinimumMember_f905b5b5-3cee-4629-b267-604fc700549c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_832a5189-4107-4ae5-862b-e44c47e642ef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_192dafaf-6198-45f1-928d-c4074d7d6265" xlink:to="loc_srt_MaximumMember_832a5189-4107-4ae5-862b-e44c47e642ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dcbb8394-b2dc-483e-adfc-25c979ff4827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ShareBasedCompensation_dcbb8394-b2dc-483e-adfc-25c979ff4827" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_920bd96b-d872-4b91-bcb1-ff888be20ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_920bd96b-d872-4b91-bcb1-ff888be20ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_91dec463-c824-4a44-95bf-d0fd15913626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_91dec463-c824-4a44-95bf-d0fd15913626" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6358f35d-5a6f-4411-ba17-586a2c22ef88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6358f35d-5a6f-4411-ba17-586a2c22ef88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ded1f32f-3b13-4ba5-adea-2fb0f5924814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ded1f32f-3b13-4ba5-adea-2fb0f5924814" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c635ba96-32e8-4b5d-bd2d-8fb8f5348180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c635ba96-32e8-4b5d-bd2d-8fb8f5348180" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e87c344e-39c6-4880-ba12-bc9d22c775ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e87c344e-39c6-4880-ba12-bc9d22c775ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c84bacc7-8c41-428f-b786-27ee035df544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c84bacc7-8c41-428f-b786-27ee035df544" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_c3664e5e-78e6-4977-be5b-005b11c5d67a" xlink:href="ino-20240630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_c3664e5e-78e6-4977-be5b-005b11c5d67a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f3b002bf-e142-46aa-b994-22b564d072c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f3b002bf-e142-46aa-b994-22b564d072c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_7995ac95-483e-40df-b588-ffd29e6cb34e" xlink:href="ino-20240630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_7995ac95-483e-40df-b588-ffd29e6cb34e" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ffe7d8a2-054f-4eb7-986c-9fe6da43b893" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ffe7d8a2-054f-4eb7-986c-9fe6da43b893" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_889eee59-7d1e-425a-8638-6e32a54fc3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ffe7d8a2-054f-4eb7-986c-9fe6da43b893" xlink:to="loc_us-gaap_AwardTypeAxis_889eee59-7d1e-425a-8638-6e32a54fc3ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_889eee59-7d1e-425a-8638-6e32a54fc3ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_889eee59-7d1e-425a-8638-6e32a54fc3ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_889eee59-7d1e-425a-8638-6e32a54fc3ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f49188bf-ef4a-45d2-8f2a-19a75fecb389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_889eee59-7d1e-425a-8638-6e32a54fc3ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f49188bf-ef4a-45d2-8f2a-19a75fecb389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_4abefe5b-d137-4e7b-b014-69bc717fee55" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f49188bf-ef4a-45d2-8f2a-19a75fecb389" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_4abefe5b-d137-4e7b-b014-69bc717fee55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_407b0b03-da1d-495c-b163-cb63ff3399f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_407b0b03-da1d-495c-b163-cb63ff3399f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35d0411b-52e8-4274-9e31-111df4d21a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35d0411b-52e8-4274-9e31-111df4d21a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a9a6cf8-2e47-4e2f-8904-713cb0f5430c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a9a6cf8-2e47-4e2f-8904-713cb0f5430c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_99efc163-87e3-4242-b863-5b2c7f0fdb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_99efc163-87e3-4242-b863-5b2c7f0fdb2b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_583880ed-557e-4390-b405-52b65172e0ce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:to="loc_srt_OwnershipAxis_583880ed-557e-4390-b405-52b65172e0ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_583880ed-557e-4390-b405-52b65172e0ce_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_583880ed-557e-4390-b405-52b65172e0ce" xlink:to="loc_srt_OwnershipDomain_583880ed-557e-4390-b405-52b65172e0ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ea510f82-3c8f-4a5e-b82c-276aacc70138" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_583880ed-557e-4390-b405-52b65172e0ce" xlink:to="loc_srt_OwnershipDomain_ea510f82-3c8f-4a5e-b82c-276aacc70138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_f7e15a06-abda-4cba-910c-f93bba7da5ef" xlink:href="ino-20240630.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ea510f82-3c8f-4a5e-b82c-276aacc70138" xlink:to="loc_ino_PlumblineLifeSciencesMember_f7e15a06-abda-4cba-910c-f93bba7da5ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18db0824-b496-4ff1-b9ca-e1c51e1c3ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18db0824-b496-4ff1-b9ca-e1c51e1c3ddc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_18db0824-b496-4ff1-b9ca-e1c51e1c3ddc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18db0824-b496-4ff1-b9ca-e1c51e1c3ddc" xlink:to="loc_us-gaap_RelatedPartyDomain_18db0824-b496-4ff1-b9ca-e1c51e1c3ddc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_63c094ba-fdca-4f43-84f4-f959dd35bb30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18db0824-b496-4ff1-b9ca-e1c51e1c3ddc" xlink:to="loc_us-gaap_RelatedPartyDomain_63c094ba-fdca-4f43-84f4-f959dd35bb30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_8ca1d21a-5caf-4390-ad04-7e82259bf607" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_63c094ba-fdca-4f43-84f4-f959dd35bb30" xlink:to="loc_srt_AffiliatedEntityMember_8ca1d21a-5caf-4390-ad04-7e82259bf607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f9382f5-2e35-43b0-8b54-0d8ddc1994b8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:to="loc_srt_CounterpartyNameAxis_4f9382f5-2e35-43b0-8b54-0d8ddc1994b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f9382f5-2e35-43b0-8b54-0d8ddc1994b8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4f9382f5-2e35-43b0-8b54-0d8ddc1994b8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f9382f5-2e35-43b0-8b54-0d8ddc1994b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0935949d-0744-4de5-b35a-02dc46f7fd04" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4f9382f5-2e35-43b0-8b54-0d8ddc1994b8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0935949d-0744-4de5-b35a-02dc46f7fd04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_f38f18e9-7d8d-49e3-a357-3c55be80bc53" xlink:href="ino-20240630.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0935949d-0744-4de5-b35a-02dc46f7fd04" xlink:to="loc_ino_TheWistarInstituteMember_f38f18e9-7d8d-49e3-a357-3c55be80bc53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_afd0feaa-2bff-4c1c-ab57-399af6774844" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_afd0feaa-2bff-4c1c-ab57-399af6774844" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_4e99ba95-7596-4a3b-a532-6e1fdd8dff0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_4e99ba95-7596-4a3b-a532-6e1fdd8dff0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_d75f02f8-6a68-4f2a-b667-947183555ba9" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_d75f02f8-6a68-4f2a-b667-947183555ba9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_f627e9f1-e066-42b7-85c0-f9061266c5af" xlink:href="ino-20240630.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_CollaborativeArrangementTerm_f627e9f1-e066-42b7-85c0-f9061266c5af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_b60fdab3-5730-4e18-a889-ec2c5528a132" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_b60fdab3-5730-4e18-a889-ec2c5528a132" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_721fc0e0-976b-4be6-9e16-68688100c71e" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_721fc0e0-976b-4be6-9e16-68688100c71e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_85d4f495-8057-4d4d-83a9-57fb6036a154" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_85d4f495-8057-4d4d-83a9-57fb6036a154" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_548e80b4-8ace-44f9-93fb-d6ea35c6859d" xlink:href="ino-20240630.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_GrantProceedsReceived_548e80b4-8ace-44f9-93fb-d6ea35c6859d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e7fb2a0-3043-4b4a-834f-77661242b347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e7fb2a0-3043-4b4a-834f-77661242b347" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e164c2e3-5127-41f1-894f-48d4c02503d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e164c2e3-5127-41f1-894f-48d4c02503d8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e102e01-738b-4090-9eac-47145053da34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e102e01-738b-4090-9eac-47145053da34" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_804e6334-635d-4ddc-855d-20ebb93c13a4" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_804e6334-635d-4ddc-855d-20ebb93c13a4" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_3a837ba2-17b1-4bc1-80da-3d4fd31982b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_3a837ba2-17b1-4bc1-80da-3d4fd31982b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3a837ba2-17b1-4bc1-80da-3d4fd31982b9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_3a837ba2-17b1-4bc1-80da-3d4fd31982b9" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3a837ba2-17b1-4bc1-80da-3d4fd31982b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_20b86196-3219-4f37-9b2d-28780cac33a5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_3a837ba2-17b1-4bc1-80da-3d4fd31982b9" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_20b86196-3219-4f37-9b2d-28780cac33a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_24dd1f89-028c-4f2a-b940-42c3e1e8adec" xlink:href="ino-20240630.xsd#ino_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_20b86196-3219-4f37-9b2d-28780cac33a5" xlink:to="loc_ino_SanDiegoOfficeMember_24dd1f89-028c-4f2a-b940-42c3e1e8adec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_07f58d73-a9c9-4421-90b9-d8557765749c" xlink:href="ino-20240630.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_20b86196-3219-4f37-9b2d-28780cac33a5" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_07f58d73-a9c9-4421-90b9-d8557765749c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_054bbe91-4841-4146-a19a-024430807bcf" xlink:href="ino-20240630.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_20b86196-3219-4f37-9b2d-28780cac33a5" xlink:to="loc_ino_SanDiegoCaliforniaMember_054bbe91-4841-4146-a19a-024430807bcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e92bdf4a-f802-4e4d-a768-95e2ae775ef9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:to="loc_srt_RangeAxis_e92bdf4a-f802-4e4d-a768-95e2ae775ef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e92bdf4a-f802-4e4d-a768-95e2ae775ef9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e92bdf4a-f802-4e4d-a768-95e2ae775ef9" xlink:to="loc_srt_RangeMember_e92bdf4a-f802-4e4d-a768-95e2ae775ef9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2fbe6d7f-a0d0-4a7b-b7bc-25ce13424bc2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e92bdf4a-f802-4e4d-a768-95e2ae775ef9" xlink:to="loc_srt_RangeMember_2fbe6d7f-a0d0-4a7b-b7bc-25ce13424bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f96eda91-756c-4e62-b171-6d56455d2200" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2fbe6d7f-a0d0-4a7b-b7bc-25ce13424bc2" xlink:to="loc_srt_MinimumMember_f96eda91-756c-4e62-b171-6d56455d2200" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_325b98a7-6a86-408d-98ea-1848597f4ee1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2fbe6d7f-a0d0-4a7b-b7bc-25ce13424bc2" xlink:to="loc_srt_MaximumMember_325b98a7-6a86-408d-98ea-1848597f4ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b1a9fe8a-c122-4c84-b8e2-ab1f18bd4e7f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:to="loc_srt_LitigationCaseAxis_b1a9fe8a-c122-4c84-b8e2-ab1f18bd4e7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b1a9fe8a-c122-4c84-b8e2-ab1f18bd4e7f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b1a9fe8a-c122-4c84-b8e2-ab1f18bd4e7f" xlink:to="loc_srt_LitigationCaseTypeDomain_b1a9fe8a-c122-4c84-b8e2-ab1f18bd4e7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1927eb8e-73e4-4fcc-891a-4de44d60428c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b1a9fe8a-c122-4c84-b8e2-ab1f18bd4e7f" xlink:to="loc_srt_LitigationCaseTypeDomain_1927eb8e-73e4-4fcc-891a-4de44d60428c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_e360e8bf-a1d9-43b2-87c4-28bd1fdbce29" xlink:href="ino-20240630.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1927eb8e-73e4-4fcc-891a-4de44d60428c" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_e360e8bf-a1d9-43b2-87c4-28bd1fdbce29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember_d92a6116-7613-4121-81c2-2b79f3af2a1c" xlink:href="ino-20240630.xsd#ino_BehestiVKimEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1927eb8e-73e4-4fcc-891a-4de44d60428c" xlink:to="loc_ino_BehestiVKimEtAlMember_d92a6116-7613-4121-81c2-2b79f3af2a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4d9d79e8-e48e-4052-8534-e90484043661" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4d9d79e8-e48e-4052-8534-e90484043661" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_856e19a1-b05b-4b63-942d-65a6f2a2397a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_856e19a1-b05b-4b63-942d-65a6f2a2397a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6b27f394-ffd5-496c-88ea-d7888b1b3423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6b27f394-ffd5-496c-88ea-d7888b1b3423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_a9667f8a-43be-44d1-be73-8c7fc3eb13b7" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_a9667f8a-43be-44d1-be73-8c7fc3eb13b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1fb11564-1aeb-46a3-99b1-a593151dc183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LeaseCost_1fb11564-1aeb-46a3-99b1-a593151dc183" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_81df44f9-e232-4fd7-a0e7-2629ae32ff1b" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_81df44f9-e232-4fd7-a0e7-2629ae32ff1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a4d75743-4b00-4e10-836a-14d95f572d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a4d75743-4b00-4e10-836a-14d95f572d1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_bca9461d-3887-4709-a57c-610b4faccb91" xlink:href="ino-20240630.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_bca9461d-3887-4709-a57c-610b4faccb91" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_7d048c5f-76e7-4ce6-ac27-57af0a006c98" xlink:href="ino-20240630.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_7d048c5f-76e7-4ce6-ac27-57af0a006c98" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_60e6eea6-be0b-43ed-845d-35a30ed7c98c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_60e6eea6-be0b-43ed-845d-35a30ed7c98c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_6bf5b318-f858-422c-b00e-849d7a173439" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_6bf5b318-f858-422c-b00e-849d7a173439" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3101f00c-87d2-47a2-bffb-40404331ab40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:to="loc_srt_CounterpartyNameAxis_3101f00c-87d2-47a2-bffb-40404331ab40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3101f00c-87d2-47a2-bffb-40404331ab40_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3101f00c-87d2-47a2-bffb-40404331ab40" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3101f00c-87d2-47a2-bffb-40404331ab40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3101f00c-87d2-47a2-bffb-40404331ab40" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_76a933ba-8a83-4863-8f25-8091089e2393" xlink:href="ino-20240630.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:to="loc_ino_AdvaccineMember_76a933ba-8a83-4863-8f25-8091089e2393" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_59e37d33-bf52-40b0-b9f7-44e5a0b077cb" xlink:href="ino-20240630.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:to="loc_ino_ApolloBioMember_59e37d33-bf52-40b0-b9f7-44e5a0b077cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_8416bc86-1b7d-4210-af47-c3f021a6c673" xlink:href="ino-20240630.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_8416bc86-1b7d-4210-af47-c3f021a6c673" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_1c2b13a6-db9d-4d13-8bbf-4fbf4ca60c94" xlink:href="ino-20240630.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_1c2b13a6-db9d-4d13-8bbf-4fbf4ca60c94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5d3b5922-6f32-45c8-93a0-8772b4c6b5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5d3b5922-6f32-45c8-93a0-8772b4c6b5bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d3b5922-6f32-45c8-93a0-8772b4c6b5bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5d3b5922-6f32-45c8-93a0-8772b4c6b5bf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d3b5922-6f32-45c8-93a0-8772b4c6b5bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b546e3ec-633c-453e-9cd2-f3e95d35e316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5d3b5922-6f32-45c8-93a0-8772b4c6b5bf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b546e3ec-633c-453e-9cd2-f3e95d35e316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_000aaba4-aa97-488a-806a-e8433b657786" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b546e3ec-633c-453e-9cd2-f3e95d35e316" xlink:to="loc_us-gaap_CollaborativeArrangementMember_000aaba4-aa97-488a-806a-e8433b657786" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a9830e85-345c-4f35-920e-897bc8e3fe35" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:to="loc_srt_ProductOrServiceAxis_a9830e85-345c-4f35-920e-897bc8e3fe35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a9830e85-345c-4f35-920e-897bc8e3fe35_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a9830e85-345c-4f35-920e-897bc8e3fe35" xlink:to="loc_srt_ProductsAndServicesDomain_a9830e85-345c-4f35-920e-897bc8e3fe35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a9830e85-345c-4f35-920e-897bc8e3fe35" xlink:to="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_e017799e-c64e-4e01-bb64-a133b312d446" xlink:href="ino-20240630.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_e017799e-c64e-4e01-bb64-a133b312d446" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_dd7980dd-cb8a-4697-8120-0bd94c4415e5" xlink:href="ino-20240630.xsd#ino_INO4800Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:to="loc_ino_INO4800Member_dd7980dd-cb8a-4697-8120-0bd94c4415e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_8c3445cd-8a21-4629-b825-db138b6211cc" xlink:href="ino-20240630.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_8c3445cd-8a21-4629-b825-db138b6211cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_b11ae8ab-1a0a-4e32-a3cb-d0361976ab3a" xlink:href="ino-20240630.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_b11ae8ab-1a0a-4e32-a3cb-d0361976ab3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_b5790bb7-b9b0-42b9-bda7-3158b6fd54ac" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_b5790bb7-b9b0-42b9-bda7-3158b6fd54ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_fbee874f-540f-4fcf-a06f-51f7ae6800f7" xlink:href="ino-20240630.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_fbee874f-540f-4fcf-a06f-51f7ae6800f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_1c7e7f09-9599-474f-bcb4-58963566b7e6" xlink:href="ino-20240630.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_1c7e7f09-9599-474f-bcb4-58963566b7e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b9cc751e-4aa4-4f13-bd78-42d62b960d69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b9cc751e-4aa4-4f13-bd78-42d62b960d69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_620a7cd5-9051-4b90-abc7-c6f7fafb3d7a" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_620a7cd5-9051-4b90-abc7-c6f7fafb3d7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_7271801c-e55b-472c-91b8-d23f636666b7" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_7271801c-e55b-472c-91b8-d23f636666b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_09d27051-50d8-4406-a1d5-bb6857b3d100" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_09d27051-50d8-4406-a1d5-bb6857b3d100" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_21611c1b-b826-4dc7-b44c-51d8f6ba578b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_21611c1b-b826-4dc7-b44c-51d8f6ba578b" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#GeneosTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e6cb8392-54ba-4661-82b1-8f31c1220835" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:to="loc_srt_CounterpartyNameAxis_e6cb8392-54ba-4661-82b1-8f31c1220835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6cb8392-54ba-4661-82b1-8f31c1220835_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e6cb8392-54ba-4661-82b1-8f31c1220835" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6cb8392-54ba-4661-82b1-8f31c1220835_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fedf6c9-61bf-47b9-891e-3e61b55299ec" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e6cb8392-54ba-4661-82b1-8f31c1220835" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fedf6c9-61bf-47b9-891e-3e61b55299ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_152ea9af-dc81-4f57-81ae-81329394674c" xlink:href="ino-20240630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fedf6c9-61bf-47b9-891e-3e61b55299ec" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_152ea9af-dc81-4f57-81ae-81329394674c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_150a0cb9-3a58-4798-ab0b-3fb18ffe68cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_150a0cb9-3a58-4798-ab0b-3fb18ffe68cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_150a0cb9-3a58-4798-ab0b-3fb18ffe68cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_150a0cb9-3a58-4798-ab0b-3fb18ffe68cc" xlink:to="loc_us-gaap_ClassOfStockDomain_150a0cb9-3a58-4798-ab0b-3fb18ffe68cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_150a0cb9-3a58-4798-ab0b-3fb18ffe68cc" xlink:to="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_0a3bcf50-23c9-4b63-8cb7-b014febc3362" xlink:href="ino-20240630.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:to="loc_ino_SeriesAOnePreferredStockMember_0a3bcf50-23c9-4b63-8cb7-b014febc3362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_73242bf5-df3c-4f11-89d4-cf27cedc113f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:to="loc_us-gaap_CommonStockMember_73242bf5-df3c-4f11-89d4-cf27cedc113f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_39b8e369-4c07-442b-845f-3484104f04eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:to="loc_us-gaap_PreferredStockMember_39b8e369-4c07-442b-845f-3484104f04eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_830435ce-d618-4c52-bcde-6a8f6c7ed9a8" xlink:href="ino-20240630.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_830435ce-d618-4c52-bcde-6a8f6c7ed9a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_bdf76da7-5695-48ab-b161-827f2a47ec64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:to="loc_srt_OwnershipAxis_bdf76da7-5695-48ab-b161-827f2a47ec64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bdf76da7-5695-48ab-b161-827f2a47ec64_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_bdf76da7-5695-48ab-b161-827f2a47ec64" xlink:to="loc_srt_OwnershipDomain_bdf76da7-5695-48ab-b161-827f2a47ec64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d586f48e-302b-4a43-940b-7a3c6dc0c86b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_bdf76da7-5695-48ab-b161-827f2a47ec64" xlink:to="loc_srt_OwnershipDomain_d586f48e-302b-4a43-940b-7a3c6dc0c86b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_c7c2a0f5-b4c5-4d01-a3f2-5ac51c531dd6" xlink:href="ino-20240630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_d586f48e-302b-4a43-940b-7a3c6dc0c86b" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_c7c2a0f5-b4c5-4d01-a3f2-5ac51c531dd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_2cd8a72e-ed1d-49f7-af8a-a4c458ddd488" xlink:href="ino-20240630.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_2cd8a72e-ed1d-49f7-af8a-a4c458ddd488" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_03cbf939-2a54-4521-afc1-877ff1552f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_03cbf939-2a54-4521-afc1-877ff1552f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1326ea60-22c0-4e12-96ee-39190f43dd14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_EquityMethodInvestments_1326ea60-22c0-4e12-96ee-39190f43dd14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_32b10e99-1830-4e57-bdc0-90f5ac525f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_32b10e99-1830-4e57-bdc0-90f5ac525f4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_65514d51-e80b-4842-a686-47b336aa94d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_65514d51-e80b-4842-a686-47b336aa94d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_fab1a060-e568-4cd8-9d9e-e0fd34f0e7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_fab1a060-e568-4cd8-9d9e-e0fd34f0e7d3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_eb54cca7-6307-408e-8e87-c5dba1c9d079" xlink:href="ino-20240630.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_eb54cca7-6307-408e-8e87-c5dba1c9d079" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_bd19a35f-632b-4ae2-b423-2bc5616b7727" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_bd19a35f-632b-4ae2-b423-2bc5616b7727" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_ce412b70-f7b9-46dc-8424-4486a45f5bb6" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_ce412b70-f7b9-46dc-8424-4486a45f5bb6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_15a8a549-ac85-4cb8-9fe3-3fcef5675e85" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_15a8a549-ac85-4cb8-9fe3-3fcef5675e85" xlink:type="arc" order="7"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ino-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0d8c4537-ca52-4f1a-a8a1-280952f330d4,g:ffaafe34-d428-4f21-bdf4-6dece8c876eb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_08f1729c-9ba8-4686-8434-7e7ea4398436_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of pre-funded warrants, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a24826f-cb92-4a0c-b123-d71e969f9f53_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8a2c2bb2-5157-4117-80c4-650945b3ae8a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b78598a1-d516-4c26-83db-d0f6afec6f7a_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_88fee8ee-b429-4daf-b223-75dce0adc867_negatedTerseLabel_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest on senior convertible notes</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_label_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense" xlink:href="ino-20240630.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestIncomeExpense" xlink:to="lab_ino_NonCashInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_23c6c11f-0303-4dce-b340-020dd7597e01_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_51706829-fb96-4523-a9ea-4e7115244e12_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_4efe4088-1c66-49ad-b8c8-857249cb0205_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7aefcbc7-16ef-40b1-a956-417abcb7bd1b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64e6fa00-41ff-4491-b87b-e80d4acdea7b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e1b3f922-4b8d-4bc0-8941-f9593fbd38a7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ede70491-30b9-4580-9dd2-acbf7d73e110_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_155eb9ff-4973-45bc-bb2d-0d3de66f114d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_55881b9a-cb92-43dc-95f3-90ee5718c5d2_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20240630.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f48726c5-fa56-4bf1-a7eb-fa7da646990b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_c7ba96fd-abbb-4ea1-8eb8-25511dbd7a68_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9ef98f07-20a9-443d-9dbc-c8a90bec9f63_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d79ce1c7-51ff-48ab-9ec8-75988fb8ce79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_311b3780-3a76-430a-8871-c128f3535ed7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_890e581a-9dc2-4d07-a3bd-5b84934c06b2_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contra-research and development expense</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20240630.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d16b2fe8-dc7e-4d56-88de-aa3cbd550872_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_2e9950f8-7d57-4eb4-9854-b1e93403926f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d7a17d44-aeac-4eb4-9c59-c3dfd52b0733_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5b5dcf12-5604-4948-b3dd-c5b0ad228348_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_dd0c25aa-1b1d-4e01-b0a6-f1707be6986f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6b78ee04-2f6e-4c96-bd01-ba601146acc2_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0547444e-31cc-4bc6-9e40-bbd17c32bd00_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_bc6d8675-74fb-4874-95d7-3ac45d3c0ae7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized loss on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1195972b-bb83-4220-9e7e-50b5b5ba89cb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_6311bb03-d17d-4d04-8b9b-7f32925c1b73_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_939574ac-dc79-4e75-8fa9-3eddfefa769e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f5dbecb7-a40b-43eb-8659-210113739557_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6c3267a3-64e6-42d1-998c-d85ade3ebb1d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c42685a4-3d00-4aee-8631-05a740daccd8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_a5a306d9-7597-46da-b88b-0aa61364fd8c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of discounts on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bd0c4dd-ea54-48ea-bbf8-f18a25b40751_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_770ca409-db34-4e15-b8e2-3a051607c89e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_5d987ba6-e3a8-4765-9e09-b20f9263c5fc_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8a70c4ea-28fc-43ab-b57e-9bb967963453_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4292f215-ea31-4489-b403-065d9feb5db6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_502946cc-8472-45da-b61c-02812f1c9e5f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses - Clinical Trial Accruals</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3f0b31f6-4b5d-4014-8edc-755960ec580e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7d61586e-f0b6-4f0f-a070-7eda44ae166b_netLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_a6acbd69-423b-4857-8b31-9c88b966806b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a1c42c00-b6a6-4e26-bb8a-136f81f13b46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_605a2c9c-aa48-46ab-967b-7e98649b266f_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20240630.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e50be168-8f52-466d-9468-b982f4141dbe_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO4800Member_ee4898c5-6c9d-4ef4-98a3-b658ba4e2247_terseLabel_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INO-4800</link:label>
    <link:label id="lab_ino_INO4800Member_label_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_documentation_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member" xlink:href="ino-20240630.xsd#ino_INO4800Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member" xlink:to="lab_ino_INO4800Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1dbc8ee4-8fae-44f6-a729-1592cf3f0937_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_add5665a-a4c4-4ff3-a5ac-109aafef8a1b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdf7ac10-7571-40e4-b100-9a1edf612d35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_dec328df-b941-4ba5-ae5b-c1a7406df201_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_5ef31322-0a06-4101-914a-44f7ed5de438_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5006fa5f-b3cf-4aea-af70-8971a79c3dbe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_172edef5-af07-4d55-8776-d709d5cf05ae_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantLiability_a83b3a80-2bc5-4e78-81f9-6a52a00ba1bb_terseLabel_en-US" xlink:label="lab_ino_GrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant liability</link:label>
    <link:label id="lab_ino_GrantLiability_label_en-US" xlink:label="lab_ino_GrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Liability</link:label>
    <link:label id="lab_ino_GrantLiability_documentation_en-US" xlink:label="lab_ino_GrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantLiability" xlink:href="ino-20240630.xsd#ino_GrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantLiability" xlink:to="lab_ino_GrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55dd01c5-4c8c-4ed7-a595-9bbe86cccb3c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7488cee8-8367-4d5c-b47d-684bbc21dabd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_9515f0e2-914e-4230-9a38-5ee2fb0eb7f6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e13c0c67-cb9a-4c4c-9cff-6aea960527a2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation cost related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_f8bb28d8-da2a-40da-9d46-ee4bf71ec9fb_verboseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_c5f1a05e-89e1-4b30-b841-da9eea62f658_terseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20240630.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BehestiVKimEtAlMember_458839e2-11a5-45ae-8f4f-8f748ab16ccf_terseLabel_en-US" xlink:label="lab_ino_BehestiVKimEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Behesti v. Kim, et al.</link:label>
    <link:label id="lab_ino_BehestiVKimEtAlMember_label_en-US" xlink:label="lab_ino_BehestiVKimEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Behesti v. Kim, et al. [Member]</link:label>
    <link:label id="lab_ino_BehestiVKimEtAlMember_documentation_en-US" xlink:label="lab_ino_BehestiVKimEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Behesti v. Kim, et al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember" xlink:href="ino-20240630.xsd#ino_BehestiVKimEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BehestiVKimEtAlMember" xlink:to="lab_ino_BehestiVKimEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c4b493cc-e9da-406d-bf69-2c40e5276043_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7120b7d7-0d3a-48a5-b466-4d6a9a5f40d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_c8ff26ce-a392-460b-bc0d-821b6fee44af_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bill and Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20240630.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ff136f14-a3c2-49f0-8fcf-4786b83a7fcd_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_433b466c-f99b-482b-8dbc-411d20429267_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_915c4eab-d568-4618-bd52-10a96c1f44c2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_0e2b1bd1-ac83-4645-ba78-8917f9d516aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_fe635a52-5f27-4333-8257-2e52c2e52457_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_57381b66-6ed0-42ba-adf2-6a9a76a22ef8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_9d657dd0-c3af-4b75-b4bd-73981d57d48b_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20240630.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1ed6efb4-c2ad-45b7-abb8-64bc5d82bbaa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1acf4f75-176a-4bcc-8395-e50bc22886b7_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4cc4b661-b618-466d-aa6e-4f2ec9f8f991_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_01452501-df22-42ec-9525-b766e6565a81_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0fa77e70-fe9d-4ef6-8445-2f1c908c622c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d325337a-6d95-4437-a637-930b33f872c4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2021SalesAgreementMember_36cb91db-b8d7-4f9c-bf47-5cd6cb58914d_terseLabel_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement</link:label>
    <link:label id="lab_ino_A2021SalesAgreementMember_label_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_A2021SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember" xlink:href="ino-20240630.xsd#ino_A2021SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2021SalesAgreementMember" xlink:to="lab_ino_A2021SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4396d69b-0021-4cbb-a38f-bca110a96408_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8c4a9e4b-a104-4807-b08d-97ad02d89eb0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_e930cc37-dac0-4314-9ef9-154aeed30601_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract_378b736a-d128-4513-afd7-ca2d1843f2b9_terseLabel_en-US" xlink:label="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="ino-20240630.xsd#ino_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1b4937cb-92eb-4c6c-84f3-4c0d6bddd737_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_bbdd70ef-21ba-4c14-8ff9-06406c212f99_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7da0c52a-96e6-4a29-bb5e-006df4fe6089_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45a4a04b-f5bb-4269-85a0-697a653f04ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_08cbb3bb-79b7-43fa-b662-fc2a314b3986_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_0f33868d-2583-4875-98e0-4efa2db732f2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4400f843-2c11-409e-8725-c65c7ad2fd79_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_56208d04-5249-46f9-82c6-76e2d6668b1f_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_65e6a200-816f-4321-9677-a5a737adaf0c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_9ce99efb-9991-44f1-9687-8af3cb8ec320_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_948046d1-f09a-44da-9c0c-610801fe0ec1_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage-Backed Security, Issued by US Government-Sponsored Enterprise [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_7e7004e5-f39c-415f-8a17-5a626736c962_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_049df4b8-0507-40e9-9b6e-99b2fa136fbc_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20240630.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0330352b-aca6-4ac4-bf46-2a66e0524272_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1168bb86-d76f-40da-8eb1-817fb4cf3301_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_cfc8a32d-0712-4584-afc6-23acd1909562_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d066afbc-3eb5-4ddb-82f2-58edf1dc3f1a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Liquidity</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c58ebad-96b7-4f9d-8b19-7d42c274b7ef_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1e276c27-a815-45e7-b3b0-704ea23d8f43_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f233b388-057a-43b9-a479-a0ce8df1039e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bad4426f-32a3-4f3d-b587-af92ec603b9f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d05c961f-5fee-48a3-bbe3-795df74b3c0d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_781447d7-9668-4841-9cf2-cdd6807f02ca_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_66bd3742-bf66-4131-8add-3ed06d17d8ea_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9a795671-6325-42af-9b13-e81e56388361_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_8b401465-d3a2-4e5d-9383-cce322a1d3c4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_f6402df5-5c6c-44c1-a39e-6ab39a4303a6_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_9b609d34-79f3-4c20-beb0-ead8d7806b27_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">(Loss) gain on investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_bc3e6024-5d51-46b8-bb6d-1ebfd2b05b35_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on equity investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20240630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_86e0e06f-87b7-4089-ae60-82b4cfc00496_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_788407c1-17d2-4d2b-a220-ffada0eb5bb2_terseLabel_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</link:label>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_label_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]</link:label>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_documentation_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:href="ino-20240630.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:to="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2de5dfa7-a261-4e4b-9b6a-f68335ed2c5b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_6abf0333-ea6e-4457-bc20-5f1039fcd8cd_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_832dfb41-044d-45dc-87e9-978da0da32c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_9a88af34-9b21-4a38-a25c-193960fbfbd9_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_9365817a-499c-4026-a7e2-7d7f5d623396_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20240630.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_795ae8a2-c8ec-4e89-ba93-15d1dd05f00f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a00024cd-6a30-4e59-920b-ebff70d9d121_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e010ff58-904b-4a6a-bdcc-4e49b77860b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_073e37a4-7878-40a9-ae4d-49823c60cb2e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent (in percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d51e6e73-7190-43ea-a40c-d3f6611c112b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6a7dddfa-bb45-4b42-9661-89c2b074948a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e73cddfc-7b1e-49f9-a2c0-fb8f9b7e670b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2e8807e7-0bd7-41b4-8806-c55956757353_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e695e795-ac65-4af9-83dd-07ef2867e1f3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AdvaccineMember_a5dfeba0-124f-46f3-b5cf-9bdbbc4d480b_terseLabel_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advaccine</link:label>
    <link:label id="lab_ino_AdvaccineMember_label_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaccine [Member]</link:label>
    <link:label id="lab_ino_AdvaccineMember_documentation_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember" xlink:href="ino-20240630.xsd#ino_AdvaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdvaccineMember" xlink:to="lab_ino_AdvaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_4e29b61c-3e6b-47c5-9828-7ccf6eebf01d_terseLabel_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, sales proceeds of any common stock, percentage (in percent)</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_label_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_documentation_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:href="ino-20240630.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:to="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_9632f687-9fb8-4019-8af2-1afdd0671593_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_6654077c-457d-4ded-a785-746ce2af6d96_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_811b0fbf-3f4d-48dc-bf5b-aab0d90b52a1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_8a8702c8-5ba6-4b14-bb08-5e67bc010ceb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ab771655-0d0e-4a45-9ee3-f4eade2da581_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_8c0ca9c0-550f-4a68-b311-182c79edd6b6_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold, percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:href="ino-20240630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6756ba32-0098-4e0d-be39-4bf702bdc0ed_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_a7b4a716-a342-4d53-837e-5889e913fd4e_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred grant funding, from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_43d9c82b-4316-425f-9579-cf585eed2158_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20240630.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_1faa52cc-f808-40f8-97e0-2e697fa8eac7_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49f96b9e-84cf-4d49-a9d1-92a50be86cc7_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_cd82e7c4-5ab0-42fe-9392-6775069e223e_terseLabel_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="ino-20240630.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_332bf4dc-db8a-4c2e-9e2d-3339a5c8e741_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bd9f9722-97b2-425d-ad61-099f68011686_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_f4fddb5c-fe7e-4c32-ba4f-a72ce20f3c15_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2b4db673-fe9f-4223-8a3a-0ed619077a0e_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_b0c133f9-b8df-4c18-8368-d8cf56ec754f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef7d1330-bdf0-462d-bc1d-cd6040ee1ae5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_0a9f2baa-2707-4b02-a354-876e27fbbf2e_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20240630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0f539eb1-3d64-4c1e-92f0-f6bbad986658_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_c6a211a6-2a37-45af-99b8-9c25839d93a7_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2a0c0576-ff72-4f9b-b9dc-5b86a3c81672_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_198a092b-1155-45f4-8097-5253b57b2124_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e1e6badd-90d4-493f-9cc9-150dbff05754_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_a1d7c003-dab2-45dc-adad-e47c759c80db_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_1db20d3d-6440-49b1-9e06-cac0b514e400_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember_0f65090f-bc4a-405e-afe1-23eb3b97b58b_terseLabel_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market-Based RSUs</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember_label_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Market-Based [Member]</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember_documentation_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Market-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:to="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_89505f07-1071-4fea-a246-63f13c843307_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_73d21019-dd82-45c9-8a3b-b3ad75b3dc08_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6fa804cb-17c6-41a1-83b4-99cda6156a03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4683ae1d-ae3f-4e75-8d26-838851627af2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3be14f30-9124-41c7-8943-0e6948418f9a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_a9cd2084-b671-4298-b8fb-5a47a541ed44_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20240630.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_6f3e7190-acae-42c1-8121-2a34b7001fd5_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_dfe18706-7fee-4dd1-ba73-1ba0ebb476ab_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_fd3e6ff3-3613-44af-b4bf-b08ac0ae1593_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability from affiliated entity</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_9d3f5a6c-5ab2-4a06-ab65-28e9482f02c9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Product</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a660b316-7a5c-4e3d-979d-6f09d97f7d94_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_c28841d0-a79e-4cdb-8775-951923eae26c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1464305d-c18f-4d2f-b790-e9694258bcba_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_4a3431f7-7ca2-4b09-8f01-4e33bb8697fb_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_81833739-b54e-4293-8fa1-56c8a2b6d526_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_646609b0-7ca7-425d-9c66-f8a218b9ecc8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8c80a3ab-51b4-4a00-b275-16660bf85729_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_3b26c45b-4a7c-4d74-a52d-7b0ab92ce363_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_be13bf77-0c6e-45de-bd99-9664ecd56218_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_249a4aa0-d421-433c-8071-e927814c28fb_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5e26bcc0-7e6f-4032-a1be-902819c1f1af_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_2fde12fb-9519-4ff9-bac3-c10a418182a9_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_61b6e472-5271-481d-b113-79be1156e70f_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20240630.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1220d76f-e04e-4e67-b763-e044b41c210d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_58324d30-6d5c-40e0-b6cd-101bd5ec15c6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_73772775-c724-4f9a-bbe9-00722b1701f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0e22e89d-907c-408a-997f-61bd9073641c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_9f5d8a6f-08a9-48cf-8052-c685f51a83ad_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_9b22320a-ed6d-4796-b55e-eb5ff09ba0e3_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Maturity&#160;(in&#160;years)</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20240630.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_67af9339-3fd9-4edc-9357-6454c4d9291b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_df40c1d9-deac-4511-95ae-60e89b3cb45d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_805eed05-5c8a-4c11-a6a2-784cf82c05a3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of capital assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2f0e51d8-4536-4e78-8102-3d2c20fb3ca5_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_6348a643-2627-40e2-8d29-836d43f86aab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt interest based on the fixed rate (in percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6d666efe-c7d8-415d-ad6e-36fe10037689_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of pre-funded warrants for cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_8ec7ee16-573a-4b63-823e-8bb0eeca3a2e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_9e0f2177-966d-4077-a5a5-a71764c62238_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b90d1437-a59b-4c4f-bde1-4831991355f1_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5f3f69b1-0d2e-43e4-99e2-6b0d12f2c197_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f54f19c1-6a09-4bf1-bff6-956c820b0178_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative arrangements and other contracts</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb41dca9-5091-4bc9-9de2-526128a906ca_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0a3c4438-87af-48d0-a60e-df43da0e1435_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_681e6abb-b728-4b41-943c-eb8c82b6cd20_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d87d4b1d-9a03-4528-b54d-e3004dffdd79_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e411cb89-9e4f-430f-86c8-224a7159df37_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0812fba3-515e-43db-bfdd-721d738c43b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0f912c6d-7325-4e5f-aae6-52d7b4ce75e5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4a4e1cf2-071f-4003-bac3-ce930afc3d3e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_232e4fdc-02b9-4d04-8a2e-605790a8223e_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Resulting in again on remeasurement</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d66454d-bf10-480e-8852-5b2cf979e762_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_ba7408f7-3cce-404d-ae47-f38e7f39ed02_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_f1ffe519-f4e4-4f80-a10c-e2a1dc8442c5_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_55a02293-24ad-491b-9a37-4b2a54b06888_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20240630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6152ee48-f297-4dd4-8bf0-d2d094fba456_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8237723f-1c97-4c40-829d-0b50982757d1_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dd15dd08-20a2-44a8-b93e-90fa08c888fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_584d4fa5-11d8-4aa9-bf75-af97e96097b3_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_85ddfbb9-fa4a-4fa1-bdbf-ab13eaf24e3f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a1da59d8-177d-4a9f-812e-e98e3991f64d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_190079ee-7115-4e97-8aba-89e8d57d444d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_63bdeccf-8ee2-433b-8819-e0495dad384e_terseLabel_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A One Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember" xlink:href="ino-20240630.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesAOnePreferredStockMember" xlink:to="lab_ino_SeriesAOnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_3873f606-ac95-4d28-80cd-29bcd5b7e65e_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2b345461-ad68-4d1f-a65b-6cc177c71471_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e7d91cb-4b7a-4a61-8269-d5fe98c1bf81_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_449ff465-5906-4eea-9bbd-8c3373a73f2f_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fd02498-67d9-4a57-9c1c-384d887d6e7e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_ee27c446-8f2d-41a3-b523-7eb57d151b0e_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20240630.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_754b5085-0b3f-40f0-9857-d887f14d7b56_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of cash settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_9d1e5a20-0b21-4c70-9e5a-a47de1063a75_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_e46fbfbe-94e5-4168-a825-45c177b69765_terseLabel_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_label_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_documentation_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember" xlink:href="ino-20240630.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoCaliforniaMember" xlink:to="lab_ino_SanDiegoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_b5e665e8-54f1-4cad-b873-e90b7c543959_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:to="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_fad9399a-ed36-4a2a-9f36-78ea5990314b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summary of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_37830107-3647-4ac5-ace8-6285c6bf5ced_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapital_ef06b901-6cdd-4fdb-8876-125dfb03ab76_terseLabel_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ino_WorkingCapital_label_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ino_WorkingCapital_documentation_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital" xlink:href="ino-20240630.xsd#ino_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapital" xlink:to="lab_ino_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2022InducementPlanMember_e97df0f7-4fcc-4ab1-a204-afdf9013f4db_terseLabel_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_label_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan [Member]</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_documentation_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember" xlink:href="ino-20240630.xsd#ino_A2022InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2022InducementPlanMember" xlink:to="lab_ino_A2022InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_e7aa0ce6-3196-464a-8dc4-d648873a1e82_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability, including from affiliated entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20240630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidClinicalExpensesCurrent_b7c32a27-70f0-4033-9c72-1a53364a81ed_terseLabel_en-US" xlink:label="lab_ino_PrepaidClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid clinical expenses</link:label>
    <link:label id="lab_ino_PrepaidClinicalExpensesCurrent_label_en-US" xlink:label="lab_ino_PrepaidClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Clinical Expenses, Current</link:label>
    <link:label id="lab_ino_PrepaidClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_ino_PrepaidClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Clinical Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidClinicalExpensesCurrent" xlink:href="ino-20240630.xsd#ino_PrepaidClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidClinicalExpensesCurrent" xlink:to="lab_ino_PrepaidClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_2997713b-5ff3-4f77-917f-786bd3e09c74_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:href="ino-20240630.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_56473615-0c90-4531-b0fd-d571208dfc39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_815b33c0-d993-4ea3-b381-c392d92e829d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_955dcc25-a4d3-4e94-ae6f-33f5b128447d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, restricted stock units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_f4c877c6-7109-4ad6-8df7-191b2eac7aa8_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoOfficeMember_959afbd3-6f7f-4a94-847d-a84a9fd79351_terseLabel_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_label_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_documentation_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember" xlink:href="ino-20240630.xsd#ino_SanDiegoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoOfficeMember" xlink:to="lab_ino_SanDiegoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_11d612bc-fc60-4b85-b9e9-31c69aeacf4e_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area leased (in square feet)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_bb25936a-254d-4c4b-a198-6392e54905f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6048f4f4-d1f4-4a46-abf2-e0237248205e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5d39afa5-cbd2-444a-983d-52c8bd8414cf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a878eff1-3955-4c0d-817c-ce2a7c606701_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_42314b05-c742-4dbb-bcc3-70cbc6c18ee8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_547edba0-2cd6-4915-b93b-7cce5eedcdfd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6ba2eeb6-9451-472c-b56b-dfaac42a33f2_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20240630.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_a9261605-081c-4bef-9157-5427d7ee5244_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock as part of litigation settlement</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_12047b6c-dd4c-41f6-9511-a5a12d3472f2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1a7e2180-1e7d-4a57-97e5-71ff23d9db24_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_104216ad-7f20-4379-9fa0-5c21583cfeac_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_678a068a-8a06-4129-93b4-5566cf010144_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities, current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_52d540dd-8d41-496c-be89-ee34fab2350b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_206969e7-90ca-4c16-9410-672b0cd68182_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_f3bda52a-e235-4839-8bab-fa8597d56caa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_469b6280-3a72-4339-9e1f-24443cab63d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1c0342af-3d4d-4f50-a725-727dd7168b2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_8bfd5d1b-e9fb-4c11-84dd-ccabe437daff_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate proceeds</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20240630.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_e70bffb4-346d-4e2c-8537-9d73acb85fac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1a12dcc7-90ff-4e40-acd5-e3b186ffbe22_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Grant Date Fair Value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:href="ino-20240630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0cc351df-b467-40dd-aad8-828d2f531b1d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e5525035-4949-4f1c-b2f6-90f051cd6e1b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_593f64ee-3d10-4707-8871-c2744aee2883_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:href="ino-20240630.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_06dcddce-d2a2-40d6-b25a-c75871f8b31b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b3e6035c-d45b-4d5b-b2ad-e774c280a4e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_299151ab-aa35-4164-9d6e-f3b10262bba9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b68914cb-d8f0-4a18-be3c-0a18c0391f9b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_c8fe26ec-c894-47db-8ab9-e21f13f04276_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_bdf6ed89-218d-40ce-a368-5a347f41b36c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_81eb69c3-8160-4794-b34c-ee17a48de115_terseLabel_en-US" xlink:label="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Assumption Used in Monte Carlo Simulation Method</link:label>
    <link:label id="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="ino-20240630.xsd#ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_971a3465-5c5b-4489-a20b-cb0692e28cb1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4000a8c3-e26d-49ac-aa21-bc377455205b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_04d9a995-ceac-405e-b603-3ed4e8aa3c90_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07405d81-4cad-47e7-a66d-cc9a6e47f0b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, net of financing costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_f15358f8-3a21-43c7-ac70-d46ef0964ea7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in a gross unrealized loss position for more than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b086ed79-ef26-4b6d-ac07-f5c6e7ee3e32_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_eca16bcc-d337-457d-a0dd-8895a14a329d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_7de2311c-d4f4-4be3-99e5-8c2094c97e74_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_d394de3a-7ef6-4b42-897a-25cc8ba4acb9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_a8bb308e-73e9-4969-b06f-c89e9c1cc2a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d4b48de8-ed82-4f72-b450-a05ed7fd551e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8dbc81d7-5257-48c5-a6af-4228df25c160_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses, including due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e2581a59-40b5-4fb0-a028-35f26db90a2e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_03bd2145-b90d-497e-b6cb-858008f8c664_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c10d263f-50d7-4471-a663-005b4e422ae3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7a0c5a07-b815-4c12-bf2e-c1dccff94f95_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04747ce3-ba02-4cf1-aaf4-09289921d557_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b8595aa3-2ee6-4e04-8ad7-dd8c471e1301_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a0f66c89-56ea-498e-a4ee-5436bfc89801_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_dfbadebe-e156-4749-8da6-7500b4c165c2_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20240630.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ad9decac-5c28-4f8a-a383-0ea8ae658766_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_2d5de992-db6c-4610-b061-2296db476c5a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, contractual interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4339bf36-f50b-4546-bff8-fc6ebae604f7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_47af085e-e3aa-4260-a012-2cfd40a14ac2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6739341c-b151-41eb-9960-8671c66b87be_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Critical Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_854d2252-ba2e-42ca-bcc3-47e6e6a5d839_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, other shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_a70a0d9b-80f4-4d2a-b50e-3b1dd7ad2c92_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_db8f03b7-4895-4d2b-bc52-039e1ba4d86c_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20240630.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a4837fe9-2b6b-41d8-84e9-fe50da6d6de8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0053fda1-abad-4f6d-a555-7c7f1186c7f8_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_a89e0f81-f952-47c2-aa65-91f08b037c21_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_9c832eb2-7069-4fdf-9d70-37caa1301894_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_80592931-fdfb-4488-9ff9-7d85d9621232_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_70de75cf-39a1-4974-9aee-210f41d3a5ae_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_2f1c99cc-c616-49b3-9f1e-2bedf75694c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6af92e11-b210-4d98-9e4e-a76ee8e069aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_95e1952d-dd22-4ee8-87d0-64d0551c6c5b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_cfb32149-1373-4c24-b205-036d718d17c9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_031d5bb5-4618-4a4f-a944-4c3935481c9a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_c091e777-7773-4666-a3f6-87cf80f23e29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_8673244e-c72f-4673-a222-84064dfb2ea0_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities that are measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9fd290d3-9755-431d-942f-32730fdf04ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_b192627f-5c5d-44f5-949e-114014639ad6_terseLabel_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Stockholders Return</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_label_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Total Shareholder Return [Member]</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_documentation_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Total Shareholder Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:to="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a62fe34e-73c7-4189-9633-afb2bc2c36c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dd61417d-40ce-430e-a441-2a99b94895b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b99e745c-e42e-4f74-b711-cbac22a7e8de_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_89fd2ce9-bdb3-4b90-bc6a-e2a201a3ea7c_netLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_aacc311d-91a4-4c5f-82e4-b042197d6c97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_03b9886a-1392-4e3e-89a3-0923f4770727_terseLabel_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, common stock ownership (in percent)</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_label_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Percent</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_documentation_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:href="ino-20240630.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:to="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_e2c5194f-a165-46bd-846b-29e82f7f7a38_terseLabel_en-US" xlink:label="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average pre-funded warrants (in shares)</link:label>
    <link:label id="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_label_en-US" xlink:label="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants</link:label>
    <link:label id="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_documentation_en-US" xlink:label="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:href="ino-20240630.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:to="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3736331d-c826-405a-a3eb-7a29368d366e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_1decfe72-4035-4771-8520-dcdc8c679dc7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_495ec821-e7aa-4154-825c-7fb69e0902f8_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9f6c9f3c-6de5-4616-ad63-b61efe0d2994_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (loss) gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3fbd9b64-f3ac-400a-8389-499ad0cbcbdb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_94c1b873-590e-42d3-ac2e-d993c13b3060_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56aae8fa-d5c4-4ca8-af6d-433314fdbb05_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f6a22e0f-37c3-46a0-9db4-ea940f4fe5b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5aa049db-aebc-488c-a9b9-7b148ff76b14_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_239657cc-81e5-4c8a-bece-7387d4f8cb57_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_47d01210-4e10-43e0-8dad-152f23f7bd57_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2023IncentivePlanMember_8ecd080c-43a4-4dcc-aff6-5e0c34accaeb_terseLabel_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan</link:label>
    <link:label id="lab_ino_A2023IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2023IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember" xlink:href="ino-20240630.xsd#ino_A2023IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2023IncentivePlanMember" xlink:to="lab_ino_A2023IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_cfc81c76-082f-4895-9b7f-345f67634a31_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20240630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cef90cdb-a5eb-48fe-819d-4f6b0890d452_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b40d3bb6-502f-46fe-bc55-1b72611f3fac_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5da74355-5cd2-458a-b2eb-ed0d6cd4534b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_054e48e7-c7af-4eb3-9476-6420fa00f2df_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, amended amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAmendedAmount" xlink:to="lab_ino_CollaborativeAgreementAmendedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_75885bcb-06f8-4ddc-9fd2-29c46931bfbc_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_5d06daf9-09e8-4de8-ba7f-9a5be05c3631_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, funding received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived" xlink:to="lab_ino_CollaborativeAgreementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_e32903e8-9870-439e-b310-df14c2a49626_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_9fb51fd8-78f1-4675-8952-5e6fa86fa7dc_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d5642850-0827-46f0-8787-ccb7de931ea8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a38fd02b-de05-4753-af8a-5be65e026390_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_294ebc2b-33c5-49c8-8cc5-7561886c3323_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa0ed064-867c-4ce0-b8c9-d62fa7aa288e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1094aef9-948e-489e-b98a-a6aef5eb240d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_53482071-c26d-4ec8-908e-e13d9fff5912_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnderwrittenRegisteredDirectOfferingMember_2e67b2ac-f80f-4ea8-a928-12c4ae8421d7_terseLabel_en-US" xlink:label="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Registered Direct Offering</link:label>
    <link:label id="lab_ino_UnderwrittenRegisteredDirectOfferingMember_label_en-US" xlink:label="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Registered Direct Offering [Member]</link:label>
    <link:label id="lab_ino_UnderwrittenRegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwritten Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:href="ino-20240630.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:to="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_14eb531b-9450-42ba-a0ab-9bcdc5914b3d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_9a348beb-62a0-4c5a-9257-2b09f02adbb4_terseLabel_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-2 One Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-2 One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-2 One Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember" xlink:href="ino-20240630.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesA2OnePreferredStockMember" xlink:to="lab_ino_SeriesA2OnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_b68b6ffa-09ed-4a22-89d0-d361fad79ccb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements and Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3795d583-0ebf-4373-9889-691410bfe4a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_dfeb9e3d-db44-4ad9-bbca-16a12eac124b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd8f985e-161f-4c41-bfa4-f93da5a44df8_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_268ff799-6278-4903-b4c3-23baa43e1bd2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidManufacturingExpenseCurrent_bc17ddca-d3bf-4250-9b26-1611d8b5590c_terseLabel_en-US" xlink:label="lab_ino_PrepaidManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpenseCurrent_label_en-US" xlink:label="lab_ino_PrepaidManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Manufacturing Expense, Current</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpenseCurrent_documentation_en-US" xlink:label="lab_ino_PrepaidManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Manufacturing Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpenseCurrent" xlink:href="ino-20240630.xsd#ino_PrepaidManufacturingExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidManufacturingExpenseCurrent" xlink:to="lab_ino_PrepaidManufacturingExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_079c26dc-a6c9-4aeb-8383-fe0f66b2e575_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_75bc0f77-dd6b-4307-94b6-e96ddc8e697a_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, term (in years)</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20240630.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4a94703-8993-4b1e-92f0-1aa53caeb7fa_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7caaf777-73e4-4a0e-8e35-70987abd8420_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_04808b52-6c53-432f-bf7c-694b5379a8ac_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_label_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_documentation_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:href="ino-20240630.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:to="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_a880ad3f-d601-486d-978a-d9870fdee82e_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_ae8139f6-e9c2-4822-8c5f-29f41890160e_negatedTerseLabel_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss from equity method investment, recorded and allocated to investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_label_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_documentation_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:href="ino-20240630.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:to="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7f18b783-0aea-413b-9edc-4ed268352ec4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_71b0f60d-4ff8-4c91-834f-843013162d11_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_69c40785-d5d3-46c2-9549-34e4d3fa15e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2da2010e-211b-4751-a76e-d5beb323b936_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4759cd69-a6c1-49df-8f7f-ef7b501a3f39_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_01ffc18d-1f08-486a-b094-a728488dcc14_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_952f3ad6-bd4d-4cee-91a4-11428f437082_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_37af8bc8-cbd0-4d4e-89dd-b0896794641d_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contractual term (in years)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20240630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_cf4cfc67-8cea-4bb9-9c2b-268299ce1173_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_ee4accac-076d-44f7-8437-efe1f618ee5c_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development (in years)</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b56d9746-2807-4836-93c0-16e23cb3f2b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cef0a1e9-047d-4a41-b151-66e46617f806_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_313260a8-5abb-41f6-abe5-4cbb38a2ca4d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_5ef47360-3eb3-49e7-80a2-6c5a9d751a30_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20240630.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0e3a71a8-06a6-4bd4-86e4-2b5f06afc6ba_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_341f2239-f393-42ac-8516-52923b51e972_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:href="ino-20240630.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_fe557c2d-2bbe-44a5-bed3-e217e7c410a7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages paid</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_29061b13-9357-4400-84ea-b62ce3356072_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation, Liquidity and Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_5b4bbcea-a915-45b3-bc59-36ac1495db25_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_facbbddb-d58e-4906-b241-997245135df4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f92938f1-1184-4ecb-bf7a-1207efff0f83_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_44aa9e48-f839-424e-9e1f-29bf6769fa6e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e19773a8-9aeb-48e1-b843-261cb3e84001_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1339b72c-0632-4058-b73d-64d01cab0873_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e667b93e-2f58-4b4c-af0e-b1791cd57760_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_27ef8cce-7469-4254-be64-f99db6eb249b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_7ca9ffe3-b3f3-40ad-a449-f2e1db63a1f9_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20240630.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_b54eb77a-e006-40d3-9c65-c87e7583f3a6_terseLabel_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of shares settlement</link:label>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_label_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss, Value of Shares</link:label>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_documentation_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss, Value of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:href="ino-20240630.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:to="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ba790d4e-0129-4e56-84d7-c1dc6e10d9ef_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f9b7d55d-ea65-4fac-a990-5ab671f16328_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_85340325-1a3f-4fd3-92fc-5a0b05b357fa_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_885f7ddf-e718-4ec5-ad13-ec251c5a8d2c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_27006770-aa8a-48eb-acdd-38ac09ff1633_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WeightedAverageNumberOfSharesOutstanding_ee4c23b4-b857-4b58-bf02-5517fb72d62d_terseLabel_en-US" xlink:label="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_ino_WeightedAverageNumberOfSharesOutstanding_label_en-US" xlink:label="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Shares Outstanding</link:label>
    <link:label id="lab_ino_WeightedAverageNumberOfSharesOutstanding_documentation_en-US" xlink:label="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding" xlink:href="ino-20240630.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WeightedAverageNumberOfSharesOutstanding" xlink:to="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_302749c5-df8d-4d61-85e6-52b138949027_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_label_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items [Abstract]</link:label>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_documentation_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract" xlink:href="ino-20240630.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract" xlink:to="lab_ino_CertainBalanceSheetItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_756cc647-77e2-471a-a912-0642dee0f0fd_terseLabel_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone-Based RSUs</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_label_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Milestone-Based [Member]</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_documentation_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Milestone-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:to="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_95717c76-dbc1-4cca-978c-f7a3b18c5334_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_76daed29-b9fd-4c04-a6eb-8978e6ff73cc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c9bfd3f1-63ca-44c7-880d-fc0d0c498fdf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_148243a6-43cb-434c-adee-fa00ed387af4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c8098d15-5edf-4956-a5ec-cc82c0deb316_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_4818f711-a009-4362-b0aa-539f4424f1d7_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20240630.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0523c645-dcc7-41d4-a75f-1e0c15f9ccf9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1aceafc8-74de-4714-ba94-17760eea8443_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c2250888-5db8-4cb9-bf50-ed47cea795ae_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_ec03b028-2b5f-45ad-810d-ea4bada480e9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares used to compute net loss per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_339018ad-b291-4de6-b03b-cde7895af2c8_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty period (in years)</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20240630.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_03ba8f5b-b5d2-44c4-adfa-925e092fd424_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_cbb48daa-ed70-4bd3-99c1-6b3315aa368c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1f7b6284-0ba6-432b-b472-6f822baef6a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2a67268f-9f0a-4954-830a-ea9a0c0a6e2a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_78781caa-9565-47a3-a26f-892a5c8b6aea_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2e551d44-c36d-4961-b3a0-3b007906e899_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_7a55b627-e34e-4379-9fd8-df2a1442e161_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20240630.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be7a26dc-b8b8-4675-badb-07b84b5ea695_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a2cf2370-4c81-45b5-8f65-6189d17108c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_45e728a9-c061-451b-a599-65eebc81f833_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement weighted average price (in dollars per share)</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20240630.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_a09be30e-3caa-4e8c-a4f6-da10c1e46515_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20240630.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_3932da76-c457-4303-b456-73b31d67bc2d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_982c85b5-e1c6-4cae-941f-8e438bf24389_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1400f12c-406c-46ec-9811-a2105ae05d00_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_9d5b3781-2ac4-44b9-b9f8-bec599c94c73_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, base rate percentage (in percent)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:to="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_2fd0b75d-7a13-4cbc-9d3c-abd117c06b81_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ed099ebf-f447-460a-b6f4-8dc61f471920_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_03110124-13e1-4a86-9030-6a87fd7af067_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e39ae294-9d52-4a07-9f72-5b5204b4e0b8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_8cbd3612-a823-42cc-a393-2941274a5b74_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseOperating_17a1d4dd-5834-412d-99ed-510ad0c254e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseOperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseOperating_3232c1b6-5bd0-4100-a1a1-7c2ded3df5e1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseOperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseOperating" xlink:to="lab_us-gaap_InterestExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_e7a731a2-ae13-40bc-8e01-04d8ebaba304_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7d31b35f-8e3c-421f-891f-bce9b4172e97_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b26eeaae-2c95-4d23-91ee-a2e495227b59_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5192c4b4-ac8c-4c81-8dbd-e59c6d9671c6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_4a236d23-6470-4241-ab65-34fa958cea4c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest (in percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dcfc6060-1351-4121-93a5-0437a203cc21_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_41815f76-76e6-409a-89f9-8e1b5ca02eb6_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b248b19-bf3a-4bd6-8df5-397e431281ba_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares_a8a3f67e-5465-4d64-b987-7c263d7a1707_terseLabel_en-US" xlink:label="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in settlement (in shares)</link:label>
    <link:label id="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares_label_en-US" xlink:label="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party, Shares</link:label>
    <link:label id="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares_documentation_en-US" xlink:label="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:href="ino-20240630.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:to="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d6575ef8-0052-4777-ab3d-e66690c2813f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance-and market-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_063253d0-7203-4f60-b7dc-2be0c06d2521_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Agreements To Sublease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Agreements To Sublease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:to="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b4b9f4e6-cdb8-4c09-b187-162016705347_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_a41a1c97-b193-4710-b2b5-cb35a1e38581_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lassa Fever and MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20240630.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_abc66c2a-b2b8-4b49-aafc-4e2376f5f995_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_d4a6262b-30e0-4736-b8cf-dbdad8d2cc72_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_484208f4-003a-4478-b7e1-db8d6c34e395_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a443a03a-163b-493a-8204-482d146a9b50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ino-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0d8c4537-ca52-4f1a-a8a1-280952f330d4,g:ffaafe34-d428-4f21-bdf4-6dece8c876eb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/Cover" xlink:type="simple" xlink:href="ino-20240630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_13a54045-84f2-4181-942f-59fe7515b196" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_DocumentType_13a54045-84f2-4181-942f-59fe7515b196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_787e2e75-6961-46c1-b21f-526344f5a0cf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_DocumentQuarterlyReport_787e2e75-6961-46c1-b21f-526344f5a0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8eed6e02-b06c-42c0-9cb8-5b947e178e68" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_DocumentPeriodEndDate_8eed6e02-b06c-42c0-9cb8-5b947e178e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2896d99f-7afd-4d92-b33d-8695b1387edf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_DocumentTransitionReport_2896d99f-7afd-4d92-b33d-8695b1387edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6c5ca7c7-e7af-4a35-a0cf-9359006a16a3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityFileNumber_6c5ca7c7-e7af-4a35-a0cf-9359006a16a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5adde35e-1dd7-420a-a7f2-ce848c0adfb5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityRegistrantName_5adde35e-1dd7-420a-a7f2-ce848c0adfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bf3e88f4-a1ac-4674-91ac-bdd23cc62428" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bf3e88f4-a1ac-4674-91ac-bdd23cc62428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_69c88e74-294b-409e-bcad-e73b848b7062" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityTaxIdentificationNumber_69c88e74-294b-409e-bcad-e73b848b7062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6c4ddb53-14f5-4202-94b8-cc4bfc8111ed" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityAddressAddressLine1_6c4ddb53-14f5-4202-94b8-cc4bfc8111ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_0bf8ab14-ccb5-4e1f-abae-bce5c06ada75" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityAddressAddressLine2_0bf8ab14-ccb5-4e1f-abae-bce5c06ada75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_396e82cb-69a9-420c-8019-6682706a59bb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityAddressCityOrTown_396e82cb-69a9-420c-8019-6682706a59bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3299b9fc-00f4-4a8f-afc8-58a969291f1b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityAddressStateOrProvince_3299b9fc-00f4-4a8f-afc8-58a969291f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4c112e2c-e4ca-4665-8ee5-c18154d298b1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityAddressPostalZipCode_4c112e2c-e4ca-4665-8ee5-c18154d298b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4dba9bbd-8ab3-4013-89b2-fa34438ec239" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_CityAreaCode_4dba9bbd-8ab3-4013-89b2-fa34438ec239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_592ba4f2-d871-4185-a94c-a45feee4287c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_LocalPhoneNumber_592ba4f2-d871-4185-a94c-a45feee4287c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_809c5dc7-ec0d-4b04-b2af-1ee61a6c3846" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_Security12bTitle_809c5dc7-ec0d-4b04-b2af-1ee61a6c3846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c31085d5-7185-473d-9190-8ea6e929cf82" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_TradingSymbol_c31085d5-7185-473d-9190-8ea6e929cf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_753018e8-45fb-4490-ab0b-cd8e32f83fde" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_SecurityExchangeName_753018e8-45fb-4490-ab0b-cd8e32f83fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a58947c2-d0a4-4730-a1f9-ad3513a861bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityCurrentReportingStatus_a58947c2-d0a4-4730-a1f9-ad3513a861bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_556767d4-0485-4c84-ab6b-5339fec8ac0b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityInteractiveDataCurrent_556767d4-0485-4c84-ab6b-5339fec8ac0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b4e523e6-0aa6-49db-affd-122e87b4019e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityFilerCategory_b4e523e6-0aa6-49db-affd-122e87b4019e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_435ffda3-4602-4d63-b564-87640ece3177" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntitySmallBusiness_435ffda3-4602-4d63-b564-87640ece3177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7e5b1d61-56d6-4b04-916b-66cff18b8a54" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityEmergingGrowthCompany_7e5b1d61-56d6-4b04-916b-66cff18b8a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_be50eada-b0c2-45ae-ba9c-37636ef3687a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityShellCompany_be50eada-b0c2-45ae-ba9c-37636ef3687a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0f329415-ce96-4fdb-b1bd-2a6e3698b2ce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0f329415-ce96-4fdb-b1bd-2a6e3698b2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b23ebb8c-7311-44f8-a7d1-79dc6d687ae4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_AmendmentFlag_b23ebb8c-7311-44f8-a7d1-79dc6d687ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0bf92ea3-3402-4929-bc4a-93ef910fd70a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_DocumentFiscalYearFocus_0bf92ea3-3402-4929-bc4a-93ef910fd70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_badd8e1d-a94f-4dfe-ad33-2e6bd4ad3bff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_DocumentFiscalPeriodFocus_badd8e1d-a94f-4dfe-ad33-2e6bd4ad3bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1b410702-93ce-4e72-936d-b0cff9861dad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_EntityCentralIndexKey_1b410702-93ce-4e72-936d-b0cff9861dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c4b1fa74-d5f1-4fdf-be54-af9ff1b84521" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b21693a3-ca8b-4ce7-8715-f6d6c9faa266" xlink:to="loc_dei_CurrentFiscalYearEndDate_c4b1fa74-d5f1-4fdf-be54-af9ff1b84521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3cc69a-4d2e-4f26-ad94-ae3239d8d8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fbedf581-446b-451e-87b8-ae75189202fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3cc69a-4d2e-4f26-ad94-ae3239d8d8a0" xlink:to="loc_us-gaap_StatementTable_fbedf581-446b-451e-87b8-ae75189202fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bf0a701c-ac38-4abc-b719-6c93bf6c9021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fbedf581-446b-451e-87b8-ae75189202fd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bf0a701c-ac38-4abc-b719-6c93bf6c9021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d28858ec-c565-49f2-8cc5-b39232dc3c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bf0a701c-ac38-4abc-b719-6c93bf6c9021" xlink:to="loc_us-gaap_RelatedPartyDomain_d28858ec-c565-49f2-8cc5-b39232dc3c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_32c82f4b-bc08-40cb-a9c6-a278a60adc61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d28858ec-c565-49f2-8cc5-b39232dc3c3b" xlink:to="loc_us-gaap_NonrelatedPartyMember_32c82f4b-bc08-40cb-a9c6-a278a60adc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_794fd077-52c4-4a48-bd28-61269fe2ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d28858ec-c565-49f2-8cc5-b39232dc3c3b" xlink:to="loc_us-gaap_RelatedPartyMember_794fd077-52c4-4a48-bd28-61269fe2ddba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b8246f86-4d7d-42dd-9763-d7a69265a530" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fbedf581-446b-451e-87b8-ae75189202fd" xlink:to="loc_us-gaap_StatementLineItems_b8246f86-4d7d-42dd-9763-d7a69265a530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b8246f86-4d7d-42dd-9763-d7a69265a530" xlink:to="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9e02d40-8009-4b7d-8643-ac84d929b156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9e02d40-8009-4b7d-8643-ac84d929b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_dcccb636-a209-46ed-a4a4-60c9c1e5d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_us-gaap_ShortTermInvestments_dcccb636-a209-46ed-a4a4-60c9c1e5d7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_407a7d08-dda2-45cf-bc9b-11740e8033ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_407a7d08-dda2-45cf-bc9b-11740e8033ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d879576f-265d-4d07-950b-40cad18f10e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d879576f-265d-4d07-950b-40cad18f10e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_648c0ba9-9829-4f7c-b970-726e4185cfc0" xlink:href="ino-20240630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_648c0ba9-9829-4f7c-b970-726e4185cfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a762e3ec-8e8f-4c88-8e87-049f7a6fc617" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40de74f6-5325-410b-bcbd-89ecf40326c9" xlink:to="loc_us-gaap_AssetsCurrent_a762e3ec-8e8f-4c88-8e87-049f7a6fc617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de3cd34e-ff28-42bb-a54d-197c2f4fd9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_de3cd34e-ff28-42bb-a54d-197c2f4fd9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_249fe031-6697-48c1-97fc-fd24c41992f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_249fe031-6697-48c1-97fc-fd24c41992f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7312efd9-8af2-466a-b0da-0baf256afda9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7312efd9-8af2-466a-b0da-0baf256afda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_62e3f116-5221-414d-95b4-d3ce46d9b54b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_62e3f116-5221-414d-95b4-d3ce46d9b54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5edc4405-009a-4974-bc17-21213fe0ae90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8585c9b2-5beb-4501-a7f7-1a748ab19fad" xlink:to="loc_us-gaap_Assets_5edc4405-009a-4974-bc17-21213fe0ae90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b8246f86-4d7d-42dd-9763-d7a69265a530" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c4f28786-0926-4789-afec-bbbf71a6e6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c4f28786-0926-4789-afec-bbbf71a6e6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_23633dd8-a370-470d-aabb-b2a73a41d842" xlink:href="ino-20240630.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_23633dd8-a370-470d-aabb-b2a73a41d842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae96af40-e4bc-4c81-8105-fe03df05ca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae96af40-e4bc-4c81-8105-fe03df05ca5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_b57d8aa9-ba16-4291-ade2-2ae8f6205c91" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_ino_DeferredGrantFundingCurrent_b57d8aa9-ba16-4291-ade2-2ae8f6205c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4bc0d9de-ae1f-4a5e-aadf-a28c289b9bdd" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4bc0d9de-ae1f-4a5e-aadf-a28c289b9bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_243f8a40-afec-4446-8f60-915b8c95857e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_243f8a40-afec-4446-8f60-915b8c95857e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ed2a9af9-a745-4bd1-9aeb-3f18a4035f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c19df937-6541-4645-a9c2-5421db64a042" xlink:to="loc_us-gaap_LiabilitiesCurrent_ed2a9af9-a745-4bd1-9aeb-3f18a4035f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d9456116-03e9-434f-b23c-ecdd1e55c459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d9456116-03e9-434f-b23c-ecdd1e55c459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7cfd0ad7-ab0f-41c5-a6f2-bf75306482d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:to="loc_us-gaap_Liabilities_7cfd0ad7-ab0f-41c5-a6f2-bf75306482d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5916f41f-e966-403b-8cb1-24c02ebc2dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_PreferredStockValue_5916f41f-e966-403b-8cb1-24c02ebc2dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b3c5f573-7c65-4e27-b77f-a486177abe81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_CommonStockValue_b3c5f573-7c65-4e27-b77f-a486177abe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d1d08fbe-780c-4d68-bcfd-c18e9d1a13a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d1d08fbe-780c-4d68-bcfd-c18e9d1a13a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71f1cf97-dec4-47b4-b9f6-2c3ee1f8593d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71f1cf97-dec4-47b4-b9f6-2c3ee1f8593d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d4a9c6f7-dbc6-4f96-932f-d7ed11f9f890" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d4a9c6f7-dbc6-4f96-932f-d7ed11f9f890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b7d25d3-a173-450a-a6cd-aa5506e48c30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e86c65ba-9b62-40e4-ad65-d5cba43c5272" xlink:to="loc_us-gaap_StockholdersEquity_7b7d25d3-a173-450a-a6cd-aa5506e48c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d7aa974-a69f-436d-bbed-45b4a596e772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d84f1b9e-051a-4090-b9c0-55da24502192" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d7aa974-a69f-436d-bbed-45b4a596e772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2a679791-2962-47a3-9b53-f133fc4c8587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0adf58c3-5c87-4e28-87dc-18f70424b716" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2a679791-2962-47a3-9b53-f133fc4c8587" xlink:to="loc_us-gaap_RevenuesAbstract_0adf58c3-5c87-4e28-87dc-18f70424b716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_923c9c5a-7710-4228-bbd7-eb4b102a0ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0adf58c3-5c87-4e28-87dc-18f70424b716" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_923c9c5a-7710-4228-bbd7-eb4b102a0ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_12577060-23f1-4d41-afc1-00c5729c3f68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2a679791-2962-47a3-9b53-f133fc4c8587" xlink:to="loc_us-gaap_OperatingExpensesAbstract_12577060-23f1-4d41-afc1-00c5729c3f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f755f9ad-67f9-4407-be9e-00e969d9415a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_12577060-23f1-4d41-afc1-00c5729c3f68" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f755f9ad-67f9-4407-be9e-00e969d9415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_041dc42c-78a4-4e76-baaf-9ec8d8d232e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_12577060-23f1-4d41-afc1-00c5729c3f68" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_041dc42c-78a4-4e76-baaf-9ec8d8d232e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dac94979-bffe-4832-ab48-8517078c4b27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_12577060-23f1-4d41-afc1-00c5729c3f68" xlink:to="loc_us-gaap_OperatingExpenses_dac94979-bffe-4832-ab48-8517078c4b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ff82061-92de-4d3b-958d-ac3550ff6178" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2a679791-2962-47a3-9b53-f133fc4c8587" xlink:to="loc_us-gaap_OperatingIncomeLoss_7ff82061-92de-4d3b-958d-ac3550ff6178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88774c7e-92c2-4a29-9ca6-f6fb9057633b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2a679791-2962-47a3-9b53-f133fc4c8587" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88774c7e-92c2-4a29-9ca6-f6fb9057633b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_907cbb0e-3572-43cf-b7f0-7e18f64f7785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88774c7e-92c2-4a29-9ca6-f6fb9057633b" xlink:to="loc_us-gaap_InterestIncomeOperating_907cbb0e-3572-43cf-b7f0-7e18f64f7785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating_6999120f-524f-4958-a115-ea175e3e116a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88774c7e-92c2-4a29-9ca6-f6fb9057633b" xlink:to="loc_us-gaap_InterestExpenseOperating_6999120f-524f-4958-a115-ea175e3e116a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_7fa1ffbf-2644-47a9-91eb-0d97c707ef5c" xlink:href="ino-20240630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88774c7e-92c2-4a29-9ca6-f6fb9057633b" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_7fa1ffbf-2644-47a9-91eb-0d97c707ef5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_55abc1c3-3145-43fa-9c26-370d0de4b3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88774c7e-92c2-4a29-9ca6-f6fb9057633b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_55abc1c3-3145-43fa-9c26-370d0de4b3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_506cfced-a393-4571-bf2b-74e90bbf1243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88774c7e-92c2-4a29-9ca6-f6fb9057633b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_506cfced-a393-4571-bf2b-74e90bbf1243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1f4f2b44-dd8e-43e9-84de-c323391ee12a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88774c7e-92c2-4a29-9ca6-f6fb9057633b" xlink:to="loc_us-gaap_NetIncomeLoss_1f4f2b44-dd8e-43e9-84de-c323391ee12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2fac9cb3-09e3-455d-af72-46a6dae6676b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2a679791-2962-47a3-9b53-f133fc4c8587" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2fac9cb3-09e3-455d-af72-46a6dae6676b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6470194c-6b27-4e3c-9806-1d7dbf7d3346" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2fac9cb3-09e3-455d-af72-46a6dae6676b" xlink:to="loc_us-gaap_EarningsPerShareBasic_6470194c-6b27-4e3c-9806-1d7dbf7d3346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b3c04976-9afd-4cb1-ae6d-6456a8b89928" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2fac9cb3-09e3-455d-af72-46a6dae6676b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b3c04976-9afd-4cb1-ae6d-6456a8b89928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_12cc01b6-ec79-4c14-a338-6acefd56b5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2a679791-2962-47a3-9b53-f133fc4c8587" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_12cc01b6-ec79-4c14-a338-6acefd56b5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c8494821-06d3-49d1-905c-c354f8c634db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_12cc01b6-ec79-4c14-a338-6acefd56b5b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c8494821-06d3-49d1-905c-c354f8c634db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e0e8e585-b293-4548-9336-d2170661e9db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_12cc01b6-ec79-4c14-a338-6acefd56b5b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e0e8e585-b293-4548-9336-d2170661e9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedStatementsofOperationsParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e526a860-09d0-4e0f-abd6-7745bc295861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_b30f2166-d0b6-464f-b6af-49260e4a5949" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e526a860-09d0-4e0f-abd6-7745bc295861" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_b30f2166-d0b6-464f-b6af-49260e4a5949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c759159f-dd0f-4caa-bb39-c96ecb9c33dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_50339a07-bab9-454f-90fb-3b2d19e1da8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c759159f-dd0f-4caa-bb39-c96ecb9c33dc" xlink:to="loc_us-gaap_NetIncomeLoss_50339a07-bab9-454f-90fb-3b2d19e1da8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_88889001-b325-4aa4-9274-8816666e4e24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c759159f-dd0f-4caa-bb39-c96ecb9c33dc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_88889001-b325-4aa4-9274-8816666e4e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c2ffe18c-8d3f-476b-956a-12dc5a82cbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_88889001-b325-4aa4-9274-8816666e4e24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c2ffe18c-8d3f-476b-956a-12dc5a82cbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_490b183d-eb1f-409d-bcf8-7f0f1d8cb607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_88889001-b325-4aa4-9274-8816666e4e24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_490b183d-eb1f-409d-bcf8-7f0f1d8cb607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_aeec3963-db22-4e26-94cf-f3750f71a427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c759159f-dd0f-4caa-bb39-c96ecb9c33dc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_aeec3963-db22-4e26-94cf-f3750f71a427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d9a6f152-09be-4952-8b23-4e4c049ad340" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_799a15b4-c784-44ab-9acf-8b2b6d50410b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d9a6f152-09be-4952-8b23-4e4c049ad340" xlink:to="loc_us-gaap_StatementTable_799a15b4-c784-44ab-9acf-8b2b6d50410b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_de45cd97-14e6-42f1-a3ed-30eaebb37145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_799a15b4-c784-44ab-9acf-8b2b6d50410b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_de45cd97-14e6-42f1-a3ed-30eaebb37145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_de45cd97-14e6-42f1-a3ed-30eaebb37145" xlink:to="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_94e8842d-a16e-4398-a78e-13b2ccf72e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:to="loc_us-gaap_PreferredStockMember_94e8842d-a16e-4398-a78e-13b2ccf72e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0f333a31-d4df-481a-b210-b9bac66cc23f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:to="loc_us-gaap_CommonStockMember_0f333a31-d4df-481a-b210-b9bac66cc23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_623b76a4-e1a5-431e-8282-2d5be1854bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_623b76a4-e1a5-431e-8282-2d5be1854bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ca52c778-624b-4d64-89c9-27db2944c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:to="loc_us-gaap_RetainedEarningsMember_ca52c778-624b-4d64-89c9-27db2944c59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472ba77e-e29b-49a4-a965-2ea8575face0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9d9d559-63c5-453b-9f49-bbc25262b769" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472ba77e-e29b-49a4-a965-2ea8575face0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_78292f59-60b7-4d60-b238-635e8bb68ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_799a15b4-c784-44ab-9acf-8b2b6d50410b" xlink:to="loc_us-gaap_StatementLineItems_78292f59-60b7-4d60-b238-635e8bb68ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78292f59-60b7-4d60-b238-635e8bb68ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_fab3b6be-7b08-41aa-8e61-b29f544e2424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_SharesIssued_fab3b6be-7b08-41aa-8e61-b29f544e2424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_734df0c9-d2e2-4193-a4d1-91eab734cea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockholdersEquity_734df0c9-d2e2-4193-a4d1-91eab734cea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4a661fa6-ad61-465c-8b02-5583eadefe9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4a661fa6-ad61-465c-8b02-5583eadefe9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d3e2643d-c5fe-4e9b-8837-41e16be9ce2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d3e2643d-c5fe-4e9b-8837-41e16be9ce2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b02393ea-d8cf-4a16-a78d-4e63b31f02da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b02393ea-d8cf-4a16-a78d-4e63b31f02da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0e19afb8-fff4-40eb-bf55-dca6f7b2c45a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0e19afb8-fff4-40eb-bf55-dca6f7b2c45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7df554f8-7117-4de2-a6fb-b3500674ced0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7df554f8-7117-4de2-a6fb-b3500674ced0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d26f411e-306e-476b-bd99-09fa3c60b7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d26f411e-306e-476b-bd99-09fa3c60b7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_435024e5-386b-48c4-bedf-e9585adce526" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_NetIncomeLoss_435024e5-386b-48c4-bedf-e9585adce526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9d602719-310e-43e3-ad09-7a3bdd5b6b64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9d602719-310e-43e3-ad09-7a3bdd5b6b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4f2a601c-e8f8-49c3-ab1f-a26774288323" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4f2a601c-e8f8-49c3-ab1f-a26774288323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_7393fee5-2acc-4859-b774-7a553fbd9660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_SharesIssued_7393fee5-2acc-4859-b774-7a553fbd9660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8fceb70-c9de-4382-a72d-74cc8560d2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d699d1f5-8c60-4254-af39-963e3a4ad671" xlink:to="loc_us-gaap_StockholdersEquity_a8fceb70-c9de-4382-a72d-74cc8560d2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a2245720-3d30-4b69-8fca-54912dffede9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a3f45f33-bfc2-422e-a19e-ab20e6e1548f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a2245720-3d30-4b69-8fca-54912dffede9" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a3f45f33-bfc2-422e-a19e-ab20e6e1548f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20240630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d4c528dd-e91f-4231-b26e-7956445aea7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4093a803-8628-455b-86f8-b381bb313a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4c528dd-e91f-4231-b26e-7956445aea7c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4093a803-8628-455b-86f8-b381bb313a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_951df7ac-0a2e-4abf-8338-5db3213c8f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4093a803-8628-455b-86f8-b381bb313a5d" xlink:to="loc_us-gaap_NetIncomeLoss_951df7ac-0a2e-4abf-8338-5db3213c8f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4093a803-8628-455b-86f8-b381bb313a5d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1a855ccc-3405-4ad1-84b9-8374fc65323d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_us-gaap_Depreciation_1a855ccc-3405-4ad1-84b9-8374fc65323d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_30fc799a-234d-4353-b3a4-5af3b69d8e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_30fc799a-234d-4353-b3a4-5af3b69d8e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_cf519889-3b03-44ab-9eb9-fc6aea89a5da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_cf519889-3b03-44ab-9eb9-fc6aea89a5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_95838dbe-ec42-45e5-9e51-3713cd51bea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_95838dbe-ec42-45e5-9e51-3713cd51bea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_33132ee1-43c3-4bb1-a58c-803d0312b732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_us-gaap_ShareBasedCompensation_33132ee1-43c3-4bb1-a58c-803d0312b732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_580d6bea-cbff-42a2-8d5d-b681204e9a73" xlink:href="ino-20240630.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_ino_NonCashInterestIncomeExpense_580d6bea-cbff-42a2-8d5d-b681204e9a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_3193042a-34ef-4e22-9f7d-65bb9399af70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_3193042a-34ef-4e22-9f7d-65bb9399af70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_c2d9d755-b581-49bd-859a-1d5f8d72dceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_c2d9d755-b581-49bd-859a-1d5f8d72dceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8bf28e45-3968-4094-b0ef-403ab4a3b305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8bf28e45-3968-4094-b0ef-403ab4a3b305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_9f69a694-6482-4e3d-ac33-bc2174784f32" xlink:href="ino-20240630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_9f69a694-6482-4e3d-ac33-bc2174784f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_04dac534-dd2e-4752-aa6d-c04164a19616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_04dac534-dd2e-4752-aa6d-c04164a19616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b0ea3804-03d0-409b-b965-5e0e878169ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e76724d-bdd0-4b2c-bde0-eb7b68d00bb6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b0ea3804-03d0-409b-b965-5e0e878169ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d0705cab-e707-4dcc-bbad-646094107d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b0ea3804-03d0-409b-b965-5e0e878169ce" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d0705cab-e707-4dcc-bbad-646094107d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_94ab8760-09f9-453c-b1d6-d0a8446e979e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b0ea3804-03d0-409b-b965-5e0e878169ce" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_94ab8760-09f9-453c-b1d6-d0a8446e979e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a731f476-8e39-4fef-8fd7-6493e7965a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b0ea3804-03d0-409b-b965-5e0e878169ce" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a731f476-8e39-4fef-8fd7-6493e7965a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c151a66e-3545-4957-a341-84d8d8994754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b0ea3804-03d0-409b-b965-5e0e878169ce" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c151a66e-3545-4957-a341-84d8d8994754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_afd1c845-ba32-4ded-b04f-4b2a5a2d23eb" xlink:href="ino-20240630.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b0ea3804-03d0-409b-b965-5e0e878169ce" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_afd1c845-ba32-4ded-b04f-4b2a5a2d23eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_9133029e-2b25-46b4-ac81-0be0437d34a7" xlink:href="ino-20240630.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b0ea3804-03d0-409b-b965-5e0e878169ce" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_9133029e-2b25-46b4-ac81-0be0437d34a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_72a08e15-fe2b-4444-95d4-3ac674eef475" xlink:href="ino-20240630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b0ea3804-03d0-409b-b965-5e0e878169ce" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_72a08e15-fe2b-4444-95d4-3ac674eef475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc837d40-bd17-44cf-9a1a-94a163f0e0df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4093a803-8628-455b-86f8-b381bb313a5d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc837d40-bd17-44cf-9a1a-94a163f0e0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5603699-e381-4945-b5d0-93a4da88eabe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4c528dd-e91f-4231-b26e-7956445aea7c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5603699-e381-4945-b5d0-93a4da88eabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_186d1c4c-3e1d-4991-902b-62bf2b676240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5603699-e381-4945-b5d0-93a4da88eabe" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_186d1c4c-3e1d-4991-902b-62bf2b676240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_74202013-bd1a-4dcb-8d3f-d4695a7408fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5603699-e381-4945-b5d0-93a4da88eabe" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_74202013-bd1a-4dcb-8d3f-d4695a7408fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4231d7bf-9288-48e2-84a8-ff4c8bd38aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5603699-e381-4945-b5d0-93a4da88eabe" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4231d7bf-9288-48e2-84a8-ff4c8bd38aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f7052214-3e97-45f4-b64e-ba73e0d11131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5603699-e381-4945-b5d0-93a4da88eabe" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f7052214-3e97-45f4-b64e-ba73e0d11131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_be2edd4f-5bf4-4999-b5cc-da879a919a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5603699-e381-4945-b5d0-93a4da88eabe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_be2edd4f-5bf4-4999-b5cc-da879a919a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_719429b2-dcb6-4e29-a9b0-138ea25fa3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4c528dd-e91f-4231-b26e-7956445aea7c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_719429b2-dcb6-4e29-a9b0-138ea25fa3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_91bf5753-085e-4809-baef-7cf59bee2e05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_719429b2-dcb6-4e29-a9b0-138ea25fa3f0" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_91bf5753-085e-4809-baef-7cf59bee2e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_4d54a92c-ef4c-4a5f-8ce6-4356b4555c78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_719429b2-dcb6-4e29-a9b0-138ea25fa3f0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_4d54a92c-ef4c-4a5f-8ce6-4356b4555c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ceeeab98-baba-4029-b20d-1a6eae92dcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_719429b2-dcb6-4e29-a9b0-138ea25fa3f0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ceeeab98-baba-4029-b20d-1a6eae92dcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b248dc86-6052-42e7-a99e-1120d4fdd93a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_719429b2-dcb6-4e29-a9b0-138ea25fa3f0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b248dc86-6052-42e7-a99e-1120d4fdd93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_bd1421f4-8d64-47ad-8a31-fbf7688d6ccc" xlink:href="ino-20240630.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_719429b2-dcb6-4e29-a9b0-138ea25fa3f0" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_bd1421f4-8d64-47ad-8a31-fbf7688d6ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19adbbda-c440-4831-b76e-426a82cca87b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_719429b2-dcb6-4e29-a9b0-138ea25fa3f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19adbbda-c440-4831-b76e-426a82cca87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79fd1fdd-b761-4f6e-ac14-0db760643197" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4c528dd-e91f-4231-b26e-7956445aea7c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79fd1fdd-b761-4f6e-ac14-0db760643197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e2a50e8b-2eff-4fb6-8ac4-4b7510306d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4c528dd-e91f-4231-b26e-7956445aea7c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e2a50e8b-2eff-4fb6-8ac4-4b7510306d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56ada0f4-c9f4-4931-8b14-902d5685189a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4c528dd-e91f-4231-b26e-7956445aea7c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56ada0f4-c9f4-4931-8b14-902d5685189a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_402c3643-ca0c-4b78-9aeb-2907fb866ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4c528dd-e91f-4231-b26e-7956445aea7c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_402c3643-ca0c-4b78-9aeb-2907fb866ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6eb5fc45-98e8-44e7-894b-cad10a7aef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4c528dd-e91f-4231-b26e-7956445aea7c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6eb5fc45-98e8-44e7-894b-cad10a7aef4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b97382b9-fee2-4239-8c6b-e09f7bd56391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6eb5fc45-98e8-44e7-894b-cad10a7aef4d" xlink:to="loc_us-gaap_InterestPaidNet_b97382b9-fee2-4239-8c6b-e09f7bd56391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_db362ccc-bd08-43bc-ba27-567df1b27beb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6eb5fc45-98e8-44e7-894b-cad10a7aef4d" xlink:to="loc_us-gaap_StockIssued1_db362ccc-bd08-43bc-ba27-567df1b27beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20240630.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ec019e8d-63ca-4494-b2d8-c39a0960cbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_e2fdc925-1e6c-432a-aa83-d640eb95465e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ec019e8d-63ca-4494-b2d8-c39a0960cbdc" xlink:to="loc_us-gaap_NatureOfOperations_e2fdc925-1e6c-432a-aa83-d640eb95465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20240630.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2dc63244-2322-4cf6-8701-21ce188ea618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2dc195cd-f5f8-40fd-ac92-f120c0239515" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2dc63244-2322-4cf6-8701-21ce188ea618" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2dc195cd-f5f8-40fd-ac92-f120c0239515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20240630.xsd#CriticalAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4debf0e0-8231-4c6c-a9ec-34c84c1477b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_545dfc2f-a0c0-41da-b83d-aaadccde396d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4debf0e0-8231-4c6c-a9ec-34c84c1477b6" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_545dfc2f-a0c0-41da-b83d-aaadccde396d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="simple" xlink:href="ino-20240630.xsd#ShorttermInvestmentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_84099183-00df-4012-9852-3eeb5d0ce967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1abc11e8-1c1d-426c-9a4e-7515b1739adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_84099183-00df-4012-9852-3eeb5d0ce967" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1abc11e8-1c1d-426c-9a4e-7515b1739adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e24d43ac-172d-4f3d-ac65-f91f9b22e222" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_84099183-00df-4012-9852-3eeb5d0ce967" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e24d43ac-172d-4f3d-ac65-f91f9b22e222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="simple" xlink:href="ino-20240630.xsd#CertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_4fcc3d1b-680f-4e73-ba71-67814b9bb31d" xlink:href="ino-20240630.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_f44f4055-6551-43cb-844b-dda054c52494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_4fcc3d1b-680f-4e73-ba71-67814b9bb31d" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_f44f4055-6551-43cb-844b-dda054c52494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20240630.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_26b25e7d-43a3-4d2b-8317-47629224f6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_28868f7f-1267-46bb-8cc4-32abb4936c23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_26b25e7d-43a3-4d2b-8317-47629224f6a8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_28868f7f-1267-46bb-8cc4-32abb4936c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20240630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_866eb377-267d-4882-9ca9-1560af0a00ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8294a42d-6d66-4a34-9090-6a46e7c5ed6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_866eb377-267d-4882-9ca9-1560af0a00ea" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8294a42d-6d66-4a34-9090-6a46e7c5ed6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ino-20240630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_533156ac-cbd7-4de1-8991-12a0f702092a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_bfb83fe2-98c9-4bc6-bd88-89fa49f6dc52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_533156ac-cbd7-4de1-8991-12a0f702092a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_bfb83fe2-98c9-4bc6-bd88-89fa49f6dc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20240630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_883ec4ce-2385-4063-9051-9e868eef826a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_13c2e3c4-1e6b-4234-9071-0c972602e76d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_883ec4ce-2385-4063-9051-9e868eef826a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_13c2e3c4-1e6b-4234-9071-0c972602e76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20240630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a9ddf8c6-889c-4507-a58e-f561bc4822c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7591128d-df76-4f28-9c67-452d03cc2555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a9ddf8c6-889c-4507-a58e-f561bc4822c7" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7591128d-df76-4f28-9c67-452d03cc2555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ino-20240630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_528ca342-e6d7-46cc-9f70-7434f4da1241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_97ebeda0-3137-44b9-9680-076328ad2960" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_528ca342-e6d7-46cc-9f70-7434f4da1241" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_97ebeda0-3137-44b9-9680-076328ad2960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20240630.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68489384-f571-463d-9cb8-931568275e23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_543e1640-2418-4222-abb8-48dfd3fd7b17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68489384-f571-463d-9cb8-931568275e23" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_543e1640-2418-4222-abb8-48dfd3fd7b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20240630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3614dfb1-f713-4904-884c-84852cca5b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2369a507-2a45-4211-be1c-cbaced39360a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3614dfb1-f713-4904-884c-84852cca5b5f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2369a507-2a45-4211-be1c-cbaced39360a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20240630.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_dc92f956-e93d-4a84-9e8b-08c90035b1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_284e7cb8-3f2d-43ca-9640-1684030c0874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_dc92f956-e93d-4a84-9e8b-08c90035b1d0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_284e7cb8-3f2d-43ca-9640-1684030c0874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20240630.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9ea5c5c8-9b7d-4cfb-869a-60890c0ecc86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7d065d14-b0b9-40ce-96a6-d9bb7ecaeae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ea5c5c8-9b7d-4cfb-869a-60890c0ecc86" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7d065d14-b0b9-40ce-96a6-d9bb7ecaeae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_cebd7e7c-77d1-4d7a-9a27-efc5935b7ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ea5c5c8-9b7d-4cfb-869a-60890c0ecc86" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_cebd7e7c-77d1-4d7a-9a27-efc5935b7ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c15de736-92b3-4bd4-890b-45bb4e0454d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ea5c5c8-9b7d-4cfb-869a-60890c0ecc86" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c15de736-92b3-4bd4-890b-45bb4e0454d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_f5eb2a32-5568-40a8-b7db-6691ed47b720" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ea5c5c8-9b7d-4cfb-869a-60890c0ecc86" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_f5eb2a32-5568-40a8-b7db-6691ed47b720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_c351d3bd-f5bf-4be1-8127-24c46c8e913d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ea5c5c8-9b7d-4cfb-869a-60890c0ecc86" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_c351d3bd-f5bf-4be1-8127-24c46c8e913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20240630.xsd#ShorttermInvestmentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8059bdd1-63f8-4571-a69d-c41e69cb1383" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_53b6db58-e2ed-406e-9c3e-5df5b20d33e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8059bdd1-63f8-4571-a69d-c41e69cb1383" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_53b6db58-e2ed-406e-9c3e-5df5b20d33e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1fe7f517-1f4c-4036-8f81-4b0a91e68386" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8059bdd1-63f8-4571-a69d-c41e69cb1383" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1fe7f517-1f4c-4036-8f81-4b0a91e68386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="ino-20240630.xsd#CertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_adad392e-130d-4311-a1e2-ef67dc73ad7f" xlink:href="ino-20240630.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_e7e89059-feaa-4d4f-9d5d-3c6b83c39204" xlink:href="ino-20240630.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_adad392e-130d-4311-a1e2-ef67dc73ad7f" xlink:to="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_e7e89059-feaa-4d4f-9d5d-3c6b83c39204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0e498fb3-187f-419b-b756-ae1332d21579" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_adad392e-130d-4311-a1e2-ef67dc73ad7f" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0e498fb3-187f-419b-b756-ae1332d21579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20240630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_b721d344-90da-40fe-94b6-d8049c666fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_c7da6b4f-ba02-4d3f-a8a0-9f0ed56c5464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b721d344-90da-40fe-94b6-d8049c666fd0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_c7da6b4f-ba02-4d3f-a8a0-9f0ed56c5464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20240630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_38ed2ba6-5f10-4c65-9e83-d4d5df275d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_9c742864-ad90-4857-86d2-2be98965d45e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38ed2ba6-5f10-4c65-9e83-d4d5df275d73" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_9c742864-ad90-4857-86d2-2be98965d45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3e439bac-958f-4728-b3ce-302e3edc4fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38ed2ba6-5f10-4c65-9e83-d4d5df275d73" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3e439bac-958f-4728-b3ce-302e3edc4fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20240630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63e3f937-febe-4b93-84ef-4d937a87c330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4002e8ef-56e1-40c9-b382-ffa49b9319dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63e3f937-febe-4b93-84ef-4d937a87c330" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4002e8ef-56e1-40c9-b382-ffa49b9319dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_e0767702-fc6b-4589-bf2a-d6b9725a5d12" xlink:href="ino-20240630.xsd#ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63e3f937-febe-4b93-84ef-4d937a87c330" xlink:to="loc_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_e0767702-fc6b-4589-bf2a-d6b9725a5d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ino-20240630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0fc4157-5901-4612-b041-b7e7a6b89efc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d0af52a9-809a-43fe-a2f3-e08d5334ad77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0fc4157-5901-4612-b041-b7e7a6b89efc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d0af52a9-809a-43fe-a2f3-e08d5334ad77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2eb698c1-ee01-49e4-9114-c0e3fd273b66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2eb698c1-ee01-49e4-9114-c0e3fd273b66" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1ceed53a-1070-43f4-99d6-9a0d32c04889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1ceed53a-1070-43f4-99d6-9a0d32c04889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80dd381a-65b4-4813-b654-2e28351ece66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1ceed53a-1070-43f4-99d6-9a0d32c04889" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80dd381a-65b4-4813-b654-2e28351ece66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember_074a0245-3e1d-4aaa-9bb9-3fe4198470cd" xlink:href="ino-20240630.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80dd381a-65b4-4813-b654-2e28351ece66" xlink:to="loc_ino_UnderwrittenRegisteredDirectOfferingMember_074a0245-3e1d-4aaa-9bb9-3fe4198470cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b677c5b3-4076-4d0b-be1f-77f1a8372497" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b677c5b3-4076-4d0b-be1f-77f1a8372497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d35a4ea0-53ac-4cb3-bd17-262c0264d4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b677c5b3-4076-4d0b-be1f-77f1a8372497" xlink:to="loc_us-gaap_ClassOfStockDomain_d35a4ea0-53ac-4cb3-bd17-262c0264d4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_30924e22-672f-4291-adb3-39f8d8cce30a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d35a4ea0-53ac-4cb3-bd17-262c0264d4f5" xlink:to="loc_us-gaap_CommonStockMember_30924e22-672f-4291-adb3-39f8d8cce30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3bbd30c-efa7-4bdb-9cc3-2c19fc1cc117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3bbd30c-efa7-4bdb-9cc3-2c19fc1cc117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aecbe33c-8c0b-415e-ba78-26ffd4e21d26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3bbd30c-efa7-4bdb-9cc3-2c19fc1cc117" xlink:to="loc_us-gaap_EquityComponentDomain_aecbe33c-8c0b-415e-ba78-26ffd4e21d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4690e9a6-e271-48db-a5e5-3aa1e891ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aecbe33c-8c0b-415e-ba78-26ffd4e21d26" xlink:to="loc_us-gaap_CommonStockMember_4690e9a6-e271-48db-a5e5-3aa1e891ad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0b42299b-2e77-435d-a4ed-8509947b70bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aecbe33c-8c0b-415e-ba78-26ffd4e21d26" xlink:to="loc_us-gaap_WarrantMember_0b42299b-2e77-435d-a4ed-8509947b70bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_31c21484-1c91-4215-9b62-b980c970acce" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_99457ffd-5e51-4065-b34e-6a34f8e84d33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_NetIncomeLoss_99457ffd-5e51-4065-b34e-6a34f8e84d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_f75751ee-e116-4474-aac3-a32761fd09cb" xlink:href="ino-20240630.xsd#ino_WorkingCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_ino_WorkingCapital_f75751ee-e116-4474-aac3-a32761fd09cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed4f32aa-b70c-4cad-8e71-6877f7f737e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed4f32aa-b70c-4cad-8e71-6877f7f737e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8054999d-6d0b-4b4c-86d8-16271b2b9c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8054999d-6d0b-4b4c-86d8-16271b2b9c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cf1ba595-1157-4430-a1f3-7beec34b7fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cf1ba595-1157-4430-a1f3-7beec34b7fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_275d4065-c0b5-4a95-ba37-f284ff15a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_275d4065-c0b5-4a95-ba37-f284ff15a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_55e7bb2c-dd1d-42af-a26f-46b3c82c6d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_55e7bb2c-dd1d-42af-a26f-46b3c82c6d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c3a76e61-1f6b-45c6-b983-fdc714c5a3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c3a76e61-1f6b-45c6-b983-fdc714c5a3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f6060200-0ea9-49ef-8ad0-c39a546b6641" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f6060200-0ea9-49ef-8ad0-c39a546b6641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27cd791c-2c85-4a28-b436-ff8e0bec9f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27cd791c-2c85-4a28-b436-ff8e0bec9f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3bc6b1f2-f694-4f16-9192-304f088964f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_61288a26-f3fb-4668-a80c-c2fbf4203830" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3bc6b1f2-f694-4f16-9192-304f088964f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_27e1ca2b-88f0-44a6-bc2f-7f1a0f5012df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9959b725-9b49-4c5b-9b25-007f2f0714ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_27e1ca2b-88f0-44a6-bc2f-7f1a0f5012df" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9959b725-9b49-4c5b-9b25-007f2f0714ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_61b4c210-387f-4834-94d3-c9ce5021c4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9959b725-9b49-4c5b-9b25-007f2f0714ae" xlink:to="loc_us-gaap_FinancialInstrumentAxis_61b4c210-387f-4834-94d3-c9ce5021c4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_61b4c210-387f-4834-94d3-c9ce5021c4c1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_263aa408-1ffc-4879-b51f-dce530acec79" xlink:href="ino-20240630.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:to="loc_ino_MutualFundsMember_263aa408-1ffc-4879-b51f-dce530acec79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_9f89502a-fd58-48c1-acf5-d9c8dbbf7c57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_9f89502a-fd58-48c1-acf5-d9c8dbbf7c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ae89d809-a93e-446f-968e-a98fe61b537e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ae89d809-a93e-446f-968e-a98fe61b537e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_73caf577-3926-40e1-ba12-31507967bc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad490aec-4efe-450b-8e39-43110a5661a9" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_73caf577-3926-40e1-ba12-31507967bc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3ce66935-791e-4ddd-bad4-fa930998af73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9959b725-9b49-4c5b-9b25-007f2f0714ae" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3ce66935-791e-4ddd-bad4-fa930998af73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_8bfbf175-bda0-47c0-a9e6-7c505a7ccab5" xlink:href="ino-20240630.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3ce66935-791e-4ddd-bad4-fa930998af73" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_8bfbf175-bda0-47c0-a9e6-7c505a7ccab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3ce66935-791e-4ddd-bad4-fa930998af73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8f3624e0-9e93-4882-b72e-975d200e03e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8f3624e0-9e93-4882-b72e-975d200e03e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9094f3ae-d42b-45af-bc33-23e81a2c6652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9094f3ae-d42b-45af-bc33-23e81a2c6652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bb3cf2e3-f287-4217-811e-0f5564db889a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bb3cf2e3-f287-4217-811e-0f5564db889a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_81841bce-99e6-4b3b-ac7f-718a29b48925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f493cd07-bfc4-43ac-8584-3f0d86b4df4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_81841bce-99e6-4b3b-ac7f-718a29b48925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d3aa2dc3-b896-40b7-a6b0-14934143cd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_11ffe297-2728-41fb-b33c-eeb4ff0bc25e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d3aa2dc3-b896-40b7-a6b0-14934143cd9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_11ffe297-2728-41fb-b33c-eeb4ff0bc25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f908212f-60dc-41a0-b76f-deb5ba96aad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_11ffe297-2728-41fb-b33c-eeb4ff0bc25e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f908212f-60dc-41a0-b76f-deb5ba96aad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f54bb00b-6f2f-4760-a08b-ca0ecbbe80ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f908212f-60dc-41a0-b76f-deb5ba96aad9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f54bb00b-6f2f-4760-a08b-ca0ecbbe80ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5a2d23d8-6593-47cc-8a7f-b654be674cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f54bb00b-6f2f-4760-a08b-ca0ecbbe80ac" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5a2d23d8-6593-47cc-8a7f-b654be674cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_11ffe297-2728-41fb-b33c-eeb4ff0bc25e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e6660142-1ba3-4466-be26-059223bdcc81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e6660142-1ba3-4466-be26-059223bdcc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3a7d6962-d545-4566-96cc-e892965c4233" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3a7d6962-d545-4566-96cc-e892965c4233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b347eb79-e2b9-4d75-8538-08451f1272be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b347eb79-e2b9-4d75-8538-08451f1272be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b3068066-a059-46b8-9649-7cbeaf545030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b3068066-a059-46b8-9649-7cbeaf545030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_87f46994-8d9d-4fc1-bcf4-666dc6bf89ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_87f46994-8d9d-4fc1-bcf4-666dc6bf89ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_3269c315-7475-47a9-a179-7ba3f00ebc72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_3269c315-7475-47a9-a179-7ba3f00ebc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_e7f96b96-22d4-494a-9f75-cf16fa4d8fee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_181c7127-2808-40ef-aede-f6a75a5bcd34" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_e7f96b96-22d4-494a-9f75-cf16fa4d8fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c491bcf1-54e0-4d97-a580-bb1b40e9242d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c491bcf1-54e0-4d97-a580-bb1b40e9242d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_efb85c4a-0a5a-4caa-98c8-ca598b9ceab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_efb85c4a-0a5a-4caa-98c8-ca598b9ceab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c236ed2b-ec7b-4931-a323-030a248bcbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_efb85c4a-0a5a-4caa-98c8-ca598b9ceab9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c236ed2b-ec7b-4931-a323-030a248bcbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d8ed6a82-c053-4d87-995b-e943c9611db2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c236ed2b-ec7b-4931-a323-030a248bcbe8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d8ed6a82-c053-4d87-995b-e943c9611db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_93888533-350a-42a7-86bf-517cdfd6007a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:to="loc_us-gaap_FinancialInstrumentAxis_93888533-350a-42a7-86bf-517cdfd6007a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_93888533-350a-42a7-86bf-517cdfd6007a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_59f3fc76-fb08-4113-ba0f-64c201db8173" xlink:href="ino-20240630.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:to="loc_ino_MutualFundsMember_59f3fc76-fb08-4113-ba0f-64c201db8173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_53c54668-510a-49e5-b1ac-6a4bcdced7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_53c54668-510a-49e5-b1ac-6a4bcdced7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_60477faf-771a-4be3-b236-9ed5d596fad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_60477faf-771a-4be3-b236-9ed5d596fad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_9ae93ce8-fd85-4bfa-9305-6d0399e734eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bfb25c6-e74d-458e-af1b-8cacff1c505d" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_9ae93ce8-fd85-4bfa-9305-6d0399e734eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a71919b3-4e1d-4d5c-afd3-d649f8122fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a71919b3-4e1d-4d5c-afd3-d649f8122fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b51e4d3-ab90-4f4a-b1a0-50502147d8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a71919b3-4e1d-4d5c-afd3-d649f8122fd2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b51e4d3-ab90-4f4a-b1a0-50502147d8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c7dbf695-969e-48aa-95c8-789fc250fb30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b51e4d3-ab90-4f4a-b1a0-50502147d8a6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c7dbf695-969e-48aa-95c8-789fc250fb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7f194786-0afb-486e-b954-c49cf1dbd090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b51e4d3-ab90-4f4a-b1a0-50502147d8a6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7f194786-0afb-486e-b954-c49cf1dbd090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_85719e47-4aee-40b4-b5b9-08d78045050e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b51e4d3-ab90-4f4a-b1a0-50502147d8a6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_85719e47-4aee-40b4-b5b9-08d78045050e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a2c89470-2ad7-4f3f-92a3-c9be77f36c55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3ff9e68e-dd76-4609-ae93-8b3888ccfe71" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a2c89470-2ad7-4f3f-92a3-c9be77f36c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3a274872-42e7-4106-9e05-274d08df5f06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a2c89470-2ad7-4f3f-92a3-c9be77f36c55" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3a274872-42e7-4106-9e05-274d08df5f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f01e90f9-77ac-4229-a414-e268f10a09c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3a274872-42e7-4106-9e05-274d08df5f06" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f01e90f9-77ac-4229-a414-e268f10a09c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_77b20f5c-1fad-4b31-a2c3-40de178d49e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3a274872-42e7-4106-9e05-274d08df5f06" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_77b20f5c-1fad-4b31-a2c3-40de178d49e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_62941f76-8a7f-4e6a-9844-c3fb4b7b4f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3a274872-42e7-4106-9e05-274d08df5f06" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_62941f76-8a7f-4e6a-9844-c3fb4b7b4f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_9de714f8-7653-45da-8997-82233d8caf6e" xlink:href="ino-20240630.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidClinicalExpensesCurrent_9cfebd94-2719-4b01-8fdf-b5c53fe4a51e" xlink:href="ino-20240630.xsd#ino_PrepaidClinicalExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_9de714f8-7653-45da-8997-82233d8caf6e" xlink:to="loc_ino_PrepaidClinicalExpensesCurrent_9cfebd94-2719-4b01-8fdf-b5c53fe4a51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_58b5da44-5458-4f01-9024-57f57e962821" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_9de714f8-7653-45da-8997-82233d8caf6e" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_58b5da44-5458-4f01-9024-57f57e962821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_014e05d5-3c92-47d4-9373-0c8ddc78d2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_9de714f8-7653-45da-8997-82233d8caf6e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_014e05d5-3c92-47d4-9373-0c8ddc78d2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_4b30216e-3247-4027-92b1-0488245ca587" xlink:href="ino-20240630.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_140d36ed-1005-460f-8156-693c52c4643c" xlink:href="ino-20240630.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_4b30216e-3247-4027-92b1-0488245ca587" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_140d36ed-1005-460f-8156-693c52c4643c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8b4e65a9-2283-422f-8bd7-56c675ebf2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_140d36ed-1005-460f-8156-693c52c4643c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8b4e65a9-2283-422f-8bd7-56c675ebf2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b417759f-7ad0-4afe-bcbe-b6ebd007fda2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8b4e65a9-2283-422f-8bd7-56c675ebf2cb" xlink:to="loc_us-gaap_RelatedPartyDomain_b417759f-7ad0-4afe-bcbe-b6ebd007fda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_3d4ea2ee-00b5-4621-b133-670d9436b318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b417759f-7ad0-4afe-bcbe-b6ebd007fda2" xlink:to="loc_us-gaap_NonrelatedPartyMember_3d4ea2ee-00b5-4621-b133-670d9436b318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:href="ino-20240630.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_140d36ed-1005-460f-8156-693c52c4643c" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_34ce760c-b419-44de-a636-c48aceaa41d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_34ce760c-b419-44de-a636-c48aceaa41d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_5bb07161-96b7-41e7-a6b5-f456adc6c382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_us-gaap_AccruedSalariesCurrent_5bb07161-96b7-41e7-a6b5-f456adc6c382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_43e9ee3a-2a7d-4dd4-abcb-e94b5c532d97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_43e9ee3a-2a7d-4dd4-abcb-e94b5c532d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c526b506-3fef-47f2-ac2c-cf3f2b2478d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c526b506-3fef-47f2-ac2c-cf3f2b2478d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpenseCurrent_10862a43-8568-4e88-9ecb-8cecd204b933" xlink:href="ino-20240630.xsd#ino_PrepaidManufacturingExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_ino_PrepaidManufacturingExpenseCurrent_10862a43-8568-4e88-9ecb-8cecd204b933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantLiability_d6656122-2878-4d4d-b594-a61a71d04b46" xlink:href="ino-20240630.xsd#ino_GrantLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_23fe3e5c-ff07-4c06-a1c5-d246e43c38aa" xlink:to="loc_ino_GrantLiability_d6656122-2878-4d4d-b594-a61a71d04b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#ConvertibleDebtDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_15a08898-7548-4d50-92f5-ed266e4b343a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f0341c5c-0223-45ed-8d76-197e11fdd26f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_15a08898-7548-4d50-92f5-ed266e4b343a" xlink:to="loc_us-gaap_DebtInstrumentTable_f0341c5c-0223-45ed-8d76-197e11fdd26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fea92008-9291-4812-8a13-2c8f1151a7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f0341c5c-0223-45ed-8d76-197e11fdd26f" xlink:to="loc_us-gaap_DebtInstrumentAxis_fea92008-9291-4812-8a13-2c8f1151a7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b172176-f0f0-4324-b537-d1d9b0371e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fea92008-9291-4812-8a13-2c8f1151a7b5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b172176-f0f0-4324-b537-d1d9b0371e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7dc07fa5-271d-4cd6-8bbc-3603bf257fad" xlink:href="ino-20240630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3b172176-f0f0-4324-b537-d1d9b0371e64" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7dc07fa5-271d-4cd6-8bbc-3603bf257fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c8191b31-b588-48fb-8eeb-4d153da7eb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f0341c5c-0223-45ed-8d76-197e11fdd26f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c8191b31-b588-48fb-8eeb-4d153da7eb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_faaade06-2f2f-4871-b2e7-673ac2ef2a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c8191b31-b588-48fb-8eeb-4d153da7eb9c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_faaade06-2f2f-4871-b2e7-673ac2ef2a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_41c8aa2d-56ef-4f3a-ab39-ab16b3344a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_faaade06-2f2f-4871-b2e7-673ac2ef2a9f" xlink:to="loc_us-gaap_ConvertibleDebtMember_41c8aa2d-56ef-4f3a-ab39-ab16b3344a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f0341c5c-0223-45ed-8d76-197e11fdd26f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d0deffdb-58c6-4be0-bbc1-084664e5ee0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d0deffdb-58c6-4be0-bbc1-084664e5ee0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_112cb84a-3fc6-43ef-9a9b-10cb3ec15ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_112cb84a-3fc6-43ef-9a9b-10cb3ec15ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_ce59c930-6f17-4051-8b5e-32c07cb3d5db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_ce59c930-6f17-4051-8b5e-32c07cb3d5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_fbfcb5b7-7b2f-43ff-9341-6e8801f65183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_fbfcb5b7-7b2f-43ff-9341-6e8801f65183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating_285ff7b1-d215-4175-8cc7-e459bd56e78e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_InterestExpenseOperating_285ff7b1-d215-4175-8cc7-e459bd56e78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_121add1a-da0d-440d-9406-16b1d32e1a93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5bddb8e7-ab0a-4bd0-8363-6379fac67eb4" xlink:to="loc_us-gaap_InterestExpenseDebt_121add1a-da0d-440d-9406-16b1d32e1a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a9116aeb-7101-4cdc-b7c2-a588eaea984f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0350b3f8-1fbb-4be3-a0b8-6fe04c010929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a9116aeb-7101-4cdc-b7c2-a588eaea984f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0350b3f8-1fbb-4be3-a0b8-6fe04c010929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_90098619-4d98-4c9f-9534-ef470b136a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0350b3f8-1fbb-4be3-a0b8-6fe04c010929" xlink:to="loc_us-gaap_StatementClassOfStockAxis_90098619-4d98-4c9f-9534-ef470b136a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b05d034-c642-4538-bf2c-b9a21048160c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90098619-4d98-4c9f-9534-ef470b136a0d" xlink:to="loc_us-gaap_ClassOfStockDomain_0b05d034-c642-4538-bf2c-b9a21048160c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6af4c2a6-cc90-41ed-9256-896f260fb6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b05d034-c642-4538-bf2c-b9a21048160c" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6af4c2a6-cc90-41ed-9256-896f260fb6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cc4d965b-9562-4c5a-99d9-60bbd930e187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0350b3f8-1fbb-4be3-a0b8-6fe04c010929" xlink:to="loc_us-gaap_ClassOfStockLineItems_cc4d965b-9562-4c5a-99d9-60bbd930e187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc4d965b-9562-4c5a-99d9-60bbd930e187" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_00e34281-4012-4895-afb9-5f5967343dca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_00e34281-4012-4895-afb9-5f5967343dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c741c755-cab5-401f-be92-2522c5fcb725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c741c755-cab5-401f-be92-2522c5fcb725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3aea9eaf-c2a3-45ca-af05-a461f091a3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_CommonStockSharesIssued_3aea9eaf-c2a3-45ca-af05-a461f091a3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a818100e-d867-4abc-b4d0-8980b07bdb44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a818100e-d867-4abc-b4d0-8980b07bdb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_70f9b1a9-b88c-4cea-9ede-fe31c3e17336" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_70f9b1a9-b88c-4cea-9ede-fe31c3e17336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f5d18420-d841-4c0e-8eee-29b76cbef489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f5d18420-d841-4c0e-8eee-29b76cbef489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5e5e2e1b-a0fe-4105-9e45-2f425bf58580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5e5e2e1b-a0fe-4105-9e45-2f425bf58580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5adca82c-50f2-4b27-8d09-f0334f373dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fed8eee3-0c80-4ef2-8635-f9db796e4ff1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5adca82c-50f2-4b27-8d09-f0334f373dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_da0718d6-274e-49d3-8027-4a10ff095e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_da0718d6-274e-49d3-8027-4a10ff095e9f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19903d09-4d58-43f9-b410-197c96573db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19903d09-4d58-43f9-b410-197c96573db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e7b841e4-0e38-438c-9dad-57d19a830e16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19903d09-4d58-43f9-b410-197c96573db9" xlink:to="loc_us-gaap_ClassOfStockDomain_e7b841e4-0e38-438c-9dad-57d19a830e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ce46e4a5-6436-48e2-a63e-55c5a8b05cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e7b841e4-0e38-438c-9dad-57d19a830e16" xlink:to="loc_us-gaap_CommonStockMember_ce46e4a5-6436-48e2-a63e-55c5a8b05cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_84c8747d-e600-4555-b3ad-49530a539e12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_84c8747d-e600-4555-b3ad-49530a539e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b71818d8-5f3c-4726-a073-c51d40f219d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_84c8747d-e600-4555-b3ad-49530a539e12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b71818d8-5f3c-4726-a073-c51d40f219d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember_a584b723-03d1-4bc5-937a-20a03be1601e" xlink:href="ino-20240630.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b71818d8-5f3c-4726-a073-c51d40f219d5" xlink:to="loc_ino_UnderwrittenRegisteredDirectOfferingMember_a584b723-03d1-4bc5-937a-20a03be1601e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_5d99666f-efdf-4eab-87b0-b9a395d0285a" xlink:href="ino-20240630.xsd#ino_A2021SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b71818d8-5f3c-4726-a073-c51d40f219d5" xlink:to="loc_ino_A2021SalesAgreementMember_5d99666f-efdf-4eab-87b0-b9a395d0285a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3e2e0bd2-4ae1-416a-bf1f-7fdb5cfb372f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_srt_LitigationCaseAxis_3e2e0bd2-4ae1-416a-bf1f-7fdb5cfb372f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_40bfe8b4-2d76-44b5-9636-8ebccd48c56e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_3e2e0bd2-4ae1-416a-bf1f-7fdb5cfb372f" xlink:to="loc_srt_LitigationCaseTypeDomain_40bfe8b4-2d76-44b5-9636-8ebccd48c56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_a5b2edac-7e42-4e93-8ce7-209894ccd3e7" xlink:href="ino-20240630.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40bfe8b4-2d76-44b5-9636-8ebccd48c56e" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_a5b2edac-7e42-4e93-8ce7-209894ccd3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e082f92b-a82e-4769-8cb8-19fccf199e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_us-gaap_PlanNameAxis_e082f92b-a82e-4769-8cb8-19fccf199e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e082f92b-a82e-4769-8cb8-19fccf199e50" xlink:to="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember_379f9299-cd3e-4061-b4cf-22ff5e7ffce7" xlink:href="ino-20240630.xsd#ino_A2023IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:to="loc_ino_A2023IncentivePlanMember_379f9299-cd3e-4061-b4cf-22ff5e7ffce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_2bdc1fca-d1aa-43da-8be7-87b006afcb7c" xlink:href="ino-20240630.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:to="loc_ino_A2016IncentivePlanMember_2bdc1fca-d1aa-43da-8be7-87b006afcb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_16b1e735-2f25-4fe1-9f27-1e8b44ab4909" xlink:href="ino-20240630.xsd#ino_A2022InducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:to="loc_ino_A2022InducementPlanMember_16b1e735-2f25-4fe1-9f27-1e8b44ab4909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_16a390f3-425e-47da-a410-232a31de0b6a" xlink:href="ino-20240630.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f65282ba-b3dc-460e-9835-a6ba285f89f0" xlink:to="loc_ino_A2007IncentivePlanMember_16a390f3-425e-47da-a410-232a31de0b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d87048d9-3448-4ad4-86a6-439cf206ec90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d87048d9-3448-4ad4-86a6-439cf206ec90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc66aa10-bfff-4314-b359-f206364cc034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d87048d9-3448-4ad4-86a6-439cf206ec90" xlink:to="loc_us-gaap_EquityComponentDomain_bc66aa10-bfff-4314-b359-f206364cc034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6959f515-3054-485a-9535-546011dcd90e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bc66aa10-bfff-4314-b359-f206364cc034" xlink:to="loc_us-gaap_WarrantMember_6959f515-3054-485a-9535-546011dcd90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_000af9b6-78f2-487c-9bfb-ed6a1abbf697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bc66aa10-bfff-4314-b359-f206364cc034" xlink:to="loc_us-gaap_CommonStockMember_000af9b6-78f2-487c-9bfb-ed6a1abbf697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2df755cc-e1b2-4292-8c91-7d8e36b4a2db" xlink:to="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14fff475-dc21-4a3a-9b07-be9c4fca1ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14fff475-dc21-4a3a-9b07-be9c4fca1ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_a62f7187-62af-43be-b1f2-7e5765a72908" xlink:href="ino-20240630.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_a62f7187-62af-43be-b1f2-7e5765a72908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_9dc769b2-3871-4d7b-a401-bb581ea04dad" xlink:href="ino-20240630.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_9dc769b2-3871-4d7b-a401-bb581ea04dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_99c158c8-bb6e-4e43-925a-fe865bdb9b08" xlink:href="ino-20240630.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_99c158c8-bb6e-4e43-925a-fe865bdb9b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_2b5a7d8f-bb78-4d75-9e9f-17fbae4d5590" xlink:href="ino-20240630.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_2b5a7d8f-bb78-4d75-9e9f-17fbae4d5590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_ec3ecad7-ed49-49fb-a4be-d5c77bd62c56" xlink:href="ino-20240630.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_ec3ecad7-ed49-49fb-a4be-d5c77bd62c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_27be5cd2-13c9-485d-a52e-00e9151566ba" xlink:href="ino-20240630.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_27be5cd2-13c9-485d-a52e-00e9151566ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_111e7aff-cd6a-4378-8cf8-550ab3e460d6" xlink:href="ino-20240630.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_111e7aff-cd6a-4378-8cf8-550ab3e460d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_521156a8-4128-4e12-803f-f1e347889b70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_521156a8-4128-4e12-803f-f1e347889b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529c817-b7a9-4f6b-8e78-9d6277e630bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529c817-b7a9-4f6b-8e78-9d6277e630bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63eb8324-fe33-4444-b543-3d21a8a4b714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63eb8324-fe33-4444-b543-3d21a8a4b714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_2ebeb52c-340d-4f3c-a7d9-568f3e549a76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_2ebeb52c-340d-4f3c-a7d9-568f3e549a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f65e762a-6179-4edb-8a39-187e22a30e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f65e762a-6179-4edb-8a39-187e22a30e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ff68caa7-1039-4416-a7e9-017846fa08ff" xlink:href="ino-20240630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18de24e0-23d0-4a6f-b1d4-49b940dc8b4c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ff68caa7-1039-4416-a7e9-017846fa08ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f5f27e20-f2b9-497c-abf0-72738c8e8dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c3241fa8-2472-4a2f-a8ff-2b9267692f12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f5f27e20-f2b9-497c-abf0-72738c8e8dc1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c3241fa8-2472-4a2f-a8ff-2b9267692f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a8dfa6a7-30a3-4667-a78a-30042096dc76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c3241fa8-2472-4a2f-a8ff-2b9267692f12" xlink:to="loc_us-gaap_NetIncomeLoss_a8dfa6a7-30a3-4667-a78a-30042096dc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3349da3b-ed88-4a53-8d86-db866f573fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f5f27e20-f2b9-497c-abf0-72738c8e8dc1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3349da3b-ed88-4a53-8d86-db866f573fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding_e296b701-a333-407e-b2b7-7a6009cb93b4" xlink:href="ino-20240630.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3349da3b-ed88-4a53-8d86-db866f573fa2" xlink:to="loc_ino_WeightedAverageNumberOfSharesOutstanding_e296b701-a333-407e-b2b7-7a6009cb93b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_e25bfc45-04f7-4058-81d7-88013bc2a24e" xlink:href="ino-20240630.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3349da3b-ed88-4a53-8d86-db866f573fa2" xlink:to="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_e25bfc45-04f7-4058-81d7-88013bc2a24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5504ea62-b2cf-43c2-b5c8-acf5d3464ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3349da3b-ed88-4a53-8d86-db866f573fa2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5504ea62-b2cf-43c2-b5c8-acf5d3464ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a4e29044-5687-41f6-9110-096db5945a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3349da3b-ed88-4a53-8d86-db866f573fa2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a4e29044-5687-41f6-9110-096db5945a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_3609d01a-c2a7-4086-969f-2e7b909c97c2" xlink:href="ino-20240630.xsd#ino_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3349da3b-ed88-4a53-8d86-db866f573fa2" xlink:to="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_3609d01a-c2a7-4086-969f-2e7b909c97c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_900c35ac-7ee8-4c5e-8d5a-4be4711e2d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_3609d01a-c2a7-4086-969f-2e7b909c97c2" xlink:to="loc_us-gaap_EarningsPerShareBasic_900c35ac-7ee8-4c5e-8d5a-4be4711e2d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e030c45e-f72f-456d-bb49-fa0cda1a5615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_3609d01a-c2a7-4086-969f-2e7b909c97c2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e030c45e-f72f-456d-bb49-fa0cda1a5615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#NetLossPerShareAntidilutiveDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_24570eee-fe85-460d-b4d8-4c108c84f2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6c378a3d-0b45-4923-ae89-4581cb3d54e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_24570eee-fe85-460d-b4d8-4c108c84f2ed" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6c378a3d-0b45-4923-ae89-4581cb3d54e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b77f91-2749-473a-924f-ad47188f297a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6c378a3d-0b45-4923-ae89-4581cb3d54e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b77f91-2749-473a-924f-ad47188f297a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b77f91-2749-473a-924f-ad47188f297a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b1741eee-6558-470a-bdd2-2b91a9100689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b1741eee-6558-470a-bdd2-2b91a9100689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_95e9045a-717b-4e15-b589-230dd48d1a63" xlink:href="ino-20240630.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_95e9045a-717b-4e15-b589-230dd48d1a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_14c225b2-cfeb-4f8d-a35d-21f1d2db6635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_14c225b2-cfeb-4f8d-a35d-21f1d2db6635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_6ce101aa-7143-4dd1-9bc6-0c7c093181b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_6ce101aa-7143-4dd1-9bc6-0c7c093181b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_19af3ee9-5b96-4c04-923a-f36585bdf96d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a765a56-ae52-40c8-a01b-1b5aaf9bcc45" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_19af3ee9-5b96-4c04-923a-f36585bdf96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9909960b-587a-434e-8a58-e9a0e8576977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6c378a3d-0b45-4923-ae89-4581cb3d54e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9909960b-587a-434e-8a58-e9a0e8576977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_463ee7f0-5bcc-45a3-bb5d-781dbd687518" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9909960b-587a-434e-8a58-e9a0e8576977" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_463ee7f0-5bcc-45a3-bb5d-781dbd687518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#StockBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb8045eb-8d38-4724-bebd-9ef699391bca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3accf127-84a8-488a-b122-f87227e5c288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb8045eb-8d38-4724-bebd-9ef699391bca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3accf127-84a8-488a-b122-f87227e5c288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_618b43b2-bb9e-4d74-a627-3adc4dc13ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3accf127-84a8-488a-b122-f87227e5c288" xlink:to="loc_us-gaap_AwardTypeAxis_618b43b2-bb9e-4d74-a627-3adc4dc13ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_140762b4-5818-4b24-b5b5-1a91ee6f7ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_618b43b2-bb9e-4d74-a627-3adc4dc13ff8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_140762b4-5818-4b24-b5b5-1a91ee6f7ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_61f55391-8f08-4527-91e0-f94b631cad96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_140762b4-5818-4b24-b5b5-1a91ee6f7ab2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_61f55391-8f08-4527-91e0-f94b631cad96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_30cbfab1-71a2-462e-b246-80223ff371ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3accf127-84a8-488a-b122-f87227e5c288" xlink:to="loc_srt_TitleOfIndividualAxis_30cbfab1-71a2-462e-b246-80223ff371ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81306a4f-1460-4614-b7af-60ade689d5f4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_30cbfab1-71a2-462e-b246-80223ff371ac" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81306a4f-1460-4614-b7af-60ade689d5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_69a7139e-708c-45af-9eda-aac200c617b1" xlink:href="ino-20240630.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81306a4f-1460-4614-b7af-60ade689d5f4" xlink:to="loc_ino_EmployeesAndDirectorsMember_69a7139e-708c-45af-9eda-aac200c617b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3accf127-84a8-488a-b122-f87227e5c288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_96f1a890-8d9b-432c-8915-3a26b9dc6dac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_96f1a890-8d9b-432c-8915-3a26b9dc6dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_009349aa-378c-42bd-b1e4-804c7d5bc282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_009349aa-378c-42bd-b1e4-804c7d5bc282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_02a23b21-872e-4920-b0fc-ab58db0e0a66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_02a23b21-872e-4920-b0fc-ab58db0e0a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6e0e6965-3fc4-467a-9256-87bbd8f7d583" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0cc197b-9ad3-4ad8-843b-34573d4ca1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6e0e6965-3fc4-467a-9256-87bbd8f7d583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9f13945-937b-40fc-b02d-ff5209981787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9f13945-937b-40fc-b02d-ff5209981787" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8525a05d-8281-44b2-92db-0d32ab474bab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:to="loc_srt_TitleOfIndividualAxis_8525a05d-8281-44b2-92db-0d32ab474bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41130c8d-ee62-4881-a307-5d7011cac827" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_8525a05d-8281-44b2-92db-0d32ab474bab" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41130c8d-ee62-4881-a307-5d7011cac827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_acdc7048-5904-4c24-a676-0e1fa329a980" xlink:href="ino-20240630.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41130c8d-ee62-4881-a307-5d7011cac827" xlink:to="loc_ino_EmployeesAndDirectorsMember_acdc7048-5904-4c24-a676-0e1fa329a980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_fcb9418a-ba59-48ca-a253-62113276fd71" xlink:href="ino-20240630.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41130c8d-ee62-4881-a307-5d7011cac827" xlink:to="loc_ino_NonEmployeeMember_fcb9418a-ba59-48ca-a253-62113276fd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_205e57d2-8b27-41d1-860b-cbd30d1f5659" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_205e57d2-8b27-41d1-860b-cbd30d1f5659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_82f7f222-8cfa-443c-ab66-e9a08bdedcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_205e57d2-8b27-41d1-860b-cbd30d1f5659" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_82f7f222-8cfa-443c-ab66-e9a08bdedcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a15175d3-e5cc-4428-9517-c77af80745ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82f7f222-8cfa-443c-ab66-e9a08bdedcb0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a15175d3-e5cc-4428-9517-c77af80745ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_385397c3-7ca5-494a-9ef4-a3462eff7726" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82f7f222-8cfa-443c-ab66-e9a08bdedcb0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_385397c3-7ca5-494a-9ef4-a3462eff7726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_096b1e92-daf6-4b28-b4c8-b9df615a0517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:to="loc_us-gaap_AwardTypeAxis_096b1e92-daf6-4b28-b4c8-b9df615a0517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34048ee2-732f-43a3-82d3-75fd124380b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_096b1e92-daf6-4b28-b4c8-b9df615a0517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34048ee2-732f-43a3-82d3-75fd124380b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_5d7f9687-6c52-4e40-9189-8cc2fbc76eb7" xlink:href="ino-20240630.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34048ee2-732f-43a3-82d3-75fd124380b3" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_5d7f9687-6c52-4e40-9189-8cc2fbc76eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_468f5d6c-997d-4f34-ae4c-4789032d8cab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34048ee2-732f-43a3-82d3-75fd124380b3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_468f5d6c-997d-4f34-ae4c-4789032d8cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_944c75a3-da37-43d7-82a8-c2b9d1180839" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_468f5d6c-997d-4f34-ae4c-4789032d8cab" xlink:to="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_944c75a3-da37-43d7-82a8-c2b9d1180839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_2ab9967a-9bfb-4fb8-9dbd-6823e10f914a" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_468f5d6c-997d-4f34-ae4c-4789032d8cab" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_2ab9967a-9bfb-4fb8-9dbd-6823e10f914a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_8d880fc1-0175-4235-832d-4eb5560e754c" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_468f5d6c-997d-4f34-ae4c-4789032d8cab" xlink:to="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_8d880fc1-0175-4235-832d-4eb5560e754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_44f04a6a-4dbf-47c3-aae6-25e29b6ee5d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:to="loc_srt_RangeAxis_44f04a6a-4dbf-47c3-aae6-25e29b6ee5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_192dafaf-6198-45f1-928d-c4074d7d6265" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_44f04a6a-4dbf-47c3-aae6-25e29b6ee5d5" xlink:to="loc_srt_RangeMember_192dafaf-6198-45f1-928d-c4074d7d6265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f905b5b5-3cee-4629-b267-604fc700549c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_192dafaf-6198-45f1-928d-c4074d7d6265" xlink:to="loc_srt_MinimumMember_f905b5b5-3cee-4629-b267-604fc700549c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_832a5189-4107-4ae5-862b-e44c47e642ef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_192dafaf-6198-45f1-928d-c4074d7d6265" xlink:to="loc_srt_MaximumMember_832a5189-4107-4ae5-862b-e44c47e642ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7deb3a93-cdd3-4961-8659-9c68a65076e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dcbb8394-b2dc-483e-adfc-25c979ff4827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ShareBasedCompensation_dcbb8394-b2dc-483e-adfc-25c979ff4827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_920bd96b-d872-4b91-bcb1-ff888be20ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_920bd96b-d872-4b91-bcb1-ff888be20ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_91dec463-c824-4a44-95bf-d0fd15913626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_91dec463-c824-4a44-95bf-d0fd15913626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6358f35d-5a6f-4411-ba17-586a2c22ef88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6358f35d-5a6f-4411-ba17-586a2c22ef88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ded1f32f-3b13-4ba5-adea-2fb0f5924814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ded1f32f-3b13-4ba5-adea-2fb0f5924814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c635ba96-32e8-4b5d-bd2d-8fb8f5348180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c635ba96-32e8-4b5d-bd2d-8fb8f5348180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e87c344e-39c6-4880-ba12-bc9d22c775ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e87c344e-39c6-4880-ba12-bc9d22c775ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c84bacc7-8c41-428f-b786-27ee035df544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c84bacc7-8c41-428f-b786-27ee035df544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_c3664e5e-78e6-4977-be5b-005b11c5d67a" xlink:href="ino-20240630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_c3664e5e-78e6-4977-be5b-005b11c5d67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f3b002bf-e142-46aa-b994-22b564d072c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f3b002bf-e142-46aa-b994-22b564d072c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_7995ac95-483e-40df-b588-ffd29e6cb34e" xlink:href="ino-20240630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20638634-c492-4aa2-9b61-96c4ed11adb4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_7995ac95-483e-40df-b588-ffd29e6cb34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6d61431-8219-40cd-8acc-b9e46d33544d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ffe7d8a2-054f-4eb7-986c-9fe6da43b893" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6d61431-8219-40cd-8acc-b9e46d33544d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ffe7d8a2-054f-4eb7-986c-9fe6da43b893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_889eee59-7d1e-425a-8638-6e32a54fc3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ffe7d8a2-054f-4eb7-986c-9fe6da43b893" xlink:to="loc_us-gaap_AwardTypeAxis_889eee59-7d1e-425a-8638-6e32a54fc3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f49188bf-ef4a-45d2-8f2a-19a75fecb389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_889eee59-7d1e-425a-8638-6e32a54fc3ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f49188bf-ef4a-45d2-8f2a-19a75fecb389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_4abefe5b-d137-4e7b-b014-69bc717fee55" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f49188bf-ef4a-45d2-8f2a-19a75fecb389" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_4abefe5b-d137-4e7b-b014-69bc717fee55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ffe7d8a2-054f-4eb7-986c-9fe6da43b893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_407b0b03-da1d-495c-b163-cb63ff3399f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_407b0b03-da1d-495c-b163-cb63ff3399f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35d0411b-52e8-4274-9e31-111df4d21a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35d0411b-52e8-4274-9e31-111df4d21a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a9a6cf8-2e47-4e2f-8904-713cb0f5430c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a9a6cf8-2e47-4e2f-8904-713cb0f5430c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_99efc163-87e3-4242-b863-5b2c7f0fdb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d18431-44a6-4a7a-9f86-2fc0b1cc51a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_99efc163-87e3-4242-b863-5b2c7f0fdb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_731afc04-add0-4503-990b-204d0285fb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_731afc04-add0-4503-990b-204d0285fb4f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_583880ed-557e-4390-b405-52b65172e0ce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:to="loc_srt_OwnershipAxis_583880ed-557e-4390-b405-52b65172e0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ea510f82-3c8f-4a5e-b82c-276aacc70138" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_583880ed-557e-4390-b405-52b65172e0ce" xlink:to="loc_srt_OwnershipDomain_ea510f82-3c8f-4a5e-b82c-276aacc70138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_f7e15a06-abda-4cba-910c-f93bba7da5ef" xlink:href="ino-20240630.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ea510f82-3c8f-4a5e-b82c-276aacc70138" xlink:to="loc_ino_PlumblineLifeSciencesMember_f7e15a06-abda-4cba-910c-f93bba7da5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18db0824-b496-4ff1-b9ca-e1c51e1c3ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18db0824-b496-4ff1-b9ca-e1c51e1c3ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_63c094ba-fdca-4f43-84f4-f959dd35bb30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18db0824-b496-4ff1-b9ca-e1c51e1c3ddc" xlink:to="loc_us-gaap_RelatedPartyDomain_63c094ba-fdca-4f43-84f4-f959dd35bb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_8ca1d21a-5caf-4390-ad04-7e82259bf607" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_63c094ba-fdca-4f43-84f4-f959dd35bb30" xlink:to="loc_srt_AffiliatedEntityMember_8ca1d21a-5caf-4390-ad04-7e82259bf607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f9382f5-2e35-43b0-8b54-0d8ddc1994b8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:to="loc_srt_CounterpartyNameAxis_4f9382f5-2e35-43b0-8b54-0d8ddc1994b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0935949d-0744-4de5-b35a-02dc46f7fd04" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4f9382f5-2e35-43b0-8b54-0d8ddc1994b8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0935949d-0744-4de5-b35a-02dc46f7fd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_f38f18e9-7d8d-49e3-a357-3c55be80bc53" xlink:href="ino-20240630.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0935949d-0744-4de5-b35a-02dc46f7fd04" xlink:to="loc_ino_TheWistarInstituteMember_f38f18e9-7d8d-49e3-a357-3c55be80bc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_19e4af45-0bfd-446a-8cdd-1543ef8071aa" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_afd0feaa-2bff-4c1c-ab57-399af6774844" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_afd0feaa-2bff-4c1c-ab57-399af6774844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_4e99ba95-7596-4a3b-a532-6e1fdd8dff0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_4e99ba95-7596-4a3b-a532-6e1fdd8dff0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_d75f02f8-6a68-4f2a-b667-947183555ba9" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_d75f02f8-6a68-4f2a-b667-947183555ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_f627e9f1-e066-42b7-85c0-f9061266c5af" xlink:href="ino-20240630.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_CollaborativeArrangementTerm_f627e9f1-e066-42b7-85c0-f9061266c5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_b60fdab3-5730-4e18-a889-ec2c5528a132" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_b60fdab3-5730-4e18-a889-ec2c5528a132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_721fc0e0-976b-4be6-9e16-68688100c71e" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_721fc0e0-976b-4be6-9e16-68688100c71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_85d4f495-8057-4d4d-83a9-57fb6036a154" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_85d4f495-8057-4d4d-83a9-57fb6036a154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_548e80b4-8ace-44f9-93fb-d6ea35c6859d" xlink:href="ino-20240630.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_GrantProceedsReceived_548e80b4-8ace-44f9-93fb-d6ea35c6859d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e7fb2a0-3043-4b4a-834f-77661242b347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e7fb2a0-3043-4b4a-834f-77661242b347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e164c2e3-5127-41f1-894f-48d4c02503d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e164c2e3-5127-41f1-894f-48d4c02503d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e102e01-738b-4090-9eac-47145053da34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e102e01-738b-4090-9eac-47145053da34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_804e6334-635d-4ddc-855d-20ebb93c13a4" xlink:href="ino-20240630.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fc6edd24-4799-4d0d-8530-14942563e2f8" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_804e6334-635d-4ddc-855d-20ebb93c13a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c721d4fe-79bf-4ad0-a1ee-0f43f33f07d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c721d4fe-79bf-4ad0-a1ee-0f43f33f07d0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_3a837ba2-17b1-4bc1-80da-3d4fd31982b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_3a837ba2-17b1-4bc1-80da-3d4fd31982b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_20b86196-3219-4f37-9b2d-28780cac33a5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_3a837ba2-17b1-4bc1-80da-3d4fd31982b9" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_20b86196-3219-4f37-9b2d-28780cac33a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_24dd1f89-028c-4f2a-b940-42c3e1e8adec" xlink:href="ino-20240630.xsd#ino_SanDiegoOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_20b86196-3219-4f37-9b2d-28780cac33a5" xlink:to="loc_ino_SanDiegoOfficeMember_24dd1f89-028c-4f2a-b940-42c3e1e8adec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_07f58d73-a9c9-4421-90b9-d8557765749c" xlink:href="ino-20240630.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_20b86196-3219-4f37-9b2d-28780cac33a5" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_07f58d73-a9c9-4421-90b9-d8557765749c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_054bbe91-4841-4146-a19a-024430807bcf" xlink:href="ino-20240630.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_20b86196-3219-4f37-9b2d-28780cac33a5" xlink:to="loc_ino_SanDiegoCaliforniaMember_054bbe91-4841-4146-a19a-024430807bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e92bdf4a-f802-4e4d-a768-95e2ae775ef9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:to="loc_srt_RangeAxis_e92bdf4a-f802-4e4d-a768-95e2ae775ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2fbe6d7f-a0d0-4a7b-b7bc-25ce13424bc2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e92bdf4a-f802-4e4d-a768-95e2ae775ef9" xlink:to="loc_srt_RangeMember_2fbe6d7f-a0d0-4a7b-b7bc-25ce13424bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f96eda91-756c-4e62-b171-6d56455d2200" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2fbe6d7f-a0d0-4a7b-b7bc-25ce13424bc2" xlink:to="loc_srt_MinimumMember_f96eda91-756c-4e62-b171-6d56455d2200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_325b98a7-6a86-408d-98ea-1848597f4ee1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2fbe6d7f-a0d0-4a7b-b7bc-25ce13424bc2" xlink:to="loc_srt_MaximumMember_325b98a7-6a86-408d-98ea-1848597f4ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b1a9fe8a-c122-4c84-b8e2-ab1f18bd4e7f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:to="loc_srt_LitigationCaseAxis_b1a9fe8a-c122-4c84-b8e2-ab1f18bd4e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1927eb8e-73e4-4fcc-891a-4de44d60428c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b1a9fe8a-c122-4c84-b8e2-ab1f18bd4e7f" xlink:to="loc_srt_LitigationCaseTypeDomain_1927eb8e-73e4-4fcc-891a-4de44d60428c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_e360e8bf-a1d9-43b2-87c4-28bd1fdbce29" xlink:href="ino-20240630.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1927eb8e-73e4-4fcc-891a-4de44d60428c" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_e360e8bf-a1d9-43b2-87c4-28bd1fdbce29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember_d92a6116-7613-4121-81c2-2b79f3af2a1c" xlink:href="ino-20240630.xsd#ino_BehestiVKimEtAlMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1927eb8e-73e4-4fcc-891a-4de44d60428c" xlink:to="loc_ino_BehestiVKimEtAlMember_d92a6116-7613-4121-81c2-2b79f3af2a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f73eb059-494f-4c68-80bf-cf63c759f6f2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4d9d79e8-e48e-4052-8534-e90484043661" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4d9d79e8-e48e-4052-8534-e90484043661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_856e19a1-b05b-4b63-942d-65a6f2a2397a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_856e19a1-b05b-4b63-942d-65a6f2a2397a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6b27f394-ffd5-496c-88ea-d7888b1b3423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6b27f394-ffd5-496c-88ea-d7888b1b3423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_a9667f8a-43be-44d1-be73-8c7fc3eb13b7" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_a9667f8a-43be-44d1-be73-8c7fc3eb13b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1fb11564-1aeb-46a3-99b1-a593151dc183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LeaseCost_1fb11564-1aeb-46a3-99b1-a593151dc183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_81df44f9-e232-4fd7-a0e7-2629ae32ff1b" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_81df44f9-e232-4fd7-a0e7-2629ae32ff1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a4d75743-4b00-4e10-836a-14d95f572d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a4d75743-4b00-4e10-836a-14d95f572d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_bca9461d-3887-4709-a57c-610b4faccb91" xlink:href="ino-20240630.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_bca9461d-3887-4709-a57c-610b4faccb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_7d048c5f-76e7-4ce6-ac27-57af0a006c98" xlink:href="ino-20240630.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_7d048c5f-76e7-4ce6-ac27-57af0a006c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_60e6eea6-be0b-43ed-845d-35a30ed7c98c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_60e6eea6-be0b-43ed-845d-35a30ed7c98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_6bf5b318-f858-422c-b00e-849d7a173439" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_18a927aa-01ad-4484-ae36-8ba77488b2bd" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_6bf5b318-f858-422c-b00e-849d7a173439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ae609822-2021-4a61-b45e-7b670d390bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ae609822-2021-4a61-b45e-7b670d390bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bf56c304-a261-4f65-927f-adf82faad4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bf56c304-a261-4f65-927f-adf82faad4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ad4a2f4c-e529-4b3d-b1fc-723b9457ec36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ad4a2f4c-e529-4b3d-b1fc-723b9457ec36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b26077b2-f178-4a05-aca1-cfd757376ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b26077b2-f178-4a05-aca1-cfd757376ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ba81f26c-c6b7-4fcb-ab50-ea6610742a03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ba81f26c-c6b7-4fcb-ab50-ea6610742a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_dcfda5bf-edbf-4533-8693-69ec0d8d9f29" xlink:href="ino-20240630.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_dcfda5bf-edbf-4533-8693-69ec0d8d9f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31d1b42b-9ce4-4475-9cd8-eddd33a937c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31d1b42b-9ce4-4475-9cd8-eddd33a937c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7ab8d99b-6bae-49cc-a676-5b5187df8ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7ab8d99b-6bae-49cc-a676-5b5187df8ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_57e65f52-91a6-432d-91f7-9daee354da73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_OperatingLeaseLiability_57e65f52-91a6-432d-91f7-9daee354da73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ba076b96-7989-440b-8f30-a977f2c4515c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ba076b96-7989-440b-8f30-a977f2c4515c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_64ad42d3-d09b-4f88-97f0-49202973fc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_64ad42d3-d09b-4f88-97f0-49202973fc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_355a70da-35e8-41f3-aae2-68c76626add8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_355a70da-35e8-41f3-aae2-68c76626add8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1facfcf8-9c74-4dd3-8658-dbda36a6f8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa9dac-6e6b-432f-9668-383b8b0ad8da" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1facfcf8-9c74-4dd3-8658-dbda36a6f8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d5c59ad-e566-46d9-8de3-a0ea72cf8a23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d5c59ad-e566-46d9-8de3-a0ea72cf8a23" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3101f00c-87d2-47a2-bffb-40404331ab40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:to="loc_srt_CounterpartyNameAxis_3101f00c-87d2-47a2-bffb-40404331ab40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3101f00c-87d2-47a2-bffb-40404331ab40" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_76a933ba-8a83-4863-8f25-8091089e2393" xlink:href="ino-20240630.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:to="loc_ino_AdvaccineMember_76a933ba-8a83-4863-8f25-8091089e2393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_59e37d33-bf52-40b0-b9f7-44e5a0b077cb" xlink:href="ino-20240630.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:to="loc_ino_ApolloBioMember_59e37d33-bf52-40b0-b9f7-44e5a0b077cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_8416bc86-1b7d-4210-af47-c3f021a6c673" xlink:href="ino-20240630.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_8416bc86-1b7d-4210-af47-c3f021a6c673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_1c2b13a6-db9d-4d13-8bbf-4fbf4ca60c94" xlink:href="ino-20240630.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6adf0fed-064e-4c01-9da0-739fd52f0e77" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_1c2b13a6-db9d-4d13-8bbf-4fbf4ca60c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5d3b5922-6f32-45c8-93a0-8772b4c6b5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5d3b5922-6f32-45c8-93a0-8772b4c6b5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b546e3ec-633c-453e-9cd2-f3e95d35e316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5d3b5922-6f32-45c8-93a0-8772b4c6b5bf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b546e3ec-633c-453e-9cd2-f3e95d35e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_000aaba4-aa97-488a-806a-e8433b657786" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b546e3ec-633c-453e-9cd2-f3e95d35e316" xlink:to="loc_us-gaap_CollaborativeArrangementMember_000aaba4-aa97-488a-806a-e8433b657786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a9830e85-345c-4f35-920e-897bc8e3fe35" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:to="loc_srt_ProductOrServiceAxis_a9830e85-345c-4f35-920e-897bc8e3fe35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a9830e85-345c-4f35-920e-897bc8e3fe35" xlink:to="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_e017799e-c64e-4e01-bb64-a133b312d446" xlink:href="ino-20240630.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_e017799e-c64e-4e01-bb64-a133b312d446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_dd7980dd-cb8a-4697-8120-0bd94c4415e5" xlink:href="ino-20240630.xsd#ino_INO4800Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:to="loc_ino_INO4800Member_dd7980dd-cb8a-4697-8120-0bd94c4415e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_8c3445cd-8a21-4629-b825-db138b6211cc" xlink:href="ino-20240630.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_8c3445cd-8a21-4629-b825-db138b6211cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_b11ae8ab-1a0a-4e32-a3cb-d0361976ab3a" xlink:href="ino-20240630.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89eeb56c-1276-485e-b426-ae8180502602" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_b11ae8ab-1a0a-4e32-a3cb-d0361976ab3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_923f9f12-3fda-42c8-adfb-0902b686c943" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_b5790bb7-b9b0-42b9-bda7-3158b6fd54ac" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_b5790bb7-b9b0-42b9-bda7-3158b6fd54ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_fbee874f-540f-4fcf-a06f-51f7ae6800f7" xlink:href="ino-20240630.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_fbee874f-540f-4fcf-a06f-51f7ae6800f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_1c7e7f09-9599-474f-bcb4-58963566b7e6" xlink:href="ino-20240630.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_1c7e7f09-9599-474f-bcb4-58963566b7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b9cc751e-4aa4-4f13-bd78-42d62b960d69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b9cc751e-4aa4-4f13-bd78-42d62b960d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_620a7cd5-9051-4b90-abc7-c6f7fafb3d7a" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_620a7cd5-9051-4b90-abc7-c6f7fafb3d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_7271801c-e55b-472c-91b8-d23f636666b7" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_7271801c-e55b-472c-91b8-d23f636666b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_09d27051-50d8-4406-a1d5-bb6857b3d100" xlink:href="ino-20240630.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_09d27051-50d8-4406-a1d5-bb6857b3d100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_21611c1b-b826-4dc7-b44c-51d8f6ba578b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_509df4b9-9e24-4159-b2b7-16a4b7553cf9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_21611c1b-b826-4dc7-b44c-51d8f6ba578b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDetails" xlink:type="simple" xlink:href="ino-20240630.xsd#GeneosTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_cc9a9284-7a72-4c23-8ab4-fca7641747e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_cc9a9284-7a72-4c23-8ab4-fca7641747e2" xlink:to="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e6cb8392-54ba-4661-82b1-8f31c1220835" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:to="loc_srt_CounterpartyNameAxis_e6cb8392-54ba-4661-82b1-8f31c1220835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fedf6c9-61bf-47b9-891e-3e61b55299ec" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e6cb8392-54ba-4661-82b1-8f31c1220835" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fedf6c9-61bf-47b9-891e-3e61b55299ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_152ea9af-dc81-4f57-81ae-81329394674c" xlink:href="ino-20240630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fedf6c9-61bf-47b9-891e-3e61b55299ec" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_152ea9af-dc81-4f57-81ae-81329394674c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_150a0cb9-3a58-4798-ab0b-3fb18ffe68cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_150a0cb9-3a58-4798-ab0b-3fb18ffe68cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_150a0cb9-3a58-4798-ab0b-3fb18ffe68cc" xlink:to="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_0a3bcf50-23c9-4b63-8cb7-b014febc3362" xlink:href="ino-20240630.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:to="loc_ino_SeriesAOnePreferredStockMember_0a3bcf50-23c9-4b63-8cb7-b014febc3362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_73242bf5-df3c-4f11-89d4-cf27cedc113f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:to="loc_us-gaap_CommonStockMember_73242bf5-df3c-4f11-89d4-cf27cedc113f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_39b8e369-4c07-442b-845f-3484104f04eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:to="loc_us-gaap_PreferredStockMember_39b8e369-4c07-442b-845f-3484104f04eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_830435ce-d618-4c52-bcde-6a8f6c7ed9a8" xlink:href="ino-20240630.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f6e7c1ad-2041-4409-900f-b5ce1e0e03b8" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_830435ce-d618-4c52-bcde-6a8f6c7ed9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_bdf76da7-5695-48ab-b161-827f2a47ec64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:to="loc_srt_OwnershipAxis_bdf76da7-5695-48ab-b161-827f2a47ec64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d586f48e-302b-4a43-940b-7a3c6dc0c86b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_bdf76da7-5695-48ab-b161-827f2a47ec64" xlink:to="loc_srt_OwnershipDomain_d586f48e-302b-4a43-940b-7a3c6dc0c86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_c7c2a0f5-b4c5-4d01-a3f2-5ac51c531dd6" xlink:href="ino-20240630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_d586f48e-302b-4a43-940b-7a3c6dc0c86b" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_c7c2a0f5-b4c5-4d01-a3f2-5ac51c531dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_44329281-9746-443c-a4a4-b550aa4b92ed" xlink:to="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_2cd8a72e-ed1d-49f7-af8a-a4c458ddd488" xlink:href="ino-20240630.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_2cd8a72e-ed1d-49f7-af8a-a4c458ddd488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_03cbf939-2a54-4521-afc1-877ff1552f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_03cbf939-2a54-4521-afc1-877ff1552f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1326ea60-22c0-4e12-96ee-39190f43dd14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_EquityMethodInvestments_1326ea60-22c0-4e12-96ee-39190f43dd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_32b10e99-1830-4e57-bdc0-90f5ac525f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_32b10e99-1830-4e57-bdc0-90f5ac525f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_65514d51-e80b-4842-a686-47b336aa94d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_65514d51-e80b-4842-a686-47b336aa94d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_fab1a060-e568-4cd8-9d9e-e0fd34f0e7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9b3d3d64-0701-4adc-b67c-c04e7c55c903" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_fab1a060-e568-4cd8-9d9e-e0fd34f0e7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20240630.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:href="ino-20240630.xsd#ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ino-20240630_g1.jpg
<TEXT>
begin 644 ino-20240630_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
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M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
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M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 4$7?<=D=]1:7J;G86
MKXF9TB(U,_'$+>);TM-)(7K7DW5++A;LHS=+OPV/M7Y&?K@CCDG=7R\WAJF1
MIV\??KQ6Z-ZM/3N59P:2&S5LQ%#8@E!_(XY8C.,Q?R<2=D!K@T657;4[-%K:
M7<7.Z/E\23'Q2-DM/VI6+JN:?OR2EC9'-_*66NT<N/M2B_2=RE8?@/, Q50!
M$1 $1$!*WW/_ &GFT!NE7PF0L^#@-P?4M.W.OJ>*+--/(.FK1,Q,P.5VY-C'
ME<7$1R?5*XQ@\D=S5:W2"Q)#)'-"9130R!+#+&[C)%+&3''(!-YB0&S$+MYL
M[,[*^/V"^T?'NGM=IK5)F+Y5JY8G4,3%U'#G<4[5;KGSYLUUAAR<#._/JMZ!
MR]IW9@,Q$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %1:[S;X^
M]S?LY5_ >)5Z546N\V^/O<W[.5?P'B4!@HB(@"(B *17NE?IB]L_[?J[^#W5
MRCJ4BO=*_3%[9_V_5W\'NKD!=[1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 14=]%
M\0.I/LSI+\9,<J8RN<]]%\0.I/LSI+\9,<J8R (B( B(@"NT]T=\0FBO[L?A
MF\J2RNT]T=\0FBO[L?AF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$!Z.3QE>[6L4
M[<$5JI:AEKV:T\8RP6*\P/'-#-$;.$D4L9$!@3.)"3L[.S\*F%WF_8"L[/ZD
M^%\'!+-M_J*U.>(E;Q)?@&X3O*>GKLIN1, "3OB+$QD=NI&44DDEJK.<ETM=
M:;P[1X'7>F\MI34M(+V'S%62K9B+AI(W)N8K567ARKW*DO18JV X.&>,#'W<
M.!KND66';)[).>V<UE;TUEAELXZ7JMZ=SGA=%?-XHB9@F%QY".[5)_5LC5Y8
MX+ >((O5GJRRXGH B(@"(B +E6AM<Y;3.9QFH,#>FQN9P]R&_CKT#\206:YL
M8.XOR$L1\/'/!*)0V(#D@F XI#%^*H@+U/8([:V)WIT>&4C:*CJ;%>%3U3A1
M)_S)=<2\.[48B(Y,7D1 IJDCNY1$TU29WFKD1YSK7X]F'M(ZAVHUACM8Z<-B
ML5>JOD,?+(85,SBIR KF+N]'/SJ;PPEAEZ3>K;AKVXP(X6$KT/9YW^T]N9I/
M%ZOTU9\?'Y&/B6 W'UK'7HV%K>,O1B[^%;IR/T2#]"8N$T3G#+&9 =VHB( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4
M_#E54T$ 1$0!$1 %>&[J?Z7[;C['Y?\ &3,JCRKPW=3_ $OVW'V/R_XR9E 2
M%(B( B(@"(B (B( B(@"(B *O1WX7>(RZ*PW\R31N0*OJW4M,9M3Y"J0^/@-
M,6F,&IQ2,[O7RF?%BC$F;Q:N*:Q.#Q36J4X3 ]KSM+8C:/;W4>NLOT2#B*1M
MC:!2>$66S=@7BQ&*C/AW$KMUXXY)!$WAK^-8Z#:)V?7SYO,Z@W&U/FM6ZBME
M:RN=R,^2R^0)GZ'L3ORU>L!D3C#7B:.M3@ZB&O5BAC=^D!ZI^\"_#^&H94M4
MS()X6!->7"2WCD9:VE%-/I*NA.-DT^DIRJAM*+FB/>/^)?HE'T>J6UU\7S-/
MK"KJFU\)3>\8OT2D^CV9U[I?3DUHQBKQ.3MQSY<  MY<F[^0BWGQS]1V;GW+
M([ :+KU&$I>)YF;GEV^="_\ V1?CGC^F/Y/<++FFD-(22S5,1AJ-BW<MS15J
ME.I"=BY=M2NP1QQQQ,4DTTA<,PB+NWR,PMY6.>Q/W0%6F%/4V[$0W+SC'/4T
M7'(!T:9.[&!9ZQ$1-?L"W2SXZO(U*$NL;$U[EABLWQGX@86D4>;E6\CEOY./
M7M+(R&OU(=-H_K3DXUQZ*4N9QBX,T?AW+U2[DIKWBFN>R?2JI/UD^O7X02<G
MMT6R;*X>::3'5:5Z[6MUZ61>8,=;EJSQ5+YUR<+ TK4D85K)5R;IF&&4WB)G
M$V9_)?)DE"Y%TP6'C<F\V9^@GY^1C;S;R^N/O6P-U-MAIS-84M.9; X?(X H
M0K_ US'5)\8,,0],,<=*2$J\30#QZN\0 4#B+PN#BSM"?VE>XJTAF"L97;'-
M6M%Y,GEE^ [SR972\\CNYA'7ZG;*8ANIW%WCLWZ@QL 18^)V,SC#A3V@-)OL
M=>HXMF"W)JN_F^E4*+?N^9R5PLKEMLFU5;'?>3E!=%F>+O!S5/+4M.S8V.*3
ME5R1IG*2779RE)3COOM%V5]-EM)K<@4V'[8>[NTLL;:/U5;;%QEU%IW,L69T
M],+F\AQ^H63\2DTA<N4N*LX^SR1.,[>(?5/EV:N_:T/G3KXO<K$VM"924@B;
M+5VERVEI3?@>9K$0-D\4Q$_T5FE/1B!B.QD8A9N8$]^^RINGM--+'K?2MR+%
M1GTQ:BQ[?"NG+(NSD,@Y.JQ-3)V8N8,G'0M#TD_@>&X2'CFS8Z^/LN($_P"L
M[._O\OE_D[^7O4C:YX>\.<24_28PHE.Q-QS]/LKC:VUWG.M2KNDO57PLE'[/
MNO<C?2_$/B+AVSZ/F5W2K@]G5?"<H**>W2,MK*X_!U246NO5;&PST;K7#ZAQ
MU?+8+*8_,8RV#25[^,MPW:DPN+%[$]<SC<F8FZAZNL'?@A9_)<H6O=VFW.UU
MMKDGR^@M3933]@C$[$5&PY8V^P.SL&1QDGB8^\#MR+>LUY)(Q<O!.,GZE.1V
M:>_KDB>#%[O:8\-V=@?5>DXS.)QX\CR.G9S.:(F=OGD^,NV!D(O8QM8 ]JMO
M%OL]ZK@\UNGRCJ5"Z\L$JLJ*^'DRDXV[+I]39*<GU52[%@>%/&K2M148W2^A
MW/9>_+FI;[?RB2<.O^4C&,>SFRRTBZ:V7[0VB-Q,:.6T3J?$ZCI<-XCX^T)6
M:I.S/X5^A)X=_'SMRW57O5J\XOY%&R[DY4$9.-93.55U<ZK8/EG79"5<X27=
M2A)*46O@TF2_3="R,9URC.$EO&<)*49)]G&46TU\TSU[=.&Q%)!/%'-!,!1S
M0S ,D4L9MTG')&;$!@8NXD),XDSNSL[.H@NU'W,.V.MRMY7282;>:FG>68K.
M& IM/W;!\DQWM/22A5AYE?JDDP\F,.1SD.=K$KB03#(LKH/$N?I=WGX&5=C6
M=.;RY>Y8EVC;6]Z[8_LV1E'?KMN8_5M$Q,ZMU9>/5?![[*R*;COTWA+[4)?M
M0<7\RC-V@^PWNSLZ<EK56"')Z:@*1GU3I\I<KA&BZ3\.6\SP17L5SPW7\(TX
M(0/V0L2CT2'AV$V/R0<^R)GY\^\2=_-WYY=_-_/E;%F2,3%P(6(29Q(29B$A
M)N'$A?R)G;EG9_)V?S43O:H[GC:[<+Q\E@J[[?:F-B,,CIRM &(M2OR_.5T]
MQ#2G$G?DY:!XRXY<$]DQZXY+.\'>T?"7+3K>/Y;Z1^F8L7*O^=;C[N<?VITR
MGOVC3%(KKQ;[/D&Y7Z/>ZK$W)46-1;?PC:MHR^$8V1CMZV%/%\#?QIO-C;,M
M?J?J)HB8HC?R\SB)BB-^/+DA=^/+EE]^EN=+R$.3K^"3NPO9A\X>?-NHP-W.
M)O=R[/*S/[3N(_0Y9]J_L0;E;'RP3ZEJULMIB[<>ACM3X>3QZ%BR\,UD*ERG
M)Q>QMPZ]>>8([$15Y(X97@MS%'*,>(D5O'Y 6Y< ,OJ<.+\M]3Z_[:_;Q6]G
M/PY\4L6R[4,+!RLU5JNO7-+G7CZQB2<-ZHVY5*Y[/+B^>&'J5=],=]_HZ;;*
M?^(_A3A9UMN/Q#I4)Y="4/I^/%4ZC1S1WKE*V"<K8*+4ZZ[U?0T^:,-GN<JN
MW&=O)V=B^5G]_P!=G;ZWR_\ UJ:WN-]RRK:]U+IR27B#4.EVR,8D_D62P&0K
MQ^'&WGQ))4RM^4WY9G"HS%RX@R@JL1>K $74Q"PNP.S\MTB[LW'U&8>EOU^>
M5GMW8&M_@7>305EY& +F4MX>4G=F%H\M3N4F%^KR]J22(6X_1.+MY\<<G/9'
MX.R>%N/_ !%X&R[(W.C0M7QU.*<8Y65H6I861I^2JVWRJW%G??&&\I05JBI/
MWFXZ]CR$]"XYR=/=G-#DLH\Q+E5KIRZ:X6<K[*>-=?+E;WAS;;]&R[*B\,O*
MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
M[*GWVV++_P U_<'EW?C45EN7\_)HH&9OUF;AF;Y&9F_6H1_="K&^$](J7:?$
M%5C_ !KT[4(Q_P![(@OQ\G_ZLPX/[,L^+:^/+C9*V_Z[?Y'1,9^Y>KFLU%CZ
M5N],_$5.M-8D\V9W:*,CZ1Y_1&[, ,_EU$S+\J\W+>]=#=I?4OJ>GPI@7$N5
MM!7\O)W@@;QYW]_T+NT,1<<_T87\F7-[V>?#&?&?&_#'"T5+EUC6,3%R7#?F
MKT^,_/U*Z/SHT^G)N7\ST[E%M4X(CG9F-0E]7?=",FNZJWWM?XQK4W^1U!V=
M]^M7:*U/<U?I6:K6U)/1R5*+*6:460/%OF"!K=S'166.".]ZN,M2&::*88JU
MFP'A%U-T_5U-+G-2Y&7.ZOSN5S^6G=SFR.<R%K)7"8G=_#CEMRRO%7#Z&&M!
MX=:&-AB@BCC 1;K;;V^U>M%#!#)9OW[;15J\$16+-B0G&&"O7KQB<LT\LO4T
M<40%+(1,(,[NS*7[LX=T!NWN"=;(ZG:+;S3DK!*4N8C*QJ2S"3]3#2P,;AZL
MY!Y%-E[=$X',#&G<<9(1_M'S\S0]#JADY+P\'EHKQZFXQC;]'HCM5C40C%W3
MKJB]H4U1DH[OW>K;G&[#US5<B>G:97;'"QYJN,:^E4&HQC*3WVJKZQY5*;7N
MQ271=(N9<O1I,P0B)R.[,'DSD1/Y"P"W+N1/PS,W+N_DS<\*0'LW]V+O%ND\
M%V3%GH?3<SB_PYJNM9J3SPD'B#-C,"30Y.]&0N#PSRM1I3]8O#<,6D(++?9@
M[LS:;:SPKN*P(YO48!Q)J?4A-E<GU/QU/2AE'X.Q(\MPWP;3K2D/#3SSDW6I
M >/Y?R_TJOO&'M)3ESTZ+C<B[?3,N*<OQJQDW%?&,KIR37VJ4^A+7"?L^X]3
MC=JMSR+>[IKD^7\)W-*3^<:XPV]+&N\679>[HC:C;KU;(9*A\WFI8/!E?,:H
MKU[%.O;B]II\5@7:7'X_IE^>5SF]?NP.,3^O221M*I2XXV 6$681%F81%F9F
M9O)F9F\F9F\F9O)E_:*M6M<09NHW._.RKLJU[[2MFVHI_=A#I"N/PA7&,5Z(
ML#IFD8N%6J<6BNBM;>[7%1WV]9/[4Y?M2;D_5A$18<R(1%Q;6.M\-IW'SY;/
M93'X;&5AZK%_)VX*-2)N'=F*>P<<?47#L <]9NW "3\,OM"$I248Q<I2:48Q
M3<FWV22W;;]$CZRDHIMM));MM[))>K;Z)'*5XY4)':$[]#;#34D^.T51RFX6
M5C=P:U0$,9IF(V9^>O,7?S5<X)P<7Q>,N5I&ZQ*[#('2\(V_'>?[Y;DG-6^:
M#YC,%,Q#\":0C?'N<;N7#7,X?BYRR?2[QF,%VC3E!A<J/6SF\O\ "_@=KVI<
MLYT+ HEL_-S=ZYN/[&/%2O;VZKGA7!]/?2>Y''$?BMHVG*2ED+(LCNO+QVIK
M?YV-JM+X\LI-?JEK[M ]N3:K; "'6&LL32R#1E)%@JL[9+4$XBS\/'AJ'CW@
M W9P&>Q%!6<_9>=B\E!IO[W^69O%/0VKT9'0@\P#4FKI/6;9OU<,=73U$FKP
M#Y,037<I8(Q)QDQ\!"Q/ S#I2&.22S=E>6Q-(4T\TLAS6)Y2\SEFE-RDEE-_
M,I)#(R?S)W=?M+J"E5<(H8Q*20PCB%FZI))#?I".,&Y<S,G81 1(B=V$6=^%
M8OA?V>]&PN6S-=FI7+J_.?E8R?QCCUO=KXJZVZ#[N*](!U_Q^U'+<JM,H\B#
M>RG!<\]OG;-;+\:X1DO21V3NWN_N+N5;>]KS5^;SX\N45*W<.##5&)W?IIX6
MMX&*JOP["4D51IY1 &GFE<6)=<0XO'4F]IQ(A9O(69F_O^?^A9^[&=V+OAN*
MT-F/ QZ/PTWAE\*ZRDGQ3O7-G)Y*V(BK6LQ/)T,_A!+3J0E)TC+9KQGXHS8;
M!]QQMCI]H+FM[>2W R<?0906I9\-I\9AX=W'%XZR-BU$Q-Y09'(6Z\@N0SUY
M6XZ<_KGBIPWH5?T>NVJR5:VCAZ;779R-?=?EN&/4UV<960DO2+,)IOAKQ-KL
M_.RYV45SV<K,F<Z^9?C)2NGOUV<8;?/J5CMNM%:JUG='%:'TOF=1W"-HWCPN
M.L6XX7]W5<NB#4Z$3<LQV+UBO!&SL\D@L_*L>]V3W=6X.@[.I\GN'+@H<3K#
M2\FG\AI**:3*6SCL&,C27[$71CHWBADM53@AENL;69Q:8683DFZT?H;"Z>I1
M8W XG&X7'0LPQ4<52K4*D;"S,/1!5CBC;AF9FX'W,S+E'"K=QWX\YNK4786/
MBU8F'<E&;DW?D349J<??VA77M*,9+DK<XR6ZL)ZX(\%-/TBZK+E;9D9=3<H3
M_DZXR<7"3Y=Y3GO&4E[T^5I]8'4FQ6X46J-*8K,12-*9M=QUPNOQ"'*8/(6\
M'EX93Z0YGKY3'7*\[=+=,T4@<>RNW%$3W76ZX6M1=H[;MY!<MO\ ?35LM&+V
M0:/%:NF;/\0P"[^'#\,RYB4G_P"LLSSE\OE+LH>X@T[Z)F74[-1WA;7OW\G(
MKAD4-_-TVP;)BQ[.:$7^*?XQ;C+^*81$6&/V"(B (B( B(@"(B (B( HZ.](
M[-7\TG:7-04ZSSY_3#%JG >%$\MF6QC:\SWL? P_/#?)8T[5<8 8_&LM5=HS
MECB<9%UX=D!K;@)B9G;S9V9V=O<[.W+.R_I9W]Y%V;?YF&[.H,/5K^!@\NXZ
METYTM\Y;%Y669Y*L7R"V.R,5VBT3<>'## 3 ,4L7."" (B( B(@/8J7)J\L5
MBO*<%BO+'/!-&3C)#/";212QDWF)QR")B3>8D+.ROH]AOM%1;H[8Z7U6Y!\)
M2TFQ^?A$G)Z^>QGYDR3/S[0A9EC:_78G<O5;<'4_7U*A,IV^XR[2A8/667VX
MR$[MC=7UGR6&$G'I@U%BXG>>(.7%V;)XII'/CK?QL96$8V\:61@+6J(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B(#&GM?]H&MMAMSJ?6<Y1O/C:+Q8J W%GN
M9J\8T\56$78NOKN31'*S 3#7CFE/B.,R&@GE,G9O6K-VY-)9N7;,]RY9E,I)
M;%NU*<]FQ+(3N1R332'+(9.Y&9.1.[N[J?;OVNTHV2U#@MKL?,Y5M/11:AU"
MP/[!9C(021XJF3=7G)1Q<DEP^0Z6'+5V W,90"OV@"(B (B( O#OQYO[F7E9
ME]@3LWONGNEIS3,T3RX>";X<U&WM=/P#BI89+<!./F(WYI*V,ZN1X>ZSB3'T
M\@6A^Z5[-+[>;38ZS>@\+4&LY!U/ENN/HF@KV80CPV.+GVNFKC1CG(7XZ;=V
MX[>R3*3Y?G'$("( +  "PB LPB(BS,(B+,S"(LS,S-PS-Y,OT0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!8%=Z!\0>YGV#A_"N/6>JP*[T#X@]S/L'#^%<
M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
M$1$ 1$0!$1 $1$ 1$0!?)SV;JXRC=R5Z:.M2Q]2Q>N6)2Z(H*M2$Y[$TA/Y#
M'%%&9F3^3"+NOK*,+O>=ZOF/V4S]>";PK^KYH-(U&9W8SBR82RY5AX^1\/5O
M@?+.SB?1Y.0NP%0;?K=FSKO6FI]8V^MI=19FYD@C/Z*"I+)TT*S_ %/5J(5X
M.&9A;P^!81X9NI41 $1$ 1$0&<O=Q; %N-N_I/#S0O+B,;:^:3/.XN\;8S".
M-H:\CMY<9#(-1QW'+$P6CD'EHBXO5,W#<,W#-Y,S>YF^10#=PSL3\'Z3U/N%
M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B ^=E\M7H5+
M5ZY*%>I3KS6K4\C\!#7KQE+-*;_(,<8$9/\ 494$NUYO[9W.W&U3K.8S>OD\
MC)%AX3\O5,#1_,F'K,/DPNU**.>PPLS27)[,[BQ2DS6=^^B[2?S';8%I2C9\
M'-;@2R8D6C-QFBP%;P9<],W2[/X=F*2#$R<^119&46\_-J>R (B( B(@"(N2
MZ-T?D=0Y?&8'#UWM97,WZN,Q]=O^MMW)@@A8GX?HC8S8I9']F.(3D+@1=T!8
MG[AWLV.P:CW4R-?CQ'/2^F2D9^7 /#L9Z]%Y\/&4OJF.BD;GDZ^0C]GI]JR(
MNG>S]LWC]OM&:<T;C."K8'%UJ)3L#1O<M #%=OR"WNDNVRFLFSN_2\G2S\"R
M[B0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %@5WH'Q![F?8.'\*X]9Z
MK KO0/B#W,^P</X5QZ HR(B( B(@"(B M_=QC\2EC[=]0?O3#J9)0V]QC\2E
MC[=]0?O3#J9) $1$ 1$0!$1 $1$ 1$0!$1 8E=NS=[YA=HM?:E$VCLU<!8I8
MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
M*ZM:=_1NC\'Z TMI..3B74NHBOSQL[L14<!7\5^6]Q UZ[2=Q^0QC+WBRJF(
M B(@"(B *SSW!>SXU\%K77<\7S[*9"KIJA*_R4\7$-Z\T?RLTMN[7&5V\C>K
M&SN[Q>584B9F=W]S,[O^LRO?=W?M$^A]F- X*2/PKCX9LQD6=F8_A'4%B?.6
MP-_>7@29!ZL;EYM!!$'D(,+ 9IHB( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
M_FS_ "B8$Q1RQD<<@D!D+W<>[Z[<.+WITB%LRKT]886.O5U7AHNH!BM&'$>4
MH1R$9EB<FX225OGDSU91FHS3'+7\24#/M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$3W?5?$)G/L
M]I3\.55305R_OJOB$SGV>TI^'*JIH( B(@"(B *\-W4_TOVW'V/R_P",F95'
ME7ANZG^E^VX^Q^7_ !DS* D*1$0!$1 $1$ 1$0!$1 5F._TQ3CG]N+_#])XC
M/4V)W?CJCN4)G'CCCEFD9W\^>']WRJN;'I=[N0N6HG(9ZQ42CD G&2(Q#K"2
M,A=B Q*-B QX<2#D79V5I_O]M*E)H_;[/,/LT=4W\,9-QY/F,-->CZO+JX;X
M!DZ7YX9R=N.3;BJ+E=12XS)-*'/AV*L8FS?TT4DW#_4=V8F;]9_[]]O!#)C9
MP_I^^VU?TJJ2^#65<UO^4HOKZ,JUXJXV0L[-6-)1NFL>RMOINE"KF73;NHR2
M^9*-M3WJ_:#T;X4!ZLCU9CX6$6HZNQE7)2, ^_C,5@HYLY";R:2YD;@CQSX?
MO9Y*=K/2#*3/%#KW;C)U.7Z9<AI#(5<D#<\-U?!>9/%2"#>9&X9.:3CR"(R9
MF*M_C-S F<0)F,B=A$7%W(B)^EA9N.IW=^&%FY=_D^1<BKY_%W&\V'WNSN#L
M[,[>3L[/SYL_D[>]G\G;GR6S:SX3<.:AO*S3L>N;[V8N^++=_>:QW"$I/OO9
M"6[WWW(\T_Q1XET[:-KMM@O2S:];?+S4YI?*,EMV+KNT7>E[%:R\*.AKW&8N
MW,["-#4S2Z<M"?'+@[Y4*]8NE_9ZH[,D9%PT9FSB[Y\XW)5KD$5JI8@M59P&
M6"S6ECG@FC)N1DBFB(HY )O,3 G%V]SK743Z8H66?H,'ZOT),S<\_K^7UERC
M;W4FL=$3%:T7J?/::D(_$-L)E+-*O-(/FQV*D$C4[+L_N>S!+Q^V_,1:W[,E
M$MY:=J5M3^[5EU1NB_D[J?*E%?/R;"2-&]HZIN,<[$4'ZRKE*MKYJNU23_Z2
M)L.^5Y5-':[OFM^]+O%%EK&GM;40]F2+4&)>ID7C;WM7RN$L8[HF<N.9KU')
M-T=0M$S]!!);M1W_ -HBXT4.M]&:CTS.["TUK$G!J/' ;OPY,PMC\CX0MYNX
MT9)7;R"(GY9H@UOP+XBP]W'%AF07W\.V-C_Z&:JO;_FU27S):TCQ6T3,VY<M
M4R?W<A<G_73E6OSFBP"BP\V=[?\ LUKUHVTSN%I^U8D;EL??GEP66;Y/:Q.>
MAQN1'VO98GK=)/\ 0$7+<Y?QRB0L8NQ"3,0D+LXD+MRQ"3>3L[<.SMY.S^2B
MS/TW)Q9NK*Q[\:Q=Z[ZITS7XQLC&2_<;]C9E5T5.FVNV#[3JG&<7^$HMK^)^
MB+PSKRO$>@(B(#X6HM,8W,5):&6Q]+)T9Q<9J>0JP7*LHNW2XR5[ 21&SL[M
MP0.W#J*7?;N5]G-5^/:T_2NZ RLO6;3::G?X)\4N7%SP%QY\?#$Q=+/!C1QT
M;@Q,/29>(TNZ+.:)Q-J&FS\S S,C%DVG)562C">W965]:[%\K(R7R,7JFB8>
M;#DR\:G(CZ>9",G'^;+;F@_G%IE/+>SN:]Z=&O/9TW)B]PL5%R498B1\7GGC
M;CGQL+DC>'K9W=A&CEK[FP];C$Y>&T8>HBNX:_+A]38;(8/*P/Q-C\Q0LXR_
M'[1 Q/6MQ0RO&1"31RL#QR,W5&9CPZV)*ZVW-V=TKK2@6+U9I[#ZBH$Q,U?+
M4*]P8^KCJ*$I@*2 RZ1Y. XS=F9NKA3WPU[2>?3RUZGBU9L%LG=0UCW_ #E*
M&TJ+'^S"-"_:V(5XD]GW3,INS"LGAV]TGO97OZ)2WC;'\7*S\#7U2X3'W&YC
M(6=V^A+CS\O=Y?5_:7S\1H6M6M1V9  SKB[5O)B:'JZN2CYY8>&,V%FX9G,B
MXY4Y?>>=W]LOMCCJN9TSE<_I_4>8M].,T9!;#+8FU7B=GOW.+XED\33AY8?&
M^$K%=YY8:E.@(]95X']TMR(--8P[#]$EV5GBH5G\_%FX_HAMSY00\]<A?+[,
M;/U&RL?I'$V%Q!@U9&/CV2JLM3C#,H46K*)J49PC+S*Y.NQ)QNKE)0G!\LU.
M+Y8:CP#FZ9G/$R,B&0H\KA7"2L7,WO"4VTG'D2YDIQ4EO&;:BMY8Z=K3<U@A
MCTU3D]J3HLY4A?Z&-G$ZU1^//F0N9Y6?C@1A'A^M^FU)Z+SL\^*V?UAK.6,&
MDUCK6>K5E<7:0\?IFG#C^EBXX* <E-D6'I=^)AG9_-E2*SMNU?M33R/);NW)
MR-V;VI;%F<^& 6Y^CDD)@C!N&;D0'AN.-H1W<W9S':?8_;;03QL%O"Z;KSY?
MI;I8]09N:?/ZBE9G9B%I<YE,A((%R48$($1N/4\9^T-JL<30Z,&,OK<[+ANO
MUJ<>+MME\>ESQDEVV?RV++<!Z6J=DNOEP<IR_6LGLM_Z/,E\$D9KHB*DI)H1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!<1U]HJCJ/"9; 9*-I:
M&9QUS&6P=A=_ N0' 9"Q,[=8,?7&[M[)B)?(N7(OROHA;"=5D5.NR$JYPDMX
MSA-.,HR7JI1;37JF?2RN,XRA-*49Q<91?52C);-->J:>S* VX&ALCI;.YS2^
M6!PR>$R%[$W!82$3EJR'#XT3%P7@V08;%<G^C@EC-N>IG4<V,9H[0L7T,=D6
M+ZS!*S$WG];ZO]Y6HN^L[.1XC4^)W*QT'&.U'#%B,YX8/TP9V@!/3MR.+<,V
M2QPC [DS,T^-<G(SLL(U<<]2>ME+\+_H+DSCY</T2&\L1?MQF!-^NM*_N9NB
M2X7XQ\2^$[>;=TZ-J>!S;?78&/D9]2O2[2WAJ6'"<ETC9S5R>ZV*78&A2TO4
M]6TR>^U;A*EOO/';FZK-^SWKLAS;??YH]TT9/V<Y0I"[1B'(\^T7']_CW,WE
M\O\ H69.Q78"WJW/:"Q@]*V,-AI^EPSVJGEP.,>(G%O'KQS029*["PDQC)1Q
M]B.0/:B(_-FB)BU'D(;4-J&W/6MT[$5FK8KF\4U:S6E:6O8A,?,)H98PECD]
MXF(DWN9;!?NX>V-4WJVRQ&HSFA^:3'!'A=8TXQ:/U;4%2"-Y[ 0_H*F5B*+)
M4V#JC".P59C*2M*P]/?%WCO4M$PJLC QJ;(V6.JZ^WGDL:4EO4_*ARIJSWES
MRGR1FHQ<).<3)>'WA-IV5D2CGWVV6QCSPA'9>;L_?^LGS-<O1N,8)M-M22BS
M ;8#N'M&XQH+FY6H<AK.ZS"<N)Q96-/X #ZF)XGEKSOF;@"W,3S-<H/*S-(U
M>N[^&TT.U^S&D]$X\,5I'3F&TYCP;CU;$4*](9'?CJ.8X0&2>4G9BDFG.260
MO;,R)W=^S45)>(N-M5U:3>?FWWQWYE4Y<F/%_&&/7RTQ?S4.9^K9:31>&,#3
MHJ.'BTT=-G.,=[&OA*V6]DE\G+;X((B+5C/!$7SLEEJU*"2U<L05*T+=4MBU
M-'7@C'W=4DLI!&#<_*1,R^4FVDENWT27=OX(-GT449N]_>Z[%Z(.:J>K&U1E
MH7<7Q6CZDV<-C;WC-E(FCP-8@+AI(I\J%D>7Z8#<29HBMZ>_OUME/%J[<Z)Q
M.GX"Z@'+:HDES>2Z'\FDKXVC/C\?5G#CK K5C*POSTG5]E^J1>'_  FU_4N5
MTZ?;55+JKLM?1J^5_>CYNUED?G578:=K/'VD8"?GYM3DNGEU25L]UZ-0W47_
M #Y1+4I$S,[N_#-R[N_DS,WO=W^1F6!V^/>8[)Z \6+,ZYQE[(0]7.(TX[ZA
MR3R"[CX)18OUB&O+UMX9-;GKC&3_ #XHQ9R:GON_VA=UMR_$'6^ML[EJ,Q$1
MXGUIL=A'8O>!8C'C5H2 WFXC-!+T\OTNS.ZZ4IZ5QU(68R!NG] #"S<,W'EP
MW'][Y/<IQX?]F:*Y9ZIJ$I/[U&%!12__ .B]-OX/;'CMMTD_2&->]HK'@Y0T
M_%=LNRG:W+K_ **OHOSM:?P)^=Y/2 ;]KQ:VVVWQ5P?Q ARVM+<;S>;,T4K8
M3#3S1#TOR3@>;DZQ=F?PW9^8I-W>VKO?N,4HZEU[F8\?-Y? ^"(-.8>.-_?&
M5;$!5EMBS\NTF2LWIVZG'QNC@6QF+45.$XX:T7B32F,4,8B\LTTINS!'%&#.
M4DAN["( )&3NS"SOY+,?:/L![Z[@>">%T-?QN.FZ?^5]3R1:<QT8$_3XOAWR
M#*60;CVO@_&79!X\XV4O8?!?"W#]:NG1@8S759.=9"=K:[^7;E2DXR?ZM/*W
MV42,LCC7BO79.O&CD\C[PIA*,4G^M"A)-?.QO;NV87U='TJSD<I Y$_6;M[1
MD;OR1$3^\G=WZB)W=_?SRO8L9_&TQ=@$&X^4W;_SXY5B'9WN!H3\*QN-KZY8
M?D#EQ6CZT5.-_+EXBR^6@N2F'5[)%%C8#,'=P.$^DFEWV0[OS9_;WPI--Z'Q
M 7H>''+90),YEW-GY\3X1RYW+$9,7M#X)1#'R[1" \"VJZ_[0VAXF\<2-^H6
M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
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MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!0$=_UAO%T3H.^P^=355RN1^?D%O$S/T_1,+<G7%V=Q=WZ>&<6=^J?=0M
M]^OBVEV=QEGCDJFM\/P_3RXC8H9>(GZOT#=70S_(3NS>_CD"HFB(@"(B +\Y
MAY F^J)-_?9V7Z(@-A%V:,_\*[=:%R3OU/>TCIVRY/SR[RXFH7+]3,_+\^?+
M,_U5W<L,>[LS'KVQFUDW+%X>C,/2=Q$Q]K&P-CBZO$Y)S8JKM(;>Q(;$<7$9
M RS.0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!46N\V^/O<W[.5?P'B5>E5
M%KO-OC[W-^SE7\!XE 8*(B( B(@"D5[I7Z8O;/\ M^KOX/=7*.I2*]TK],7M
MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQ
MRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B *[3W1WQ":*_NQ^&;RI+*[3W1WQ"
M:*_NQ^&;R DG1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 4/7>J]WF&Z&%?6&E:D8Z^T_4-W@BC$9-58F #-\5(3=+GDJWF>'FD
M<NIWDQY\!8BDKS"H@-;E)&0$4<@'')&1!)'(!1RQF#N)QR1FPF$@$SB8&S$!
M,XDS.W"_A6/>^&[N[PWO[OZ)H^P3M-KK#U1^A)WZ"U/3@%O<_(#FXH^..&RC
M1OSD)E7"0!$1 $1$ 1$0$_O= ]XB^G[5+:?6U]_@*_8*/2&9O6'Z,+>G=G#3
M]B67Z#&7IG+X,,C8*5V7U3V:UB%JUI+E:W#_ #?79^';Z[.WFSM\CMYM\BMG
M]TEWB'S=8V#;C6-SG66$I".%R5DQZ]3X>I'T=!F_#R9K&0@'K9'S+D*O3>YE
MGBO&($X*(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1 %>
M&[J?Z7[;C['Y?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B
M (B( B(@/#LL"NW#W=V@]\\3X.=KMB=34X)(L+K#'5XGRM#J9W"M<'JA;,8E
MI>F63&6YA%B8CIV*4YE.^>RP7[;W;KTWLS@_&M,&6U3D(S^ M-PRL,UA^#%K
M^0-N2IXF P=IK#MXDTC-6JA),3N&?X8>H?3L?]%NY9O/]2Z7M+M[W-O[OE\N
M_F^9]5R<WF>YN8?7\K"IQ+K-0E7'$C'>UV_9V]%%?:<V]E6H>^Y[*"YMBDCV
MP.[_ -P-F=10834U6O9H9!II,-J7'.<F&RD$!,TG2\C--4N1,492T+0C.+&S
MPE8B%YET9A]/P40X!NN4F9I)B9NHO?Y#_2!SY]+/Y_HG=VY63/:!WVU3N-J*
MUJ?5V4DR>4L_.P\O"IT:HD11T,;48B"G1@<G\.$"(B=REL2S3G)*?09_^7_B
MKU8.1F/'IAFSIEDQ@ED2QXRA5.SU<5)M[+HGTC&4DY1A!;15,-:UJO)NL^B1
MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!0;=_1E_"VOTS
M3_JS6=8^.'?\Z8K)%[V\F_HORL[O\G'FIR579](%SK-A]M<7SYRY7.Y'CAN>
M*U*I5YYXYX9[G'OX?EN6?AG8"LJB(@"(B +P3\,[_4;E>5X>$I/G8?1R>P'O
M?VC]D?)O-_-V\F\_J("_9V(,)\&[.[84NE@*OH73(R,PL/,I8FJ<IDS<MUR2
MD<AOR_)D3N[N_*RE77^TV(''Z6TU0 >@:> P]5@XX<6@Q]>/AVX;AVZ?-N&_
M69=@( B(@"(B (B( B(@"(B (B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2J
MBUWFWQ][F_9RK^ \2@,%$1$ 1$0!2*]TK],7MG_;]7?P>ZN4=2D5[I7Z8O;/
M^WZN_@]U<@+O:(B (B( B(@"(B (B( B(@"(B (B("*COHOB!U)]F=)?C)CE
M3&5SGOHOB!U)]F=)?C)CE3&0!$1 $1$ 5VGNCOB$T5_=C\,WE265VGNCOB$T
M5_=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( OD9_ 4LK1MXW)58+V/OUYJEVG:C&:O:K3@44T$T1LX2
M1R1D0D),[.SKZZ("DGWD78-N[,ZI\?&1V+6A-0333:>OF)'\&S.Y22Z>OS\D
MWK-0'ZJ4\K@5^BS&W7/6M],;:V&N^>R6G]Q-+9?2&IJC6\5EZY12=/ V*E@?
M:JY"E*[.\%ZE.P6*TS,_3(#"8G$1QE1A[679=U!M%K&_I3.@4D0.5G"Y80Z:
MN;PYF[5K\'#NP2,S>#=K._54MA)$_5'X4L@&-"(B (B( B(@.=;9;E9O1V?Q
M6I].7Y<;FL-<BN4;4+OY'&_MPS!RPSU+,?77N59>J&U6EE@E$HY"9[Q78>[9
M&$WGT;7SM%HZ6<I-'3U/@O%:2;%9-A]HX_T<N-O,!6<;9<6>2 GBE8+4%B*.
MAVLF.R9VI=0;0ZQI:LP)>*#,-/-XHSZ:V;PYRA)9H3^]@E9P&:E9Z7.I: )&
M8HWECD O\(NIMC]Z]/;AZ8Q>K=,71NXG*P-)&[\#8JSC[-BA>A8B>O=IR]4-
MB$G?I-NH".(HY#[90!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 1/=]5\0F<^SVE/PY55-!7+^^J^(3.?9[2GX<JJF@@"(B (B( KPW=3_
M $OVW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0'AUK
MT^VOOO\ S2=WM=:LCG>Q0M9R>AAI.OK!\)AR;&8PX2]W@V(*S7(VX;AK/FS%
MRKRG;-W6/0^U.X.JHI'BLX?2N8GI2"_!1WY*DE>@8?5(+<T)B+>;N/#<+75Z
M;B:,(XQ;@8QC 6;W,P\"S-^MPK7>S-HL6]3U&2]Z*IPZ7\I;W9'Y],;;;T;(
M5\8<]JK&QD^CY[YKYK:%?]=O\#N?!?)^U_I7MZMU6]:'U&N7$TP_/C9_.*(O
MT#?4.1OVV#S]Y,[<?#*#3KE,7F[-P _TTC\]+?K<^;_]EG7.>R_M#7W#USB<
M'F<U3T_AK$QWM29_(7:U"#&X2IQ-D)@L6S"%K<L?%6A%[;E:FAXC, -E:'4,
MVO'ILNL;C756[+&DY-0A%R>T4FY-I=(K=R>R2;97S1.'_IF4IRBI0A.,:XO9
M*=KY>7??IR0^U+?IOMOT4D3D]R!V"QRED-Y-5T6*CCK$D&A:5J+D;60AYCM:
ME>,_9*&@;E5Q!$#\W@GO1.!5*DIVF.5$;J/O9.SAMKBL?IO 9Z3.5<)1KX['
M8?1.)M9:""G2B&""&/)S>IX-R  $2\3+>,9\G)R[D;X$;G>D&7)?$BT-MMT\
ML0PWM5Y7W>_IE+&X@"ZF\Q9X?A.-_?\ /N/=2+B'A?B?BC4+,U:9E54R?)BQ
MRDL6NG&BWY<8_2)5\V^[G9*M2Y[)3:6S25I<+B'1-%QHT3SL=S7O7.J7FRLM
M:7,VJ^?;TC%2:Y8J*?9LLT\KC^I=6XK"U9;V8R>/Q-* 7.:YD[M:A5A!O><M
MBU)%%&+</R1FS-P_FJ4FY'>G=H?5WB1R:QCTW5E_^T](XJKAXP9W\V"].V0S
M/'#]'!94VX;W=7+OA!JBGFM2VFOZGS&4SUP2(AM9O(VLE-&Y_1>"=V:;P1)_
MT$/0#-Y,WDRV?1_9GS[&GG:AC8\7U<<:NS)G^#<_H\(OTW3FE\S2]9]H'2L?
M=456727;S)0JC^*Y?-DU\MH[_(N;[I][7L)I7Q8Y-=4\]9B=Q>KI2O8U"Y%Q
MY,%JA')CB$G\FD:YX;/YF;-YJ-K<_P!(1J<R0Z$VSR5I_='D-6Y6MC@8F?CG
MX*PXY4YHR]XN>6J2,S^U$S\BU>6'3./K\=9AY?(S<_\ APO%C/XJFW+^'Y>3
M.9"+<_(WR>]_+C_ZU+&C>SSH&-L\B.3G2_S][A#?Y5XRI?Y3G,C'4_:!U3(;
MCA8ZJ7HZZ>9_G.[FC^<8KXDB&YW>[]H/53R14<_C]'4Y7-O TSAZ@V6B-OZ&
M^1RP9.V)#Y=,]0J<P\<B8NZP1U3E]6ZJG>SJS4^HM1R'[1GJ#-Y++=71YB+M
MD+%@.EN&88^AHQ;@6$19F;N';;LY;JZT\-])[>:FR%>7AXKCXN7'X\P+CID;
M(9)JE0H7Y;YZ,Q W]-Y.RS^VT[D?>C.D$NILMI;1E8OHHI+DNH<L+MY_G3%@
M&+Z7]S$.;(F?GF+AFYV9ZAPGH":5FDX,X?:C4J7E/;XQJ4\J;7;=J3^!@U3Q
MEK;3\O+=<NSL=BJV?P<^2B*?P32(?H-*T*_T9Q>7R"S?M\,WE[_Y<K])<KBZ
MW'# 3\\,Y.+<O\G#>_GY/)^?[ZM%;:]PMMS3\.;5^I]4ZIF%@>2M4GKZ>QTA
M-R\@FU*.;).!>0B462K2B+<N;D_+2/[4]@[9[1(Q_,YM[INI-$S,-VW2^%\B
M_'N*3)9@[]Z4F][%)8)V?W.RTK6/:/T6C=8E&7FS79J$<>E_\Y:_-7_Y=_'?
MT-DTWV?-5R-I9^="F+[QC.5D_P"C6E#_ +8I:;<;/[AZS,(]&Z U3G0,NAKF
M/P=WX+ V\^F;,SPPXFN7'N:Q=BY^3E2!;<]R_OEJ'PI,U-IO1M:1A(OA/)29
M.]&!/P0M1Q$5B$I@;S\.2_!&7N\=N>5;\CB$!$ 9A$!81$681$1;AA$6X9A9
MF9F9O)F;AE^BBC6?:2U>[>.'BXF'%]I2YLFU?[4O+J_?0R2]&]GW1<?:5\KL
MJ?KNU5!_BH\UG_:K\/C5-[27<(:OQ>WN0R6WVO7U1N%CN+@8;(86OA\+FZ<4
M<CV<;C?^4;UFCER?HDH6;M^Q2L'$5.>"KZV-VG3*UGKG5K7+F.S5K+8^[2LS
MTLAB[,<V*M4;=:0H;-*[1<*\\%FO,!13U[0--%()1R,Q,[-MYU6>[]/N:X]T
M\?>W<VSQXAN7B*+'G\%6<8X]=8FD!$YP0]/A_-70@ZFI2]47PQ7 <=9,YXL>
M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( JKO?]ZI:;7>@<(Q>>-TE?RA!RW+-F\P=02<6;EN
MI]/FPN3NS]),#,['S:B5-'OJ=4?".^^3K]74.$TSIO#AYL["SQ6\R0#Q[F:7
M,R<L_FQN?R<(")U$1 $1$ 7.-L,$>4U/IO%QL[R9+4.$QX,P]3N=W)U:PLP\
MMU.Y2LS#RW+OPN#K+OL!:3^&][=K:''5TZRQ.4<?JAI^0M02,[</R/AXLNMG
M;AQY9_)W0%]"&(8P&,&Z0 1 !;W,(LS"S?K,W"_5$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!46N\V^/O<W[.5?P'B5>E5%KO-OC[W-^SE7\!XE 8*(B(
M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
M(B( B(@"(B BH[Z+X@=2?9G27XR8Y4QE<Y[Z+X@=2?9G27XR8Y4QD 1$0!$1
M %=I[H[XA-%?W8_#-Y4EE=I[H[XA-%?W8_#-Y 23HB( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"KB=\-W
M=KSC?W?T31YFC"2UKS$50!O&AC%B/5%6(&%RFA%B?. +&<T3#D6%CBN'+8[7
MY3P!*!QR ,D<@$$D9BQ@8$SB0&!,XD)"[B0DSL3.[.W" UNB*8?O6.[T/;'-
M'K32E,OF U!=83IUH"\+265G%R?'F\?4,>(O2C))BYC&**M+(V)?VAI%9AX0
M!$1 $1$ 1_J(B M:]T5WB+:PH5ML-:7NK5F*JDVG,G9=V/46(J WYBGF)^F3
M-8N'R\^B3(8^-I^F6Q5O3R3MK7#8#4%_$WJ>3Q=RSCLEC[,-RA?IRE#:IVZY
MC)!8@E'S"2,Q$F?S9^.DF(7<7NM=W#V\:.\^EGCR#UJ6N,!'##J+&QD(#<!V
M8(<]CX7=B]1NDSM/&+$U"YU5C+PSK',!(^B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1
M$0!$1 %>&[J?Z7[;C['Y?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B
M( B(@"(O#H"M3Z2.#_,KM47#NS:HSPN7'LL18>%V%R]S.3"3LS^;L).WT+JJ
M-<EX"*-OT3N;M^LW#?6^7_,K=_I'>'(]K]OLBW4XUMRHJ)\<=+>OZ3U/.Q&W
M3RW#XWI$N6%NOI+DC#BG_,?,O'R"(LW[7+_Z7?W*_7@/8GPSB+]6[,B_Q>39
M+^J2( X]A_ZUFW^I7+_LXK^LLU^CH;)-9S&O]Q+4+/'BZF-TEAI2!G9[=]SR
MF<(2?V@DKU(<+&SC]%'?F%_H>%:V41_<B[<!@.SYIBWX;#/J>_F]0S%T=!R#
M/D9J-5SY9G)FJ4(?"-_)XG!Q=Q<5+@JE^+.LO-XAU*S?>%5[Q*UZ*&(E0]OE
M*<)V/YS?X$N\*8:HT_&CMUG#S9?%NWW^OX1:C^"01$4<FQ!$1 $1?$U!J7'8
MFI-D,K?I8RA6C*6S=R%J"E4KQ W)R36;,D4,48-YD<AB(MYN[+[1BY-**;;>
MR26[;?9)+JV?#:2W?1+NWT2/MKQRHHM\N^;V0T=XT&.SEC761BZQ&IHV&/(U
M3D%W;I^&YI:V%('?AVE@NV!('YC\1VZ7ATWG[]7=74?C5M$Z=PNA*A\@%N>0
MM3YIAXX\09[52ABX9'XZQC^"[#1<N#RV&9C4F</>#VOZCRRKP9XU+V^NS7]&
MAL^S4)KSYQ_:KIFOF:5K7B)I& GYV97.:_Q='ULOPWC]7%_*4XLMH9_4>/Q5
M66]E+U3'4H6ZIK=ZS#4K1,S._)SSG'&/DSOYDW/#\*+S>_OFMC=(%/4H9^UK
M7+0.0O0TC1GOU&-AY;KS\XUL 0]3>&;5,C;L0GRTE<>'XJ3:_P!:ZYUU8/(Z
MVU9J+4TYD?1\-9:W:J5^LNN4*>/.5L=CX.2;BM1K5:S=;L$3>;+B<&G\?4'F
M0X^6;W#Q\GU^?_-3OP[[-.+#:>IYUN1+HW5BQ5%2?JI66*RVR/\ -C1+YHA+
MB#VB8INO3\9.7;FLWMG\MH0Y8P?\Z5B)@M[>_9W1U 4M306GL)HK'GR(W[X'
MJ+4+MSRQQ%*5;"TG<7<3B/&Y,F^CBM1OPS16;G;@:ZW#L-:USJK.ZF()/%BA
MRM^66A7DYYZZN.9PQ]4F;RZX*L9](BSD["W'RL"]K*6@QVG<-D<WD#=ABHX?
M'6\M>D-V\ACIT()[!D[-Y"$3N_G\G"D9V<[I7?36HQ6<CC*6A,;,P$TVJ;)!
MD&B+SZAPE ;%V.1AY_,]]Z$S'TA*,7)&,K5:;POPS!3Y=/T]Q7NV62C+*GTZ
M\L['9E6;[]H.6WP2V(XLUGBSB*3A37DSKD^J2<:8K?IO&/+3#\9-?CON1EU]
M.4*C-XA@W'Z$?/ZGN\N&_O\ _@OI8JV]RW'CL+CK63R$O]!IT*D]^Y+P[#S'
M5JQR2DW+MR31\-SYNRM#;(=Q/MUAFBL:YSV:UW?'I*2 .K3>"ZF?GI"A2M6L
MB8\<B?K&9F8VX,8XG\FEMVHV!T1H6GZCHW2> TU6?I>5L/BZE*:R8CT--<LQ
M1-9NV'%NDK%N:><V^BD=1[Q#[2&E8_-#3L:_.FNBLE_>M#_:3LC*]K]ET5[]
MMUW-NT7V>L_(<;-4S54GLY50?FS7QBU!QJ7X^9-+X/L5$]G>ZOWYUR\<\^GJ
M^BL3(S$V0U;<CIS&#\<^!A*;W,QXC,3&/KM3'P2#RX67+R7L=M3L"P;&UM*1
M3ZJL:ES>I!RDEUFH14,;4@QKTQ'U.)YK%J0BDM^W)/,S<,(C$S\D5T#A58N^
MZUNU_<[ 8.,V./3^D:\DK,_/A7LUD;L\\3M[F)Z-+&2\LS.0RCSY"RU/@?Q9
MUK7];IQ[94X^%&N^ZW&QZME*,*I1KY[;79:]K9UM\LX1;^YMT-ZUWPST?1-,
MLMQZI3RG.JNN^V6\DY33GRQ@H06]<;%UBVEZ^I6I[7,XO4PE?Y3L7K'U^((J
M\?/UN?6?V_/R?A6;_1?-X'O;>;A:%EFZI-+ZJJ9RI#YOX=#5%%Q(N?T(R9##
M778&=VZF,^&<R<JLO:?R'K&9K5F?D:5$6=F]S26)"E/]9^AHF=O^RWUE+=Z-
M3N'+B-^\_IXCZ*>J]N<LSQ\NWBY7 9G!W\>_#/TEX6-LY_CJ'EFD=P(6ZQ.6
M/%S2%E<+Y\=O?HA#,AOZ.BV,YO\ Z!VI?SO@93@"WR7BQ?W^:+^?FN3C_%P9
M>Q1$7/HFX(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( NN-X-<CI
MC2FIM2&X\8' 9?+\'] 18ZA8M@!>;<]9Q,''+<N[-RW*['4>7>NZO^!>SUNC
M:8N@[&GGQ41=3"[2YBY5Q@<.[MR[O:X$6Y<G=F9G]SY;0<'Z5G86-MNLC+QZ
M'^%MT(/^$CR9]_E476_Y.JR?]"#E_8:_AYY9@!I#*223Y]8D-W*224_:(S)_
M-R,W(R=_>3\NN5Z9S4&.M#*;\2B/SOEGX%R\G=WX]DNGR;GW<\\KX=2!A%S+
MW"W+\_49O_9<?,GD(C?Y2YX^HWR-^LS<<+J%*?7=>GP_AL52R,6%E,Z)[\DX
MN,]GLWS=))OX->ZUZKH98T-?UIF%I?#/J]W/')=/'/#MYOT\LY?4Y;GCEE]:
M2GC+C>3L+O[^>';S_:_E_>5CWN.^SUI'56P.6BU?I;!:DI9;7^<F"#.8BGD8
M_#IXW"T(I('N5Y'CE@GAM/#9K$TD$CEX4D<P'QW;O=W%NU>?&:?1^1S6@,B;
MF4;5)2SN$$R^A:3$9*P%EX0]KIBIY>@3\MS([-P\-Y7CSI6+J.5IV=3D4?1K
MYT?2815],N39.4HPVNAL]TXPKM?3OUV7@L\!,JS&JS--R8[VUJQ4N7E26^[4
M5S;U2].LI5]_EUK#;::LUAH2V>0T)JC,Z;L&3'+\#9"6M7LDW#=5RBSO3MNS
M-PSVZ\SBWD/#.I1]F._&W<TY)'6UMA<#KG&B[,=J&$M.Z@ >&'EK5/Q<19$&
M'D8CP]>:0R)Y+_''3P3>'N<-\=(--8P<6*U[0A?D3P-IJ.5./S?K?#Y4X?;8
M6Y*&M>N&SNP1/.3MS&MJ1\O@;98W5.!R^!R .P24<_BKV'O 7GQS6R->M.W4
MW+B_1P0MU"[CYK9YXG"_$T'+;3]0DX[2G!QCEP6W3>4/+RZOES./;;;NC7(Y
MG%W#DDI+(C5%[J+W=4NO79/GHF^O7;X_'8ML[)]]7LEJLX*F8RF0T)DYN@6@
MU51DBQOB$_!"V?H^N8F$ ?CF7)6,<)<^PQ,SNTJ&F-78K-U([^'R5#*T9A$H
MK>.MP7:QB3,0N,U>22-^6?GZ+E:\,H<9<;RZ0=_^Z3>?]YV_]^%R+0^:U1I&
MV.1T7JG.Z;M@7/C:?R][&/(W/4\=B*I/%%:A)_.2O:CF@E]TD9L[LHMXA]FG
M"LWGIF;=C2ZOR<F*R*M_11G'R[81^<O/EZ_(W_0_:,E%JO4\-)]%SU[U2_%J
M7/7-_P UUHV':*H%L[WVN\NEO!@U9C<)N!2BZ ,[,?S.9F0!YZG^$L95GH-*
M?+<D>#D'R9N@7?J4N>R/?=;.:G&&#4,N5T!D#X"6+457Q\8,O#<M'F<;ZS7:
M%RY:*:Y%1(A9SDBA8288*XA\&.(-.WE+">74O\;@R^D+\?*2CD16W7>5*C\R
M;="\3=&U!+RLR%<VE]7?]4^OIS-NIOY*QOY$Q2+AVB=PL#J6C#E-.9O$9_&S
ML[PY#"Y*GE*4K"_#O%:HS3P&S/Y%TF_#^3\/[N8J+K*Y0DXSC*$HMJ49)QE%
MKNFGLTUZIF^0FI)2BU*+6Z::::^*:Z-!$1?0^P1$0'A8U;M]CC:W73R'JK0F
MF\M8E<G.])C8:^1<R;AY/A&HT%WQ&]XR>/U"_N=9+(O5AYU^/-68]UM%B[64
MV3JFOPE!QDOWGX9&-7;%PMKA9!]XV1C.+_%23132[[WL.:3V TGIO7VW53+Q
MTLGJ@<!FL/DLM-D,;3CM8ZY;HSXZQ9@FR<,\EBH<<@6\A<@.)V:&* @=RJ0:
MVUA:SV2LY.YTM+.XL,8<N$,,8L$40N_F70+>T3\=9N1,(L_2VPK])(TW'<[*
M.KL@;,Y:?U3MWDHW=F=QDOZUPNE^1=WY%WCU"8NXL3])$+LPN1#KJ%?;P-U_
M*U'05=EW69%U.;D8KNMDYV35<*+HJ<Y;RDXQR(K=MO9+=MD;YW#F#AYDK<;%
MJHG.I)NN/*N64GNHQ7NQ3E!-J*7;X$M_<5YSU#M4;4GXC1^LWLW0Y<7+K:YI
MO+1/&S,S]+G[F-^&'Y79O-;,E:R;N/,.5WM3[2"+2/ZOE\K==H@<W8:NGLM(
M3GPS],;-_1#\F ?-W9;-E0/[2BC^FL/;O^C*^;_\UE;&X\/?R,O](_\ NQ"(
MBKN9X(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"_B0&)G$F8A)G8A
M=F<29VX=B9_)V=O)V?R=E_:("BGWB_9N/;#=;4>&@B>/"92<M1:<+A^CX*RT
MLDSU!?C_ /-EWUK'-R[D\->"4WZI>&P;5NCOM>S5\U>W5;6V/@ZLQH&>2S9>
M.)CELZ:R#QQ9.(R'@W:A8"IDHR?Q AABO,P#ZS)(-1= $1$ 1$0!3Y]Q3VDV
MQ&I\YMED+##3U2!9O A(Y=(YW&U>G(UXGYZ1._B( G(7;VGQ(]+B9$TL!BYQ
MMGN%D=):BP>I\3(462P&4I9:F0FX=4M.<)O!,FY^=60$Z\XNQ#)!+)&8&!$+
M@;%A%UGLUNEC=;:4T]JW$2#)C]0XFGE*_!,11>LPB<M67I=V&Q3G\6K9C?VX
MK$,L1LQB3-V8@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(N
M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
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MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB + KO0/B#W,^P</X5QZSU6!7>@?$'N9]@X?PKCT!1D1$0!$1 $1$!;^[C'X
ME+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B (B(
M"!OOW=A7RVB<!N!3@Z[6DLDV-RD@CR8X3.F$,<I\>\*V7"C'QQ[+7CD=Q #=
M54UL1-Y=L*.M=*:ATGDA9Z6H,3=Q<Q$+'X7K4)!%8$7=N3K3>'/'P[.QQB[.
MS^:U\6MM'9#3N9R^G\M"5?)X/)WL1D(2]\=S'69*D[,[>1@\D1%'(/(21N,D
M;N!"[@<81$0!$1 %:][C'M&MG=#Y7;R]8ZLCHJRUO& ;MU2Z=S,\THM%R7)M
MC\HUJ*5F%F@BMT1ZG\41&J$LP^P;VCRVLW0TWJ>60AQ!V6P^HA;GA\%E#C@N
MS.+?1O0+P<D <.YE38!X(A)@+YJ+\:]B.:,)8C"6*4!DCDC(3CDC,6(# Q=Q
M,#%V(2%W$A=G9W9U^R (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"P6[QSM&_S,
MMIM2YJM/ZOFLG ^G=.D+LTHYC+PS0Q686=VYDQU4;63'R-F]39S @8F?.E5%
M.^T[2HZKW%JZ)Q]AI<3H"&6&WX9<Q2ZDR<<$N0ZG'V9#QU0*M'WD]>R5^#V)
M/'% 0L"/#,S>YF9O[W^?^^OZ1$ 1$0!$7\D3,SN_DS,[N_U&;WN@)QNXOV$;
M.[@Y?75N'KIZ)QSU\>9?0MG<]%8J,8^YG.MB1R O]$P>N1DXL3QDULQ1[=U_
MV>GVZV>TY1LP>!F-0"^J\VQ!T3-=S,-<J\$S<\M)3Q<./ID!,+@4!"0"?7S(
M2@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( J+7>;?'WN;]G*OX#Q
M*O2JBUWFWQ][F_9RK^ \2@,%$1$ 1$0!2*]TK],7MG_;]7?P>ZN4=2D5[I7Z
M8O;/^WZN_@]U<@+O:(B (B( B(@"(B (B( B(@"(B (B("*COHOB!U)]F=)?
MC)CE3&5SGOHOB!U)]F=)?C)CE3&0!$1 $1$ 5VGNCOB$T5_=C\,WE265VGNC
MOB$T5_=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/XDC$A(39B F<2
M$F9Q(7;AQ)G\G9VY9V?R=G=G51'O8>[Q_F<98]=Z/I,.A,Y:_-U&L!=&ELS9
MD=W@8&Y&/"Y&0NK'.+C'2L/)CO#BA]1\2WBN+ZUT7B]1XC(X'-TH,EB<M3GH
M9"C9!CALU; .$L9MY.SNS\@8N)QFPR1D)B),!KET6>?> ]B'*;+:N.D(SV](
M9F2>QI3,2>V4M<>DI<5>D86$<IC>MHY.69K=?PKL;-XDL4.!B (B( B(@"^G
MA<U<QMRID<?9GI7Z%F"Y2N5I'BL5;5:09H+$$H\$$L4H"8$WN)F7S$0%UONT
MNWM4WCTQZAEI(*^O=/5H@S],.F,<G69Q@AU!0AYY]7LD\87HA9QI7S\+RAGJ
MN<FJUX&R^\FH-O\ 4V*U;I>YZEF<1/XT!F+G6L1%[-BC>A$XWL4+L75!;@:2
M,CB)WCDBF&.4+SO9$[5FGMX-'4]58(VAF8FIYS$&?5:PF7CC [%&?D8WDCZ9
M!FIVA!HK=62.:/AW,  RB1$0!$1 $1$ 1$0!$1 $1$ 1$0$3W?5?$)G/L]I3
M\.55305R_OJOB$SGV>TI^'*JIH( B(@"(B *\-W4_P!+]MQ]C\O^,F95'E7A
MNZG^E^VX^Q^7_&3,H"0I$1 $1$ 1$0!$1 $1$ 1$0!$1 %_+CS[_ '?4_P W
M\F7](@(1NW7W.^ UR5S5&W/J.E=6RN5BWBB$H-.9^9W(I3*. 2^!LC-SSZU5
MA.G8E%FM5@.:6\%6G>38K/:3R]G3VL,+=P>:J._SJW$\921]72%FI.W,%ZE*
M[.\5BO)-7DX=F-C$A'8GKI??+L]:.W(PYX/66#J9FEQ)ZN<HE'=H2RBPE8QU
M^%PMT;'L@[R5Y0<GC#Q&-A85./ ?C7F:<H8NH*>=A1VC&7,OI5$>R4)R>UT(
MKHJ[6FELH6PC%0<=<3>'M&7S78SCCY#W;6WU-C_:BEO7)OO.":?5RA)O<UQ^
M4TU8I\D[>+"S_P!%!G=F;_MC[P?Z[\C\C$Z^2+>Y63^U/W)^J=/O8RFV5L]7
M8EG,WP5^6K5U+5BX<G:"8AJX[,"#-PXCZE</V1AJVI"=08:YVCM8N]8QN4Q]
MW!9>J739H7JLM6>,N7;Y]5G&.06=Q+ID!F ^.1<V\VM+H7%.GZK5YN!E5W;+
M>=>_+=5\K*9;60ZO9-QY9/[,I+J0;K&@Y6%-PR:95[]%+O7/^98MXRZ==D^9
M>J78ZWT_I$[HC)RY [^YO<SL_#L_'RM]?_Q7:=/3E.D+/,0L[?H6X=_V_J?R
M\EUG%7RV(<WB<O!/Z,H_GD)LS<=1"WM _'O=V!^/<3LN/9/4%F?ES/C_ +O/
M^;EW6ZT:A5""3BXR71I+HW\5^/S_ (]R,-4TG.R+G%Y$88_390W4]OA)=MUV
MWCONMFVNR[7S.OJ]42"!A#WM[/#D_P"W[_[RZ5SNNK5AR8"<6\_:?S?^][O[
M[O\ K+X%DG=W=_-_JKXLW_FO/=J<Y](^ZM_3O^_T_+]YG-(X8Q<?9J"G/UG/
MJW\^NY\FY.<C]1D1D_O<G=W_ /J^M[ES'05!_P T62;R?B /K^?7(_[7$;-_
M]]RN$6/=_?\ ]"[NT_CO5Z->/C@G!I#_ ._+P;_WN6']I8G-MVC\Y/;\N[_L
M7YF;U?(\NCE71V-1Z=/=75[?P7X,]@P7IFW]YU]20/K+TS%8V$MC7*Y_\?(^
M88?^RQ@W-S/K-XH0?F&H/A,WO9Y>>92_O\ WU&'GY799"ZMS+4*,T_EXG#A"
MS_+*3<!Y?*PO[3MY<LW'RK#RT3OU.[NY/R[N_F[N[^;O]5^>>7^59W3J]_??
MX+^U_EV_,WOA7$W<KY+I'W(?-O[3_)=-_F_@?#L-_+^^OBROQYM[+\^]G=O\
M[>:^W8]W\OKKG>W>VDN;F:29I H [LY@["<YL[?.XW=GX%O/KD;W<=(^T_(Y
MRM&^W9E=%<K;9*$(+=M_U+XM^B.H?ABY#YQ6K4;M[O#L3!^MQTFWU&_O,OJU
MMT]1U'^<9O("S>X9)WL W_Z.PTH?M=/G_>4EVE]BM-PU^NUB*4D;-YO/'XIG
MY>YR-W(G?ZO4L,.TOHG3V*L59,-&U*6R<K3T0D*2%HQ%G:Q&!N10^T[1N#$T
M9\LX@+@?/J\I)=4OW?\ T-7T'CW U+->%7BVR?O;6RKJG3O%.34O><H[I=-H
MR2Z;M>G$\3VH-45G9II*=X6XY\>J$<A?_?U7A%OVH_\ 0NX=/=L*L[B.4PT\
M3<MU38^P$S-]=H+'@%PWO?\ -#OQ[A=_?@H?O7CE?G+'@^\5^73_ .AO-_#^
M'9WHC%_&&]>WY1:7[TR7C2.]VF,PX!5RL$4Q^ZO<?U.9R?\ 0BT_0)ER_#-&
M9<O]#RLF-O\ <C4.EK89#36<RV!NB76UG$Y"S0,BXXY-Z\D8RLX^RXRL8N/L
MNSL_"K_XO%3WIXJM6%YYYBZ8XAXY)_-W\R=A$6;ER(B$19G<G9N765^E\%N=
MI>NUG'"=ZC"W7)0:8<E" ,WFSU#*.P(,S>;T29P9G+EFY=_#DZ7"R,H-1G&2
MVE79%2BU\))IIKY..QJ.JZ%CXTH.&=7CV2>]4<BV%4F^RY;$XM/?HO=ZOION
M6V>SGWV&ML$]>EN#CH=9XT7CCDR=*.MB=111,[L4I!#'#B<C*P.SC&<..*5X
MV:2TQF<RL'=G?M::#W1H/<TAG(+DT8==S$V6:IFL?YL+^N8V0O& &)V%K$7C
M5#)V\.P?++7*;:]JS#91XZF7#X&OD[1L<A$>/FEY87$;#LQ5G=_<-IA!N>CQ
MR)AZLT]':NR6$R%/,X/)6L9DJ9M/2R6.L'!9A)V\CAGA=GZ#%^"'EXI0)P,2
M G9X+XQ\$--S%*>+#]&Y3W:=,?[UL?PGCIJ,%Z<U#KVWW<)OH9?3N.-3TV:J
MS8RR*O\ .OZWE_6KOZ^9^$W/?MS0-A0SKRJW79*[ZJS3*##[OU_6:74$4>M,
M/1,K52)Q$>O/X:FTAW(P-G*3(86NU@8C%I,3*\,UV6PUH?7.&U+B:&=T_E*&
M:PV3KQVL?E,9:BN4;E>1N0E@L0$<9B_N=F+D"9P-A,79JH\4\%ZAH]OE9M#C
M&3:JOAO/'NVZ_5V;)<VW5UR4;(KK*"31,^B:_BZA5YN-9S;?;KELK*W\)PW>
MWR:WC+[LF<K1$6JF9"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(N$;B;DX#26)M9W4V7Q^#P],>JSD,E9CK5H^
M>>D>N1VZY3X=HX8V.60O9C G\E^E54[)1A",ISFU&$(1<I2DWLHQBDVVWT22
MW;['TLLC&+E)J,8IN4I-*,4NK;;Z))=6WT1S;E<6UEKG"Z=H2Y7/97'X;&P^
M4M[)W(*-42Z2)@\:P<8/(8@3QQ"[R2<.P"3^2KS=J+OTQ,K.(V@Q(RL[G$VK
MM1U)0CX\A:QB<!(\,Y._F<,N9\+H=A>?%2,Y1M!YN'NOJO7>3^%]7Y_)Z@R'
M+O'-D+!2QUF+ABCI518:M&)V$6>.K!")=(]3.[<J?.#_ &?-3S5&[49K3*'L
MU7*/F9DE\ZMXQIW[?6S\R+[TLA?B[QLT_ YJ\.#S[E]Y2\O&B_\ 2[2E;MW^
MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
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M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
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M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
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M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
M1%]G3FG+V8R./Q&+KG;R65NU<;CZL?'78NWIPK581Y=F9Y)I0'J)V 6=R-Q!
MG=@+"_</=FP9[6HMU<C7Y&F4NEM-'+&_YXDC@L9V_7<O)^B&6MC1L1L[<R9&
MLTC.-B-68%T;V:]D*&W&AM-:+Q_046#QL5>><&Z6N7Y.9\E=?EF)WN7I;%A^
MMNKYXS%YLN\D 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!8%=Z!\0>YGV#A_"N/6>JP*[T#X
M@]S/L'#^%<>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[
MTPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %$]WC7
M=FXK=VG+J33@U,-N)3KL,5MP&&EJ2&%N(\=FC 6)K 1L\5#*NQRUF\."<9J8
M@$,L*(#7+ZTT5E].96_@\]C;>)R^,L25;V/O0E!9KS1DXNQ 3<'&?'7#/&YP
M6(B":"22&0#+BZO!]O#N\M,;TXM[!>'A=:X^L<>%U)%&_M,S.4>.S44;=5[&
M')[G=GM47(Y:1CU30STU][]C-4;=:BN:7U=C)<9EJ;]3"[^)5NUB=VBO8ZTS
M-'<HSLW,4\?FS\QS!%,$D0 =2(B( B(@"(B +.WL>=X;K_9NR,&)M/F]+R&Y
M6](Y:Q,^,=R+JDFQ<W$LN%N'Y]4M2,JTQ/UW*=H@CZ<$D0%[KLD]O?;[>&F/
MS/Y%J.?CB8[VE<J<-?-5>D!*62")C<,E2C<NGUVB\L0\-XXP&31K-;E:X/!Y
MN[C+M7(XVW9H9"E*,].]3GDK6ZLPL[#+7L0D$L1LQ$/4!"[B1"_(D[//EV.^
M^]RV(&K@MVZLV=QX>%7BU=BX(VS5:/V8VDS./ HH<H$0^W-<I##D#!B,JN0M
M.[R@6BD77&UF[NF=;8B#.Z3S=#/8FQRP7*$XRB!M]%#/&_3-5L!^CKV8XIP_
M1QMRW/8Z (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"+Y&?U!1Q5*SD<G<JX_'TXBGMW;
ML\5:K6A'Z*2:>8@CB!N6;J,F;EV;WNS*!3MA=][A</ZW@MI:T>H,F#G!)JO(
MPR#@*I\=)28NH10V<Q)&7+!/,U;'N8M)$^0KNW6!,9O[VE-%[98<\WK/.5,5
M6X)JM8B:7)9*86Y:OC,?&[VKDSOQSX0/'$S]<\D4;.;56>VUWN&L=RVN8#2K
M6M%Z+F\:"2&"SQG\[4+D.,O>KNS4JUF)W\?$X^0XG$RKVKU^'GJC.W2W9U+K
M;,3Y_5F:O9[,6&Z3NWY6,@B9W<8*T(#'7IU0)W<*M2&"N#N[A$/+\]>( S(B
M( B(@"(B (B^UIO3>0S.0I8G$TK.1R>2LQ4Z%"G"4]JW:F+IC@@BC9R,R?S?
MRZ0%B,R$!(F ^. $3B(B1$3L(B N1D1/P(B(LY$1.[,(BSN[NS,SNK-'=G=T
MPV.>AN#NMC0/(-X%S3NC;L/4V-,7&6#*:AA-^D[[.PG6Q$L;C1(6EO==IVK5
M.\^[?[J6AMZU+6VX$-;*:Z<?%QV+8ALXK2O6[.!@[BT=[.L#,TEQQ>O0(I(*
M'B$SWI9LN$ ;_,O*(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@
M,%$1$ 1$0!2*]TK],7MG_;]7?P>ZN4=2D5[I7Z8O;/\ M^KOX/=7("[VB(@"
M(B (B( B(@"(B (B( B(@"(B BH[Z+X@=2?9G27XR8Y4QE<Y[Z+X@=2?9G27
MXR8Y4QD 1$0!$1 %=I[H[XA-%?W8_#-Y4EE=I[H[XA-%?W8_#-Y 23HB( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
M6LQK4W\_JLBN/[DE\CR?^BV+Z>8ODIK^V+?\370AZ/WVK3,0?0.(B8B87DDU
MQI#H!G?Z,_"RTLG2/O?PXY#X;V0)^&?M72GHU':5R!AZ_/MM@87=O$>]JO)7
M+0LY.WSNOBM.7H)"9FZG$KT+=)ATFY=8AL"47VN]HS7Y+:-6FUO]:&/<W^/U
MF39'^&WR/TAPUC+_ "C_ !DO[(HIA[;>BHYV4XSUEO!CJT3^<M?3.F;%B8..
M?9"WE<A%'([^7M/3!AY^@+CSDSV0]&L[.>EY(+>H8]7[AW(B&3HU-GO4L2,H
MMP_3B=,5<''8KDW/55R]C+1.[N[\\ P6"46H:GXP\292E&>J751DMFL6-6+T
M^"GCPKLV:Z/W^J[[[L]U6D8T-MJHO;];>?\ WFU_ Z:V<[.V@]O:38[0VC].
MZ3IL#1O#@L32QSR Q=3#-+7A":=F+S;QI).'X=O<R[D7E%'%^1.V<K+9SLG)
M[RG.3G.3^,I2;;?S;,BDDMDDDNR71!$1?D?(1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B +P[<KRB ZPW8V6TGKO$R8+66G<1J3$R%XGJ67I0VXXI6 HQL5BD%Y
M:EL ,QCMU3ALQL9-'(/4_-?#M.>CR8>X=G)[3:KFP4I,YCIC4XR9+%N?!.\=
M#-P.V2H@3LS#%>K99NLG=K->(1C:R\BVWACCK5='EO@9EE,&]Y4RVLQY_'FI
ML4J^9]N>*C8EVFC$ZGH6)F+;(IC-^D_LV+\)QVEM^RVX_%,UWN^_8#WIVREF
M^:G0>;^#X7?C/86 L_@) 9^&D+)8H; TA-_H(\I%0LFPD30=+<K$VAJ(@)^D
MN'$G$P?]"3/P0F+^XF=G9V=F)N';R6SR(6)G9V9V=G9V=N6=G\G9V?R=G;R=
MEB/O-V"MF]P'.35FW.F<G:DX8LE#1^"<OPS<=+9G#'C\J _+TC<87=F=V<F9
MVG_0O:6>T8:IIW-Z2NPI[;_/Z/?+;=_ZPEOV2711MJ?A5"3<L7(Y7Z0NCV_Y
MR"W7_1M_,H!X[4\$G R.T;\>_EW#]?GY/V_+ZZY?$XFW+=)"[<<MP[.WD_O;
MEG;_ -O)6L-P/1^=F<DYG@<GK'2YERXA6RL.6K1\^Y@CR]6S.XM\OB6C(F_1
M,_FL3=1^CL96N1GIK=R%AY+PZV9TH;D3<NX-);HYL09_)F-VQQ,[NY"(\,!2
M+B>-W#5Z3>9=B-_=R,6_I^=$+XK^GM\S4<KPZU2OI&JN]?&NVOM^%CK;_=^!
M N]@RA>N[_.B^3AN6Y^H_'^9=GV>UEVBJ6$H:8TGO;F=+Z:Q=,<?C\1C,'A*
M\E6F#/T1-F0JGEG(>HG::.>&9O+VWX;B4ZUW#6\4),U;5FVU\.IV8[-W4V,-
MP9O(NB'363'K=_)P8NEFX)C?GI7KW^XTWE@A\0,IM[<D9_SO4SN>:1_KB5W2
MM*'^_(+_ "<+VY?B!PSEJN.3G:;E1A+FKCE5PMC">W+S*.14^26S:YMHM?$\
M&E<+ZMIUEMN'A6X\[5M:Z:X>^MT^JCO&3W2;:ZLKD;F[7[IZTG*?6&ZFH=7$
M9D?5J?4FJ,XT;GSU#7@R=VW!7B9G<0@KC#!&'SN...-NE=>8[L43^0SY^M$#
M<>S6QTDO#?4%CM5Q]W][R]_RV.['<X;[1ETC@L',W2S]<6IL8P\_*/$Q1'U-
M\K]/3YMP7OXY?@^Y4WKMDPSMH_&-Y>W>U!8D%O+SY;&8K('Y<\/T@_G[N6X=
M\I'Q)T2FO:&JZ=""72-=U&R7RA#?;\HF4D^()=/HV1O\7BQ7\90V_P#WE>/!
M=CG3D#B5VYD\B7DY!UQ4X'X]_ 0 4[,_RL]DO+AOJN_?^D]K-.X3I+&XBE7E
M%G_-+PC+:^O^:9NN9N?E83%G\O)62-NNX:O.4<FK=P:L0<MXM/3>)EF/CY?#
MR64FA;S^A;JQ/E]%R_T*DBV;[J?9C2)Q63TX6I\C#PXW-4V9,I$Q>7)!BOG6
M&Y8A8HSDH2S1/_0YAY?G3=<\=]$H3\J_(SI_JX]4HP;_ &IW^3#;]J"G\4F>
MBG@O7,S_ )1/R:WW5URV:^55'.M_E)1^>Q5CV*[*.X6Y%@(=(Z8R.0KD;!+E
MI8GI8.HS^?58R]IHJ;.P^UX$,DUJ06=X:\GN5@+LK=S+IC3A5\QN-<BU=E1Z
M) P=>,X--TY&]IQL,;M:S1B_3_1VJ4WX(2I3-Q(\UM#'UZL,=>K!#6KQ#TQ0
M5X@AAC'^ECBC$0 ?K"+,O<4"<5^-FJ:@I58VVG8\MTU3)RR)KX2R&HN/_,PJ
M>VZDY(WW0_#?"Q6K+M\NU;->9%*J+7PJ3:E_SDIKLTDST<;C*].O#5IP0U:M
M>,(:]:M%'!7@AC9ACBAAB$(XHP%F$  1$69F9F9F7O(BAMMM[OJWU;?=LD)+
M;HNB01$7P?(1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 74._NSV-W T9J/1
MN6 2I:@Q<]$C(6+U:QY34;T;.Q<38^]%6O5S9NJ.>O&8<$+.W;R(#7+ZXT=?
MT[FLQI_*Q/!D\%E+^'R$1-T]%S&VI:=AF]_(/+"11D+D!QN)@1 0D_%U=ZWT
M[K3:/</4^1U?J#&Y8,SE6K/?DQF8GH5[,M:O'5"P=>,"#QR@AB"61G;Q/#%R
M;JY=^H_R$K8O^H=3_?):_P#HD!3A17'OR$K8O^H=3_?):_\ HD_(2MB_ZAU/
M]\EK_P"B0%.%%<>_(2MB_P"H=3_?):_^B3\A*V+_ *AU/]\EK_Z) 4X5]S3&
MFKV:R6/P^,@*UD<K=JXZA7!G<IK=R8*]>-N&=V8I9!9WX]D>2?R9U<"_(2MB
M_P"H=3_?):_^B79NS7=1[/Z%U/B-787&YB3+X*>2UCOA+,SWJD5DZT]4;!U)
M &.66N,Y2UB/GP+(1609I88R$#*[LR;(4=N-!:7T71Z2'!XJM6M6&$1*]DS'
MQLI?D8?+KN9"2Q8X\VC&08A?H 6;O=$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!8%=Z!\0>YGV#A_"N/6>JZPWEVDP^O-,9C2.H L28;.5AJ7PJ3E5L%",\5AF
MBL SE$7B0AR3-SQRWR^0&N^17'OR$K8O^H=3_?):_P#HD_(2MB_ZAU/]\EK_
M .B0%.%%<>_(2MB_ZAU/]\EK_P"B3\A*V+_J'4_WR6O_ *) 4X45Q[\A*V+_
M *AU/]\EK_Z)/R$K8O\ J'4_WR6O_HD!Q_N,?B4L?;OJ#]Z8=3)+'_LV=FK2
M^U.G3TOI&*[#BCR-K*D%^X=Z?UNX$$<SM/((ET.-:+ICXX%^>/>L@$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 70>]'9=V^W#@>'6.DL+FS8/#BO6*<892L/F[-5RL#19"N+$_
M5X<5D8R)F>0#X9=^(@*]N^?<)8"X4MO;O5UW"2/UD.&U)#\+XYR=VZ(Z^3K/
M6R-.,6Y8GM19>0W<>#C87ZH>=[>[(WIT*\TM[1MW-XV+S^%M*_\ +]7H\W<Y
M:M,7RU8 %N99;..BKQ^YYW]ZO,(@-;M:K2P2G!8BE@GC=VD@GC.*:-V]XR12
M,,@$S_(0LOP6P8W<[+^WFO(2AU?H[ 9UR8F:S;H1#?B<OHBKY*!H<A6D?E_G
ME>U%)YO[7FHM-W.XEVTRS2RZ2S>?TA8+K**"24=08P"?Z 7AOE'D7B'ZGPH\
MA?+*@*F2*9'=/N/=X,&4LF"LZ:UA4#EX_4;TN)R9@S>;RX_*1!5C)W\ACKY6
MX[_59_)1N[I=FC<+1+R/JS1FH\'#%SUW;F+LOC6X?C_G2 )L:_/D[,UKGAV?
MCS9 =((OY$Q+W.S_ *SL_P#H7]( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"+PY,WO=F_7\EV%MYM-JG5T[UM+:;SFHIA?I-L-B[F0"%
M_+\\35H9(:[>8^U/)&/M#Y^;(#KY%*MM9W-.]^H_#DNXK#Z2K&[=4NI<J(3"
M/D[\4<3!E;3R</[ RA"!%[)2Q\$0R;[1=P=I:FT4VM]9Y?.S<,\M+!58<'1Z
MN&=X_6)RR5Z41?V/%$JKRC[?A0N3" %7+GS9OE=V86^5W?R9F;Y7=_)F;S=_
M)98;+]AG=G7YQ?,UH;-RTY7'_E?)5BPN% 7]YMDLIZK!88/)SCHO;L")"7@N
MQ#S<IV:[".T>@O#DTUH3!UK@-Q\*7H3S.6=WXZG;)YB2]<B$R;J>*":* 2_H
M<0,PBV6HBS,S,S,S,S,S-PS,WDS,S>3,S>YD!6AV1[@RY*\%K<36H58_9*7#
M:3JC-.7GRX'F\F#PQ-Y=)M%B)W,2Y">$AY>9O8CL#;3;<O#/IO1^-;)P>U'F
M\K'\,9D#XZ7DAR&0\>6J3L[L_J?J[.Q./'2_"S%1 >&9>41 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B<H B(@"(B (B( B(@"(B (B( B(@"
M(O'* \HO2R.2K4X)+5NQ#5K0CUS6+,L<$$0-PW5++*0QQCR[-U$3-]=8$;U]
MZYV:]NCFAUGOAMKA+< /))CI-4XRYE7 >KEXL3CIKF2GX<7'B"K(77P''4[,
MX$@B*O#K;TIOL78GJ:GN+J#49@Y"X8+;C7_#D+FSL$^9T]AJLHNX,P2Q3G";
M2 02$'40]&VO2]NR7&1B%?=F=A^A./048A)Y<^QXV<B-N?=[8!^MQYH"T@BJ
MQT_2_.R@<8%-0W;@E)O;B^8>M*T;\\.WB1Y[I-F]_(MYM\G/DNX-'^E:=C3)
MFPW=9:PT\+N[>)F-M]9S@S,[<$[8#%9R3AV?EN <N&?D6?AG L>(HNMG>^N[
M)^O3@ATUOUMW-:LFT5?'Y7,MIG*S2/U/T1XG4\6'R1$S"[NS5?9;S+AG;F27
M3FK,5F*[6\1DL?E:A>0VL;<KWJ[^7/#3U9)8G\O/R+W(#D")RB (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
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M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
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M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 5?STH?Z23=G[)[7_ ,+&B58#5?STH?Z23=G[)[7_ ,+&B4!JDE\W,_G2
MU^QYOW,E])?-S/YTM?L>;]S) ;QKLW_%WH+[2]+?@.BHGO2#.[L#M"=GG4=;
M$8X;NX.WT5O7.@7C;B[9R&,J2'EM/5I/_P#)L3'/CHX)/G$N2;&2R/$5>*S!
M+#V;_B[T%]I>EOP'17<[MSY(#1&12B8B8^8DS$W+.S\/Y^;.S.S_ %6=F=G\
MG9G9?HI_O2/.[GFV&[0>9S&(I>#M[NS-<UII,X@%H,;EISB+5^G#<.&$ZF9G
MDRM%B$'/%Y>M"+SRT+4Y0 H#9B^BD=XE%N=LI+L_G;SR:RV3@H8NE'.?SW(;
M=W'GATK9K=3\S!@?5)M.6A%R>G#5Q#S-$%^J)VJUIH^ZE[=]_LX[ZZ(W-A,R
MP5:^&#UQ2'EVO:'S<T%;4'2#.S';Q<+1YS',[MU7\9! 1-#/-SN0-,ZDH9G'
M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
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M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
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M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
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M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
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M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
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MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
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M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
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M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
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ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
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MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
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M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
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MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729077744176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,964,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729071200464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,392,404<span></span>
</td>
<td class="nump">$ 14,310,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">76,029,116<span></span>
</td>
<td class="nump">130,982,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">1,773,665<span></span>
</td>
<td class="nump">2,405,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,365,860<span></span>
</td>
<td class="nump">5,393,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">117,561,045<span></span>
</td>
<td class="nump">153,113,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">4,510,869<span></span>
</td>
<td class="nump">4,960,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in affiliated entity</a></td>
<td class="nump">2,319,975<span></span>
</td>
<td class="nump">2,780,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">8,819,399<span></span>
</td>
<td class="nump">9,491,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">585,915<span></span>
</td>
<td class="nump">605,315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">133,797,203<span></span>
</td>
<td class="nump">170,951,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">5,499,648<span></span>
</td>
<td class="nump">2,365,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,321,984<span></span>
</td>
<td class="nump">2,406,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entity</a></td>
<td class="nump">21,918<span></span>
</td>
<td class="nump">21,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,770,654<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,399,768<span></span>
</td>
<td class="nump">42,570,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">10,658,228<span></span>
</td>
<td class="nump">11,032,066<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">37,057,996<span></span>
</td>
<td class="nump">53,602,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">25,962<span></span>
</td>
<td class="nump">22,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,783,074,886<span></span>
</td>
<td class="nump">1,740,954,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,685,672,105)<span></span>
</td>
<td class="num">(1,622,965,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(689,536)<span></span>
</td>
<td class="num">(662,601)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">96,739,207<span></span>
</td>
<td class="nump">117,349,129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">133,797,203<span></span>
</td>
<td class="nump">170,951,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">16,634,761<span></span>
</td>
<td class="nump">19,847,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 1,921,457<span></span>
</td>
<td class="nump">$ 1,070,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729071876432">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 100,762<span></span>
</td>
<td class="nump">$ 225,971<span></span>
</td>
<td class="nump">$ 100,762<span></span>
</td>
<td class="nump">$ 340,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,090,989<span></span>
</td>
<td class="nump">23,743,970<span></span>
</td>
<td class="nump">44,001,307<span></span>
</td>
<td class="nump">53,920,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,206,686<span></span>
</td>
<td class="nump">13,523,098<span></span>
</td>
<td class="nump">20,781,337<span></span>
</td>
<td class="nump">27,413,708<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,297,675<span></span>
</td>
<td class="nump">37,267,068<span></span>
</td>
<td class="nump">64,782,644<span></span>
</td>
<td class="nump">81,334,189<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33,196,913)<span></span>
</td>
<td class="num">(37,041,097)<span></span>
</td>
<td class="num">(64,681,882)<span></span>
</td>
<td class="num">(80,993,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,307,358<span></span>
</td>
<td class="nump">2,168,233<span></span>
</td>
<td class="nump">2,807,648<span></span>
</td>
<td class="nump">4,375,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(313,488)<span></span>
</td>
<td class="num">(177,833)<span></span>
</td>
<td class="num">(626,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">(Loss) gain on investment in affiliated entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(334,294)<span></span>
</td>
<td class="nump">156,745<span></span>
</td>
<td class="num">(460,312)<span></span>
</td>
<td class="nump">773,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (loss) gain on available-for-sale equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20,820)<span></span>
</td>
<td class="nump">922,941<span></span>
</td>
<td class="nump">480,057<span></span>
</td>
<td class="nump">4,141,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,571<span></span>
</td>
<td class="num">(1,427,867)<span></span>
</td>
<td class="num">(674,647)<span></span>
</td>
<td class="num">(3,853,543)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (32,237,098)<span></span>
</td>
<td class="num">$ (35,534,533)<span></span>
</td>
<td class="num">$ (62,706,969)<span></span>
</td>
<td class="num">$ (76,183,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="num">$ (2.48)<span></span>
</td>
<td class="num">$ (3.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="num">$ (2.48)<span></span>
</td>
<td class="num">$ (3.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares used to compute net loss per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,197,802<span></span>
</td>
<td class="nump">22,029,486<span></span>
</td>
<td class="nump">25,244,657<span></span>
</td>
<td class="nump">21,784,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,197,802<span></span>
</td>
<td class="nump">22,029,486<span></span>
</td>
<td class="nump">25,244,657<span></span>
</td>
<td class="nump">21,784,343<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729075126368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.083333<span></span>
</td>
<td class="nump">0.083333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729070548336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,237,098)<span></span>
</td>
<td class="num">$ (35,534,533)<span></span>
</td>
<td class="num">$ (62,706,969)<span></span>
</td>
<td class="num">$ (76,183,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(376)<span></span>
</td>
<td class="nump">32,403<span></span>
</td>
<td class="num">(2,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="num">(13,322)<span></span>
</td>
<td class="num">(108,089)<span></span>
</td>
<td class="num">(59,338)<span></span>
</td>
<td class="nump">9,773<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (32,250,420)<span></span>
</td>
<td class="num">$ (35,642,998)<span></span>
</td>
<td class="num">$ (62,733,904)<span></span>
</td>
<td class="num">$ (76,176,371)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729067878096">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th" colspan="2"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">21,090,938<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 222,362,756<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,090<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,710,888,191<span></span>
</td>
<td class="num">$ (1,487,847,784)<span></span>
</td>
<td class="num">$ (698,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13,999,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,901<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(424,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(424,748)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,809,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,809,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40,649,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,649,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">117,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,918)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,918)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">21,894,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">199,213,682<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,894<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,728,271,686<span></span>
</td>
<td class="num">(1,528,497,101)<span></span>
</td>
<td class="num">(582,797)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">21,090,938<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222,362,756<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,090<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,710,888,191<span></span>
</td>
<td class="num">(1,487,847,784)<span></span>
</td>
<td class="num">(698,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(76,183,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">22,339,428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">169,371,568<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,338<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,734,072,126<span></span>
</td>
<td class="num">(1,564,031,634)<span></span>
</td>
<td class="num">(691,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">21,894,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">199,213,682<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,894<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,728,271,686<span></span>
</td>
<td class="num">(1,528,497,101)<span></span>
</td>
<td class="num">(582,797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,429<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,915,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,914,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,077<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(32,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,917,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,917,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(35,534,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,534,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(108,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108,089)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(376)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">22,339,428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">169,371,568<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,338<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,734,072,126<span></span>
</td>
<td class="num">(1,564,031,634)<span></span>
</td>
<td class="num">(691,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">22,793,075<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">117,349,129<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,792<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,740,954,074<span></span>
</td>
<td class="num">(1,622,965,136)<span></span>
</td>
<td class="num">(662,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,620<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,225,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,224,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,558<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(174,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(174,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,525,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,525,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(30,469,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,469,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(46,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,403<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">23,371,253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94,441,963<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,748,529,814<span></span>
</td>
<td class="num">(1,653,435,007)<span></span>
</td>
<td class="num">(676,214)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">22,793,075<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">117,349,129<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,792<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,740,954,074<span></span>
</td>
<td class="num">(1,622,965,136)<span></span>
</td>
<td class="num">(662,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(62,706,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(59,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">25,963,544<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">96,739,207<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,962<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,783,074,886<span></span>
</td>
<td class="num">(1,685,672,105)<span></span>
</td>
<td class="num">(689,536)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">23,371,253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94,441,963<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,748,529,814<span></span>
</td>
<td class="num">(1,653,435,007)<span></span>
</td>
<td class="num">(676,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,536,258<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,059,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,536<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,057,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants for cash, net of financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,146,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,146,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,033<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(172,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(172,510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,514,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,514,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32,237,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,237,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">25,963,544<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 96,739,207<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,962<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,783,074,886<span></span>
</td>
<td class="num">$ (1,685,672,105)<span></span>
</td>
<td class="num">$ (689,536)<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">All share amounts in this column, including appropriate reclassifications between common stock and additional paid-in capital, have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729075132400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.083333<span></span>
</td>
<td class="nump">0.083333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729077422400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,237,098)<span></span>
</td>
<td class="num">$ (30,469,871)<span></span>
</td>
<td class="num">$ (35,534,533)<span></span>
</td>
<td class="num">$ (40,649,317)<span></span>
</td>
<td class="num">$ (62,706,969)<span></span>
</td>
<td class="num">$ (76,183,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916,019<span></span>
</td>
<td class="nump">1,410,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">145,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,336<span></span>
</td>
<td class="nump">739,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,984,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,039,486<span></span>
</td>
<td class="nump">6,727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NonCashInterestIncomeExpense', window );">Non-cash interest on senior convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(355,654)<span></span>
</td>
<td class="nump">93,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of discounts on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,154,822)<span></span>
</td>
<td class="num">(2,402,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Loss on sales of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,557<span></span>
</td>
<td class="nump">3,853,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,930<span></span>
</td>
<td class="nump">334,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Loss (gain) on equity investment in affiliated entity</a></td>
<td class="nump">334,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156,745)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,312<span></span>
</td>
<td class="num">(773,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">20,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(922,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(480,057)<span></span>
</td>
<td class="num">(4,141,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, including from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,563<span></span>
</td>
<td class="nump">6,621,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, including from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,237<span></span>
</td>
<td class="nump">41,191,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
<td class="nump">17,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses, including due to affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,362,045)<span></span>
</td>
<td class="num">(43,955,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,134,266<span></span>
</td>
<td class="num">(4,421,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(458,376)<span></span>
</td>
<td class="num">(1,406,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability, including from affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,489)<span></span>
</td>
<td class="nump">1,185,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,969,306)<span></span>
</td>
<td class="num">(68,979,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,359,747)<span></span>
</td>
<td class="num">(106,741,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale or maturity of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,196,528<span></span>
</td>
<td class="nump">173,898,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(487,832)<span></span>
</td>
<td class="num">(320,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of capital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,348,949<span></span>
</td>
<td class="nump">72,906,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,415,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,146,397<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,284,801<span></span>
</td>
<td class="nump">2,915,179<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,675<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(414,377)<span></span>
</td>
<td class="num">(456,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,669,496<span></span>
</td>
<td class="nump">2,458,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,403<span></span>
</td>
<td class="num">(2,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,081,542<span></span>
</td>
<td class="nump">6,383,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,310,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,329,359<span></span>
</td>
<td class="nump">14,310,862<span></span>
</td>
<td class="nump">46,329,359<span></span>
</td>
<td class="nump">46,329,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 34,392,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,712,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,392,404<span></span>
</td>
<td class="nump">52,712,543<span></span>
</td>
<td class="nump">$ 14,310,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,487<span></span>
</td>
<td class="nump">533,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock as part of litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729180363408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA delivery devices are designed to optimally deliver the plasmids into the body's cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a life-long, rare disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in August 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729075113936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation, Liquidity and Risks and Uncertainties</a></td>
<td class="text">Basis of Presentation, Liquidity and Risks and Uncertainties<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June&#160;30, 2024, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2024 and 2023 and the condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three and six months ended June 30, 2024 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2023, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;6, 2024. The balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of June&#160;30, 2024 and December 31, 2023, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $32.2 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$62.7 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six months ended June 30, 2024, respectively. The Company had working capital of $91.2 million and an accumulated deficit of $1.7 billion as of June&#160;30, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed an underwritten registered direct offering (the &#8220;Offering&#8221;) relating to the issuance and sale of 2,536,258 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $110.4 million as of June&#160;30, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are expected to be sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the Offering described above, and the receipt of net proceeds of $5.2&#160;million and $5.5&#160;million under a Sales Agreement during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2024 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended, to effect a 1-for-12 reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;).  As a result of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The reverse stock split was reflected on the Nasdaq Capital Market beginning with the opening of trading on January 25, 2024. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from "Additional paid-in capital" to "Common stock" on the balance sheet and statement of changes in stockholders&#8217; equity. Any fractional post-split shares as a result of the reverse stock split were eliminated by the payment of cash for the value of such fractional share. As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and outstanding shares of Series C Cumulative Convertible Preferred Stock and to the number of shares of common stock issuable under the Company's equity incentive plans. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reverse stock split did not change the par value of the Company's common stock or the authorized number of shares of the Company's common stock. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078572896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Critical Accounting Policies</a></td>
<td class="text">Critical Accounting Policies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729075168816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of June&#160;30, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,541,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,042,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,498,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,676,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,674,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,979,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435,449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,498,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,481,043)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,029,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,389,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,522,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,164,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,873,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927,161)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June 30, 2024, the Company recorded gross realized gains on investments of $300 and $500, respectively, and gross realized losses on investments of $2,000 and $693,000, respectively. During the three and six months ended June 30, 2023, the Company recorded gross realized gains on investments of $200 and $500, respectively, and gross realized losses on investments of $1.5&#160;million and $3.9&#160;million, respectively. During the three and six months ended June 30, 2024, the Company recorded net unrealized (loss) gain on available-for-sale equity securities of $(21,000) and $480,000, respectively. During the three and six months ended June 30, 2023, the Company recorded net unrealized gain on available-for-sale equity securities of $923,000 and $4.1&#160;million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three and six months ended June 30, 2024 and 2023. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of June&#160;30, 2024, the Company had 22 available-for-sale securities with an aggregate </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">total unrealized loss of $3.5 million. Of these securities, 19 had been in a loss position for longer than 12 months as of June&#160;30, 2024.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;June&#160;30, 2024&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at June&#160;30, 2024, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,498,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,498,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,674,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,674,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,029,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,172,707&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,856,409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,349,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,492,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,856,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,056,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,763,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,836,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at June&#160;30, 2024 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain or loss on investment in affiliated entity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at June&#160;30, 2024 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of June&#160;30, 2024 or December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of June&#160;30, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,541,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,042,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,498,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,676,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,674,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,979,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435,449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,498,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,481,043)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,029,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,389,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,522,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,164,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,873,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927,161)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June 30, 2024, the Company recorded gross realized gains on investments of $300 and $500, respectively, and gross realized losses on investments of $2,000 and $693,000, respectively. During the three and six months ended June 30, 2023, the Company recorded gross realized gains on investments of $200 and $500, respectively, and gross realized losses on investments of $1.5&#160;million and $3.9&#160;million, respectively. During the three and six months ended June 30, 2024, the Company recorded net unrealized (loss) gain on available-for-sale equity securities of $(21,000) and $480,000, respectively. During the three and six months ended June 30, 2023, the Company recorded net unrealized gain on available-for-sale equity securities of $923,000 and $4.1&#160;million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three and six months ended June 30, 2024 and 2023. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of June&#160;30, 2024, the Company had 22 available-for-sale securities with an aggregate </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">total unrealized loss of $3.5 million. Of these securities, 19 had been in a loss position for longer than 12 months as of June&#160;30, 2024.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;June&#160;30, 2024&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at June&#160;30, 2024, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,498,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,498,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,674,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,674,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,029,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,172,707&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,856,409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,349,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,492,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,856,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,056,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,763,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,836,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at June&#160;30, 2024 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain or loss on investment in affiliated entity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at June&#160;30, 2024 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of June&#160;30, 2024 or December 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729070481328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text">Certain Balance Sheet Items<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical expenses (a)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,410,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,024,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,983,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,365,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393,665&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,642,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses (b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,432,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,634,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,847,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a)        As of June 30, 2024 and December 31, 2023, balance includes $22,000 and $1.5&#160;million, respectively, of prepaid manufacturing expenses.</span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;As of June 30, 2024 and December 31, 2023, balance includes $2.3&#160;million and $4.3&#160;million, respectively, of liability for unused grant funding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078711472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5&#160;million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7&#160;million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $16.9&#160;million obligation in full, including accrued interest.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the six months ended June 30, 2024,&#160;the Company recognized $178,000 of interest expense related to the Notes, all of which related to the contractual interes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">t coupon. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and six months ended June 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,&#160;the Company recognized $313,000 and $627,000, respectively, of interest expense related to the Notes, of which $267,000 and $533,000, respectively, related to the contractual interest coupon.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729171542208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of June&#160;30, 2024 and December&#160;31, 2023: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,963,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,963,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,793,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Stock and Pre-Funded Warrants</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 18, 2024, the Company closed the Offering of Shares and Pre-Funded Warrants (see &#8220;Liquidity&#8221; in Note 2 above). As the Pre-Funded Warrants are indexed to the Company's own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Pre-Funded Warrants as additional paid-in capital on the Company's condensed consolidated balance sheet as of June 30, 2024.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Pre-Funded Warrant has an initial exercise price per share of $0.001, subject to certain adjustments. The Pre-Funded Warrants may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the Company&#8217;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of 19.99% upon 61 days&#8217; notice to the Company subject to the terms of the Pre-Funded Warrants.  As of June 30, 2024, no Pre-Funded Warrants had been exercised.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents were entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the three months ended March 31, 2024, the Company sold 543,620 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $9.76 per share, resulting in aggregate net proceeds of $5.2&#160;million. During the year ended December 31, 2023, the Company sold 875,305 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $6.33 per share, resulting in aggregate net proceeds of $5.5&#160;million. The registration statement relating to the shares of common stock issuable under the 2021 Sales Agreement has expired, and in August 2024 we terminated the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company issued 760,083 shares of common stock pursuant to the securities class action settlement, as described in Note 11.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#8220;2023 Plan&#8221;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2023 Plan will not exceed the sum of 1,166,666 shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#8220;2016 Plan&#8221;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At June&#160;30, 2024, the Company had 800,051 shares of common stock available for future grant under the 2023 Plan, 188,804 shares underlying outstanding RSUs and 276,163 shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over three years and have a maximum contractual term of ten years. The 2023 Plan terminates by its terms on March&#160;24, 2033. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024, the Company had 142,295 shares underlying outstanding but unvested RSUs and options outstanding to purchase 947,606 shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over three years and have a maximum contractual term of ten years. Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan will not exceed 166,666 shares. At June&#160;30, 2024, the Company had 110,527 shares of common stock available for future grant under the 2022 Inducement Plan, 10,274 shares underlying outstanding but unvested RSUs and options outstanding to purchase 38,318 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on M</span>arch&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At June&#160;30, 2024, the Company had options outstanding to purchase 97,618 shares of common stock under the 2007 Incentive Plan. The outstanding awards granted under the 2007 Incentive Plan are fully vested and generally have a maximum contractual term of ten years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729173482816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The outstanding Pre-Funded Warrants (see Note 7) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the three and six months ended June 30, 2024 given their nominal exercise price.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and RSUs and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the Notes previously issued by the Company (discussed in Note 6) was considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three and six months ended June 30, 2024 and 2023, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options, service-based RSUs, performance-and market-based RSUs and the potentially dilutive shares issuable upon conversion of the Notes prior to their repayment on March 1, 2024 would have been anti-dilutive.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share for the three and six months ended June 30, 2024 and 2023 are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,237,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,534,533)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,461,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,029,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,197,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,029,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.61)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,706,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,183,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,376,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,784,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,244,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,784,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.48)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three and Six Months Ended June 30</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-and market-based restricted stock units</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783,353&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729075195152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to service-based RSUs, performance-based RSUs  and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2024 was $1.5 million and $3.9 million, respectively, of which $581,000 </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $1.6 million, respectively, was included in research and development expenses, and $890,000 and $2.3 million, respectively, was included in general and administrative expenses. Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2023 was $2.8 million and $6.4 million, respectively, of which $1.3 million and $2.7 million, respectively, was included in research and development expenses, and $1.5 million and $3.7 million, respectively, was included in general and administrative expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024, there was $3.7 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.6 years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $8.80 and $6.96 for employee and director stock options granted during the three and six months ended June 30, 2024, respectively, and $7.20 and $11.28 for the three and six months ended June 30, 2023, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2024, there was $3.4 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 1.7 years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $11.00 and $8.61 for service-based RSUs granted during the three and six months ended June 30, 2024, respectively and $9.24 and $10.32 for the three and six months ended June 30, 2023, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2024 was $43,000 and $146,000, respectively. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2023 was $146,000 and $366,000, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-and Market-Based RSUs </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2024, the Company granted 82,000 performance-and market-based RSUs (such performance-based grants, the "PSU Awards") to key employees under the 2023 Plan. Each PSU was expressed as a target number of RSUs. With respect to the PSU Awards, the Company's Board of Directors established specified performance goals and corresponding performance periods over which the goals must be attained, the satisfaction of which are conditions to earning the PSU Awards and vesting of the underlying RSUs. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the target number of RSUs underlying each PSU Award, up to 70% (the "Milestone-based RSUs") will vest based on the achievement of specified milestones relating to the development, regulatory status and commercialization of the Company&#8217;s lead product candidate INO-3107 (each, a "Milestone," and collectively, the "Milestones"). Each Milestone has a specified deadline for achievement ranging between the end of 2025 and the end of 2027.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining 30% of the target number of RSUs underlying each PSU Award (the "Market-based RSUs") will be eligible to vest based on the Company&#8217;s achievement of total stockholder return relative to a peer group consisting of companies in the Russell 2000 Biotechnology Subsector index (the &#8220;Relative TSR&#8221;) over the period beginning on June 1, 2024 and ending on December 31, 2027 (the &#8220;Performance Period&#8221;), expressed as a percentile ranking.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Marked-based RSUs, if any, actually earned based on the achievement of the Relative TSR goal may range from 50% of the target number of RSUs for performance at a specified threshold percentile, to 100% of the target number of RSUs for performance at the target percentile, and up to 150% of the target number of RSUs for performance at or above a specified maximum percentile. In the event that actual Relative TSR performance is between the threshold and target levels or between the target and maximum levels, the number of RSUs earned based on Relative TSR will be determined based on linear interpolation between the specified percentiles. If the Company&#8217;s actual Relative TSR performance is below the threshold percentile, then no RSUs would be earned based on Relative TSR. The number of RSUs earned based on Relative TSR may not exceed the target number of RSUs eligible to vest based on Relative TSR if the Company&#8217;s total stockholder return is negative for the Performance Period.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values the Milestone-based RSUs based on the grant date closing price per share. The Company recognizes stock-based compensation expense over the performance period, if it is probable that the performance condition will be achieved. Adjustments to stock-based compensation expense are made, as needed, each reporting period based on changes in the Company's estimate of the number of units that are probable of vesting. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values the Market-based RSUs on the grant date using the Monte Carlo simulation method, a generally accepted statistical technique used to simulate a range of possible future stock prices for the Company and the peer group. The determination of fair value is affected by the Company's stock price and a number of assumptions including the expected volatility and the risk-free interest rate. The Company will recognize stock-based compensation expense ratably over the performance period of the award. The market-based RSUs will cliff-vest at the end of the three-year period ranging from 0 percent to 150 percent of the target number of awards granted. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Monte Carlo simulation method were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:78.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the Milestone-based RSUs was $629,000 based on the grant date closing price per share of $10.96. As of June 30, 2024, the underlying performance milestones of the Milestone-based RSUs were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the three and six months then ended.</span></div>The grant date fair value of the Market-based RSUs was $263,000 based on the fair value of $10.69 per share as determined using the Monte Carlo simulation method. For both the three and six months ended June 30, 2024, the Company recognized $8,000 in stock-based compensation for the Market-based RSUs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729070479488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned 597,808 shares of common stock in PLS as of June&#160;30, 2024, representing an ownership interest of 17.8%, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar") and an Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.6&#160;million, for the preclinical development and translational studies of DMAbs as countermeasures for COVID-19, with funding extended through August 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The sub-grant also includes an option for an additional $1.6&#160;million in funding through September 2025. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company received a $1.2&#160;million sub-grant through Wistar, which was amended in 2024 to $2.4&#160;million with funding through November 2024, with an option for an additional $4.2&#160;million in funding that extends the sub-grant through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (dLNPs) for vaccination against HIV infection.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three and six months ended June 30, 2024, the Company recorded $9,000 and $149,000, respectively, and for the three and six months ended June 30, 2023, the Company recorded $179,000 and $390,000, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to collaborative research agreements. Research and development expenses recorded from Wistar for the three and six months ended June 30, 2024 were $455,000 and $1.0 million, respectively. Research and development expenses recorded from Wistar for the three and six months ended June 30, 2023 were $510,000 and $932,000, respectively. At June&#160;30, 2024 and December&#160;31, 2023, the Company had an accounts receivable balance of $1.8 million and $2.4 million, respectively, and an accounts payable and accrued liability balance of $1.9 million and $1.1 million, respectively, related to Wistar. At each of June&#160;30, 2024 and December&#160;31, 2023, the Company recorded $22,000 as deferred grant funding on its condensed consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078722576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies                                                  <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 56,600 square feet of office, laboratory, and manufacturing space in San Diego, California and approximately 57,400 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of June&#160;30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2.9 to 5.5 ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company entered into a lease agreement for research and development laboratory space in San Diego, California. The total space under the lease is approximately 5,600 square feet. The term of the lease commenced on February 10, 2024 and the initial term is 4.3 years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the lease. Rent payments under the lease will include base rent with an annual increase of approximately three percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of June&#160;30, 2024, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,467,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,115,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,135,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,980,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,658,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0%</span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2024 were $521,000 and $1.4 million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2023 were $856,000 and $1.7&#160;million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third and fourth quarters of 2023, the Company entered into agreements to sublease a total of approximately 4,400 and 7,000 square feet, respectively, in its Plymouth Meeting headquarters, in each case with sublease terms through December 31, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters, with one sublease term through March 31, 2025 and the other month-to-month.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The plaintiffs&#8217; complaint was later amended to include certain of the Company&#8217;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $30.0&#160;million in cash and $14.0&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers paid the $30.0&#160;million cash component of the settlement. During the three months ended March 31, 2023, the Company issued 760,083 shares of common stock pursuant to the securities class action settlement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserted state and federal claims and was based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accused the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff sought unspecified monetary damages on behalf of the Company as well as governance reforms. Between June 2020 and August 2020, additional shareholder derivative complaints were filed and later consolidated by the court. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, an additional shareholder derivative complaint was filed in the Delaware Court of Chancery, asserting substantially similar claims as those in the consolidated derivative action. In May 2022, the Delaware Court of Chancery entered a stay of the litigation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania. The proposed settlement provided for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the court entered an order preliminarily approving the proposed settlement of the derivative claims, in accordance with a Stipulation of Settlement. The Stipulation of Settlement contemplated that, following the settlement hearing and the final approval of the settlement by the court, the Company would implement certain corporate governance reforms described in the Stipulation of Settlement. The preliminary order also approved the form and manner of the notice of the Settlement. As part of the Settlement, in July 2023 the Company paid $1.2&#160;million to plaintiffs&#8217; counsel for their fees and expenses. In October 2023, the court entered an order and final judgment approving the Settlement, which became effective in November 2023. The Company has implemented the corporate governance reforms in response to the provisions of the Stipulation of Settlement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. The Company filed an answer to VGXI&#8217;s </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. In October 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On February 29, 2024, the Company filed a motion for summary judgment. On April 1, 2024, GeneOne filed an opposition to the Company&#8217;s motion for summary judgment. On June 28, 2024, the court denied the motion for summary judgment. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078692112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. In the fourth quarter of 2022, the Company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility was assured. For the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2023, the Company received funding of $1.2&#160;million and $2.4&#160;million, respectively, from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. No funding was received during the three and six months ended June 30, 2024.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), which was amended on June 14, 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three and six months ended June 30, 2024, the Company received funding of $101,000 from the ApolloBio Agreement that was recorded as revenue. There were no significant reimbursable program costs under the ApolloBio Agreement during the three and six months ended June 30, 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI, pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56&#160;million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. For both</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the three and six months ended June 30, 2024, the Company received no funding related to these grants. During the three and six months ended June 30, 2023, the Company received funding of $303,000 and $1.9&#160;million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of each of June&#160;30, 2024 and December 31, 2023, the Company had $2.2&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded as an accrued liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheet related to these CEPI grants.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. For both the three and six months ended June 30, 2024 the Company received no funding from CEPI related to these grants for INO-4800. During the three and six months ended June 30, 2023, the Company received funding of $135,000 and $188,000, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of DMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three and six months ended June 30, 2024, the Company recorded $0 and $39,000, respectively, as contra-research and development expense related to the Gates DMAb grant. During the three and six months ended June 30, 2023, the Company recorded $12,000 and $70,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of June&#160;30, 2024, the Company had $49,000 recorded as an </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheet related to the grant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729170851296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</span></div>&#160;For the six months ended June 30, 2024 and 2023, the Company did not record any income tax provision/(benefit) due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078678528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos Therapeutics to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a series of financing transactions through June 2020, the Company held less than a majority of the outstanding equity of Geneos on an as-converted to common stock basis, which triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance. Accordingly, the Company deconsolidated its investment in Geneos in 2020.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its investment at fair value. The Company determined that its investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment is marked to fair value.&#160;There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 was allocated to the equity method investment, reducing the balance to $0 as of March 31, 2021. The remaining $4.2&#160;million loss was allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, reducing the balance to $0 as of March 31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of its Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-2 preferred stock was based on the per share price paid by third-party investors. The Company concluded that its Series A-2 preferred stock investment was a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any further investment in Geneos subsequent to March 31, 2022. The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, Geneos completed the closing of its Series A-3 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately 23% of the outstanding equity of Geneos on an as-converted to common stock basis. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span>immunotherapy and CELLECTRA&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729070335504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,237,098)<span></span>
</td>
<td class="num">$ (30,469,871)<span></span>
</td>
<td class="num">$ (35,534,533)<span></span>
</td>
<td class="num">$ (40,649,317)<span></span>
</td>
<td class="num">$ (62,706,969)<span></span>
</td>
<td class="num">$ (76,183,850)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078493952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078623104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Liquidity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June&#160;30, 2024, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2024 and 2023 and the condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three and six months ended June 30, 2024 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2023, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;6, 2024. The balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of June&#160;30, 2024 and December 31, 2023, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $32.2 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$62.7 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six months ended June 30, 2024, respectively. The Company had working capital of $91.2 million and an accumulated deficit of $1.7 billion as of June&#160;30, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed an underwritten registered direct offering (the &#8220;Offering&#8221;) relating to the issuance and sale of 2,536,258 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $110.4 million as of June&#160;30, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are expected to be sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the Offering described above, and the receipt of net proceeds of $5.2&#160;million and $5.5&#160;million under a Sales Agreement during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2024 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div>The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements and Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div>The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses - Clinical Trial Accruals</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The outstanding Pre-Funded Warrants (see Note 7) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the three and six months ended June 30, 2024 given their nominal exercise price.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and RSUs and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the Notes previously issued by the Company (discussed in Note 6) was considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three and six months ended June 30, 2024 and 2023, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options, service-based RSUs, performance-and market-based RSUs and the potentially dilutive shares issuable upon conversion of the Notes prior to their repayment on March 1, 2024 would have been anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to service-based RSUs, performance-based RSUs  and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078459040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Summary of Investments</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of June&#160;30, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,541,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,042,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,498,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,676,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,674,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,979,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435,449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,498,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,481,043)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,029,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,389,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,522,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,164,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,873,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927,161)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2024:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,498,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,498,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,674,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,674,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,029,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,172,707&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,856,409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,349,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,492,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,856,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,056,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,763,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,836,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078561232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule Of Prepaid Expenses And Other Current Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical expenses (a)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,410,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,024,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,983,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,365,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393,665&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,642,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses (b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,432,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,634,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,847,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a)        As of June 30, 2024 and December 31, 2023, balance includes $22,000 and $1.5&#160;million, respectively, of prepaid manufacturing expenses.</span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;As of June 30, 2024 and December 31, 2023, balance includes $2.3&#160;million and $4.3&#160;million, respectively, of liability for unused grant funding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729075209040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of June&#160;30, 2024 and December&#160;31, 2023: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,963,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,963,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,793,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078675440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share for the three and six months ended June 30, 2024 and 2023 are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,237,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,534,533)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,461,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,029,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,197,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,029,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.61)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,706,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,183,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,376,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,784,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,244,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,784,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.48)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three and Six Months Ended June 30</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-and market-based restricted stock units</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783,353&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078696256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Significant Assumption Used in Monte Carlo Simulation Method</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Monte Carlo simulation method were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:78.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729075284736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of June&#160;30, 2024, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,467,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,115,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,135,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,980,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,658,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729071223184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 18, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,237,098<span></span>
</td>
<td class="nump">$ 30,469,871<span></span>
</td>
<td class="nump">$ 35,534,533<span></span>
</td>
<td class="nump">$ 40,649,317<span></span>
</td>
<td class="nump">$ 62,706,969<span></span>
</td>
<td class="nump">$ 76,183,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,685,672,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,685,672,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,622,965,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,284,801<span></span>
</td>
<td class="nump">$ 2,915,179<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.083333<span></span>
</td>
<td class="nump">0.083333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember', window );">Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of stock</a></td>
<td class="nump">$ 33,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember', window );">Underwritten Registered Direct Offering | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">2,536,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember', window );">Underwritten Registered Direct Offering | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">2,135,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729071683264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 79,498,907<span></span>
</td>
<td class="nump">$ 134,873,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">11,252<span></span>
</td>
<td class="nump">36,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(3,481,043)<span></span>
</td>
<td class="num">(3,927,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">76,029,116<span></span>
</td>
<td class="nump">130,982,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">45,541,438<span></span>
</td>
<td class="nump">55,389,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(3,042,831)<span></span>
</td>
<td class="num">(3,522,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 42,498,607<span></span>
</td>
<td class="nump">$ 51,866,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity&#160;(in&#160;years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 29,676,056<span></span>
</td>
<td class="nump">$ 75,164,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">24,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(2,473)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 29,674,100<span></span>
</td>
<td class="nump">$ 75,189,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity&#160;(in&#160;years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 2,979,591<span></span>
</td>
<td class="nump">$ 2,978,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">10,735<span></span>
</td>
<td class="nump">11,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">2,990,036<span></span>
</td>
<td class="nump">2,990,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">1,301,822<span></span>
</td>
<td class="nump">1,340,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(435,449)<span></span>
</td>
<td class="num">(403,973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 866,373<span></span>
</td>
<td class="nump">$ 936,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729072742080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>position </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>position </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gain on investments</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss on investments</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">693,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="num">$ (20,820)<span></span>
</td>
<td class="nump">$ 922,941<span></span>
</td>
<td class="nump">$ 480,057<span></span>
</td>
<td class="nump">$ 4,141,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | position</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in a gross unrealized loss position for more than twelve months | position</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares) | shares</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729071617136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 76,029,116<span></span>
</td>
<td class="nump">$ 130,982,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">42,498,607<span></span>
</td>
<td class="nump">51,866,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,990,036<span></span>
</td>
<td class="nump">2,990,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">866,373<span></span>
</td>
<td class="nump">936,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">76,029,116<span></span>
</td>
<td class="nump">130,982,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">2,319,975<span></span>
</td>
<td class="nump">2,780,287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">78,349,091<span></span>
</td>
<td class="nump">133,763,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">72,172,707<span></span>
</td>
<td class="nump">127,056,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">2,319,975<span></span>
</td>
<td class="nump">2,780,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">74,492,682<span></span>
</td>
<td class="nump">129,836,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">3,856,409<span></span>
</td>
<td class="nump">3,926,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">3,856,409<span></span>
</td>
<td class="nump">3,926,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">42,498,607<span></span>
</td>
<td class="nump">51,866,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">42,498,607<span></span>
</td>
<td class="nump">51,866,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">29,674,100<span></span>
</td>
<td class="nump">75,189,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">29,674,100<span></span>
</td>
<td class="nump">75,189,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,990,036<span></span>
</td>
<td class="nump">2,990,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,990,036<span></span>
</td>
<td class="nump">2,990,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">866,373<span></span>
</td>
<td class="nump">936,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">866,373<span></span>
</td>
<td class="nump">936,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729195302208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Prepaid and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidClinicalExpensesCurrent', window );">Prepaid clinical expenses</a></td>
<td class="nump">$ 2,341,285<span></span>
</td>
<td class="nump">$ 3,410,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">3,024,575<span></span>
</td>
<td class="nump">1,983,223<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other assets, current</a></td>
<td class="nump">$ 5,365,860<span></span>
</td>
<td class="nump">$ 5,393,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729072883184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidManufacturingExpenseCurrent', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantLiability', window );">Grant liability</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade accounts payable</a></td>
<td class="nump">4,487,282<span></span>
</td>
<td class="nump">3,577,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">8,642,497<span></span>
</td>
<td class="nump">9,837,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">3,504,982<span></span>
</td>
<td class="nump">6,432,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 16,634,761<span></span>
</td>
<td class="nump">$ 19,847,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccountsPayableAndAccruedExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable and Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccountsPayableAndAccruedExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Manufacturing Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729067553696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Feb. 19, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,415,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOperating', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 313,488<span></span>
</td>
<td class="nump">177,833<span></span>
</td>
<td class="nump">626,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">Convertible senior notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible senior notes</a></td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOperating', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="nump">627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 533,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729071351456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">25,963,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">25,963,544<span></span>
</td>
<td class="nump">22,793,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729073916528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
<th class="th"><div>May 16, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 24, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember', window );">2023 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember', window );">2022 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares', window );">Shares issued in settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember', window );">Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent', window );">Class of warrant or right, common stock ownership (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember', window );">Underwritten Registered Direct Offering | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember', window );">Underwritten Registered Direct Offering | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent', window );">Class of warrant or right, common stock ownership (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | 2021 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage', window );">Sale of stock, sales proceeds of any common stock, percentage (in percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Common Stock Ownership, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ClassOfWarrantOrRightCommonStockOwnershipPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Awarded to Other Party, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LitigationSettlementAmountAwardedToOtherPartyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2022InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_A2021SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_A2021SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729068110720">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (32,237,098)<span></span>
</td>
<td class="num">$ (30,469,871)<span></span>
</td>
<td class="num">$ (35,534,533)<span></span>
</td>
<td class="num">$ (40,649,317)<span></span>
</td>
<td class="num">$ (62,706,969)<span></span>
</td>
<td class="num">$ (76,183,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WeightedAverageNumberOfSharesOutstanding', window );">Weighted-average common shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,461,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,029,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,376,386<span></span>
</td>
<td class="nump">21,784,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants', window );">Weighted-average pre-funded warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,736,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">868,271<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,197,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,029,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,244,657<span></span>
</td>
<td class="nump">21,784,343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,197,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,029,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,244,657<span></span>
</td>
<td class="nump">21,784,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.48)<span></span>
</td>
<td class="num">$ (3.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.48)<span></span>
</td>
<td class="num">$ (3.50)<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WeightedAverageNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WeightedAverageNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729067890336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Anti-dilutive (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">1,783,353<span></span>
</td>
<td class="nump">1,823,765<span></span>
</td>
<td class="nump">1,783,353<span></span>
</td>
<td class="nump">1,823,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">1,359,705<span></span>
</td>
<td class="nump">1,263,891<span></span>
</td>
<td class="nump">1,359,705<span></span>
</td>
<td class="nump">1,263,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">341,373<span></span>
</td>
<td class="nump">305,434<span></span>
</td>
<td class="nump">341,373<span></span>
</td>
<td class="nump">305,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-and market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">82,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">254,165<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">254,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729170947264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted Average Assumptions (Details) - Stock Options - Employees and Directors<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.42%<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="nump">4.23%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">106.00%<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729068350320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 23, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,039,486<span></span>
</td>
<td class="nump">$ 6,727,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="nump">$ 11.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage', window );">Threshold, percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 9.24<span></span>
</td>
<td class="nump">$ 8.61<span></span>
</td>
<td class="nump">$ 10.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-and market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage', window );">Threshold, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMilestoneBasedMember', window );">Milestone-Based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="nump">$ 10.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember', window );">Market-Based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="nump">$ 10.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember', window );">Market-Based RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember', window );">Market-Based RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember', window );">Total Stockholders Return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage', window );">Threshold, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">581,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="nump">$ 366,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMilestoneBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMilestoneBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729078642368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details) - Market-Based RSUs<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">3 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729068002720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,090,989<span></span>
</td>
<td class="nump">$ 23,743,970<span></span>
</td>
<td class="nump">$ 44,001,307<span></span>
</td>
<td class="nump">$ 53,920,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,773,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,773,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,405,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAmendedAmount', window );">Collaborative agreement, amended amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Collaborative arrangement, term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
<td class="nump">149,000<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,000<span></span>
</td>
<td class="nump">$ 510,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">$ 932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding, from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAmendedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Amended Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAmendedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729071124192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>director</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178; </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of cash settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares', window );">Estimate of shares settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares', window );">Shares issued in settlement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember', window );">Behesti v. Kim, et al.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">57,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet) | ft&#178;</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract (in years)</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease', window );">Lessee, operating lease, base rate percentage (in percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Agreements To Sublease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseNumberOfAgreementsToSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Awarded to Other Party, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LitigationSettlementAmountAwardedToOtherPartyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss, Value of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LossContingencyEstimateOfPossibleLossValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729074060944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2024</a></td>
<td class="nump">$ 1,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">3,467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">3,555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,955,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">2,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">16,115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(3,135,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">12,980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,321,984)<span></span>
</td>
<td class="num">$ (2,406,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 10,658,228<span></span>
</td>
<td class="nump">$ 11,032,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729071135616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,762<span></span>
</td>
<td class="nump">$ 225,971<span></span>
</td>
<td class="nump">$ 100,762<span></span>
</td>
<td class="nump">$ 340,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Collaborative agreement, funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Collaborative agreement, funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Collaborative agreement, funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139729072343776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent (in percent)</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember', window );">Series A-2 One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Resulting in again on remeasurement</a></td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment', window );">Loss from equity method investment, recorded and allocated to investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MWK\PW)\8M6G?N=TJ8U35'JZE !6P!O#_2L%L>#BQK_&ZU[:+_P!02P,$%
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M7<:0)]%VN.U \;5IX>ZY@H;0O);PIX *#8#O2\[5XT ;Z/]FI+\ 4$L#!!0
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M?/J;?C]TQ$D!1"P%\*$ 5@M02P%R*$#4 H&E #T4H.<VB1T*L',+!(<"@5(
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M547AB67#8UJO3+[?4,BQ"PDVAP1;0((ED& <"$RB$CM2B3G' V^:W7XPBT7
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M)(BT"P =E*H-)OO8JX%WNV$+O*&I(8YPB()(4=43@^T4,1S1.$3JSI&;C)G
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M)5"U%.LR+8K],%3G)% 9%!2-0Z')].ME4.R605\X+Q7KXNB48!QKRV%0>?2
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M[10%C%#"?%]](IK). @#?((JQZ-7(ZE;%?SS1U3N"D:/7L.]UVH(=1/+$=6
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M(T#V+;TARU,3:<-UJ8GK!&H 0\/^:%O(,,':"=NONP#+^^]B?OAI.-S?J3X
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MC;B.KHW!<8!4X;[FJ%,^EBD$'0X73G"V'KCHJ%<X8_"''!=3L;10^?^*SX,
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M2,TUHQ>E@X0FOTZ??NV9;27.1:4& :&R%% %%\Z@6(T<NU.9.S)V3"\F3_9
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M8.Y(RY JN-MF4;B.&F<;IRC@_<Y;JB 1J*B,U7:S2_1_7XB:2G2*08:QHEA
M%#M>LJ+H@P@QB*X\_('XUI9]?[?<.\@-^:#JOE6[8!W'8H<]1(EP@@W *JR'
MLS)%ZU";#[-@:%N.SSB4'!]S /NZT=17L ]MV4\"&^< YQ37H20TH)Y03\<]
M&74.BO!M)O9(M(N*831ZSUD>=N%65)R:J'$G0S]3,*&4C1)L*X4L\=HZ5E1L
MYPT/(PP3ZCNE/U6L,+YK$K?&;O%6_8!\6\>4]>Y@1"W6!;<]6.%JD\1F,5-<
M%8\>GZ)YOJO/166W6$;O25&/!WH?B+/!\I4' LNG G(U2%/@NB;[),A!VU:7
M'3W&DIU83T;#2]_9Q"KH!CLBG.Q[,T]'5RBTXR9>%'DNHN/3;6I8'>ZBBW0%
M>S!/%]E/X*(@I*8U7//)SV\SY"->#M-#L$V\D.%5@MZ/?RO<I\FQ ?;7UH;^
M@0\8;NCS?P%02P,$%     @ &8 (66.K!P8@"P  M3P  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL[5M9D]LV$OXKJ(DKL5,<#0]==.RI\I'L9C?)
M>C-Q]F%K'R *DE F"1D 9ZS\^OVZ24K4-1G'SM8^\,$>'D"CCZ\;_1&E9W?&
MOG,KI;SX4.2E>WZQ\G[]].K*92M52#<P:U7BS<+80GK<VN656ULEYSRIR*_B
M,!Q?%5*7%]?/^-D;>_W,5#[7I7ICA:N*0MK-2Y6;N^<7T47[X&>]7'EZ<'7]
M;"V7ZD;YM^LW%G=76RES7:C2:5,*JQ;/+UY$3U^.:#P/^%6K.]>Y%F3)S)AW
M=//]_/E%2 JI7&6>)$C\N56O5)Z3(*CQOI%YL5V2)G:O6^G?L>VP92:=>F7R
M?^FY7SV_F%Z(N5K(*O<_F[N_JL8>5C SN>/_Q5T]=H05L\IY4S23<5_HLOXK
M/S1^Z$R8AF<FQ,V$F/6N%V(M7TLOKY]9<R<LC88TNF!3>3:4TR4%Y<9;O-68
MYZ]O5L;Z2Z]L(;XO;Y7S<+AW0I9S\9W45OPJ\TJ)'Y5TE57\[MF5Q[HT^RIK
MUGA9KQ&?66,L?C2E7SGQ;3E7\_WY5]!WJW3<*OTROE?@WZIR()(P$'$8#^^1
MEVR=D+"\Y(R\CN6!>*UFGNW_]GVE_4;<J*RRVFOEQ+]?S)RW -)_3CFA7F-X
M>@U*KJ=N+3/U_ +9XY2]51?77WX1C<-O[K%@N+5@>)_TSQ3&S[V&^&6EQ,+D
MR'Q=+H7&X#;[A5D(>2MU+F>YND1QN70R5\+MG"T=C4&HU3;4O-9KE:EBIJQ(
M(GZ:/!4O3@Q]!<A1J"J9X]IY\1=KG!-O2Y2N7/^FYL</V(H?I7V'6M@84_'\
M157.G;B\O!2/Q' 4C(91,$RFN/GRBVD<Q=_@ZG$2A,,XF";1$QH4!\-T&HS#
MB7@[N!D(;]DKFZY]/RBL[E>R%)&(TV \&0?A:"Q&T40\QO1)\J1^/ RB,!2O
ME/5ZH3/I%1L[5VOCM-^7$J23-!BED8C"8)*,("<-G]#C- S"9%SK@E);9AM1
M()A+7%_.9/8.QG<T^UI$01)&P32.MQ8^'B:C8#A,GXCI>!PDDP168C&R,H65
MCT04!?$HKCTQG$;P1D*>(*M@1A2-FR@=A>]/B]1H%"33-(BGZ6&D1C$B-9V2
M?B.8"8.&8?2P2$U&030>!I-I+.)AD (%K61Z@^4F\<.#!=\AVO#<)$RA5[@-
M5A)_7+"&(0"9=H(5)A"/ *0);!N/*3[),)A.$)N8HH7'X^&D]D8:3V 3XS9"
M^J13Z! EXNN?C'!(6V0E-C]:;B/FL&@@7N,&Z>R1W'YEE>*T=/H#U.0RKZC,
M[Z=CP*-?F6(MRPTV\\Q8&K/DP&[#ND03 8>50G?J"_SW"*[A11Z-0@A$^5PK
MWLWS3<#/#^3DN%,G!<5!V(H:IPG=[(O[(\8EGVA<_+F,BP8CM AYSMT."4P&
M:?O@T\T\%\,2.5CM4O,QZ?>$K24=3]1X5>^K'0R3\H_CB,+QI-9\. W_W. <
M:/W1ZJ9QLH/2<!"=\S.2"-FCK$9QFLE<EAD$W"FK2)5<.H<Z@?71+O..F&55
M4>68@$?0VXH,BENUHB[X5G'LL:':CXH;#R%7#+!O0Q5@AA_-]:V>*ZJ7!UCJ
MZ(5-^(1+)-379997M):FR8U8/#0%O6,%,P-E2H<QN'(FUW,VS'G\V:(6],)*
M:M#=X-0^OA^^E80E\>\T#G?:KV @:N?2JB76$MYXN+\3;O8C%Y9=R@S$/Q:T
MF.L*"T24\JHSI<A.-# \E^LYY1D%(S?E4MFFL,=M)$[T+P-NB%IC8+@V<^P2
M>4[ O"7"(;0GX=:C:]+F3),TIPZU8[ W>$1]&1HVH3$%PG?QI+9+8T5M8?B\
M(F^(#-?8CVHWV 9J:^,QG(!ZBRV58T*!RY2EV'S7H.YP\;L5@9G>+&A3ON7=
MV+ G#Y3(M[L?O9.TIW$P,MKSP:RT.PPV.1&UCA D?2.144M;?:/#!G*1:AR(
M6PF/5DZ\KR0, <PH9Q9H+8QU#6!1/@(Q0[:5!O;K0A,BO:E7+FF?.Z$]%,N@
M]U*1E-9YA-IRB5=;]%O"VB*OJ)5A1-.[.3@<V@E9RGQ#8Q1%U]65G59QT)[-
MP*IUF&C%0;?;V57\!X#A5-O,]69M-1IO#:RU(-B9M&>"$[5VY*%F*'Q'?1$%
MJS%>NW<<'9-I3FI..BI\U/=T]!F(ESS/-"6AGHX Y8W-C(4'8'P%!-1UAW+[
M,)?;?-SYM4$1MT23;U 8G==%VY M*@YT)MT* 3-WG$,SJE@Y?2Z U(4U!>28
M@VK0Q>=,Y1K!<_RP.@H7*4LN[.0:N>-%1CL0]56TO?O[JYUC"=M-BXH:D2G:
M11CP>[(QKMXY*&#^9.$^\.K@@*!Y&BV8GE)U/N5&2DC?A(-A5=1\CS.T6P&H
M5%I:B7?L)KVW96HN*M?NY!V"6*XK?Q+"3\]2S$,7BE^XV/^S,N2*-U;3AGNC
MER4WY*A$>]<[2MO= /?(Q!Z;.[C9L8KVZBR)Z'"YSF4[K?U[CCGL.%P[\OC)
M PE#R]_::8?WM?_<:<]TZ-PD#B+\F\ 123 =$8?:,9#O.Y4?2%@L=%[7"=IA
MD/AQD$0I*,JH<W7HBUJ1!G!G8 :".07]28,0K!<W0P0G#L93(J([K7;A^3_&
M^XGO&O=@_IA&?W[<=[CQP<U'X+Y#BSN7'X=[HL/[N.\^>2#N6RK<3CN\OQ?W
M76(<@2^'0%841X+8\SB8I/%'('\";A-/)YVK/X;\*$F"R3@)B#_B#FDY)9/"
M*6._U6L7HA^X3XI:N4>%DYIT[9AZ+$31A0+MJ6<#O%(YVN/-WLZUW:U95U;]
M?0W,HOYHLV9\!@3].Y63K2>S3^\YDS>U0X<&XLT/-_N--5B4J2AJM$72I'TQ
MHW023.$E4!6TZH@X%&7001!_X=]U*]A8*4]9V[99:<?70_YNX!+QD[H3WWZH
M&ZKVNU0S0*[7.7!-A:;A?Z(^;:F_I;PM#SX0D*]W#5_'*5^Y$U14,I&DEK)F
M8@WM.D&V&JXE&K)%'C_BO[9A! _EP9;YX=%D?7\*#!HDQ@]#8G:F-&Q!^?NI
M?R]$=:F)]* OWH&5Z;65I9/UV5$- *;:U<S!$[!D.R%H9X!+DX)*9JLF* P>
MIGGH[#;KANM5'@[YC=XUV6!F=![ &$'4Y#Z:S<PS,(XI%D'[P)7<MDKH:Q;@
M35 =.4S*TV*T!LP(0-DT-"PD-$%[>RHQZ\R94[R@,L66OD-(RRI"&6^KAA?1
MN'H7JTDD\[M&9"-KZ^F.F4KSZ#E(:4:>9#'M76W_?38 <C3?G5:>XM19J]&O
M<0UQ1-70K9:<D=-I/?H>8INN>,>!O<I6I4;,'?F+V^NF)I^AO;N$;:.ST"4R
MGZAUQWEU/X$5P5(;PE&:\G)&CMAA@W)!E0ZL]M"=( 76S(SEU)IMNB8W<\FN
MX'R '>AO+NU10%MG%V:N<@?( RU(]+EV7%>)!;;$J>.<?=3"(5R!:MR>5*%Q
M^#8S:X*Z.8HU7M?H:QNHYL57[>>!MKSM1\,=AZ-3F';?6-JJ++G^^D^44F=K
M&T])Q1 %B[[*8;@SE<T4.PKQX_"7I@%)TJ8P%ZM3+!Z1.>KZ!O><'8ZV9X>C
M_\'9X>=>HS\[[,\.^[/#_NRP/SOLSP[[L\/^[+ _.^S/#ONSP_[LL#\[[,\.
M^[/#_NRP/SOLSP[[L\/^[+ _.^S/#ONSP_[LL#\[[,\.^[/#3SX[O.K\E+10
M=LD_F'6"@U?_JG3[=/N;W!?U3U%WP^L?]&(O6U+QR=4"4\/!9'0![L\_DJUO
MO%GS#U-GQGM3\.5*28":!N#]PB#RS0TML/VE\O5_ 5!+ P04    "  9@ A9
MZ#S6*5$#  "Y!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RE5=N.
MVS80_96!N@@2@+!NM"QO; /VID52(.@BVS8/11]H:6P+H4B5I.+=O^^0LA4O
MLED@R8O$R\R9<SB<X>*HS2=[0'1PWTIEE]'!N>XZCFUUP%;8B>Y0T<Y.FU8X
MFII];#N#H@Y.K8RS)"GB5C0J6BW"VJU9+73O9*/PUH#MVU:8APU*?5Q&:71>
M^-#L#\XOQ*M%)_9XA^ZO[M;0+!Y1ZJ9%91NMP.!N&:W3ZPWW]L'@[P:/]F(,
M7LE6ZT]^\JY>1HDGA!(KYQ$$_3[C#4KI@8C&?R?,: SI'2_'9_3?@G;2LA46
M;[3\V-3NL(S*"&K<B5ZZ#_KX%D]ZIAZOTM*&+QP'VWP>0=5;I]N3,S%H&S7\
MQ?WI'"X<RN0;#MG)(0N\AT"!Y1OAQ&IA]!&,MR8T/PA2@S>1:Y1/RITSM-N0
MGUO=H'&4.M@(*52%<!=NPCN'K5W$C@)XL[@Z@6T&L.P;8 6\U\H=+/RJ:JP?
M^\=$;&27G=EMLF<!?^_5!/*$099D_!F\?%2;![S\^]7"/^NM=89NR;]/"1]P
M^=.XOG*N;2<J7$94&A;-9XQ6+WY)B^3U,ZSYR)H_A_Z].?IA,+@UV(FF!J%J
MT.Z AFZ@,:@<"&O16:@T5:-U2-L[( /8:4EEW:C]-5"N<,P5O,$*VRTAY&E8
MR4?PBA@UE9" ]]19+%IX*5Y!QG*>LJR<0LYXFC#.,_@C4.A.?J-YSB@ F\ZF
MD+)YF;.,P*]@RO)BRLHB&<;SG!7%%-95I7M%S#OQ(+82@S115:;'"\2?D?6G
M$35ZR,=QKH S7LY(44;CG.C.6)D5GE"(7>G6!Q>A-96LX!GC\QG,69G/6)KP
MD_BOJ+[<OO)H"2?I&12,YQDK4TXQTH(5.6>S(O43 N(S-N,\G.[:>F6/I?B3
M^$H.HQ8WW(M&5;*O*>)5EK$D28+]53J94A>2DE@SZLFVP]!5Y0/S <ZI:H7J
M=U1)O:$C'+E/ OF?HS+)S^$'/OS+PA-\9".VC6S< R740*]Z2T>Y-X(N]*Y7
M-9&;/%6>\44[;='LPZ/A;PEE>.BLX^KX+JV'=OS%?'C4W@NS;Y0%B3MR32:S
M:01F>"B&B=-=:,Y;[:C5A^&!WE8TWH#V=UJ[\\0'&%_KU?]02P,$%     @
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MR_56&L%*FCFT60M8HP5:/81#X$K 16Z,7$MH@&G"X?7L, I:I$IG(0ZIPI@
MQ+GUPR(5Z/496VM5NN<RY* %]DFW\),A*)# "R189B^@.^6UM+B&V$-'H3+#
M<')54!E5R(Q;7*QXX13YD7JB"H;L'4_S$Q:PG"RHX#!L@$;$5Z<4*$ ! O<
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M>,LY*D.(:H^J(76Y']%K7!]?NOVCPPJ':T([_)'WZ(D_?6Q'5]?W;CZR&UX
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M#Z9(O\#:/AC"(I# 3;-Q5;O> '1$_5,NYNH'-EXTQ52\K86/PG<HG =[,>!
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M!.!4VFVJG&1*<A1E/'W%.VC#ZIR:@9GZF+RCP@<5-?EM=6LK]1FO%>C[T%=
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M".LRA)(PGAU,/S,@6*8M7V:+@#Y[&-G&.>TKLA+" NZS[HIQ>&1FFZ? WQ.
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M6H#G654U\0-MT/VX[LW_ 5!+ P04    "  9@ A9X8&047D+  "Z(   &0
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MF5RG,B1'F8HSJQQ,#R_,4KS1I2P3+7-QCI?!+>+?1POG+7+I/[L\%!38WZT
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M5C<Q1:$L9;3^IOKB2;_IT^=.-)(3+*?24.+TP\?1_L%DPH[79:.ZU=Y8K=B
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MUU!/Y31G[L*=QOA_./"V*S]B7B4CG4)&H]46T(!_#;&FG5<@" QD*+Z4=/&
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M9/ST\2!<2S4/WE3\ZS3 WIN"/V:*.@TMP/=+8WSS0 >T_UWA\+]02P,$%
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M &D#S/-<"'V<V WZWT_Z!U!+ P04    "  9@ A9>!/+F-L/  !F+0  &0
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MJX!GBO!LJ"0/P8>CA^U=2+<4<Z1-EW?\P_M8U87E6,S:H2_(\E>DEK#18Y)
M.W9G;%J3=U1PAJ*UEI[UQCZ!#-*S(!<A_%E\3<81M2J4<TCL+*P4<ZFM:/K
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MJWKJWKW]LQ?0XPA'G.=V^QF'$A<,<D6Z!$] ,;%QG':CHAC@P%C02R[PF;W
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M%+K=Z8LW#;]).S/>FQ5_7"K$J:4!^)W>U4A?:(/\:O6K_P%02P,$%     @
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M?>&U"ULO_:MJ4EM\HWER@8]BJ=T%/)_5"-W5PBE8/[-'?P-02P,$%     @
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MJ_%I@WYV=0_:8NG(A@LN2R /_B:\L= :<OV![P28FT5H,9*S#\L1=3.@)M]
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M<K6D'!E1\XJ?5)2M"NU4<&U!Z 1@>P)<W#G&F*]00:_K9GMG^\J:M*<MV.W
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MFJP I;E0F@>E^5!: *6%4%H$I<4H6E=FV]P(_?^:'*&?M%)^KZ[4V2*#)CY
M:1Z4YD-I 9060FD1E!:C:%V1;;,N='7:Q>/N3(E4&<M2NE757];:Y$!KXTM[
M:NYK#9IA :6Y4)H'I?E06@"EA5!:!*7%*%I7:]N$#5V=L7'ZW,J7A,F.9&_V
MJ]K'V2,W:!8'E.9":1Z4YD-I 9060FD1E!:C:-W?FFX33 SMITZK&-!\%"C-
M@=)<*,V#TGPH+8#20B@M@M)B%*TKSFU>BZ'.:P%/J[3>.M,JNFF-QGL_*+M7
M5^MLF4'36* T#TKSH;0 2@NAM A*BU&TKLRV:2R&<B7^?S3B:YWNC_B,?:U!
MLU*@-!=*\Z T'TH+H+002HN@M!A%ZVIMFY5BJ+-2VG$<H3\H2S-.6[7]58V9
M)\U@JNMTML:@&2M0F@>E^5!: *6%4%H$I<4H6J.QX<Y;G9:4/=4O'N.D'HPU
M+U?9'-V\W.Q#_4JOO>.N?A7H/<=#_2IJWB*UQ3=O4ON8L*>LX"2G<^E*NQS+
MOB-K7D[6[(AR5;]3ZFLI1+FL-Q<TF5%6%9#?S\M2O.Y4#C:OB+O]$U!+ P04
M    "  9@ A935&,P,$%  "X'@  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6RU66MOVS84_2N$-PPM4$<BJ6?G&$B=M<W0 $6-=!^&?:!MVA:BAT?2
M2;-?/^H140^*@5KU2Z+'O<>'5]0]1^3B,6/W_$BI -^2..67LZ,0I[>6Q;='
MFA!^D9UH*N_L,Y80(4_9P>(G1LFN2$IB"]FV9R4D2F?+17'M,ULNLK.(HY1^
M9H"?DX2PIW<TSAXO9W#V?.%+=#B*_(*U7)S(@:ZIN#M]9O+,JE%V44)3'F4I
M8'1_.;N";U?8S1.*B*\1?>2-8Y /99-E]_G)S>YR9N>,:$RW(H<@\M\#7=$X
MSI$DCW\KT%G]FWEB\_@9_7TQ>#F8#>%TE<5_13MQO)P%,["C>W*.Q9?L\2.M
M!E00W&8Q+_Z"QRK6GH'MF8LLJ9(E@R1*R__D6U6(1H+$T2>@*@%U$[R!!%PE
MX&*@);-B6-=$D.6"98^ Y=$2+3\H:E-DR]%$:?X8UX+)NY',$\OU,6-B+BA+
MP$WZ0+F0CTAP0-(=>$\B!KZ2^$S!+27\S&AY;P[6Y3,'V1Y</9 H)IN8SN64
MFG,24["FVS.+1$0Y>'5-A;S/7\NDN_4U>/7KZX4E).W\QZUM1?%=21$-4/3
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M)056;I.6)R([%3N-FTR(+"D.CY3L*,L#Y/U]EHGGD_P'ZLWJY?]02P,$%
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MBDK ?+_(#7GMWE1/^=L_U?'Z?U!+ P04    "  9@ A95;ZHYH@"  "3!@
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M!,GX/SU7=UO1QOVTXI_AAF]Q1&:*'/HY82]$F?_RDVYKO_:Y!!+F0<)\2%@
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M^:(C:*8KXD<J9'VMFY'\! *F N3[.:7BK:.*[.JCRO\+4$L#!!0    ( !F
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M]0'Y_F-1B)<758+],^>O_P=02P,$%     @ &8 (6=><)4@T!0  F!H  !D
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MISMUM:OV/ISZP9 !K'7BU#:P_/L;.]D<<(9#W?U"_#+/,_.,!WO&>R&?U 9
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M?<F3;;E_^GV2Y\FF_+CFP8JG10+Q^T.2Y*]?B@+V_RO Y1]02P,$%     @
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M5'<P+M*R_I\\'-I.C1&)]Z4HLB98]B!+\L,K_=(,Q$F Y*@#K"; >AXP^4J
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M(5UR2,T7#DK.BJLT%\KDY,_W:Z4EO))_V3PW0<;V(.8[O59[FK*Y!Q^B8O+
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ &8 (6;@)/U-E!   F2$   \
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ME+U1N,-.BQ:/$T47H!T4 K\Y4ZH".0KQ4992YR "R(2 3"X".6]P\*<!9$I
MIA>$_#L)(#,",KLD9!I 7A.0UY>$S +((0$YO"3D=0#YAH!\<TG(80#YEH!\
MRPOY8-=2J^=VAY"Z$ ];L(=N > [ O =+^!'Z9039B5F%AQV;7N\$G?JGUH5
MRH>!?$!%\@'SQ;:J-:88Y[FIM4>[B1E>\UQ!.)$Q:1MFW<PWQOH>.K@24[T#
MYYO^KKWJGZ3J.)'R3<PM'$P^, 'Z5X-M3B&F^-!T9I*R3<ROFUV3(N%1Q026
MG;N0$DS,;)BY-_GCQI0%6/>;^ ,?$;\/V2BOQ,QBN<=Q[XQS8@86KZFT$))1
M,HF9;=+.6@\#31NJ*QS)M9U"/LHC,;-(OC2-R#:3UN_%PDKDRW\.T3$ED9C9
M(CAKE0K""3X?300$_7/XHT02,YOD%I<R<FD:N^U C-<6H"4.TVQ*(0FS0J8Z
M-Q6(A?S6F;.$4D;"K(S/H,$XL=A@4K"%&A7G7J$\\M<A(+DX89;%3.[%KHTI
M[<\;7TR4RTOCZDZ 22A=),RZF&JG,"0WCV[1) 9CB\_P^N7=1ZDC858'F6=U
M5E )99&$V2)D#M/%I)22<"]0SN<PXFHA0TS*+ FS64[E"PT?4KC?0TA*+@FS
M7%XF#B<1*;4DS&HYET'\  UK))1A4NY%"J5I<15B4M))F:5#AZ*P3I)2ZDF9
MU4.'H@XF61ECE@^-&19T4LH_*??2A<0,2SHIY9^4NSQ&!/:>F(68E'_2"_JG
M)\8A)N6?E+]$UEE'BZL)('?9B>PI)9^463XG#=D3\[JJI-V')?J4$E#Z*P3T
M$O->VG:Y$]:_*0%ES (ZH7*<2QRXJ/$.,"$F):",64 G,<?HREZARCJL]F24
M@#)N 9W+.GKB+U#K$),24,8MH/.8S?T98I(O9WY%[>PTYERMPV)01@DH8Q;0
M^6)0&SQ#3$I &?L;&BK5[(68E( R=@$1F-WWAI2%,O;ZVNG2U0]?AIB4A3)F
M"YVM%ATXPQ><E(6N6POUCW\%*&"E-!3W> B'[;DL\YD5S<?A545VW9055W59
MWF+;@[XSLCC^L^#XKX@/WP%02P,$%     @ &8 (63B#;R;$ 0  #1X  !H
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MF*X]/VM\_CVISN=[X_7QE^7/27Q?U!>< _S]77P#4$L#!!0    ( !F "%F
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M+GAM;%!+ 0(4 Q0    ( !F "%ELH<X\[P   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !F "%F97)PC$ 8
M )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ &8 (65'\>03]!0  O!\  !@              ("!#@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !F "%D5\6,LF@8
M ,(=   8              " @4$.  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    "  9@ A9R&L]!^ &  "H'@  &               @($1
M%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ &8 (62*>
M!7]5 @  H@4  !@              ("!)QP  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( !F "%E 40HTA@,  '(,   8
M  " @;(>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  9
M@ A96U#*5M /   EE   &               @(%N(@  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ &8 (60C>B -: @  O04  !@
M         ("!=#(  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( !F "%G0L_\*F0P  .=G   8              " @00U  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  9@ A9>^A6U>8'  #N$
M&               @('300  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ &8 (66/0N=7##0  ,R8  !D              ("![TD  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  9@ A9?LE/).4$
M  "M"P  &0              @('I5P  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( !F "%ECJP<&( L  +4\   9              "
M@05=  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ &8 (
M6>@\UBE1 P  N0<  !D              ("!7&@  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    "  9@ A9]@AH%P($   C"0  &0
M        @('D:P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( !F "%E>[([)J0D  "\;   9              " @1UP  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ &8 (68.6VREH!@  ?Q$
M !D              ("!_7D  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    "  9@ A9X-G%K$8+  !>)   &0              @(&<@
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !F "%FN7%5N
M> 8  %01   9              " @1F,  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ &8 (65YZV<Q-$@  :#<  !D
M ("!R)(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  9
M@ A9X8&047D+  "Z(   &0              @(%,I0  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !F "%G]PB1+6@,  % '   9
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M970R-2YX;6Q02P$"% ,4    "  9@ A9H$.JPFD%  !R#P  &0
M    @(''TP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M !F "%D-^?X]C@,  'X(   9              " @6?9  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ &8 (6:Y#[&C( @  7P8  !D
M             ("!+-T  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    "  9@ A9KUSPI%0$  !Z"P  &0              @($KX   >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !F "%G5>Z0[. ,
M *L'   9              " @;;D  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ &8 (62;UF308 P  X08  !D              ("!
M)>@  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  9@ A9
MI=;H,?('   N3@  &0              @(%TZP  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( !F "%E-48S P04  +@>   9
M      " @9WS  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ &8 (6:?QQ_LD!   %1,  !D              ("!E?D  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  9@ A9>) G4HH(  #A40
M&0              @('P_0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( !F "%E5OJCFB (  ),&   9              " @;$& 0!X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ &8 (6104Q7!4
M P  20L  !D              ("!< D! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    "  9@ A9PIIP7+($  "7'P  &0
M@('[# $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !F
M"%F;AJI,.P,  & -   9              " @>01 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ &8 (665=M B?"@  ?WX  !D
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M=#0T+GAM;%!+ 0(4 Q0    ( !F "%GRH23FPP(  *X&   9
M  " @<PW 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
M&8 (69>B-?RH!P  M4H  !D              ("!QCH! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    "  9@ A9JN#A,+<)   S?   &0
M            @(&E0@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( !F "%E TW=,T@,  .P.   9              " @9-, 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ &8 (67G^T!/,"
M,F,  !D              ("!G% ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    "  9@ A9$:^SUX %  "]*0  &0              @(&?
M60$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !F "%F'
M$F[K0@,  # 4   -              "  59? 0!X;"]S='EL97,N>&UL4$L!
M A0#%     @ &8 (69>*NQS     $P(   L              ( !PV(! %]R
M96QS+RYR96QS4$L! A0#%     @ &8 (6;@)/U-E!   F2$   \
M     ( !K&,! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !F "%DX@V\F
MQ $   T>   :              "  3YH 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( !F "%F A/B=P $    >   3
M  "  3IJ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Z #H S0\  "ML
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>273</ContextCount>
  <ElementCount>259</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>66</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Critical Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPolicies</Role>
      <ShortName>Critical Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Short-term Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</Role>
      <ShortName>Short-term Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CriticalAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</Role>
      <ShortName>Short-term Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/NetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtDetails</Role>
      <ShortName>Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Net Loss Per Share - Anti-dilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails</Role>
      <ShortName>Net Loss Per Share - Anti-dilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails</Role>
      <ShortName>Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Geneos Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ino-20240630.htm">ino-20240630.htm</File>
    <File>ino-20240630.xsd</File>
    <File>ino-20240630_cal.xml</File>
    <File>ino-20240630_def.xml</File>
    <File>ino-20240630_lab.xml</File>
    <File>ino-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20240630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="658">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ino-20240630.htm": {
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "ino-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "ino-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ino-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 211,
   "keyCustom": 48,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 32,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2024": 3,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 273,
   "entityCount": 1,
   "segmentCount": 66,
   "elementCount": 529,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 658,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.inovio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "9952152 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-38",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "longName": "9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952157 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.inovio.com/role/OrganizationandOperations",
     "longName": "9952158 - Disclosure - Organization and Operations",
     "shortName": "Organization and Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties",
     "longName": "9952159 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inovio.com/role/CriticalAccountingPolicies",
     "longName": "9952160 - Disclosure - Critical Accounting Policies",
     "shortName": "Critical Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements",
     "longName": "9952161 - Disclosure - Short-term Investments and Fair Value Measurements",
     "shortName": "Short-term Investments and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItems",
     "longName": "9952162 - Disclosure - Certain Balance Sheet Items",
     "shortName": "Certain Balance Sheet Items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "longName": "9952163 - Disclosure - Convertible Debt",
     "shortName": "Convertible Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "longName": "9952164 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inovio.com/role/NetLossPerShare",
     "longName": "9952165 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inovio.com/role/StockBasedCompensation",
     "longName": "9952166 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "longName": "9952167 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inovio.com/role/CommitmentsandContingencies",
     "longName": "9952168 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "longName": "9952169 - Disclosure - Collaborative Agreements",
     "shortName": "Collaborative Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "longName": "9952170 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "longName": "9952171 - Disclosure - Geneos Therapeutics, Inc.",
     "shortName": "Geneos Therapeutics, Inc.",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies",
     "longName": "9954471 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables",
     "longName": "9954472 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)",
     "shortName": "Short-term Investments and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsTables",
     "longName": "9954473 - Disclosure - Certain Balance Sheet Items (Tables)",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "longName": "9954474 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.inovio.com/role/NetLossPerShareTables",
     "longName": "9954475 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inovio.com/role/StockBasedCompensationTables",
     "longName": "9954476 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesTables",
     "longName": "9954477 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
     "longName": "9954478 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-69",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
     "longName": "9954479 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
     "longName": "9954480 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9954481 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails",
     "longName": "9954482 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)",
     "shortName": "Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ino:PrepaidClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ino:PrepaidClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
     "longName": "9954483 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ino:PrepaidManufacturingExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ino:PrepaidManufacturingExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.inovio.com/role/ConvertibleDebtDetails",
     "longName": "9954484 - Disclosure - Convertible Debt (Details)",
     "shortName": "Convertible Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-126",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:DebtInstrumentFaceAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
     "longName": "9954485 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "shortName": "Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9954486 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails",
     "longName": "9954487 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "ino:WeightedAverageNumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails",
     "longName": "9954488 - Disclosure - Net Loss Per Share - Anti-dilutive (Details)",
     "shortName": "Net Loss Per Share - Anti-dilutive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
     "longName": "9954489 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Weighted Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-168",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-168",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9954490 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
     "longName": "9954491 - Disclosure - Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details)",
     "shortName": "Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-200",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-200",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "longName": "9954492 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-207",
      "name": "ino:CollaborativeAgreementAmendedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
     "longName": "9954493 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
     "longName": "9954494 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "longName": "9954495 - Disclosure - Collaborative Agreements (Details)",
     "shortName": "Collaborative Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-235",
      "name": "ino:CollaborativeAgreementsUpfrontPaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
     "longName": "9954496 - Disclosure - Geneos Therapeutics, Inc. (Details)",
     "shortName": "Geneos Therapeutics, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-270",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-270",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20240630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ino_A2007IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "A2007IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2007 Incentive Plan",
        "label": "2007 Incentive Plan [Member]",
        "documentation": "2007 Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2016IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "A2016IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Incentive Plan",
        "label": "2016 Incentive Plan [Member]",
        "documentation": "2016 Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2021SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "A2021SalesAgreementMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Sales Agreement",
        "label": "2021 Sales Agreement [Member]",
        "documentation": "2021 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2022InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "A2022InducementPlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Inducement Plan",
        "label": "2022 Inducement Plan [Member]",
        "documentation": "2022 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2023IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "A2023IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Incentive Plan",
        "label": "2023 Incentive Plan [Member]",
        "documentation": "2023 Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AccountsPayableAndAccruedExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "AccountsPayableAndAccruedExpensesLineItems",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses [Line Items]",
        "label": "Accounts Payable and Accrued Expenses [Line Items]",
        "documentation": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AccountsPayableAndAccruedExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "AccountsPayableAndAccruedExpensesTable",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses [Table]",
        "label": "Accounts Payable and Accrued Expenses [Table]",
        "documentation": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total",
        "terseLabel": "Accounts payable and accrued liabilities, current",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payable",
        "label": "Accounts Payable, Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable from affiliated entities",
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued clinical trial expenses",
        "label": "Accrued Clinical Trial Expense, Current",
        "documentation": "Accrued Clinical Trial Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r724"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r65",
      "r134",
      "r573",
      "r604",
      "r608"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r14",
      "r442",
      "r445",
      "r514",
      "r599",
      "r600",
      "r885",
      "r886",
      "r887",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r764",
      "r1029"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r897",
      "r898",
      "r899",
      "r900",
      "r968",
      "r1030"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r361"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of pre-funded warrants for cash, net of financing costs",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r29",
      "r89"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AdvaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "AdvaccineMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advaccine",
        "label": "Advaccine [Member]",
        "documentation": "Advaccine"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affiliated Entity",
        "label": "Affiliated Entity [Member]"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r716",
      "r776",
      "r941",
      "r983",
      "r984",
      "r986"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r803",
      "r813",
      "r845"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r806",
      "r816",
      "r848"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r807",
      "r817",
      "r841",
      "r849",
      "r853",
      "r861"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocated share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r395"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r270",
      "r271",
      "r736"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ino_ApolloBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "ApolloBioMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ApolloBio",
        "label": "ApolloBio [Member]",
        "documentation": "ApolloBio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r108",
      "r129",
      "r155",
      "r194",
      "r198",
      "r206",
      "r207",
      "r249",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r433",
      "r435",
      "r486",
      "r569",
      "r658",
      "r732",
      "r733",
      "r764",
      "r784",
      "r935",
      "r936",
      "r987"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135",
      "r155",
      "r249",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r433",
      "r435",
      "r486",
      "r764",
      "r935",
      "r936",
      "r987"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463",
      "r752"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross\u00a0Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross\u00a0Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r265",
      "r568"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt Securities, Available-for-sale [Abstract]",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "netLabel": "Short-term investments",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r265",
      "r462",
      "r561",
      "r752",
      "r755",
      "r910",
      "r972",
      "r973",
      "r974"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Liquidity",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "ino_BehestiVKimEtAlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "BehestiVKimEtAlMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Behesti v. Kim, et al.",
        "label": "Behesti v. Kim, et al. [Member]",
        "documentation": "Behesti v. Kim, et al."
       }
      }
     },
     "auth_ref": []
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "BillAndMelindaGatesFoundationMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bill and Melinda Gates Foundation",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "documentation": "Bill And Melinda Gates Foundation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation, Liquidity and Risks and Uncertainties",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r79",
      "r80"
     ]
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device",
        "label": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "documentation": "CELLECTRA 3PSP Proprietary Smart Device [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r127",
      "r722"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r76",
      "r151"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r76"
     ]
    },
    "ino_CertainBalanceSheetItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CertainBalanceSheetItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Balance Sheet Items [Abstract]",
        "documentation": "Certain Balance Sheet Items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r777",
      "r778",
      "r779",
      "r780"
     ]
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "(Loss) gain on investment in affiliated entity",
        "negatedLabel": "Loss (gain) on equity investment in affiliated entity",
        "label": "Change in Value of Investments in Affiliated Company",
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r131",
      "r132",
      "r133",
      "r155",
      "r183",
      "r184",
      "r186",
      "r188",
      "r196",
      "r197",
      "r249",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r331",
      "r332",
      "r335",
      "r338",
      "r345",
      "r486",
      "r614",
      "r615",
      "r616",
      "r617",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r646",
      "r667",
      "r690",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r871",
      "r892",
      "r902"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r196",
      "r331",
      "r332",
      "r333",
      "r335",
      "r338",
      "r343",
      "r345",
      "r614",
      "r615",
      "r616",
      "r617",
      "r743",
      "r871",
      "r892"
     ]
    },
    "ino_ClassOfWarrantOrRightCommonStockOwnershipPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "ClassOfWarrantOrRightCommonStockOwnershipPercent",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, common stock ownership (in percent)",
        "label": "Class Of Warrant Or Right, Common Stock Ownership, Percent",
        "documentation": "Class Of Warrant Or Right, Common Stock Ownership, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coalition for Epidemic Preparedness Innovations",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional revenue to be achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty period (in years)",
        "label": "Collaboration Agreement, Royalty Period",
        "documentation": "Collaboration Agreement, Royalty Period"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAmendedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborativeAgreementAmendedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, amended amount",
        "label": "Collaborative Agreement, Amended Amount",
        "documentation": "Collaborative Agreement, Amended Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborativeAgreementAwardedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "documentation": "Collaborative Agreement, Awarded Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded option amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "documentation": "Collaborative Agreement, Awarded Option Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses to reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "documentation": "Collaborative Agreement, Expenses To Reimburse"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborativeAgreementFundingReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, funding received",
        "label": "Collaborative Agreement, Funding Received",
        "documentation": "Collaborative Agreement, Funding Received"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, funding to be received",
        "label": "Collaborative Agreement, Funding To Be Received",
        "documentation": "Collaborative Agreement, Funding Received for Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, period to receive funding for research and development (in years)",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "documentation": "Collaborative Agreements, Upfront Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements and Revenue Recognition",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r115"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Product",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "ino_CollaborativeArrangementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "CollaborativeArrangementTerm",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, term (in years)",
        "label": "Collaborative Arrangement, Term",
        "documentation": "Collaborative Arrangement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r283",
      "r284",
      "r714",
      "r924",
      "r929"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r779",
      "r780",
      "r897",
      "r898",
      "r900",
      "r968",
      "r1028",
      "r1030"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding",
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, other shares, outstanding (in shares)",
        "label": "Common Stock, Other Shares, Outstanding",
        "documentation": "Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r646"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r646",
      "r664",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r572",
      "r764"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r139",
      "r141",
      "r145",
      "r562",
      "r582",
      "r583"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "Convertible Debt, Current",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r303",
      "r304",
      "r314",
      "r315",
      "r316",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible notes",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r335",
      "r777",
      "r778",
      "r779",
      "r780"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r306",
      "r333",
      "r521",
      "r539",
      "r566",
      "r725",
      "r727"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DNA-Encoded Monoclonal Antibody Technology",
        "label": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "documentation": "DNA-Encoded Monoclonal Antibody Technology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r153",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r291",
      "r292",
      "r302",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r318",
      "r325",
      "r326",
      "r328",
      "r494"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r96",
      "r98",
      "r161",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r762",
      "r893",
      "r925",
      "r926",
      "r927",
      "r978",
      "r979"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r494",
      "r495",
      "r739",
      "r740",
      "r762"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt interest based on the fixed rate (in percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r304"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r327",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r762",
      "r893",
      "r978",
      "r979"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r161",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r762",
      "r893",
      "r925",
      "r926",
      "r927",
      "r978",
      "r979"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r33",
      "r36",
      "r48",
      "r87",
      "r88",
      "r161",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r327",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r762",
      "r893",
      "r978",
      "r979"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities in a gross unrealized loss position for more than twelve months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain on investments",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized loss on investments",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities in a gross unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r267"
     ]
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual Maturity\u00a0(in\u00a0years)",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "documentation": "Debt Securities, Available-for-sale contractual maturity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Resulting in again on remeasurement",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ino_DeferredGrantFundingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "DeferredGrantFundingCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant funding liability",
        "label": "Deferred Grant Funding, Current",
        "documentation": "Deferred Grant Funding, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "DeferredGrantFundingFromAffiliate",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred grant funding, from affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "documentation": "Deferred Grant Funding, From Affiliate"
       }
      }
     },
     "auth_ref": []
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant funding liability from affiliated entity",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "documentation": "Deferred Grant Funding, From Affiliate, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r363",
      "r391",
      "r392",
      "r394",
      "r749"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r181",
      "r183",
      "r186",
      "r187",
      "r188",
      "r193",
      "r422",
      "r431",
      "r459",
      "r460",
      "r563",
      "r584",
      "r729"
     ]
    },
    "ino_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "documentation": "Earnings Per Share, Basic and Diluted EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r183",
      "r186",
      "r187",
      "r188",
      "r193",
      "r422",
      "r431",
      "r459",
      "r460",
      "r563",
      "r584",
      "r729"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r190"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r189",
      "r191",
      "r192"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation cost related to unvested stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options to purchase common stock",
        "terseLabel": "Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "ino_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Directors",
        "label": "Employees and Directors [Member]",
        "documentation": "Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r120",
      "r142",
      "r143",
      "r144",
      "r162",
      "r163",
      "r164",
      "r167",
      "r174",
      "r176",
      "r178",
      "r195",
      "r253",
      "r259",
      "r273",
      "r347",
      "r406",
      "r407",
      "r418",
      "r419",
      "r420",
      "r423",
      "r430",
      "r431",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r458",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r497",
      "r499",
      "r514",
      "r580",
      "r599",
      "r600",
      "r601",
      "r623",
      "r690"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Geneos",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r204",
      "r207",
      "r248",
      "r879",
      "r919"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in affiliated entity",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r485",
      "r723"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment in affiliated entity",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r462",
      "r485",
      "r566",
      "r567",
      "r752",
      "r770",
      "r772",
      "r972",
      "r973",
      "r974"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized (loss) gain on available-for-sale equity securities",
        "negatedTerseLabel": "Net unrealized gain on available-for-sale equity securities",
        "verboseLabel": "Net unrealized gain (loss) on available-for-sale equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r918"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r803",
      "r813",
      "r845"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r800",
      "r810",
      "r842"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r472",
      "r473",
      "r475",
      "r526",
      "r527",
      "r528",
      "r739",
      "r740",
      "r745",
      "r746",
      "r747",
      "r752",
      "r755"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463",
      "r464",
      "r466",
      "r752",
      "r973",
      "r976"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Investments and Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r560",
      "r752",
      "r756"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r356",
      "r463",
      "r473",
      "r526",
      "r745",
      "r746",
      "r747",
      "r752"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r356",
      "r463",
      "r464",
      "r473",
      "r527",
      "r739",
      "r740",
      "r745",
      "r746",
      "r747",
      "r752"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r463",
      "r464",
      "r465",
      "r466",
      "r473",
      "r528",
      "r739",
      "r740",
      "r745",
      "r746",
      "r747",
      "r752",
      "r755"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463",
      "r464",
      "r466",
      "r752",
      "r973",
      "r976"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r472",
      "r473",
      "r475",
      "r526",
      "r527",
      "r528",
      "r739",
      "r740",
      "r745",
      "r746",
      "r747",
      "r752",
      "r755"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r976"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r268",
      "r269",
      "r327",
      "r343",
      "r448",
      "r480",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r581",
      "r735",
      "r752",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r765",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r914",
      "r915",
      "r916",
      "r917",
      "r969",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets and liabilities that are measured at fair value on recurring basis",
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r807",
      "r817",
      "r849"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r807",
      "r817",
      "r849"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r807",
      "r817",
      "r849"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r807",
      "r817",
      "r849"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r807",
      "r817",
      "r849"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on sales of short-term investments",
        "label": "Gain (Loss) on Sale of Other Investments",
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "GeneosTherapeuticsInc.Member",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geneos Therapeutics, Inc.",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "documentation": "Geneos Therapeutics, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r670"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ino_GrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "GrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant liability",
        "label": "Grant Liability",
        "documentation": "Grant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ino_GrantProceedsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "GrantProceedsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contra-research and development expense",
        "label": "Grant Proceeds Received",
        "documentation": "Grant Proceeds Received"
       }
      }
     },
     "auth_ref": []
    },
    "ino_INO4800Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "INO4800Member",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INO-4800",
        "label": "INO-4800 [Member]",
        "documentation": "INO-4800 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r891",
      "r923"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share of net loss in Geneos",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r66",
      "r102",
      "r194",
      "r203",
      "r207",
      "r248",
      "r578"
     ]
    },
    "ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss from equity method investment, recorded and allocated to investment",
        "label": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "documentation": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r280",
      "r282",
      "r467",
      "r469",
      "r474",
      "r594",
      "r596",
      "r675",
      "r720",
      "r754",
      "r999"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r282",
      "r467",
      "r469",
      "r474",
      "r594",
      "r596",
      "r675",
      "r720",
      "r754",
      "r999"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r411",
      "r412",
      "r413",
      "r414",
      "r619",
      "r751"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses, including due to affiliated entities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, including from affiliated entities",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial expenses",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets and liabilities, net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets, including from affiliated entities",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant funding liability, including from affiliated entity",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants",
     "calculation": {
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average pre-funded warrants (in shares)",
        "label": "Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants",
        "documentation": "Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r807",
      "r817",
      "r841",
      "r849",
      "r853",
      "r861"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r789",
      "r865"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r789",
      "r865"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r789",
      "r865"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, contractual interest",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r322",
      "r329",
      "r741",
      "r742"
     ]
    },
    "us-gaap_InterestExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Non-cash interest expense",
        "label": "Interest Expense, Operating",
        "documentation": "Amount of interest expense classified as operating."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r564",
      "r889"
     ]
    },
    "us-gaap_InterestIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income, Operating",
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r668",
      "r706",
      "r707",
      "r732",
      "r781",
      "r782",
      "r888",
      "r1032"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r149",
      "r150"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of discounts on investments",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment owned (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636",
      "r699",
      "r703",
      "r705",
      "r775"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term Investments and Fair Value Measurements",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r117",
      "r214",
      "r215",
      "r481",
      "r482",
      "r996"
     ]
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "LassaFeverAndMERSVaccineMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lassa Fever and MERS Vaccine",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "documentation": "Lassa Fever And MERS Vaccine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r763"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r508"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r508"
     ]
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area leased (in square feet)",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, base rate percentage (in percent)",
        "label": "Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)",
        "documentation": "Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total remaining lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: present value adjustment",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "ino_LesseeOperatingLeaseNumberOfAgreementsToSublease": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "LesseeOperatingLeaseNumberOfAgreementsToSublease",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of agreements",
        "label": "Lessee, Operating Lease, Number Of Agreements To Sublease",
        "documentation": "Lessee, Operating Lease, Number Of Agreements To Sublease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, remaining lease term (in years)",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r980"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, term of contract (in years)",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r52",
      "r54",
      "r55",
      "r56",
      "r57",
      "r155",
      "r249",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r434",
      "r435",
      "r436",
      "r486",
      "r645",
      "r730",
      "r784",
      "r935",
      "r987",
      "r988"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r99",
      "r575",
      "r764",
      "r894",
      "r920",
      "r977"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r126",
      "r155",
      "r249",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r434",
      "r435",
      "r436",
      "r486",
      "r764",
      "r935",
      "r987",
      "r988"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_LitigationSettlementAmountAwardedToOtherPartyShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "LitigationSettlementAmountAwardedToOtherPartyShares",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in settlement (in shares)",
        "label": "Litigation Settlement, Amount Awarded to Other Party, Shares",
        "documentation": "Litigation Settlement, Amount Awarded to Other Party, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r28",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages paid",
        "label": "Loss Contingency, Damages Paid, Value",
        "documentation": "Amount of damages paid to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r930",
      "r931",
      "r932"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of cash settlement",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r289",
      "r290",
      "r396",
      "r737"
     ]
    },
    "ino_LossContingencyEstimateOfPossibleLossValueOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "LossContingencyEstimateOfPossibleLossValueOfShares",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of shares settlement",
        "label": "Loss Contingency, Estimate of Possible Loss, Value of Shares",
        "documentation": "Loss Contingency, Estimate of Possible Loss, Value of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNumberOfDefendants",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of defendants",
        "label": "Loss Contingency, Number of Defendants",
        "documentation": "Number of defendants named in a legal action."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r358",
      "r396",
      "r466",
      "r555",
      "r593",
      "r595",
      "r609",
      "r637",
      "r638",
      "r698",
      "r700",
      "r701",
      "r702",
      "r704",
      "r718",
      "r719",
      "r734",
      "r743",
      "r748",
      "r755",
      "r756",
      "r760",
      "r761",
      "r767",
      "r937",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "McDermidVInovioPharmaceuticalsIncAndJJosephKimMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim",
        "label": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]",
        "documentation": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r358",
      "r396",
      "r466",
      "r555",
      "r593",
      "r595",
      "r609",
      "r637",
      "r638",
      "r698",
      "r700",
      "r701",
      "r702",
      "r704",
      "r718",
      "r719",
      "r734",
      "r743",
      "r748",
      "r755",
      "r756",
      "r760",
      "r767",
      "r937",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_MinorityInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestLineItems",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Line Items]",
        "label": "Noncontrolling Interest [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interest (in percent)",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest, ownership percentage by parent (in percent)",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestTable",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Table]",
        "label": "Noncontrolling Interest [Table]",
        "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r63",
      "r67"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. agency mortgage-backed securities",
        "label": "Mortgage-Backed Security, Issued by US Government-Sponsored Enterprise [Member]",
        "documentation": "Debt security collateralized by real estate mortgage loan issued by U.S. government-sponsored enterprise (GSE), including, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and Federal Home Loan Bank (FHLBank)."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r940"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ino_MutualFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "MutualFundsMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Mutual funds",
        "label": "Mutual Funds [Member]",
        "documentation": "Mutual funds."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.inovio.com/role/OrganizationandOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Operations",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r78",
      "r103",
      "r124",
      "r138",
      "r140",
      "r144",
      "r155",
      "r166",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r185",
      "r249",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r422",
      "r431",
      "r460",
      "r486",
      "r579",
      "r666",
      "r688",
      "r689",
      "r782",
      "r935"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r172",
      "r179",
      "r193",
      "r211",
      "r212",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r272",
      "r273",
      "r281",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r483",
      "r484",
      "r496",
      "r497",
      "r498",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r557",
      "r558",
      "r559",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r612"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r172",
      "r179",
      "r193",
      "r211",
      "r212",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r272",
      "r273",
      "r281",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r483",
      "r484",
      "r496",
      "r497",
      "r498",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r557",
      "r558",
      "r559",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r612"
     ]
    },
    "ino_NonCashInterestIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "NonCashInterestIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash interest on senior convertible notes",
        "label": "Non-Cash Interest Income (Expense)",
        "documentation": "Non-Cash Interest Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ino_NonEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "NonEmployeeMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Employee",
        "label": "Non Employee [Member]",
        "documentation": "Non employee."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r807",
      "r817",
      "r841",
      "r849"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Abstract]",
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r731",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "negatedLabel": "Less: current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "netLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r763"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r763"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geneos Therapeutics, Inc.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r94",
      "r610",
      "r611"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r580"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on short-term investments, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r247"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain Balance Sheet Items",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r922"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r805",
      "r815",
      "r847"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r808",
      "r818",
      "r850"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r808",
      "r818",
      "r850"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire additional interest in subsidiaries",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of capital assets",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967"
     ]
    },
    "ino_PlumblineLifeSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "PlumblineLifeSciencesMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plumbline Life Sciences",
        "label": "Plumbline Life Sciences [Member]",
        "documentation": "Plumbline Life Sciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plymouth Meeting, Pennsylvania",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "documentation": "Plymouth Meeting, Pennsylvania [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r774",
      "r777",
      "r778",
      "r779",
      "r780",
      "r1028",
      "r1030"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r331"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r646"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r331"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r646",
      "r664",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r571",
      "r764"
     ]
    },
    "ino_PrepaidClinicalExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "PrepaidClinicalExpensesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid clinical expenses",
        "label": "Prepaid Clinical Expenses, Current",
        "documentation": "Prepaid Clinical Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expense and other assets, current",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event."
       }
      }
     },
     "auth_ref": []
    },
    "ino_PrepaidManufacturingExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "PrepaidManufacturingExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid manufacturing expenses",
        "label": "Prepaid Manufacturing Expense, Current",
        "documentation": "Prepaid Manufacturing Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of debt",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of pre-funded warrants, net of issuance costs",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of stock",
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r614"
     ]
    },
    "ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings",
        "documentation": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of capital assets",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale or maturity of investments",
        "label": "Proceeds from Sale of Short-Term Investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock option exercises",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r556",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r721",
      "r744",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r933",
      "r934",
      "r939",
      "r998",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r556",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r721",
      "r744",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r933",
      "r934",
      "r939",
      "r998",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed assets, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r507",
      "r565",
      "r577",
      "r764"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r350",
      "r358",
      "r386",
      "r387",
      "r388",
      "r396",
      "r466",
      "r529",
      "r538",
      "r555",
      "r593",
      "r595",
      "r609",
      "r637",
      "r638",
      "r698",
      "r700",
      "r701",
      "r702",
      "r704",
      "r718",
      "r719",
      "r734",
      "r743",
      "r748",
      "r755",
      "r756",
      "r760",
      "r761",
      "r767",
      "r775",
      "r928",
      "r937",
      "r973",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r350",
      "r358",
      "r386",
      "r387",
      "r388",
      "r396",
      "r466",
      "r529",
      "r538",
      "r555",
      "r593",
      "r595",
      "r609",
      "r637",
      "r638",
      "r698",
      "r700",
      "r701",
      "r702",
      "r704",
      "r718",
      "r719",
      "r734",
      "r743",
      "r748",
      "r755",
      "r756",
      "r760",
      "r761",
      "r767",
      "r775",
      "r928",
      "r937",
      "r973",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Axis]",
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r717",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Domain]",
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r717",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r800",
      "r810",
      "r842"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r357",
      "r518",
      "r519",
      "r570",
      "r576",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r663",
      "r665",
      "r697"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r518",
      "r519",
      "r520",
      "r521",
      "r570",
      "r576",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r663",
      "r665",
      "r697"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r671",
      "r672",
      "r675"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r357",
      "r518",
      "r519",
      "r570",
      "r576",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r663",
      "r665",
      "r697",
      "r986"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r519",
      "r522",
      "r620",
      "r621",
      "r622",
      "r673",
      "r674",
      "r675",
      "r694",
      "r696"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of convertible senior notes",
        "terseLabel": "Repayment of convertible senior notes",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r306",
      "r333",
      "r521",
      "r539",
      "r566",
      "r726",
      "r727"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r720",
      "r732",
      "r995"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses - Clinical Trial Accruals",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r801",
      "r811",
      "r843"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r802",
      "r812",
      "r844"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r809",
      "r819",
      "r851"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-and market-based restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "ino_RestrictedStockUnitsRSUsMarketBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "RestrictedStockUnitsRSUsMarketBasedMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market-Based RSUs",
        "label": "Restricted Stock Units (RSUs), Market-Based [Member]",
        "documentation": "Restricted Stock Units (RSUs), Market-Based"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RestrictedStockUnitsRSUsMilestoneBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "RestrictedStockUnitsRSUsMilestoneBasedMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone-Based RSUs",
        "label": "Restricted Stock Units (RSUs), Milestone-Based [Member]",
        "documentation": "Restricted Stock Units (RSUs), Milestone-Based"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "RestrictedStockUnitsRSUsTotalShareholderReturnMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Stockholders Return",
        "label": "Restricted Stock Units (RSUs), Total Shareholder Return [Member]",
        "documentation": "Restricted Stock Units (RSUs), Total Shareholder Return"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r89",
      "r574",
      "r603",
      "r608",
      "r618",
      "r647",
      "r764"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r162",
      "r163",
      "r164",
      "r167",
      "r174",
      "r176",
      "r178",
      "r253",
      "r259",
      "r273",
      "r406",
      "r407",
      "r418",
      "r419",
      "r420",
      "r423",
      "r430",
      "r431",
      "r440",
      "r443",
      "r444",
      "r447",
      "r458",
      "r497",
      "r499",
      "r599",
      "r601",
      "r623",
      "r1030"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from collaborative arrangements and other contracts",
        "terseLabel": "Revenue from related parties",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r194",
      "r199",
      "r200",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r348",
      "r349",
      "r556"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "SaleOfStockSalesProceedsOfAnyCommonStockPercentage",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, sales proceeds of any common stock, percentage (in percent)",
        "label": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "documentation": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SanDiegoCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "SanDiegoCaliforniaMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Diego, California",
        "label": "San Diego, California [Member]",
        "documentation": "San Diego, California [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SanDiegoOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "SanDiegoOfficeMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Diego, California",
        "label": "San Diego Office [Member]",
        "documentation": "San Diego Office [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Summary of Investments",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]",
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26",
      "r901"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r970",
      "r971"
     ]
    },
    "ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r671",
      "r672",
      "r675"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Assumption Used in Monte Carlo Simulation Method",
        "label": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Weighted Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r85",
      "r87",
      "r88",
      "r89",
      "r131",
      "r132",
      "r133",
      "r196",
      "r331",
      "r332",
      "r333",
      "r335",
      "r338",
      "r343",
      "r345",
      "r614",
      "r615",
      "r616",
      "r617",
      "r743",
      "r871",
      "r892"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r58",
      "r59",
      "r87",
      "r88",
      "r89"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ino_SeriesA2OnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "SeriesA2OnePreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-2 One Preferred Stock",
        "label": "Series A-2 One Preferred Stock [Member]",
        "documentation": "Series A-2 One Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SeriesAOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "SeriesAOnePreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A One Preferred Stock",
        "label": "Series A One Preferred Stock [Member]",
        "documentation": "Series A One Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series C Preferred Stock",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r881",
      "r938"
     ]
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Service-based restricted stock units",
        "terseLabel": "Service-Based Restricted Stock Units",
        "label": "Service-Based Restricted Stock Units [Member]",
        "documentation": "Service-Based Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, restricted stock units (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contractual term (in years)",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold, percentage",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r883"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Critical Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r152"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r131",
      "r132",
      "r133",
      "r155",
      "r183",
      "r184",
      "r186",
      "r188",
      "r196",
      "r197",
      "r249",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r331",
      "r332",
      "r335",
      "r338",
      "r345",
      "r486",
      "r614",
      "r615",
      "r616",
      "r617",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r646",
      "r667",
      "r690",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r871",
      "r892",
      "r902"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r62",
      "r63",
      "r120",
      "r142",
      "r143",
      "r144",
      "r162",
      "r163",
      "r164",
      "r167",
      "r174",
      "r176",
      "r178",
      "r195",
      "r253",
      "r259",
      "r273",
      "r347",
      "r406",
      "r407",
      "r418",
      "r419",
      "r420",
      "r423",
      "r430",
      "r431",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r458",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r497",
      "r499",
      "r514",
      "r580",
      "r599",
      "r600",
      "r601",
      "r623",
      "r690"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r195",
      "r499",
      "r556",
      "r613",
      "r634",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r669",
      "r670",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r690",
      "r776"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r195",
      "r213",
      "r499",
      "r556",
      "r613",
      "r634",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r669",
      "r670",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r690",
      "r776"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r804",
      "r814",
      "r846"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock as part of litigation settlement",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash, net of financing costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r89",
      "r614",
      "r690",
      "r709"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r89"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash, net of financing costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r89",
      "r623",
      "r690",
      "r709",
      "r783"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r58",
      "r59",
      "r89"
     ]
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number of shares issued (in shares)",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate proceeds",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sale agreement weighted average price (in dollars per share)",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum authorized amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r81",
      "r648",
      "r664",
      "r691",
      "r692",
      "r764",
      "r784",
      "r894",
      "r920",
      "r977",
      "r1030"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r154",
      "r330",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r347",
      "r449",
      "r693",
      "r695",
      "r713"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split, conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ino_TheWistarInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "TheWistarInstituteMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Wistar Institute",
        "label": "The Wistar Institute [Member]",
        "documentation": "The Wistar Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r908",
      "r985"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Domain]",
        "verboseLabel": "Financial Instrument [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r327",
      "r343",
      "r448",
      "r480",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r581",
      "r752",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r765",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r914",
      "r915",
      "r916",
      "r917",
      "r969",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Bill Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r745",
      "r747",
      "r752",
      "r997"
     ]
    },
    "ino_UnderwrittenRegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "UnderwrittenRegisteredDirectOfferingMember",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Registered Direct Offering",
        "label": "Underwritten Registered Direct Offering [Member]",
        "documentation": "Underwritten Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized loss",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r774",
      "r777",
      "r778",
      "r779",
      "r780"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding used to compute basic and diluted net loss per share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r188"
     ]
    },
    "ino_WeightedAverageNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "WeightedAverageNumberOfSharesOutstanding",
     "calculation": {
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding (in shares)",
        "label": "Weighted Average Number Of Shares Outstanding",
        "documentation": "Weighted Average Number Of Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "totalLabel": "Weighted-average common shares outstanding used to compute basic and diluted net loss per share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r188"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares used to compute net loss per share",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20240630",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "label": "Working Capital",
        "documentation": "Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001055726-24-000046-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-24-000046-xbrl.zip
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M%@34R;[5"4/-I_2PBX+A7%3C#<!-+Q>B;S<<7 /+>FB#?V_94ETP=9"CQOT
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M\I)D4(*DVEO6MP&< L<FI;>\<"UER5H+'C)C^S!5FQ"X%],7N:.D14.'T/1
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M&\9GDAT8?G^^<>8.K6??^)YUF%&BXIT>631Y4Z<EX,@BV"=3MD6ABNP?ZH;
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MQ*N2RBNY[78Q/#)MP;A3?>Z<.,NA>IS.,96!NG5!I&]=J'NJPPV,=G:/KVH
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M35!D40$CR]1,*(YT2P!PI,JV]C^RTIC?- [F,YB")]A\#"#XV00C-,%+X+Z
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MA[M0E0W$$TGOQ>;P8@T+>"[H[H0[SR9 -/2EOT(3-A*0=@3+&@6NYPN5%TQ
M61J"TNZXL']K9J%.&[C\S0X&$@I6#PL;P;J?&#XE A[R<N<)OHKU9P]5O8D=
M8GD\D05^-P[]P%O F9CV J]A>+H^=TGA6WQ8/6T#WLJ/"=_8EGYW"EQ5&R #
M40HGDCRY\+_0E)'F'G +#S \QHEDAYD=^46BNC31]5B$)$LGTB#H[7AXB$ "
M=(!:V&D0<5G@AN7_(.1U1Q993602H*&)W2I2Q]66WM-]KK"Y^.V O[9 "2*5
M#5C % B$&W9H>2P+Q(C#)F@GB(R*-7J_@>7I!]8L:J,Q"8D.1J8_!7QV7XC%
M#-$DM&VPE>&I$\^=P7/<);F5)M\ALRW ;9\^#'/8C(M%$*98$8+C9H1.%HSK
MH=LVV,"<].DQL7,&[2X;UHQ6.S&%S LD,IJ(Y(G5K@?MDH19U4A#69:ZCZ,I
M&X<VNY_@B \:Z'$#JPC\&V?\V3*'EDVO^$)=*MGXWOF&KT4W%26ADL+\'9[_
MWG9'/Q+)JK?@N$;F'.TU+V2KU+(ZR3T0:7 NY(,C2V .+(;\"$7X:!*<.%X3
MOYH)("%2I"4-:A%>!+9(C,3B<"R%?N3U2]YO.?,P*%<JWI68@*7VX3D,5-2Z
M[=[ V-= Q:Y>=?+>P2?RU7)1 '2M5[=%:6VCOWJ@XIIRDXL<T(<L6B(>+0F&
MS+V<9K:=U(:@.?\1CN=ZCAGO^>L\NDL<DO8=/3W-:+F*4/N?T$5M]P&453#D
M4'T! ^&&PET2'S;'/WWS&8UHCE;*WF9JOAHP/\("J ^A$Q X[\FA\KOC#N%Y
MSZCHT<=WI'?F *XV -\5X)N"6GM;12+LJTGDZ9K=/$Y=+[A"8RCMSCKX2,53
ME1LWBSO.XO;4+:J^=,.Y1=G/5>-)=^[8<,;U*T5;O)P*E/YI2E"T;NM:5V5]
MT)>-SL[EI?5I<](0RL422O<TA&(TA-(0RJGW5HE0C ,0RLH&;5KO ANT-01R
ML032.SJ![&_0<4U:?YVYK55YD&/3UKI_FG&HVJ!UK0YDHZ?+2D'=2--__P(P
M:W 2S-([#69=.&8-#C%$;:6DUY6]2?H&H^J(4<K1,6I_W:^/,]7A]*/JZGK5
M*P]P5)VKUW2J'IQFE(RN1:-D.EI=>E4W+=#WBEB':(&^6HPU\XHO&Z-.$\?4
MNPVKNG#$.D3<;S6K,NK&JAIO[2[#U1JK=7"(D. &S+G7NNX;AJP5S-!IG"$7
M@%9'#Z3I^PND-1A51XPZ39!)'S2,ZJ+1ZA 1II6,JMNI&Z.Z>.<CU7))?K7:
MA WLJ](D]DNG&KCC)-RXJ[2N>X;<40>RHNS+J-_L%,_ W'_%Z'B(V-L&Z*@"
M.JJR O_U]I8!W*#C^:/C:8(S70T' _6[AJQW]C5^N\'&\\?&HT=TNGN/Z!P.
M#87R&ZT@ K-.K8OJ4A19WW+-9F7[6-G%6V!WJ<Z,CF1.)I;-&]5A!\A@T21Z
M;&UJ%36SKZPX4*A44P;RH%<VX:,)E9XW%JVVD/:"14:#19>.1:L-F_58M%IM
MO,1BP09]-K9$=D6?II3N-(YUT3NUN&/J"8?17ECI;3.M=X> !*%HW!7Y@^6/
M;!>QM;*2,VA=]_JRI@_DSJ!LV--YS>?=@UG<$'5#U"<(Z^R+J(T.$+4NZP-5
M-OKY\5L-43=$W1#UL8)C>R-J98_1L(:F&YIN:'KK$.-F-+W2NC?V7NQ\6F(F
MW\"O-)1CT\$?T8Y./V.%QAK6>,;*!S9B.#).-&%6^'CEHCDKS2B56@P(J>&B
MFE$J9].=O1FE<AGG&+%M*>+8K_/X+G& 0C-.I1FG4ELP-^-43@SP9IQ*,TZE
M65PS3J49I]+T]CZ<D_(T?8@,K77=560L(M<[.V<,U">QK:&4RZ64TPQ4,?2&
M4AI*.?7>JE'*T2>J&-VZ9;DV%-)0R H*.7HG**-ITE<O>ZL9J;(%V9RFW971
M:UWWNK+2'\@]M9E\<9FH=9JA*D:_0:U+1RWEZ%-5C$'=NJDU*+5?E#KZ6)7>
MN37H._WXDKI>]<H#'<U8E>KLYC2MNWI*-*Q 4YMA!9>)64=OP]7;7\I\@U*U
M1*G31#1[6L.L+AVSCCY:I5>[*5"-U[89K;(;$9UFMDJOV[H>:(:L&SLSY\8E
M4DN\.GI(K;>_D%J#4K5$J=.$FWJ]AE5=-EX=?;Q*KW9SH"[>"=F,5]DWV:BG
M&:_2&[2N%:TC#_I@WBL[#[RJ=(QG8/2_8GP\S7R5?@?P4>W)G:XAPQH:?&SP
M4>#C::(T?6HI-5 -N3?8N4U<@XT7@XU'C^ST]Q[9.?J E6XS8*5963-@I1FP
M<GKV??@!*WV*F/;Z'5GM[VM.X)FI!Q>/18<?L-+7&RRZ="PZZ("5_B76#C;H
ML[$ELBOZ-(5UIW&MUV3 RD67X>X9.I?$5(XT6J7?P^B#)O<,358[^ZH0V].!
MGBB6?+C=-?1<%4"71-)'&JS2[V, 9R#W,<>CTS\Y23=4W5#U!5/UD2:K] =[
M#(,U--W0=$/36\<6]S!99;#W>N<:3%9IJJ7W7BU]^@76]:H&< W@3@"X[/0H
MP;J_AC,02Z-SFB:E=$$J4I=W28E\G68@_5?H,-'VO4/C0'04CK[E8UC;G4BS
M5!MGR73&4EF?,6G*[+$T7*2'4O$I5*;'N!.5?*I_\6D+,QJL(,UIZ(*,$Z5>
MF(U.V,*A5E8F\&[ATI>#[[+T\!E6]CWU=G,T KD)%X.4IINRCRE5$?PI+-G/
M:PF90N"[KY^6]80D/>#^Q6'C]Z9M.B/V*)Y63?T?**WK[J G]PL,>EC8; 8+
MYNO$4X*MXP0O/#*' (@*"@[L(OCB%?AA=#V_Y+]=.$1"K(\_1U/3>8JF7407
MF/.Y#;(?58HAWPH\@<'W8P![6_K=@?MM0+ZQ]&1:#L<.>*V?O$(<Q"^^Q"@H
MDD87Q J/S5T/C] 2JP;,0RV%CM4/X!\Z*UB^.X]=\&FZ*8UY'(N@/!-/A":B
MA5EX2(!S" T:M!8EIUT!$ESY<-0% "G:W[&V 6N%'9BYA5NK$U[:67Z'>(HT
M8SDA@:7HDQ1/%"O0U78/Y[I1UQ2XYIW';!.'KXAQ;D*?3]TH5-Y.<HLY!+P)
M@_);<H,Z3C3.3U&60);Z.8W3]^94!0SH]./*G,!BWYGVB[GP42:E]C2SG*LE
M&"YO?Z5L*H7 9'(P"' + ]B>RRGG'9 N\_ J6+!9F[5(4P^9_G]8XS$S=;-K
M='1-T<W):& ,F#+IC3HFFW2UL?&_O=;U=V*1P*3^\U?S^D143,A5", #OC$'
M0%*<*L'N%D4L53"9UT64L<0_A'34>MJ5UBK_5J5OTZ3"ITBB*=R-7#JGG^W)
MM3&U@C8V*NXUE2AF:UL)K%;3+%"!+-.V%RF%#2\,/-BF4).X2H%O],.A#W(,
MH!C?($=W,(<6S,S15(AY4D< 4"Y<%"SFZ%6 V\( 1,J_\3NA$28SBE#/,+,:
MG3L,2-6@J:2I6:834N^6X#GQW!G(M+GG3ICOP])!C\7%X\OP'; -67J96K#"
MF0DK\5FA<LJU1\057#)*QQ&NQJ,EPF("+Z0B/!F_$@-279IM!6!UHD>*9\60
M3FV3673UV/+8""%)CXG^XOM?M0<0VGB_7[QX/*?4N\3Z!&B>3<]BH(4@_)QQ
M"%M9$-#Q?<^P9<_GKT<H<PH+V&CJ6'#F/L)K+ 5NE#!1<"99%3 ZG8GE@"X)
M6)8&'A]5"V\$N3_FRP-F<C5$0"2X@;3 '#_T<^ $%N2Y0^1#C+ [M65Q+^Y+
M+C]@WP("-[W<@4; GKEC9ON \H MH"J!J4BV!3QK9/I3:6*[+RG@9+$6 $(Z
M+<?;PB4(@,>4"1_#!8O<6</7'/LL,9M7?/$+'_SK^Y'"G#T-/W\<*=4.J7,"
M>K<;Z_DF:?3!CD_AU!J=IXGJ)# L1GQ7\MW0&[%VJ<5<3Y8-QPK81LCJN *E
MM8CA$&OELY$+&#D@4V[TYFX*]&8@*O-,H+!<+Z,-L$,K'<Z5WNX>X7AR(^_H
M>+KMR*H7'IIE&W[99*<AA+>AY\'2N9O_.US]WG9'/Q)37.6N #@#-KX)Q&?X
M+ 9F^QRM"R\$_14;0:+]).Q^Z9&,Y3LP8OV<WRAS&L5J#'_']6;[L1SWW>-H
MRL:AS>XG#R!Q36O\\2<0&S"%&V=<L$]DC@6;U9:W57^B%-OELHYDZ8CO-"+,
MC Z5F6B>GU9>Y+&+<?JX@\S!CFMWN"U799*Y,6AWM=7SJS=]E**UU36CL#?_
M7.M7NV/5H@:K'_4*IQB?U6A2%(]2)!DK;&Y-$=M9P6"G.=PU"8X</BL\/J%5
M#JN#9A)$TF4$7Y$%R(18E=Z8;Y?TMRWZ\[W:BN[BG M49 3$;P7 (S5&J"^5
M(RE4T*7IBJSVN_O-O:AG.G.#?1M@7W%3WP-@7Q?3^'2E(^OZGM/X#M=&X- 5
MW"?%$CYW?BZX>L3,F]KMBHPZ8T%G#<YM2<5 4@&%4.[V=F;43>ED#3%I=2?U
M/6(2%CG)@[XFJ^J^&JR=NHIR;VG03>GASJ"Y'(I<S=NSQ!BY$;G_<%O2[+>N
MN[)F=.6^<93JPWKKZ@TE-Y1\#-EZ"$H>$"4/--DP]FQ7'YV2-\OT71D:V" )
M6*SR"FF/XB79P)FFK'E4I<A6$@VZ$6FP#^8"-PB'#Y]X(1M_MLRA95-:2'$T
MJ-OIK(H&U23\$^U/FO,-4AS(Y%M,G'5-#*B) 34QH!K%/YH8T(XQH+V'6$ZA
MXGSWS#%+*C4$"]^;1_1UZ<*OJFIWS?"TK-)#:!;EOSCCKZXSVDCKC?0@I76M
MRWJ_)ZO]@WOQS\LT?=7&Y^LQ+]=,6=LOM:D8".CV>G)_]]&73<QL#Y@B#$;*
M/09SBM(4FXC9]J()@?EHVIA^OZ'[)2(-K77=EPU=E?5!TYWV$G%G+:/='G?T
MUC5V">O)2D>O">Z<>YI;[1=X.7EX/&\CY]=[,]Q#$MZ%\Y35\HB' G(NX2WT
MM^480;=#V4_ >7#:64TF!1XYP^["46NUN#HD:AFM:T/6-57N*SM+LYH,H=S(
M_,[.$FHBPP<"S>60:"5'66%T<+L(<;>#:5B&;&BZW#/V/%BPMLD>#4DW)'UZ
M(_%@)(V]IL&(U'MR3]^7$5FCK(\]9FML^:AC9T]@%9,D_G<3UZ['@5E*ILB%
M*>6XQM]R1G8XAN7\;>NT0_PK5W[QQ73""3PIQ$X'.V4#=SN#UK6JRIV":0>T
MNTHKSZ19H6C=_\J->.4*CN9MER57 3+8\)<L><R?LQ&VS+(7,IY@5-PP2R\E
M-IG+>RZ\$I1_,WS+(9C_>30*4,KQZ!^>Z001JUY4QAD%L+U=EO4N<*8ZWO<Z
M!UNPVKK6URVX ,GMZ(74OR5TJ!_-$RZ%NE4"\A5TU\CT8%C56V./I% Y77##
MSAR]%9TYDA2S$W7B,*IVXL QO4EG[7PJHJ+ENG# 9P5=.%R'!#[J#_C,;5IO
M\ >OANL1FU_0$]]9 >@OHPW86QH"C\RQ@#J^ND&JPV3]>^TH*CI\'>D3&WHA
M]D$"G1/8KC(@QO7%]$932>&?R)E.9AB@M!EF>6(3*^O9#)@TM\U1W$BT&I-6
MNVM:OB*&W<4MHS[!BVYFJ'M79H)ZU9;UQK%6UFU=]_H%2L@Z"?/TY+$G@C]H
M'R-KCB/6: 51N[;2_<*B0-2N.0QM]8;O,-6/^<$W6,$C=I(=/S /$P#-)Q;O
M\DI-MFFL.("R!1F'7% /F6@WK[/F/O@[KBNF>)]3O$,4/PX9UV'>()%@.V6U
M\QLQ _I=^>TM[U3&^0.UM0+[BOKQ)O3C3B:,]QMSI;]"8$(3BUKV^H$5A 'O
M23<,%]B";AYZ?H@2&"[]%L)J%%V_D:BO)I%I,A51NAD1(B@#3:/VSP ZN&S<
M!NZ!7='<$6-CT:@.[XP708NL2,6]8MTE*8[@;_L$+[OS<0,C=C_!XZM,+& >
M][KMLLB\H(TS:GI&C'@90SB&A0YUE<2$^B$8UJ(1<K9#7"85WQ(4$.?I Y91
M\SR?S:PKTP$9C!TA$?? 6C(]ZD L>#T]Z)'- ZZ%*W%OR05<B#TG3<GCN%J=
MK1R4B@<E5/QW[(4IX:9G:1($7.,@==)23A@A:<"2?4>M.:?, >5X9EH.DD=%
MRNBOIHQO8$<NJ!GB_22E5FQ#&BK:LD9[L$9L)+B$B# );5L6%A;N;AF5SHV2
M/KF<#_K63VD&5T]]B;A>UN*4.4C2Q^VQD?OD4'/QBB<\*':U)#WK.22%H^(>
ML-+$5JU5G2PJZ,M*KU_L9:'^HH+XA1="HB[?O(-H$*$_" +;QJMY5]:E2W!G
M^,B06H?2XVK7$QX/&?N4AG-@\U)TW*=J[4ZKF7I,M.M=A71:+4&Y3TK0.D>B
M!,Q>5;0]^1L533G2LC605&JO<-D%WI<-Z3FFY8.>U>;R*+5?; ME%._W\,>T
MU8K!$NMJQ8BU?$+K66?,I=:UH-U0J.HT@6 SC]BKG/R@ED]^V-SIU]-BIU\S
M+J(V:VG&1=1D7$2IPU8[F2.\5]41_ABXHQ]3U\;V^Q]I2A#*TE6N<;1@EUWC
MJI%WC:>?+$9K2?P-6SG)^2L*7JQNVK4ZWZN EOA^<6N;?KX3=Q<=.6N;4XL3
MI^.IG148-9%/N@](%@Y>\L,9]?O/-=@WPV#J>J3NHE)B^;ZHPYF)*-X<R(=Y
M'@W, EB5]Y]/AS'%5R*6^6[3R,#1NQ\,^NV^5KGY 8BWSJ"[GSX#2EOO:7MJ
M?K"WC@RU7)3>5C2C;HO2VDIG]:*:-A$7M:?MNT-<YM8'Y]D8XSX,_,#DPW](
MHE5IC'')AWP6IW<3*RVOM*_+':EI^]M\E5X1]89,U:X_&^W\U4"O%OV" (ZG
MK .]Y;8/68JR-#>C@7,K_;4/S*,YS"O3>0NR:/C+Z%T/IG?O\9CO'_C"Y)%Y
M3VU_=39/V6JTPZQFT+K&)G+Y"IR\XQN#TC0F^H"#+9:I[MRK(HO'A5<X2SXA
M/!&:50,#6J=U;70Z&!@H# Y<9G^B!A</AXM<?ZF,AYAZWI4'AB9W=R\.:M#P
MU:-AR@JLC(MJ@XL-+I;C8@7%;W=<U*@ K3?0Y,[NDTV.@8NU[WI3UZL:P!VK
MC=%V7?1.;+L^,NS:Q0G^5GJ(0W?[,685$'JKN5K\QJHVI+:F/J5\2>N$_O9+
MZA[7K+W ]G/%HK'JF>ULOAHXK:DSV%>'D!IT^F@0:G>$VM(&[37(U"!3#IDR
MVGL>:?JMZ[+"E 9ASAYAJFE%&R',H#X(TY@<NY@<&P]]VK@!P)K<]_QS3I:D
M2$_<O*] 5!I+"8;I*!RE%@(177T*J:[H7Z:';3C\4AADMJB>IA-,U&+@9NY9
MMJ3T1>E=MIN [6)3$?SH/JH_AKUS#E&V:^F-S^):Z\_67Z$UMH*%J+?&HD9,
MYY54R1RZS^QM&YLNX0N*G@2OD1!,/Y-*CB0SU'UQN$U#YR$R0GD.Z!M<FHN]
M-U\LGTDSQ@*ZV6.P&H]Z(?CXP"&#+9J^'U5T2XRR@=]FH8 55]Y8P('&:(T9
MS^#&KYCU#%_%==J60)(HD[5P6_!_X'FB=!PK6:^H%'B.J(BEK]F-PBO'6#,S
MII>CGXM*6Z+^._X4MV?F&_=4*P[E;/7/T ^LR>*W.F H$=U'+'+. U&:(A"Q
M1A; "$ #%/%&>-: S0"3V-Y=V_*BS' W^NL<I(@X]Q.QGGOO&R[ZHUC& ZXB
M_M(7W_I*@2C5.V5FO"SYX?!/-J)N B,0?R:6AH_QB B#>=UT$8+-S 7B=@24
M,16( R8'<#*P^\"R4]^),F,@1(GGQDMO O>)4;?I%RN84J\*<S*Q;,L,!-F[
MO!=U$'C6D%H@H.L&VQJ\I7<[;I"<"%5KNQY=!:=A%IVF(&X /[8I"::P7FLV
M8V-\H[W 0\5*4E>"GU3A(SU9S]32"[@2AX\? I[$[\2'B<V\N*$])F8Q<SW\
M!K"F8HF\D:F0U].MGPJQ(.4[OW]QF.=/K;DHDR^JD=<54*;:@[P^]?>E='A1
MLP"4GLH.S BB-- XH"*0R*(.<1Z7ZT=8,@*(/'$<2< 6OXK9C,,(8&Q*MOL"
MSX13F,(^<8I\\C0\<^2@/T% ^MOT(=#TPT)9Q<Z-Q6#&.D#)4*2QN8@+0V _
MR$FR8B=-D=1\@'DS?P6K;Q?V%)3AX85T.S6!K3/F)-1Y1@7^Q*[O4;P_\QPM
M:EFD*EEA2BEEO(.!BPS\YOL748,3JQ@'J0DS4(:M+]'*EV(B@*^T=D&YQM#T
M&2_%>_QRRCHVZ1%PW9=NGCS&VSREF]W@"2Q?$/6^X>P=F0EH-))/%P$IDPZ'
MI2Q).6WJ@=&S\++X01-1Z$]=:GBQO<F+_%!X9'0SO-1,MT>*.]MPT0WWA'.D
MKXKUQ]WR_GS<K,5UQR#X8OZT9N$L<=INUQQ*UUK7&DXH7=/PAB1UT5%@IY]G
M"[LGDM"C'D$I /.&,_";%=A<!TY/(*)6,4[458IA;R*\A(.O,OLM[BY%\#/C
MTC1:7-0OZ'YRXRS2.7DK6\'H.L"J %*QE'OR7) <' WC!DBH,?"^9@D*48NF
M8.JYX=,T#[*DVU(1P-O2!]X-E/>.P=X0F9X0O.N,2"]=,H?HO96]+V6-RC*8
M&:_O)J*+KW1,[F079[".%?.Z)AMJ08U_8COE:'0U"'F[(<Z24&\ MH@*0$R^
M6\;N,G!25T/I7^+E-_S=I&ZO")7I!FI8O?PLM<10H 8"H1U016*:/3GI=ER5
M&^AE=U7"EO*'7]R1BVZHS*)Z@ /MLN$C,8-*406UE.+44-#V=7>"Z)V0(/JM
MZWZO*VN=?!I*[0BB=T""H+9<6K[I[.$)HJ07W?$(HMM!@EC35)I+;'BWY0?"
MU^-C5)Z.F^N&O"$@=;,J]D*1*PBKA==@#[HRV,^Y!6JQS(N<02T.G\#,YX7+
M+]S.L!S>T:1,L)V9I5!!#"]Q'5$#7IGOE'ET$/4^@];/VZX]L@!T+4(^TJMN
M7DQT_GUW:9;/@^D%BT?Q@FJ\IPMF?L_HR)U^ =F5H%"ZGR1A6M(_DAR7DMB[
M'R^:>DF"/CGRK"%W[I"[55%JB!\5_>_<Q7$_YXT6D5"^,:!.:Q1$&432[X #
MY6[W>A(",IKW+B 9GOX'X *CP/700^S.4_2N2?<SQQJ&OG3GH)(-AIGT8,-J
MEXP]C3Z-#;.XCR+JLIR4TCC%?4)IXD*G$&\BSC'0Y> F:1#!6C1:0,(H^@()
M$2S(UK?'W_W6VY2_D+Z^0K-Y+.Y&5Y(/%EAPA1R.=\.TXOV):V"=;#:WW07#
MCEKC!$(.]XB#D.*^EC,\^/C$I!=T:,_1'$3?_H(#2S0KX<>XD!2#'R*73BF1
M3*H1XD_"1XK\AAG>0@:G\ $*EIH15-&Z0" *ARY*8,Z&PME*#U\9!QZL\:D3
M8WV/^'&;,G-OT#OV1-SM_2*YY(%WYB3^S'7#^\FNJ5A==!+*BF'(AE%@+0CH
MSNW0)ZM4_!U#TF-!Z#DB&(2^=F3;^&\<'E([BE%*R4D7X(S'A>[)4#5>*-0S
M:@2+RH,IZ#12%7@W6@\!,&$6=E7EQK2@NY0'.7WJXDTBG)3%N9N@H*U*5C2C
M [,J5NB=(V'%LVG9J(]]<CV:V% 9.7#V,):8=?.QFC(!;D8O);_7),1S$/RU
M@-CD&@&/.V63SK\^Z3_?IZ8C)/!7[(?K ]O_*AQ*%:&I ZGU^W*_8!9O!$W>
M86Q!8><4PJ)@(>Z_=VBE8PJXW9U+'[K=UK7:,X"EE"M]Z5T*Y2:]6^ A(+)'
M8"6P%48I1R A&#B-$YJ)ODG5\%!Z8@[8D=B-&H]8 IGDK>GBI>>;6FV+>?3C
M#W@O[!YL6,L=*QFP@[P=O1N'WHL+NV1. FLCZO:*'@Q_.9F%X# U4:\ 9DWN
MWTQ?2-) $JFV=I]DL6Z[1^%_ODW>_QU>O]DV>[!-YA1O,O8TBX.,#4<?=0K4
MRT3(2NB%G)ESY5#3SDZ%.I1(6I<Q5U^NBO/I=%56!^4.KA*N.@R1%_"7)RQV
M'4?:.VCWSX(Q5U'OR4:G7*-;%ML%*A&GK#08EMALD1JU!1_-=<X].A\U.L?@
MH]JI^:BAK.2CG^(&A62)B^R5)77-<4&6>CP9AF.#,*AFYI@5881,9%: 15$;
M29&6]H2HXG!+$!Y@82*'Y7.G(S+PL^/4]P[/@1!^"#7#I'\!Z11Y0,8Y#XB9
M<1PD[H%Y[/YHX1/!G!J'8M 1@KKU-LYYB6*L49AZ;/DCL-4P_\Z+W!WP:CA_
M=/*&\/;%LOM#J/-@H .C$<E_E-.UPC,"3#3^?<X\PDG,V(L^2V52Q9X.."D+
M%@N(S/,$<2(&0)SZ5L?;0X\(YE%PWWSL'Z'O**:?@NU1? 49X%=HJ/TJ&V%K
M2P!*_6QZ6M=F+4U/ZYKTM"[OOJP6=E_6"KLB)QU\3W$LA9[4RJKSNIX-)W>?
M&N@^7>T\/9P;<=VHPKJX$0U 4$7IR%TU/R9M5S=B3@G:PJ-X,#@>VO8UT*/8
MD=5>98?BD4S?=9#=N^EK=%O76E_6E/Y6EF\>G6+W4NX;:03_#3.9"MQT6:/C
M)X4)^QK$PFV<<JE1,$<7/M67),,I1S_%T<$;'@V*8]T$5K73Z:T,!K?HBNPW
MK;<\P"A,*G3_Q>#. ?HDBDOY@<'1)*Y*GA("^Z.!@!ED*_-N\EN4WL:B9^^$
MOVY6[?X)'Q,>>[*Q)>'GT*>2\RMW-]7Q88T1=X,)A$Y\8[L[DWHG=R:M=,KG
M:2SOOMG'2/2>L6(D.C)+_2B5?,6#8/IMJ>(DF(^FAS,]_2B1,3\0!:OTEIFY
MT<]/?L&9NI\QNQP>Q<M7I:U&OO!G%[RQ\LB7Y;T]N+8U6A3L<+#YR)>3%E.O
MY.Y :@ 2S!RU\122\DR+'$WS4+!P\GU%:8'QY9';;DY.[$BOR.7;%GFV,BPN
MS;_&2?HA?VR>Q976-E-&7>^M*$_&V:P\TRZ]JJMH5=$*Q))2SQ=W#,M@ TQ]
M%-H<_R(0;#C-4L<"2>8(U['CHI1<+I)=FQ!8>ZSZ8-F$."5X)<#'S\8<81$W
MN5]C#VG@,=,/8U_OC('=.TYJF5)'E7$&<W4LLA(\-K%9D<OGY!KD*."5]7,7
M_2OH0AXCP*B8$_VYHC)V- H]R9JD<TL! MPO#4SLE-XL$L/<+8Y.YRPU\]*H
MN(S9I=5BB5Y<*!5?RVF;[QY4#0M4/3Y]/9[4B6.DGBTW].TXOSAKODAO,&@0
M^GXJJ=;@2G74$@#5(#]B*BUK<A6OIR5PBZ\C3==D#)5BL>A7P#/,Y%R5-(M9
M']#G#TK+MY+. RE;5S"?"+,]1O786'+'.2IW2/GBZ9E*>O&P6"6.,".%+=%H
M[CEFI,W8.'D$LF*LRTY?[*4. C94L.LLNY>IQ"VN>H^ $-\7^@GS34,6.(
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M*#6;6PXZO(&E1:,4'^-IFA]_\CG)GSQW=DM./EI\?BYB?@;BX")&8./D5SZ
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MQ^:NA\^#3_"RKZ8_-O^2;LVY!9J]](52BZ(OQ[ Q?-X3MMKDZXN@ PL#;AT
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MANFGXQ2JE#Z18"-I$WR!-NI5/JXB<RG_DIM:?"G\0J[T+.UJF5UD%A0)K?3
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M</FIMYJV+?!2O$?\,7+]@%);0\_+-EC'<E3QIF(0R^2"P0)L7CI0T10HF4&
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M%WR63^9*/9XH-_,"J?+_MLD $^LJ6*U:T*GDM-DBQ<?ZF0+@9^8<3_OZ;-H
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M@N68I QQXUN6/@D0I*;<76D1F[\-[AC'@'H18/D]S!P10 A;2X-T6]%7\D6
M@EU$-4=$DH(MBY@L(8E/D1UKB;6U,N#R&)8DW7A 9:K*L'50;5J7U$QQ-VJ@
M\1;>PW]8A*_?JI9MA8T]8P/4MC!I!;UEB$URFT1X"091D&6>:.\#N!\1H@?Y
MWH?!.2)W#+T[["><W(6)]PE^-@D&U.\:%'@?/A_LD@KS7[O>?R69FMYZ_PHG
M/K4W'(61;0W]&U@%\-=-3I AYXBDA]K9&5I9QD5W$61PS6+[-5P@%^781VM!
M=V'6-YGZ4C-"RP168[N=$W[Z;:A&3D/T*T)53C7\?CP,J.L0PJ=$P7U6A-AJ
M-%)C00$JO8C8B&8$B/T".R!P2V&&;?@(L]JZ(6'EL&<63]' P"C8=02)LR2&
M[^99\.:'HU'F96A0Y,"IT%H/1R',">P&E2.(VC"8@()#0#E]=1M$(ZUY3HN<
M$0KE5*6I![8[I#FP$PL^;<*7,EB.L"S0#]-8S;+__%_'W<[16T*ZJ4Y1?V>(
MALX=,652T]PR-WU;S0:4E6091.,B,>YUFE6/B.H?RA \S%;)75NB-?11D,>"
M_+K8:92W!F4&[%FLQO!38M2X-08&$'XP36&NX90MB$SE><3H.,M<%Z>OYY3@
M&DU'OP$1.<XGB D"#QUK;G]V?E.])SO-C;809-F*C3EZ"SH^O0=;R787F%UD
M.1GT5Z-/8D3A RL[@K%N?:\AIE5KB@EG=/N 9BQMJR+_P3(K^AV3PJ]&-WB@
MJR\/NU[M+[,\(IC,XI01L"@H)X,O#F4!%_&2(D>[CZX?4%98:8W^]\Q!=AL$
M:4J 9M,@9$MR TCB8&\IDB!ZP-L$'(X-\_+%V/7.N2F #>640C@EOTNOZHK(
ML'E1NZ-*B*$2+>G-]<X9I>#&S)'SX:6U[.?D"OG9)_11K$)MUF]UT'GUT]'A
MGK]WW&MP7!D"*Q&7ZT_A#30RIL2WW(U=/ZUF55W-X<Z@LH1W+ $W66\[!4D4
M+=#;AG:ICACZ68%-DX>HM)$FIE"CV7URC:SU<@W#% RFI [IV>NT7*\6=J1]
MW^=&*5C1XWW0??43;7/]-NF4;FG-BGJDGG<5;VVNZIC!B9M@-(\FRA[S=OH(
M3Z)/(-4"<YC!LHW:";JDHT,*XMYB_:,*1EF9V&!09(()7E6[^HGHAJ45CX(P
M(G:;&"#ODGH(ZYBF!>G963%%-&R&&:_ ()JWP*4 A955G&F"\(&,8HKK&. _
M28U'MV+,UG&>)E%5X7R82NP<G(;]'N,\&=P[57C@\*:?57ZOE%4:]VA*I\6X
MR')]$ZWVN>@BEO12@FLDK;B,8^FHA^O(AI<V+KM^I7W[HMVI<Z-S%:&1HH3_
MP-&=W>+Y4&<@NE9D715]U)9R-L"R$-85I.9NX5U),N4DBMB]=F;!5P=M6EC!
M3.8_?PXFTH?NP6!FH)*-A-GHXQ-U2=M'L,F3,"?SR/LSP=-"AE0@0#TWGT_D
M6E4WB;\WK>[=,:TE$SBZ1\GDTA84B .,WB1WX=!"TZ-+#<,38DHO/EZ.JXC!
M2;J1(4?8NV&VB0=FE )]8-97L!3):VXDIC/M[31548CPK'!^;+=RC-<Y)(IX
M/IK&("P]3:8)2B3G/:4S7_6\>4?J2YXJMJV683/+4LSC'G]WN?96&TBO6I(*
MN;(;Q'!2.%@L)' H$.&"F0:UH==$)D(.KE@A_N\WX7P'0*WAU&EJ<N,8/DB(
MK5^SNHKR*C>0X RBJR?GS.E6!62<Z@@O^OFCTGVJ_, 5_65C]3XIHB%!+,LT
MA")A7=.$L)OKRHNC_ F=+UBU>^OY%(CK&L<5)\"D$]V4+^8,& [_H\*F_W('
M/LV(W=>_$E]<Q(ZOTFK)D[&B%Z.[DA?CG-5"A% AW\_*_@O*;>PN<%^@BZ[!
M+0J*JHHT:PQ3A@MWO:^DA5R!UEUN7-)R5<B@(-+ZLQB.B3S*]\7=<Y:F?35
MZ\*TA,&C*'5*J7>P,;0GA#"7\F X3"<#WFS2(FA"&8>\1@NH<?V8VHJ^A]]_
M^9_+C?8T&'.GS(:TJF!5=N$L5G"RW^D3)D'AWXAT.L;V"S-\)LYGE0Z5P1B&
M 5,*=\P)'/VB8G45H[=F!(0"9F&,C4'Q:Q\CIO(U2^<\&2L*$A!O=P9"E'*G
MY9'T549M,Y/'R+PVJBF=&D9VG7 .)HL,;EN,9&HF,7."!5HIFO#]L=N4*?4%
M&3(()6D;I.\JMGIBLW6@&UOH%NKX2C,VLLL_BYBO*S)J-?*=SNS4^U.,7;\Y
M3N.S):VRW'<B/AQ?X0&Y$15N W&@!40P57G8J#'JB:+^9>,?0-7AYF5$OS/"
M'?=Z.L5^'^6D@9(<@ZTB*N(]8ER45%NB0NJEWY8I,"\QW6&9^JK4YKN^BTF8
M$=,'8\!PU#S%V&2&O6WDL(L886] A( .?FL%?WF>2*M-Q/8XU.4L<9?WBI0,
M3524>K[#&8+V^NBMNXJ2\<S[.4QTIS7-$P+3.:72+3A)Q\!G_N(]:=QC%8^#
ML<33V-8P?=R,+X%D6$)MY6 $\N'T%0YOK!.@";XWG^LW!<W.[%[1,/B0X1_;
MG+[Y.7TGVYR^;4[?-J?OVW/ZUC%[KR1T?"Q#GA:Y-EE(+%82I$4\I0&V#T6A
M6^*E(XI,5"VG%M7%FJM4_<Q[)EJ7"'GCWRJIJS<%-<Q+6>$%ZQ:$+";NH?_)
M.+NL Y@L)\P7[&,, 3MW;9CZXTHS:AXWI/J/8 Q*2):Q9@TR$ /*TC+**!'D
M_(,]E **NC!GX4\*O'<7CI,T*3)J#85A-/R-BD:EA\U9ETAG#;=T16O1&CN;
M:S": B^^='I)3V<P/E2+/KMX__[B[//U*4P9E3S8]0$Z7;Q3JU?+/78^Z4L8
ML)IB*.LLJWW2VDQ[2D[=7#*7-U6-1(YH9?H*(3OAJ7-"!^NW?J,5Z8-J/PI"
MZE:L[3)_OLI?-DU7,"Z!9<)E'1N_*]S_49@O8Q<L81'4U>>25[+_IQJP5##5
M-M54.U3.T2.5%E$MF@J$>J.FN:'43J-X</7URCMBN# 36*=*)3)0XD3N[)N9
ME03TF4[U)2G1IZ46RM(DDIA/$=*HLDX4K<:=.4I[-#;Q4Y^BE:Q*1^+)KJN*
MV$[UMH=D^[D;N&!+8&2[K[O>E=,6N'OBMKNKBG$G8I45$^JJ;==^I4-C'3U$
MA2EAC;@VBMIFNN@-["(Y=B?)7EKV=G"=V;PQ&A2(,-MJ$,T:1),W11_JLHJ$
M\P885W[M4*9<]0=&@E^J J.ER2KQV@]TK[)U7,]\UQL)!QB1+B?\M\P$I![4
M+0)B&Z*<O6ZO$I:X1PP)@8U.A8S2,",_49%7"G/"EL)6M\('[F^L\SXR0U<#
M"M9E!0FKTIRI)VR6 W%&5!QC6[[&0Q)@DEFNGQ\#>:;LAT:!>8=M95%RA#GQ
MA6"H_ET@X[#9P*;K[ 1_/PQ'(T4Y;*::R<'!\*4?;"V3&+<6SG_&0R%(%# F
M?)9RM&#R((_SS)Z F0>\?510$@YL8C9"'4FG8'&U =4[V8@G"I,1LSR2V_#[
M6[2_8IU[,M-*!@Z4%9@(PL/P'E,]EE.'%0QAOIERZK&<W?Q[MDP]EHZF<4&6
ME@]PT":/*:*L )F.-E_O;SD& <M#;@W?(18V;(8O4Y5=*,\G55R9(9DIEJPN
MN,UT4&LG72NGQK>Y)=6QIJVI+;SB'^G- 5('-D>T3"H3.;!M)IZMO)B&,5T;
M8 ;A73@LB!"1$F()30 +QU)L7\+3?2<9D-L9#Z1.>Z5S<ICQ:M5SYK!6\*LN
M)S3;H+'0P[+8=7/2>;6P4W?O&=AL<YE>I[OKK=9T^0R[__;)CW6G3E-@'DPY
MB' 6)<!-&IHM'^S7RTH/]G'L<@OFTMA6&<YJ\&;5GM%-GB]^0<-KN_/\88LE
M8"L$WLN)^M/A'1AK"%[T<YA,RP5YWDWQUVU2P/W:];WW^? 1=9OGV(GY*DY<
MPY;9FX=.Y#D$)ERWY@!@W]]J._H:N59W[ZWY%?W=>?NF5 (FU6_X5C2[B+$E
M8D4<T>0[WNN6!WE5U=?86>L7NB5D#,(CH>2&WY1W:@PW61BV?18?4%]!F\K(
M-X!;CP\,01F)DJGOA-N4V(B3"6:& ]W^I1K9NAYY@ 5.9/=<?KS:V3_>VZ.-
M%^D"4T]#K-MFM>4,/@]\[W,0W@<@DGY-0&?[5R+)51^"05!XK]T0?RGV#SLJ
M^_8+""C,N*;A]([1&+V>FZI,M@:]&Z9SFND$11T1[_ )$;&04JFS6 <EZFKS
M&CF[FW R;32CVN\"K7EO'"5]K)R^11R9'JA+8S?%K28EX5(@48HA"4^9[>1H
M):P>;)HX5D-)\Y+L6]*X]-NY=#Z<LGZLSX"%-58GB':&>A[I=YC*3<_(9(4>
M)$<NRQV$/1S$U<A;"@&<H"T/0#A#%/+6"]IU=L[F#H/:P4JGI!P1U@N^77;4
MU(?1:M#H<XG G1E;F=5:6(OFYLU!@=+IXOJ<;6!!7"*ZC %KA NZW:#])"DO
M5+;/'ATR >_LZO?+\YW.B0?*I4J!HX[!LO7Z28+)M/H>N9NBW]@\)K$UG$IR
M3_E9L H,<A=+LXNU1"58Y)F&/8G9:6AC.@WWN')ZBIVX;L5WY5HR.=6*$YUD
M(#K#04W>L,9NO'>2D3HHLAS=WCK<1:ET2GM@G9SW)A[$1WAZ<^9]!JU]X!WO
M'>]ZURJ<]-%JY:(A\K7:0Z4;C9B%XQCVDU +>4H[V"B)B@#<.RV70:OJB^ V
MJVHZFI<P:"PR37-GQFSGG<I0<80[]FXQ,F=3W/C%-9$27&B9FF";58@^"KSX
M F*Y8GIKK[W"N:R.&XWYMRF<>)Q++[-KF<+*B:X'RR2Z/J!D>_^E%H3]0!J@
M:.>@DOK5NV/DJH/Y^9*Y#+6;RQ&!VNW=;2_(;#RC@SFESM]P2(3=NO,72+2F
M>LRCU=I$='N'+S'+XU<_?:S#)-9K2/6-%VIA-C"L%JTO1I5>2]&[JHTZQ61*
ML*: ,7+R.![N.BYL69.3F08'J3I'\^Q.L"(<F^Y:&W_:]B14FI*F8*W1USCJ
M*[MYYIM7;_SGX3K-CJ,GJGQ:[A#81&\DJ-=VKUXUFM_:XN[L^S70E;(*7-_S
M=HO9/#O?8JX;R4Q$O__R/SN]SAY<]VU6Z-R3[^YMLT*W6:';K-!OS I=Y 5_
M*4Q'L%3//YYZX612Q)0K%$PI08!\8]9E.%09<")FO3GZ<YB+3E.U,Z#2W8P_
M& 0$<=&?>;]^^MUW'8SB0"JF:-):9^-&YU>@ZIB'><3[(OHF+)$C@S9B]P #
M]&@I>RV)C:2T =-KD'QQH;!G_>G@%L/8PR;#[ 1Y>P,DE&T2$JD,M>A_%R$K
M5AC&Y#/%HFPN]Y $LSSXB@%N/ET\;7ZQ]DTX2"$AC)K#K<M<3R[^!+8*RQ.3
M<@U\65KS7PTEQBWJ@W$AXI;D9$B6!R2$;%UPBRX?H+HOBC/P2@7!L"?H^6PZ
M[S29!5$^LU"G!E<F\/*0E-(I-R"BT#X&UX$Y1%ZL<B^#4]%XYA3@=I[DDA>^
M/CSK*+G?X7_EB3:@ASNY IW6Y[]-%@1.C[RQ#(5F]P#>3VD.%'<TR8M4MNT"
MNNHK.MNU^VI#U09/6\/B\1Z0FQMW2CM&:4OG1CN)TA?1]C7O\"?,!1\N;C]V
MN(>M!9N[CWFDGDA]>)KECFY(A]&^$4#LOA>.&$,&$T#S,!+E<QJFM@K,'%:0
MY0@S3U_+9],@9X_]G3(F:<0VR5!S79,*8R^-/8P-XY9UO+C%IO>C^_*.YO<%
M$G:)Z4]GXB3^ Z[CF3B(+[Y*N.(TR[ WPO!S\'55$+G#SJI.EN.7GW,7+U%S
M,ZL&OXO.+&Y@PHW^._@W+8%B9*GXQU?;HY,%T&7?O$ES75*'O17/='_O9>>[
M_^JG>!D7&BIZ6!X=4+"58QID+P!_ @-\(B$[&\9J.O+576Z]->1M*SK<SI(@
MLB7:%]-PJ"8@\#ZE"N2)&F*J&>@C<7(G89KU6_#2JB\H_G<AY_V6'6\6O)UT
MFK.+3Y=^0X.14E8=I2FS3J6]-K6D!9N!_#[(LL ;J3L)WGVXN+ZIX9X$-DVJ
ME!8@P7B?)N8$M5&Z/(KBOE]N[W:XV#O^C@4;JNL/#;(<'KSZZ>!P0=#( $]3
MOFJP0"W;[RR>.>MC>2+3EH7 U*\E, +'<V[#(HV*FT&*U$LY?/73" ;;06VM
MIL)1->!0(R"85(PL!\9(51.V0E]R,"1^W"%2X7]W*SD<F*]):0V2P&#+6-PD
M$AM83DP'(JV3D/0CBBI!2E:,( )$KUI!S8!6+QY=O2P#U%22+6!G86X#':T/
M!>8=-X!34YUL#/JA&QPSZ=LU+T,&9F0ZYGY/3;>\BOT$A\A]A,#HG5$+P1$6
M=@16&Q'"F'^RDAX"W^ *."+>![/V14.,CZ Q?P/?VEN:;3T@F'>X:LAQO_M\
M<SM>4DO25[_LQ "JIAA%UH"4O5@#>FS+9[_7;$4\<..6L!E.$&:\]TB=4KO[
M*R<M/&C^5HX>H>-@]V2U9(46"I!D4C%X&,[$>(@:LG]:<PA.B:_I*D0D&)Z.
M:8",OZPFY59H"<MR5]S[@_D ;Z>#05JHX7M;WG+&\,VG\?!C$@N6\\H'L*JA
MO'_X(M/L8E)+/4MG@0:VEI+>M<FY!!DWS-0MS5Y4"LY/?^L'$7F LUOL'%F[
MAZ2/"#O>N*R'RU*CDCUML'!;@[(*PVM$YL &S(H7?;E(PR*#I7Y'>J]^.ID3
M7M#YQ@AF[.KRI&OK/RIZHY-IS8T^M7)_6\"&>[G*W'3J$E(N10)<0/]E]G/%
MG3Q^HIW<?_7388-4<G<2S*@O-A)RR;G/DES_N]C2EV ]ASF6_;Y^=?G[Y:LW
M!NKE7TFJ N^C_H%]$/;@5Q5$,.SK5__Z>/DK_(:2_3EUOF)&E4X(SN"&&KC2
MV/XW[.K)$^TJVLP+Z!,V3D4JY0!HB1(KA84QL@VN'I5H"H'!42FKPM1;A-"5
M[X:$@^%[7V+,"P>N:R$R>I]N/ODF\]@=9*@B6$<Z<_>800(>O+$'<[KX?-/&
M'J(2U= MI>'B1VCO[= 052"YD5.&H"VRE:RB1S"*#CJ/JD#/M3R.5K6*#KK/
M.+E5S2+K$6E3CY'*[0FO@;5T\-S6TA$VLNH=/):U=+#_S/,_1FOI^+AQ_HT9
MW4O30]EVXCIT:NNTDN6T?N[U%>,)/V,H_3^#R?2M]P'X?SP,O%_(3?8.[84-
M1:ZR4#:=8U_6H]4PQQOW*!K908L1N\*5J(FWXTZS[5?2&X9WC Y1=WV>?SCM
M,R++<(B(+-P7C6+^84SPX%AS-@PSZFH_I2BI*662_"R,F88PB!K<Q@E!M"(Z
MQ2WL,]XNQ>_66H1T\2$'=#R*"A7_%=!@OU[^+@-5M1=*B$%_@V3FN,H'\.-D
M$)&:B"U@^@GY5]GK.PF^*,GJ-3,+")A!]X./DGOIU3D<1FJ'4XIL]2<KZ;K9
M3^=$TX?01+F]S8JDT.(H^"92P!#Y;J>=%/09P'9B5LY#Q%S=N<M,<<75M^1
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M4AH/2.)6<H5+VE=IG6)+></=*L%^ #T$O:R7XJVXNH]5FMV&TT\&8O'GV:>
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MLQ;:*M_Q,Q*H,28MXK::J>B:Q-4$[M&">I+SLM?M6ID,RJO1M<*D9>48$+_
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MO-[WCP\Z-0?[]F!>_&".#I_W5#92=#_,"?9RHON*I/7"BA'O== >\UI"Q]U
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M$8;/Y&(@<^")&M]V@"Z )IT&G7_4<(<ZE;*6X,^73V5%:055!Q@@7,&Q@4N
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ME2 D4\X:>9%.DI"*8C5,)VGTW/NJW/L $<^^,.R49(0:GTHH9C,FH&:U5FQ
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M6=]0XN]:FZWBZ]X6,?[FU+X^['*T3AS)BUL15A /?[X:.KIFES%'X[*0>/'
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M%BT9Z?9Y7T*)+2@Q<SLS)B:"Q<&:KD+<C/Q6:ZR*&DK'51@G8C_'F]\IKV9
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MM)=/2+:I,B*!+1^9Y?:*3ASU1HX9[:M1VBK?-VG7A8.9Z8<16TJM.>0'N&9
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MP20. I/].D8T<'J5;6(.RYK;X,+2C_Q_\1K"/;7=%:MB7+@!6UD3335^>MU
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MV]-7CKQ="%[?O7NKV><K'I[@K?7[7;C2GW"OIT^CV6,1.RQ.^%[NS(N,!?0
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MXV$X])ZG5C]Y$2T=P870E" I/IUE+IYYUG8MK0E:0 JNB=H,LRL4*,7SE#&
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MPF?8GX?]_>DT8'^_9Q:<5Q1M,Q)2TU4ER' R/2V$$ZKQ0HLIDB]C>,=@^'#
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M?B^097(8BL62N:G(%HIQI Q44:TO5N'&]H@\5K2P<.0JSD#/Q]G[6F&-60>
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MF/A8,1\GXL37(QMO)-#A6ZAQXW)HI_KIIYHC+]8&Y*E#@;!\&E'G%=+R8/W
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M('3U8S^7^<D,1#),(1\@,00-7UAN@*BPF%495ST)I,-),YICN8C.[U:9\(1
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M;05PAXF5L^>QF /4A&"$APJ<I-2X@!LE3)V]J"J3TD(7\G-G)3;N-,9Q]Q@
MYAPI<SQD<=- =F<&<X>L3"5N#]@NI+>#2W<$]*\PM)MW&%_K-TU+-1;C.:=/
MJE+:U">3*J.T)96!&&6*&?I.P"3@VRLD>\8+A^\%/1@*M^LW'() FJZC^.4;
M+H4FCQZ7O\[; ;C @&5;SR?'RAY_E.8U]6,']=*E)0ZK:TG+()&!"3^4,6&P
M/U6%K7&R8P2;W(XP7(9R?0,D*E/VA)'%A/. X#*KIU"#T-&G4SEKZ&MQ'I@
MR0$')=&QI-A>%RC6 &.D<Y/:-<GU-WBO8&. /<G,6")=4A>08I."C0*R)'/X
M(&M#D(HU[*)'CR?G4@U"G\? BIUX"#1$*]WHQY'):)A]4J@D&)+FM5*45BJD
MMJY3*N&;CAS52 :WX\?!PT*9/I"J\"(3 )?B.4C,T-2#;?;D6HB%AE@<_=$A
M%BN'A[*>CAX0CG#K6X'9%==8M9T.1#X@\NT3%!%Q==J4M$<XNT4IOV ?,^D;
M7+A(V2Q 481W#RST$HK@SN9_B8460'^-=0Y3+=AN-RW(077;FL-]6-P(BT64
MO[0 2'::LB0Q['\DP<U+P6%/&-0M@ 5$0+DWMT[Y75X@A.[.W-A[&,SGQ1K[
MQ0F2 .O(F]]7*<-TW6*AJU;>(A>+\CHN<]2A>5RTSAV?!**(#XZINK7?.)_K
M1U//?L/"L_X30QA<!AFAEURAMQ?(%O.GY$)@SJ^S#-'7\<>YRK1BXBT->!6U
MC5<NM5W<,>HTQ ,ZG[GT..]&"'R5.Q84(]I%F3@-H=K"(*Y,=1L6<&% MUH
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M%2Y]7-B:\OJL,5LU*#HJN@ON/WY"5Q<8^N8,7/+EE_\#4$L#!!0    ( !J
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MF5GW#C-+H0!*7@.#3>Q/\[U&_@=A2[\:V8.;?5E<;H2>NAS(^7)0ZB%QY S
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MCK[C,O=X4 PS3# &#(,'Y;& "YE!DCYH(KXQJGE?RL[H7AJS>M);#^G=*^=
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M'(W.KQ?YNNJYXGWBVB5'\ R"0B5K*<( !9W1,4=:T+JL"^N_^=DSHE]9-SR
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M0DLP@D8NK"G9=KG:N_/@PU3K9O+KX<#V[8C<7;SLL/FN_H,JY;IT":91VRS
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MZ@B,Z<AYTMG8+F%%+3&]&(;N5)EW2>EV9E9<GVF+C80/BHR,B5@ N:I5ZD.
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MP6G)@"NOA#:2%KS6B42/86IWVW6?Q'\ZO_')_*";>U2A* TL%K+TE0G@4L[
M:8G'6AN;A]!Z'7P*T&W=8C5ESOUW5'VI:-?W4;4<P(??1SBIS6?F)X3:2><8
M9M#:(BCI&43%--G2T6AN!;+4*=C[D1(*-UZZ^_NGWO0[;B'GQ@5/+H$LS^FZ
M0&E8=>C6Z[=?>6@#1:Q2YP92[%FQ&#1GQ0F0R16RU322-202"&M"C7!F7';:
M-?=!H0]4(NI'G^L(K_'-Q,>3L]-('^"[8<'/:8BCA!?U<HO%6MO90(@Y@$J1
M[&_.$A0O8PPV$\[RB GYR"NV6]!F([&/V\NLEQK#73:7.7FYRY'5R@!1>?*N
M2N$0?0J G!PK^D/FW/J ISNZP]^F>]98#R<OU_$L9U 71#U%>]Q%LYM8C;[T
M]P!--A!^+[VN[B S,C&O:.DKF?"HHB0X^I,60>USECI&V3H?>EMT>"0$8G=L
M6$?FC6W!HU*&)\,*Z,V\H^A%M;<4>+T! 9U"65A'(=>#8G1":!^+82V:**]^
M^RYJ"V^FDW%3@3:N??AJ?%8O@;_5P=6PBT4Q3C)JG"@:!$I->"(#%[4"EAUQ
MEWL:>@N;?]6[#]\^:"+UUH6C\=O9)!V'*1Y]G>#\6.@VQ(MNPAU MJPNW!78
M]D\ -M?A>%L*:%VDN#-8YJ7VRF=@5BE0&35$J0,PD9,RQ19:Y9X_2QXX5M@1
M2=:1>^-SAR_'^,_A=!8FM1[*<'8VN^P>+EWA#FO8J*OQ12@A2&W)1]<ZHF,Q
MZ5OY-"L/'>Y[_I9+Z/:CBG%C.?9P$/%V7I:M#KB>NN2?PDD8+6NX30>!1E,P
M!!"QD"&3>.W36;%Y'XJQ5KGF53 >PK-;6['Y55(ST?= BU^)LY-Y%:1%2.'E
MD=Q5_8&?SM^/1_7NB01*C_FZ^,I H?<Q> U65W<IR A!2P$&><E$\5)8Z\I
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M+0J1MU#>]9<^0^4]66:-9]X[$M37N<'VJB8'U;4D\N +^4J0N*"U)#D%T:&
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MAUN/W=<.#VL)?MQ&:HWCV8Z^T?8W_FDX7D+1'J7-4A)'-;&510;1%TL>*^I
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MS[//JP L64D920 0"   7WX S^MHVC)B8D;*JDJ2,O(2?U&@2<M;@>UAL
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M\D=L_Z0+E;_$#(@_]->V?ZV??18 P'OUXINHO[:9) , =?X  .'\7]MHOP$
MF"]QJQW]F_7@_Y$OEDY.G_A96:%0*(N5&8CE#X?^L_Q/._P[Y&^>Q_+'=/_L
M'DIQ,W-C9ULGRC_\!K*WM7>&4#I^,@:943+_]TG\=P_\U^U@4C4S-X.8@5]&
M:+YDF178XB7<8%,K)RM[,*45^/\MB'_GL/]._LSK%\')>0+@&K$ L$9Q ;!'
M0P X'%0 K'[&BP;XSW&31]8$_+'SM"AV_LS[OPCP?YP5)O*/#T<KB[^,$U-5
MIP0Y0US^U/VQ+0'P !0 )@ 70 0@!]  W@"8 >P 'H  X#U  B +4 *H W0
MA@ 0P!)@!X  H !/P!=  " 4$ 6(!Z0 ,@$Y@$) &: 24 =H!K0#>@"#@%^
M*< "8!6P!3@ G *N ?= (! 1B [$ 1(!*8"O@8Q =B O4!@H 90'J@)U@!^!
M%D PT!GH"?0%A@)C@"G [\!"8 6P =@.[ >. >> :\ ]X#GP#@86!@T&%X8,
MA@Z&%887Y@.,'(PZC &,!8P#C#N,'TP$3!),%DP)3"U,.\P@S!3,*LP!S!4L
M !85%A^6"I89EA=6#%8)5A?6'!8"ZPT; IL FP5;!ML(VPL[ ;L*>PA["X<
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M+;+-,-,X:"Q.(OT E;Y/?P"HO"O5+.\82TL_L?4WWU]BVV_XH/NR01['*S^
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M#D,C#K6=80YZ!Y#TA&..N"4''KG$0?U2,S_0GJQ>]>>BW%$P7RC);M=+Z+#
MB>)[:DWYAPI,X3)8G!OJ(V,[1.(Z7KMHLRAQ\AQR4B\ZJ1<"@=QO#':V??6P
M$PBAV> *%>":3XRWK]?:V[CW:2@9-F7E+E +^JCU>A'P;A:>V+^""Q!KY7@X
MI36%\6<W4Z1%/!:81#F_,^4^.]8VHL^@5)Z8)GP2\ASWA[P$G@LBL.TR( B%
M24T_PE[('13G;0DL-O&M+=V04^^_UOE]7H.'L0%F+00XA"A88L:)7C>'O])8
M]5("GH1?=]O^N8-X;I,JLWXV.X_=1F#7/5\H4&,/38D*>5R$O?+],#K1HC$5
M'S;3[QJ8^>B84$?8N:Z4T+7'!3F;-,S9Q'3D",_(WH0X6Z79Q=YC*7"&*S#]
M_1*R4[1U#@^MV>R;1*M:2#J[;/A&Y+E?YV'NL=+GS@_1KRX<5N<(+W)Z,A:X
M#+T -DM5 VVL4M?%T<%1ZF-[8!WBF];\4<K=FC*_<T/=MTJC3L0["ZBT\N54
MZY*"[/9+4:?CN /KO()OFI>,O_,,ET$K3.3^[1-]?_GP"175W:(X3PA0%*1W
MB:K$P>1JK\=7C=SP!S;35=7/L9M54[X@ZB9@H@9+O/O+'I-]XH^/;STC?=QB
M2E/7 .2(VS0Z>L#ZQE7L.+2C%*I&.[G4IW4XCJTR#C&=PNB7H30(K?1#.#E;
ME%M-IUI;AFYJI6G;"TUG175VZ_<\!WF$D7,7MF;A09ELZSZ:H4VABS&I49+-
MU[R+@=N>QIZ("XBBPOA?3K/D%71ZW(X-#$J?_LMAT.V5<%/SFF.UR(DL!_[R
M>NXU9F,">8= O&3QZ(4,G,JIV'E%F+'[>Z(G4%$(?YM:LRU0(=I=$$O6RP72
MDH.CI9XD8:H?H67_X/%Y3*WRP"H'W1 7K?*U?SAOLOB;HU^(QY4[:"[IA]>K
M'6,H.AY:+B^M 4A:1N,5[&9\DC.Q <W(RHR6X\]:1K.A<2"8>N/WTLEI]U@,
ML*-9GQ=?%)(85OQAT'NLX9U;F]0VTX*"+T8*N+8 RX2+;=;U="^O\SN(>[=[
MMP_G)OH2+FL/2M=9.]M]/YH]+19/9<)G-*Z]5?]V#%.U%'V"GYTO2Z=!$U-S
MI \,XQ["5!O%<$^4[QXK"C-$4_"HDB^HTA6^MN660,)@F2TGJ+M"M_TV\SW1
MO2Y:BBG@'&;/T;@Q1^/SJOS'V%UL54TU,93UJ[#+65%UN*SGJ>]1BBTFK;?7
MC&4'I&TYN9/E)>IFC!K.E#?W$4K7?W&6ME@L!8:<]J(!T%FX93<ZC4,\?5I3
M3[PWODNY>Y2<.1R/U"DV:K68FG#0\J7/E@@<E2;2&E/TTO_7[YPEFIKAXKW/
ME"=]2\X4V24YA<**Z31<7.*_D'('MF\3<F#(F>CK C^J7#CZ8NLDU8C&MB;\
M>8W.BS!4[YIAS&&&+8LM*$EL\@I]:.E*-8L*S@[_H>@V5MG94/H%1MCKKYU>
MIE^\OC;S;#W*Z\\.+V_%V$ )2-Q]8S5NHZ9N5'MS1N2R<<*T?LG-C87VU:$Y
MJ:\S_[2->X=G^1#>L'K+<-5KE-B6K5@<8M>C8)E[:7__^SSW <TEFVI]FX=.
M<0SU\C2&%)N1.(YKDS?2[%NWHOGWV%7ZNRP]4VTFL2EG]UK"&^E"".9"*HW#
MH$V.CHGQ]<N7.*T]JHZOL,>-%*PL6%=2I^8>(;CJIJX@M-[5"I&%&=\# W'F
M'YH_O\>Z^*%XHV(&6&U)PXZ3/^=UW2C/([_&M>/[-K@::_YQ D-IG".M6+=A
M!2U":#45JYL)9#==_3$,8D!_R#R=E<P[,M'- CC+<ZO2"4B<554/@A8\Y2OM
M_6XOVD0#.!R_!HX'H"GVC+OB$93F @*9OX1'URVKM7F?^/ /6F8T^E+@IUVQ
M1D\S@VQ9CXJ#[-V$*KT%EAI[^S.F1(W@R@K=5+],^6<3%_,>HJPL<HO6MT:T
M^Q[=B!(P=L,XS\#[>8TRXA2QC752\EA'@&15:]N86GEJS(5W]+& K*.5LY%8
M\_#LB&%8C5'.O#I7T[FK)P"Y-71&B]S#=8Z)T-MX):\);=#R/XM3CUGKDE![
M?>VYUW?+,B([P<C;8%?H?=O?066K771TAB]?6S1:IEG.SE%/X]">D96L6?O1
M->XX5\@C/ZTY7K*!*Z717YI0)"2<CSZBA]@X,W*9DX\Z!>UJNB6OK[BQUSI4
M%5YCW*OLZ:&^I5BX6$\'1$NWY.,R<F-^4/8'$X0HRU :NGV^BO/GG"(43]>F
MTQ/RB=N30?2!UJTRB^AS/(!?+Y95UFBD8K451BJ%GV'VX<;G^0+I@L)Z9_7@
M720'>Q-OMJ]SDUT;5[[#15:: -^/FK#3\0,%F'7;KP')8M/$Y:70R:0_9_"2
MFP*&A9&?_]-P^@B=_8.<O84K?@\ZG8_!A5V[.P<I9%C;<1W?*Z=P[2%'P_SS
MMN4I#VV=(=#/CR@JH20]*;Y>N6?V=W9@E9QB=0(RZ=+,1J%<UT^[XAD_^9KE
MLL&YV7%O:W0(7Y%BDBO9/;TY'^'0)HK>:6S<8S4ML])Q_-/@R'2/U2K;D'XB
MC81Y<C31<I*V//'H4(IL_81W,O_JIVDB%& 5\EKC@S4(%$==G,=BY8975NW\
M7!TADAS%#XG":WN9[%.'UXS?P],=#3D>0U2NG>&@F:C*&Q>\M ??#J;'O>JV
M?PMDB)".)E]MW93H5$%$5EJO 5G>G.<+O;3<_L3__\G"\/]*E430;^U:F;0%
M:4S^3!NZXD','%+%H'ID,*JH)@3:]6B#M(S\MF)$#1>Y;EI-[>)R?99:",C/
M7T W3E_!XE@ZM:*FNWHYQ,-B,&>^+1F1CR-$?DW$1G5%BE6^YQ?X<D/T$30S
M6*7"%?UJ4/+O9MESG)P-F<\8,BQ-61Y!96F+,@F?,+*RGG@\7OFG"ZV+B%^\
M,YG?[0!#\> -<KP=;&SFW&O2N(,6(G@OAUO4MH:7PF<#LXW7T VRZ=WP2U1+
M>L!-T4W">#*NF#HV;7O^\<R!JW7!Y$-Z)8G_7>WV#$5"@F'Q%^ 'Z4<3B> 1
MY1KV2N()NN874+2\F>5^4=?_+0?2?UT?-.M;]>S@W44(8OR'RQU)_W>V@?\T
M2#>?N\;W%,<W![R_GL(O49(%_EOS?_4)!&HK8S$!9+ >;@+4?SUD0'[XH/$S
M,A+2EMS&SR_-/3K433L;T-YT;EM^CW4FEX09V9L@7#_MX"B9!2R>8AZ,DG>&
MQ929-&\B8E)7638<KGI@'W35T,%+^BW@5KVZ6713SN0K.D([1XFD?IQ(N>7"
MU;:Q=2L>=F$")H45JXP,?[&'LFOD1',+!QU6LI\M&\,F-,/;INLNZDB^06)\
MS:E$Q"-(ZUT3E1)3-.ZQ&H\TAY_BT44'UKU]GIJ')ELX=VG6.C*>]0V?V>GF
M&-3 ,_YFP.GGOH>C:A.8H;@.Y#%NWM4O.A^VU^#FS0?',Z/^NULGF_]IMWMI
M[/J[5Q.:W,YS^L;@"H)L9)U[ABE,T@=<FI>& X5! $^&:U$D30<E=#W-E)\T
MN5]I\J_:9M_V^Z,PV>IP=\^L7V9-$YDE*42FZ)7[I!#%_-6[6)S50? H,K.C
M[?"OMMTH^?/*#?>;$[#&W5#4,'.CN*1BJD?7W=9VFR.3W&VV*&PQD>4;9;)?
M-LOC8RU@8P"BC:,0QMCS^3GGK.4)%?1[NK1[K@AJ:V38<W%\ 8!+^"KPG4(X
MX&&B7T!#:Z6>RHI=@&#NM!;O6[J?\V X^1KK^I#/3A<3"7@4RO%*GFO8;0^R
M!?3+:UZ4^JEEER7FRW@^7'9"\D;$O9_&LZQ)>=WO\LR!C-I%M7>O?<IN*ARF
MV67&]OWKZ\]KX>1]; 4/G!\QQI"_PS(>#)7+! ]FIM=_J7)>NI*^A$J("@+6
MUMEO'T=KJUN@K:5JS<.2AC3B *LWP>/$MV;G%NO%)PH?SLG0N!)RQ^>-@.\)
MWEO]0]UQH3=YN65UC9\2H8$TK8X$U*Y;P^7Y'W ??U[:<PKO.FU7@_PTHE^=
MAP"#-#NU Z-C;D<2\$ZV?N+A2=,PC#",IK0Z  3"27FC"8L]]OG>;F\_(S?Q
MU*2-$Q/YS/&8AMI/PJ]#G0S @'WRC?[!IP<O"8\M2"U(@64C(R/+#<.G_]W[
M_V!U,8_UG)LJ>S%',AD[GOEK]\9#>=#;MICBSVIYH_-9?_?I)R>7^OP?<,EW
MN?=O$\9Y;^B;Q%35-0K!%/&.-,F!!E . ]E^N!NJ9=?'M]6'UM<4?B1KY,7H
MF*84>]38R)+#MY5?=WDM_"D^-^\*-F5=+"42*%IWQ;KC=0Q(GWZGMV5^)?T)
M3;]M.I!  \[8V>%\J=YW<_O4O,^XZA 2I#Z_BW_#[^$#%<+?)W!KNK @WRA5
M4=OQ#DG:PLYV3>W? .J-:G4/;=ZIOB?[]NOFT)IK^ISM VX[<FQOJL6(IX=+
MMZ"1&Y\\+P3J3@1<60TJ/RSB'8[SNO2F4K_QCR[LZ>D(@]]C&?[=?C<I<9HC
MN7O!VE4+YEE<CTNY1SG(3 ?J)CX.>))UR'?&VS<MF-]MKWL>H69^/0S^4^W7
M>ML-=D_RL9T4B]>RLQNN7B]U5KX*>45P$/>62G-N.,1]+W$TK>E6PH5&]=;5
M"=8^M#A<<J/T0[=.;#-!O%/$^-#J6)8*+WF0A5^0BUY*9)N\#-EN*7/\A"[E
MD5S!%N6Y8R-+:O..&/A!QM3953;E\SZQ68F1B#_A/(;?>%/[3\T(Z>C>K/SY
M5Q?=WFCIDI-^OEL^>)+B)BUO,"1"-\;CCGS^R7"919O!@G+Z[LFXKL,/#9/0
M2&4^2U @Y -.CCCC^<8ZL%V5!;W>3^38$ND92/M0XD/$S,]<8])^YBH@PPU)
MEEF;<75VT==L[@VBZV*,NK"P3(T^06"N-@6():OXBI2A66M$?1_I,OXT&S"B
MNG;+M,_$C=.%!W&(,Y2&IS>Q="Q(Q-?\073/50IT2\EB>ZLO8;.I<N*?NZ(Y
M)90U(?)GVZ-ZNT_ZNJV-W@(>WK$5=-?%^VY^1;*4AP^KT,;-UD?&_X13Y*WL
M9<-<@"'#Y/UF7:(NZ_%-F'IUYI&W1D]*4IC%4QZG_.^#+VG;:(?4N? >RORG
M=ZJOKES-"3"^??1:5/^0EOG!U\C_D&Z1?JO^=O2B-/JJ[4)R9D@LY;^8%TGS
MWY,:0<<#R'KPBZ[YBSHI>(<R!O[=P8J7ZQ2WN24 "B(K;T!=UD&SY<K04XU/
MB?S^:K,27UUL+7*+,ZXJ%ZM9>0UJF1+ (N :W$B\C3-&='3(4@"-^4>KA3>&
M67'$&&Z<$CN6GHUYBL&NO"CK?A-:VW[CUX L[A:UA5$'WOZ,G>#VQ#:=G1??
M9P4:U9^/V=_$FNS3;/RISNZA@(PK._N\S!*^F9 9I_%T^D+7^%2-N#D;SK7U
MTQD_HV<'R>]48^F&^>J=<T&Q,]HM^(W,TI:UUC<%J8M^MW_[*M@CL6_%^K'#
M_V\6HK5J!_K)_D%#?HZ684K<2LBHZ.@)X@+TCDF]=RB]A][/V-*[P*&?.13H
MGWBJ\40\<E.4?+#8W%R2,E_-!S<9OF'.&_3^L5W-:Z2)!W?@C6^6Z+DU*XXJ
MV6?V>_UIC>:]&586XO=/#S\TR4*RD?-2(5A[UR3?K.E64[,83X*\2E"8.[\P
MJJC'PNC!\1$30]),(6D:XF08S4;41T==)V)/0$;Y=F1FBWA=-DC[6U%R;*8S
MEXH7V>BSU]-;-,7L^D]EM*:]T[_M=JFW3D*8:Q*#+!OFE R;S;.^PAMG6DK
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M&C?> CD$4<M/X&!G9I,Y9?9+ ;E1>9(AU^@PO\&FRJ].QV-:9GM%GGD M?B
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M7=R;RI8*4J.GK%)H=-&(8@T58%MV<D!!C(=FLAW1X1.!,+M8EQCM\$2=BGG
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M58F.84D9QMKP5,8M;>';8IVZ_9EHWC2P[-2*87N;VYLUE\<?3'-NE;4=:3J
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M#@=)6Y)6BW:IT.N&AA6MH-WU3(R78MOE6DB4TQ/ZK9;Q9::3U,7:*DM>J,'
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MKYDV&Y]%D41;)2A_9JKU"3X'[)O_=KC] ]??;@S-%CHKX( O!,J\0R=3 @T
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M?1B68]I6Y.L,<;'GPG-.+96TNE/U"[7I7,7?+)/7#7#Y9V"X1Z,K:"@Q,_!
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M"*7]J6Q_/M\Y-M%6X)!+IY $H=2^=GW1]?"M>_@ 8 U1F"^D!^QD17K]>0#
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MYA33=H\X$_(+B:R2B18G@!C\D\@NU7"1C[Y:Y%"(GWW>52X6=5(WF)S77_M
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MV#BWF,N%"I<:]#<-_?K7]CM@[)Z?AWY+$V^V;Z<8WNHQG2H18<[X)6&$/P"
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MP,KB%&)/PRP5>1[:Q_ ^S)3'PUN,FU1T<3FZV%C,X-$TAMQONQ:W-EC"T2D
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M\:8$05Q8#:"1=_VWYLB*-FIE-.5EGGENG:!#M$]9M28_B[R$^P]K^AA'"_"
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M_\X/B9PN@-*\[K9NK=&RZ-$>QCSI_Y=8L@IIC2K!&U:=)S@(1I+PR!I<.%#
MX?\UY1)_N0__K7*)ROB_JM+_VG8,;[Z81OJ5Y1;+#EVI(I%E-?HLY+'/OU=;
M^)2>A-)1EG]#]ZY&^7(N?0?M4L]H[)L$^+<NDV>K9I4'RI53?+"H$E%+/'Q+
M,E-OT&-'>KD=HLB8S&7#C,,B"&;B +G2/:G$)TV]3KK";H3Y9E59,Z?W?9XB
M25MU@6<61-0=Z P75?6;I42:&14@1FPMFE5:!PYF:X>I_KT' A-4,0 <9L _
M.C@Q1E%YR5P8J5^4-[%L8OX2M7F&9?W4G@D*!5FF,_+S+5DM4]#OKJ)4]C+
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M&3FM!Y0IDX%,Z-*/MOB4V-=HWF</WPLN5^M[XR54GKGA:SBX<3-58N)Z9>0
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M.BZ_S$+U5*E&W><9(2^W.;'O04ML(_=N]ZTJM7X:YQ+<I*&_:9=07+$,BHF
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M2M8E&[HF&VI&)X$5"X1@W6+HEB!W<@5 ;.R[S!ME[)%@^$"/B%)=QJAA$#-
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MF#BS6+"T-+AM?08$ #$Y/H@WVKW== 92>#+L!;>I#@J#!]D1 HE#_B<-&(_
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MDR,K%@C3*4RW\I5-28T>",1ZSPH"/8$"S>[\H_P?-J\<O]93*,B/8U9,=V_
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M=#]P2QXN!$_I;N(P>ST">#$3M?2<-D!.D3[TF?9?>HO^31 Y,^:G"'0P#Z\
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M=?;SUOVLAKI1M3/\RX"1:7AYL^6YZ1+E2]M7.Z+4I;T:J79BZ?W;<*DO)CS
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MXYNY(7S_-,X'=H!1@#9@*+^66\O 6[E>W=*AGW5M:=E[8*)Q?<Y4O+=_F-'
M='O.@%)OIBIWR5&/8_(LC^I:*-4I49\/ZL,)*.*._P;I&$</3]A[;](BP\?V
M8?^3BY0;MZ@]&55ZQ'[7OO!TVH))<.F,ZKJSS+3(Y:IM1_&.OC:%B&!70;%6
MZ%(B/UB"Z)-^2!<MB-NE@C AO!XVIQ0[ON"2[Z C(;UJM?)V@Z1!(QN2R]A)
MSP%WFDV5%"$%:#%[V"W5<TSOC<CRA>7%AV;"[#>#EEY=*NE5N5.\[X*&7E%I
M.F#:Z.3G1<ZO5[6@,OU>;P-BNR96PT+S#@P5'(X+WM@;!B<+>M=UD<N"C^K
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MR#1(C\@)D;23.'WQ*-  P)H_U?HB-]KN(PX!6>VM^ZF/3\LJ-C330K[LZ/8
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M@IJ3ESV@J=]4WXW^>8-P#MU\D/Y)_?M?$XE% \M<<U6G&MMR1:P:AX<ZYXU
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M-X>A1X3A-(N(L%KL22VFU.NTE"+?<B#KKK:%U\FX:S&G$ZIX;_2)C%[I+/W
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M!FF7^$TAUD[VTC0Y%U;B5)?VC]^<.S6T[6+*B7N$Y&$L@(^2W+J-\I^MN>5
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M:EBI<P.Z/M>?W-LCRS+-$65Z*NNN53F!2R3)Z"YA]>KG %$WI],:HWJ?DNO
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M/J-K!8])+5O*'O4R(CGSRF,V33/T?G8XS7+A$&VL^^L[S9O(Z9R*VE6??Q*
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M-#2T=+% BZKEC1WHL\L08'9TJFCUJ:6;+8Q7[@\X)+K]$"@HV)$N3S-.O6"
MK'<TW\CBV[T7,JE BA:LP>.?E6-Z7EU3R08?%_WUI2G\N"*UG=GFY2A^5M?[
M:;JV:?_CK1&]Z@82# Z -_[N.#4@:U*[G_=%@&P;5?N;4SKO<$HLS5VGYBWS
M>ZW\9'>A8%-"^=BA%VK@M'5;%&@]1X@>=/)ZR"6V+BN52WB&6W@[QYA>_D'
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MAH6(J^"@&/,M25B9BC/;KR.40[379N0LF]&%;P)"?^/B85;WYPVZ:AHMFCR
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M0ZN]#$4C,3HZ.KQ_T/UW?.\6A?K+J6W-UH2UY2.ZKW/6-Q:Y:)6_2&XZ?MP
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M30QOA9X0.EAGW,IY>U(1/??;0/JG;]>\-?M^[(H@/],9ZD(<+\ON,*B\I<G
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M59![+H W[*=_#G!_#PV_2O;039PD1GCMIF]8]P-?JW+1X#92C=KON%[?"TT
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MGOL; _)7N%H4U]XA(J9F?XZ=]T96UW9R^DV"OOK..%X;@W=N=@M_R/ER.A[
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M7'VX:VD[)/R$4^J:2FY8^N'L8J1.WV(*/:X),+P](X+= UH.]1186EB>\%2
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M=PAV[#3*B'"Q<ZO4ON\9R<%<\:@4&,6U1.+19VA-_XI"-T#<C/CY>XN=?@-
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MKS.L5F=+TS.]4?>A,-EUNBX\]B(VHDI\\^;[L4/@G<VN$Y $&:&-" J@S<2
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MXAC\007TP[CX;QQA!4J%,-KMUM?<4Y.![C#,F5(/N(^=)=C!-?U4NRE3?58
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M?(8\?9]A*=93;<.,/)ZZF;O''2#D8HF;1OMCI7\*,Q1?)O[GLZDFTX%K5;+
MCS[:/UV?QG44-[S[/0M@-Z!N(1!TRPP#9C5-MZR@PG)OJ2:5%\5T\97NHHTH
M"_X*_P%1#&CVE !?%W(6>0MHZ@Q:[/KIQ'J+DUD([E2%I!:]VGGATK4F8 _+
M_D'W;9HY7JF[XA_H+Z9[,]!&A8+9/=/8R6N77T_*>:/F"SPRM ?7U&#[EAY_
MT2D:35C]S%>F,<;$:S$L"2.7*\#\6 .H'@T(]&J,Y]/?:IW>7DPH6&!\R^X'
M3%4;\B0/POH:#[.G^\1*1$7X0G!E.]P/"-G32H \8("?ZMAXVRVR-@0JV2R^
MF2W%)JEKK\7FDT__3I3XV<:]<OT0_!ZO;4- )+IM)1VGW>[. CA!41GBBN.#
MF\[*ID?5<C.94(VC:_M4N#CNTM9%_I*>A028$2Y-0DR&F?R_$<C#L^D#ISG%
M"0AYA='K6U7AO^ .#O,X29BK+@IZ?93MU[&4 INF]^]2\U$?C)'OS_#\C4?"
MA1?NZ_A(/&\L;T,@5:E92&6=D97C%O$P\50^X9T62-BBG&[-5'+E+O<U\2&:
M*]F5APN[ V&ROK=)'9G79\L_]<' (RN0V9/2^TMN6)451[^>/\/VB5^)W; 2
MSJF[TI-]'[VEF7$#G>Z17ZZ+!9?679QG;GU?F:[TNTB^BP2P.MP!9,S8/AZC
MK*R+QP:*U?(+TK37C6_15+1+KZ4^_7:C5+!TSU1D K!2AVGP*GS<??=1]A?V
MI[\%@0NG\('Q!U:#PW!L(9I[E^F=OZ\U7[6*VKV".2".?M?(OD=AR!7"'%@0
M5KWI1@:\W@6VM;P&R10>M0M?/\<5B-C/XOTQL/UMZ*SQ)_SW<I$&58[A'J!)
MTVT 3[S36\"ACP8O-#:[+$<>95>853D\/P5YX@^;^32#.B#T RRH8M\1[_ T
MX88XNAV4S^A(.G=<,ULSDU5T,.6;%@HCA<;P)-@CS[*.>,GS3;AZP';6^L(*
M?<<'8S!*EIR*A:9Q7W+AZBH!VXZY?:+?AMS$SJ059[3Q]?OW-(&CLN7N?QUL
M;!CU3 _FBU\14)80V89825)%K<XOHN^.QIV96B@;[\&5-!J8P+X@DL14X[S\
M0</\IRU*)D+O\57>D?L 4K-!C@9.><=;=[_&IITM2K@$Y@4],HPK& _Y9#1W
M1S3FU>2738N%^XU0^/(K!C'2EJ\ O'OR^OS0EY?9&MDE\_E%_MINN2*GO?V]
M6D'UP#TS,TU>1T"QYTSUW$%[1;F?UC<'HHUK)O83AF(JGI(5<DK.B4*"@-RL
MP)**;<?->9HVY$M)RYK*4\F2\5ZFM37 6\/GC>BM:X:*Y#</&%@+<?F(WE('
M/W];ET[#F;99ZL@W<YZ["5*O6U)"N=$'QJ358Y&#BD^B+.L>QXTS\2D0P^AO
MKC5$'H?-I=LN9\[U6SP]]'5PBFSQ9QEROF?HV*)&K(@_,AXW)""\G35T^NAD
M=>?\L^-;_*%1]<C(VY8D'(01:^,"M]VVJ'/BY=Q7:V?SF((#MN('#"E6,"Q)
MH69WZ4E[X^Z%2=MQU^1K[O23FERI:U)DC4S">:,-.]Z@+9';;8*$>%W@S%R^
MYQ]MM/WJ2M_=N?K*I23\-7KLY0.&WHH5,&<-_@O4Y(H;XC+L^?$8RQ6;_7 8
M5WMM6"$D0,D/O0'V%OODIGV98F<:FME-U_G&*#[-":VPDGM-.RD$FR-C6&F;
M![C1"6$KMZ\E>-P40][9\R3NK/"(]A9IH$BVQ%L,4PM#_/Z"K]-WH\3UMBQ?
M+U<!B#Q9'(G%P+SQ6#'BG!53Y0W<Y/:GZ9*%1N62%QIZ]58HS9 A&<^[N9>T
MFE^#C(L0^71#38J5MG%"(EYGUZ!U19N9 1RHIDZ=#Q0JY>>&1VU4^*BDJ<IO
M6FZDI#>[?^ 5:O_B-2RQB)=*B"GT,<7Q[AJ54$I_R*CO\9Z&?<%774L!P:@6
M4\97,^64@TI]MYXK*!Z363_YUE"R*:YL*/X07;:G@;JC)D\)9[.8_M9N=5Z;
MW#N!$[\Y@U8;]VO6FATM&4'Y[/OZ5A6"8Y+ZM=U+B#K"C6L/O>]S)5GX@+%Q
M=[8Q&42Z4J5 :V-0!_?A7 MY,MS2>",L&\B3M;2BCPB9"YFFY7/'S^?FYBV;
M_3[VOK-8HOF@/?G+S3WO;>RN,YTC30,R?(GWY8'JQOJ6I>@'SQ=+K,\@'B-6
MI!Q)J K/XP"8TM7*Y85HGX(1JN3WX8M/$IY/TQDI7Z7SNJ6S/;G"9A1<7N/Q
M02D]4XYNM;5)$7.<8P_R8E1XZ>K>1"U0L%$2KVTG0(H/6OL1K/->O[^+1FU0
MPIU?^W.H3+*0A4]T$Q2@JG<\WO1:.4 W6R=R*>Z476CISDR,&!"]1_K99131
MFZM]EL:K>3^\J-#\@*&$V"XHUYNXN-RYM?V"WS)*P2E/Z*\:B&DY]==1 Q^?
MV&3]E8HB([31&LM(*)0^BBJ>"6HG=BBHJ-7N!G"V;108.X2M34PGBQ*\"I7S
MJY\V]&CL>H9 ]/9U"O?Y<3\V_Z% /]5.N\I!:RLABMA)N!P4HDY%PI-+]E4G
M3W1I0/KUS''L/:94?*"!H7)BT'SK%7=HY,DLWCU)8&=/-X?IGLTL1,.9%E27
M/ZQ.C;2AM/CUL<LB_MR3X=>@=T6"<H[WKWF-,R1PM13S,K+'YH6V-_[=1?*>
M3]R8>IF=@[A&=9UG.34+HP9J:[$IL0E^YR_+UBR:(PY,KS(BW(R="1<CPZ=@
M*LUWE)RF7'#,J2MO2GO ,.L??(+/36[:_L9O6\W%_?UW+*[)LA[-P68FSSJ
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MZEG7MF;!==CBFR3Y&+&CA<AYQMJ?6J(6Y_EDES6-]%"LY6Y#1"\\,*M2N"K
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M,I7*N\T'#$=DOOH^5P;?QG+[/IT8!@F8D]:33@([2_#B]'%6D-),;H^&CR_
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M\HNP7?>,Z-B&!G:0[\>+,/V%(=%I3FD !1A'4\_U"\.RI=.^*"^%Q8A.0E_
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MJ 1AZUDN\CQC4*G_GD8(9[8@,SM9I?(U&VN>(IM-TKU.8E\^VCO#6'7Z<Y#
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MF$<D]1%"Z_<4@#X<M2E1?>X1&K)(A-/SL9?:D3BD<5VK.W$F+BQQ)M[/5Q!
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M#AA(M8'+38\&_E+1E_\ZPPCTH_AY-3[1OMH^]LA3!IX;)TO+I1W^(_ZO46X
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MQ6_2,DB)#_]NS\ UNU:4]7J0=:=NP?TPW?Q[0NL1/3_6N)E!W#SN!/>M"*S
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M5OCU,N+OM"-X!ZQ1DJ1K$<@DR>=1K)_RD_1PY\S#6#LRUN.D0']8,EA,B5W
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M5'9-+X[,U(*5RR(//F%_CKQPI/:D2,*+GZ.V *.QLK0I=X857%G,^YK84GD
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M"97+,",+&!-0G(M6?M*Y+3":RL5*_=7S]4KNJ/W"94$?Q57H:>0[3W>!7.1
MM/95*6M$-I/=I!^JN@IB4< 9FM_<)W*'(7-YT.P.<!'RBVAT=P<1'],?HREV
M?:H.+G=C[?:]<6U4*N2>[/-!*8Z'W@/N,)3VUUT$3[Y<XR6;9-<T'DQI3Z)L
M<2Q;W8B_51=2PZ@-/QZ61 %[G$F8OV1 ^MDZ>6&3E)."FK%OU!,_>,X)G:ZO
M"+O.LXZH?4E L[W35DVN8B?>=N*$@2$.G)DS?9TMHD@C,%)%:&JXY^W<%"6Z
M8?[TBMNN2F"X\6 U[3Q)!BRY9U+I#A7P@'.]9UO=5L;8."4Z2^"^L"[XN<24
MQ$T/C?40CFOC;!]%;K!DE&K'S_0B6R.O'FXI)_5<D/ME5UE52-(E3^MAD/'.
MDYPGJ$G44P.HNX>.UK8]0)XX2=0]426C) #V\Y0SLX* GFTQ_HP2R)1UY_.I
MKAU1HZ%''ID7NTD^W>.*06G=-8",,WODX' J94%"Z%+HNZ#8V4:QMX:<'VJ%
M6H;U[D6PKQY.MS]YT(ZCS*%G24+BS^FYELVD?*VYQF'W2KT'@L6E,&G.D1-I
MJ:V)$M@7#3?4='2HM#0T*,5S0K+0\"RI8*[L<Y$WCE+OV4//=BTU J:]3VP;
M"Y$DM?,CQM?MEN):,#TA8S5)QBB?\H9GB1?7%-.OX,%9/FQN*[4T$N?,#V@D
M9G1K&\4^-YAH7@2F+XK1 6T\=R$F^)B\?W!2;_6;+61NH5%^YM^Y8'Q7\YDU
M^R10;,V!WF0! 9D+U(TM1TV)WR62V+/&>;O)!:ZEW7=J7TEHTJR02\U?!&KK
ML?""$6IHVGSUY[$'%O8O!Y@@-\2D/4LH3;)SR+J*@DS!Q""?-S.(Z!^"+ 7G
MLDN,0^O<.U02N&/T0#\&SZ/DZAY2?.=1EL\OL5V/F\1&+2P,>K-7E_'7' ;*
M+$:=E))Q6G^+Y7ALBSL,S])-#\]<"Z<-FSF8/TKMHW^3\\OS<D#<^2Z!.C4O
M(F3J>[5$P-SUZ0))A"?J91G0^>1E)Q#A>"_^._NM,</5S(.SKW,.L(5WB2A
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M'/)15UHF75K:(.PMP7JZ7D9&1EL&.,PD/XHWUX[-^' S'!093KBHL3/8$-3
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M.A/"9U'(:00YU90A?$YV6R6H?Q0^.LCD,4@WRN1X.ETYR)!$UD+V9H/;71C
MJ?1E8W-^6TE_^PI:.(;.S_%R=9N+F[T_Z2*I>% JP]^"W=BV8Y1G3E*^>$9
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MWV#EF2,/8Q8T]F 9O(9"_A6*01VSDMJSU_A.L@SY3BJI,[Y#4P"/T(KQ]=H
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MZQ_ZU5Y9]*/?#L$GQQ_/;Q852TGNS.8KY7E&M#<>[/=<=72+"A]ZB\IB(EZ
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M6E/8@3S= C>K]AO/Y)]* O3-'B_@/9(IR=2UDM8.JWKS FMM=\@=HY1("3G
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MXN4$7O7Z"<=-[%;_A3YYL?\Z?4Z(,)LDOB?D];2MC7,%3HNIN,< CZ7LNS!
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MP3(>H)VI$5@RBMU9=(+.2"_!P93"39V]"DOP_1A+0H8/TL0"#Z"HA^]B!L4
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M@DEM897[]_Q1GY<VQ:5\0!<W$CR&T.WW"7(?Y>:A;]#>;O >2%T_SPAJK?'
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M8*Y[]^5?+XHM"44:]\^5)<*G<U,O*3]"E3&V])P4CKH)H*^]I/$/2?O8<;\
M6S+2AV4?35PUP/P^+$CP;5';OJBI<3_Y%"RE^L:2-@?D\I5.6H;>Y\2/^2!T
M(S3;UDP*;Y!Z"XHHG_Q2?X4H%;X#:%LT@M.A6P;9LK>"CRW6#7OEL%.%OB0B
M"WUX=1[2X,=)_"*1"Z*,WRQ3>,6FR1I!N0L$=!HZ'V/S,R++UOD>!^C69GBO
M/*B3#Y0')DEF/+;S#'G.Z6$5]^G<ZS6 /_*_1QWD[Z;94+SD'<#KSX? 0^L;
MQOLD,(\SL=]"".-Q&K>M-WJZ@QB+!?:0O] 9%SD#Q?QQ]WB_U NXH:IT0C:G
M4@RJ=!]D&G7IYJQ.59XF#TVC9WKPO' R2_>.*ES$K9D#3%Z"BG:&GY4I8_<H
MH@[53-7IODWUAGBR5:<O\J ,Q5Q?KP=/Z+_)R#16VEIG3_'ZI,)>FQKC<6[,
M_:L.&]R6BL%ABQ&7%Z:D$-EGB/7)= WC^:LD)Y2ND-J-MUB3'B'CZF?RI#H*
M9FCKD._ 1(%#YP(,;[ ^,HE9B4\X<W0\$9::B3*:9+T:P2T9'R1U<C,.U%;3
M+T&(>=="[@!RC[U 3E>6>SB7>P/7,>H=BLU0 ZE&*=? ,O2>)4>3+DK/PF!X
M\5&@8:,'MWZ+J^=7B^<MV!_!0$*F+3VB:2J[F80<Z3#HC)@^;((/JAHP1VE:
MYCZ=[UO9:!,#];PX,>@7?933VVKU^*.DZ#/A(WN5?!?UO/+QM=_6>IY#/I.=
MW./^E=^-# AKK.9\K&Z'BUH3P'5_8<S5>E@S]#KE>$Y0%VG<*SPYGAH9OL53
MVP%21>H;,=G0!YW0]F'LM9@4 V= T+6>+1J=LHDGWLNU<TFYM'AZ6W)X:&)#
MX=_T$KGLNJ^Q,2B5*^. A&OB^;V]]IN?8HAW$>.12!ZCM,$,G]\!8*@+J)=1
MU?/0]U_5>?A-GJL4!E&<7]\!XEU?CPMF8Z.S367-X]'6!&.GYTJ>\YX+8KM-
MCM5#C4=O+MLU7WP)D=C![J_> 9KW;@\WC7=;&\T1G[.-4#-!P-LSV-7N':"R
MXU&2EY?745!Y!]?B18W$3/;ZJ.36(KIS[_BZTR=[5,3R&0/HKQ(I U1%D"0L
MCW5UG>F$FB3Y:BYG_@YPV=$,=:-[)'T'$#1@/0Q\052S/LET.TD""3J;JR:Q
MG+^Y QSS[*+/]_0*325%V!XGW 'VAKHZSZ#F-\61R.9/UZNGU[!.K%E&UOBA
M>*NHGH*EYB9ZWL1TL2L0_Q3_V7?'FW4SK;>70V@^_2D52^/JH(-#2?/PVR$J
M(%!@&QA%'&A>*DD&;,\U]4GI[/P!'#-?QW@:X%6X<<O$H"^\LT5D4(>#:C]\
M_"MY=\1\7)'PP=K#7V(G8C"H%,_N+7AW;VWOQ"S7)RC5QGWK[&SQ=V?CK4FG
M@-^2L=I<3=(F@RN#\"WZ.EWMUNFWOQC!=6='!U<-/,N/%]6>,WN]L]8Q'^]U
M>+F=L[,PHY*54911]!2P._(1RR8*:1Y9\;+Y;82JEC]S&95$'XH._NJ8SS"A
M&)RURG_"/1LTUL%]R50:2 4ERM:MDM_9W<>J,E3!E9K'G/;X+QN;-33'@K)!
MA_>1N]1L?H#%V[@>989&]/H-AF7&S*)A3NARQX)#B0:8A6*(LL'LN@)=V8(J
MQFI[&CHBT5,5%%8]\F/%]:X-QS(R290Q<CF5\H]7WU^I_VKA$[09$OG<PB!9
MP\$RSOLWD>'Q8WJ)'V,04PKO)L35K-&KK1RQ/E$A7I]!L6+T)P1/5N-F[X%$
MJ9"<#2A3V2NT91U>3C)@=G.C%V)T6G@'D-FEDYA]"FF)TR805QOR4(NO)1,(
M\/P*_VP,;/\S(<0.=I\%!3YE:/?&!+K"@_<H+MSO !M.P/U;NIR-&+-^FLEF
M#&7ZGFIZ+%/[C.7KWQ2NM7)\5Q5S0=H9B#^5<TN]S7"]%I"W'KHAXF3]X\E=
MA0C3FJ@)A+*'/H(C/1JSU660#QA7XM2V$52#(Y)#,946*UB8F-33SO.V#V<E
M457ZICYK/-^6Z479CKR.V,Q)0)B!B!"YC+F<K'0#L^)]HYSB[<9LYYRMU\W&
M*<_-$3( Y!KJ_:#8?7SDVK%2-G4V%(19[$DN[AX8))!W29K1F:9@;]Q/LOW>
MH2[V/*XBWW)%F9!Z?&6:K5USH(E"J6,HK7<9O5APYMN1M6MD \D+"&OJDO U
M"HX+-UB16XE3S6'?MO @UQ2 D1<1PPG9F#@?0&)L"$6*O:>+&OIM^&N]; (G
M,HG</TD@7V9_7?T5;C*LEF:741F4A7>Y)BQS\)DJ)[12;N4#O^<^EH&K<="Q
MQFY86'.E+)WH2TUR@X,K";VDK8^Y"PWAL$[.XISP-VGHQL' -U^(AH(=-HWL
MI89 ,,*PWZHL2T.%):[6V2 DIRV.>LDS,/C9[_#TJ/=L#TCO>WKSQO@3H]W(
M2Z*)?D$U/'/X;D_JKMGB,F.>E0@1MC?/=SOEIZ-;5K31H')D3/VK.\";V^;T
MDXK.FHQS-53@W$]A<H&:5\TF2;"M2C3[ZZM.LPE;CX>:VZH29)PZC"XDVZBE
MLH9PU]?"KLDO0ZLG'C-1)I-Q]@A-.PCEGXS0:"U_LG&_U0JS)TBNH:L,U*:V
MXTP!ZR5"<3_6W:,%\>YZ6JSB9A.$]$V7QY/OF^87SF) /U>HA<L[:%#T.ZTW
M)EDLR&8]XQ2'J&UVYE\"&YFW//EZ6;$VPHM@J$-EU34;P<(B:W-,!S9C\!>)
MW7>K_Q>@:XDF$BI"P!+9F#,V[1](1*3J6[G*KVM992CILTD/I6O%2-(5A@F+
M6O&"7K,=FA7KJ"/DB6-*1!NI9$A<4XH6!OFBU)H699/F.^"C0TQ44*72?@ZH
MLAI['T]5TR5SNNZBK!M8CW+"<!VOY)-**LK:Y=S!05)K 3'W-5:3)XF5Z'E7
M/]'+"#(X,0S!1OB#^5:Y;;X4=MP[.,+TB8^)4RQ;K:*13DE&4CRTTL*95%P@
MN3.CA\>F>\/S61X%DZC\3Y\6OYKRDP6-I0"S/,06?CC/ 3*A5@MN$!W&OJE#
M^;S!PI/$)JZ2.-(]7ENL^97_[SN #5)#2'Y'WEXU'SON&I^1P7)4X=V?<Q7@
M<#W0<5S_;'F/1O":T&[_]]&NF8_*4'_T'T#34 R>OZVF33*IDBL^"^I0L=]G
M83$!/C8R,L5QL>SO%<$*D(E!ZC"N$OQ98LZ_W5TF/[=F9 ?/+$L)P?T#5S&T
MLX^BT#-VL)/:#&EAT$:XY-!YT\CS7/;F]H7$X,Z\=^R.O2LW"V9#%\X="S(_
M>^F83L3O &9Q0>GCN@\4]K7#G1FS:Q<<H]LS(%Y.YV-0OM/S  U$<YW^>1:<
M\"4RJSH;E3_)"PU]I!)U87QQ2+8S,SY9KY*??'G5O+!O'1$UL6PG L6T\B5/
M=L'174"-\)":.!QZW.FIT+D6< D;R".B-2_ (W24L;E"2"@<LY@!F7[G%2BR
M/K*8E\Y]N: 2!N*7O&4X^?-K3H=Z=,BOBU]7B()S@F4PA42D$=51@BMH+27_
M_"=5G:63M4>0FAD#:F@ZXF2MD_6J:!$Y+0J\@& 7YKA6.J_/OEUV'A7? 6YD
M+KZT^'[EWXZ7RHZ93;.,YTN\#_)<.G]1S[LV@KW=8_,,-$*X&!"E>VP.V-,>
M++%-$&]?\05-.:2HV^^A2G94[@ "S7PF^8VW$C]*MV/-W@>7Y&]OJ?8&T#WL
MIW5Q&RIJ80WRD\K<467PICQ;GF_7\!"J>=#S9 ZID1QCT+*4R55H$IF1D36]
ML;(P,B=V%!%FJC+&;Z8BZ*#RQB ZUN92^57F]47!\()P8:K9%&(@_(BGB>',
M*O+1F,D6S4HF^B*'M[31(T N!&7)8\&OP]_JIA8Y)'/B6B5N:?,LNM\0]SD_
M8US/L'9(S<2H6,1QWTD5@_%MF-*[;8'H_<4F*;8QX]YHC&G9L\ZM&G!Z\8IY
M6:6JKTNA*(>ZH,Y32]'B9H%8EQCCILV.V0S1K6G/%EB]$[3+D=K$82?%LN.*
M0W_U]&0V(*X6UKR+O:7KD*SK0YW-J;7< 3 >O54[R$DO\TPH<'Q+.&@6',^[
MU[KW0&A3T=Z\_.):^UKK%MG,+S)3?'"%N.6+/V6VR7.'@X=RLMUFZE7[A=<*
M1V<JJ%79>I=W]+XB'4[YT1+X1=9^/=6OTR1'E'-^D5*S><'3F86H/G3;Q2MN
ML<9D$36R+?NX*R6/_Q(YPJ!T[+P5@GC+)]H7_(%0G;5WMV::OOP,=P M=&,>
M@:")"H\/])O=7#2%G:N>E1ZUC_/[:.?R*;FAI%=BC>-R8$=O?Z<R':WO%2DO
MFJ=?;2<;(YLAV597[;]XYLO]%MRR:N+%P6Z.3>CQ;%7.Z?;H 1#_^6V3R\%!
M1I )? YN:![XW*Z(8,_B/HZ+=P6WKB.*=+CGA@LLP[7(Y),LI2+@/)<H-?@'
M%[7XA[53$]T!/!HWLD4COVC\VM_V/M[K3,7C<ED<K_91VKWQW;U1E2P47==
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MK)=/OX;935I<6I!,UI)9JX>]#LX%XEEV&7C8_YAG60:+W1T9(++^7U>M[%F
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M&3J).CXBS7T<>@X?ED0Z*CRNBO%>C!6<IK!0,P^@Q8B8% ?"Y(5BY1"EPI/
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M1]4\;!V:%LCZ/1L.=IQ37JW9>A%:FKOVX;SE*1/U5UY-X??E@+L[;S<&134
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M5Z#YF9FNCE=HUJ'RL44+9#0M2EY!/_DZ''S ,Q9NKHH2VDWDX[V:X<BN7B\
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M:P*Q'C2P8 KTK8YYS XG:_H,C>,5PEM>REIX(U#N5%P86<=MQ_Z):%@U&R\
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MF178)=#/XE*&^-Q9U?I! KN19(92X7L?D,\2&M$7,M^;ESZS8=#>[>,D+JP
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M%QI&&D\KH]]HQZ&?9\)+&]^#?HQL=A"L )#><\NG//'KO]'X128=%94SKP
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M"#58CR\F]GIE0!>W@@7V5^KK],&5.W?!WWN/' ,*7(E%ACHH51X-'.IN!]7
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M?W>.Q9+X_H>G?T1$^3=M=M;,RW&_=R@UJ(C2<0)%:=0_7FV+FKMG#V/$PUX
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MW'I$+^ DJH?,+K5,_"F73ZRH;T^291W7Q#;* "*GQ#@2)U9RN!=PL,FR=@_
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M*\:_CT?597U'W_*B@V=)O=)L_/"3Q,3G8#HKL^:H3.D9EG5?P*B6RZDV6(:
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M[AP-;MM;X7 W][0@@88G9-^^?K)(N*-,L8:E9XT^^\"J5SZ +?O_5=FM?ZE
M+%&T'FZ5@S3IYZ\H/2OMS\P1(<O=E;;MT28O*<2K\>UW^[MX:N3H_'P51:9)
M\>,OO>\!.=>!G#X=*DYXF=<=\^BNB3P\^HP;GY%,7U(V=G!/IFZ;H#B58U=R
MOP;0\A1$^C;%#MUC_O8;(M-XN-AX$(9190@0 /UM@?P>GOZ9#1Z@J #:  R5
M/7HU1) @ICHPJV8 O9J@(V(W'MA9-J"P/- ?>[1IP:$*.?Q>/'# (0GW!H%0
MB XH*A"!.M^QC)$Z?H'XPU;7J=(EM*EDX(FR=-(<50=ZGJXW[09"8L6,2.O"
M!M#X.5,88\ZI2XZB3KH&5T(EK#H^7RM3K,UE-M>KWYTY26=).&@5>H$]G:&%
M\I*+QE96WXL%9Q=?#(IE3?/,+S,&8EA<XX"Q=4.B^>[PDO2@VF;O!5JORT?V
MYN#*'.6SM>0XKM%\MAJ5^'23(\R^-("'1^<* U*966F['U=(%_O9.X5^VID9
MK0@['FL]<\<P2#"-,7\1VA25 H<TD4*_R/6%J)M>\2>X>R]D#T*^7$9<)FQY
M1HH8A4_L.(:&]&GE,GR)22<_UP*1O?-^T8/?.&=O"$ZVUO:,=IPS'= +3V5Z
MXH5@_/Y2<W#I'U5R[@$22[Y_!0_]XD?5DS8:-"6XI$2K(XL7$Z<(O@=\*CG;
M23P;: AP[T*U%S$7#V#>>Q7^E=-I'_O,Y!SVNN\8+>/2]'L ,=8R^II]YD35
M:?&9,E95;/\L>$7ZX/=DF5JY%%\&?WEJCU&%-8UIHAWAD F1JC2'%?6S9RCD
M2*-OE6_+NX5RV3VDKA&.?D)6\::@,&Y7@0N8DN[J57#5L.A@J( Y?.GIVU<N
MYTS/2F=/'-R![K.@79OB4L?*M=^FT]JY%*]5<*SE5A4_UQ#> X: [^(_R8C[
M$%[/91!NE$(^G"UE!S[TO5*]C%EA]^?6LKYQR%E)&8;PT. 7*F[<C!LD[<<]
M;;_F@"BY5NQ%@ARR7USIU=]LENQTJ0@AQC086L;).9(2_2L2 PX"85+G"P[%
MY)!D*=WAAZ14TRU5%$&P+1[=J(::IDPE5D%*L,16/IZ>ADTWB%VOAKD5U^4C
MKA5U4B<N3?/#TD"_'2>S:5T;D)/TBNNO=>1)9=4LR'G8LE21_D5VI*KG7GYH
MNC@I4T^/SA"NA_'7?C@_4.S16EN,Y^>RYUF;QJ@T(++-.H_=;6QMAWV*)6ZE
M5E7%^E3.SD^SM]Y&!X18FFUI+*4X.*BI K%NM8[<2(D=F6]N0HWM*2MO]Z]1
MW1>LU@?,8W'C<Q&4<Z;Y4[0<IE,J$ZO/+>6Y:L2II]6J2C=[8\HR)\^R4R=T
M13#&.#_K9P11@O#I)I<I&]CT2,8K'I3KV>EZEQY!XD@K_J^/>N3E\@<ODRJ)
M"24CBS8(JW,D.SE[WD<!QX7OLHVORU0])2Z>)TFN=Z9+5^=15_"Q&W'QL3UJ
MN[%3UB6#TW E9'0-(3(BCL["LWRR*Z268RIJ5CC8-BA?O!RG?FT7;.B!IE"!
MK58THCI]?!V8I=FOY_D]DYR\O<$R/@X]+<I69':NC;L*?ZKK1@=:G3RD%/+B
MW#,6APM%P8O(06QRY%Q<+<-;RS-1=CZI'W60VO$M/F5+)C]N^(YY\%-XS_3T
M^]_E!^<N'H6)$A7R KW1V\P_1;H^&5Q-G;.><G,,#=9JK?HGUB[2KZ@E+9\=
M)"+)?B:;)ILFRI'&83TOM[7+"V?9*WQ9V213;T9<>PW=6UR&MCHTSAD/BK]5
M[33T]L#S/T$W*CCR?K!>%K7.FTE'4?"N@PEW(=A%9$:4E;IPN4@*+;^/?9L"
M5$6)=EI?4XN%25M#SW!CU(4I'KT67DPP#7(ZF'URI/M7E9LV,2L;M;*#D3^]
MSV.TRBGM:JM\M14I<_I4ZK]TVKK:LF[?G%&3MILU?CR\V!3#>N+4][N%ROOD
MJC](1FB^?%$8EC)ZRW$R2) D)DRB-"56\GCF5R>0R&7-0H1^?Z8FW1-'2V$^
M>F0AM<V?Z<F0G?:1(G'I[%,2SZWM>-W5V ?--&M2RTTKJ3!8;.%$4WCU(US3
M)1X@7H_SRK:)HP#:4NO5H>R!J]:!WDJ6G&HF^8$9+Q%/V%^DHJ_/5ZR#W63)
M>5U%SCG.\T)9RY*<-<UX65\<*UC W]O&U72JI*_BH"@E173)N_&(U7Z[9;L#
M3IP8N<!,E(1%P1IU%;;B-! 3.UP(=:YLXAOW*XMC]RA:<7QN5!X1NV (=D1J
MF?9%MCNMD\LHF' K>>0?=\,O3EPZY-:H%$Y%!(?FA<X%:?G+B*BHB=H=3Z1/
M3E&LH,L]9'5##'9IG[AIK[<2T'G.?_L-.8N$!2I!^AH?N^-CK/8UN4:V;14Y
MD<69:L(C3%-2% ::P?DVS$]*5$6V!]Y08FCA")2C@[:4C);1U\IQ>+[P!P\R
MN_^1]9,J['_T>;"OPG4:NT]3!G11Z1R]2;2J/50PW+H_V>FV061W40":9B4^
M',^6A]KHA")8586C&RHUXZW*+&DNH^-5R!3(@4U=65E-1O.?.AG#_NI+!!K1
M5N(TV>+_VC]GV&J\*B(ZYAX@VBG:>"=^0\'DR^N$2_$-NB"L-VOR<JK%ESP9
M_$ZLILK5IVO_7.>N!:UU/%>.Z'$]$6[EN09Z,5&?!0*S3ELE4R:2!A!NDK9V
M?'D/09[V_#X,0YLQJV5@DK;K]!\B0$7W_C .XX@5@^7--Z1GH)*LD,;Q?(:!
M64RH2G;8]223.+SA-57N6;F(7^SA4![B[OQPKI.YY%UX_C"4T5MZU=Z!-(SK
M2YU>XX@GA#C_1$U:E_G:*4MW<.CPQ*2F\G#T LDSS.1Q$Z.?B--7TZ*<D)3E
MQ^7\IX[FENIW9=,AQM6IWH1X1CWI<] ^ T1]$0+1)!Y:+'J]'^<M=] AY]-X
M2P=U.).K$^,1;/': W-NL<_D2O^4$2V#6D56R%=+CZHIF?9N$?00X'A0)I)]
MA68D =._C<Z*HE^_E4^)EI[_C!>82E6\RD>'4IO@'6G+W*Q]F0+?CT(_^_QZ
MJL!1T35FHHO>P_>+9["CY<5RQC:$20?-S5.?BGX305/QO1!PM$Z<X,AFR0$<
M3VG+3'(?1FJ$9BI1<JU32/7C];<BG,KN 6%(?TV;)N O$3TBSIF*&Z7EM[^+
M,_/C](^&/<81M?.<.C/[%;RS?#6^"2\Z-S0R4KP4$D"G/Y/+ P5@1V2<F<D%
M=8;OX# DQ>*.QZ6:MX+6/F72!CQF<S(U@]"4=TM"98L^LHC-Q5A@,2&V3_5(
M+R:\3_ KW7L_8;MQ:7@WQ\&2<[<H^ZW!"<82<W-G)(ZXZTSBD"RJCXE.CGXI
MXA+7O)64+6:<^]**)K!B:U5S7L<0^"+:9U.:051#DRJA,G+3@'0,_)S5<[D=
MZM X3[2GMRJWFN3V)R,+/*3F&\ )PF!S=M&N@]TS_IB2W /:E(VW+=_.7F(6
M[HQ5=9URK1?O >V!@=.G'I<-'$EL[EGX[X=W^FE>4 66;QE (=,H [D-76PY
M&)*^3IQ2\>8PV*'BM%O!:]@2:AR<:'=)=3DBVG<I$KCV]S5\9S4WZ7>UT1_>
M"Q)BP@UT,Q [83O[UV[GD,T"7I"V:("(%@YIPH@%PVG4F_ "*UJ?CXBT =O)
M2)LV+D_'$A&Q;SN)#$Y\8)_]:JU]:U&@L8'=&T8SY2]6 QJP7[K"R68#PX['
M"NPN5QRLW"NQP&=TM(G6>8#UX';HKI&PAZ)>16E&55Z94V((GZZ#<^.\0FTE
M7HE2IU*2:&WIH+I'PS1S7[&\6J9=<NX+C154HK[,J?7>6H]Y4%$%Q>^$#$SY
M\U[SOW!CG$ 6?@^H%.%X\Z*CG.%D/E0'U["WQ;#P*>AF<T)YY-Q'9-Y3H_-4
MY:\9=<WRRS"Z->DBT  Y$S=S YZIAB9-I7IQ0UDT1[1R8R-MX#=Y00)<53;Y
MED])]IJDC@*\0;L])U!2FQMB8G/+LK;6<M2/XK T1C$YE;ID4PB;L=;%TJ\K
M)V5'J*,A^RRCI*L24BV:*%GM4GVUS-BC,\V@W%*OHG"[/;Q@<Z17KJ4?<^;4
M%;<??WP/H&W9TAPN"EO/V1<.Y#QE!8T?,AVLXN +:8OR!ATB!??]#2D[G+:6
M-.':$2WZ@YFF5J ;1L930]]V=-^B;WP?H<.%)///4X)^F//@EM,>KE2=E:=)
MBRZV/>*+F]7N>>0,W,SRU;F<840L%^SD]$-639#W&;-H%M1,JS1N5#DSJGSQ
MN 2YUTC7=@]X?IKENFQFU+@ZI*60=9<_ID'=>:MZ31S6&ZS>*7O+B*8]'L48
MYV(RXE(RQO;J.$R,\>X!5O_8-8^,:=T;%YGS&I3=9+?;GIWZ.-YNHFC5/+.?
MIN5%]O)H9W73)K9'3DI:-F=^'ER7IV+[/  C"[AR^&+*3AS[9O$/_7K:U?5K
M93'C6\75R[9K>H$-6^?&)B4Y91()GLH!T4T!91;51+M\M2AE=G>;H[E*2O5N
M;]Y6QJ@1>BRFQ4^=*96J#G(R 74(FQ*IVY/%(X_%]$WF82V=@RZVE/)/BJHJ
MCT,>CQ,Z'ZB.4 1_12)Z(GCJKO_"56:Z.8XS]O[?2#S%@J,,>Q'#1WL^0?"B
MQ%AJT);=SHU5&VQR(&(5-S[JY)= G$14E.Y1Y7"<[JCOW3U@[*Y9QS!0<;+A
M=9;@7#U"^T]%*"H6O0QB+R]5.2]+IC_E8W^D/>W,H;UN:1QA55:J)&W\Q,)!
MOM7LEE_"Y4\+J?+!R-\UYP04S2V*&0RE597EG"ZLX^[1I[%DGZ8U&ZOZ-?0U
M2A!CRI-J9B7X(R1XSLW#KO4Z#\Q,FTYN'FH=31]J_9,)$:DS&$X7^<%%8.NA
MY;OW("Z&?]2>T1@%O3_*&MEU+2N"BL^<<V2;1CZ_B23K5I(,"P/'M+L_V;1'
M,,E\IPV\-GCPTR6))@ /5)KILI94E$,KDUE9X<1LHD]W&+EZ)Y5%7.(CX:M;
M.Z\\+QKE\BM P'LI=6&*5BG.NI^_&*F8<WW3TI)Q7MN^MWP>PJ4/+I;J!EVZ
M./O4O500+T0EGPKX!2OQB81@A]JBPOYD@"_R$[DOZ(.TL',3(@4_X!I"^#4/
MAQ#8 J,<W%$NR>:9%N2,=4JBZ39G-A63;$H@:9?H=7JF069I55O59+UE@886
MF\J2RI@GD_X_+B%OH2V,&G8&^6$ENVU\\#1IJ_%]0DG"!GE3HWO *V1M:+D]
MF[0,4S5V1G6G*\O&C616;L>+"3UU^UWE32OUK0[K.E6LMNHY&I-<(Z.W0\*"
M:2:-;(J]:J;??F5*?]17>>2\/]U@ST;5!C'(&O&,%;69]S7&0DC(B]>/Q\SR
M$4=$^&.JOV^MS@SZ5AM/V 6"$3KGCM6#>P8SQI^W[>6<V#,'EH>WD++*4GP'
M,6GL<QS^W51T/[FD<;E@A(]5PZ4?LJ.DW_[5$C>0DT>X7]@P]P#O@%8HANKH
MM-+N:4IJ,=Y. !@"":<8F[,"F7+>+KFRHQF?C-4/YR[%#GJ[PYBTJ71@[/ED
M_>:-AHU_$A=KYXENM:9-R$MTQ30%41\'T<WM*[<WT+JDP"?3F2JY&:OW@-E;
M>??;T%N@5"GP+7/ET8R-2ZN__-O/@F:FH4IRF;'3/@4O21^ZF9U4K]3ZBUKH
M(%7C@Y];XWW(*E-^H6@T'"=RBG(Y"CQBW?&4 04X=,XAZ2F/O03]M74\LDW"
MO3+ZQWKP(M^/CO5$-W#AQ5;0?:+Y/$C>J[C]6 K?:[@7_Y%T8]-@W\$N^A6%
MNTNEW# U<M6)6;[H& 3+. H38IQH>'V0KMRF>1;!*2-P5A @9J;%&5D1#UM5
MFAL_TRH) [DCM>.4]W%.IJ8:RKJ13QDU*.E.MM[D6SUCV2-;XTF7)(BH^TB;
M'&+&^DQ$<.LC<C9VV9LN=.KQJWX1!E45W!J"3/4>-D=N*39I&I-W!*ED$5%U
M=4)S%&T9<L&S/L9\/SW>&!OT6!4/2Q\H]<CB^A%IV67476F5*G/IE0'EO+2H
MHV^,B\)R"P\/MMULSSO</MI*FS6'UV[BY6(]XVYJQ469U3;TMO513/N8>\T/
M3^_8[ NF_5+&Y#SPN@><Q>),H(HZC)ZX:#:++E_Y4V.=@L5;%>\!)I.</LH.
M=MF"SB(UW";E)OU@?J4A&-$L_:JM#7+7=<4%W<!7*^?D6+E?N?"H=3'PF45Y
MG\^J')Z!6&D$W,\W>)Q@\QPK9&N3Q):,+E&-Y#B,]LF5&8@L];5""JXO$RAE
MX*!C8\.C@"3=3^2G %(U-J2_C+'(0>FE0>Q[1NLA)#>@/<Z5VDFO\GURC13O
MS]F*B?2R-YFPS5.=#.=5&,)F9L#L\)?AYX4B1^KLMI/68S3W)U/%4;C2F!R/
ML#!?X$G.5W&)/<<%ZL:G;EE-MYR@#"'AF@[Y%_*:'%%#R:;-F72#T.Y*8&Q=
MX2SSH$BY5U_K#-J\I5C_:I"A"./*[4O/E!GBLJS_LR;MP/".PS+%#\S*K.8C
M^)HDW\9NL<02&.E%'X/>^**\!'W,V?4H@D?8E>[S'</&5-Z2!4D!N53]QN0R
M[ZS&Y%[Z7AJC/'-ANA+OI))CNO]KNVEQ#57"QB)S>';OX>,%5XDZ-T4+ $I/
MAD> ,&9)5_XC@UCOG8A52D^.DMWZ] :EFGJ':K!VGL7$:W'];=[0W!X[0W8?
M19 5EKTK4;GDF!REA H]Q8<EWBG7EX+CK0]0A!HU3(3B+ ?^S;[4&] ,":-)
MDI77:9&PXVP(/-/>(GQ4F_28CG_]3A[X<316N34BNGY'$/!ZBK@@,AY\DJ8$
M3!W9%961F>+1\;UP$;2MK>&:@>K)Q*I&A9'%8@N0EXY1.I*P#!/])NQA$NH,
M('1!^TD6CI'R@+WKM;<LM?E(:EDRO4ED: TJ2?J]#(G2M=R<R+J')@L"6)V5
M6DARC4J^C3QG%.>FS*CB4(7PE'E,R^/;:*PL]DPW#9:-@\21"M^7T7B1,V16
M9!:9\H5V1"BNN6[+?6=@3:/^0,;/K*(2YF<-I3Q:]52]W;7?5'>JQ>T5?,FK
M@M#-]B.Y#3@]DEJ;ZZ0I>=]+T@M_E.'XJG@2?)(V>\MH]X:]980R250F\M#+
M'F80(@3],Q>YS-JP!E6>>LK]T;(BM<_V@CK>L$^V,+Q;%F[8&YR:L5*:$[GR
M5N7#E,4S9A%<B/#[<M_VO/2=_LP<7Z9M!?_%+-?*_ADUU=H5RI-VO97''&IQ
M$ZRJH8HDPRN+!0E&\766LWN#\J*)3KMY-%$Q=]\<+P\/\Z:3[1T;0W[\-6*;
MY%T52FJ(6-J2]MJD9'O3E[V^.)'X81B>Q77%,FW7I!1=AS]4^*SZL-R(XTQ0
M:(2\J?GLE@,3$. 'W!>_!,.@&.-;M(6&T67LD=HXN;!^0^Z?^%W[AC%";5/F
M;R(^GLPVBV4\1B^MO*J;A2G;NTB/:ZXI<%6#-<K#IQLPC[U*H)!<6Q+W@,,L
MOX7=XY[,G/Y[ ,CA+/!SB[>J9D]?#BY8D;YT71)\@[X+_^CA&Q@7:0S);.4[
MCSN"]K<6WG:9+]K#*<PJ.&1O:(7]^Q\D0X6O]!2XG)ML^]3%";YP-PJ8O:2.
M>I.4ACSC)>48)F[\E3:?U00"(;+:YN?1HV.'(- EN_O,N^_LJG<A(]_FY^\!
MGU9975#7OI@RU_*$I>L5>@93ED7Q*LX$*Y?I!7;"M&9&5<N3AH_]:Q1N:5Q4
M^A2 ;V9;8K4#GV-EM^(=-/#UT6V>QU6!/(:397M0</XG4O?6;0G6Z< C%M;:
MTU6[GW>8YU<9.])"8KD<^ON77$7 5<<I_MLB#'WG66!Q%':ILH^N^%FK*6;F
MDN(X.T+;%*$:-U$[AMM:TI#:%R ?NFKAE.1JP&-Q3CY+N@O:=2SJAG!P3OVU
MGGL>^\%6'G1U,'8'Q!<)J1Q[:<]T1H]_\8"BD>)];[M= N<T\V$<$"K#D+LE
MW>60Y?;1S3,.)$J<$CK0S!_1"Y;DB?A).W51R[N^:XE84O[%51=XF:4061Y_
M4%2X@JG-Y<)_O['>$ \!!PCUO:K2;79RX<MXJ<B&N0C&Y'7RJX"Y Y]U[NW>
MR>Z+W0-8HLJ1@P:(Z^(.S2MHK7&"Q\HZ'*CEZ5KU'JK$)I;R<ZS'=?69P2B\
M>VQZ[,5<AURJ7%:OX8 7B3!],<<ARP2^L?2^WR[^$_!4?<T)9,CC>&X\V3BG
M>(9[YEO&E@OCM<:?2D^OKN2*#?:/E:7X5 57LU&*#)V[1"/Y/7MO?*1I_+<J
MZE!9%_+BYY02-$SPI>[_13IB2X8_*.Y-E7M WOB\R:O\8BX0D^PGW( JKCA#
MA:^<A^DQ VO-#W!J'O]^\.U!>!)HZ!W?R/X(<?RD+GPT:UA"$^7%5G G=15M
M0.E@5CZH9442Z*=&9$3'C4_-QDA9DR!MJM([A?3< 3E<X>B:0"G>Z!>]*?_"
MYFB^Z63Z1BHRE+^"K@+19<&EN$((U6:,J-V90+PU>/7/:'%/6<@E)PCL;]'(
M65#+3W::_G1@PTM09Z>AZ  K+J1Q [-*_'>%FZH,I&6\Q2WTU])YFEWZ\;9&
M6!:\<+CR$%&&_^*1ZEMX7RXIZ'BA43:5ZQ([!TS:;Y&>\CTAHZ+D9NLCFGS^
M5YL\)^X]0'WY')+\WV,KA.CCY0)]"0>E<G96*A)/XZP80=D/-PQQQ&LU>Q1!
M<+01D;M%%)4T&YK'@K6NZ;R&CR?C;DA!>%98OG'C<,:(1?UJ#N\U:M=>."I"
M2F2JB&'$.*8GX7U#,GEND!:MS>YDV?NDQ]&/7O]S$C@^_CQK/]A6IPB!_=)R
MU?4]YZIG_2Y(-,NI3%S6!V?;0JL-L-WQM (YX'<<8H63S?AU.GO^OUJKN(D7
M%(V^AX2&A8O .'X.=?'R1:2AD]A H@<+FV%>;"K2@>9]-!]TR^J,!GXO9N$4
M\AJ)AFQTF9;-U A$/5H>2+VZ%@D.&C60\Z5FS_BT_*EKX^H+^B%;Z^#_=+SP
M/RC+NGO5K.V/-O#=Q+IZKK2ION;3_*O2X>IRG_@KL-CR.=:1HE :/5[[OW?I
M_N^^\47&*\Q,R'<PE]WLRS/JZ503".U/%'<44&K]I?>)V\ 2P3A<BD(C[=JE
M2KQTQ0OA$T.4[#.R=FC&L=2W93LF0QW78)JRIV7&5*X!U5(/&K'9Y#>-U;%\
M& U;!%.#]-\2NPKOW#ZY.AEK$Y*/OSH.;VS--S#,MCWY"C-6DR*KBQK4^6"'
MN#)A9KTBE5O>GZ-]6#_PS]6$#3B\1(XESSMH3<I?<%HO355WE1S_,D=3#\M0
MV;TA[ R>EP?<G?RZ0:NRJ W@KRD]F:\7@_;N*8H!Q8/:C1G#AB=#+X30ZC;O
MZK2<S6(_,)Q:G;HD<ILD,C_>2);X0.W@QJ(G7'/;5^' H.'>5Y3MJ^\!J8/G
M=9_*%: (<Z"0GP\YF<>SEG/8I<6*0"3M:ORUA#!WG&2:ZSF_=H,0^=GBN5 $
M:[R494$IZO'TP6SF4UFK4)WE;MF"Z.!?L"59PZR<D+//_QO/-)">T 4]W%+N
MIAG]].F@FV9D.$'XFH<'R'&T-;*]?ZM9=61UQ+U_I6 +.GVGR':Z>=Z85^K'
M!<0EW%V22AV#7 Z^L%WSQJDQ^P'DU'_WZ&WKW&W_6R.C&J@0PWY'%&R!9,2B
M5&>;73>A\@!I]"HN-.E);%8S?C:EKG!-3&6<=IF:7.X#+TM+E).;-W!J<Q\X
MT/9/AG?LG2]ZH&"L);#:]S"T^+ILROWFC"$9BILD!527*G9+$!C3?D6SY#5E
MZTQ2>P<)_7)>3#9$<L#[01[BYF1B.C['N9U6RM2F5Z2N[G6L@>R:-'M2Q.C,
ME=8GO1^$<?G*F) JH<,U8O20@94_EWS8>. 1SONH]^%U[Z. N/"1'AX>[W_<
MP"1@(B;^?W \__]V^N EP=M'FC;V("<*7WQ(T5-)\L0R/M:S"NF)V0:M7R)N
MDDSB21'?A%V7"#H?<_3"D7)4QZ,]Y.S@Z;@G+@V>4MN1"J_-N#C'*,G#(^W?
M7.N'V8-Y?=[\Y")I5UQO(,_L<16ZC#&D7F"LN\A:0M(GC]^DEZE(TE*(\#\(
MJ=CD[$:[H]SI0=L4'@QK,-B<90RB3%A.SSOO/=\1S<"+2?],OA?3MG?@^"GG
M$U%)9I?93=)SQ5$6.5P;"^:D>\#TZ*/>ZM:K%#;<AH*+C:T:]#]/P\P+?VS5
M7<8N<1&J4S)@$<QD!]=I:>UY%9"^BH4)NV#CEZNU/AC46W8%V>3&AX$Y$JD:
M/SVY]"6_:/QU1!535.+"^<8^6.F-DE3PB9_<<1HH)M*V[[!;33-CU,^_Z &%
MIJS"UV2&2+8Z#>H#FX55X;KTH<H"F!>X9K)-DX^*$':<.V+JIYS_'4+XK')F
M3[!F)A-[?VY++A*[*/J(M5Z_X=NLD!MQ:?WT'Q29/<SD[U[DLH^%Z/9I-#/E
M?(B0"Y6?V4\Z[S)EIN7,1?PZ2/XO5;E\;DR0-E:WH'Z,T%1ZXHJYJ0I7W)E'
M,E^YEA8&_;/0[_'RU#U X6+)/VX8PVVI2:6YWEJ"@2";;M]"[LSA/^B8_Y\D
M 2O,$O37K/UO.=;G,3(655'0CO[A1M_AROK^X!.S53XKX#=$5O"QX#4^<^RS
M9D_7U^RFBJH4QSOLV/BQV. NA-X]0%:AC@U2G:X/XG+F&2DJ$.4K%7GOF:BH
MK/P%@N,C0W*#ZRA7KIXPF#7 \Y*PJ5]760QP(M0U,\.>B"A2J_J#]F4+!UKR
MW%EP^-"T6[BN;N2OOG(W+M@]'*C8B>+DLX<Z-C8[& <9-(JG6-A77^-[YD P
M@6B[;:MO[=9C]X#P;C],4YWX];Q+IICD\LY=)^1ZEKG%@3$T4#73\!Z@>^UT
MUM(.1.?TE&A7,Z%<+P^*L"5O"CL/#]R6N3WV?I_G[YX(<JUC)$AW2NX!-C"5
M2W>H)UW:H@YZ=8GEJ< >JJ$=OZCJDZ@@^9/4']/DKU$\25/!R\-8>M+X.F#^
MP4'R&5LL_B>>\B#ER8R:)E#)7BO76.A$TY\&HA;GU.NIL/T:]6>,H/4.["*1
M^&PUL4)63M,LY<0@7SI2D[]S^%#@JUDL%T'L>Q) -$#G ^!)ZJ?'NJF?=(-U
M_U&R6RN'LDVM[A7^IRZWREN6J)&!^?[APKFS0LBD]R)6.Y@C_OM6E%MR6[-P
M#SXN"]CB9M1R5F8LHZ>D@2[3HE-D-J_4D!IK>M!MT+7X-& @O&3>0H*F+WNF
MO?B]L&0>=\N8"(9I"E^[=_/AQ]@9)SZ!MUU7Z96*:,8OOV*]6^ALZS?J[+]V
M8[TZ_[*NG^2A<Z;-ZMCB4EFZ!DW>X<\GJX)U'.4=+LAL)B4]M\MJ')1HV=@1
M',Z+-H4Z8'#N ;E!_L@W:W@-0H;UA9#FMZ>?IE-BA51>NG%D=@_LX%5\I,6I
MZ[=>,B\+>46]U[QAL"%;+$>40CZIXU+Q4K=Z2VK;W)4P08Y:..'E2]]/GY2W
MS.^:"5$8Q^;8MB7#CTT+55P5YX:=^O#M\O8,1B0O\9<'UGMFN]^$KWBMM<CV
M-4,Z0IGFHM)P!UI/:YTL<?O.[$I?BQ/)J.-K][27\CSD6(_HZF>*[J5TI8]O
M[YGJZS7 GN=\I?PNR(SJ^S$0>_TX.\8BC2?87A/-J#KDG[E)>O@1.<*RMSS[
M26V[5FE02GDF4K*_3072>]/@1:::494S6-J$GA/T2&XY*+)<FA'[':G?H>-H
M]=9]UN3[DK\<U>9>B[\>H^*R58]&#071ZZ3/4\FR0OD)F?2]ZUMO7\W2J,YW
M<&E<Y ?]+K/CX2!L7'0+G1"@5$Z;G#+M6W>NS\V-*\!Q)NC"\1W$1,H5  7+
ME1U1.MERC,F1<L]R,EG4-Q@I5ZOV^"WF1YY3MWNY ^]BL,^6.;(=<ASG.5!^
M)2AI;'UEK+4;7L7G-<QR8Q9L46K[#JT>=G5;<?,5/C)EEP4, ^'UDLY"JYZ7
M^CBY9WUNVK:L9@HX12>36U7*1A;KW6*]!(]<U?6@//U:!<ZFX)&2W"!J9KJ7
M/B1.EF>64#MCJX9#[P&K8=V-&" CDPN9[>C)QHGFM:=)9($CE?;;/Y=T#=8=
MWB*QJ/Y5NT7V<ZV\,&O>Y<HVAK0:O&4S4VRAO %;$I!/4]B?+7E< @*=ABFC
M&;5?W:K?-E,+0H8?"^S9 SA.9>$T@-'M0X/W@"B@ZLO6NO=0#N4#^.A1=^O*
M V>LW^^SRY+P:D]_M!70SV0"ZW]TJ W8Z'.>VJ8<=KCOJ<1FNK$>A29%<%A@
MHT;ZCXRG%0*C;95@ 8LY'D/F<1:Q(]=O-I?8Q$+[KXY-Y]&!:EMK6""8S4WP
MF*NGF)#$2-V[_M]6IZR-&QPYSP7#.>7R>0. *J8NJ6Q\LL6FSF>VFRY3:R1D
M9>I%SSX:$9!</WQ'XAIHG9/(Z.KI&3NZ+P8[JF\!L&W;A>\[Z!TCSBF#<2?-
M<KVN^W9/:+:"7>(I4AI1)]P@]J2[@W=D6X@/*[PG]X#="KG)3Y>3QP:E_?.W
M4/V.6?.[J87/)1>HO)^)(!7ON&['I[%1A3WPV'EO%GYS_O8_#- 0_3NS3MY[
MP*A<92D7K4Q[E3W&^L(8:"IPIR!D3!T]=7X/.. 3I,OWPE2!6>D#!YM/-X?C
M^/,ZR@K6S1W#[@%MLL:5?6B_>\#5L'GE@8V\[C)7L7,SLTE0J#I.4KXC+ @0
M6D_"/$($+N ! 9[#C8336I]Y^2L?C S-DE>:.!F2ZQ?TP?0FZ^)2(9_=SWGN
MR@]?'-P#6%WZV^4P8RUEV3D9D3?E]L6Z;VZ9$%JS+(',FZ/Z?E:=):57#>%E
MPWT#^O[^W-\Q'J\,C3<I3*'HG(19>GP4QLCNV LRZ]5I$R#UNEJU/G+31D@L
MKG+/[V7+0IC\(.OCUZT*@[SOI"88XR=GI*<D'AT*MLL??@AIQY#)(P_7#_FE
MX:.'!W#XX>$_6*T9K:VW:4VG-S%'>D>MSQWA>OA>C?N:\[5$?S8]^ 1<&RW$
M7Y"]O_X"P4O--@W ZJZ*&=#+;+EKCLA) )G:4!Y)'J6T5OWL_ %J1+0IA\=*
M5J1.Q9-/#^YMFS@GMG,[9I A13X=C>$3'U1]:!LSBGBCSP?MS<%S/0^@+O2J
MV2IB?%6"L% 29TE39U:[1/O2:]AHSI*. %O]JJ,/HB>[_(RE&5),._1',W9>
ME\0MUO)+Z31>22G-CS >PAR6FV [0&]2_Q0_7,@9 URO)'GT>Y9B7[,5CE<F
M7= G$I8O4O-K0PA:%Z^M#@R'4$0SKHGC0&?9=!1[/#2YTY,=W&['#A[4!6_+
MT"=DZVMSZ&=F(FI,O:.WTG6QK]WB!^_2,D(M+=?B]5Y:_N.R-/E'MJW+OS "
M[SRMZ29'%Z0,GB!!J2;#S8P 5%6OI%W=-K=B^=<'V]JW/HBKKBX5=A"LM1G2
MQ.7;G#L(%NQLR3$F)-#O6V01?<F9+Z5LD P8559+MH$MF8!4^*ZU69BB%@B4
M4#V>M7+T(\SBADG)[?[+B=?XI#/&&?U_U3=&X6;@^W1FKMO^+IH0J,)^#_"$
M;"[]%29,RYW$IGAGW.(]8%^?*)^I0ZNE,J[J+E"W0D*I@.XR.M'FX*9HOPZS
MG+:6=S/<S#\JGHNY!V!8Y^;:@Z9O4]+QQ/.JM=W22$D2^\NPE!3]'0M)FY/:
M&94,_#]Z6IZ4#U%1"TL]&V8&B,=44@L$?3Y]&%>N$.;XZ7M)3MCZ7^/H;CZK
M(V_0NOE]5N-,$:F%:J66UL_,=0KO.ZA 49O&73/*C7YDD!V*L.SL8W&9+&(D
M9U)6BZ:;5,T(NIS2UU=(RA99!&WK7\HX(_'-T79MZ<7U,^']LU#'>K'61"@(
MZ2-PIR6Z_?S(YZ V">YR-?'8X<GK6?8!Y67B)3(X&^M\_OC=[R;I[[3-NL,W
MDW0TO3KV+E2D2A\YU<7'GC/Z]<G!TM(R#U5+)5QQZQDV!"ERA8-<.AB:EO;+
MQV#^PM_*IM=1(_O>PJ<\7AUKB.+.E_> &1[!P.DRJ=*Z3:<(H4K^BH1"4W-_
MDLBR_'1W#OUM9!Y)^Z'#$+8;\BWC\.Y%9A3V.NDS$]V?)HA5[2S[Z0SI_G;5
MS[6?];42U58AGMMNYTBH9 6HT_*L,**_D55V=XD_L[^N+L5 3*R!(#FM14_A
MR6-3D(7)A9_-J)QA6MIPJ*4J^^KT"6?,K<^O@(LAYKK/:?_698KK42BR>F7#
M4^N:B<A23]YA9)9KO'1-SG"X6UQ*%!A]&1M7+,VE&MG;P 2C2T0<)/Z!K&DJ
MW@.VXQ8#SX1:[P&@SEZQ&73)^#U 3U/VT3T@7=SA'O![[PB]< \@N-6_*))!
MVVC&7Z3= Y[LKNZOWK7#0!>N]P#P7@X\\.B'U4,:%@-]M7C#70%PT8*,LT*L
M:("2J#<F:F%_TBN][?K:MY3'5VP,,KVGXZ9.;+HBW\$1HJ_MN$3SVH/E(WL9
M/ZZ98*3 CV!SL 19?J+R8YRYAX&_6Q*4;]BL2B]"H3S 1[YRNQ'W@$]WF0X^
M-9WU2\#D=_#NK17E0_CAP57SO"?G,0CE8+$=D!UC5Y2_MY9U#;45\G/F&-O9
M1!MS^MZ*U/[9>6X1B*GXEIA79/&:CR?(R='&;(-#A[^=(D@E?R[_3H%Y&M:X
MR4K)/ 3/9(_S0CJ,K]ARYB5K9*CM+EI-YL9-G#=URK0WK^<,GR_NB\_<M $3
M-T#<RJ,'=W5U)_VM84X)&$V'T57#J;EV^UD^QY4N%>RRU=ZZ0()EOIK78!E/
M03I'\/%)<YI@0 8-GMI!%JV[2?SH\;2;,1(C21YPR,,H/<K#$YVM!RDV#-^?
M#^I5Z?H+;LC#Z1Q%OX-VN5RH::*_@EM[**W"*C>%JW<&_6W\:5\Y>$\#]VMO
MG9T.%HF'Q<82>]=J#:S6T7.D@LHX-HWK]J33QGL+:'W0OH!85=EEB[RA%?U.
M8(J/E'#G4+M$ ,0%!&) @0(9K9Q\A<5;0ZZ)<M *G'7^E[RRFP6[M_"^@XA%
M-WW[4>M:(=M)/9B^P"I/H=,PZSKJUPOX]AK'D<P[+A2!^3Y^#(5 ],GB5W^#
M2IMYTD;'Z!4#K)[71CMAH#(9*CN5I7>X':\&PUN?I.K'4?V,/=IK?GW@CG1/
M??Q=A/]=Z%=.1A1&N15H!:Q2=\#DYI:Z@[7\I*VH_%65<,XE35^ATK/V8'"@
M]?P+L^SZC0^*:+-Q)IEW,I1NZY5B5=CZQAQB/D:(05^H?6,T]ZM;A3S5!B<!
M]HXE;6I&9^#;K5UNC?F1 )R <_;;:<=+MWX')&FKHR9T$-@YE^3&SXTJQEZ!
M=AQ57>[HFYM53VZ^)Z&>('-,VH]FMEEG8KMRZN&)B9YJMHL;=N4TZ_$$Q63I
MZEO=KO%VE"\8.I0X--@S=(SK"3-#V@MW<@IQ"_:F"IYK5;L.3M)G^B_EE$FR
M42V7Z^I%LG*^$]$J^HEWT'8ZS'91*(C4 2N0E,NBU50LW9CME6COBM@*U2CN
M?BKO&Q]S?D>]=STWR!RR4)H["<63MSLRF)[5Q9J68]DO [OXRO.?^?(K4'KW
MNENL;Y0K:#:L+"^-GZD:1'(;;M(AQ*SE&,D_,M:)U4,#6LMSQYN?(=5>]R(G
MQJ.PQ+;7O!S%QS$>(:B5F_WZBT7-)KFU!/'/[DW7)P.G]X"MVYQ]85;A0CYR
M7@S*N&?R%-/=?F(4QA8MO=F2I0*/78GQP8C/F1?VV^/J3;J?<236NL!D/MM&
M&XG3H)JB+3X>U,_2!!21N&;7<\\"K/9YDC^0C\!R3#WTUG%=>@BJ90@>NWRM
M>Q_\A0W -K(%IV&#K]+RL(.T+6I@!I5"O?4HHO^#MK>,BJO;MD4A!@D6/ 1W
M".Y22(([P:60A,*E\,(AP=T*UP0-+H6[>^$.A;N[R_N^??9N[^[[[FOWGG;N
MF>M/K3^KUFICK#7'G'WTWLU\$4#GL,X*U4V+-Y;3WWDW.[1-D:+11OP(7,QL
M:5U8C\'34]=A8 Y=7_%@'@)^<;2B@IXUD;+,_%<&%4;\2<%K!7'AV7T3N-M9
M3%@H>@'(Q-,C%C8HM,488EBIF"WNS+[*>^#J JF9>SXI[#*76N:B4$0C58AA
M&R9=WIV#/?.U(]4Z?>.^X+X2*].V7L[F>?CU?4ERS^^@%OD*@2.R"%+'? N\
MNQDQC13[P#I',[X\3^F*V!XNK&JAFR?309 16"&'N-HJ;-"K*\_-AX[Y7Q)M
MBS!8+>8_""?+:OV:D1_72"*8 ,2B1(=@X5"]LH,YE*,Y]:O[A/8!G(5"583U
MN*7G=%6HXRFXJP4PXT1B:+-VWV._?"P&E!/EF<G;F1$/:"232Y4XZE(@\;N_
MW6Q>\G[RF;C;:Q?N\ZI<RJD\R,BI;KO4[]]AXJ6]KJ5U9,G["4<@V@=Z@!_)
M%#@\*?7X/Q3VE*LU,U5L>(C6^6"L62J2A<YHEFS84^OY,WT_.U@7 ;YZ: -]
M<(U-$"? M)E2DBWJ(.7?E<V^/-<ZG>%H@"HOI)(F="Z4Q?0@_).W"]R+([BY
M:BO;Z6O0>XF"@ICU.AE(C!6NC[7;.M8QR0V >LD:3*<EB3H@$\V<;'C-H5R1
MP&X#T^&7N0_-.<FR%T/%&5AK*&A\9Z09^N6&I@-;$YZ-!S650C6:RQ9_:O<B
M@JV;BD4/!.8[29L\O$*FXG4_WK+;^O&P<G+M>1K\*B#Q;D21OP?I=I*X_(FI
M51F'O6RL=P:8OMC.R\W7#XF!L$J0NJS/"9;X-_;8>?"<Z_,I.L7.Y4TH-+FZ
MQ6]HZ%_T*Q5])Z:DG5>)18@^S#C=B?S^;.:%\FUB\B8?T4RM$*:ZFR(QGQ>A
MG90SO-O0N>9)T48N!*7.7R?"2/H0.<PINPZARE=7ORT;EO'O\N^2D4U3D$WR
M]T\-PC';3-//##+;3&]*3S#TO\FFEQ[)%L6_OQA<]O,0V\L='S!;1J2YV\+L
M8B-BYNW"M!]]Q+-5NAIQJ0 =LP>9Q70M7>OG8?NU%BQKC]-CI:G$ELRYO!&+
M,@UN*&?>P"A'[U810_K,&4WD(]W#2?6M*.-+K^GOU"GZS:V68F;>K[9K<^7$
MO3.0?8&SFBZ$JX>CA"(I'+S8+OE79%"SZFS+"(!:YP+B.T0\FP0;*I[/5?EV
MMMY71"!2,$%7H&RUJ?=<M$3EO6DO.K27)\1LKR"A1SLA0\K_1+\ 7!6 'YKX
MJ0]WNOI5=F<O-ZX4IY3-%@Z:8,M\WIOT'D%T-YIT-Y[;NJNJ]*3DKXJL)KN"
M^7"-4>5EOS002SY17)'RP-#*H5N'Q2WFL#SEE):)FL=]V:5UY$1)*XR'='JW
M:S9K<""2]5!D$;\V4;S'[2UE$'#W5TGD5-7K63*+--1/9E:2@U#5(7].Q4X^
M1:O?X%2 /T<_362IY[ZNB%1FHC>!^E\!G]VO%$DM+53Q<<<-4_-/E!53B=T9
M;,_;X]X<TU3$5<O;8>R07WDD[U#QZ)%OB+6X_.(9?O4F036^"2Q53/C'L(Q'
MONI0@DNS6K,-3^V+D%07CB2S\6<CA8,UI>'!_:P>*47N"8N\%(N#"?T4*YA!
M^%55RES)Q,[$P4Q;CIFKS_>TP*Z]E8K0R*GFQDFN0=;T?MFALK#*#0?EO$HN
MM\1B]8@4!>>0!D-*<7@D4(/-Z=ME=-Q C1:Q4#4GGO472&YAI1"OI5X1A;+N
ME,67V;64M^MOOT>3A@J\DC%,,/%1O)N%"]1_5&/+KE:D; P>;%_M@Q_,%IAR
M6E@:,PPM37E,6J-JE[![H?\<M[8GB4DGOI>%.$UZL)2R[< E:+G1-ZU>)G_H
M8]Q#IXE]/]W\,I&*RX_K2^R?+A.Y'5E"]1@A7+C[PX=3,<%AOIV'W?P_ZYVF
MF[77AV]IMTKN%_ K6P >"!9@@:)8^DW[:G<*1&RJ:J=N@M&6H=-Y ]Z,L 47
MUCL[BS8\]M:,;54M0[!<66Q6)WQ>6+[]5E(W[X!,,O5E-]C1Z7,* P^!")M)
M _T6_UE\MMDE\<8#EV:%>NAOLEBR=>FT0ZZXWW@ES.Y F=UP8IC#$GXR=7TR
M#!<&\\+JB"%D&10U;';0QZ@C.L3Z<_IQ67I)"&*%85(\G23 L(D"3N5F[1KN
M- K8(=G7*P9W<K]Y<$I%#O]ZM;48OE2#\+(OA4WYEL!!&;6IH1_"\WR;<<SW
MUO^(<_S :WT#VE?_);7R2ADE>(6%FNN^SJS#_2*#IF_RM%[S]:S+IX+EI=[^
MFOGZ_=!G),K-(EHU95>Z_=AYCK@<[]>G=(+#F>@>&7.3=45\.T?^5#. 9R3^
MC('N_:L9-X8UVW?2]P2[A&6A_::YF- ^'<OX](6=PG&P<4SK07H!3=C&>:F!
M'D P"EV*U6.Z:**(>-!H\E3+E_<1#T:,Q-7:AU#NQ[U%A4%;T?<\/42L)Y.)
M[^3%C)*7K",633%QD<_=6$9(>%DN;AT.MEFR]LY7,PL>]]2G'$ :JG$;V:]R
M!?JOPBGJ<^G/9&UOZ#Q/(6KJ,Q&8-<;#C)(N]N&)BBV<F50&44N2@_>EO(<7
M1WT[%=%D K!X:TL=G;GD/JX$S$VN[25%.OZ"/M8G:QKX"/K EYFV\11P*3%A
M1)=*^/?<T-_*Q$KOP=&A)1]/I\H^8.U(4 8C 3=,30V]'(GU)C-,P0; 9<^T
MU+*Y:[E!6N[6.46VOM2+(9ZH"$FT!T6>J8;+#=\PGU2@OX1V]N)_':HQT@*S
M#H\=!<[NI3-08$%3_!-/<(CYWF^?=FA6>"9BKN*G(DT6)\&BIV!<80+LA?CS
M!3QN)F5&U+ZNM+%O5^+<:0-=%;)3B"2? F5R<%Z21P<L; "I-#@!*XT\(OZ(
ML/I"=E=M#-?7?QBJOD]@Z/VYL=O>Y:J%]2/6&5X,"U-"3SY_Y"=:1,W[#WQE
M)34!<M<ZV+_PUU+<<,- !=GUZ6!XW ?.9E'U> _Q @G_#.8>SJ(2*=CH6_L5
MRE"F/)(9$I=U:=NGW(DW,=2&H!H:?U%PN%@_+UL%V2:+:P5U=![A\9Q^Z]&3
M),C*.1_TCTE>SJ&IFUCH<;,[AYOF&'>==G7:_;-S@."]2]!5K$WI?(EL9AG%
M&_ &AM]$#+15Q=1A<2:T#>86#;)J#B\NZ>,(H _(>4N+HM-2"%AVF5>HYEV=
M&*UB=OY>Q6(+__7Z0'OREL("3%0K)-H^>YVO1*83*;#=SW6)W'/PBC$Y!C<Y
MA@A:3Y1:3Y0LJD*$>QN##8C!O6UL;'A2^6=DSF^)^I^^$#A0^41+2*;WI3\D
M)Z<C'E+A!ON-VS"0#7C: B' 389I.JF<,9E6?A.5,="+GI 5WYT<O/.%5$^[
M504F*<6!2X'MK&6P>P3/A.-"3E472]:_<9N_*1B,\]U$'E&U0Z=]X2UH -3A
M0Q,GXJ^8ZM6G<W%M>'> ^E_P]_QO- ?^CY^7;&.!D[B:,'1-)NU0&>8O['\;
MB/Y2&42O^-M ])<$CI31VC<EFN'AYJK/JK"F]7*;B%]3AF]7K0;I?DXZ]K,2
M>),L8+DF;5;DEY"3C?@/.:YML!IT$[@N9EA"!:1P9FU:@/3YU[CRFTZ1>7E\
M' +F0@+$_?E%1GP6GY;SF6!-A!9*E,(604/&;XR,PL/?A3T6>[#N861-\U5E
MN))])632UBN7^J+%%R2@P&3,5.'0YCT2 ($1-0.^,V,ZO)1F_@&2^U<+A?E]
M&6 H?R$LGINNKD'U\'%NR'SC *]R,(=%<8N5[3#F&WWJ^23Z(DA)K![EO7N7
M,O@3X4KU*UXK1?S0::-(]RN*:)- 5SKD6,;?<22^?[<!K$>_;>M*"D"DIUNY
MJPDC,I?\'&V*I\9T]Q!-@3\K[;]$-E.2I@H*BKD0N ;-)^@AUW/-YI%*1D(\
M\-9=E\Q1T=RH;ET5$$+Q@O7H7G]8QQI?:18L%C$HZ\(MVO[!L!X0,$K@Q'WY
MPIX2 G&^_&\237#==--8/A8ZUK,&;D"VK<Y>N"EAYF5-X^7A1A%/#G.ME:MU
M;=#'F/I@;LEQ[?8FJN,WE'+TJV,Y-LLWXPA)Z A7+(2MTQF9#R<43%[D>;.W
M@==!&"$9]*;,53&P;O<-XR^1H6J^.#?2Q;N:6+> QK.C9R3])P-#..)A)M'E
M_QWT]!MIZ;<.]/\Z]]9W_=>].AR^_ 7[F,T3,3'[#G?C7,!#9;QWO%2HG_NL
M-9'M@J/S0X6\T-8AR7M_J(P8DE*;BZ%QQF#](6(ZZ9 ^X"U5H)B5P%!KT(PA
M2E#(PK2MPO&!4.ZF03C6X%P]LPJ,VX8[9BG?]"KH]:^+87+9W08_>>R  E+=
ML=JT2B@?UT(U?8RRP\8PQ$;)>Q+69_K@,#2[.2M>X4UN4N6D;7G\^E RUK5T
M+VU%ZD '/4RB@Z<(+WSB#3W)\%?0?J*XJ/JUTH=#?=BPS7]"'3]KQJVV=VGK
M,:WH!@NG3.Y/]9+-Z75]J]FGIY==O]A5_A$YO-!KN4<.#[/'5BT?E(9Z:=7_
MJ7V!@O7J?WG]%Y\ .RT4SO1SZ;0W_9'J/5H"QUDW/R<S39T2U^D$U(C^B;=#
M,G:.@Q7Q'V<?N-Q4=?3S&P!KN)(^$%'TI<^R@O\=\OXO7P.\('1=MDK1B20V
M^,(:P9'P9OID$>DIVS30E-@N*E$"/=VI.,;*=\Z0'J;H,+CVJUVT4B<1H,*6
M@ZZ/L)0UV P+K"OPD8 H17?:"+*AWQO-SFZ70 2B"G6EB30/SHZ6O>+\8W4,
M/#JU&>Q,J!GG]MNZ?PT\E]2F(H!JK#']!(S2D_E"V62\FM1[ME2[.$$DACV%
MSC_^?&3;:?L1C"Z#COJC;:[K[ZX?]+\63UW)7?[)P;+IZ<ES<S[_]/%EE/F'
M_ '([)*\[78?1[ZV(;#M@8T0A7JE\DT[GJYO$A;;*!4RIBX2H=L>^^P;M]T>
MG.X&"MXO( >>(ZTR<,ZI3I'EA^+I"N3P<NTR?O1H./JOH[]K>GHBO[HD**XH
MYN"2AN>1SS&.-4NHAV(I)\E?:WGVG6+XW VZ27_(K--F@8GWFXA=&2"FA!$/
MF'AT=:U:IT@7Z^\Y%EOXW[35M=C^S6SXG['X=S=AE<U_EUY_(1;SO^U6TK$5
MF31RGH9.Z@($B&1#)F<]9JW@Q.5P$JU?_+K=CA"ZR"DU"IBF >EJ!9XJEP-S
M(X^K\]V8YUX:<ZD2@1;#,&[8_->TCW$FA#MKXQ9WW%YFKQGJ^NF)_CJFN*?A
M/"=6V3Q%MN"1+=X9H*4P1@8*>D9J_Z"4FKT=L?.B6(\HY?O;AW7:J)3J'5<'
M6\RV,&RGLQ8ID84/)T_/2 ^M5K=V);++C;-*^EKYWQ (-HG\R12I7U.3EY9=
MW2"FG+:-^-+@'H3C_ 1,GC:(##6*4'@IT[*80U:UF%<:L?W04EOOY-(YS%&F
M/[X[H/3IIK=_J,3I[.P[_O"MEN7!KHUW&E1E.85SOO@T$5/^)4M.)E5BLD*K
M;LVUO(\6:1KM.?"P*N',$9'>(EY[#\^NK*$[X4@&1N1Q;BEW?9<74IF(U#%,
MP YM$9^T[J<$H*MT.1!&.\S4F90X-%ZB?6@E@0%P/>86X.F9>[#[S$QZK;D#
ME'E.X='Y9HZ"G"3C@5[@BHT8J9>#>'HWNU;]>N.)@@OUI6>:E\*PQG$[/7K/
M0.N]Y,FZ:L?4=T*8,AIE[EP^D_W&,Q+>D9]M?N-K1);L2:VFHF$0_4E?@:>:
M'$'NC9=>[&.!2-]0E9)6D(93X@@T<T2M>ZP^MF\N,$&47-.CME2;-_)=-9.$
MFG8%1V*T--YG52+1.DF$RG;3RQI3<:_+7=UB-?'?%QO3!>8';A529VVFR&;"
M#JRN5K<^[[B0Z?;R)8NFSJ#3[V0QC[,/]W06)JQ+(QMZP_)II,L<G.E<K!)7
MXW.#Y*54;O'=I4DT860+X=,9[UXQ3Y7X1UNABH<53#^\K7/CNN6'\34_Y8O>
M/THZ-KT^&=F)E]8=+K-.77D*T)O1Y=AJ6)PX!$L8C.VD,7A=UZA$:)\V=IDN
M[Z0QGHN @8N&"]6B&W=> YDZHCJE2VNV,=^KII79HGLLO !R>@F.7&!T;Y$(
MB"T!O'\PCW\V?184[CEL80P)_> KFTL9CIIRH.\/(#&J,930;)MQ+=D^$\&4
MUC3]['GFYAOBWX%#281"'&7VJ6Y6-KF'0&!(MSL54^5V\726^:*4F4]+>Y2A
M&O*[$)3/<4VYY@7(+P[C*XF6[6]/&!9[5 6@.VIT]^'+SI8@0O+UXQS7RT(R
M<QS(H &F-_Q0'YDT\L9X*,H<S[CZ>G45[[69+4_&!4@]8J3=!U,S,11VEMT"
M47=+Y+PN*+3R,:BH[)Z6;_H^B!D!)U/!UG)P>B=RWP\P;:^\=[%E45^':IJA
MGS2(Q:#V3\6E4#,ZJ'4==XYW3H/J.3[$J6I;QO6GE?B)N&[!>#@F#S?89@/3
MW^'G-T(VD]]\O+34",Z'F;HISE(%HG[>2!"'O ^7"9E+1OS)7 BJ5D2<+@[>
MA=.D.;6PE6%G_R'_BO[!U?CJ.$VR5W)H<NWZH!Y-!EM8-V#SJUO" ]D*8:FE
MO<N7)G1ZXLI4@\,RG\*>9Z2,.&!F1Y+.E&ROZW57!F=@5/YP-TTEJVH FG.3
MN\?5X9.-J$MKR^I8R1!P0L/$H2*VF;O&1B?! W*HS9?07:2IL 4S<L-8S,GH
M&I=EKL3]J^XG^JOXR&.KOZ\42@THH5W$^"*!)6ON89?!8.K+A]Y3\I(87\(]
M8$!W]L,LFS8].+&159!A\0% C6=D,SQKRK/T9^(.3:'K;--Q)CL7NQPO9BH@
M8+,YMI*RLUK(AC^_T3@M(.7#VX:D8+=F'[/T\ Z;FLAV\V910BG1MS(4;L&2
M^:W6];%7<@M18PNMUKDP 5$ADG3DKF\O> &]8&%=@XRJ18NSK>WV[KJ+^ _I
M(),P6QB3^YC6(#Q.-][*_7(E$T59?1BF,Q06CZ>\%W=7Q'K_-7*D(4C>[/QL
M B&;/AS95/JV_CXF>.S.A:_0<;HC@5AYG=7$@5?Q&>GW5.[;(9L/M=7,9Q?<
M&K\B0H$$F Q4+Q,^O\A6GV*B_[A**#"LXD^)MYC+R)W](7>JGC=6OLC6:&W8
MDL,!JA*N%I>SU$]3:U,[1M-0NQ-L<MQZZ$<''9OB'7EIX:>R/RH:,,SG0TR<
MG>T8N8H65AL$XK$&]8A/=HU(..0-X?B_F1*:YD:U BDN[%!^&GY&TN9G6+A,
M;KC1OVXF[D] >+5/ G^F6%"G"KB4YG)%YZ!K4OW!T-/D?.-BA[JG&LJ&G[5"
M5P<I@>)-FT;?#6I(TNXERKT[EWW#-F6<X;H:*V/%?1;OFN+VF83"K2^L\U1&
M2#I\5C!-/C+@1/J5N,3H7F]LU+C)8$RR2,:59 &C>.HT7JGN=]B\7EH_/:]J
M"_NZVU[*9G21&VA*/[J$Y2K ^7XL%<B2"PK/9;EGM%Y04=C9CKJU:\4)N_4Y
M:$GU>U3>O!L\LWO,38@(\N7-9%[;WG^(>FA-1,NS5CJ5I['=6*5$(3OB=S%9
M*B.??CK;80$OO9$SW0Z,!L6G;ES]3&I]L*-_K#[J]H27)2HOUUXE'W[4.X\3
MX=@RA,H_(Q&>B&R12:5TJ8BRTAG8C#0GIV5>I2=/6UK\^-8K<[C993T$OUM2
M[+U-0-_1\=0+I[[\,'C9U.#VC'3::F%F@Y6^%C'WN,;RC+36>K9J+>AEP2AJ
M>+#PC+1DD4'CT2I5=)F/F1D^<T6-?QGX)?!B$<J%"FMLA'%Y(!"(1WAO:N-]
MW(B+^S7O/L:$I7LV\.XH?%152&UF+]QH,B6V'@LH\JGX-!7T1P;!<I)[XQ:M
M7!@!H!X:ZR-W,G0&AP]\9V^<* 5AR$</R8*G4R>T]M!6V<= #IKVH\:E,ZG%
M#K=H]%^.)MRR/_)0I*"@TI<O54Z#L/\E)]8\!#_CFS2])=+PP?,T=3(VWKU3
MG=\KJ0D/[^^]!3!!_5<CWK*D9=.L':78(T0_L2&J*CRQ5S>8>WOZX?MOU=3W
M>\/N5>+PLIER&@XF%,581&>LBM'UVZU;HN85:^%K508X&6BXP1-S'O[OZ[FO
M<@O"*QCU^XUI&5GU:ND#-WD6U.3Y6(\GAX98Q%A*@K+B%)96BUF.[F*XF&XA
M70/"++F+]V)']&^6K7##D[33C&\S^KB5QY^4X-1AK2)Z'@L!7PY?DDMR^A1@
M83QNF:1<F:<G:!1O  7F;.;XFZZ4E!S3?NN?.<3E+#B $0NVWGDQAR2_#41>
M\_2P^W^W]*>* ^$S3N'%J<ZQN63)GS"+[MRN(PZ/2<?)S=+?JE(9W4I6.TV$
M!4V#B@^4%MVBPUI?%6<5;>X\&,U5U6QMN.MD])3U?-T[N7&Q_"!37-ZTG/W]
M1J4_ZQFIT)'Z&:E,$^.K8826XZG(GR?<GJ!',@)N\M,P.A\TBXU1[MEGI)1*
MP_&6.1_S?P/H_R>\GEDK8/E>//L9J73JT7K0OO6&6N492:/V:5>#Z_\'>Z?
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MVK+?PL79HVKV_A9<.\XCFV+X8]%I/B$LF:6XI']=0+CA.EW>1_:RDKPJKW&
M(5W"@&@F_FN8B-/5DS7DI?U%@I74GN42+ 2NX4ICOVN%3__"PM*8L4_, &.>
M5PS DVOJG0PRI:.@(LP*/+<N];&XK &)6=J9U48F%N:VH7R<"Y?8\$'9W'-V
MNR&D0G&,2G2?SJY0[XM\03]+ML?2..'QMK?I(T>EMN I9NOXU]GZ?-/OV% 6
MC;G<YKSMU!CO,#BQ;!0CR7I)['LZ\W68<8;-";#+)=OTD9#.PV(.%EK1?U\W
MTPHA0AL3TV?J.SQBF%TXB]/36*M%%M=ICRL*O$TZ@1:9' ,QC\K2$G4T[CUZ
M\P&61<T9@"]F$ ]]H^JM]-L;<;C",,=(%LGTFZ$8_ ?C)C=T_[& 4$< 0+/U
MM<6= E(V8-P&\^#;Y7!*IR6"S\[VNV-<=J-<)Y]L.;2N_]7IV3%&(0P]ON2S
MP20O52RGB_WFY<6J35PVJ\B&JE8%<K^!.3.RI+#5^V1);EQ):O08>3Q?E4%L
M&)XIZZLAQ8[XIUWO193JAMJMEVJZ)Q>L92U+199=PSP7TSEI4@PLGJ=W5+VF
MJ%3Y'KGK'VSB@?EM[F--Q^N)06CJ78^, 1CG%4Q@>]\E'>V*)=4HY6H;8>LB
M,"PLW4).J>JWX>NZ*W=OA2H;,3"/DH>:0$O\_./DW55 .K6H3+^4K<D0HG7,
MU6PS>6'QR;JID!=X4IY9ZV)T0'=EWE_.E\9H9K\D?,B8OK,'Q4UP;= VV077
M<R3>49=!BT7'*+\EB#!KE7Y/16V^,\CW)I 4T)Z62PNE*R[LNPY//+&WJ!M@
M<QU@Z9'MKG)SM-OK*QQ@]:TL,EKEEX>%/>4UYM786W!/R*8<7V+&PW<>GH#2
M>PTX($=7H+0TK9STWK<X;3F!7]! B[TY_W68:A\71NAX-SN,PVZV;-[E\^1?
M2X9&"BSNWQ[.>=?\LM,O.M@NZ3:S**]%U=R<T02AX*>E!4'PM?FG>2LTJ? 8
M<^M7VL):?RRJS-R/O#>>D5 ]/YCA>C[5)!?:S4!BQ>+8-BKC&R@O69G%MBH1
M: L11I&Q[=W,_+U)S!ME"JP]*F)KQY12RZ-%7R[$:)0@Q4W474;HVQ.8.-/@
MD?$3F$/!'<_<A]$69]N&*$Z$G/!\0,S\K)3B,'M*>//&@!=T==H@N:SG0.#0
M#ZUIX8QF\OM'BMN\W)H%1*6S0[?'X;GU[T:#3&/A:@^"K<D:OVWNNWU0\N,X
MD'?- V/0"\,U?0WK:9]1%-HU=%5SI'+P</OHYF&@]W.0-,NR_XU0?PO$/8A#
M4S?K<*325AZ?IY^$-+,S 2$[U]7!YRH\>B=DV1[1MEHPR,'5+DXN5R7)DJII
M%I\=RK 6D;9=[3 4_D@U0@,;>#JC]0!WZ:=\GT]OZ+  4S%G5VPZXR<UZ)=L
ME_DK.]WUWE%H1GZZN=L>/%>->S'2R1GLZ;"V&9 [0H:S0*VBVE/*>#_6,^=%
MY^/GIR$:UNA\93 >]79M4'TJ0V_M*2IXW5CM("?UC/)AF^;(PTF)!6(^Z"2A
M[IKA^W]CU_P=-V"FD=N'VR9O@)1!2.\I*KI:$[\]M2N^0"M%J!K3:Y-T2"\!
MU6C3OW0ZE^GL)+@IL6PC(/T?.]9_=SO//:2G9_;//0[_F%ZA'>2JK5](>#2[
M9F/B\6B_Y_7AA$],?G2HPL(D6(WT481)K>)^YZP<^CKC=T%+(#BI>0H:/^Y4
M [LZ!\C\QTW=?0AO3O,:2'ZG&N]1Q3+=K-0&J&@'IYW.%?$# /QI7-TDO@H'
M:V)_-YH5W4)DE^=3TVO=#74U["PX9Z](PE]V"BMT,V)&&A2\]'HI'EWV/6LS
M.1(E\.N6 %*FX5ZYF3V]A6GO-M<","8SJ]2!T9DL_90&0C"H&LE0.4F%<G8*
M7@]D:NN 'ZP="@A@OV0G\/_'EC0I\;R:QY_#GL#)A@G*495OIU!M7UP7T]IH
M:#!'55.:[-+FKM7,%7E!BK3]N4G9OLH>8"X\XJ%%M7VA?Q,\W[?!0DX* 2/2
M#N:3DNM,3^FB!W-T_'5F)9-TDHLYEKOG%<Q@^9 B4I,TQCC=?%5_5:XG<WZS
M$M_?WX/@#10ITS+[?0^ _HA*E3.>#8WA?R%M+NOPA^3FXTO"^(3'P$9!Q09@
M9AYW48]DF$?%)@^)[V*5NP\A#<2!H][#5WZ%.KS4=FIU!")@("!%A?)B5'^4
M-&7PRZ$P2:D4K#USAK,FJX5.2-[PH[7*-\9,D=%&D"?@K$?L-4::_R@QH'/R
MK+39/9[*EV$ED#WT P@U*Y3C6R1#-@'J>OCKI,](K_TE=)(DDY/K3 [^"]GX
MWVN^_<__X#ELG5U_VW0GZ(EQ_<ZMD$48SI'ZU[<9/XX_22?']&JS5]]U+8A6
M6S_#_#,-)K/6CT[.&.320>>K(D 6#X&6W)XN#@BF[4&KNPE:^?F0M K35;EB
MGJA^^^K2NNN89#0INE4(YKS6<.UZ[#+,YU:.X4$P53%_CX:<0$CW&9E,M:Z"
MZ)M#)8P#7Z>_KT"'RJ%GD2ZYH4@>3%3@4\A=HXP2TQ@T-%H;-K!N+:M&&=G\
M]@LX/2DS3\8TN*DKX&$V-3J:Q#A\F!/'3N3=OR XS<:&>S@7L3B85.!/QC (
M7#Q@2\L_F]]GT;\=C7KVP3MK2RZM*5:_B\MIR/2*,4Y3]VN]G=?KLI.&;"QQ
MT?Q*#8=9SS1DTTBQM P:W"X?)H<A^[Y7(R3E Y3<."'=W/8#KS!*W<S,C,B6
M/\),'![54<_N5"]_0@5RK;792T QYAO-X=%)O<2)YEU$):],2'\',K#V,G\G
MDGB]B^U$:"8R/B_N=''Q,4K&>*U9.XFZ66%1G#:X[G./ND/<789<PNO,F#VS
MT"Y/15W9[Y0Q]Y?_U]%H;UYF:3PSYCQLR?=XL;*4J-(DWUBE3(T/*)"8-R3^
MYL(?'0S5M33.S.JSA32G3PH(NGJ*\+ZL<*'T_N[;A/T2T$JCW-\'1KSO)":9
M&%C'X^AG#!:6!73>3YX39[AP9X0S)9$B]:YJIQ;O;UY^]3O;C#Y9E(ND&(S"
MPJ$S,7^=TY?,W9*MAPX]9CRV$8(9<[^9W'@GI,-]X8Q94;Q-,K.0^<X3DIZ<
M)O=)\KROQ*0[Z1"%,I*RU*"6QXTH.370EBW&;;4U\>S)<.=?69QY<_LW/>DA
MHG?F5J3HED(X17T+QLU3U$USQ0S'MSP1>TTS,9OQ)125,EQG0#8OKH,_F\"!
MBQ+;S,54"_.HZN@DS+*\LXA'47O$[GQRD2X\C8Z4*S1I_G/7M B_U142!91+
MR!.FP")&1%.FLP6+\IH@G??ALO^*8/&2CA"W_%!B(?2ZCRA*>3J#M7QH.5+:
M 1WQQ\2T2%-F#8I%J*,PXNV=@GLS]./L/_/V_QLB731>R.*2ZNEU9#LWT/KC
ME $=[S\@9*KF\58%@[EG)-NIY?:C4I7)'*T&K=VP!='#N\8;X:D^M.:L_^7U
M0R/OV())9:_,9+TY0?$<\<,>_P98_S-+_D=(6CU!R^(H\L9_S! 1U<D7C:/T
MWV1!_P)&>H)8PI X!E^%YE#*W!5;%4O:0RS/L6$B^?GOT<K;Z;6(ZGI_!L\Z
M* R]=NII&#06;HC1#M6F#Z?S=1TF^AWW468S](M=K !2<E=;>Y^";)J,_E^3
M\8WZPK'4T7VJ136RI2*?I@7O]=<%OKRU(5!>I>.EG"OCD$Y( 7%5['?3:#?W
MC@N3!"N>)BLDB;5_ >=W+^TAE"XXA$8XA/:4=-X2?S?V$IK:0[QUYC(S-&H]
M<AL[6U,P/[$T3Q/**=K[YFQ&]NLPS%9+?:RMI)- B-"9$6%)N"1W=C6J@_HN
M%0&&#'N?ZS%CIY*9,=7(4SKU,TD3NH%_JVR =C)*&K9Z\<82ZV\@*S^2LF/Y
M&')PPOOT,")VLN\;%VKIN-R=H#KQ*[G%[-D8-BI!$7<ZN?9KS-5(] Y"!I*S
MH2(DH;D_$])&^B1IQE_\"#GZ-\9[O<^_R?__LPWAW^7]/T5]^G=&_%<<O/^#
M\&%U3)EO1\J8AM,&?N7/#?U*1)W ^+I'9B,\^1]X_C^C@(@G:)P%-!=;9\ \
MES+R#(>6-8$IUMA2VS3N'C1>CO,3O*CU#+\C&O(ZT@)M> @^/9H("[B7:3<D
M>D*4E<"L"4/F"*W/#OQ""-422S:*%-S-R.9Y1Z<8S58Y^T@X@ +Q=>0#^2MF
M,56VP#0?R,^,TNOBSM:$IGG<>^>\6VM?&S;!A,4B6YN)=)MN[8WJ8?K5'4O^
MH]HJF\"SO-YKDWW"_7[AV 1$@RQX+:;42G[9XLN:RSFYM7==*TGM(:#V&J$T
MXI!O&96,X2;B-S#K>J)[V&6!%\F"(:RF2G])Y>W]PZ$:)&3/WUBOAV[.?R$@
M2V)P-7D +.3%TLW 91Y?:D,(6%OH2XV5S\!!$JF%C'>O0'YL"C)&_6JF!""[
M:J1FG77[/3TEB77!JUTX#6<GC::5MO_B7UD=_K>(IBO#5N!7W/#>(73MY%M3
M+4?]B9,Z/]E*_ 4T>YYW @4M(M<T3U.:M&,%4Y9*7Q.9X[(_;4&W)-TZ6ZGE
MX/YI)FCVQ=<K=X[B5:LGFVG$LB73<#F1\+D7 PR :8 G[^@N18?%;O<UFF8G
MCR>#7X^);Z^=RN)DPN=;VS2 L)X>F'9]PYA(T. =),VUI?.Z9->*F-+'P'(A
MAC=_;(II[?Q&F\2H,65$\6UOH*<QS0._I0XE]=O72\V,XI3K>':JT3U%C:D-
M1(=#TP+-+H5Y%ISUC1@"/[";];SXO_S.#LOB!#2I5US^H/ G#HI.D>?DT*[@
MB >=E+4?A)=H7A=^70W)7>ZWIB4<3(PAS7V7W;(XZ<"_+'"I5JK13E<"YF0+
M(:-7R=^MR& IU"&*=U2?T)N<OE9--4API-<#C?58*C?Q>N(JK3U0Q!["!$RB
MARU,4L3^-A@XIJD<I(G<9J[\ZUVI)*Y/QL8&0!L2,O; G28-#;F7/06Y:^:D
M].Y\)080NB#5O4];7.*R/Y,#K0UHNYA-M ?;*SBF>NN4T1,#T1D/NN=J^9H:
MUHFSRFUXK#T P$F=7T@,=OS\8>>*$VX"X8>S$$OM^4<<O.O\D(VH*:IJ(<+H
M^8C2#O,2@<#Q%$C2:,?*GTZQ@._>^>998#F='!]+*TT31QBX_9PVC'-0*/),
M1NGL.E*$EH6-\,( /]5L4^L2ZC>OG32^Q HLK6@X*B]PLBM+679N2 WV_'#R
MY)X@/UV-RB?I>!=Z "RR!G+7>.V7'#+>R7F6[\6-'R 3V+I N>R&EA3@E\3[
M__"74;>K^X(-XK,:GM#VRAH5@-LF0A)7;L1:F,A'<#;/7=#:NM<I"58R>\O%
M(,;DGZJ,JAVD/UCU@?;:.VKI]BIV_(L;[BDU-+IM&>>,XT#X-S6)[>Z9D4H*
MC*60.=IW^^'Y B*A'*%+BD]OWR\OQRS(G-[<+7#D'9S&C&BAS2]UT2'43^C$
M]_A%=&Y/8:;TPF.LF5A$!OQIQB2)[#.\X1SKC$(Y0S3K;>=G?/7+#XM<STB;
MVX?&/*Q S3V2Z;))B-P62#2V-JE_GL^;#%XOIQ6)[>WY:<HOJT1P_4"S !U_
M#3N4 GM8Y)BU'\=6:>.+&J6NV-A'_:R!O>2;-30J'+[V>5?9IU#KI@YE?BZ[
M#P,SX<'&G];9Q.NLI#M629$;-_$J]A*4;/JMC_IB]19##C86ZSE.UZYL/DU<
MIX(C[$T+XKO=#]A/)YP;J?6HE]@+V;*@P(.:K9J9G?J6H[[DH\W2'NG<B\G&
M[#][Y7N*%MK$R'B_GECI93*#N''L;,X;=78ERV3$CWH"!7DIJ<MI!0X6V0::
ML+L_2+Y_92_UDL2^AQF[]P,7*A(2#!4)C3TXC N-ZZ_!-O<U@WE-+\+P:]](
MG_?C^1+[LNN4NM=\0=#!S*OLEO[^8P&/<1L$&=EHP83=3N=O&WUVE66;M*V[
MX7[/;9;E?AO\,8HBRN6R^8W#^1[KEA<SP]GN<W GNT0A:).CQ0-1(U_T+8'!
MA>?YH%%O?X:*V]*AS;PX;M7\RZ_[X;"0R$_EO9$Y1T]T:EQV/:7T1*A!(Z@E
M^K%T<4&!9>K6P+CU,@,+T.]ULTKW*+ZD*;?[URYLZ7V+0R8E<D=/PHWGI"%)
MP RQ]]3F11*LU :H:X%TJ&O(1/ESYS^]4U-9@%3$Z]_D$TEE/6JV^(]2EK/O
MN&F*;X&"QID-8P0W4ST5$^5D+([S#W]:P%K'4NE7"^O-E4IHZ_@\>U%M0QQ5
M(CF!(GH>L][YY!I/E=ONT-J,'Z.I*K'SZ3RA09J6CQWUH?U@NJKH.[L[RW3Y
M4>T>BPA>^P$"SF1F$U=,A?BEI+_JN@&]4 "1/4J!-,K]5W!9^X5!KAM_K=L
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M8A6D1C!<F$*THSE[%I$*5!?-"LM^%<U1==_B_9-)G$F>N8C(&\<:\$KU1!F
M3#+*8>CWU$>9@HSGT2_#S0)\H<:.QXV31X))?.:)S[O_(,4*<8(NVL])QG^E
M <@"FD[S@N^( BY8R-H->$=&IV&/Z695#<9I4/NI,WJW(2#VC_/2ME^9B]EO
MNW-M<#IZ"'/'-%-0.^);&41[3#/"Q< >E3'C>GDN^9LY"%\+"^=7&3I>RA:@
MAB2+* .?D,^^DA>;&3",O4AA#P^X@!ME&&3/>(6JW"'7LV?'",(+?*]W%/K3
M& MG-WWV3X3/6N=_/#R+T2CQQ/> *HWGOC:63?591$;;=6)L1"(8?@8S5$*$
MI**G"J%?.<W;),KJ&BZ/71O^N%TW(C!B^[KX1X)IM2T& R]?]##BY)-BYQ62
M#J03-3A\R_38\__\<N][\RS;>O@Z66?];94AY/@/7T)D-\6:Q/6LL1/PN@4Z
MUGP!)K;<VR'M*^:P"0F,KRT+]%J,([5(CL\U.MIB?ME@K.F9]&Y@"Z4995?V
MY<L,:65F.?:+?C3;DX0Z2\6R-RI47VK^E'Y9_&X>UT:06K@UO^JV*RE5(BV!
MW96P1#\1VC[)OX-R,2%PXUQD^MK@-I14WTO-4W0%1($=4OF-MC?^X$&,6ZM%
M9(($V=FHG.>'CFYNN>/"Q--6R-]F-(C8U*K2O:J)\>7AG\F_N+#]9DW,DA![
M0F<YGM*WC0P5LI*,5?BF1B7%C,2PZ,1#I[J+0M>CE2E%F)367D+(C-UF0:/_
MB:L7NJWW+.>7U?ZA8$2&,\U)%9>5Y8A?Y/+@&DWHI?3WN/!>S /_T+)?-N,.
MN*!NSK_\ZU8AZKPZZJ&13TA,K4R'A7BT*V0/]; Q^-:ONB!:U^]( R>ZMH&P
ME^NV!-GY^ZXZ'LP'1#5&;%K+-GVOG1A,:>Z&"SLL_4V&[7!&8)9Y]7 P0/[4
M?RRE.=5"QVLLE+#/ =YYF9V!5C@<OP&,2;1W\77$MOH=^ANGQPC@&AU#^+;@
M6T96"O+\N5US5_G@!YXF_,.Q/]]N(@*$4IL-Z963/;UJ0%<;>14&Y<^)5]3Y
M\1]=Y_RD?12)Y^KG+QY M/)@F0%1?_9/)42-96HS\K@!0V8,V :;FC_6[IM)
M2GE]& P40E?_?B&](&VD*&A!OJR!Q+E>PL13$FKR47I.*EF MD X37O^!T*\
MC(S>3A1BTV.+&^^C+D,P,FC8N1FL]738C4CUUD6DR:YM&+_;C!]^/.N6\F/$
ME)E;R(7H4.R(.CC!AK4H*E76^U-<Q#V>IVSW("R1N=-#I\C/E5OIE!LRUKF)
M<@Q^:@@\!V5<7'S"%)S&*J 4SM<7G;-#[C*2E&@Q1A5\3;B7+>/ -@[&,A?:
M%R[FMLELN <=6]3AG-S&?"QM83-N5$A3H1ED:ZK]L4%K7%7]"&?X*YO]MV-B
M'*X-);4*NB14]YD.@+'2TL?\%K'U!HN9?2M6R<0!VM"MX_BYT1K=($>FJ$Y3
MVYB]EMNY/\E:5?OW)1S,=C>E\Y]"G!C >Y-@4%.I$J(V&MWTQVO3<H,R+V,,
M(6PG,L65HE%N+LV^*0IS-I NJ@$!>3A25#+T<NAS#:4EZKL4AB&-].*!ZU-,
M,9@WE0',VPC6:6ZE2S_>9D6-RI7F$D\C[RG[+[+*3<V:7NL)P =%4\$(2,MV
M W_V;&;KX W B5Z*NR:-(3;I]ZE3N67O<BV4)9<G#2[Y6MBA=F_,L4CSY49B
MESK]HZPH(]KR$6A!PE2H"7&]A#&#KM3YD"WI1VS6P/0+P*W^K.Q3A[=44"[H
M4N91:EG>LYJQJN6OU=$V:(&^1(]YY>$=!Y"B4PKE<17ZMJ>K@%<(^:Q<(P-P
MG;<F@$PQM_V7Z!')#> !8VYLP^KH.MUCP=3/QDR4FAF\"PF$@WI^&H/@I)6Y
M AZ-!BQ7AU7*J :O4S)$_8G+A:[.!+UT>0B$-,(N9=;-DEIUS,]MB]-&;65+
MPPL5('T'O!?9REN3B!\UCNNGS42$)8Z8R67.2I[1IC=))7IT1/A@$+%6J,RM
M\IIW-?M+KUF,/+&?/*-9*#=H*A+.CG?1[54EJ=DIXGHZT>%TROBT>T=JT!,-
M9C+4O;5SWWD>VDST$GU'.ABF],N'&5H%5=O;I2K,LU59S*CD8W2F%?%/E?.R
MK19WT;BB8LO^GM%3LFW,NE<V5B%7R<6 YG]\[TR@W%M-Y7[2P-M:G\$&=0K_
M29DC\$F/<U8?P1("YB-*0ZT$\TZ3I3F3E8FKSVIU<D#IF$S(+EE!@-I<M&9Z
M$IN"_85S?N-0B^TK<U3%X@V ['"!BY?6$VB8DK&FT>1W6$#$-GP,]5Q)#9IK
M/MD> >Q?N6.O/QW4)LGY'ZAT!7C"213'//L/+EP7ZIK)?N+PLD(_0WVWFGL*
MX3T[C:=%'7MBO&!I2[M<TWJ.TZ*Q[U_A13,YQY@-@>^_[*W-1.!NX>,RSCV?
MM:.K#')6.2W%&]E6+I_WCD<PBM(J(FOPVJRW9&\O0]:3,VG,6>>2X:?G/_BO
M[8Q!*@]@?G&CTON[(" 6)&TZP=!Q#]OI".(;U+;O@W];^'#5--S27J7'/,:_
M@M*6M9>4=-Z/'F:'GA I3<9'#+>9]Q9U1^/]I."1QCQVP839W<"(M4]--E-J
MG-DN?5\JTU3X.%0A42V(VG*M40[[1)1@O!7U"__3U*&A23%X02LF<:5XX @]
M\7 #&]+XY/OP/EIR"GSMNZEDWDJ9=_YPKP<0<!WVE*9O?N=ZR3T ?@4]J?(D
M Q^UG7<87.2_0 ;EF$P$*#A;$^57.'@7*+E3=('W?>[>EZ ZZ<>0,GRB#_CY
M(#>4'%)L+#<MK+8M@+P]=_T)W7KF"<'D"C+GVE]=\4Z@KZ0=/]@Y&6]BEABA
M17R>?WHF%DT&5Z3 F#57I$942=N. /T9?6E1T&..ZXYKS8,+:4/$-S/.CJ1Q
M$<>. :,8X%&GJNQQ1&.F85?X56D?,#?3M:.>FG7'MZ<-A#P71C<=E7@U2H,W
ML87#\TNSY\:+OF^OB"0?ZE'=@5K9MIF\@?0JT&8='J"XWGA@<2N"*"SJ$GV:
MW%8UZCD^KXM0,%+$N+0..QKG;CF;5=T /L-LQO<F C,@!"$F)+0ATS^YM7<W
MULZB,&;M5M!0+/H4<\!I-'MT%DQ_?'F9A"K6WMT\3>V]:GNCZ(^E,NG<O?H^
M>@.8<KYN\/5=N"0KO@&4SMX O$M+8)?DN)U@X +>0R'P2E>A!;[[CP<#I?HW
M &N@XNQ)J=(@Z#26>1,>!,7CUS;W^U)O ";4@3M3IQ$S"_4RBEN:Y45UR%,A
MO1L \ : K>1+A<5=-KZ^MKT!!-V1(B,S6)XE'5ZH"3^*B9*UDE>-G3AWZ JB
M9AU#I<13P[!=CZHD)38PN9X>I=Y"4U\@)_LW@,2RF)/^)7DH;+5>@JGJ5>JM
MKR?TAW6TV[[2 4P[=$!)!:7,^7FL+K_*$8;=/808V7=R SBX!@JL'+MW9"JU
M,Z+]PY4OGY3T)F@=N%W;RQ]_*4O5[X2!CO0O)B;[0M"U@A5H_;2C$>2%J_4-
MP+@+J7K9=% 0#P=N=LAYBX+G1/=7AG<,GOP(:-;B/I95W.@?R(Y-<3$VE-C8
M -U_99TCF"NYZ7Z[VS(UE6M\SF.NM;HTKB_)SWR^"ICO([?209*/:MP3X"*R
M6G7*"+P!6!!17I^_"8Q1BHAB4]Y1"%F7+#4KDDQ5E*DG_,65*H"L=<<BO':P
M;5M6L3D] S']*_NB<2^FMT[V$^]T_-;2')_@N'_26.U)>CTUV" B\UW(58#E
M0+)]MNS+FSU,D%?&8+="D,#C[S4'*O3W%;^1#E832=;RR]]981#;W>[)1:26
M+N]>%M"<%%R'#TQPW0"Z54Y)^^IT<U>=TDXX+K-3ND*REFC[KL8_2^Y03 KI
M@25)=)H5:6,X5"1I\%?$_E"1)W80)E];X?'1(UE)3C(2H3&:RO[#3%F->SDS
M5O(-1]O/%N9TE"CA];UJM"1Z&X2E]H5L<0,C]T>8'@!7MFZM(9(_M(W)5%2W
M_?">CF]2S>IQ9J"%A4S*'<H' T+*CVNJ*:YTDRD8SZW*?Z 51F5*+8.*8&&_
M?ZLT-H$^V%3JO6\,=D47I]%^C.W]UI806<3I9Q^6;9HU2+?GV>)L27M81<J2
MS-W!&<T?I#O@-HK6D^ 4@V[G5Q3"R8]B1"[UH)]:&C,[#W^)#U4T,@;F"52F
MKDS$A-1%'OR!]X _J)O/)@\^WV;]HRC!UX?\W<7644_CU_2+K:GQ=Z\^K#RE
MVW%SX;WKZS3.R'9]3+Q0$CNS+WW@#^V1.?R\[LC^)(3H*'5F+*/RF#>$*0M)
MWT'LF>BCRGUP**)VK7I$D_F!V3=1)M>M6Z_<7W$1B7R]Y+PS[X.S:EO0^2YY
MH2$8<UT+9!S;R6<O "8.-H5/.[HY%PL.Q/4",RRM'!L3Z>H+ZQG-O]UG3QE:
MNN-1\<1S@/_/(*OX,B%'<B\+#_V.;_GV"!*AB,#+!ED'&RV_0M6/I;NU+)0N
M--P 'ET]>CQ'.R&MW(\?%'+(08X%7^6JY6QYCZFWXO_F$1@\7+LE<>!>CKQL
MNP%4'"G\N+0&KB#P/"&I"BY''YE]6D+8< ^/MZ8O3G7T VC9&/UR"W)SPD#%
M"T>_%E!7GI KJ-5$8>/JB")?%-)VQ%(A@,B_4HO^:ZFN[:--</1O[2$T^1V?
M#\3Q>!O/YE!JC:9R#S^3%7Q@Q;7]EI.FR*=X@X\_,-QU6?94#4Z%?]4QO3P]
M!S^PF*5+1?B+,CR>SZGS/+-R? PML?PG!>G6/-YPB,JD#Z X'AJC[_M1W?*!
M.J$G%F(9R"SF#V;XY%<K)5<7(@4G/J()_SV>T,^0-FLP%>GV)X'PX_/(/(9!
MK/-LER/.MD+%_Q-<ZF("4=HV8\Q9 KI]G4%D%"N]),1YG/?5JNG*GCU ?'Z_
MXUSX>WA.:ZZTFF".\$QMLHZ29;?"QX=S&"H'J5DL7;/S#I /7KUOV)2):MF5
MF/4NGPDL&3$,EWCM6C%!-6ND=LK7.F*TTS-"V1Z5H;/+);F1PZJD3#I8V,?=
M*YP\@4=DYR=F?3N3MM@9M[ XUO"6N,5;"ITY%CE+0W:U^H/RPMD,+,-B857F
M@BS?<Z7.>=:(V1QHG@X3")@?C@S=37MGG_1E\O47/0OG*[;6<MLGYE-NZ[.0
MMTX@I\#6\7GE*[)P63[&FL_IIY 8O,&1'ZP?N0J[?1($=+CJ'VNVXJGDW9RC
MXI./RZ1/_"!05-!OS%T>%2H?(.,<./$MX;9G!A&'[IVP-X1*::'9+@P<G9;Z
M73(%TF7:_?W?%?EX6Z5-$M<P.I4^-(;2R Q9/KYYPC(6)E!6_U53*I?&9+5
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MILW$P98^1U)1VW**!2ZD WE<NETC*:I4:H/E>70;^!&AO),W&,0&AY!/GX_
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M&A1-002E6J=!$_IUG/W*IR43 LBSQE[J[F#9/Z[HK>YV@7>&%):8[K9F?MH
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M%NP2T!VJXVE>(LGB@[U9&2AE(IR972X_WY>CI)5QD]U#@9#U%<BSL]0Q6G1
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M.'I9Q9.%"--;'-=RZ:=7[ASK6HE"7NE^008A0I/GN5=:F^O O;"EOUS$WAO
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MHT":D6M0-B.9DSA\(YAI>7*\2K>WI5A:HF-F]EW'+_6K*A7*"YYCT=FKC,Y
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ML9"@"EV7^+8^O%&$T;;?B LJX1S:K6+B_=S58=1_[5'Q_D3M*7&EK'A4,\V
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MZ57:U+D\;A_W:.Z:4 ZYKSU>/0=KR_K]\4/0CV"9O.Z[W[ZV@X^W<B,]C6\
M=8V@X6&TGQVC8;$#L4J\KXP+*3+FIS+)RC"'U.>5_OZ_/ %@4L[VCQ4=BBXR
M7[>([7[B4ISPK):GI/-:3-E![8"R-,/&QK;7@+K>'V@(:QP#.2DJC;:)"+K2
MZ*I>$NYI(\%OA/VG-?8D\OCISN*DQ; SWZ*($X[RR8BDCTX3X<R8*M>+HV>4
M445+?#^V]9-&,,KIGWT/&'Y.V-VAA###CLOG*E0L=-Y=:I]I1^_TB44C&8GM
MC:\_!_!Y1_S,T^5T/%O)[Y.KI'3NDV]^&Z85<4RV@_D#%W[N3M&3.WG"]\!>
MG&$OZI%UPZIE\#T*1QFI?>BZM-45^.*.AMU/!MZNQ*"L"Y%WN+*?ZD5U$%Y>
M2G2OQ13[LFN.^2S1+<L!-*>3F^[RT%-!S%V/9;I1E0>1DB'_9];Q/S<X]I?(
MFPMM.H$H1'4X>GE;43&R)-5R%._7OW\A-F\^A[X#?F!+]FZO67H%L$&V\?UK
M8A>V;.;]TX:'IQFI.K8'4A=-614R* 8'S?+#JM%F4CUCM)9PDN%4#@_-W[G8
M(XDULK.S;U7R/(DZB3DFZX#1E8Q\G6[\?G0W2M2I//X6=0F%8HQ@;K\V6GGJ
M76A'J19;J%UQ[['M_12B[P3>_Z]Q\OT[%.AK/Y/PG:)S8 -F.QBXGRCR_FO^
M?V;KPGS"DC+HF;Z3X_Q>>N@U'0URR#P*=A@8K?"G H,26(C(^I^"%+3?=.K@
M%1/YB>84-M!?QQ^#'Z=FWK([6^[-&D#W5DO[P6,H$D8$%G(EMKX%!F0.H'->
MDMD?CCP=Z0Q8=K##^-?K3)I07Z[W:HJ<E7"FQPW_\00;HV@.T0>U33I5O^IF
M+C.>PO5/GJPWOVQ_,$57^+7C=[AR)3,W[@;@6S;9?7!^]>A\P:3,[824F6OS
M(A8M%\ DD7/<C#D,HA64VKQ.1<95EJM%@?-ZYEDK7.MI!X+1-&,A[:\;+U!5
MJ)\R+^!+/>[G#5;,B^4:P2\K"Q26^>3NQS7]/D#XYCS.Y0*E""G$MJ8*7BGL
M5 E6E<.Y[L[I%"KUX/UO (IV(2^>>/K."/4)K8CH^CV6:SKP78C GH9PR,D)
M\>&@49>JXHT;M.IG::<U(6WZ'3N.DQTDAY''W7IGDPM"B]O37X9)YC"UIPD4
M<#U]9XU;Y^D'?BC;N!SZ@<5?O\+#GH.8WV=(FYT=MS0Q92W.!@_!@_+E1,;,
M9?5L.#ZC,# 36HLI@O3VF,J7Y.9;(7[,4>-ZJ[J[J_!AJK*2?8>B])9!)*)%
M:$?W@C$DV5FS_NS%R-MW4J87,L+O*JK:Z+XCSY @Z!FLCVB0=2JZ^N_\'DM^
M+P@8H<T07=EQ"^]JRJR*99>8( MS%L< FF)T1H-]:'HVMA?\:IYS$_Q-7WO[
MEIJRS)YXI/U2=NL"^K(#OP1TN'H@H"3N\JS/IBTR/ZR; C#PY+<V"4.-%BWL
M<]]3LENAHI^)FN"RLJ6!T&B(5&.=>7$EAB5!YU'Q]K#@O9^AOKYE@DBQ<__Q
M'!L1$X<$;2>*J)F^.X<U"%V4>,<>2??+A=?><J@JF;2!C8/,:^/DUH+HV5T9
M8WR)_U@KN;7!:M&\_*D5PKM^B-O-:IC_5,D-.W<UO;+=CD6^F]V#.[6A:ST[
MI?>?NFW#0Y81E4<-8:Z?I%D=WN8HV%6&/!T<7AFY]+MU%JK8/](]!_=H?N2Z
M,'4#D%DA=:!IS8UPW[T!%!TEIZ2P XU&D_/HMLNU6-S @1,#FD*K'1_T8-9E
MW@%6<^CF6CA)99#SF'E-/GCUB7@L*>U*XJ_H<QO$:$1)YI*EOC3I@PYJ9\HO
MJ@,:UJ;N'_)\4H1>+=><#7%LGLFIF>=3[Z,>1BR;-!K\%/LZ3.:G2, ^]_E9
M&H742U8;Y1D\U/W%I_C MJ=GIZ+BTZ&MV&B+\&K^^8-(LW U3$)<V,'Z<7YB
M"[!U4*=\H.>[3\& _>S0Q!3OU+:N@XPHBVTXWQO.OK'09CYA.Y?._3[-[@1[
M .%*ZY^I!;I6 ?\8\/@>WX)"6E#0,RLOGK#UY?9C57WKS2V^_\7>6T?%M6S[
MPATAA.#!@WL([@X)04)P"&[!FN TTC@DN+MK<(= XQJ<II'@-#3NT+C[V^>]
M=\?;^XQSOG/O.^?</[ZW:XP>_9MKU>I17;-JUJRY9LUI9:"S "IAVW)57^'5
M5'NQYUFKJ%>ML'_D0#D;YK-F[7UJ!K<M.%_P;'39?F$F=-(L]SYKB\?99CBS
MWEL4V/N,PE/\U\E.NG-]"FC\^IDR:?E*])$"!NLDRX]D:9'@,UE: 6E$7' ]
M'1(1PU$OT@QQJYET.;=\<7&!;J.3'VP]Y45D>XKW\SW/;R*>?1#OO3'_ZXW
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M;>'+5G2G9*>T)*W G_&&5JVYO%>LN1IING=?3!"+JV<I?#*7-L?B'^RGN!X
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MSR*!_*WL#X_ A*;6D+_] 9B7<X(PY9R5,Q\REYRUW%&]J%=^+Z#5]/B2$<C
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M1$/ZC$ )\-17 @/1JF5DW-BL^(#':RLTW:;#IH.(N*-U6#2Y.$3X22[?!;%
M!$DA9_(+ REFE0I:X%HZM\@5>M\T^"[("-=M7XFGC ;0_1- BWC^3XN^/YPY
M*QTKFEY@VV'-F=;)XBZ%G'$? QWK).9/2C.J-!KER+^\">O1HP4%>[XZ@H0)
M'\NO'SBAT(_J>1R_K&._#E*[^TO<\:VX/U#1^,M2H(/^CS/M.^1*%U"K!T".
MTA^HMVH!?W0!2?#UH68V?@ 4.8LOTE?>AX![>UVT;?CF=P;%:L:=N4<W.<Q<
MB\@'U\.<_:L%2F<\Q%A-(GP-+$RM@SF%G3XLT[KY4=%9_,T1]O23RQ^<1NIP
MS_V1#X!"%V&YN;%7!<(.RQ4SN4#[7.MM+3?0U$JS=F>WM23->">6\=!>F$![
M7%-4Y5\WG:"O_0^-%?\#]4@17Y/BUK\\[#Y[X@'@F=A^3?='"D5 ?=8CMXV:
M1_/"Y'!H?2HK.J'*9T(HZR!V^@$@F:=F7">#4J]C0I[G]$LG"C/L+.H3>N+'
M^<"SM)?:2=T_K.E\1.,1;G;42]Z2J';_#<LC>V^/ZT;D!V X?:CRZ_70=WB1
M'P;U% 4!*=T_>Q ?9-,_Z,/A\&ED\ LGER(7]\PI<TH-"QT'L47SLBLI?-NC
M;>N6#=O+%#+]:\[$++]N>7E,TI;D,=L&9J@E=6)/:^]<"U]YQ]KI0G8VEA)Z
M<C&]2  3?$$P6XP2"I]93>3&247+!26BY49J!9L^8@AG_P]>P.P> ,17_PIF
MJ/RCH?Q'HT&3X1_NQT=9)PX;@1\ <L8\WAGHG,OV,4J8./6?R^$X5;8]VZ]T
MGW6JBD<!-8G ZT%YWHK*Y$7_(LZ@=]4S#U )=8'Y=&5W6^236<T*0:_B\*A=
M,_.3\C$;5A*^YI(2A+YSL]0%<!/O30I8]_8JD/E-W$YWU6SF0H,:P X>"B4;
M'1_E-X1,U,)36'2SGAZ08R"PX&^H% >["';@P%U&,,2 FG@6UE^W0+Q:KBF3
M>$F2J/;L(H%K=M#MUJVXZF.;^5SF&S[ZV2_=.^Z$#,9S-,E#UTK(F7:T/@N;
M&]:&6S7>A8/VSZ+;<TS J^)?;NU^RRZKH@%?(9=HC[("HZNULG_P^"]NT0Y(
M24!_Q/"0LPYTS[X*_IJ5UP!BQ$.]0^,^E#"^7_F+3R2087D.:GU,;?P7S^2_
ME/6,+"@<?IN1T9*12'O _[D\#8$JR M$;*=G% L80]_++*6W8R"<ZLPQ7&^+
ML&%C_,3Z\ PX-&76YU=K?N9H8'&AH_M')-->^\C6!<QF\;KS+^D^5.H*ES_1
M(:H<! WSV*+LKOI9I^](?;B^NNXI/4W'B!QMI[C7[SJ[NA*W@^U6&.*%U+..
M2>SUL79!ZN-NYA)_&P-S4)TN>U'*C!2H8"8J8YE38Q(;M2XSEDZ-YTTR+6P2
M(ASFV4:?2V,WRGU5IC#A'=FKT4BR78X("(H]W 4Z93?B.>QCTC<)5CWS83 !
M]^$)-T<''_Y496.,0/"Z*VSH!R_.]_>T%VY*LH?>9RYRJPP<[GZJS+.L.#NJ
MF+WQ)A2:NUO\]OC@\P!1Q<%)SI6 K6Y6T:U/"M@K<TH_I]CHM44$8VMC!GM!
ME5,?952W"8?KQV/U HP[7#[3-YG:_>XALU\V X''YXN!*VKE+IAV^'1#NAHV
MM8<[8!.(BYH)9D=:?Q/UN#;GKLNQO?$V<"EY,3-A=W&?9T&+^N@)4WT]G?GM
M@9IPI@7E;HC^6$WV_:WO X 1?2YI!15CO60U+J-@7?KE1H6@>N=,IX?#R>NU
M3U?T$*NT+[5'(J\TT7=FG1/G@@)L1?9T=;8K**[GQ4J$>Y6<TJQ*F6,:FPV;
MW,<<LK1L"[(GNX$RD\5G#$7#/+:>9YBN7"XV'08,YJ#GS.$<TI3"D0*KM@G3
MR?L]>%<85]>C3T#(J3Y9=LPSE,A)T(6/!VSQ>&:_SS'P1EJ?UK=C<)[E#F1I
M;8(M_OJ(4])+X;A=22G-WN!>T!N[4<U]+PYC+_<H8GUO88*0CO#X9+TJN>S;
ME6/7J=_53:,M^7',$:-D06MVR?8O7WU:_0GKI &<1;L!!E6E8/KQ+3CIK0&+
MYE$\WP/@(F&U RPX'BV0,)<B$N(FB*KW:<E;]/8I0 TB/C!BVM)@5W*P>*UD
MQ;./EU?5$*J^3N@SQ/X<9K5[;Y%6 =Q<-^(T/S[6^#!7L5PZK (M=7E6]@[F
M6G.ZP* =%974!35C"&BY#VBJ$C.4@MV]B&5-VR^$1]" M$4%=+)HL;'X>152
MN&(XW1S>A5Y-D292&X>O9;.,BI\*!B5M*DR+N(R^5AIHIQ7R*8WZE/OL 6#I
M<L4Q=_Z]\$@V,]2576_P 1"O!"V_T-2KLUI7)]OUB8_W]B PF:D8$ YH)'Q,
M3EO )?ABS?KE>G[(]N<=[JLS+=CLEV+(CQN#IUP*EN_,7:V@^QJ/D>4(6 '/
MLN:@+6]_+?B3.QT&N>LP)K^B]'FZ-6>SSA!QN](IN%CADOJ-&O]+D:E??=.E
M&,X['9B61]CRRIK!U(&<]XD"N;@ RC*:P=:>QR##B-2"[_D:?+-@D7H%-4:6
MD$K_ZE=A4;>#;SQL\]8B+MX?+J(3E+(MLDU"#$Q52U@]WR@4^PQ_M(+(<H_V
MKC*/5V+JV+_7*'?M?'56*D5&L!3(9Q3YVBA80B#W$1 '@(L+_$LQ.*8)G+/9
MOZZ?K)^OEI"S#<MYATO4<?S?YF#Q.^B,=8\\Y[?G >:.-GY^F5_$Z3A*2VU\
M9D6AIM)**DR$9W(@I7/F"-R)=#]*MI<8GF\)QG2X7I4Q'&\LZ\T:Z#XT/=26
MN_3TEYP7)>*LRR\T2EOL%_D1(RVQADH:\@T')^[(V:7\=+]F5K1KXHK<L(BS
M\?/@N@YD,8XD.3/ @VNJDESYA_/J8VRR[X%4B=+@(Q%.!]L*_>NH_[+&]X]6
M:H(+GM[4UE2HR>%E_XLI&69PA5" O;E#ZCS4M]5U+M %R&1*Z+(*IY"]39G\
M^<>? ML.N:@@[P,F+B/T WHWZ&!+A;%3PLLL@Q<E4J:[2I^LR64!)HDZJX)R
M6E%9C_NE3$GR [EPN)HA#/TJ<Q$H^:?Z%+%D%&]JK32()3^>R_?U#AC&!,$J
M-B3D" 5.OO2^"S;\CI+6.OHOX.I?A[$IXT^RX+@^D0?R1'Y'?VD$20C,/RP6
M5/^A''ZD!0S]R1TOM2)!%L<OXK#('OWJ(.:?5KO_ 1/Z;L*]Z5F\FG>P%Y*=
MN>0H;_C EF,W:H5*<MO$%5VA(A%EQ2@W0>X^N@TX,MPUQ\^3WD=\:3)9_>;M
M>E'V]9_H&WW45O(D\(W]DJMS9&SGQI!?5^A9*"A0]<=5,Z]>&2:A1$.5N&80
M04QX2,K:D^4D;YK'K<V;"/JO#:IS<ZWZ+FBT9]'+M73BZ*OI&7,Y0E="([JT
MBIRV6ID3VFZ8"%>!&<,2"I?Z9EIW)^8AUCU2%_Z(L)%E&^8' /ODUHF+H.4X
M$4P#0+BA;;V:4TG9N.GCWM))Q=NL4\[R,IV0)A%MU<6"*I,[],M\ZRJ=*D?_
MTY%CG.I;PHX(!+*]/O7X99#F%O*9,S0D=:@)%_,RO2VX=.W[%P>"/&_#S80]
M*<:T&P-+5G['AB0;KB&6)CG^K#%"]+(<7UD991- UA;*<IO*F@'U==8+D8#C
M@:_%L4PQ\V*K\TL=\=6?R[;+C90%7>^D3QO24_SXTV!1 Y($)HP^U)%M&JOM
MD^;'*LU-^JG\Z)(M4:6_B8>.+B)1%UMC9!MO@[?XYH?'UE8G:\@AJTSRK"B^
MMTZ^[&OR<HC?MCYEOWVV#/^39TRPY!<N@'<^]#.Z;C6SA9J*9S5U:<.63 '7
M"C]FFE,  ;?M(@HZ)-05"R9[2G0F>]A9:51"5_BE-N:.BA<[XEAR#65BL66V
M\ZH[>D7^G6**MRK='0DUQ_;W/P=POA%5J_9UX$#;1EU0+2QM\&<7M==/(/8C
MK"P$6O9.[@WFKG?&#E"#>*F[*/R/I0-BBP'H<<\?:;)YPMLTP49V"7\Y[M*F
MZ7(,M./WH4\D99\Q!SM?]9SP9D,<QA/Z[C6A&BQL^"AW&W"6PI(.(S_HL!"[
M[<\0-%>V;A%$(;#Y^1Z%[^':N X>JLX2/^4+ _\307.7U>(YQN38LWY_:%/F
M:X;01^Q;H"<<869%8=S_N_!C#"[(#PZM#0[MFZ)\ <LT<*U5HI1W3V5KB)OF
M=UD(Y?*L;\*^;1Q_/NQ>T&<8-69T?+G&Z!^4E-(:C,2LF7,X'"DX]>:MMO=0
MV3BNNN5,>;*:OQ9$'7VT7J(XC+POW$$B%46<VM$Y51XMI[C]-RXR?\+_]R!1
MD*UG6\EQ, 804=&;IEEZ#5/>(N?TMA!*W^-CJ]7UESJ(V5=[<6Z@E)#GII=R
MK_Y5. QA!7%S$+2?<K:-3X C:'K7E_M_[;K8"5IM%IONX?!GX4[WJP,WH?"T
M *ZMKV7@EGW 8/>&C@F(\[PG94' ,=EBN]]0^6,/J<8JA>BP=P7R_O[;!0OK
MM.B0\%D0[9FH</!$%3;[RI(SPVO11%NW0\?QSV6XW&ZN("GJ1@_.JBOA>4P<
M_.=3Y&$7=H^FKFP:I@@DR>%K9*RET>W87:=*;UG?TSHL2I'YCQR8@\'.D5?I
MHH/6F832&2U.+:>7FKM*BHJNFU%8@R!*$;>C/A&W\JC=E76>!:%#?)<OJHUD
M$=W?+,L( 7,[Q#"2$/ZD1OBO5RM/4V[A<+B;YL'$?/"Y"\>&&WG%+^XAQE$X
M.5- I76#"]B\42>=KV%]_O*H3?.Z<N2])<5VN5\_)^C[[B^:S;C>=6Y> 1=S
M6TE4*N4@BO/MB+1$.SH4&A4];D&$3[6&FWO53IE5\\E5ECA=YX+G(2VX-1&X
M"K^XXI\^T7^?N/]\KEADV\K&3KFEI>#R,4)^<&0$<BCE)I1QZ>UIFP@$&YVL
M?RT)969;%Z5\@S)2M%^^<S_R9#=5K'4!.RN'_8F*R750%%N@/9OGK:)(TO/F
MK<OUH-+)>G-R\2?]E[,40P:Y)^>RN9/30JB9HG6./AZG;O9+FF;X#P#=4Y_:
MKU$<MGRI\5=V0#T&U4>KZ]X_&LVN[*(]Q2BO@:LC&_=O&5KNQ"THCS!&;IX_
MQY,2&G-!V5?#Y=@5Q9 8OJ-3RGH,NB(+J)+NW%\X,N&S<\2[F1Z/:B R% A+
M;!E[K#BX1BO'(]'3Y3"HA"/(+1Z']U60/RWX)ODYH90X_LU7YVQ!]][E;5?=
MP&U7$(DNUL%Q%>>(>D!*"WPF*LL%\T O,2IW.YV!4GM>_A/6>@?/*Z'U ISU
MUFPW7EZQZM6D+="S35CWE3+!BI09BV'N,J#9_7Q/P:BI938S*#*N =0G)W(-
MH1KTO#H[;3A:7S[9:.;&1*!DFVQ[!K9.:60DNZ=F6!/@T)B?MQ1D1_,]IF1+
MC"O.2CH2DT314M'=1$&807@;SF!"78Q][7U#/;JE6W?WV=+U9&>HOYI]WMN*
M!5_MVXC/H_WX)+ [6FWJ:BN^3K9A:^MU;[=LZ#<R<M:2!GWT$4MS]R,>A/F=
M%M;@P7Y@ _Z).'0=7U[ZWMM HC*[4/@1,I%IIL3&((";:(VNO9"S4?MMRDQR
M;A(3"I26 7Q,1<UP @2;@[5)"T^?H>+AO0OM-.:,#CO^M7I4L]T]<J8C]*L7
MXUYA8^B8ZC5GG@?S/M -_N/&IXS]S".47#0.!WR?UIW88C3^ +" %4:)N9YH
MJ^=XY+K<\+Q=SS'IU(Q)"]-&GK_XCLTRLC=1ZGW_2<#<',SBZ)F#B(ZNG6TP
M4"8P^>75H3/6]VY''U0(4G@ :&/1)+YGI_50&)$\3R,@O6&%.4LLC$,\TI*&
M(MKV26>1;C)LV1,Z7:H?L*'3Z%JW#'PJQ^>*;WC,H&$G([6$GT5:4E+FBC=Q
M<8C-ZUH7FMGS;KFZ;38RW7)6"Z94JX![[12;S"1^S4S"XFG"<<U$M2/,'%^4
M?<LXITN?\I9VLN"^,^ ()/[6VD6F$OP5W3.<9N@LJ>Z_[Q7BG_!/^"?\$_X)
M_X1_PC_AG_!/^"?\$_[_ J9__YNWCP:>#+#+T<:6*Z*QZE9AZOR*TIMB@9'A
M2&)V.<NQY''VBC3SJ^#Q3VOAMGKM9J2>;VT$:1\$SBZS_L2F2][F5>3:4/_I
MWNA:);!=85JXW-,7_*9?WQ.57'%PZ0/-F\-=NX]V56#&XN)]MN\30"R)9=^Y
M")^NZ$;(#Z64\1G+ZK &[J=5BO9I'YZ^Q''&.;6IE)NKUC,U)K@ @BFS!4[Q
MC5^Z.2)=X?T1C1<>GRG+^U(?CSTOZ5,:NT5^!WU3> ]>BD^;"]N@J"DG/>FJ
M#Z'PR(.WWH:YU4-'8O<Q*;=UP#S0-,QYLS*>P^9FUY2(^BE'/VYA>\49# T'
M1?*LQ"6R!O,U[4OSQWW!.;OF'KO-C+OCON2\[;HNO*4,HYI]ZXZL!0Z0#W=*
MHQ2,:CU!4%QN]&:(^KGN8(.YK6F2HN6@AG&S;K=IU95.P!I?53WS0L6]WN'X
M9*Q6%FRDO[4?ZVW(P#]DSV$_]NN_<9T=?> ?\S2LC_EOU&KAKGS]GZ_]=^'1
MP%+3@5/-<&*9)B];=J?%]3>2 0UN[8\"_9X"<W%\L<C#L&"(6T/ST?[%=\'9
MU]_F,Q\ BGTZ+ LBP_=?2M4P,G$[\KV)I\&T,>G=OCK7E$1%A2&K5-1)W>&O
M:)9,MVD(/>DG*1(U35K<!"9&=I$S$+R:Y-:F"9QO L'-S^LL6=Z=D39_/0.$
MX;1K/S^->63FK_ZY?ML'K$J)W=&[CYA7_0H;#B[&#D!_ $BFQ8W<'JW:\05[
M-8IVMI6+R_55RQ>L@/9;P48.1PR_1-_N#P_]&C+D%LE0@C4+^Z%BW,:)8RSI
M,!%XU\CDH\U4<JCTB6VOV>-]-"%^YF/G@I4GO[8VKV986L"V^J:7A663M?F'
M)(L)]&2JBSZ->4$._@  N>M*VK'-[<A^%,?=-:FU)=[O%4$_$B5AE7%H">]F
M.QQYZA"&)^S'7?V$3\4;),_U/-V4X1G-Y\_R;S__SX/V56C<D!#N9F%A87'T
MT_^"M== \/\D?_A'#RC^IVO^#AK@4*C\GZ^_76?]WVK8)A0XH+1F+9SK-\O2
MWU<,',.5N.,FS)D4T%/RUY<@Y\*$Q1"+:W^%X$ :<:+(VI]C1$H](XW89@2S
MC*LJ/&T>E^$%LA4<.E4D3%WGD#PG3^D5R<130'0YW$+\H+'A"HWV-$!O3C7N
M;8=SJ1);'*7&*]R=U>[\^O-<5-M$[P+K@.N73L?[(B+6>I ;41&\;^9YZD:W
M]1=FE"1=2WN(0Q$^AJP-BDIV=C5(S]*M^ HWA[T!XZ_F=J76)*9.=SWRZ+TX
MC/,+;N+AM6&7NNM37Y8AF' =W\;;2\9SF3S9JVL&W).WVI/XE'M]>3XS$+41
M<IWFY9!N>%R4B?KVD%4>LU]<'#>AG.IVBP']XK<=QLBK8.XHW; XKKB][#VS
MVIMO!J0ZE" >C7+?KA_3<8H[UF+:A0[7A"'%>LEY.W?8[\4UH0-/J&+^BJ6"
M;]W^M:S2.F@AKZBKM,M.[&U"V.#F47^[3#\C+.HR%B$RQP7'VR+\<Y>"M:_A
M#0[ BZ8G-+COZE;<947#>";&-;(\0' /3F?/@X_;7J"2I>AO/>DFT"6>X??8
ML#-G]$S)IST9/\,"0@4KY<*JZ55!OL,;:RGIVI&)BXAP_73W])1J_B+*Q_<=
M#ACZ!L9T%&./A[=*.@V2#LPHB=]5S34<-N#%/P XSG0+I,%&41V>#X!@^?=0
MUPAD& 3]JCUIOL==7S^FC%*RI^F33!%I3^UW!@X@XS(L5% XUJEW8?2(4JW^
ME)/_^*T."O[S+TJR754:]MG!]>YZ!"&P/..)5"+[*IR^-1&1*UFGQN7/1 Y;
MYDD,9-'M6^ZR:Y5FS9U@9E!0J<3^/6(G"1A5P2)6V:E3A?N1R@A_4GI5V]>%
MY$E)R^C3I;5.4(@;%3<NT?$S.A8)I(1\-QW;<#<; @*ICX/4IPF["7LDG?ZU
MZ.YT^'K\]Z0[NIJYQ<*MXC2QUQ"BC(_9VSD#0X/4_JR7EDB:F ?^7HDT;%)0
M!_]-K]H2,-FW5>=(DIZEFO0'=XQP>;75AW9K[(@[Q$W)OLQJ >A1>GO<T!SE
MF825SY$-ZZV^$G1C+^HZF[?]LB[QGJTH5O)IW;T2O[7/)%KY Z"GIO[(69PQ
MK4Y\QW_J ; RJWO9E".+\W+N2F2^Z@'PB:'^ ? _J'O+J+C:95T40H($EP1W
M#^[26'#7X!:L<0C6C01)D!#< C30D.!.H('&">X.#8T&=P($M]QDK77VWM_:
M>X]SQ[A[W+/.'-W]HW_4J%GS?:N>>JKJG<\G5WJF[[+=YGZAE!*;_D*)=G1?
MV_O()*/FOO$3U'>OG;%R9ZH63*IWZM=L\U"LX?[ 5= >7<J4B,KU_U:12NF_
MZ>%YH)0OMJ":XJ% <[^'E1<&F7-SC&UM\!0Q-(U!<#K\A+.EI;?KQ]7CV^(8
M?XBTE7\27]\^67D8&,+V@35[0KRS@4SB2_9$79E).HKOF_.69\/:\J?2D/0I
M%OOMSQA#'P,/EG8_OYNOT )?J)=,)RRZ.%$W3<<GB!_<\28Z:LBIIB3)XT][
M#:$7IW9AI)!=;P")<QGH1-A!+WXX']S./WG?-N^FB,V<X__#R94R*>N-_V3+
MH^_\@R;V;.>G7AVH*IAS<$5*[^]BG^-,4;P4F1F'Y!\8>;RH/2N5J#VW (RR
M;^KD&./KK.-D8XMSTLLGFW657?6K*:_[!(GZZ-H;(&9ZC;]0)G-F3/B7!61
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MJ86B"*7J_<BR%.;+?Z&DLAU6W.<(!/O=VMTIZ9GO%KZU<B&==VN[$RE\QD%
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M.40"0CR,0<9:[FL>&,MV_0%+.Y<!J@<MH>7\$[9@0W>>"&QSY575BO)RTHP
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M^J%7U/Z V((7#8,&+]"^ZD\W.$UF>0CG=0@DRDUQ2F.M#X[R=R1_8G_Q#EY
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M@_J=?C_.H$XRSL?58=5D:E0A_$I,MBQ$BB[=Z.C<:S*R![*R1TRCHV-=%41
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M6#)0)U R-5 G-46R-47G#Y7DSZMMY'[#4P+>X_<;\I9IHQPR_C?</BI>6;(
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M@:F7NCGZO5#%&08[6SO13 E%&7RY'9F;$'Q.PPUZFW]#)M4[*N:2P(N'70.
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MAI(F7_,PLG]23)AJ]J)^YS*@WN""?SRH[_KHJMIR/G(^0=8,4X?7-)J:O__
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M2=WN$ Q4OZJHQ=87-)DB>^':?X'N:LZ2.B"/%5(NN7WCYIFNSHYO9DF3M+-
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MHN<"1J^%<P_.'INS!;#)&9;T-K>,GO(/JSJU9ICNA3HNU5S:%YRS \S5FIK
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M?GR2%E9HJ>6IV."&^+!?R11V+4/K[PN=";=^9(S&[W*V_L1+ +XDF_$$NZ#
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M1,G]93"QFM*](F>;W00+(&P8&4JY/=O.J6_1)?IU=>3BIVL%Z7M9GO'[ID>
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M\.:CK0]WA32$<Q-*'#?/P"45SP9BQ]-"OS"L]H/,-OH*#=Q+D_N(N37_H''
M#^Q &;.T0?3,JCH"!:U@,-_&%)7>S?43<+=I:4W<*@^( 1LBV)O9_PQ=N\3:
MX6;*; \6D7$/NGLV.+:.%#PR!(<C!D7BJZ^KJ^^BOO>1C_G$]FY=V!9'_9BO
MBX3^F)<)PK;4D"6FJRCA-L6IQ(^6WF+%FOKE@7=O.I_5*1TH$X*+Q9D@97(G
MZI3/2.-@>)>-KMZ(IWH-B-X- X395IEKX9A N-+J>0O#5];0$1NNV#BRB&-U
M>M2T0V%@@FA!^9%IFGM37JIY/)0[9A@[A28)DZ< \V793)PT\W0E'D>/46U(
M"%V%H.20@SQ&8&P\!Q)7-6,LO'8/<%$]KUZLC=TT4ZOP/">$-V/14JTVB5>C
M+RMED-IIZES7U<R1WE,KZ8OT^R.N?K@@4KW-2^Q;84]SE4#[CJ9;.D?IUTB\
MJK8_CU.D/]6' PU=V$J:GR &@PR'M5PWYJONC@M@AMX,(WU-2ZN0P\8A!.)Z
M]$NQ[:OD@;6-Z%WMDD_;'-6>6GB;#7;X@C0Z>.@-F'%/NJ0KT\UNS6U>K8H_
MC<1K3"/\V&<Q:\6+_]'P2![81N:NME:GFJVN]*VA%ZYPQ]4TD/#_ &SY\ZD%
M(>+S21LLVT6W_\YYA&4)4[K-&C?R?O&VY%!JH\ !*>K >.=+^<I#Q6W,(X#^
MIU[;SLV\K,S/^ZUR;%=0Q'*D1<&!K**\E9!^P=XHUUQ65M84\2*Y9ED#BIV1
MY17LG#+)+8I_PR/O27P7 *<\EL" +YYJ'._N/!UZG^@&O/MBA7OYW5<(?.!K
MJCOR"&#0ZKH_]5LZ#)>6^CEM6W^AMGAT&E0FLL+XYP+(;DTLE!2CFDTK<^I.
M;=\)?HW=GPK_5( !>WFW)O O'YS]YQ(Y?%[E BG3_!'VL2:<*?M46(>FCN=:
M7YD%SP4$3P,P<7$'V\CL[VZ3XF3)B^IEE/>2G?E8E;;""^1]2R,\TY/,5JM9
M%^M9A^Z<NMJF=$V+S^N<^+OGA@Y_'75-!)JG%5E9O16\;05(05*ET,6;AOU]
MGW*/G^]L]A L*_%SBI9B_9:ZNV.758F>W6<7,:UO9Y2XVY'I2P<CQA$)<8%Y
M*'04?[PD&LYPC[T)3HMVB_74:>K3^-B6#Q2T. #ZAE0]GZYL\(Q<JRS;"5GL
M&%18,_3@:'+Y+IQ*U;]I;<J))=%N?#+>/3XHMVN(WN//_@SU$AT3O5[8K@N3
MBX]M\+95[>:U$+Q<9>K6]900,=\6TZ^5=2%.Z3DTP[;28BF6-K4PPSS DNX*
M'S+C">>EC?/(IXK3Q I=\F3(CVY::&QSA8', -SY7!->OBI.X4J'$*.$<0NX
M6\"/GTJ=W3V8^]:/ %265[P175K%P ])+6*L20FX@XTS34=*KH5+9:Z)$%(U
M9]0G/63EV_O\@1!FV^P3/<G.R<JNX*[Y!(-DBLC(S.]EM&9,KYL_0@0NSG8C
M"<,FW*T5LCK&*B(Z5RMK*HDR7*1[26HX&O;')O,5FM\-<73I-7/T$(7;=S(/
M$@+177$66D?2O2,7H W=M5BFZN?-!3)=-7.9LFEI[*2-BULS8* Z(@:3_9:G
M6!W=? S2PD\9R,4!T%A9H/B8A&ONIL[-:J3A73]#+,K0+3U;>6/,:).!<N_/
MZ^Z!QV:Z O%E!4DS"Q]A77U>H6AXV/:AW?Y!HN0@A@!5B[24=H[>((BJ+F>*
MHWTS1.]+1,Z)O<PQ;SU?-AD@2Q]=V,5ZV%HBB$-<+YKFR4!HE)YTOC^<KU(;
M%]UMRPN%"QUVP;#Q@N OWN!J^,-/,6;A!E*H@N9 0(#G^"Y4F$<C?V.!((DT
MBN-<!+)IVN6>T3+XXU\;^%/=;)EPV:"'GH4 ZR;/;Y[)UJ>QYRY.,ZRK>XM,
M5]["NGJO=)9F[[.BVL;.F/ 9",_2Z0*!SX^81IC%I.IC _@Y3HQTQ\8<IEDI
M%M<,OE**W-2#>=?Z$E +G=^_LX&<F3H5QL#5JL<_C/+HZQAU)1&L,RNL[F>8
M4"T)GYB7!&"VU:P/[2" Q?MJEV>ZPG$VQ;<L312=!=4@]-^3P%(B<GU5#G/M
M",E+XY)884)Z7]M:P3')PY.QD6[-2#['#A2?;O;-RE0RJU&!,\\1;0H]X?C$
MP%W>>N;+F@N%!YN63#Y]V]52\K)6;1E]6,$&?[,*N7( P=#>NI]G!Z3#E&$:
M0DR6WBF@I2B<19"ZGT2BD9N8#HECY[5+; H*#][8LG5W1GLS=M-'6<C%;R,5
MRA?.4NAXU2(:%O.A8V/ D&WFNQ(=KZO#^I*T;K_.A_3AT.Q@FSFAN,M' '$3
MS#C'C1J703YJ>EX1K6C5?:DAHLK]BEFCS&CDZ,44<\*4];M/LGKN)O[*&,8<
M-E3AIA1?<>=+R-7F+H&U%S:"J3;Y4\F]?XS+T#)[FFEKP8I.'*4(R1TFK1OW
MWWR+C:\<U'+?,$37T, $_Q;,",$59XR'RM2&U].'065BY"VG4H>,_%LL3Q*J
M1[DA<+R>%^]4I$W@KY]L*@R-U$ O[A!JQE[UN8YN*L8)I?OWRCZ') )-W0=[
M37FS]WRZ&WR.G_LP5!+B.K;6-)-<U[*3;-+U8E>L+N=QOJ<=6JJ_*OBZ2*&^
M(,1_,K@VYZ7UE4D\*0L')?->2FYR>#DV0P/=P%RGO>")5JIQQ+OW3QOP"/#
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MUXY:YFDW5XXP!<J:&Z;6@6_Z..;)2_<6''4Z?=DL4NCX@W,@,DJ"+:!_&:/
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M9P R"S9F*IL^$KBBQ7\L$/O4O[/QOL+XZZEQ+%NR,9V\7S(5<Y+.."X;./E
MIV9A,-2+>=?F*'Z6 ]\$7Y"T:[H>_$&6A& X[!LKPELLB_5+A&7V33EA01'6
MSQR)%%#8^;BQ'W.'"NL+\TNF)77U9';D/9(+=4V3HB 3;VHQ)MM$>XJ(=,H
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M-'LV)Q I)'^[?I^^%_5 \6P@I,3LQIJDC[3 V^%1T47J,4*(Z>/<^OEHN=#
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M4S'>VS.\O$D:3DG7&?3WY7SV0AFXSXW+I#8_ZEMUL7'*P+5JT/U5@4&6\H>
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M81Q/;UKFF:RAKJK(ZIYWD.]FW.J:7(/X0];L.$37LAYY'T)D(MI,+3?WDV^
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MC"T]C'96#<2.>T#1BG._<0J!^F?[]")/W2P ^*[@.J>7FI6S$2$.91Z:^+L
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M1LBJ[/5H8_/L-"GNIIWD'>1Y9)LB"VAIU"-"AM1/D"8\MUG%&0>WUWRW2T/
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MW']>N9S4@MH$,3<[B7;+T++ZLXO<M'IA=-DTAH)CKF]?.*5'6G0R/S9 VYV
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M68,\?Y:>Q&/Q<TW"T)19C*C/XNX%(=WWXLJ?,B0" WQM(/K^Z2#)<&^M9.9
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M)OZ32G.Z; R!A^G?Z!\=L,Z6C[..3IB E<UY&WD*[>MBIT9L+CN5C&GXR-&
M':L6C6EU5 QJS:99>*LR8TCG%PS&TP<HU(-_K#(,=OR:L$-[%A;+*2U@3_9M
M5$:?!L"ZMR3H<W2WB!//VL&VS0N.S)"Q]^0I8VC4YK3OX3W38),S"\*,N3R6
M,^77CU0Z60)<.DFS"40?L'10_Q$!?L6"P84-"P=ZBTNBYH$K ],7 E0A;P2
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M18RG86K.^YQLD2@3.A/VY*JY'$C#['\P+TARI'<P]UR=48C;I]*SYA[%C*=
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M@]?Q5HSSF/?J0\'8#SR]S-V?J')=G#EUL;Q:\]^R>/HXFA,/_1RG$:<5N_,
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M+Y;+W=YN<M/I'YY?*&.>^2Q)VA,U)Y)\?.LW&S)7_?+;5\/C5ZON?(:Z2U4
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M7]>+-A);HA7R810SSGHHI$!JY,U("62[GQ106WU:4P;%'N!3>Z-DH#2X1S?
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M* _EH3R4A_+_2YI]9/P=4$L#!!0    ( !J "%EK/06GV.@  -_["  4
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M35\HO3.2"H(#$;MNZ 6!<+U%_T1S/,9J@R\#5PYFWAKB__+/;N3\ZXX%I'B
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M:]?V+(:.@)9LPR"I6:V CM O]5WK&3/-/E'(L.L%N@@"Q\F2P,<><UT<.*G
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MAAM,6G80Z]RTPY;D:W4&7*_4B$?)*J+;JNN\>R?%09W_B^WO9GM?>I9_PK<
M6P(VC*".$]2RLJTBMM?Z_&)3X-YB_V4S(&QU: 92G[>'LQDT!UV>#:>!1XN_
M%(_Y^[QBM_F#X!]7I3K=_I4L(1F^ U-,;-B_?+W^A!1I:4'6I4 -!RA;E?L5
M])HRX?JQXB%(QJ/$EM" 600($%8S>36D-8H.#\T[6UQ80[A^1%AGN&$?NU5Q
M)]7C01T6;7LI9Y[O4S]1F2 QP8%/4TR"6/[A,)'(W9_CIUJ%]X:(3*R_BB16
M-)M.51?F7::/ J2WJI\K-DQ1&XEO81+#N^ -B&2K'=XQ$O/VQ1L0\J!!WM!8
MPYK$*NC37GJOVNN4"[E_"@(ORK#O$5]NHGR.:9C(34"6>H)%CM30#.+U'Y*8
MV+%OZR5\*E9/^0I=2R?C@3"Q5I7NE^IV=L'>M*'8CJ=_^>?$<^-_1:+A#5@,
M^! ^[H0LC=P,AYD0.$@DAI0*'\=IR#.Y!?69PQ=REY"O^$U-RGH.$%^2TX_2
MB+N\4&V.Y):GJ<9T-CQQX@9!S&.Y18\2"4_@XI1E'F:<1XD39X['2 ?/AT*S
M<I -<#;$]%._VJVA+5STK/QYDL)L?#O_!;JLZS*GZUI=SE.;X&MBMQ;0:9EL
ME5D^)#!OO>23 AX4/CX]TLR\-Q?@!*\^2J;4U0'UJ<K]EUP_%E%$N1\''J99
M%.' ]5V<$,ZQ+[@3<3?FB0#%W$^3FMC[VA#NZJEVI%44@8,;I [@I:>@=E"
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MT8YTPA&FS!>1_!YQR$,7!Q%-,*41QZZ@&?>H$U(_U*L,/@W"9Q4)5RD>/RF
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ML/C'*LY[!LC@>KSGT(*[05?KNJI)TSOXFV KN9H^?RHX9$-]>H:I72'0_GI
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M=,K]+"01PV%3#H_('0BA48B]1*1!XF6.QU)8)\TA<I,?/_2([R>+79<KOF;
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M7Z(A)GC;IVKA95RX7D:;VP@XR+(44\)\S%R'!&[B)A[1.E;1I#=UFD)+"Q%
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M&D^8*?97\7MW2JWZ!Y6K0OZ5M4T+K\IW]VIS]:GHC\@+EC\NQ>?M[?\P\;V
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M)C[3+5XN $K_X#H+8&;'4FO @8Z;8 !&#I/Z:RUV5 2+-SP(PE\VFDO<U#(
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M>B1#A*C0L!=AE+*((Q%DGNM'?I:1%&0_].C.;$MV7*A?^GS+A]F=DB:4FC;
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M1J9CS*$=9\YFQPS,N,STE?2,TOMC#S-F;=;J'L/[V6=73O]E>KZ= >--#&G
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MY6"$EF?=L*&LHLBZ@HCT/=#4Y1==T0=6<!]#;5P3.,8"Z.WO0C4[P;=0G$,
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MI9DE.*KB."E1E:C.TS%AJ$BC#*5Q&2<TC429&V4_PLAZ5CX;1H*>$[T';\J
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M!<V(,%(\)RGXCB#<Y-5W1 -)-5!DX44$]G$9UQ9.I(6I ["@5N4#C@IS4?&
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M2EZ$<>W%D3E\VTK$M+CI66'/KR%7<L*64D<UT&351ODX?Q'*8_KCU[MO@>)
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M>Q>F^=7L>?@R)9]@DGEFKD0$ZUBJO>X=1/)(ZLQ$])D'+IOW"WN$E'']OH[
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MVK/+@2VL\.Q2-*QYZ<M O(Q<?-7G-CDI0#K8*%M$<,U*0$S2UQE^48A:!&[
MJU2@2*M9'4ZEFI=Y/4'.V.T$3^?1M-+)#]H:9DM/H 'N#A[K/#3PY<'WF&M_
M>_!4$R,?3.%: /,1:QJ] !>%)%BI^L >LE3M^XWM0-CQUZ:7BWRL3<(FUOO
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M*CIYB&\8KQ\FX X@<O\AZ=7LX7W8^_G9V<OYXO>PR)-LO,^\:'#)U*:TFG9
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M1E8G3Y_-L/ XV)HHIB>L;6/H\I$X"6DPBPB8;"3?1O(Z*4@"DRP(Y6**S8N
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M&'0 _AUKEH+EGOLH06&=MI=U(L%F"=DH7QP7HC2WP0UK#@<SQZ>\CFZEGIY
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MS&C0_A@>QX%%#NO%-;X4',L+K[+J>X:0V>?1&#[I)BN.WA82Y=RK7#$G6*:
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M=%C ;EP>[^"#@)L*7/!),J^$2;)XG98MRZG[OGL\U#P]"4M)I'J G!V_GX&
MUF?Y8EF(-X*3 JOQHZ7@'M!WFL C_AYO8Y:9U4PY2Q%1CH#?XL'&Q,$B!EP-
MC!A-7:_B)CN#Y@Y89%U %H-)5T-FKP"<.?3LGL)U$!K%3DNR[*.5"]XFII!Q
M%&P)K33VUC-FQ0OA<M/Z:L;QO1AT]@3LP7*LW?[ 3MZ-XF5W"@:MOXU=I&#&
MDJ0-PE3[]2.XX1AQZEDD4=L0?0^O8=/8;6/H<&EV!5E;/6_SYKI;S*\^Q[CJ
M[3&9S&[&/^QD9-?$8)6$#HHA:SQPAE."#'8&!?" E))"<=,')SLGJA/O5 4T
M99G>B')Y:\>CU$T?T""X<]& ,M:Y[1?A$BQ8DZ.M.6=88^5\G^B4Y\:O$\54
M5<D<Q.+:]E(.L5F>U-%0%W)=X*0Q13SR@*P"^]*(2&U42L14Q#"_G;!N(.51
MC.Q!O&P! +<'9')1!I60Q;GDBLW5FP&KB H?">,4S+=>UP)](%#=)!DFK*?B
M'L"YR@+_/)J,KA?7MZDR1L9@054I(<$FBI(B1Q1!,@C)A0@4IB\@\D>35A;Z
M$)%U)?A76_#VKP<+9U0XHZU"TFJ).-8!&1TM(IIK853B,9(2@G\X:45;LH3@
M!_.OLN _C>:CRR6;W^9LO*SS'+$F@<>#/*&@\[SFR.E(D74D$>T"CZI7L;8=
MTO]YYKI![L<X]0_D;E/8R&TCUD8Q,51%6#4"MG PBKU'VA";TS,Y#Q)S\*&+
M(^1^_GIGQ*'R?!8: YE;V8_\[-_%Z?4H_/%Q^=IW=F6GU];'Q7SD[7CV<>+!
MV?JO_^IF\?O5_QW=*L?()(ZYT8@EP>34;XJT\AP\*A=("LY'VB=U9LC<K0!G
MJ+2[%V1]96B]B5>Y=>T?L/CW\Y/QFH!@J)6$2*0D8> \4X(T\111ITQB-E%+
M^EQL;1R\G@%2'!R',Z^!"*[-Y_&GN] 1HBVPQUJ$B<T9VZ!X+0 <:6=S^JMV
MX+F]R#OUIS;RWDO;+\>00V6ELB+E]'O,\2:3RR5-)]-HN_3)3L+O$Q#0\F\7
M/)B@3-0H<IT;"PN:PY(XB@8#?9@S*4D//=-WOA;?E <*N#LRMYM13(_I^AJS
MPK[];9F2J(6,Q%B"8./E5"')D.$T("DL[#9+F5&E2SWW6UF+EZN'H>V(DFD4
M;YF.W+MWLHH\DHZJQ S/G<\%*'D)AD*^< A* \>(8YR6;H6\>U4MNO/'P]D!
M$FGP5,QM'W(7A_OJ#N!23%?,7/W_A352J@2.+_@1.74IP'Z*BB'M5?)@;A#F
MU, S<O?L+9I:QSDQ"TNB"7T&B\X]QB](<H0(R1&Q$12QM+F,OR/("L.((,$3
M75YMK2>OF_A^7.TTA+\-*J$OB^RWGJ:[7-K9>?=M ?Y,!KW.C<MROF2DC()O
M'!2R."I$)37 *IH2<0/5S[9YZ^:^OZ3B*<;]%E1.-YO=1V_?O)_-1]>@4T_3
M&7PP IKR%RXL#TJH9<8D7A:$P$@S:1$!!T4DH6@@I;O4]%I8W7SYHZJJXG*I
MK<;Z$+1LG[5N<#R[<-X:+DE 3&N%N,(&]+/R2!+L>++>.]/KKF'OF>LFVA]-
ME1U7 K7Q=7=5_"W.Y^-UA9*<0[FN,W'>G<ZOXG29<;<F3P7,M1<)*0D:FOLH
MD?54(:%LPA9CZ8WN [#]IZZ;@'\TA!U9!NV=E[>F0,ZZG 0+IL"%Q%'&:"5X
M&AA,2Q8#TES %A*6X1@4T%.Z#<C.157.S7_!@_) @;2'L'?V&CS;V9D=A:5N
MOI N"<>(1DF+W+"8>@2'?P2:3%"6*,99Z3[7.Y94.0__!=%UD#!>72[UM\7U
MM9W>=.G#8KZ8QG4(WY+1Z[ZG!S3\+#/O<?.OAS*@3F:VMM8$"\99S 78P--$
M1DH-IAMSVF$;="C]JE(A,_NQ)WY;#./F5ARK-XV03X /L ([_F>TTPL;)3::
MTDP!0=Q*@AP7$2DG%0[,8.=+)ZT/7^VKRNO> W-]G@J.(,\63O0^E+Y;Q"^@
M-\[_C.,?\3/P_0K<KR2D9[F9*P42>9("P4F6D U)TV1MX.XE'DK[K+7NTVEC
MJ#U4EJ\(LWD_GO_97<#Z+4W<HRBH0=RQ@!Q)'BG*G.%"1<]D):BNEUCWT;4]
MA Z1W&L#)B M7C@JL5*.HD04V.@6"V2])<BG?'G*E/2Q*C3S(NN^VC8*SKVE
M]\K@^:%;3"^<U211Z9&73N5(5I?;E6 4K90$*TXM?HD E6UKK/L@W"8X]Y9=
M[>OQ;;2==V]BOM,X23#9'74!MI@5+J$8<M$FP1C2TC D3?2Y&YU)O=(1]I^Y
M[DOR\?'V O)X19KP@I% '*<.&9]C^;D"R]@'#62&P)@U3/G214;[KJWN^W)[
MFF\O60W'8#>WX^-C\/=) "XNFRN&]W]Y^.IM*P/K8#<9AZ2S$7'C/;)2222<
M(%J!OV;]BQ[)SRVT[C-U(^@L(L7]H6I64)W$RUPLY;R8UGR&R@OPPZ1(@B)#
MK,S\"_"OI!#P-$8F>+"J-":?64K=I^N70UT)232@ I\AX[9VM+-826<D4D;G
MVDS8(9T81M8HE:CG@HC2K]7;5U3YJ;HZOH8(YE#U=4R@Y<Z':Y(DMX'3P%#
MH)9YTAH9E3#H9L"(42QY5CHO<>>B*K]=5X?;0/$<@+CY$=#VCSBZO (@G_R
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M9W84"@EJTY#5ZJ$,E]<6SM2.J<I/[K#"I==82#4^-V:U,B<#!;>#-[7-SMN
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M&LWF!9^ZGQ^UESA;NL[:R:#: OQ9LQQZ$_+,D+VB%5JZS-K.FNHW_[?*O[P
M=XW=2Y(M767U9%9%D=[V)[\SW#]ULVWQ6D/:P#\>NY<06[G VLJ>ZM;.$\O[
MT.VW<<!>XFKI FH;6VI7J,T&5::HD, VC==+7BU=&&UA2@M7_$6ZFCT<J)>
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M+?P[OD9??Y!_.#N+_^=__7]02P,$%     @ &H (612;.YT&"   +"<  !4
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M017J005Y<-SI/2W\R(-M^'D'#CL]]")S\=W!;E&92&3M=E]"?!T#AJO9*50
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M*'XCU;1TVK#Q$:52+2^#J$AL&G];"%IF&'!LF[OK"&N4,@Z^<VD;[$NAF&%
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M+3(P,C0P-C,P+GAS9%!+ 0(4 Q0    ( !J "%F7(?7$U1D  $7U   4
M          "  :D, @!I;F\M,C R-# V,S!?8V%L+GAM;%!+ 0(4 Q0    (
M !J "%D.%B&RG5$  "F$ P 4              "  ; F @!I;F\M,C R-# V
M,S!?9&5F+GAM;%!+ 0(4 Q0    ( !J "%G!(%7Q'BD& (<%!P 3
M      "  7]X @!I;F\M,C R-# V,S!?9S$N:G!G4$L! A0#%     @ &H (
M66L]!:?8Z   W_L( !0              ( !SJ$( &EN;RTR,#(T,#8S,%]L
M86(N>&UL4$L! A0#%     @ &H (63ZZ!_:"A@  .C$& !0
M ( !V(H) &EN;RTR,#(T,#8S,%]P<F4N>&UL4$L! A0#%     @ &H (612;
M.YT&"   +"<  !4              ( !C!$* &EN;RTV,S R-#$P<65X,S$R
M+FAT;5!+ 0(4 Q0    ( !J "%EH)S,^^0<  $@E   6              "
M <49"@!I;F\M-C,P,C1X,3!Q97@S,3$N:'1M4$L! A0#%     @ &H (64_U
M2/D:!@  >B   !8              ( !\B$* &EN;RTV,S R-'@Q,'%E>#,R
;,2YH=&U02P4&      H "@"0 @  0"@*

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>ino-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:ino="http://www.inovio.com/20240630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20240630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2024-08-08</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-19</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsTotalShareholderReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>ino:position</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="agreement">
        <measure>ino:agreement</measure>
    </unit>
    <unit id="director">
        <measure>ino:director</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-29">0001055726</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-30">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-12" decimals="6" id="f-147" unitRef="number">0.083333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-12" decimals="6" id="f-276" unitRef="number">0.083333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-71" decimals="6" id="f-368" unitRef="number">0.083333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">25964268</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="0" id="f-31" unitRef="usd">34392404</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="0" id="f-32" unitRef="usd">14310862</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-3" decimals="0" id="f-33" unitRef="usd">76029116</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="0" id="f-34" unitRef="usd">130982913</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="0" id="f-35" unitRef="usd">1773665</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="0" id="f-36" unitRef="usd">2405228</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="0" id="f-37" unitRef="usd">5365860</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="0" id="f-38" unitRef="usd">5393665</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity contextRef="c-3" decimals="0" id="f-39" unitRef="usd">0</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity contextRef="c-4" decimals="0" id="f-40" unitRef="usd">20432</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="0" id="f-41" unitRef="usd">117561045</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="0" id="f-42" unitRef="usd">153113100</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="0" id="f-43" unitRef="usd">4510869</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="0" id="f-44" unitRef="usd">4960986</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-3" decimals="0" id="f-45" unitRef="usd">2319975</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-4" decimals="0" id="f-46" unitRef="usd">2780287</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="0" id="f-47" unitRef="usd">8819399</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="0" id="f-48" unitRef="usd">9491735</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="0" id="f-49" unitRef="usd">585915</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="0" id="f-50" unitRef="usd">605315</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="0" id="f-51" unitRef="usd">133797203</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="0" id="f-52" unitRef="usd">170951423</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="0" id="f-53" unitRef="usd">16634761</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-6" decimals="0" id="f-54" unitRef="usd">19847744</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-55" unitRef="usd">1921457</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-8" decimals="0" id="f-56" unitRef="usd">1070519</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent contextRef="c-3" decimals="0" id="f-57" unitRef="usd">5499648</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent contextRef="c-4" decimals="0" id="f-58" unitRef="usd">2365382</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="0" id="f-59" unitRef="usd">2321984</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="0" id="f-60" unitRef="usd">2406522</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent contextRef="c-3" decimals="0" id="f-61" unitRef="usd">0</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent contextRef="c-4" decimals="0" id="f-62" unitRef="usd">87489</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent contextRef="c-3" decimals="0" id="f-63" unitRef="usd">21918</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent contextRef="c-4" decimals="0" id="f-64" unitRef="usd">21918</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-3" decimals="0" id="f-65" unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-4" decimals="0" id="f-66" unitRef="usd">16770654</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="0" id="f-67" unitRef="usd">26399768</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="0" id="f-68" unitRef="usd">42570228</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="0" id="f-69" unitRef="usd">10658228</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="0" id="f-70" unitRef="usd">11032066</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="0" id="f-71" unitRef="usd">37057996</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="0" id="f-72" unitRef="usd">53602294</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="0" id="f-73" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="0" id="f-74" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="0" id="f-75" unitRef="usd">25962</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="0" id="f-76" unitRef="usd">22792</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="0" id="f-77" unitRef="usd">1783074886</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="0" id="f-78" unitRef="usd">1740954074</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="0" id="f-79" unitRef="usd">-1685672105</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="0" id="f-80" unitRef="usd">-1622965136</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="0" id="f-81" unitRef="usd">-689536</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="0" id="f-82" unitRef="usd">-662601</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="0" id="f-83" unitRef="usd">96739207</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="0" id="f-84" unitRef="usd">117349129</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="0" id="f-85" unitRef="usd">133797203</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="0" id="f-86" unitRef="usd">170951423</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="0" id="f-87" unitRef="usd">100762</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="0" id="f-88" unitRef="usd">225971</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-89" unitRef="usd">100762</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="0" id="f-90" unitRef="usd">340914</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-9" decimals="0" id="f-91" unitRef="usd">23090989</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-10" decimals="0" id="f-92" unitRef="usd">23743970</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="0" id="f-93" unitRef="usd">44001307</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-11" decimals="0" id="f-94" unitRef="usd">53920481</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-9" decimals="0" id="f-95" unitRef="usd">10206686</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-10" decimals="0" id="f-96" unitRef="usd">13523098</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="0" id="f-97" unitRef="usd">20781337</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-11" decimals="0" id="f-98" unitRef="usd">27413708</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-9" decimals="0" id="f-99" unitRef="usd">33297675</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-10" decimals="0" id="f-100" unitRef="usd">37267068</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="0" id="f-101" unitRef="usd">64782644</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-11" decimals="0" id="f-102" unitRef="usd">81334189</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-9" decimals="0" id="f-103" unitRef="usd">-33196913</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-10" decimals="0" id="f-104" unitRef="usd">-37041097</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="0" id="f-105" unitRef="usd">-64681882</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-11" decimals="0" id="f-106" unitRef="usd">-80993275</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating contextRef="c-9" decimals="0" id="f-107" unitRef="usd">1307358</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-10" decimals="0" id="f-108" unitRef="usd">2168233</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-1" decimals="0" id="f-109" unitRef="usd">2807648</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-11" decimals="0" id="f-110" unitRef="usd">4375404</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpenseOperating contextRef="c-9" decimals="0" id="f-111" unitRef="usd">0</us-gaap:InterestExpenseOperating>
    <us-gaap:InterestExpenseOperating contextRef="c-10" decimals="0" id="f-112" unitRef="usd">313488</us-gaap:InterestExpenseOperating>
    <us-gaap:InterestExpenseOperating contextRef="c-1" decimals="0" id="f-113" unitRef="usd">177833</us-gaap:InterestExpenseOperating>
    <us-gaap:InterestExpenseOperating contextRef="c-11" decimals="0" id="f-114" unitRef="usd">626976</us-gaap:InterestExpenseOperating>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-9" decimals="0" id="f-115" unitRef="usd">-334294</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-10" decimals="0" id="f-116" unitRef="usd">156745</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-1" decimals="0" id="f-117" unitRef="usd">-460312</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-11" decimals="0" id="f-118" unitRef="usd">773384</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-9" decimals="0" id="f-119" unitRef="usd">-20820</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-10" decimals="0" id="f-120" unitRef="usd">922941</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="0" id="f-121" unitRef="usd">480057</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-11" decimals="0" id="f-122" unitRef="usd">4141156</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-9" decimals="0" id="f-123" unitRef="usd">7571</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-10" decimals="0" id="f-124" unitRef="usd">-1427867</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="0" id="f-125" unitRef="usd">-674647</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-11" decimals="0" id="f-126" unitRef="usd">-3853543</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="0" id="f-127" unitRef="usd">-32237098</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="0" id="f-128" unitRef="usd">-35534533</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-129" unitRef="usd">-62706969</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="0" id="f-130" unitRef="usd">-76183850</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-131"
      unitRef="usdPerShare">-1.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-132"
      unitRef="usdPerShare">-1.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-10"
      decimals="2"
      id="f-133"
      unitRef="usdPerShare">-1.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-10"
      decimals="2"
      id="f-134"
      unitRef="usdPerShare">-1.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-135"
      unitRef="usdPerShare">-2.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-136"
      unitRef="usdPerShare">-2.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-137"
      unitRef="usdPerShare">-3.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-138"
      unitRef="usdPerShare">-3.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="0" id="f-139" unitRef="shares">27197802</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="0" id="f-140" unitRef="shares">27197802</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-10" decimals="0" id="f-141" unitRef="shares">22029486</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-10" decimals="0" id="f-142" unitRef="shares">22029486</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-143" unitRef="shares">25244657</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-144" unitRef="shares">25244657</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="0" id="f-145" unitRef="shares">21784343</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="0" id="f-146" unitRef="shares">21784343</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="0" id="f-148" unitRef="usd">-32237098</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="0" id="f-149" unitRef="usd">-35534533</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-150" unitRef="usd">-62706969</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="0" id="f-151" unitRef="usd">-76183850</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-9" decimals="0" id="f-152" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-10" decimals="0" id="f-153" unitRef="usd">-376</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-154" unitRef="usd">32403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-11" decimals="0" id="f-155" unitRef="usd">-2294</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-9" decimals="0" id="f-156" unitRef="usd">-13322</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-10" decimals="0" id="f-157" unitRef="usd">-108089</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="0" id="f-158" unitRef="usd">-59338</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-11" decimals="0" id="f-159" unitRef="usd">9773</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-9" decimals="0" id="f-160" unitRef="usd">-32250420</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-10" decimals="0" id="f-161" unitRef="usd">-35642998</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="0" id="f-162" unitRef="usd">-62733904</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-11" decimals="0" id="f-163" unitRef="usd">-76176371</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-13"
      decimals="INF"
      id="f-164"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="0" id="f-165" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-14"
      decimals="INF"
      id="f-166"
      unitRef="shares">22793075</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="0" id="f-167" unitRef="usd">22792</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="0" id="f-168" unitRef="usd">1740954074</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="0" id="f-169" unitRef="usd">-1622965136</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="0" id="f-170" unitRef="usd">-662601</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="0" id="f-171" unitRef="usd">117349129</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-18"
      decimals="INF"
      id="f-172"
      unitRef="shares">543620</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-18" decimals="0" id="f-173" unitRef="usd">544</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-19" decimals="0" id="f-174" unitRef="usd">5224589</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="0" id="f-175" unitRef="usd">5225133</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-18"
      decimals="INF"
      id="f-176"
      unitRef="shares">34558</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-18" decimals="0" id="f-177" unitRef="usd">34</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-19" decimals="0" id="f-178" unitRef="usd">-174282</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-20" decimals="0" id="f-179" unitRef="usd">-174248</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="0" id="f-180" unitRef="usd">2525433</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="0" id="f-181" unitRef="usd">2525433</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="0" id="f-182" unitRef="usd">-30469871</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="0" id="f-183" unitRef="usd">-30469871</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-22" decimals="0" id="f-184" unitRef="usd">-46016</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-20" decimals="0" id="f-185" unitRef="usd">-46016</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-22" decimals="0" id="f-186" unitRef="usd">32403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-20" decimals="0" id="f-187" unitRef="usd">32403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-23"
      decimals="INF"
      id="f-188"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="0" id="f-189" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-24"
      decimals="INF"
      id="f-190"
      unitRef="shares">23371253</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="0" id="f-191" unitRef="usd">23370</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="0" id="f-192" unitRef="usd">1748529814</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="0" id="f-193" unitRef="usd">-1653435007</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="0" id="f-194" unitRef="usd">-676214</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="0" id="f-195" unitRef="usd">94441963</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-29"
      decimals="INF"
      id="f-196"
      unitRef="shares">2536258</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-29" decimals="0" id="f-197" unitRef="usd">2536</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-30" decimals="0" id="f-198" unitRef="usd">17057132</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-9" decimals="0" id="f-199" unitRef="usd">17059668</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-30" decimals="0" id="f-200" unitRef="usd">16146397</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-9" decimals="0" id="f-201" unitRef="usd">16146397</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-29"
      decimals="INF"
      id="f-202"
      unitRef="shares">56033</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-29" decimals="0" id="f-203" unitRef="usd">56</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-30" decimals="0" id="f-204" unitRef="usd">-172510</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-9" decimals="0" id="f-205" unitRef="usd">-172454</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="0" id="f-206" unitRef="usd">1514053</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-9" decimals="0" id="f-207" unitRef="usd">1514053</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-31" decimals="0" id="f-208" unitRef="usd">-32237098</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="0" id="f-209" unitRef="usd">-32237098</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-32" decimals="0" id="f-210" unitRef="usd">-13322</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-9" decimals="0" id="f-211" unitRef="usd">-13322</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-33"
      decimals="INF"
      id="f-212"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="0" id="f-213" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-34"
      decimals="INF"
      id="f-214"
      unitRef="shares">25963544</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="0" id="f-215" unitRef="usd">25962</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="0" id="f-216" unitRef="usd">1783074886</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="0" id="f-217" unitRef="usd">-1685672105</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="0" id="f-218" unitRef="usd">-689536</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="0" id="f-219" unitRef="usd">96739207</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-38"
      decimals="INF"
      id="f-220"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="0" id="f-221" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-39"
      decimals="INF"
      id="f-222"
      unitRef="shares">21090938</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="0" id="f-223" unitRef="usd">21090</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="0" id="f-224" unitRef="usd">1710888191</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="0" id="f-225" unitRef="usd">-1487847784</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="0" id="f-226" unitRef="usd">-698741</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="0" id="f-227" unitRef="usd">222362756</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-44"
      decimals="INF"
      id="f-228"
      unitRef="shares">760083</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-44" decimals="0" id="f-229" unitRef="usd">760</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-45" decimals="0" id="f-230" unitRef="usd">13999240</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-46" decimals="0" id="f-231" unitRef="usd">14000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-44"
      decimals="INF"
      id="f-232"
      unitRef="shares">43901</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-44" decimals="0" id="f-233" unitRef="usd">44</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-45" decimals="0" id="f-234" unitRef="usd">-424748</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-46" decimals="0" id="f-235" unitRef="usd">-424704</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-45" decimals="0" id="f-236" unitRef="usd">3809003</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-46" decimals="0" id="f-237" unitRef="usd">3809003</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-47" decimals="0" id="f-238" unitRef="usd">-40649317</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="0" id="f-239" unitRef="usd">-40649317</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-48" decimals="0" id="f-240" unitRef="usd">117862</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-46" decimals="0" id="f-241" unitRef="usd">117862</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-48" decimals="0" id="f-242" unitRef="usd">-1918</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-46" decimals="0" id="f-243" unitRef="usd">-1918</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-49"
      decimals="INF"
      id="f-244"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="0" id="f-245" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-50"
      decimals="INF"
      id="f-246"
      unitRef="shares">21894922</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="0" id="f-247" unitRef="usd">21894</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="0" id="f-248" unitRef="usd">1728271686</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="0" id="f-249" unitRef="usd">-1528497101</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="0" id="f-250" unitRef="usd">-582797</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="0" id="f-251" unitRef="usd">199213682</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-55"
      decimals="INF"
      id="f-252"
      unitRef="shares">425429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-55" decimals="0" id="f-253" unitRef="usd">425</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-56" decimals="0" id="f-254" unitRef="usd">2914754</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-10" decimals="0" id="f-255" unitRef="usd">2915179</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-55"
      decimals="INF"
      id="f-256"
      unitRef="shares">19077</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-55" decimals="0" id="f-257" unitRef="usd">19</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-56" decimals="0" id="f-258" unitRef="usd">-32311</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-10" decimals="0" id="f-259" unitRef="usd">-32292</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-56" decimals="0" id="f-260" unitRef="usd">2917997</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-10" decimals="0" id="f-261" unitRef="usd">2917997</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-57" decimals="0" id="f-262" unitRef="usd">-35534533</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="0" id="f-263" unitRef="usd">-35534533</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-58" decimals="0" id="f-264" unitRef="usd">-108089</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-10" decimals="0" id="f-265" unitRef="usd">-108089</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-58" decimals="0" id="f-266" unitRef="usd">-376</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-10" decimals="0" id="f-267" unitRef="usd">-376</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-59"
      decimals="INF"
      id="f-268"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-59" decimals="0" id="f-269" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-60"
      decimals="INF"
      id="f-270"
      unitRef="shares">22339428</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="0" id="f-271" unitRef="usd">22338</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="0" id="f-272" unitRef="usd">1734072126</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="0" id="f-273" unitRef="usd">-1564031634</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="0" id="f-274" unitRef="usd">-691262</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="0" id="f-275" unitRef="usd">169371568</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-277" unitRef="usd">-62706969</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="0" id="f-278" unitRef="usd">-76183850</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="0" id="f-279" unitRef="usd">916019</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-11" decimals="0" id="f-280" unitRef="usd">1410649</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="0" id="f-281" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-11" decimals="0" id="f-282" unitRef="usd">145417</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="0" id="f-283" unitRef="usd">672336</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-11" decimals="0" id="f-284" unitRef="usd">739469</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="0" id="f-285" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-11" decimals="0" id="f-286" unitRef="usd">1984444</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="0" id="f-287" unitRef="usd">4039486</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-11" decimals="0" id="f-288" unitRef="usd">6727000</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestIncomeExpense contextRef="c-1" decimals="0" id="f-289" unitRef="usd">355654</ino:NonCashInterestIncomeExpense>
    <ino:NonCashInterestIncomeExpense contextRef="c-11" decimals="0" id="f-290" unitRef="usd">-93489</ino:NonCashInterestIncomeExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="0" id="f-291" unitRef="usd">1154822</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-11" decimals="0" id="f-292" unitRef="usd">2402451</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-1" decimals="0" id="f-293" unitRef="usd">-692557</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-11" decimals="0" id="f-294" unitRef="usd">-3853543</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="0" id="f-295" unitRef="usd">-21930</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-11" decimals="0" id="f-296" unitRef="usd">-334297</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-1" decimals="0" id="f-297" unitRef="usd">-460312</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-11" decimals="0" id="f-298" unitRef="usd">773384</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="0" id="f-299" unitRef="usd">480057</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-11" decimals="0" id="f-300" unitRef="usd">4141156</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="0" id="f-301" unitRef="usd">-631563</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-11" decimals="0" id="f-302" unitRef="usd">-6621990</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="0" id="f-303" unitRef="usd">-48237</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-11" decimals="0" id="f-304" unitRef="usd">-41191898</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="0" id="f-305" unitRef="usd">-19400</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-11" decimals="0" id="f-306" unitRef="usd">-17154</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="0" id="f-307" unitRef="usd">-2362045</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-11" decimals="0" id="f-308" unitRef="usd">-43955799</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="c-1" decimals="0" id="f-309" unitRef="usd">3134266</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="c-11" decimals="0" id="f-310" unitRef="usd">-4421691</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet contextRef="c-1" decimals="0" id="f-311" unitRef="usd">-458376</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet contextRef="c-11" decimals="0" id="f-312" unitRef="usd">-1406066</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="c-1" decimals="0" id="f-313" unitRef="usd">-87489</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="c-11" decimals="0" id="f-314" unitRef="usd">1185913</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="0" id="f-315" unitRef="usd">-56969306</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-11" decimals="0" id="f-316" unitRef="usd">-68979134</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-1" decimals="0" id="f-317" unitRef="usd">29359747</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-11" decimals="0" id="f-318" unitRef="usd">106741680</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-1" decimals="0" id="f-319" unitRef="usd">85196528</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-11" decimals="0" id="f-320" unitRef="usd">173898007</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-321" unitRef="usd">487832</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-11" decimals="0" id="f-322" unitRef="usd">320898</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-323" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-11" decimals="0" id="f-324" unitRef="usd">6071000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="0" id="f-325" unitRef="usd">55348949</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-11" decimals="0" id="f-326" unitRef="usd">72906429</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-1" decimals="0" id="f-327" unitRef="usd">16415000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-11" decimals="0" id="f-328" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-1" decimals="0" id="f-329" unitRef="usd">16146397</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-11" decimals="0" id="f-330" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="0" id="f-331" unitRef="usd">22284801</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-11" decimals="0" id="f-332" unitRef="usd">2915179</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="0" id="f-333" unitRef="usd">67675</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-11" decimals="0" id="f-334" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings contextRef="c-1" decimals="0" id="f-335" unitRef="usd">-414377</ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings contextRef="c-11" decimals="0" id="f-336" unitRef="usd">-456996</ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="0" id="f-337" unitRef="usd">21669496</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-11" decimals="0" id="f-338" unitRef="usd">2458183</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="0" id="f-339" unitRef="usd">32403</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="0" id="f-340" unitRef="usd">-2294</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="0" id="f-341" unitRef="usd">20081542</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-11" decimals="0" id="f-342" unitRef="usd">6383184</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="0" id="f-343" unitRef="usd">14310862</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-43" decimals="0" id="f-344" unitRef="usd">46329359</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="0" id="f-345" unitRef="usd">34392404</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-64" decimals="0" id="f-346" unitRef="usd">52712543</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="0" id="f-347" unitRef="usd">533487</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-11" decimals="0" id="f-348" unitRef="usd">533487</us-gaap:InterestPaidNet>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="0" id="f-349" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-11" decimals="0" id="f-350" unitRef="usd">14000000</us-gaap:StockIssued1>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-351">Organization and Operations&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#x2019;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA delivery devices are designed to optimally deliver the plasmids into the body's cells. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a life-long, rare disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in August 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp;amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-352">Basis of Presentation, Liquidity and Risks and Uncertainties&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June&#160;30, 2024, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2024 and 2023 and the condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three and six months ended June 30, 2024 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2023, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;6, 2024. The balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of June&#160;30, 2024 and December 31, 2023, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss of $32.2 million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$62.7 million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and six months ended June 30, 2024, respectively. The Company had working capital of $91.2 million and an accumulated deficit of $1.7 billion as of June&#160;30, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 18, 2024, the Company closed an underwritten registered direct offering (the &#x201c;Offering&#x201d;) relating to the issuance and sale of 2,536,258 shares (the &#x201c;Shares&#x201d;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and short-term investments of $110.4 million as of June&#160;30, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are expected to be sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the Offering described above, and the receipt of net proceeds of $5.2&#160;million and $5.5&#160;million under a Sales Agreement during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2024 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 24, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended, to effect a 1-for-12 reverse stock split of its common stock (the &#x201c;Reverse Stock Split&#x201d;).  As a result of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The reverse stock split was reflected on the Nasdaq Capital Market beginning with the opening of trading on January 25, 2024. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from "Additional paid-in capital" to "Common stock" on the balance sheet and statement of changes in stockholders&#x2019; equity. Any fractional post-split shares as a result of the reverse stock split were eliminated by the payment of cash for the value of such fractional share. As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and outstanding shares of Series C Cumulative Convertible Preferred Stock and to the number of shares of common stock issuable under the Company's equity incentive plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reverse stock split did not change the par value of the Company's common stock or the authorized number of shares of the Company's common stock. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June&#160;30, 2024, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2024 and 2023 and the condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three and six months ended June 30, 2024 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2023, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;6, 2024. The balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of June&#160;30, 2024 and December 31, 2023, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss of $32.2 million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$62.7 million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and six months ended June 30, 2024, respectively. The Company had working capital of $91.2 million and an accumulated deficit of $1.7 billion as of June&#160;30, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 18, 2024, the Company closed an underwritten registered direct offering (the &#x201c;Offering&#x201d;) relating to the issuance and sale of 2,536,258 shares (the &#x201c;Shares&#x201d;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and short-term investments of $110.4 million as of June&#160;30, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are expected to be sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the Offering described above, and the receipt of net proceeds of $5.2&#160;million and $5.5&#160;million under a Sales Agreement during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2024 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-5" id="f-354" unitRef="usd">-32200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-355" unitRef="usd">-62700000</us-gaap:NetIncomeLoss>
    <ino:WorkingCapital contextRef="c-3" decimals="-5" id="f-356" unitRef="usd">91200000</ino:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-8" id="f-357" unitRef="usd">-1700000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-65"
      decimals="INF"
      id="f-358"
      unitRef="shares">2536258</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-66"
      decimals="INF"
      id="f-359"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-66"
      decimals="INF"
      id="f-360"
      unitRef="usdPerShare">7.693</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-67"
      decimals="INF"
      id="f-361"
      unitRef="shares">2135477</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-68"
      decimals="INF"
      id="f-362"
      unitRef="usdPerShare">7.692</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-68"
      decimals="INF"
      id="f-363"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c-69" decimals="-5" id="f-364" unitRef="usd">33200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-3" decimals="-5" id="f-365" unitRef="usd">110400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-20" decimals="-5" id="f-366" unitRef="usd">5200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-70" decimals="-5" id="f-367" unitRef="usd">5500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-369">Critical Accounting Policies&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-370">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;).</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-371">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-373">Short-term Investments and Fair Value Measurements&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of June&#160;30, 2024 and December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,541,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,042,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,498,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,676,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,674,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,979,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,498,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,481,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,029,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,389,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,522,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,164,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,873,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three and six months ended June 30, 2024, the Company recorded gross realized gains on investments of $300 and $500, respectively, and gross realized losses on investments of $2,000 and $693,000, respectively. During the three and six months ended June 30, 2023, the Company recorded gross realized gains on investments of $200 and $500, respectively, and gross realized losses on investments of $1.5&#160;million and $3.9&#160;million, respectively. During the three and six months ended June 30, 2024, the Company recorded net unrealized (loss) gain on available-for-sale equity securities of $(21,000) and $480,000, respectively. During the three and six months ended June 30, 2023, the Company recorded net unrealized gain on available-for-sale equity securities of $923,000 and $4.1&#160;million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three and six months ended June 30, 2024 and 2023. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of June&#160;30, 2024, the Company had 22 available-for-sale securities with an aggregate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;total unrealized loss of $3.5 million. Of these securities, 19 had been in a loss position for longer than 12 months as of June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;June&#160;30, 2024&#160;were primarily due to changes in interest rates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at June&#160;30, 2024, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,498,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,498,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,674,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,674,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,029,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,172,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,856,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,349,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,492,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,856,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,056,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,763,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,836,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at June&#160;30, 2024 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or as a gain or loss on investment in affiliated entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at June&#160;30, 2024 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of June&#160;30, 2024 or December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-372">Short-term Investments and Fair Value Measurements&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of June&#160;30, 2024 and December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,541,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,042,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,498,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,676,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,674,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,979,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,498,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,481,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,029,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,389,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,522,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,164,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,873,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three and six months ended June 30, 2024, the Company recorded gross realized gains on investments of $300 and $500, respectively, and gross realized losses on investments of $2,000 and $693,000, respectively. During the three and six months ended June 30, 2023, the Company recorded gross realized gains on investments of $200 and $500, respectively, and gross realized losses on investments of $1.5&#160;million and $3.9&#160;million, respectively. During the three and six months ended June 30, 2024, the Company recorded net unrealized (loss) gain on available-for-sale equity securities of $(21,000) and $480,000, respectively. During the three and six months ended June 30, 2023, the Company recorded net unrealized gain on available-for-sale equity securities of $923,000 and $4.1&#160;million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three and six months ended June 30, 2024 and 2023. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of June&#160;30, 2024, the Company had 22 available-for-sale securities with an aggregate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;total unrealized loss of $3.5 million. Of these securities, 19 had been in a loss position for longer than 12 months as of June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;June&#160;30, 2024&#160;were primarily due to changes in interest rates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at June&#160;30, 2024, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,498,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,498,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,674,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,674,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,029,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,172,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,856,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,349,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,492,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,856,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,056,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,763,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,836,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at June&#160;30, 2024 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or as a gain or loss on investment in affiliated entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at June&#160;30, 2024 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of June&#160;30, 2024 or December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-374">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of June&#160;30, 2024 and December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,541,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,042,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,498,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,676,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,674,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,979,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,498,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,481,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,029,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,389,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,522,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,164,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,873,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-72" decimals="0" id="f-375" unitRef="usd">45541438</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-72" decimals="0" id="f-376" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-72" decimals="0" id="f-377" unitRef="usd">3042831</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-72" decimals="0" id="f-378" unitRef="usd">42498607</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-73" id="f-379">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-74" decimals="0" id="f-380" unitRef="usd">29676056</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-74" decimals="0" id="f-381" unitRef="usd">517</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-74" decimals="0" id="f-382" unitRef="usd">2473</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-74" decimals="0" id="f-383" unitRef="usd">29674100</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-75" id="f-384">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-76" decimals="0" id="f-385" unitRef="usd">2979591</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-76" decimals="0" id="f-386" unitRef="usd">10735</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-76" decimals="0" id="f-387" unitRef="usd">290</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-76" decimals="0" id="f-388" unitRef="usd">2990036</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-77" decimals="0" id="f-389" unitRef="usd">1301822</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-77" decimals="0" id="f-390" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-77" decimals="0" id="f-391" unitRef="usd">435449</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-77" decimals="0" id="f-392" unitRef="usd">866373</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="0" id="f-393" unitRef="usd">79498907</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="0" id="f-394" unitRef="usd">11252</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="0" id="f-395" unitRef="usd">3481043</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="0" id="f-396" unitRef="usd">76029116</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-78" decimals="0" id="f-397" unitRef="usd">55389289</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-78" decimals="0" id="f-398" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-78" decimals="0" id="f-399" unitRef="usd">3522888</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-78" decimals="0" id="f-400" unitRef="usd">51866401</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-79" id="f-401">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-80" decimals="0" id="f-402" unitRef="usd">75164782</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-80" decimals="0" id="f-403" unitRef="usd">24938</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-80" decimals="0" id="f-404" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-80" decimals="0" id="f-405" unitRef="usd">75189720</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-81" id="f-406">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-82" decimals="0" id="f-407" unitRef="usd">2978917</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-82" decimals="0" id="f-408" unitRef="usd">11709</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-82" decimals="0" id="f-409" unitRef="usd">300</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-82" decimals="0" id="f-410" unitRef="usd">2990326</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-83" decimals="0" id="f-411" unitRef="usd">1340439</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-83" decimals="0" id="f-412" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-83" decimals="0" id="f-413" unitRef="usd">403973</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-83" decimals="0" id="f-414" unitRef="usd">936466</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="0" id="f-415" unitRef="usd">134873427</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="0" id="f-416" unitRef="usd">36647</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="0" id="f-417" unitRef="usd">3927161</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="0" id="f-418" unitRef="usd">130982913</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-9" decimals="-2" id="f-419" unitRef="usd">300</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-1" decimals="-2" id="f-420" unitRef="usd">500</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-9" decimals="-3" id="f-421" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-1" decimals="-3" id="f-422" unitRef="usd">693000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-10" decimals="-2" id="f-423" unitRef="usd">200</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-11" decimals="-2" id="f-424" unitRef="usd">500</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-10" decimals="-5" id="f-425" unitRef="usd">1500000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-11" decimals="-5" id="f-426" unitRef="usd">3900000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-9" decimals="-3" id="f-427" unitRef="usd">-21000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-428" unitRef="usd">480000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-10" decimals="-3" id="f-429" unitRef="usd">923000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-11" decimals="-5" id="f-430" unitRef="usd">4100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-3"
      decimals="INF"
      id="f-431"
      unitRef="position">22</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-5" id="f-432" unitRef="usd">-3500000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="c-3"
      decimals="INF"
      id="f-433"
      unitRef="position">19</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-434">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,498,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,498,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,674,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,674,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,029,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,172,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,856,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,349,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,492,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,856,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,056,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,763,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,836,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-84" decimals="0" id="f-435" unitRef="usd">42498607</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-85" decimals="0" id="f-436" unitRef="usd">42498607</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-86" decimals="0" id="f-437" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-87" decimals="0" id="f-438" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-88" decimals="0" id="f-439" unitRef="usd">29674100</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-89" decimals="0" id="f-440" unitRef="usd">29674100</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="0" id="f-441" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-91" decimals="0" id="f-442" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="0" id="f-443" unitRef="usd">2990036</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-93" decimals="0" id="f-444" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-94" decimals="0" id="f-445" unitRef="usd">2990036</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-95" decimals="0" id="f-446" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-96" decimals="0" id="f-447" unitRef="usd">866373</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-97" decimals="0" id="f-448" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-98" decimals="0" id="f-449" unitRef="usd">866373</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-99" decimals="0" id="f-450" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-100" decimals="0" id="f-451" unitRef="usd">76029116</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-101" decimals="0" id="f-452" unitRef="usd">72172707</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-102" decimals="0" id="f-453" unitRef="usd">3856409</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-103" decimals="0" id="f-454" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-100" decimals="0" id="f-455" unitRef="usd">2319975</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-101" decimals="0" id="f-456" unitRef="usd">2319975</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-102" decimals="0" id="f-457" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-103" decimals="0" id="f-458" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-100" decimals="0" id="f-459" unitRef="usd">78349091</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-101" decimals="0" id="f-460" unitRef="usd">74492682</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-102" decimals="0" id="f-461" unitRef="usd">3856409</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-103" decimals="0" id="f-462" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-104" decimals="0" id="f-463" unitRef="usd">51866401</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-105" decimals="0" id="f-464" unitRef="usd">51866401</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-106" decimals="0" id="f-465" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-107" decimals="0" id="f-466" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-108" decimals="0" id="f-467" unitRef="usd">75189720</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-109" decimals="0" id="f-468" unitRef="usd">75189720</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-110" decimals="0" id="f-469" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-111" decimals="0" id="f-470" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-112" decimals="0" id="f-471" unitRef="usd">2990326</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-113" decimals="0" id="f-472" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-114" decimals="0" id="f-473" unitRef="usd">2990326</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-115" decimals="0" id="f-474" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-116" decimals="0" id="f-475" unitRef="usd">936466</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-117" decimals="0" id="f-476" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-118" decimals="0" id="f-477" unitRef="usd">936466</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-119" decimals="0" id="f-478" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-120" decimals="0" id="f-479" unitRef="usd">130982913</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-121" decimals="0" id="f-480" unitRef="usd">127056121</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-122" decimals="0" id="f-481" unitRef="usd">3926792</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-123" decimals="0" id="f-482" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-120" decimals="0" id="f-483" unitRef="usd">2780287</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-121" decimals="0" id="f-484" unitRef="usd">2780287</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-122" decimals="0" id="f-485" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-123" decimals="0" id="f-486" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-120" decimals="0" id="f-487" unitRef="usd">133763200</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-121" decimals="0" id="f-488" unitRef="usd">129836408</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-122" decimals="0" id="f-489" unitRef="usd">3926792</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-123" decimals="0" id="f-490" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-124"
      decimals="INF"
      id="f-491"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c-1" id="f-492">Certain Balance Sheet Items&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.289%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical expenses (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,410,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,024,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,983,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,365,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,393,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.289%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,487,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,642,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,504,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,432,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,634,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,847,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (a)        As of June 30, 2024 and December 31, 2023, balance includes $22,000 and $1.5&#160;million, respectively, of prepaid manufacturing expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;As of June 30, 2024 and December 31, 2023, balance includes $2.3&#160;million and $4.3&#160;million, respectively, of liability for unused grant funding.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.289%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical expenses (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,410,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,024,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,983,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,365,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,393,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <ino:PrepaidClinicalExpensesCurrent contextRef="c-3" decimals="0" id="f-494" unitRef="usd">2341285</ino:PrepaidClinicalExpensesCurrent>
    <ino:PrepaidClinicalExpensesCurrent contextRef="c-4" decimals="0" id="f-495" unitRef="usd">3410442</ino:PrepaidClinicalExpensesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-3" decimals="0" id="f-496" unitRef="usd">3024575</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-4" decimals="0" id="f-497" unitRef="usd">1983223</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="0" id="f-498" unitRef="usd">5365860</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="0" id="f-499" unitRef="usd">5393665</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-500">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.289%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,487,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,642,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,504,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,432,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,634,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,847,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (a)        As of June 30, 2024 and December 31, 2023, balance includes $22,000 and $1.5&#160;million, respectively, of prepaid manufacturing expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;As of June 30, 2024 and December 31, 2023, balance includes $2.3&#160;million and $4.3&#160;million, respectively, of liability for unused grant funding.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="c-5" decimals="0" id="f-501" unitRef="usd">4487282</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="c-6" decimals="0" id="f-502" unitRef="usd">3577826</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-5" decimals="0" id="f-503" unitRef="usd">8642497</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-6" decimals="0" id="f-504" unitRef="usd">9837104</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-5" decimals="0" id="f-505" unitRef="usd">3504982</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-6" decimals="0" id="f-506" unitRef="usd">6432814</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="0" id="f-507" unitRef="usd">16634761</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-6" decimals="0" id="f-508" unitRef="usd">19847744</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ino:PrepaidManufacturingExpenseCurrent contextRef="c-3" decimals="-3" id="f-509" unitRef="usd">22000</ino:PrepaidManufacturingExpenseCurrent>
    <ino:PrepaidManufacturingExpenseCurrent contextRef="c-4" decimals="-5" id="f-510" unitRef="usd">1500000</ino:PrepaidManufacturingExpenseCurrent>
    <ino:GrantLiability contextRef="c-1" decimals="-5" id="f-511" unitRef="usd">2300000</ino:GrantLiability>
    <ino:GrantLiability contextRef="c-70" decimals="-5" id="f-512" unitRef="usd">4300000</ino:GrantLiability>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-513">Convertible Debt&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5&#160;million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $16.9&#160;million obligation in full, including accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the six months ended June 30, 2024,&#160;the Company recognized $178,000 of interest expense related to the Notes, all of which related to the contractual interes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;t coupon. For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;three and six months ended June 30, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;,&#160;the Company recognized $313,000 and $627,000, respectively, of interest expense related to the Notes, of which $267,000 and $533,000, respectively, related to the contractual interest coupon.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-125" decimals="INF" id="f-514" unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-126" decimals="INF" id="f-515" unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-125" decimals="3" id="f-516" unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-126" decimals="3" id="f-517" unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-127" decimals="-5" id="f-518" unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-126" decimals="3" id="f-519" unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-128" decimals="-5" id="f-520" unitRef="usd">16900000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:InterestExpenseOperating contextRef="c-129" decimals="-3" id="f-521" unitRef="usd">178000</us-gaap:InterestExpenseOperating>
    <us-gaap:InterestExpenseOperating contextRef="c-130" decimals="-3" id="f-522" unitRef="usd">313000</us-gaap:InterestExpenseOperating>
    <us-gaap:InterestExpenseOperating contextRef="c-131" decimals="-3" id="f-523" unitRef="usd">627000</us-gaap:InterestExpenseOperating>
    <us-gaap:InterestExpenseDebt contextRef="c-130" decimals="-3" id="f-524" unitRef="usd">267000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-131" decimals="-3" id="f-525" unitRef="usd">533000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-526">Stockholders&#x2019; Equity&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of June&#160;30, 2024 and December&#160;31, 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.095%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.136%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,963,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,963,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,793,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances of Common Stock and Pre-Funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 18, 2024, the Company closed the Offering of Shares and Pre-Funded Warrants (see &#x201c;Liquidity&#x201d; in Note 2 above). As the Pre-Funded Warrants are indexed to the Company's own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Pre-Funded Warrants as additional paid-in capital on the Company's condensed consolidated balance sheet as of June 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each Pre-Funded Warrant has an initial exercise price per share of $0.001, subject to certain adjustments. The Pre-Funded Warrants may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the Company&#x2019;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#x2019;s election to a lower or higher percentage not in excess of 19.99% upon 61 days&#x2019; notice to the Company subject to the terms of the Pre-Funded Warrants.  As of June 30, 2024, no Pre-Funded Warrants had been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2021, the Company entered into an ATM Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with outside sales agents (collectively, the &#x201c;Sales Agents&#x201d;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents were entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the three months ended March 31, 2024, the Company sold 543,620 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $9.76 per share, resulting in aggregate net proceeds of $5.2&#160;million. During the year ended December 31, 2023, the Company sold 875,305 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $6.33 per share, resulting in aggregate net proceeds of $5.5&#160;million. The registration statement relating to the shares of common stock issuable under the 2021 Sales Agreement has expired, and in August 2024 we terminated the 2021 Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, the Company issued 760,083 shares of common stock pursuant to the securities class action settlement, as described in Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#x201c;2023 Plan&#x201d;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#x2019;s common stock that may be issued under the 2023 Plan will not exceed the sum of 1,166,666 shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#x201c;2016 Plan&#x201d;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At June&#160;30, 2024, the Company had 800,051 shares of common stock available for future grant under the 2023 Plan, 188,804 shares underlying outstanding RSUs and 276,163 shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over three years and have a maximum contractual term of ten years. The 2023 Plan terminates by its terms on March&#160;24, 2033. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2024, the Company had 142,295 shares underlying outstanding but unvested RSUs and options outstanding to purchase 947,606 shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over three years and have a maximum contractual term of ten years. Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#x2019;s common stock that may be issued under the 2022 Inducement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plan will not exceed 166,666 shares. At June&#160;30, 2024, the Company had 110,527 shares of common stock available for future grant under the 2022 Inducement Plan, 10,274 shares underlying outstanding but unvested RSUs and options outstanding to purchase 38,318 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on M&lt;/span&gt;arch&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At June&#160;30, 2024, the Company had options outstanding to purchase 97,618 shares of common stock under the 2007 Incentive Plan. The outstanding awards granted under the 2007 Incentive Plan are fully vested and generally have a maximum contractual term of ten years.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-527">&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of June&#160;30, 2024 and December&#160;31, 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.095%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.136%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,963,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,963,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,793,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-528"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-529"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-530" unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-531" unitRef="shares">25963544</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-532" unitRef="shares">25963544</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-533" unitRef="shares">22793075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-132"
      decimals="INF"
      id="f-534"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-133"
      decimals="INF"
      id="f-535"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-133"
      decimals="INF"
      id="f-536"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-133"
      decimals="INF"
      id="f-537"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-133"
      decimals="INF"
      id="f-538"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-132"
      decimals="INF"
      id="f-539"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-68"
      decimals="INF"
      id="f-540"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipPercent contextRef="c-66" decimals="4" id="f-541" unitRef="number">0.0999</ino:ClassOfWarrantOrRightCommonStockOwnershipPercent>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipPercent contextRef="c-134" decimals="4" id="f-542" unitRef="number">0.1999</ino:ClassOfWarrantOrRightCommonStockOwnershipPercent>
    <ino:StockSalesAgreementMaximumAuthorizedAmount contextRef="c-135" decimals="-5" id="f-543" unitRef="usd">300000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage contextRef="c-135" decimals="3" id="f-544" unitRef="number">0.030</ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="c-136"
      decimals="INF"
      id="f-545"
      unitRef="shares">543620</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="c-136"
      decimals="2"
      id="f-546"
      unitRef="usdPerShare">9.76</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="c-136" decimals="-5" id="f-547" unitRef="usd">5200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="c-137"
      decimals="INF"
      id="f-548"
      unitRef="shares">875305</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="c-137"
      decimals="2"
      id="f-549"
      unitRef="usdPerShare">6.33</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="c-137" decimals="-5" id="f-550" unitRef="usd">5500000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:LitigationSettlementAmountAwardedToOtherPartyShares
      contextRef="c-138"
      decimals="INF"
      id="f-551"
      unitRef="shares">760083</ino:LitigationSettlementAmountAwardedToOtherPartyShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-139"
      decimals="INF"
      id="f-552"
      unitRef="shares">1166666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-140"
      decimals="INF"
      id="f-553"
      unitRef="shares">800051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-140"
      decimals="INF"
      id="f-554"
      unitRef="shares">188804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-140"
      decimals="INF"
      id="f-555"
      unitRef="shares">276163</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-141" id="f-556">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-141" id="f-557">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-142"
      decimals="INF"
      id="f-558"
      unitRef="shares">142295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-142"
      decimals="INF"
      id="f-559"
      unitRef="shares">947606</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-143" id="f-560">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-143" id="f-561">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-144"
      decimals="INF"
      id="f-562"
      unitRef="shares">166666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-145"
      decimals="INF"
      id="f-563"
      unitRef="shares">110527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-145"
      decimals="INF"
      id="f-564"
      unitRef="shares">10274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-145"
      decimals="INF"
      id="f-565"
      unitRef="shares">38318</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-146"
      decimals="INF"
      id="f-566"
      unitRef="shares">97618</us-gaap:CommonStockOtherSharesOutstanding>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-147" id="f-567">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-568">Net Loss Per Share &lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The outstanding Pre-Funded Warrants (see Note 7) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the three and six months ended June 30, 2024 given their nominal exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and RSUs and refle&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cts the potential dilution that would occur if securities or other con&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the Notes previously issued by the Company (discussed in Note 6) was considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three and six months ended June 30, 2024 and 2023, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options, service-based RSUs, performance-and market-based RSUs and the potentially dilutive shares issuable upon conversion of the Notes prior to their repayment on March 1, 2024 would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share for the three and six months ended June 30, 2024 and 2023 are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,237,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,534,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,461,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,029,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,197,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,029,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,706,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,183,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,376,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,784,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,244,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,784,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three and Six Months Ended June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-and market-based restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,783,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-569">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The outstanding Pre-Funded Warrants (see Note 7) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the three and six months ended June 30, 2024 given their nominal exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and RSUs and refle&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cts the potential dilution that would occur if securities or other con&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the Notes previously issued by the Company (discussed in Note 6) was considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three and six months ended June 30, 2024 and 2023, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options, service-based RSUs, performance-and market-based RSUs and the potentially dilutive shares issuable upon conversion of the Notes prior to their repayment on March 1, 2024 would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock contextRef="c-1" id="f-570">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share for the three and six months ended June 30, 2024 and 2023 are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,237,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,534,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,461,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,029,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,197,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,029,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,706,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,183,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,376,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,784,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,244,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,784,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="0" id="f-571" unitRef="usd">-32237098</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="0" id="f-572" unitRef="usd">-35534533</us-gaap:NetIncomeLoss>
    <ino:WeightedAverageNumberOfSharesOutstanding contextRef="c-9" decimals="0" id="f-573" unitRef="shares">25461260</ino:WeightedAverageNumberOfSharesOutstanding>
    <ino:WeightedAverageNumberOfSharesOutstanding contextRef="c-10" decimals="0" id="f-574" unitRef="shares">22029486</ino:WeightedAverageNumberOfSharesOutstanding>
    <ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants contextRef="c-9" decimals="0" id="f-575" unitRef="shares">1736542</ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants>
    <ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants contextRef="c-10" decimals="0" id="f-576" unitRef="shares">0</ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="0" id="f-577" unitRef="shares">27197802</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="0" id="f-578" unitRef="shares">27197802</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-10" decimals="0" id="f-579" unitRef="shares">22029486</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-10" decimals="0" id="f-580" unitRef="shares">22029486</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="INF"
      id="f-581"
      unitRef="usdPerShare">-1.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="INF"
      id="f-582"
      unitRef="usdPerShare">-1.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-10"
      decimals="INF"
      id="f-583"
      unitRef="usdPerShare">-1.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-10"
      decimals="INF"
      id="f-584"
      unitRef="usdPerShare">-1.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-585" unitRef="usd">-62706969</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="0" id="f-586" unitRef="usd">-76183850</us-gaap:NetIncomeLoss>
    <ino:WeightedAverageNumberOfSharesOutstanding contextRef="c-1" decimals="0" id="f-587" unitRef="shares">24376386</ino:WeightedAverageNumberOfSharesOutstanding>
    <ino:WeightedAverageNumberOfSharesOutstanding contextRef="c-11" decimals="0" id="f-588" unitRef="shares">21784343</ino:WeightedAverageNumberOfSharesOutstanding>
    <ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants contextRef="c-1" decimals="0" id="f-589" unitRef="shares">868271</ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants>
    <ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants contextRef="c-11" decimals="0" id="f-590" unitRef="shares">0</ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-591" unitRef="shares">25244657</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-592" unitRef="shares">25244657</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="0" id="f-593" unitRef="shares">21784343</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="0" id="f-594" unitRef="shares">21784343</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-595"
      unitRef="usdPerShare">-2.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-596"
      unitRef="usdPerShare">-2.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-597"
      unitRef="usdPerShare">-3.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-598"
      unitRef="usdPerShare">-3.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-599">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three and Six Months Ended June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-and market-based restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,783,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-148" decimals="0" id="f-600" unitRef="shares">1359705</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-149" decimals="0" id="f-601" unitRef="shares">1359705</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-150" decimals="0" id="f-602" unitRef="shares">1263891</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-151" decimals="0" id="f-603" unitRef="shares">1263891</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-152" decimals="0" id="f-604" unitRef="shares">341373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-153" decimals="0" id="f-605" unitRef="shares">341373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-154" decimals="0" id="f-606" unitRef="shares">305434</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-155" decimals="0" id="f-607" unitRef="shares">305434</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-156" decimals="0" id="f-608" unitRef="shares">82000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-157" decimals="0" id="f-609" unitRef="shares">82000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-158" decimals="0" id="f-610" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-159" decimals="0" id="f-611" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-160" decimals="0" id="f-612" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-161" decimals="0" id="f-613" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-162" decimals="0" id="f-614" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-163" decimals="0" id="f-615" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-164" decimals="0" id="f-616" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-165" decimals="0" id="f-617" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-166" decimals="0" id="f-618" unitRef="shares">254165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-167" decimals="0" id="f-619" unitRef="shares">254165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-9" decimals="0" id="f-620" unitRef="shares">1783353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-621" unitRef="shares">1783353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-11" decimals="0" id="f-622" unitRef="shares">1823765</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-10" decimals="0" id="f-623" unitRef="shares">1823765</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-624">Stock-Based Compensation&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to service-based RSUs, performance-based RSUs  and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2024 was $1.5 million and $3.9 million, respectively, of which $581,000 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $1.6 million, respectively, was included in research and development expenses, and $890,000 and $2.3 million, respectively, was included in general and administrative expenses. Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2023 was $2.8 million and $6.4 million, respectively, of which $1.3 million and $2.7 million, respectively, was included in research and development expenses, and $1.5 million and $3.7 million, respectively, was included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2024, there was $3.7 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $8.80 and $6.96 for employee and director stock options granted during the three and six months ended June 30, 2024, respectively, and $7.20 and $11.28 for the three and six months ended June 30, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2024, there was $3.4 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 1.7 years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $11.00 and $8.61 for service-based RSUs granted during the three and six months ended June 30, 2024, respectively and $9.24 and $10.32 for the three and six months ended June 30, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2024 was $43,000 and $146,000, respectively. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2023 was $146,000 and $366,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-and Market-Based RSUs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 23, 2024, the Company granted 82,000 performance-and market-based RSUs (such performance-based grants, the "PSU Awards") to key employees under the 2023 Plan. Each PSU was expressed as a target number of RSUs. With respect to the PSU Awards, the Company's Board of Directors established specified performance goals and corresponding performance periods over which the goals must be attained, the satisfaction of which are conditions to earning the PSU Awards and vesting of the underlying RSUs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the target number of RSUs underlying each PSU Award, up to 70% (the "Milestone-based RSUs") will vest based on the achievement of specified milestones relating to the development, regulatory status and commercialization of the Company&#x2019;s lead product candidate INO-3107 (each, a "Milestone," and collectively, the "Milestones"). Each Milestone has a specified deadline for achievement ranging between the end of 2025 and the end of 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining 30% of the target number of RSUs underlying each PSU Award (the "Market-based RSUs") will be eligible to vest based on the Company&#x2019;s achievement of total stockholder return relative to a peer group consisting of companies in the Russell 2000 Biotechnology Subsector index (the &#x201c;Relative TSR&#x201d;) over the period beginning on June 1, 2024 and ending on December 31, 2027 (the &#x201c;Performance Period&#x201d;), expressed as a percentile ranking.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of Marked-based RSUs, if any, actually earned based on the achievement of the Relative TSR goal may range from 50% of the target number of RSUs for performance at a specified threshold percentile, to 100% of the target number of RSUs for performance at the target percentile, and up to 150% of the target number of RSUs for performance at or above a specified maximum percentile. In the event that actual Relative TSR performance is between the threshold and target levels or between the target and maximum levels, the number of RSUs earned based on Relative TSR will be determined based on linear interpolation between the specified percentiles. If the Company&#x2019;s actual Relative TSR performance is below the threshold percentile, then no RSUs would be earned based on Relative TSR. The number of RSUs earned based on Relative TSR may not exceed the target number of RSUs eligible to vest based on Relative TSR if the Company&#x2019;s total stockholder return is negative for the Performance Period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values the Milestone-based RSUs based on the grant date closing price per share. The Company recognizes stock-based compensation expense over the performance period, if it is probable that the performance condition will be achieved. Adjustments to stock-based compensation expense are made, as needed, each reporting period based on changes in the Company's estimate of the number of units that are probable of vesting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values the Market-based RSUs on the grant date using the Monte Carlo simulation method, a generally accepted statistical technique used to simulate a range of possible future stock prices for the Company and the peer group. The determination of fair value is affected by the Company's stock price and a number of assumptions including the expected volatility and the risk-free interest rate. The Company will recognize stock-based compensation expense ratably over the performance period of the award. The market-based RSUs will cliff-vest at the end of the three-year period ranging from 0 percent to 150 percent of the target number of awards granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant assumptions used in the Monte Carlo simulation method were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.808%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of the Milestone-based RSUs was $629,000 based on the grant date closing price per share of $10.96. As of June 30, 2024, the underlying performance milestones of the Milestone-based RSUs were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the three and six months then ended.&lt;/span&gt;&lt;/div&gt;The grant date fair value of the Market-based RSUs was $263,000 based on the fair value of $10.69 per share as determined using the Monte Carlo simulation method. For both the three and six months ended June 30, 2024, the Company recognized $8,000 in stock-based compensation for the Market-based RSUs.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c-1" id="f-625">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to service-based RSUs, performance-based RSUs  and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-626">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-168" decimals="4" id="f-627" unitRef="number">0.0442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-169" decimals="4" id="f-628" unitRef="number">0.0345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-170" decimals="4" id="f-629" unitRef="number">0.0423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-171" decimals="4" id="f-630" unitRef="number">0.0405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-168" decimals="2" id="f-631" unitRef="number">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-169" decimals="2" id="f-632" unitRef="number">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-170" decimals="2" id="f-633" unitRef="number">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-171" decimals="2" id="f-634" unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-168" id="f-635">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-169" id="f-636">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-170" id="f-637">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-171" id="f-638">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-168"
      decimals="INF"
      id="f-639"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-169"
      decimals="INF"
      id="f-640"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-170"
      decimals="INF"
      id="f-641"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-171"
      decimals="INF"
      id="f-642"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation contextRef="c-172" decimals="-5" id="f-643" unitRef="usd">1500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-173" decimals="-5" id="f-644" unitRef="usd">3900000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-174" decimals="-3" id="f-645" unitRef="usd">581000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-175" decimals="-5" id="f-646" unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-176" decimals="-3" id="f-647" unitRef="usd">890000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-177" decimals="-5" id="f-648" unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c-178" decimals="-5" id="f-649" unitRef="usd">2800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-179" decimals="-5" id="f-650" unitRef="usd">6400000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-180" decimals="-5" id="f-651" unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-181" decimals="-5" id="f-652" unitRef="usd">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-182" decimals="-5" id="f-653" unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-183" decimals="-5" id="f-654" unitRef="usd">3700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-3" decimals="-5" id="f-655" unitRef="usd">3700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-656">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-9"
      decimals="2"
      id="f-657"
      unitRef="usdPerShare">8.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-658"
      unitRef="usdPerShare">6.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-10"
      decimals="2"
      id="f-659"
      unitRef="usdPerShare">7.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-11"
      decimals="2"
      id="f-660"
      unitRef="usdPerShare">11.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-184" decimals="-5" id="f-661" unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-185" id="f-662">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-186"
      decimals="2"
      id="f-663"
      unitRef="usdPerShare">11.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-664"
      unitRef="usdPerShare">8.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-187"
      decimals="2"
      id="f-665"
      unitRef="usdPerShare">9.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-188"
      decimals="2"
      id="f-666"
      unitRef="usdPerShare">10.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation contextRef="c-189" decimals="-3" id="f-667" unitRef="usd">43000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-190" decimals="-3" id="f-668" unitRef="usd">146000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-191" decimals="-3" id="f-669" unitRef="usd">146000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-192" decimals="-3" id="f-670" unitRef="usd">366000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-193"
      decimals="-3"
      id="f-671"
      unitRef="shares">82000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-194" decimals="2" id="f-672" unitRef="number">0.70</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-195" decimals="2" id="f-673" unitRef="number">0.30</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage contextRef="c-196" decimals="2" id="f-674" unitRef="number">0.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage contextRef="c-193" decimals="2" id="f-675" unitRef="number">1</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage contextRef="c-197" decimals="2" id="f-676" unitRef="number">1.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-195" id="f-677">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-198" decimals="2" id="f-678" unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-199" decimals="2" id="f-679" unitRef="number">1.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <ino:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-680">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant assumptions used in the Monte Carlo simulation method were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.808%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-200" decimals="4" id="f-681" unitRef="number">0.0460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-200" decimals="2" id="f-682" unitRef="number">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-200" id="f-683">P3Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-200"
      decimals="INF"
      id="f-684"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue contextRef="c-194" decimals="-3" id="f-685" unitRef="usd">629000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-194"
      decimals="INF"
      id="f-686"
      unitRef="usdPerShare">10.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation contextRef="c-201" decimals="INF" id="f-687" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-202" decimals="INF" id="f-688" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue contextRef="c-195" decimals="-3" id="f-689" unitRef="usd">263000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-195"
      decimals="INF"
      id="f-690"
      unitRef="usdPerShare">10.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation contextRef="c-203" decimals="-3" id="f-691" unitRef="usd">8000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-200" decimals="-3" id="f-692" unitRef="usd">8000</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-693">Related Party Transactions&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owned 597,808 shares of common stock in PLS as of June&#160;30, 2024, representing an ownership interest of 17.8%, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dr. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar") and an Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.6&#160;million, for the preclinical development and translational studies of DMAbs as countermeasures for COVID-19, with funding extended through August 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The sub-grant also includes an option for an additional $1.6&#160;million in funding through September 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company received a $1.2&#160;million sub-grant through Wistar, which was amended in 2024 to $2.4&#160;million with funding through November 2024, with an option for an additional $4.2&#160;million in funding that extends the sub-grant through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (dLNPs) for vaccination against HIV infection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three and six months ended June 30, 2024, the Company recorded $9,000 and $149,000, respectively, and for the three and six months ended June 30, 2023, the Company recorded $179,000 and $390,000, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to collaborative research agreements. Research and development expenses recorded from Wistar for the three and six months ended June 30, 2024 were $455,000 and $1.0 million, respectively. Research and development expenses recorded from Wistar for the three and six months ended June 30, 2023 were $510,000 and $932,000, respectively. At June&#160;30, 2024 and December&#160;31, 2023, the Company had an accounts receivable balance of $1.8 million and $2.4 million, respectively, and an accounts payable and accrued liability balance of $1.9 million and $1.1 million, respectively, related to Wistar. At each of June&#160;30, 2024 and December&#160;31, 2023, the Company recorded $22,000 as deferred grant funding on its condensed consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-204"
      decimals="INF"
      id="f-694"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-204" decimals="3" id="f-695" unitRef="number">0.178</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <ino:CollaborativeAgreementExpensesToReimburse contextRef="c-205" decimals="-5" id="f-696" unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm contextRef="c-205" id="f-697">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementAwardedAmount contextRef="c-206" decimals="-5" id="f-698" unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAmendedAmount contextRef="c-207" decimals="-5" id="f-699" unitRef="usd">13600000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount contextRef="c-208" decimals="-5" id="f-700" unitRef="usd">1600000</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:CollaborativeAgreementAwardedAmount contextRef="c-209" decimals="-5" id="f-701" unitRef="usd">1200000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedAmount contextRef="c-210" decimals="-5" id="f-702" unitRef="usd">2400000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount contextRef="c-210" decimals="-5" id="f-703" unitRef="usd">4200000</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:GrantProceedsReceived contextRef="c-211" decimals="-3" id="f-704" unitRef="usd">9000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived contextRef="c-212" decimals="-3" id="f-705" unitRef="usd">149000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived contextRef="c-213" decimals="-3" id="f-706" unitRef="usd">179000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived contextRef="c-214" decimals="-3" id="f-707" unitRef="usd">390000</ino:GrantProceedsReceived>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-215" decimals="-3" id="f-708" unitRef="usd">455000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-210" decimals="-5" id="f-709" unitRef="usd">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-216" decimals="-3" id="f-710" unitRef="usd">510000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-217" decimals="-3" id="f-711" unitRef="usd">932000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-218" decimals="-5" id="f-712" unitRef="usd">1800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-219" decimals="-5" id="f-713" unitRef="usd">2400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-218" decimals="-5" id="f-714" unitRef="usd">1900000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-219" decimals="-5" id="f-715" unitRef="usd">1100000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ino:DeferredGrantFundingFromAffiliate contextRef="c-218" decimals="-3" id="f-716" unitRef="usd">22000</ino:DeferredGrantFundingFromAffiliate>
    <ino:DeferredGrantFundingFromAffiliate contextRef="c-219" decimals="-3" id="f-717" unitRef="usd">22000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-718">Commitments and Contingencies                                                  &lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 56,600 square feet of office, laboratory, and manufacturing space in San Diego, California and approximately 57,400 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of June&#160;30, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of 2.9 to 5.5 ye&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ars, which represent the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Company entered into a lease agreement for research and development laboratory space in San Diego, California. The total space under the lease is approximately 5,600 square feet. The term of the lease commenced on February 10, 2024 and the initial term is 4.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The base rent adjusts periodically throughout the term of the lease. Rent payments under the lease will include base rent with an annual increase of approximately three percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of June&#160;30, 2024, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,696,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,467,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,555,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,310,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,135,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,980,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,322,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,658,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2024 were $521,000 and $1.4 million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2023 were $856,000 and $1.7&#160;million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third and fourth quarters of 2023, the Company entered into agreements to sublease a total of approximately 4,400 and 7,000 square feet, respectively, in its Plymouth Meeting headquarters, in each case with sublease terms through December 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters, with one sublease term through March 31, 2025 and the other month-to-month.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#x2019; fees. The plaintiffs&#x2019; complaint was later amended to include certain of the Company&#x2019;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $30.0&#160;million in cash and $14.0&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers paid the $30.0&#160;million cash component of the settlement. During the three months ended March 31, 2023, the Company issued 760,083 shares of common stock pursuant to the securities class action settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Derivative Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserted state and federal claims and was based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accused the Company&#x2019;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#x2019;s management, policies, practices, and internal controls. The plaintiff sought unspecified monetary damages on behalf of the Company as well as governance reforms. Between June 2020 and August 2020, additional shareholder derivative complaints were filed and later consolidated by the court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, an additional shareholder derivative complaint was filed in the Delaware Court of Chancery, asserting substantially similar claims as those in the consolidated derivative action. In May 2022, the Delaware Court of Chancery entered a stay of the litigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania. The proposed settlement provided for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, the court entered an order preliminarily approving the proposed settlement of the derivative claims, in accordance with a Stipulation of Settlement. The Stipulation of Settlement contemplated that, following the settlement hearing and the final approval of the settlement by the court, the Company would implement certain corporate governance reforms described in the Stipulation of Settlement. The preliminary order also approved the form and manner of the notice of the Settlement. As part of the Settlement, in July 2023 the Company paid $1.2&#160;million to plaintiffs&#x2019; counsel for their fees and expenses. In October 2023, the court entered an order and final judgment approving the Settlement, which became effective in November 2023. The Company has implemented the corporate governance reforms in response to the provisions of the Stipulation of Settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VGXI Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#x2019;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#x2019; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#x2019; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. The Company filed an answer to VGXI&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;counterclaims, disputing the allegations and the claims raised in VGXI&#x2019;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#x2019;s counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GeneOne Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#x2019; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#x2019;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#x2019;s fees, and costs. In October 2021, GeneOne filed its answer to the Company&#x2019;s counterclaims and new matter. On February 29, 2024, the Company filed a motion for summary judgment. On April 1, 2024, GeneOne filed an opposition to the Company&#x2019;s motion for summary judgment. On June 28, 2024, the court denied the motion for summary judgment. A trial date for this litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#x2019;s complaint. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#x2019;s consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-220" decimals="0" id="f-719" unitRef="sqft">56600</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-221" decimals="0" id="f-720" unitRef="sqft">57400</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-222" id="f-721">P2Y10M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-223" id="f-722">P5Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-224" decimals="0" id="f-723" unitRef="sqft">5600</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-225" id="f-724">P4Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease contextRef="c-224" decimals="2" id="f-725" unitRef="number">0.03</ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-726">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of June&#160;30, 2024, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,696,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,467,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,555,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,310,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,135,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,980,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,322,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,658,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-727" unitRef="usd">1696000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-728" unitRef="usd">3467000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-729" unitRef="usd">3555000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-730" unitRef="usd">2955000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-731" unitRef="usd">2310000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-3" decimals="-3" id="f-732" unitRef="usd">2132000</ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-733" unitRef="usd">16115000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-734" unitRef="usd">3135000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-735" unitRef="usd">12980000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-736" unitRef="usd">2322000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-737" unitRef="usd">10658000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-738">P4Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="3" id="f-739" unitRef="number">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost contextRef="c-9" decimals="-3" id="f-740" unitRef="usd">521000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-5" id="f-741" unitRef="usd">1400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-10" decimals="-3" id="f-742" unitRef="usd">856000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-11" decimals="-5" id="f-743" unitRef="usd">1700000</us-gaap:LeaseCost>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-226" decimals="0" id="f-744" unitRef="sqft">4400</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-227" decimals="0" id="f-745" unitRef="sqft">7000</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseNumberOfAgreementsToSublease
      contextRef="c-228"
      decimals="INF"
      id="f-746"
      unitRef="agreement">2</ino:LesseeOperatingLeaseNumberOfAgreementsToSublease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-229" decimals="0" id="f-747" unitRef="sqft">13500</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-230" decimals="-5" id="f-748" unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ino:LossContingencyEstimateOfPossibleLossValueOfShares contextRef="c-230" decimals="-5" id="f-749" unitRef="usd">14000000</ino:LossContingencyEstimateOfPossibleLossValueOfShares>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-230" decimals="-5" id="f-750" unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ino:LitigationSettlementAmountAwardedToOtherPartyShares
      contextRef="c-138"
      decimals="INF"
      id="f-751"
      unitRef="shares">760083</ino:LitigationSettlementAmountAwardedToOtherPartyShares>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="c-231"
      decimals="INF"
      id="f-752"
      unitRef="director">8</us-gaap:LossContingencyNumberOfDefendants>
    <us-gaap:LossContingencyDamagesPaidValue contextRef="c-232" decimals="-5" id="f-753" unitRef="usd">1200000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-754">Collaborative Agreements&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#x201c;Advaccine&#x201d;), which was amended and restated on June 7, 2021 (as amended and restated, the &#x201c;Advaccine Agreement&#x201d;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;) and 33 additional countries in Asia. The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#x2019;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#x2019;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. In the fourth quarter of 2022, the Company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility was assured. For the three and six months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2023, the Company received funding of $1.2&#160;million and $2.4&#160;million, respectively, from Advaccine that was recorded as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contra-research and development expense. No funding was received during the three and six months ended June 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), which was amended on June 14, 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the three and six months ended June 30, 2024, the Company received funding of $101,000 from the ApolloBio Agreement that was recorded as revenue. There were no significant reimbursable program costs under the ApolloBio Agreement during the three and six months ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously entered into agreements with CEPI, pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56&#160;million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. For both&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the three and six months ended June 30, 2024, the Company received no funding related to these grants. During the three and six months ended June 30, 2023, the Company received funding of $303,000 and $1.9&#160;million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of each of June&#160;30, 2024 and December 31, 2023, the Company had $2.2&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recorded as an accrued liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated balance sheet related to these CEPI grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. For both the three and six months ended June 30, 2024 the Company received no funding from CEPI related to these grants for INO-4800. During the three and six months ended June 30, 2023, the Company received funding of $135,000 and $188,000, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of DMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three and six months ended June 30, 2024, the Company recorded $0 and $39,000, respectively, as contra-research and development expense related to the Gates DMAb grant. During the three and six months ended June 30, 2023, the Company recorded $12,000 and $70,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of June&#160;30, 2024, the Company had $49,000 recorded as an &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accrued liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated balance sheet related to the grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-233" decimals="-5" id="f-755" unitRef="usd">1200000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-234" decimals="-5" id="f-756" unitRef="usd">2400000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-235" decimals="INF" id="f-757" unitRef="usd">0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-236" decimals="INF" id="f-758" unitRef="usd">0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved contextRef="c-237" decimals="-5" id="f-759" unitRef="usd">20000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod contextRef="c-237" id="f-760">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-237" decimals="-3" id="f-761" unitRef="usd">101000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-238" decimals="-3" id="f-762" unitRef="usd">101000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-239" decimals="INF" id="f-763" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-240" decimals="INF" id="f-764" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-241" decimals="-6" id="f-765" unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment contextRef="c-241" id="f-766">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-241" decimals="0" id="f-767" unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-242" decimals="0" id="f-768" unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-243" decimals="-3" id="f-769" unitRef="usd">303000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-244" decimals="-5" id="f-770" unitRef="usd">1900000</ino:CollaborativeAgreementFundingReceived>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c-245" decimals="-5" id="f-771" unitRef="usd">2200000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c-246" decimals="-5" id="f-772" unitRef="usd">2200000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-247" decimals="-5" id="f-773" unitRef="usd">9000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-248" decimals="-5" id="f-774" unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-249" decimals="-5" id="f-775" unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-250" decimals="-5" id="f-776" unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-251" decimals="-3" id="f-777" unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-252" decimals="-3" id="f-778" unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-253" decimals="-3" id="f-779" unitRef="usd">135000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-254" decimals="-3" id="f-780" unitRef="usd">188000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-255" decimals="-5" id="f-781" unitRef="usd">2200000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-256" decimals="-5" id="f-782" unitRef="usd">1100000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-257" decimals="-3" id="f-783" unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-258" decimals="-3" id="f-784" unitRef="usd">39000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-259" decimals="-3" id="f-785" unitRef="usd">12000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-260" decimals="-3" id="f-786" unitRef="usd">70000</ino:CollaborativeAgreementFundingReceived>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c-261" decimals="-3" id="f-787" unitRef="usd">49000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-788">Income Taxes &lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.&lt;/span&gt;&lt;/div&gt;&#160;For the six months ended June 30, 2024 and 2023, the Company did not record any income tax provision/(benefit) due to the Company&#x2019;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-789">Geneos Therapeutics, Inc. &lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company formed Geneos Therapeutics to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following a series of financing transactions through June 2020, the Company held less than a majority of the outstanding equity of Geneos on an as-converted to common stock basis, which triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019; economic performance. Accordingly, the Company deconsolidated its investment in Geneos in 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon deconsolidation, the Company recorded its investment at fair value. The Company determined that its investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment is marked to fair value.&#160;There have been no observable price changes or impairments identified since the deconsolidation date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share of net losses of Geneos for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 was allocated to the equity method investment, reducing the balance to $0 as of March 31, 2021. The remaining $4.2&#160;million loss was allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, reducing the balance to $0 as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Geneos completed a second closing of its Series A-1 preferred stock financing, in which the Company did not participate. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos&#x2019;s Series A-2 preferred stock was based on the per share price paid by third-party investors. The Company concluded that its Series A-2 preferred stock investment was a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not made any further investment in Geneos subsequent to March 31, 2022. The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, Geneos completed the closing of its Series A-3 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately 23% of the outstanding equity of Geneos on an as-converted to common stock basis. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&#160;&lt;/span&gt;immunotherapy and CELLECTRA&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment contextRef="c-262" decimals="-5" id="f-790" unitRef="usd">-1500000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-262" decimals="-3" id="f-791" unitRef="usd">-434000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-263" decimals="-3" id="f-792" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-264" decimals="-3" id="f-793" unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-265" decimals="-3" id="f-794" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-266" decimals="-5" id="f-795" unitRef="usd">-4200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-267" decimals="-3" id="f-796" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-268" decimals="2" id="f-797" unitRef="number">0.35</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries contextRef="c-269" decimals="-5" id="f-798" unitRef="usd">2000000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-270" decimals="2" id="f-799" unitRef="number">0.28</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount contextRef="c-271" decimals="-3" id="f-800" unitRef="usd">165000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-271" decimals="-5" id="f-801" unitRef="usd">-2200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-272" decimals="-3" id="f-802" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-272" decimals="-3" id="f-803" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-273" decimals="2" id="f-804" unitRef="number">0.23</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-9" id="f-805">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-9" id="f-806">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-9" id="f-807">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-9" id="f-808">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-135"
          xlink:label="f-135"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-142"
          xlink:label="f-142"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-132"
          xlink:label="f-132"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-133"
          xlink:label="f-133"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-143"
          xlink:label="f-143"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-140"
          xlink:label="f-140"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-131"
          xlink:label="f-131"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-137"
          xlink:label="f-137"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-145"
          xlink:label="f-145"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-146"
          xlink:label="f-146"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-144"
          xlink:label="f-144"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-136"
          xlink:label="f-136"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-134"
          xlink:label="f-134"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-138"
          xlink:label="f-138"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-139"
          xlink:label="f-139"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-141"
          xlink:label="f-141"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-135"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-142"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-132"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-133"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-143"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-140"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-131"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-137"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-145"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-146"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-144"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-136"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-134"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-138"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-139"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-141"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-202"
          xlink:label="f-202"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-271"
          xlink:label="f-271"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-252"
          xlink:label="f-252"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-190"
          xlink:label="f-190"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-196"
          xlink:label="f-196"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-232"
          xlink:label="f-232"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-167"
          xlink:label="f-167"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-173"
          xlink:label="f-173"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-228"
          xlink:label="f-228"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-253"
          xlink:label="f-253"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-233"
          xlink:label="f-233"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-222"
          xlink:label="f-222"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-177"
          xlink:label="f-177"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-270"
          xlink:label="f-270"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-215"
          xlink:label="f-215"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-229"
          xlink:label="f-229"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-197"
          xlink:label="f-197"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-223"
          xlink:label="f-223"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-172"
          xlink:label="f-172"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-166"
          xlink:label="f-166"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-256"
          xlink:label="f-256"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-203"
          xlink:label="f-203"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-257"
          xlink:label="f-257"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-214"
          xlink:label="f-214"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-176"
          xlink:label="f-176"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-247"
          xlink:label="f-247"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-246"
          xlink:label="f-246"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-191"
          xlink:label="f-191"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">All share amounts in this column, including appropriate reclassifications between common stock and additional paid-in capital, have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-202"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-271"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-252"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-190"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-196"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-232"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-167"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-173"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-228"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-253"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-233"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-222"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-177"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-270"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-215"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-229"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-197"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-223"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-172"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-166"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-256"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-203"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-257"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-214"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-176"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-247"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-246"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-191"
          xlink:to="fn-2"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
